<SEC-DOCUMENT>0001564590-15-002929.txt : 20150428
<SEC-HEADER>0001564590-15-002929.hdr.sgml : 20150428
<ACCEPTANCE-DATETIME>20150428163208
ACCESSION NUMBER:		0001564590-15-002929
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150428
DATE AS OF CHANGE:		20150428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		15799042

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-10q_20150331.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:12pt;font-family:'Wingdings'">&#120;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended March 31, 2015 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:7pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:12pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> to <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number 000-30171 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">68-0359556</p></td>
</tr>
<tr>
<td valign="top"  style="width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top"  style="width:4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">501 Canal Blvd </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richmond, California 94804 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(510) 970-6000 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:7pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:7pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:7pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font><font style="font-family:Times New Roman;">&#160;&#160;(Do not check if a smaller reporting company)</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:7pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160; <font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:7pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April 24, 2014, 69,582,797 shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding. </p>
<p style="margin-top:4pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-top:0pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I. FINANCIAL INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.72%;"></td>
<td style="width:87.19%;"></td>
<td style="width:5.09%;"></td>
</tr>
<tr>
<td valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Financial_Statements"><font style="text-decoration:underline;">Financial Statements (Unaudited)</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Balance_Sheets"><font style="text-decoration:underline;">Condensed Consolidated Balance Sheets at March 31, 2015 and December&#160;31, 2014</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Operations"><font style="text-decoration:underline;">Condensed Consolidated Statements of Operations for the Three Months ended <br>March 31, 2015 and 2014</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Consolidated_Statements_of_Comprehensive"><font style="text-decoration:underline;">Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended <br>March 31, 2015 and 2014</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Cash_Flows"><font style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2015 and 2014</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Notes_to_Condensed"><font style="text-decoration:underline;">Notes to Condensed Consolidated Financial Statements</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Managements_Discussion"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Quantitative_and_Qualitative"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures about Market Risk</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Controls_and_Procedures"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="2" valign="middle"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II. OTHER INFORMATION </p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="middle"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Legal_Proceedings"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Risk_Factors"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Exhibits"><font style="text-decoration:underline;">Exhibits</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="2" valign="middle"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">SIGNATURES</font></a><font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="2" valign="middle"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some statements contained in this report are forward-looking with respect to our operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our strategy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">product development and commercialization of our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">partnering; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">revenues from existing and new collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our research and development and other expenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">sufficiency of our cash resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our operational and legal risks;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our plans, objectives, expectations and intentions and any other statements that are not historical facts. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should&#8221; and &#8220;will.&#8221; These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Many of these risks are discussed in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations&#8221; in this Form 10-Q. Sangamo undertakes no obligation to publicly release any revisions to forward-looking statements to reflect events or circumstances arising after the date of this report. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form&#160;10-Q. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ZFP Therapeutic<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> is a registered trademark of Sangamo BioSciences, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I. FINANCIAL INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;<font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top" style="width:88.67%;">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Financial_Statements"></a>FINANCIAL STATEMENTS </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Balance_Sheets"></a>CONDENSED CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited; in thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,256</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,030</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,932</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,638</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,368</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,946</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190,879</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, non-current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,822</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,479</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, in-process research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLERS' EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,806</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,704</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,853</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Escrow liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,184</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,968</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,882</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues, non-current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,049</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,579</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Common stock, $0.01 par value; 160,000,000 shares authorized, 69,497,256 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; 69,062,394 shares issued and outstanding at March 31, 2015, and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; December 31, 2014, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">695</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,637</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534,518</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(333,869</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(328,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207,488</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,633</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,505</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Statements_of_Operations"></a>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited; in thousands, except per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,568</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research grants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,491</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,116</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,980</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,083</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,712</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,221</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,611</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,067</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,572</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit from income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,319</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,572</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.08</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in computing basic and diluted net loss per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,283</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,199</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Consolidated_Statements_of_Comprehensive"></a>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited; in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,319</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,572</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain on available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,269</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Statements_of_Cash_Flows"></a>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited: in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,572</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,953</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible impairment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit from income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,730</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,477</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,732</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,150</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,723</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,888</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by / (used in) operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,393</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,379</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,955</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,786</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,084</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,448</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,887</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from public offering of common stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,786</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes paid related to net share settlement of equity awards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,371</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,637</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,030</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,186</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,823</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment included in accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Notes_to_Condensed"></a>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1&#8212;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (&#8220;Sangamo&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2015. The condensed consolidated balance sheet data at December&#160;31, 2014 were derived from the audited consolidated financial statements included in Sangamo&#8217;s Form 10-K for the year ended December&#160;31, 2014, as filed with the SEC. These financial statements should be read in conjunction with the financial statements and footnotes thereto for the year ended December&#160;31, 2014, included in Sangamo&#8217;s Form 10-K, as filed with the SEC. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements prior to the adoption of ASU No.&#160;2009-13, Revenue Recognition&#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)<font style="font-style:normal;">. For revenue arrangements entered into before January&#160;1, 2011, that include multiple deliverables, the elements of such agreements were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements after the adoption of ASU 2009-13.<font style="font-style:normal;"> ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (VSOE), if available; third-party evidence (TPE), if available and VSOE is not available; or the best estimate of selling price (ESP), if neither VSOE nor TPE is available; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG (Shire), in January 2012 and Biogen Inc., formerly Biogen Idec Inc. (Biogen) in January 2014 were evaluated under these amended accounting standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company&#8217;s performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred to the extent such amounts have been agreed to with the respective collaboration partner. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Standards </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2014 the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-15, <font style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font> (ASU 2014-15). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting ASU 2014-15 on its consolidated financial statements will be material.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 the Financial Accounting Standards Board issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with&#160;Customers</font>&#160;(ASU 2014-09). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&#160;15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2&#8212;FAIR VALUE MEASUREMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for sale-securities and the contingent consideration liability.&#160;The fair value of these assets and contingent liability was determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value measurements of our cash equivalents, available-for-sale marketable securities and contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,558</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,374</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally classifies its debt instruments as Level 2. Instruments can be classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingent Consideration Liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2013, the Company acquired Ceregene and recorded a liability for the estimated fair value of contingent consideration payments to former Ceregene stockholders, as outlined under the terms of the merger agreement with Ceregene. These contingent payments are owed if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. The fair value of this liability is estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. <font style="letter-spacing:-0.1pt;">The Company has classified this liability as Level 3.</font> </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent changes in the fair value of this contingent consideration liability are recorded to the research and development (R&amp;D) expense line item in the Condensed Consolidated Statements of Operations as operating expenses. During the three months ended March 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of the in-process research and development (IPR&amp;D) assets acquired from Ceregene (see Note 6). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of December 31, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of March 31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3&#8212;MARKETABLE SECURITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo generally classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value, with the unrealized holding gains and losses included in accumulated other comprehensive income. Investments that have maturities beyond one year as of the end of the reporting period are classified as non-current. The Company&#8217;s investments are subject to a periodic impairment review, and the Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company&#8217;s investments (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Losses)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,062</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,444</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,533</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,558</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,831</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,217</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,399</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,374</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no other-than-temporary impairments of its investments for the three months ended March 31, 2015 or the twelve months ended December&#160;31, 2014. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4&#8212;BASIC AND DILUTED NET LOSS PER SHARE </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of stock options, which are anti-dilutive. The total number of shares subject to stock options outstanding excluded from </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consideration in the calculation of diluted net loss per share for the three months ended March 31, 2015 and 2014 were 7,624,600 and 7,302,366, respectively. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5&#8212;MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Biogen Inc. in Human Therapeutics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014 Sangamo entered into a Global Research, Development and Commercialization Collaboration and License Agreement (the &#8220;Biogen Agreement&#8221;) with Biogen, pursuant to which Sangamo and Biogen collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&#8217;s zinc finger DNA-binding protein (ZFP) technology for hemoglobinopathies, including beta-thalassemia and sickle cell disease (SCD). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Biogen Agreement, Sangamo and Biogen jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP Therapeutic developed under the Biogen Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (IND) application for ZFP Therapeutics intended to treat SCD. For both programs, Biogen is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Biogen Agreement. At the end of specified research terms for each program or under certain specified circumstances, Biogen retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any&#160;licensed product to treat beta-thalassemia and SCD&#160;developed under the Biogen Agreement, and Biogen agrees to compensate Sangamo for such co-promotion activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo received an upfront license fee of $20.0 million upon entering into the Biogen Agreement. In addition, the Company will also be eligible to receive $126.3 million in payments upon the achievement of specified research, regulatory, clinical development milestones, as well as $167.5 million in payments upon the achievement of specified commercialization and sales milestones. Biogen reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. In addition, Sangamo is eligible to receive contingent payments upon the achievement of specified regulatory, clinical development, commercialization and sales milestones. The total amount of potential regulatory, clinical development, commercialization and sales contingent payments, assuming the achievement of all specified milestone events in the Biogen Agreement, is $293.8 million, including Phase 1 contingent payments of $7.5 million for each of the beta-thalassemia and SCD programs. In addition, if products are commercialized under the Biogen Agreement, Biogen will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Biogen Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All contingent payments under the Biogen Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Biogen Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&#160;that can be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance, (ii)&#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&#160;that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Biogen Agreement, assuming all other applicable revenue recognition criteria have been met. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the Biogen Agreement, Sangamo grants Biogen an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Biogen Agreement. Sangamo also grants Biogen a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, of Sangamo&#8217;s interest in certain other intellectual property developed pursuant to the Biogen Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Biogen apart from the research services to be performed pursuant to the Biogen Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a forty-month estimated initial research term during which the Company will perform research services. As of March 31, 2015, the Company has deferred revenue of $14.1 million related to the Biogen Agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Biogen for the three months ended March 31, 2015 and 2014 are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Biogen Collaboration:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,523</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,533</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,056</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,083</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related costs and expenses incurred under the Biogen agreement related to the beta-thalassemia project, which is co-funded with California Institute for Regenerative Medicine (CIRM), were $1.4 million and $1.3 million during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses for other projects including sickle cell disease under the Biogen agreement were $1.1 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Shire International GmbH in Human Therapeutics and Diagnostics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2012 the Company entered into a collaboration and license agreement (the &#8220;Shire Agreement&#8221;) with Shire, pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&#8217;s novel ZFP technology. Under the Shire Agreement, the Company and Shire may develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets will be used for treating or diagnosing hemophilia. In June 2012, Shire selected a fifth gene target for the development of a ZFP Therapeutic for Huntington&#8217;s disease. Shire has the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. The initial research term of the Shire Agreement is six years and is subject to extensions upon mutual agreement and under other specified circumstances. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Shire Agreement, the Company is responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimburses Sangamo for agreed upon internal and external program-related research costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement. In addition, the Company will also be eligible to receive $33.5 million in payments upon the achievement of specified research, regulatory, clinical development milestones, including payments for each gene target through the acceptance of an IND or CTA submission totaling $8.5 million, as well as $180 million in payments upon the achievement of specified commercialization and sales milestones. The Company will also be eligible to receive royalty payments that are a tiered double-digit percentage of net sales of licensed product sold by Shire or its sublicensees developed under the collaboration, if any. To date, no products have been approved and therefore no royalty fees have been earned under the Shire Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All contingent payments under the Shire Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Shire Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&#160;that can be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance, (ii)&#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&#160;that would result in additional payments being due to the Company. Accordingly, revenue for the achievement of milestones that are determined to be substantive will be recognized in their entirety in the period the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Shire Agreement, assuming all other applicable revenue recognition criteria have been met. In 2014 Sangamo recognized a $1.0 million milestone payment related to our hemophilia program.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a six-year initial research term during which the Company </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will perform research services. As of March 31, 2015, the Company has deferred revenue of $6.8 million related to the Shire Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Shire for the three months ended March 31, 2015 and 2014, were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Shire Collaboration:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,979</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,064</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related costs and expenses incurred under the Shire agreement were $4.5 million and $4.8 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2007 Sangamo entered into a license agreement (the &#8220;Sigma Agreement&#8221;) with Sigma-Aldrich Corporation (Sigma). Under the Sigma Agreement, Sangamo agreed to provide Sigma with access to our proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (DAS). Under the Sigma Agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using Sangamo&#8217;s ZFP technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company&#8217;s ZFP technology in the research field. Sangamo has transferred its ZFP manufacturing technology to Sigma. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2009 Sangamo expanded the Sigma Agreement. In addition to the original terms of the Sigma Agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the Sigma Agreement as expanded in 2009, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock and a $15.1 million upfront license fee. The upfront license fee was recognized on a straight-line basis from the effective date of the expanded license through July 2010, which represents the period over which Sangamo was obligated to perform research services for Sigma. Sangamo is also eligible to receive commercial license fees of $5.0 million based upon a percentage of net sales. As of March 31, 2015 Sangamo has received the entire $5.0 million of commercial license fees and is eligible to receive royalty payments of 10.5% of net sales and sublicensing revenue.  In addition, upon the achievement of certain cumulative commercial milestones Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Sigma for the three months ended March 31, 2015 and 2014, were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Sigma Collaboration:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenues</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related costs and expenses incurred under the Sigma agreement were $0.2 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreement with Dow AgroSciences in Plant Agriculture </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2005 Sangamo entered into an exclusive commercial license agreement with DAS (the &#8220;DAS Agreement&#8221;). Under the DAS Agreement, Sangamo provides DAS with access to our proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP transcription factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic, therapeutic or prophylactic purposes. The DAS Agreement provided for an initial three-year research term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants or plant cell cultures. Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended the DAS Agreement to extend the period of reagent manufacturing services and research services through December&#160;31, 2012. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DAS Agreement also provides for minimum license fees each year due to Sangamo every October, provided the Agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years. The Company does not have any ongoing performance obligations under the agreement with DAS. DAS has the right to terminate the agreement at any time; accordingly, the Company&#8217;s actual license fees over the term of the DAS Agreement could be lower than $25.3 million. In addition, each party may terminate the DAS Agreement upon an uncured material breach by the other party. In the event of any termination of the DAS Agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted access to Sangamo&#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no revenues or related costs and expenses recognized under the DAS Agreement during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Funding from Research Foundations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">California Institute for Regenerative Medicine - HIV </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2009 CIRM, a State of California entity, granted a $14.5 million Disease Team Research Award to develop an HIV/AIDS therapy based on the application of ZFN gene editing technology in hematopoietic stem cells (HSCs). The four-year grant supports an innovative research project conducted by a multidisciplinary team of investigators, including investigators from the University of Southern California, City of Hope National Medical Center and Sangamo BioSciences. Sangamo received funds totaling $5.2 million from the total amount awarded based on expenses incurred for research and development efforts by Sangamo as prescribed in the agreement, and subject to its terms and conditions. The award is intended to substantially fund Sangamo&#8217;s research and development efforts related to the agreement. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo resulting from sales of a commercial product resulting from research and development efforts supported by the grant. As of December&#160;31, 2013, all revenues under the award had been recognized and all funds had been received. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no revenues attributable to research and development performed under the CIRM 2009 grant agreement during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM grant agreement were $0.2 million and $0.3 million during the three months ended March 31, 2015 and 2014, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 CIRM agreed to fund a $5.6 million Strategic Partnership Award to fund clinical studies of a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of its ZFN genome editing technology in hematopoietic stem progenitor cells (HSPCs). The four year grant provides matching funds to support evaluation of the Company&#8217;s stem cell-based ZFP Therapeutic in a clinical trial in HIV-infected individuals conducted at City of Hope. The Company expects funding for this grant to commence in 2015.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no revenues attributable to research and development performed under the Strategic Partnership Award during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM Strategic Partnership Award were $0.3 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">California Institute for Regenerative Medicine - Beta-Thalassemia </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2013 CIRM granted Sangamo a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its ZFN gene editing technology in HSCs. The four-year grant provides </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">matching funds for preclinical work that will support an IND application and a Phase 1 clinical trial in transfusion-dependent beta-thalassemia patients. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo, or its collaborators, from sales of a commercial product resulting from research and development efforts supported by the grant, in accordance with Title 17, California Code of Regulations, Section&#160;100600. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue attributable to research and development performed under the CIRM grant agreement for beta-thalassemia was $0.7 million and $0.4 million during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM grant agreement were $0.7 million and $0.4 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6&#8212;INTANGIBLE ASSETS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets for IPR&amp;D consist of two clinical product candidates from our 2013 acquisition of Ceregene. IPR&amp;D is an intangible asset classified as indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of these intangibles assets are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERE-110 for the treatment of Alzheimer's disease</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,640</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERE-120 for the treatment of Parkinson's disease</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable intangible assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2015, the Company received clinical data demonstrating no statistically significant difference between the control group and the group treated with CERE-110 for Alzheimer&#8217;s disease. Subsequently, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. Given these results, the Company does not believe the programs have an alternative future use for itself or other market participants. Accordingly, during the three months ended March 31, 2015, the Company recognized a $1.9 million impairment charge related to these assets. The impairment is recorded in R&amp;D expense in the accompanying condensed consolidated statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7&#8212;INCOME TAXES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#8217;s history of losses. Accordingly, the Company&#8217;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2015 the deferred tax liability of $0.7 million that was recorded upon acquiring the IPR&amp;D assets in 2013 was adjusted due to the impairment of these assets. This resulted in the recognition of a $0.7 million income tax benefit. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8&#8212;STOCK-BASED COMPENSATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,262</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">834</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,953</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;<font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. </font></p></td>
<td valign="top" style="width:88.67%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Managements_Discussion"></a>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements containing the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;continue,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You should read the following discussion and analysis along with the financial statements and notes attached to those statements included elsewhere in this report and in our annual report on Form 10-K for the year ended December&#160;31, 2014 as filed with the SEC. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. Our current mission is to develop ZFP Therapeutics<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font>, or human therapeutics based on our proprietary zinc finger DNA-binding protein (ZFP) technology, through early stage clinical testing, strategically partner with biopharmaceutical companies at points of value inflection and have the partner execute late-stage clinical trials and commercial development. In the long-term, our goal is to integrate marketing and development operations and to capture the value of late-stage and commercial ZFP Therapeutic products for ourselves. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our licensed partners are the leaders in the research, development and commercialization of ZFPs, a naturally occurring class of proteins. We have used our knowledge and expertise to develop a proprietary technology platform. ZFPs can be engineered to make ZFP nucleases (ZFNs), proteins that can be used to modify DNA sequences in a variety of ways and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. As ZFPs act at the DNA level, they have broad potential applications in several areas, including human therapeutics, plant agriculture and research reagents, as well as production of transgenic animals and cell-line engineering. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main focus for our company is the development of novel human therapeutics and we are building a pipeline of ZFP Therapeutics. Our lead ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of our ZFN technology and is being evaluated in a Phase 2 clinical trial in HIV-infected subjects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014 we entered into a collaborative partnership with Biogen Inc., formerly Biogen Idec Inc. (Biogen) to research, develop and commercialize our preclinical ZFP Therapeutic development program in hemoglobinopathies, targeting sickle cell disease (SCD) and beta-thalassemia. We also have a collaborative partnership with Shire International GmbH, formerly Shire AG (Shire), to research, develop and commercialize certain of our preclinical ZFP Therapeutic development programs, including programs in hemophilia, Huntington&#8217;s disease (HD) and other monogenic diseases. We have proprietary preclinical programs in several lysosomal storage disorders (LSDs). In addition, we have research stage programs in other monogenic diseases, including certain immunodeficiencies, as well as central nervous system (CNS) disorders and cancer immunotherapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the potential commercial applications of ZFPs are broad-based and we have entered into strategic partnerships in fields outside human therapeutics to facilitate the sale or licensing of our ZFP platform as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">We have a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon our ZFP technology as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr</font><font style="font-size:8.5pt;font-family:Times New Roman;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font><font style="font-family:Times New Roman;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">We have a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, we have provided DAS with access to our ZFP technology and the exclusive rights to use it to modify the genomes or alter protein expression of plant cells, plants or plant cell cultures. DAS markets our ZFN technology under the trademark EXZACT</font><font style="font-size:8.5pt;font-family:Times New Roman;"><sup style="font-size:85%; vertical-align:top">TM</sup></font><font style="font-family:Times New Roman;">&#160;Precision Technology. We have retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic or prophylactic purposes. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses since inception and expect to incur losses in the future as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborations and research grants. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2015, we incurred a consolidated net loss of $5.3 million, or $0.08 per share, compared to a net loss of $7.6 million, or $0.12 per share, for the same period in 2014. As of March 31, 2015, we had cash, cash equivalents, marketable securities and interest receivable totaling $226.1 million compared to $226.6 million as of December&#160;31, 2014. As of March 31, 2015, we had an accumulated deficit of $333.9 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues have consisted primarily of revenues from partnerships of our ZFP technology platform in both therapeutic and non-therapeutic applications, including license fees, research reimbursement and milestones, royalties, as well as revenues from research grant funding. We expect revenues will continue to fluctuate from period to period, and there can be no assurance that new collaborations or partner funding will continue beyond their current terms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the development of our ZFP technology platform, we are focusing our resources on higher-value ZFP Therapeutic product development and less on our non-therapeutic applications. Development of novel therapeutic products is costly and is subject to a lengthy and uncertain regulatory process by the FDA. Our future products will be gene-based therapeutics. Adverse events in both our own clinical program and other programs may have a negative impact on regulatory approval, the willingness of potential commercial partners to enter into agreements and public perception. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Critical Accounting Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements and the related disclosures, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that there have been no significant changes in our critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2014, as filed with the SEC. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Three months ended March 31, 2015 and 2014 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except percentage values)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,568</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,103</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research grants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,491</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,116</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,375</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues consist of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Shire, DAS and Sigma. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues from our corporate collaboration agreements were $12.7 million for the three months ended March 31, 2015, compared to $7.6 million in the corresponding period in 2014. The $5.1 million increase in collaboration agreements revenues was primarily due to an increase of $6.2 million in revenues related to our collaboration and license agreements with Sigma and Biogen, which was offset by a decrease of $1.1 million in revenues related to our collaboration and license agreements with Shire and <font style="color:#;">Open Monoclonal Technology, Inc.</font> The revenues from Sigma included recognition of revenues under our license and royalty agreement of $4.5 million. The revenues from Biogen included partial recognition of an upfront payment of $20.0 million and $1.5 million in revenues from research services. Research grant revenues were approximately $0.8 million for the three months ended March 31, 2015, compared to $0.5 million in the corresponding period in 2014, primarily due to an increase in revenue from CIRM related to the beta thalassemia program under the collaboration agreement with Biogen. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except percentage values)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,980</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,083</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,897</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,712</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,985</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of salaries and personnel related expenses, including stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing expenses, allocated facilities expenses, subcontracted research expenses and expenses for technology licenses. We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our HIV/AIDS program in the clinic and if we are able to move our earlier stage ZFP Therapeutic product candidates into clinical trials. We also expect that expenses related to research performed under our collaboration and license agreements with Biogen and Shire will increase our research and development expenses during the terms of the agreements. Pursuant to the terms of the agreements with Biogen and Shire, future expenses for research activities under the collaboration will be reimbursed, including internal employee and external research costs related to the programs. The reimbursement for these services will be recognized as revenue as the expenses are incurred and collection is reasonably assured. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $15.0 million for the three months ended March 31, 2015, compared to $12.1 million in the corresponding period in 2014. The increase of $2.9 million in research and development expenses was primarily due to an increase of $0.9 million in salaries and benefits, $0.7 million in external expenses, lab supplies and other expenses related to our hemophilia, beta-thalassemia, SCD and HD programs, $0.6 million in stock-based compensation expense and $0.5 million in clinical trial and manufacturing expenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General and administrative </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and personnel related expenses, including stock-based compensation, other expenses for executive, finance and administrative personnel, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we pursue clinical and commercial development of our therapeutic programs, we expect the business aspects of the Company to become more complex. In the future we may be required to add personnel and incur additional expenses related to the maturity of our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $4.7 million for the three months ended March 31, 2015 compared to $3.6 million for the corresponding period in 2014. The increase was primarily related to an increase of $0.4 million in stock-based compensation expense and $0.2 million in salaries and benefits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2015, we had cash, cash equivalents, marketable securities and interest receivable totaling $226.1&#160;million compared to $226.6 million as of December&#160;31, 2014. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most significant use of capital pertains to salaries and benefits for our employees and external development expenses, such as manufacturing and clinical trial activities, related to our ZFP Therapeutic programs. Our cash and investment balances are held in a variety of interest bearing instruments, which can include obligations of U.S. government agencies, U.S. treasury debt securities, corporate debt securities, commercial paper securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our agreement with Shire, we received an upfront license fee of $13.0 million. Shire will reimburse us for agreed upon costs incurred in connection with research and development activities conducted by us. We are also eligible to receive milestone payments based on our achievement of specified research, regulatory, clinical development, commercialization and sales milestones, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which depends upon ours and Shire&#8217;s ability to continue to progress our programs under collaboration. In 2014 we recognized $1.0 million milestone related to our hemophilia program. We will also be eligible to receive royalty payments that are a tiered double-digit percentage of net sales of products developed under the collaboration, if any. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement with Biogen, we received an upfront license fee of $20.0 million. Biogen will reimburse us for agreed upon costs incurred in connection with research and development activities conducted by us. In addition, we are eligible to receive development milestone payments upon the achievement of specified regulatory, clinical development and commercialization milestones. We will also be eligible to receive incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product, if any. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flow </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating activities. <font style="font-weight:normal;">Net cash used in operating activities for the three months ended March 31, 2015 was $2.4 million. Net cash provided by operating activities for the three months ended March 31, 2014 was $11.4 million. Net cash used in operating activities for the three months ended March 31, 2015 primarily reflected the increases in net loss for the period as well as a decrease in accounts receivable, accounts payable and accrued compensation, partially offset by the increases in stock-based compensation. Net cash used in operating activities for the three months ended March 31, 2014 primarily reflected the increases in deferred revenues related to our collaboration agreement with Biogen, accounts payable and stock-based compensation, partially offset by an increase in accounts receivable and decrease in accrued compensation. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing activities. <font style="font-weight:normal;">Net cash provided in investing activities for the three months ended March 31, 2015 was $18.4 million, while cash provided by investing activities was $3.9 million for the three months ended March 31, 2014. Cash flows from investing activities for both periods primarily related to purchases and maturities of investments. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing activities. <font style="font-weight:normal;">Net cash provided by financing activities for the three months ended March 31, 2015 and 2014 was $3.2 million and $101.4 million, respectively. Net cash provided by financing activities for the three month period ended March 31, 2015 was primarily related to the issuance of common stock upon exercise of stock options. Net cash provided by financing activities for the three month period ended March 31, 2014 was primarily attributable to $93.8 million in net proceeds from the public offering of the Company&#8217;s common stock completed in March 2014 as well as proceeds from the issuance of common stock upon exercise of stock options. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Capital and Capital Expenditure Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate continuing to incur operating losses for at least the next several years. While our rate of cash usage may increase in the future, in particular to support our product development endeavors, we believe that the available cash resources as well as funds received from corporate collaborators, strategic partners and research grants will enable us to maintain our currently planned operations through 2016. Future capital requirements will be substantial, and if our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital to fund our operations, including ZFP Therapeutic development activities, through equity or debt financing. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to develop our technology and our ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors and are not limited to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the initiation, progress, timing and completion of clinical trials for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the outcome, timing and cost of regulatory approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the success of our collaboration with Shire, Biogen and other partners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">delays that may be caused by changing regulatory requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the number of product candidates that we pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and terms of future in-licensing and out-licensing transactions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of procuring clinical and commercial supplies of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or invest in businesses, products or technologies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of litigation. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;<font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top" style="width:88.67%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Quantitative_and_Qualitative"></a>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary exposure to market risk is interest income sensitivity relating to our cash, cash equivalents and investments, which is affected by changes in the general level of U.S. interest rates. We do not have any foreign currency or other derivative financial instruments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our market risks at March 31, 2015 have not changed materially from those discussed in Item&#160;7A of our Form 10-K for the year ended December&#160;31, 2014 on file with the SEC. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IT<font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EM&#160; 4.</font></p></td>
<td valign="top" style="width:88.67%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Controls_and_Procedures"></a>CONTROLS AND PROCEDURES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, and not absolute, assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As required by the Securities and Exchange Commission Rule 13a-15(b), we carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Change in Internal Control over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II. OTHER INFORMATION </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 1.</p></td>
<td valign="top" style="width:88.67%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Legal_Proceedings"></a>LEGAL PROCEEDINGS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not party to any material pending legal proceedings. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 1A.</p></td>
<td valign="top" style="width:88.67%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Risk_Factors"></a>RISK FACTORS </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An investment in our common stock involves significant risk. You should carefully consider the information described in the following risk factors, together with the other information appearing elsewhere in this report, before making an investment decision regarding our common stock. While the risk factors set forth below update and supplement the risk factors set forth in our Annual Report on Form 10-K for the year ended December&#160;31, 2014 (2014 Annual Report), you should review our 2014 Annual Report, including the section under the caption &#8220;Item 1A. Risk Factors,&#8221; together with the other information appearing elsewhere in this report, before making an investment decision regarding our common stock. If any of the risks described below or in our 2014 Annual Report actually occur, our business, financial conditions, results of operation and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or a part of your investment in our common stock. Moreover, the risks described below and in our 2014 Annual Report are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects or financial condition. You should carefully consider these risk factors, together with all of the other information included in this Form 10-Q as well as our other publicly available filings with the Securities and Exchange Commission. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Development, Commercialization and Regulatory Approval of our Products and Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ZFP Therapeutics have undergone limited testing in humans and our ZFP Therapeutics may fail safety studies in clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are conducting an on-going Phase 2 clinical trial (SB-728-mR-1401) of our ZFP Therapeutics for the treatment of HIV/AIDS. Preliminary data from these studies demonstrates that treatment of aviremic HIV-infected subjects with SB-728-T has been well-tolerated. In addition, data from Phase 1 and several Phase 2 clinical trials of our ZFP Therapeutic, SB-509, for diabetic neuropathy and ALS demonstrated that the drug was well tolerated in these studies. However, if one of our ZFP Therapeutic fails one of its safety studies, it could reduce our ability to attract new investors and corporate partners. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of these studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic approach. Our clinical studies are a highly visible test of our ZFP Therapeutics and our investors assess the value of our technology primarily based on the continued progress of ZFP Therapeutic products into and through clinical trials. If clinical trials of our ZFP Therapeutic products were halted due to safety concerns, this would negatively affect our operations and the value of our stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our progress in early Phase 1 and Phase 2 trials may not be indicative of long-term efficacy in late stage clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results in early phases of clinical testing are based upon limited numbers of patients and a limited follow-up period. Typically, our Phase 1 clinical trials for indications of safety enroll less than 25 patients. Our Phase 2 and late-stage clinical trials generally enroll a larger number of patients. Accordingly, any positive data obtained in early Phase 1 and Phase 2 trials may not be indicative of long-term efficacy in late-stage clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2011, we announced preliminary data from our Phase 1 clinical program to develop SB-728-T for the treatment of HIV/AIDS. The data demonstrated a statistically significant relationship between SB-728-T and the reduction of HIV viral load. In January 2012, we initiated a Phase 2 clinical study (SB-728-902, Cohort 5) and a Phase 1/2 clinical study (SB-728-1101) for the treatment of HIV/AIDS. In December 2013, we presented data from all cohorts of these two clinical trials. Three of seven evaluable subjects in Cohort 5 showed a decrease of greater than one log in their viral load during a sixteen week treatment interruption (TI) with one subject achieving a transiently undetectable viral load during the TI period and one subject achieving control of their viral load during TI for a prolonged period (&gt;70 weeks as of January 2015). In subjects in which viral load decreased, a measurable anti-HIV immune response was also observed. Additional data were presented from the Company&#8217;s Phase 1 study (SB-728-902, Cohorts 1-3) that demonstrated a long-term decrease in the peripheral blood mononuclear cell (PBMC) HIV reservoir using a sensitive test for integrated HIV DNA in nine of nine subjects over a 36 month period (median decrease 0.9 logs). Additional subjects were enrolled into the SB-728-1101 study to define the optimum dose of Cytoxan required to safely enhance engraftment and an additional 12 subjects have been enrolled to further test this dose including nine subjects in an ongoing Phase 2 clinical trial (SB-728mR-T-1401) that is also testing repeat dosing of modified T-cells. However, there is no guarantee that these and other future studies of SB-728-T in later stage trials involving larger patient groups may produce positive or similar results as those obtained in earlier trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials even after achieving promising results in earlier stage clinical trials. If a larger population of patients does not experience positive results, or if these results are not reproducible, our products may not receive approval from the FDA. Failure to confirm favorable results from earlier trials by demonstrating the safety and effectiveness of our ZFP Therapeutic products in late stage clinical trials with larger patient populations could have a material adverse effect on our business that would cause our stock price to decline significantly. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process, and we may encounter unanticipated toxicity or adverse events or fail to demonstrate efficacy, causing us to delay, suspend or terminate the development of a ZFP Therapeutic. If these potential products are not approved, we will not be able to commercialize those products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA must approve any human therapeutic product before it can be marketed in the United States. The process for receiving regulatory approval is long and uncertain, and a potential product may not withstand the rigors of testing under the regulatory approval processes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before commencing clinical trials in humans, we must submit an IND application to the FDA. The FDA has 30 days to comment on the application, and if the agency has no comments, we or our commercial partner may begin clinical trials. While we have stated our intention to file additional IND applications in the future, this is only a statement of intent, and we may not be able to do so because the associated product candidates may not meet the necessary preclinical requirements. In addition, there can be no assurance that, once filed, an IND application will result in the actual initiation of clinical trials. Clinical trials are subject to oversight by institutional review boards and the FDA. In addition, our proposed clinical studies require review from the Recombinant DNA Advisory Committee (RAC), which is the advisory board to the National Institutes of Health (NIH), focusing on clinical trials involving gene transfer. We will typically submit a proposed clinical protocol and other product-related information to the RAC three to six months prior to the expected IND application filing date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">must be conducted in conformance with the FDA&#8217;s good clinical practices, within the guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and other applicable regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">must meet requirements for Institutional Review Board (IRB) oversight; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">must follow Institutional Biosafety Committee (IBC) and NIH RAC guidelines where applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">must meet requirements for informed consent; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">are subject to continuing FDA oversight; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">may require oversight by a Data Safety Monitoring Board (DSMB); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">may require large numbers of test subjects;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">may be suspended by a commercial partner, the FDA, or us at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or if the FDA finds deficiencies in the IND application or the conduct of these trials. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">While we have stated our goal is to file IND applications for several ZFP Therapeutic programs in the future, we may encounter difficulties that may delay, suspend or scale back our efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have previously announced a strategy for our ZFP Therapeutic programs that enables the potential filing of two to four new IND applications per year in the foreseeable future.&nbsp;&nbsp;The preparation and submission of IND applications requires us to conduct rigorous and time-consuming preclinical testing, studies, and documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and clinical protocol of new ZFP Therapeutic products. We may experience unforeseen difficulties that could delay or otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of our ZFP Therapeutic products and fail to demonstrate consistency in the formulation of the drug. Our preclinical tests may produce negative or inconclusive results, which may lead us to decide, or regulators may require us, to conduct additional preclinical testing. If we cannot obtain positive results in preclinical testing, we may decide to abandon the projects altogether. In addition, our ability to complete and file certain IND applications depends on the support of our partners and the timely performance of their obligations under relevant collaboration agreements.&#160;If our partners are not able to perform such obligations or if they choose to slow down or delay the progress, we may not be able to prepare and file the intended IND applications on a timely basis or at all. Furthermore, the filing of several IND applications involves significant cost and labor, and we may not have sufficient resources and personnel to complete the filing of all intended IND applications, which may force us to scale back the number of IND applications or forego potential IND applications that we believe are promising. Any delay, suspension or reduction of our efforts to pursue our preclinical and IND strategy could have a material adverse effect on our business and cause our stock price to decline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to find acceptable patients or may experience delays in enrolling patients for our clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience difficulties or delays in recruiting and enrolling a sufficient number of patients to participate in our clinical trials due to a variety of reasons, including competition from other clinical trial programs for the same indication, failure of patients to meet our enrollment criteria and premature withdraws of patients prior to the completion of clinical trials. The FDA and institutional review boards may also require large numbers of patients, and the FDA may require that we repeat a clinical trial. Any delay resulting from our failure to enroll a sufficient number of patients on a timely basis may have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, we cannot predict the timing of any future revenue from these product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize any of our ZFP Therapeutics to generate revenue until the appropriate regulatory authorities have reviewed and approved the applications for the product candidates. We cannot ensure that the regulatory agencies will complete their review processes in a timely manner or that we will obtain regulatory approval for any product candidate that we or our collaborators develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. Regulatory approval processes outside the United States include all of the risks associated with the FDA approval process. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited experience in conducting clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced clinical program is our Phase&#160;2 trials to evaluate the safety and efficacy of a ZFP Therapeutic for HIV/AIDS. However, the FDA will require additional clinical testing which involves significantly greater resources, commitments and expertise and so it is likely that we would need to enter into a collaborative relationship with a pharmaceutical company that could assume responsibility for late-stage development and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience in conducting advanced clinical trials and may not possess the necessary resources and expertise to complete such trials. We have entered into collaborative agreements with Shire and Biogen to provide funding and assistance in the development of our ZFP Therapeutics through the clinical trial process. Under the agreement with Shire, we are responsible for all activities through submission of IND applications and European CTAs and Shire is responsible for clinical development and commercialization of products arising from the alliance. Under the agreement with Biogen, we are responsible for all research and development through the first human clinical trial for the treatment of beta-thalassemia and both parties are responsible for research and development through the submission of IND for ZFP Therapeutics to treat sickle cell disease (SCD). However, there is no guarantee that we will be able to enter into future collaborative relationships with third parties that can provide us with the funding and expertise for later stage trials. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulatory approval, if granted, will be limited to specific uses or geographic areas, which could limit our ability to generate revenues. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory approval will be limited to the indicated use for which we can market a product. Further, once regulatory approval for a product is obtained, the product and its manufacturer are subject to continual review. Discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product, manufacturer, and manufacturing facility, including withdrawal of the product from the market. In Japan and Europe, regulatory agencies also set or approve prices. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if regulatory clearance of a product is granted, this clearance is limited to those specific states and conditions for which the product is useful, as demonstrated through clinical trials. We cannot ensure that any ZFP Therapeutic product developed by us, alone or with others, will prove to be safe and effective in clinical trials and will meet all of the applicable regulatory requirements needed to receive marketing clearance in a given country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, our ability to market a product is contingent upon receiving a marketing authorization from appropriate regulatory authorities; therefore we cannot predict whether or when we would be permitted to commercialize our product. These foreign regulatory approval processes include all of the risks associated with FDA clearance described above. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Commercialization of our technologies will depend, in part, on strategic partnering with other companies. If we are not able to find partners in the future or if our partners do not diligently pursue product development efforts, we may not be able to develop our technologies or products, which could slow our growth and decrease the value of our stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to rely, to some extent, on our strategic partners to provide funding in support of our research and to perform independent research and preclinical and clinical testing. Our technology is broad-based, and we do not currently possess the resources necessary to fully develop and commercialize potential products that may result from our technologies or the resources or capabilities to complete the lengthy marketing approval processes that may be required for the products. Therefore, we plan to rely on strategic partnerships to help us develop and commercialize ZFP Therapeutic products. If we are unable to find partners or if the partners we find, such as Shire and Biogen, are unable or unwilling to advance our programs, or if they do not diligently pursue product approval, this may slow our progress and adversely affect our ability to generate revenues. In addition, our partners may sublicense or abandon development programs or we may have disagreements or disputes with our partners, which would cause associated product development to slow or cease. In addition, the business or operations of our partners may change significantly through restructuring, acquisition or other strategic transactions or decisions that may negatively impact their ability to advance our programs. There can be no assurance that we will be able to establish further strategic collaborations for ZFP Therapeutic product development. We may require significant time to secure collaborations or partners because we need to effectively market the benefits of our technology to these future collaborators and partners, which may direct the attention and resources of our research and development personnel and management away from our primary business operations. Further, each collaboration or partnering arrangement will involve the negotiation of terms that may be unique to each collaborator or partner. These business development efforts may not result in a collaboration or partnership. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loss of partnering agreements would not only delay or terminate the potential development or commercialization of products we may derive from our technologies, but it may also delay or terminate our ability to test ZFP Therapeutic candidates for specific genes. If any partner fails to conduct the collaborative activities successfully or in a timely manner, the preclinical or clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under typical partnering agreements, we would expect to receive revenue for the research and development of a ZFP Therapeutic product based on achievement of specific milestones, as well as royalties based on a percentage of sales of the commercialized products. Achieving these milestones will depend, in part, on the efforts of our partner as well as our own. If we, or any partner, fail to meet specific milestones, then the partnership may be terminated, which could reduce our revenues. For more information on risks relating to our third party collaborative agreements, see &#8220;Risks Relating to our Collaborative Relationships.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to license gene transfer technologies that we may need to commercialize our ZFP technology. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to regulate or modify a gene in a cell, the ZFP must be efficiently delivered to the cell. We have licensed certain gene transfer technologies for our ZFP in research including AAV and mRNA technology. We are evaluating these systems and other technologies that may need to be used in the delivery of ZFP into cells for <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> applications, including ZFP Therapeutics. However, we may not be able to license the gene transfer technologies required to develop and commercialize our ZFP Therapeutics. We have not developed our own gene transfer technologies, and we rely on our ability to enter into license agreements to provide us with rights to the necessary gene transfer technology. Our approach has been to license appropriate technology as required. The inability to obtain a license to use gene transfer technologies with entities which own such technology on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of our therapeutic product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our gene regulation and genome editing technology is relatively new, and if we are unable to use this technology in all our intended applications, it would limit our revenue opportunities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology involves a relatively new approach to gene regulation and genome editing. Although we have generated ZFPs for thousands of gene sequences, we have not created ZFPs for all gene sequences and may not be able do so, which could limit the usefulness of our technology. In addition, while we have demonstrated the function of engineered ZFNs and ZFP TFs in mammalian cells, yeast, insects, plants and animals, we have not yet demonstrated clinical efficacy of this technology in a controlled clinical trial in humans, and the failure to do so could restrict our ability to develop commercially viable products. If we, and our collaborators or strategic partners, are unable to extend our results to new commercially important genes, experimental animal models, and human clinical studies, we may be unable to use our technology in all its intended applications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected value and utility of our ZFNs and ZFP TFs is in part based on our belief that the targeted editing of genes or specific regulation of gene expression may enable us to develop a new therapeutic approach as well as to help scientists better understand the role of genes in disease, and to aid their efforts in drug discovery and development. We also believe that ZFP-mediated targeted genome editing and gene regulation will have utility in agricultural applications. There is only a limited understanding of the role of specific genes in all these fields. Life sciences companies have developed or commercialized only a few products in any of these fields based on results </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from genomic research or the ability to regulate gene expression. We, our collaborators or our strategic partners, may not be able to use our technology to identify and validate drug targets or to develop commercial products in the intended markets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective delivery of ZFNs and ZFP TFs into the appropriate target cells and tissues is critical to the success of the therapeutic applications of our ZFP technology. In order to have a meaningful therapeutic effect, the ZFP Therapeutic must be delivered to sufficient numbers of cells in the targeted tissue. The ZFN or ZFP TF must be present in that tissue for sufficient time to effect either modification of a therapeutically relevant gene or regulation of its expression. In our current clinical and preclinical programs, we administer our ZFP Therapeutics as a nucleic acid that encodes the ZFN or ZFP TF. We use different formulations to deliver the ZFP Therapeutic depending on the required duration of expression, the targeted tissue and the indication that we intend to treat. However, there can be no assurances that we will be able to effectively deliver our ZFNs and ZFP TFs to produce a beneficial therapeutic effect. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are conducting proprietary research to discover ZFP Therapeutic product candidates. These programs increase our financial risk of product failure, may significantly increase our research expenditures, and may involve conflicts with future collaborators and strategic partners. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary research programs consist of research that is funded solely by us or by grant funding and in which we retain exclusive rights to therapeutic products generated by such research. This is in contrast to certain of our research programs that may be funded by corporate partners in which we may share rights to any resulting products. Conducting proprietary research programs may not generate corresponding revenue and may create conflicts with our collaborators or strategic partners over rights to our intellectual property with respect to our proprietary research activities. Any conflict with our collaborators or strategic partners could reduce our ability to enter into future collaborations or partnering agreements and negatively impact our relationship with existing collaborators and partners that could reduce our revenue and delay or terminate our product development. As we continue to focus our strategy on proprietary research and therapeutic development, we expect to experience greater business risks, expend significantly greater funds and require substantial commitments of time from our management and staff. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our technology proves to be effective, it still may not lead to commercially viable products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our collaborators or strategic partners are successful in using our ZFP technology in drug discovery, protein production, therapeutic development or plant agriculture, they may not be able to commercialize the resulting products or may decide to use other methods competitive with our technology. To date, no company has received marketing approval or has developed or commercialized any therapeutic or agricultural products based on our technology. Should our technology fail to provide safe, effective, useful or commercially viable approaches to the discovery and development of these products, this would significantly limit our business and future growth and would adversely affect our value. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our product development efforts are successful and even if the requisite regulatory approvals are obtained, our ZFP&#160;Therapeutics may not gain market acceptance among physicians, patients, healthcare payers and the medical community. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of additional factors may limit the market acceptance of our ZFP Therapeutic products including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">rate of adoption by healthcare practitioners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">rate of a product&#8217;s acceptance by the target population; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">timing of market entry relative to competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">availability of alternative therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">price of our product relative to alternative therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">availability of third-party reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">extent of marketing efforts by us and third-party distributors or agents retained by us;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">side effects or unfavorable publicity concerning our products or similar products. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, even after we have obtained the required regulatory approval for our ZFP Therapeutic products, we may not be able to commercialize these products successfully if we cannot achieve an adequate level of market acceptance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We currently rely on third parties to conduct some or all aspects of manufacturing of our ZFP Therapeutic product candidates for preclinical and clinical development.&nbsp;&nbsp; </font>If one of our third-party manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts, to find new suppliers or manufacturers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have limited experience in, and we do not own facilities for, clinical-scale manufacturing of our product candidates and we rely upon third-party contract manufacturing organizations to manufacture and supply drug product for our preclinical and clinical studies.&nbsp;&nbsp;The manufacture of pharmaceutical products in compliance with the FDA&#8217;s current good manufacturing practices (cGMP), requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide study drugs in our clinical studies would be jeopardized. Any delay or interruption in the supply of clinical study materials could delay the completion of our clinical studies, increase the costs associated with maintaining our clinical study programs and, depending upon the period of delay, require us to commence new studies at significant additional expense or terminate the studies completely.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All manufacturers of our product candidates must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have little control over our manufacturers&#8217; compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall or withdrawal of product approval. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical studies, regulatory submissions, approvals or commercialization of our product candidates, entail higher costs or impair our reputation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current agreements with our suppliers do not provide for the entire supply of the drug product necessary for all anticipated clinical studies or for full scale commercialization. If we and our suppliers cannot agree to the terms and conditions for them to provide the drug product necessary for our clinical and commercial supply needs, we may not be able to manufacture the product candidate until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers, which could have a material adverse effect on our business. New suppliers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not currently have the infrastructure or capability to manufacture, market and sell therapeutic products on a commercial scale. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order for us to commercialize our therapeutic products directly, we would need to develop, or obtain through outsourcing arrangements, the capability to manufacture, market and sell our products on a commercial scale. Currently, we do not have the ability nor the financial resources to establish the infrastructure and organizations needed to execute these functions, including such infrastructure needed for the commercialization of any product from our HIV/AIDS or AD programs, which can be complex and costly. If we are unable to establish adequate manufacturing, sales, marketing and distribution capabilities, we will not be able to directly commercialize our therapeutics products, which would limit our future growth. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Industry </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our competitors develop, acquire, or market technologies or products that are more effective than ours, this would reduce or eliminate our commercial opportunity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products that we or our collaborators or strategic partners develop by using our ZFP technology platform will enter into highly competitive markets. Even if we are able to generate ZFP Therapeutics that are safe and effective for their intended use, competing technologies may prove to be more effective or less expensive, which, to the extent these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and less expensive. Competing technologies may include other methods of regulating gene expression or modifying genes. ZFNs and ZFP TFs have broad application in the life sciences industry and compete with a broad array of new technologies and approaches being applied </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to genetic research by many companies. Competing proprietary technologies with our product development focus include but are not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">For ZFP Therapeutics: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">small molecule drugs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">monoclonal antibodies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">recombinant proteins; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">gene therapy/cDNAs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">antisense; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">siRNA and microRNA approaches, exon skipping; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">CRISPR/Cas9 technology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">TALE proteins and MegaTALs; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">meganucleases. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">For our Non-Therapeutic Applications: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">For protein production:</font><font style="font-family:Times New Roman;"> gene amplification, meganucleases, TALE technology, insulator technology, mini-chromosomes and CRISPR/Cas9 technology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">For target validation:</font><font style="font-family:Times New Roman;"> antisense, siRNA, TALE technology and CRISPR/Cas9 technology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">For plant agriculture:</font><font style="font-family:Times New Roman;"> recombination approaches, mutagenesis approaches, meganucleases, TALE technology, CRISPR/Cas9 technology, mini-chromosomes; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.67%;margin-left:11.33%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">For transgenic animals:</font><font style="font-family:Times New Roman;"> somatic nuclear transfer, embryonic stem cell, TALE, CRISPR/Cas9 technology and transposase technologies. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to possessing competing technologies, our competitors include pharmaceutical and biotechnology companies with: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">substantially greater capital resources than ours; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">larger research and development staffs and facilities than ours;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">greater experience in product development and in obtaining regulatory approvals and patent protection. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These organizations also compete with us to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">attract qualified personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">attract parties for acquisitions, joint ventures or other collaborations;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">license the proprietary technologies of academic and research institutions that are competitive with our technology, which may preclude us from pursuing similar opportunities. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us. In addition, any products that we develop may compete with existing products or services that are well established in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adverse public perception in the field of gene therapy may negatively impact regulatory approval of, or demand for, our potential products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our potential therapeutic products are delivered to patients as gene-based drugs, or gene therapy. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy is unsafe, and, consequently, our products may not gain the acceptance of the public or the medical community. Negative public reaction to gene therapy in general could result in greater government regulation and stricter labeling requirements of gene therapy products, including any of our products, and could cause a decrease in the demand for any products we may develop. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Laws or public sentiment may limit the production of genetically modified agricultural products, and these laws could reduce our partner&#8217;s ability to sell such products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genetically modified products are currently subject to public debate and heightened regulatory scrutiny, either of which could prevent or delay production of agricultural products. We have a research license and commercial option agreement with DAS through which we provide DAS with access to our proprietary ZFP technology and the exclusive right to use our ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants or plant cell cultures. The field-testing, production and marketing of genetically modified plants and plant products are subject to federal, state, local and foreign governmental regulation. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of our genetically modified products in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our product development programs or the commercialization of resulting products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA currently applies the same regulatory standards to foods developed through genetic engineering as those applied to foods developed through traditional plant breeding. Genetically engineered food products, however, will be subject to pre-market review if these products raise safety questions or are deemed to be food additives. Governmental authorities could also, for social or other purposes, limit the use of genetically modified products created with our gene regulation technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the regulatory approval for genetically modified products developed under our agreement with DAS was obtained, our success will also depend on public acceptance of the use of genetically modified products including drugs, plants, and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public attitudes. Our genetically modified products may not gain public acceptance. The subject of genetically modified organisms has received negative publicity in the United States and particularly in Europe, and such publicity has aroused public debate. The adverse publicity in Europe could lead to greater regulation and trade restrictions on imports of genetically altered products. Similar adverse public reaction or sentiment in the United States to genetic research and its resulting products could result in greater domestic regulation and could decrease the demand for our technology and products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Finances </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have generated operating losses since we began operations in 1995. Our net losses for the years ended December&#160;31, 2014, 2013 and 2012 were $26.4 million, $26.6 million and $22.3 million, respectively. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZFP technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. As of March 31, 2015, we had an accumulated deficit of $333.9 million. Since our IPO in 2000, we have generated an aggregate of approximately $331.4 million in gross proceeds from the sale of our equity securities. We expect to continue to incur additional operating losses for the next several years as we continue to advance our ZFP Therapeutic product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to raise additional capital, which would harm our ability to develop our technology and products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and ZFP Therapeutic product development activities. While we believe our financial resources will be adequate to sustain our current operations at least through 2016, we may need to seek additional sources of capital through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approval of potential products, a process that could cost in excess of hundreds of millions of dollars per product. Furthermore, we may experience difficulties in accessing the capital market due to external factors beyond our control such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will materially adversely affect our business and our ability to develop our technology and ZFP Therapeutic products. Furthermore, any sales of additional equity securities may result in dilutions to our stockholders and any debt financing may include business and financial covenants that restricts our operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are at the development phase of operations and may not succeed or become profitable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We began operations in 1995 and are in the early phases of ZFP Therapeutic product development, and we have incurred significant losses since inception. To date, our revenues have been generated from collaboration agreements, other collaborations in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. Our focus on higher-value therapeutic product development and related collaboration requires us to incur substantial expenses associated with product development. In addition, the preclinical or clinical failure of any single product may have a significant effect on the actual or perceived value of our stock. Our business is subject to all of the risks inherent in the development of a new technology, which includes the need to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">attract and retain qualified scientific and technical staff and management, particularly scientific staff with expertise to develop our early-stage technology into therapeutic products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">obtain sufficient capital to support the expense of developing our technology platform and developing, testing and commercializing products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">develop a market for our products; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">successfully transition from a company with a research focus to a company capable of supporting commercial activities. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Relationships with Collaborators and Strategic Partners </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in their self-interest, which may limit our ability to implement our strategies. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in its self-interest, which may limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our collaborators and strategic partners may control aspects of our clinical trials, which could result in delays and other obstacles in the commercialization of our proposed products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For some programs, we depend on third party collaborators and strategic partners to design and conduct our clinical trials. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these collaborators or strategic partners withdraws support for our programs or proposed products or otherwise impair their development; our business could be negatively affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2012, we entered into a collaborative agreement with Shire, pursuant to which we are engaging in a joint program with Shire to research, develop and commercialize human therapeutics and diagnostics for hemophilia, Huntington&#8217;s disease and other monogenic diseases based on our ZFP technology. Under this agreement, we are responsible for all research activities through the submission of an IND or CTA, while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in January 2014 we entered into a collaborative agreement with Biogen for the clinical development and commercialization of therapeutics based on our ZFP technology for hemoglobinopathies, including beta-thalassemia and SCD. Under the agreement, we are responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP Therapeutic developed for the treatment of beta-thalassemia. In the SCD program, both parties are responsible for research and development activities through the submission of an IND. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under these agreements with Biogen and Shire, they will have control and broad discretion over all or certain aspects of the clinical development and commercialization of any product developed under the agreements, and we will have little, if any, influence on how these programs will be conducted. Our lack of control over the clinical development in our agreement with Biogen and Shire could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from completing the intended IND filings in a timely fashion and receiving any milestone, royalty payments and other benefits under </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the agreement. In addition, under their respective agreement(s), Biogen and Shire have certain rights to terminate the agreements by providing us with advance notices, therefore, the actual milestone payments that we may receive under these agreements may be lower than the full amounts stated above. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our collaborators or strategic partners may decide to adopt alternative technologies or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of ZFP&#160;technology. Additionally, because many of our collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this would delay our ability to test our technology and would delay or terminate the development of potential products based on our ZFP technology. Further, our collaborators and strategic partners may elect not to develop products arising out of our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. If any of these events occur, we may not be able to develop our technologies or commercialize our products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not successfully commercialize ZFP-based research reagents, ZFP-modified cell lines for commercial protein production, or ZFP-engineered transgenic animals under our license agreement with Sigma-Aldrich Corporation or ZFP-based agricultural products with Dow AgroSciences, or if Sigma-Aldrich Corporation or Dow AgroSciences terminates our agreements, our ability to generate revenue under these license agreements may be limited. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2007, we entered into a license agreement with Sigma to collaborate in the application and development of ZFP-based products for use in the laboratory research reagents markets. The agreement provides Sigma with access to our ZFP&#160;technology and the exclusive right to use our ZFP technology to develop and commercialize products for use as research reagents and to offer services in related research fields. Under the agreement, Sigma has exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and, certain ZFP-engineered transgenic animals for commercial applications. In addition, under our license agreement with DAS relating to plant agriculture, DAS has the exclusive right to develop agricultural products using our ZFP technology in plant cells, plants or plant cell cultures. Both Sigma and DAS have the right to sublicense our technology in their respective areas. In addition to upfront payments, we may also receive additional license fees, shared sublicensing revenues, royalty payments and milestone payments depending on the success of the development and commercialization of the licensed products and services covered under both agreements. The commercial milestones and royalties are typically based upon net sales of licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that we or our collaboration partners will succeed in the development of commercially viable products in these fields of use, and there is no guarantee that we or our collaboration partners will achieve the milestones set forth in the respective license agreements. To the extent we or our collaboration partners do not succeed in developing and commercializing products or if we or our collaboration partners fail to achieve such milestones, our revenues and benefits under the license agreements will be limited. In addition, the respective license agreements may be terminated by Sigma and DAS at any time by providing us with a 90-day notice. In the event Sigma or DAS decides to terminate the license agreements, our ability to generate revenue under such license agreements will cease. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our collaborations with outside scientists may be subject to change, which could limit our access to their expertise. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We work with scientific advisors and collaborators at academic research institutions. These scientists are not our employees and may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. Although our scientific advisors and academic collaborators sign agreements not to disclose our confidential information, it is possible that some of our valuable proprietary knowledge may become publicly known through them, which may cause competitive harm to our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Intellectual Property and Business Operation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because it is difficult and costly to protect our proprietary rights, and third parties have filed patent applications that are similar to ours, we cannot ensure the proprietary protection of our technologies and products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend in part on obtaining patent protection of our technology and successfully defending any of our patents that may be challenged. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and can involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in patents we own or license. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to various license agreements that give us rights under specified patents and patent applications. Our current licenses, as our future licenses frequently will, contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may be forced to delay or terminate our product development and research activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our present and any future sublicenses, since our rights derive from those granted to our sublicensor, we are subject to the risk that our sublicensor may fail to perform its obligations under the master&#160;license or fail to inform us of useful improvements in, or additions to, the underlying intellectual property owned by the original licensor. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are unable to exercise the same degree of control over intellectual property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent applications may not be prosecuted as we desire or in a timely manner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we or our licensors were the first to make the inventions covered by each of our pending patent applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we or our licensors were the first to file patent applications for these inventions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the patents of others will not have an adverse effect on our ability to do business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">any of our pending patent applications will result in issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">any patents issued or licensed to us or our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">any patents issued or licensed to us will not be challenged and invalidated by third parties;&#160;or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we will develop additional products, processes or technologies that are patentable. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE, CRISPR/Cas9 and other DNA-binding proteins, and that these groups and companies have filed patent applications. Several patents have been issued, although we have no current plans to use the associated inventions. If these or other patents issue, it is possible that the holder of any patent or patents granted on these applications may bring an infringement action against our collaborators, strategic partners, or us claiming damages and seeking to enjoin commercial activities relating to the affected products and processes. The costs of litigating the claim could be substantial. Moreover, we cannot predict whether we, our collaborators, or strategic partners would prevail in any actions. In addition, if the relevant patent claims were upheld as valid and enforceable and our products or processes were found to infringe the patent or patents, we could be prevented from making, using, or selling the relevant product or process unless we could obtain a license or were able to design around the patent claims. We can give no assurance that such a license would be available on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent claims. There may be significant litigation in the genomics industry regarding patent and other intellectual property rights, which could subject us to litigation. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets, however, are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information or enforce these confidentiality agreements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaborators, strategic partners, and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be able to receive patent protection or protect our proprietary information. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in molecular and cellular biology. We routinely use cells in culture and gene delivery vectors, and we employ small amounts of radioisotopes in trace experiments. Although we maintain up-to-date licensing and training programs, we cannot completely eliminate the risk of accidental contamination or injury </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the use, storage, handling, or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials. However, if we are unable to maintain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. To date, we have not experienced significant costs in complying with regulations regarding the use of these materials. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to attract, retain, and motivate skilled personnel and cultivate key academic collaborations will delay our product development programs and our research and development efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends on our continued ability to attract, retain, and motivate highly qualified management and scientific personnel and our ability to develop and maintain important relationships with leading research and academic institutions and scientists. Competition for skilled and qualified personnel and academic and other research collaborations is intense. We have experienced a rate of employee turnover that we believe is typical of emerging biotechnology companies. If we lose the services of personnel with the necessary skills, including the members of our senior management team, it could significantly impede the achievement of our research and development objectives. If we fail to negotiate additional acceptable collaborations with academic and other research institutions and scientists, or if our existing collaborations are unsuccessful, our ZFP Therapeutic development programs may be delayed or may not succeed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Common Stock and Corporate Organization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2015, the closing price of our common stock, as reported by the NASDAQ Global Select Market, ranged from a low of $12.64 to high of $18.54. During the fiscal year ended December&#160;31, 2014, our common stock price fluctuated, ranging from a low of $9.85 to a high of $23.86. Volatility in our common stock could cause stockholders to incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response to various factors, some of which are beyond our control, including but not limited to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">announcements by us or collaborators providing updates on the progress or development status of ZFP Therapeutics; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">data from clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">initiation or termination of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">changes in market valuations of similar companies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">overall market and economic conditions, including the equity markets for emerging biotechnology companies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">deviations in our results of operations from the guidance given by us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">announcement of changes in business and operations by our collaborators and partners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">additions or departures of key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">future sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">decreases in our cash balances; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">changes, by one or more of Sangamo&#8217;s security analysts, in recommendations, ratings or coverage of our stock. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price is also influenced by public perception of gene therapy and government regulation of potential products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked severe combined immunodeficiency (X-linked SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in gene therapy. Stock prices of these companies declined whether or not the specific company was involved with retroviral gene transfer for the treatment of infants with X-linked SCID, or whether the specific company&#8217;s clinical trials were placed on hold in connection with these events. Other potential adverse events in the field of gene therapy may occur in the future that could result in greater governmental regulation of our potential </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products and potential regulatory delays relating to the testing or approval of our potential products. These external events may have a negative impact on public perception of our business, which could cause our stock price to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anti-takeover provisions in our certificate of incorporation and Delaware law could make an acquisition of the Company more difficult and could prevent attempts by our stockholders to remove or replace current management. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000&#160;shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our bylaws: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">state that stockholders may not act by written consent but only at a stockholders&#8217; meeting; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#8217; meetings;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">prohibit stockholders from calling a special meeting of stockholders. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to Section&#160;203 of the Delaware General Corporation Law, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#8220;interested stockholder&#8221; and may not engage in &#8220;business combinations&#8221; with us for a period of three years from the time the person acquired 15% or more or our voting stock.&nbsp;&nbsp;The application of Section 203 may, in some circumstances, deter or prevent a change in control of our company even when such change may be beneficial to our stockholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.33%;text-indent:-11.33%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;6. </p></td>
<td valign="top" style="width:88.67%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Exhibits"></a>EXHIBITS </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Exhibits: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1&#8224;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, Development and Commercialization Agreement dated October&#160;24, 2006 between Sangamo and Juvenile Diabetes Research Foundation International.</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2&#8224;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Amendment to the Research, Development and Commercialization Agreement between Sangamo and Juvenile Diabetes Research Foundation International, dated January 8, 2010.</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rule 13a &#8212; 14(a) Certification by President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rule 13a &#8212; 14(a) Certification by Principal Financial and Accounting Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification Pursuant to 18 U.S.C. Section 1350</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-top:6pt;margin-bottom:0pt;margin-right:73.89%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&#8224;</sup><sup style="font-size:85%; vertical-align:top"> </sup><font style="font-style:italic;">The Company is filing a full and unredacted version of the agreement following the expiration of the confidential treatment order previously granted by the Securities and Exchange Commission.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: April 28, 2015 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO BIOSCIENCES, INC.</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ H. W<font style="font-size:7.5pt;">ARD</font> W<font style="font-size:7.5pt;">OLFF</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H. Ward Wolff</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive&#160;Vice&#160;President&#160;and&#160;Chief&#160;Financial&#160;Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sgmo-ex101_20150331717.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:center;margin-top:250pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</p>
<p style="text-align:center;margin-top:36pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">by and between</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Juvenile Diabetes Research Foundation International</p>
<p style="margin-top:250pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">page</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS.</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.1</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Affiliate</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.2</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.3</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.4</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Application</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.5</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Award</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.6</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Award Received</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.7</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercially Reasonable Efforts</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.8</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Information</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.9</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Controlled</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.10</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Default</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.11</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diabetes</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.12</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dispute</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.13</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dollars</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.14</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.15</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.16</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Field</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.17</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Commercial Sale</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.18</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Five Percent Payment</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.19</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funding Date</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.20</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAAP</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.21</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnitee</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.22</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interruption</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.23</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interruption License</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.24</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interruption Notice</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.25</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interruption Response</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.26</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JDRF </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.27</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JDRF Designees </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.28</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JDRF Indemnitee </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.29</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JDRF Interruption License Technology </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.30</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JDRF Patents </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1 .31</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JDRF Studies </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.32</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joint Invention </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.33</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joint Research Advisory Committee </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.34</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major Markets </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i-</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(CONTINUED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">page</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.35</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matched Funds </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.36</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.37</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NetSales</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.38</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Owner </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:4pt;">
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.39</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party(ies) </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.40</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.41</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Person </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.42</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Policies </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.43</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary Statistical Analysis </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.44</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prime Rate </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.45</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal Investigator </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.46</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.47</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Program Material </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.48</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Qualified Subject </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.49</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.50</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recipient </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.51</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recipient Notice Requirement </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.52</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registration </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.53</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Approval </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.54</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Plan </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.55</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Program </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.56</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Termination Date </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.57</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.58</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Designees </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.59</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Indemnitee </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.60</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Party </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.61</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sang&#225;mo Patents </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.62</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Research Program Technology </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.63</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Surrogate Endpoint Data</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.64</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Territory</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.65</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutic Candidate</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;1.66</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH PROGRAM</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;2.1</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overview</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-ii-</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(CONTINUED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;2.2</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencement of the Research Program</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;2.3</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Diligence</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3.1</p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally </p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3.2 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obligations of Sangamo</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;2.4</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modifications to JDRF Studies</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;2.5</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joint Research Advisory Committee</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.1 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Composition and Purposes</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.2 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Meetings</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.3 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discussions/Recommendations</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.4 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;2.6</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delivery of Adverse Event Data to the JRAC</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH FUNDING; RECORDS</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;3.1</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Funding</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1.1 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1.2 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitations</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1.3 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matched Funds</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1.4 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1.5 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;3.2</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Records; Reporting Obligations; Audits</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.1 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Records</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.2 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.3 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reports; Notices</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DILIGENCE; COMPENSATION TO JDRF</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.1</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and Commercialization of Product</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.2</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation to JDRF</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.3</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales Reports</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.4</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties to Sangamo</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE V</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIALITY</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;5.1</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1.1 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definition of Confidential Information</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1.2 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Disclosure</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1.3 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Required Disclosure</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1.4 </p></td>
<td valign="top"  style="width:72.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Use of Confidential Information</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;5.2</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publicity; Use of Name</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-iii-</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(CONTINUED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">page</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VI</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PUBLICATION</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VII</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INDEMNIFICATION</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;7.1</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by Sangamo</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;7.2</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by JDRF</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;7.3</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claims Procedures</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 7.4</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participation; Assuming Control of the Defense</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;7.5</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advance Payment of Expenses</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;7.6</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitation of Liability</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;7.7</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VIII</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PATENTABLE INVENTIONS</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;8.1</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;8.2</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preparation</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;8.3</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;8.4</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abandonment</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IX</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERM AND TERMINATION</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;9.1</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;9.2</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination by JDRF With Cause</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;9.3</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination for JDRF Breach</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;9.4</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Effect of Termination; Survival</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;9.5</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interruption License</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE X</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REPRESENTATIONS AND WARRANTIES</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations, Warranties and Covenants of Sangamo</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations and Warranties of JDRF</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XI</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS PROVISIONS</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governing Law</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dispute Resolution</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equitable Relief</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.6</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.7</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Counterparts</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.9</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Agency</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;11.10</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-iv-</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(CONTINUED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">page</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 11.11</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headings</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 11.12</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A<font style="font-weight:normal;"> &#8212; Research Plan</font></p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B<font style="font-weight:normal;"> &#8212; Research Funding and Milestones</font></p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C<font style="font-weight:normal;"> &#8212; JDRF Policies and Conditions Regarding Funding of Research Involving Human Clinical Trials</font></p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:14.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit D<font style="font-weight:normal;"> &#8212; Form of Press Release</font></p></td>
<td valign="top"  style="width:5.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:58.98%;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-v-</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made on this 24th day of October, 2006, by and between Sangamo BioSciences, Inc., a Delaware corporation, with its principal office at 501 Canal Boulevard, Suite A100, Richmond, CA 94804 (&#8220;<font style="text-decoration:underline;">Sangamo</font>&#8221;) and Juvenile Diabetes Research Foundation International, a Pennsylvania nonprofit corporation with its principal offices at 120 Wall Street, New York, NY 10005 (&#8220;<font style="text-decoration:underline;">JDRF</font>&#8221;).  This Agreement shall become effective on the Effective Date (as defined below). Sangamo and JDRF are each a &#8220;<font style="text-decoration:underline;">Party,</font>&#8221; and, collectively, the &#8220;<font style="text-decoration:underline;">Parties.</font>&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS,<font style="font-weight:normal;"> JDRF&#8217;s principal charitable mission is the discovery and development of a cure for diabetes and its complications, to which JDRF brings significant scientific and human resources and financial support;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS,<font style="font-weight:normal;"> Sangamo desires, among other things, to collect additional clinical endpoints during the Phase II Repeat Dosing Clinical Trial of SB-509 for the purpose of understanding the mechanistic basis of efficacy and reversal of neuropathy (as more fully described in the Research Plan); and</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS,<font style="font-weight:normal;"> JDRF wishes to support the Research Program.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE,<font style="font-weight:normal;"> in consideration of the mutual covenants set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I DEFINITIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this Agreement, the terms defined in this Article 1 shall have the following meanings whether used in their singular or plural forms. Use of the singular shall include the plural and vice versa, unless the context requires otherwise:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.1<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Affiliate</font><font style="font-weight:normal;">&#8221; shall mean, with respect to any Person, any other Person who directly or indirectly, by itself or through one or more intermediaries, controls, or is controlled by, or is under direct or indirect common control with, such Person. The term &#8220;control&#8221; means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. Control will be presumed if one Person owns, either of record or beneficially, more than fifty percent (50%) of the voting stock of any other Person.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.2<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Agreement</font><font style="font-weight:normal;">&#8221; means this agreement, together with all appendices, exhibits and schedules hereto, and as the same may be amended or supplemented from time to time hereafter by a written agreement duly executed by authorized representatives of each Party hereto.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.3<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Applicable Law</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 10.1(b).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.4<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Application</font><font style="font-weight:normal;">&#8221; shall mean Sangamo&#8217;s submitted Industry Discovery &amp; Development Partnerships Application, dated May 12, 2006 and approved by JDRF on June 29, 2006.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.5<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Award</font><font style="font-weight:normal;">&#8221; shall mean an amount up to, but not to exceed, Three Million Dollars ($3,000,000), which is to be paid by JDRF to Sangamo for the Research Program in accordance with the terms, and subject to the conditions, set forth in this Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.6<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Award Received</font><font style="font-weight:normal;">&#8221; shall mean the amount of the Award actually received by Sangamo from JDRF pursuant to this Agreement, not including any amounts refunded to JDRF pursuant to Section 3.2.3(b).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.7<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Commercially Reasonable Efforts</font><font style="font-weight:normal;">&#8221; shall mean a level of effort and application of expertise and resources that are consistent with a continuing intention to research, develop and commercialize the Product, including without limitation the reasonable time during which Sangamo is engaged in active efforts to identify a potential Third Party licensee or collaborator and negotiate a license or collaboration arrangement with such Third Party to research, develop and/or commercialize the Product, it being acknowledged by the Parties that there may be delays for regulatory or other reasons that are not within Sangamo's or its licensee&#8217;s, sublicensee's or transferee's control and such delays shall not constitute a cessation of Commercially Reasonable Efforts.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.8<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Confidential Information</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 5.1.1.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.9<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Controlled&#8221;</font><font style="font-weight:normal;"> (except in the context of Section 1.1) shall mean the legal authority or right of a Party to grant a license or sublicense of intellectual property rights to the other Party hereto, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.10<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Default</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 9.2.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.11<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Diabetes&#8221;</font><font style="font-weight:normal;"> shall mean any one and/or all of the human diseases commonly known as diabetes and the complications of such diseases.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.12<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Dispute&#8221;</font><font style="font-weight:normal;"> shall have the meaning set forth in Section 11.2(a).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.13<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Dollars</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 3.1.4.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.14<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Effective Date</font><font style="font-weight:normal;">&#8221; shall mean the date the last Party signs this Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.15<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">FDA</font><font style="font-weight:normal;">&#8221; shall mean the United States Food and Drug Administration, or any successor agency having regulatory jurisdiction over the manufacture, distribution and sale of drugs in the United States, and its territories and possessions.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.16<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Field</font><font style="font-weight:normal;">&#8221; shall mean the diagnosis, treatment and/or prevention of Diabetes in humans.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.17<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">First Commercial Sale</font><font style="font-weight:normal;">&#8221; shall mean the first sale of the Product by Sangamo or an Affiliate, licensee, sublicensee, transferee or successor of Sangamo to an independent Third Party in a Major Market country following Regulatory Approval of the Product in that country.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.18<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Five Percent Payment</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 4.2(b).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.19<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Funding Date</font><font style="font-weight:normal;">&#8221; shall mean each date set forth on </font><font style="text-decoration:underline;">Exhibit B</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.20<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">GAAP</font><font style="font-weight:normal;">&#8221; shall mean United States generally accepted accounting principles, consistently applied.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.21<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnitee</font><font style="font-weight:normal;">&#8221; shall mean either Sangamo Indemnitee or JDRF Indemnitee, as applicable.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.22<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Interruption</font><font style="font-weight:normal;">&#8221; shall occur if, at any time before the First Commercial Sale of the Product, Sangamo, its Affiliates, licensees, sublicensees, transferees and/or successors, all cease to conduct, or have ceased Commercially Reasonable Efforts with respect to, the research, development and/or commercialization of all Products for a period of one hundred eighty (180) consecutive days, except that no Interruption shall be deemed to have occurred, if Sangamo, its Affiliates, licensees, sublicensees, transferees, and/or successors suspend, postpone or discontinue the development or commercialization of a Product on account of (a) a serious adverse event; (b) a clinical hold; or (c) communications with a regulatory authority.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.23<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Interruption License</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 9.5(e).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.24<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Interruption Notice</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 9.5(a).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.25<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Interruption Response</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 9.5(a).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.26<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in the preamble of this Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.27<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF Designees</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 2.5.1.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.28<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF Indemnitee</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 7.1.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.29<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF Interruption License Technology</font><font style="font-weight:normal;">&#8221; shall mean all intellectual property, data, technical information, know-how, inventions (whether or not patented), trade secrets, processes and methods that are (a) discovered or developed by or on behalf of JDRF or its Affiliates, in the performance of the Research Program or exploitation of the Interruption License under this Agreement, (b) Controlled by JDRF, and (c) necessary or useful for the research, development and commercialization of the Product.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.30<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF Patents</font><font style="font-weight:normal;">&#8221; shall mean any Patents Controlled by JDRF or its Affiliates that claim an invention that relates to the Research Program but is not a Joint Invention.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.31<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF Studies</font><font style="font-weight:normal;">&#8221; shall mean the mechanistic add-on studies for the collection of Surrogate Endpoint Data that are described in the Application.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.32<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Invention</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 8.1.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.33<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Research Advisory Committee</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JRAC</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 2.5.1.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.34<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Major Markets</font><font style="font-weight:normal;">&#8221; shall mean the United States, United Kingdom, Germany, France, Italy and Spain.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.35<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Matched Funds</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 3.1.3.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.36<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Milestones</font><font style="font-weight:normal;">&#8221; shall mean the performance milestones for the Research Program set forth in </font><font style="text-decoration:underline;">Exhibit B.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.37<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Net Sales</font><font style="font-weight:normal;">&#8221; means, for any period, the gross price received for the Product sold or otherwise disposed of (other than for use as clinical supplies or free samples) for consideration by Sangamo or its Affiliates to Third Parties other than sublicensees, reduced by the following amounts (calculated in accordance with GAAP consistently applied by Sangamo and its Affiliates across its product lines), if not previously deducted from the amount invoiced: (a) amounts actually allowed as trade, volume or quantity discounts, including early pay cash discounts; (b) amounts repaid or credited by reason of defects, recalls, accrued or actual returns, rebates and allowances of goods or because of retroactive price reductions specifically identifiable to the Product; (c) rebates and administrative fees paid to medical health care organizations in line with approved contract terms; (d) rebates resulting from government (or agency thereof) mandated rebate programs or chargeback programs; (e) rebates paid to wholesalers for inventory management programs or distribution management agreements, in accordance with Sangamo&#8217;s practice reasonably consistently applied; (f) discounts pursuant to indigent patient programs and patient discount programs to include coupons and vouchers to the extent included in Net Sales; (g) </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">retroactive and temporary price reductions that are actually allowed or granted; (h) sales commissions paid to Third Party distributors or selling agents (which shall not include sales organizations, whether contract or internal to Sangamo); (i) sales or excise taxes, custom duties, and other governmental charges (including payments made to United Kingdom government departments under the UK Pharmaceutical Pricing Regulatory Scheme or similar programs, and government taxes, charges or penalties, such as French Social Security rebates, which payments need not be calculated in accordance with GAAP) imposed directly on and actually paid by Sangamo or its Affiliates; and (j) transportation costs, including insurance and shipping, freight, and handling charges, to the extent billed separately to customers.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.38<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Owner</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 5.1.2.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.39 <font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Partv(ies)</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in the preamble of this Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.40<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Patents</font><font style="font-weight:normal;">&#8221; means all existing patents and patent applications and all patent applications hereafter filed, including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplementary protection certificate) of any such patent, any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.41<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Person</font><font style="font-weight:normal;">&#8217; means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization or government or political subdivision thereof.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.42<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Policies</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 1 0.1(b).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.43<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Primary Statistical Analysis</font><font style="font-weight:normal;">&#8221; shall mean the analysis performed of the six (6) month follow up of all clinical endpoints of all evaluable patients participating in Sangamo 's Phase II Repeat Dosing Clinical Trial of SB-509.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.44<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Prime Rate</font><font style="font-weight:normal;">&#8221; shall mean the average prime rate published in the </font><font style="font-style:italic;font-weight:normal;">Wall Street</font><font style="font-weight:normal;"> Journal during the relevant period (calculated by dividing (a) the sum of the prime rates for each of the days during the relevant period, by (b) the number of days in the relevant period).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.45<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Principal Investigator</font><font style="font-weight:normal;">&#8221; shall mean the Chief Medical Officer of Sangamo, who will personally conduct or supervise the Research Program.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.46<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Product</font><font style="font-weight:normal;">&#8221; shall mean (a) the pharmaceutical product containing the Therapeutic Candidate or (b) any derivatives or related products that (i) encode a zinc finger DNA-binding protein designed to activate the expression of vascular endothelial growth factor (VEGF-A) and (ii) result from Sangamo's research for treatment of diabetic neuropathy.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.47<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Program Material</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 2.3.2(d).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.48<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Qualified Subject</font><font style="font-weight:normal;">&#8221; is a human subject who, on enrollment into the Research Plan, has met all of the eligibility criteria and none of the exclusion criteria in the Research Plan and has given his or her written informed consent to participate in the Research Plan.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.49<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Quarterly Report</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 3.2.3(a).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.50<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Recipient</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 5.1.2.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.51<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Recipient Notice Requirement</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 5.1.3.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.52<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Registration</font><font style="font-weight:normal;">&#8221; shall mean, with respect to each country in the Territory, Regulatory Approval for the Product filed in such country.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.53<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Regulatory Approval</font><font style="font-weight:normal;">&#8221; shall mean, with respect to any country, all authorizations by the appropriate governmental entity or entities necessary for commercial sale of the Product in that country including, without limitation and where applicable, approval of labeling, price, reimbursement and manufacturing, in the United States final approval of a new drug application or biologic license application, as the case may be, pursuant to the then-applicable provisions of the Code of Federal Regulations permitting marketing of the Product in interstate commerce in the United States, and in the European Union final approval of a Marketing Authorization Application, or equivalent.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.54<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Plan</font><font style="font-weight:normal;">&#8221; means the written protocol for Sangamo&#8217;s Phase II Repeat Dosing Clinical Trial of SB-509, that shall be attached to this Agreement as </font><font style="text-decoration:underline;">Exhibit A</font><font style="font-weight:normal;"> upon approval by the FDA, which protocol was based on the Application, includes the JDRF Studies, and has been approved by the FDA, as modified from time to time by Sangamo in consultation with the FDA and in accordance with Section 2.4.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.55<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Program&#8221;</font><font style="font-weight:normal;"> shall mean the work conducted by or on behalf of Sangamo in furtherance of the Research Plan.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.56<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Termination Date</font><font style="font-weight:normal;">&#8221; shall mean the date of completion of all activities specified in the Research Plan, including all follow-ups of Qualified Subjects and all analysis included in the JDRF Studies.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.57<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in the preamble of this Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.58<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Designees</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 2.5.1.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.59<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Indemnitee</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 7.2.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.60<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Party</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Section 7.l(a).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.61<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Patents</font><font style="font-weight:normal;">&#8221; shall mean any Patents Controlled by Sangamo or its Affiliates claiming Sangamo Research Program Technology.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.62<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Research Program Technology</font><font style="font-weight:normal;">&#8221; shall mean all intellectual property, data, technical information, know-how, inventions (whether or not patented), trade secrets, processes and methods that are (a) discovered or developed by or on behalf of Sangamo or its Affiliates, in the performance of the Research Program under this Agreement, (b) Controlled by Sangamo, and (c) necessary or useful for the research, development and commercialization of the Product.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.63<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Surrogate Endpoint Data</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in Article VI.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.64<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Territory</font><font style="font-weight:normal;">&#8221; shall mean worldwide.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.65<font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Therapeutic Candidate</font><font style="font-weight:normal;">&#8221; shall mean the plasmid, known as SB-509, that encodes a zinc finger DNA-binding protein designed to upregulate the expression of vascular endothelial growth factor (VEGF-A).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.66 <font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Third Party</font><font style="font-weight:normal;">&#8221; shall mean any Person which is not a Party or an Affiliate of any Party to this Agreement.</font></p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II RESEARCH PROGRAM</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="font-weight:normal;"> </font>Overview<font style="font-weight:normal;">. Sangamo shall be responsible for the conduct of the Research Program as set forth herein. JDRF shall provide the financial support hereinafter specified, and consultation and advice as provided herein through its participation on the JRAC as provided below.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="font-weight:normal;"> </font>Commencement of the Research Program<font style="font-weight:normal;">. If not commenced prior to the Effective Date, the Research Program shall commence as soon after the Effective Date as practicable in light of the date of the FDA&#8217;s approval of the Research Plan. If the Research Plan is approved by the FDA after the Effective Date and substantial changes are made to the JDRF Studies as described in the Application, then JDRF shall have the right to terminate this Agreement within ten (10) days following such approval of the Research Plan.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3 Research Diligence<font style="font-weight:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.1 Generally<font style="font-weight:normal;">. Sangamo shall use Commercially Reasonable Efforts to: (a) conduct the Research Program in accordance with the Research Plan; and (b) satisfy and achieve the Milestones. In furtherance of the foregoing, and in accordance with the terms and conditions of this Agreement (including, without limitation, Section 2.3.2 below), Sangamo shall commit to the Research Program directly or through Third Party contractors (i) the level of staffing required by the Research Plan, with staff that possesses appropriate experience, training and scientific expertise for the tasks to which they are assigned, and (ii) the infrastructure (e.g., laboratories, offices, equipment and facilities) required by the Research Plan.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.2<font style="font-weight:normal;"> </font>Obligations of Sangamo<font style="font-weight:normal;">. Subject to the terms and conditions of this Agreement, and without limiting the generality of Section 2.3.1 above, Sangamo directly or through its Third Party contractors shall be responsible for conducting the sponsorship, conduct and oversight of the Research Program, such responsibilities to include, without limitation:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) identifying appropriate clinical sites to conduct the Research Plan, and entering into clinical trial agreements with such clinical sites;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) providing the approved clinical sites with a copy of the Research Plan;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) identifying, selecting, and enrolling Qualified Subjects;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) providing the investigators at approved clinical sites with the required quantity of the Product or placebo (the &#8220;<font style="text-decoration:underline;">Program Material</font>&#8221;), appropriately formulated in accordance with the Research Plan;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) monitoring compliance of the approved clinical sites with the Research Plan;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) monitoring adverse events arising in the course of the Research Program;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g) providing the investigators at approved clinical sites and JDRF (the latter for informational purposes) with a copy of the current investigator brochure;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h) performing laboratory analyses on biopsies collected from Qualified Subjects as outlined in the Research Plan;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) complying with all Applicable Law and guidelines regarding administration, transportation, manufacture and production of the Program Material and any other drugs or fluids which are to be supplied by Sangamo for use in connection with the Research Plan;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j) abiding by and complying with the Policies; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k) promptly and thoroughly responding to all reasonable requests and inquiries of JDRF for information regarding the Research Program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.4<font style="font-weight:normal;"> </font>Modifications to JDRF Studies<font style="font-weight:normal;">. Sangamo shall not propose to the FDA any changes to the Research Plan that would have a material impact on the JDRF Studies without first presenting such changes to the JRAC and obtaining the JRAC's recommendation of such changes.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5 Joint Research Advisory Committee<font style="font-weight:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5.1 Composition and Purposes<font style="font-weight:normal;">. During the term of the Research Program, the Parties shall establish a Joint Research Advisory Committee (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">JRAC&#8221;</font><font style="font-weight:normal;">) consisting of four (4) members, two (2) of whom shall be designated by Sangamo (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Designees</font><font style="font-weight:normal;">&#8221;), and two (2) of whom shall be designated by JDRF (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF Designees</font><font style="font-weight:normal;">&#8221;). Each Party (a) shall select a program coordinator from among its designees to the JRAC (who may be changed at any time or from time to time by such Party), and (b) may change any of its designees to the JRAC at any time or from time to time. The program coordinator of Sangamo shall serve as the Chairperson of the JRAC. The Sangamo Designees initially shall be Heidi Kim and Dale Ando, who also initially shall serve as Sangamo&#8217;s program coordinator and the Chairperson of the JRAC, and the JDRF Designees initially shall be Richard Insel and Paul Burn, who also initially shall serve as JDRF&#8217;s program coordinator.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The JRAC shall have the authority to:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) facilitate communication between the Parties with respect to the Research Program;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) receive Quarterly Reports from Sangamo with respect to the progress of the Research Program and consider and discuss such reports;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) determine whether the Milestones have been satisfied and achieved; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) decide whether to recommend any changes presented by Sangamo in accordance with Section 2.4.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5.2<font style="font-weight:normal;"> </font>Meetings<font style="font-weight:normal;">. The JRAC shall meet once in each six (6) month period between the Effective Date and the Research Program Termination Date; provided, however, the JRAC shall meet within forty-five (45) days following JDRF&#8217;s receipt from Sangamo of a written certification setting forth Sangamo&#8217;s achievement of a Milestone. Meetings of the JRAC shall be held at such times and locations as may be mutually agreed upon by the program coordinators, which times and locations shall be communicated in writing (including, without limitation, by email) to the other members of the JRAC with reasonable advance notice of the meeting. At least one (1) Sangamo Designee and one (1) JDRF Designee shall be required to participate in a meeting for such meeting to be deemed to have a quorum of the JRAC members. So long as a quorum is present at a meeting, the JRAC may make, or decide to make, recommendations to Sangamo, or take, or decide to take, such actions as are within the scope of the JRAC&#8217;s authority hereunder. Members of the JRAC may attend each meeting either in person or by means of telephone or other telecommunications device that allows all participants to hear and speak at such meeting simultaneously.  At least ten (10) business days prior to each meeting, Sangamo shall deliver (including by email) to JDRF a written report detailing the progress made on the Research Program since the last meeting of the JRAC. In satisfaction of such written report, Sangamo may provide the most recent Quarterly Report supplemented by any new significant developments since the most recent Quarterly Report. Within thirty (30) days after the date of each meeting, the Sangamo Designees shall prepare and deliver (including by email) to the JDRF Designees written minutes of such meeting setting forth in detail all discussions and/or recommendations of the JRAC made at such meeting, which minutes shall be subject to revision to take account of the comments of JDRF&#8217;s program coordinator.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5.3 Discussions/Recommendations<font style="font-weight:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) As a general matter, and except as otherwise provided for herein, recommendations of the JRAC shall be unanimous and non-binding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Notwithstanding the foregoing, the determination as to whether or not a Milestone has been achieved and satisfied shall be subject to the unanimous vote of the JRAC. In each such instance, the Sangamo Designees shall, collectively, have one (1) vote, and the JDRF Designees shall, collectively, have one (1) vote, which, in each instance, shall be cast by each Party's program coordinator (unless such Party&#8217;s program coordinator expressly authorizes such Party&#8217;s other JRAC designee to cast such Party&#8217;s vote). In the event of a deadlock, the Sangamo Designees and the JDRF Designees shall attempt to resolve such deadlock for a period of twenty (20) days by engaging in good faith discussions. If such deadlock is not resolved after such twenty (20) day period, then, such deadlock shall be resolved in accordance with the dispute resolution process set forth in Section 11.2.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5.4 Expenses<font style="font-weight:normal;">. Each Party shall pay its own expenses (including travel and lodging expenses) incurred in connection with its participation on the JRAC.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.6<font style="font-weight:normal;"> </font>Delivery of Adverse Event Data to the JRAC<font style="font-weight:normal;">. In the event of a serious adverse event (as defined by the ICH Harmonized Tripartite Guideline on Clinical Safety Data Management), directly or indirectly attributable to the use or application of the Product, Sangamo shall deliver to each JRAC member any information and other data related to such adverse event within a reasonable time after Sangamo has had an opportunity to discuss such adverse event with the FDA. Any disclosure of patient-identifiable information of any Qualified Subject in connection with the Quarterly Reports due under Section 3.2.3(a) or any other reporting requirements hereunder shall comply with the Health Insurance and Portability and Accountability Act of 1996 and regulations, laws and guidelines related thereto.</font></p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III RESEARCH FUNDING; RECORDS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.1 Research Funding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.1 Payments.<font style="font-weight:normal;"> Subject to Section 3.1.2, JDRF shall make payments to Sangamo of the Award in accordance with </font><font style="text-decoration:underline;">Exhibit B</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.2 Limitations.<font style="font-weight:normal;"> Notwithstanding Section 3.1.1 above, JDRF shall not be required to make any payment or additional payment in respect of the Award:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) in excess of Three Million Dollars ($3,000,000);</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) unless at the time such payment is due, the Research Program is in compliance with all Applicable Law;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) if Sangamo is, at the time such payment is due, in material breach of any of its covenants or obligations under this Agreement (including, without limitation, Sangamo's obligations under Section 3.1.3 below) and JDRF provides Sangamo with written notification of such breach at least thirty (30) days before such payment due date;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) if, at the time such payment is due, a case or proceeding (i) under the bankruptcy laws of the United States now or hereafter in effect is filed against Sangamo or all or substantially all of its assets and such petition or application is not dismissed within sixty (60) days after the date of its filing or Sangamo shall file any answer admitting and not contesting such petition, or (ii) under the bankruptcy laws of the United States now or hereafter in effect or under any insolvency, reorganization, receivership, dissolution or liquidation law or statute of any jurisdiction now or hereafter in effect (whether at law or equity) is filed by Sangamo for all or substantially all of its assets; and/or</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) if this Agreement previously is terminated by any Party in accordance with Article IX, <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that any payments accrued prior to such termination shall immediately become due and payable to Sangamo upon such termination; provided, however, that JDRF shall pay Sangamo any amount not paid on account of subsection (b), (c) or (d) above as soon as the condition that caused such non-payment has been remedied or no longer exists.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.3 Matched Funds.<font style="font-weight:normal;"> The Parties agree, acknowledge and recognize that the Award represents only partial financial support for the Research Program, and Sangamo agrees to provide the balance of the funds necessary to conduct and complete the Research Program. In furtherance of, but without limiting the generality of the foregoing, Sangamo shall contribute to the Research Program, in the aggregate, an amount that is at least equal to the Award Received (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Matched Funds</font><font style="font-weight:normal;">&#8221;). Sangamo hereby covenants and agrees to solely use the Award Received and the Matched Funds to fund the Research Program.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.4<font style="font-weight:normal;"> </font>Payments.<font style="font-weight:normal;"> All payments to be made hereunder (including, without limitation, pursuant to Article IV) shall be made in United States dollars (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Dollars</font><font style="font-weight:normal;">&#8221;) and, at the option and direction of the receiving party, shall be made by cashier&#8217;s or certified check or by wire transfer of immediately available funds.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.5<font style="font-weight:normal;"> </font>Competition.<font style="font-weight:normal;"> Sangamo hereby agrees and acknowledges that nothing contained herein shall restrict or prevent JDRF's ability to provide funding to, or take any other action with respect to, any Person that competes with the business, operations and/or research of Sangamo, </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that in no event shall JDRF disclose to such Persons any non&#173;public information concerning the Research Program, including the results thereof.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.2 Records; Reporting Obligations; Audits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.2.1<font style="font-weight:normal;"> </font>Records<font style="font-weight:normal;">. Sangamo shall prepare and maintain complete and accurate books and records in accordance with GAAP documenting its expenditure of funds in connection with the Research Program (including financial records of expenditures of the Award Received and the Matched Funds), and shall keep all such books and records for no less than a period of three (3) years following the Research Termination Date.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.2.2 Audit<font style="font-weight:normal;">. At the request of JDRF not more often than once in each twelve (12) month period, Sangamo shall permit JDRF internal accounting personnel or representatives and agents of an independent, certified public accounting firm appointed by JDRF and reasonably acceptable to Sangamo, to audit and examine, during normal business hours, the financial records of Sangamo covering the previous twelve (12) month period as may be necessary to verify Sangamo&#8217;s expenditures of funds in connection with performance of the Research Program in general and the JDRF Studies in particular. Any and all records audited and examined by JDRF personnel or such representatives and agents of such accounting firm shall be deemed Sangamo&#8217;s Confidential Information. JDRF shall pay the costs of such audit and examination of such financial records, </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that, if such audit and examination reveals an over-reporting by Sangamo to JDRF of Matched Funds or expenditures attributed to the JDRF Studies of more than five percent (5%), then the reasonable costs of such audit and examination shall be borne by Sangamo and Sangamo shall reimburse JDRF for all of the reasonable costs and expenses incurred by JDRF in connection with such audit and examination.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.2.3 Reports; Notices.<font style="font-weight:normal;"> Sangamo shall (y) maintain a system of accounting in accordance with GAAP; and (z) furnish to JDRF the following reports and notices under the confidentiality provisions of Article V:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:13.6%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) As soon as practicable, and in any event within ninety (90) days after the end of each calendar quarter (including the calendar quarter ending December 31) prior to the Research Termination Date, a report describing (i) the actual costs of the Research Program during such quarter and how the Award Received and Matched Funds have been allocated and in fact used in respect of the Research Program, (ii) the Research Program work performed during such quarter, including, without limitation, Milestones achieved, (iii) a summary of all Research Program clinical data collected and analyzed during such quarter, (iv) a summary of all regulatory filings made during such calendar that materially alter the Research Plan, and (v) any other information that JDRF reasonably requests (each a &#8220;<font style="text-decoration:underline;">Quarterly Report</font>&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:13.6%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) As soon as practicable, and in any event within ninety (90) days after the end of the calendar quarter in which the Research Termination Date occurs or the termination of the Agreement becomes effective, whichever is earlier, a closing report which (i) sets forth Sangamo's final analysis, summary tables, data listings, results and conclusions from the Research Program and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such other information and materials as JDRF may reasonably request and (ii) provides an accounting of the out-of-pocket expenses incurred by Sangamo since the Effective Date with respect to performance of the JDRF Studies. If the total amount of such expenses is less than the total Award Received, then, Sangamo shall, within thirty (30) days after delivery of the closing report, refund the difference between such total expenses and the total Award Received in such manner as JDRF shall reasonably instruct Sangamo. Such closing report shall be in lieu of a Quarterly Report covering the last calendar quarter of the Research Program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:13.6%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Within sixty (60) days after the end of each fiscal year, audited financial statements as of the end of such year (including, without limitation, a copy of the consolidated balance sheet of Sangamo as of the end of such year, together with consolidated statements of income, operations, cash flow and retained earnings of Sangamo for such year), prepared in accordance with GAAP, along with a comparison of such financial statements with the corresponding periods of the prior year. Notwithstanding the foregoing, the scope of the information to be included in the report due under this Section 3.2.3(c) shall be no more extensive or detailed than the scope of financial disclosures that Sangamo is required to make by the Securities and Exchange Act of 1934, as amended.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:13.6%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) As soon as practicable, and in any event within thirty (30) days after the end of each calendar year following the Research Termination Date, a report summarizing the Product development and commercialization activities performed by or on behalf of Sangamo or its Affiliates, collaborators, licensees or sublicensees during such year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:13.6%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) As soon as practicable, and in any event promptly after the consummation thereof, any proposed license, sublicense, transfer, or subcontract by Sangamo of rights related to the research, development, and/or commercialization of the Product, any permitted assignment by Sangamo of this Agreement or its rights and/or obligations hereunder, or of any merger, acquisition, consolidation or similar transaction involving Sangamo and materially affecting JDRF's rights and/or obligations hereunder.</p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV DILIGENCE; COMPENSATION TO JDRF</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.1 Development and Commercialization of Product.<font style="font-weight:normal;"> Following the Research Termination Date, Sangamo shall use Commercially Reasonable Efforts to develop, commercialize and bring one Product in the Field to market in the Major Markets. The activities of Sangamo's Affiliates, licensees, sublicensees, subcontractors, collaborators, transferees and successors shall be attributed to Sangamo for the purposes of determining Sangamo's satisfaction of the foregoing diligence obligation.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.2 Compensation to JDRF.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) In consideration of JDRF's payments to Sangamo and JDRF&#8217;s licenses to Sangamo hereunder, Sangamo shall pay JDRF an amount equal to three (3) times the Award Received less all payments made pursuant to Section 4.2(b) (such amount, the &#8220;JDRF ROI&#8221;) as follows: within ninety (90) days of the first, second, third and fourth anniversaries of the First Commercial Sale, Sangamo shall pay JDRF an amount equal to: (i) one-fourth of the JDRF ROI, (ii) twenty-five percent (25%) of Net Sales during the 12-month period between such anniversary and the previous anniversary of the First Commercial Sale, as applicable (such period, the &#8220;<font style="text-decoration:underline;">Relevant Period</font>&#8221;), or (iii) fifty percent (50%) of the royalties received by Sangamo during the Relevant Period from its licensees and sublicensees on account of the sale of the Product, whichever is less, provided that such amounts shall be reduced as necessary to ensure that the total amount paid, when this Section 4.2(a) is combined with all payments made pursuant to Section 4.2(b), shall not exceed three (3) times the Award Received. If the amount paid to JDRF in any year is less than one-fourth of the JDRF ROI plus any deficit from a preceding year of JDRF ROI (in each case after crediting all payments made in such year pursuant to Section 4.2(b)), any such deficit shall be carried forward and added to the amount applicable under Section 4.2(a)(i) for the following year. If the total amount paid by Sangamo to JDRF pursuant to this Section 4.2 by the date that is ninety (90) days after the fourth anniversary of the First Commercial Sale is less than the JDRF ROI, then Sangamo shall continue to make payments in accordance with this Section 4.2 in the following years equal to the lesser of the remaining JDRF ROI, or the lesser of the amounts in Sections 4.2(a)(ii) and (iii) to JDRF within ninety (90) days of each subsequent such anniversary until such time as the total amount paid by Sangamo equals the JDRF ROI.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) If Sangamo is commercializing the Product in connection with any license, transfer, or sale of the Sangamo Research Program Technology, any Sangamo Patents, or any Product, to a Third Party, then Sangamo shall pay to JDRF in cash five percent (5%) of the gross proceeds that are received by Sangamo on or after December 31, 2008 and prior to the time of Regulatory Approval of the Product in connection with any such license, transfer, or sale, whether such payments are upfront license fees, milestone payments, or other fees, but excluding FTE payments or purchases of equity at or below fair market value (the &#8220;<font style="text-decoration:underline;">Five Percent Payment</font>&#8221;), up to an aggregate amount equal to two (2) times the amount of the Award Received. Such payments to JDRF will be made within ninety (90) days of receipt of such gross proceeds from any licensee, transferee or purchaser of Sangamo Research Program Technology. Thereafter, Sangamo shall pay any remaining JDRF ROI to JDRF in accordance with Section 4.2(a). For clarity, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo shall not be obligated to pay JDRF, in the aggregate, an amount more than three (3) times the Award Received when the amounts paid under this Section 4.2(b) and Section 4.2(a) are combined.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) If aggregate Net Sales of the Product exceed $1 billion Dollars on or before the fifth (5<sup style="font-size:85%; vertical-align:top">th</sup>) anniversary of the First Commercial Sale, Sangamo shall pay to JDRF within ninety (90) days after such Net Sales are achieved, an additional royalty equal to the amount of the Award Received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) If aggregate Net Sales of the Product exceed $2 billion Dollars on or before the fifth (5<sup style="font-size:85%; vertical-align:top">th</sup>) anniversary of the First Commercial Sale, Sangamo shall pay to JDRF within ninety (90) days after such Net Sales are achieved, an additional royalty equal to the amount of the Award Received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.3 Sales Reports.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.3.1<font style="font-weight:normal;"> In connection with each payment made to JDRF pursuant to Section 4.2 above with respect to which the amount of Net Sales is relevant, Sangamo shall furnish or cause to be furnished to JDRF a written sales report setting forth in reasonable detail amounts received with respect to which Net Sales during such period were calculated. With respect to sales of the Product invoiced in Dollars, the Net Sales amounts and the amounts due to JDRF hereunder shall be expressed in Dollars. With respect to sales of the Product invoiced in a currency other than Dollars, the Net Sales and amounts due to JDRF hereunder shall be expressed in the domestic currency of the country in which the sale was made, together with the Dollar equivalent of the amount payable to JDRF, calculated by translating foreign currency sales into Dollars in a manner that is consistent with the then-current foreign currency calculations that Sangamo employs for purposes of its reporting obligations under the Securities and Exchange Act of 1934, as amended.  If any licensee or sublicensee makes any sales invoiced in a currency other than its domestic currency, the Net Sales shall be converted to its domestic currency in accordance with the licensee's or sublicensee's normal accounting principles. Sangamo shall keep accurate records in sufficient detail to enable the amounts due hereunder to be determined and to be verified by JDRF.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.3.2<font style="font-weight:normal;"> Upon the written request of JDRF, at JDRF's expense and not more often than once a year, Sangamo shall permit an independent accountant selected by JDRF and reasonably acceptable to Sangamo to have access during normal business hours to the records of Sangamo from the previous twenty-four month period (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Audit Period&#8221;</font><font style="font-weight:normal;">) as may be reasonably necessary to verify the accuracy of the report furnished by Sangamo pursuant to Section 4.3.1. Such independent accountant may examine and audit the records from each Audit Period only once. Such independent accountants may be required by Sangamo to enter into a reasonably acceptable confidentiality agreement, and in no event shall such accountants disclose to JDRF any information, other than the accuracy of reports and payments made or due hereunder.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.3.3<font style="font-weight:normal;"> In case of any delay in payment by Sangamo to JDRF or by JDRF to Sangamo not occasioned by force majeure in accordance with Section 11.5, interest shall be calculated at the lesser of (i) the Prime Rate plus five (5) percentage points or (ii) the maximum rate allowed by law, calculated from the tenth (10<sup style="font-size:85%; vertical-align:top">th</sup>) day after the date upon which the applicable payment first becomes due from Sangamo.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.4<font style="font-weight:normal;"> </font>Royalties to Sangamo<font style="font-weight:normal;">. In the event that, pursuant to Section 9.5, the Interruption License becomes effective and thereafter is maintained by JDRF, in lieu of any other royalties pursuant to this Agreement (other than royalties or payments under Section 4.2 previously paid by Sangamo to JDRF in accordance with this Agreement), the Parties shall share equally, subject to this Section 4.4, any amount JDRF receives with respect to the Product (including amounts received in connection with sublicenses of the Interruption License). JDRF's share shall increase and Sangamo&#8217;s share shall decrease by two percent (2%) for each one million Dollars ($1,000,000) JDRF spends in addition to the Award Received with respect to the research, development and/or commercialization of the Product after the Interruption License Effective Date (as defined in Section 9.5(d)), except that, in no event shall Sangamo&#8217;s share decrease below twenty percent (20%). Thus, for example, if JDRF&#8217;s expenditures after the Interruption License Effective Date are ten million Dollars ($10,000,000), JDRF's share will increase to seventy percent (70%) and Sangamo&#8217;s share will decrease to thirty percent (30%).</font></p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE V CONFIDENTIALITY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.1 Confidentiality.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.1.1 Definition of Confidential Information.<font style="font-weight:normal;"> For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Confidential Information</font><font style="font-weight:normal;">&#8221; shall mean any trade secrets, know-how, confidential or proprietary information, data and test results relating to the Research Program and any other knowledge, information, documents or materials, owned, developed or possessed by Owner (as defined below), whether in tangible or intangible form, the confidentiality of which Owner takes or has taken reasonable measures to protect; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Confidential lnformation</font><font style="font-weight:normal;">&#8221; shall not include any information of Owner that: (a) is already independently known to Recipient (as </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">defined below) at the time of its disclosure without any obligations of confidentiality; (b) becomes publicly known through no wrongful act of Recipient; (c) is received from a Third Party free to disclose it to Recipient without any obligations of confidentiality with respect thereto; or (d) is independently developed by Recipient without use of any Confidential Information of the Owner; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, that, in each such instance, Recipient shall bear the burden of proving that any such information of Owner is not Confidential Information. Confidential Information of Sangamo shall include without limitation, investigator brochures, any reports, notices, data, results, case report forms and regulatory filings generated pursuant to the Research Program. The terms and conditions of this Agreement shall be the Confidential Information of both Parties.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.1.2 Non-Disclosure<font style="font-weight:normal;">. During the term of this Agreement and for a period of five (5) years thereafter, each Party (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Recipient</font><font style="font-weight:normal;">&#8221;) shall hold all Confidential Information it receives or received from the other Party (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Owner</font><font style="font-weight:normal;">&#8221;) in strict confidence, and, other than as expressly provided herein or without first obtaining the prior written consent of Owner, shall not disclose any Confidential Information to any Person, except to officers, directors, employees, consultants, committee members, volunteers, contractors, subcontractors, licensees, sublicensees, accountants or counsel of Recipient who have a need to know and who are bound to confidentiality obligations at least as restrictive as Recipient&#8217;s obligations under this Agreement. Recipient shall use not less than the same degree of care it uses to avoid disclosure of its own Confidential Information.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.1.3<font style="font-weight:normal;"> </font>Required Disclosure.<font style="font-weight:normal;"> Notwithstanding Section 5.1.2 above, Recipient&#8217;s disclosure of Confidential Information shall not be prohibited if such disclosure is required by a valid and existing order of a court of competent jurisdiction or other governmental body or agency; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that, Recipient shall have first given prompt notice to Owner of any possible or prospective order and Owner shall have been afforded a reasonable opportunity to prevent or limit such disclosure (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Recipient Notice Requirement</font><font style="font-weight:normal;">&#8221;); </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">further</font><font style="font-weight:normal;">, that the Recipient Notice Requirement shall not apply to proceedings which, by applicable law, are of a nature that the existence of such proceedings may not be disclosed or made public. In the event that Recipient discloses any Confidential Information pursuant to the immediately preceding sentence, Recipient shall cooperate with Owner, at Owner's sole cost and expense, in the prosecution of any appeal that Owner decides to pursue.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.1.4 No Use of Confidential Information.<font style="font-weight:normal;"> Recipient hereby agrees and acknowledges that, other than as provided herein or without first obtaining Owner&#8217;s prior written consent, Recipient shall not use any of Owner's Confidential Information.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.2 Publicity; Use of Name.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.1 <font style="font-weight:normal;">As soon as practicable after the Effective Date and not later than the deadline for any required disclosure of the execution of this Agreement, the Parties shall issue a joint press release announcing the execution of this Agreement in substantially the same form as the press release attached as </font><font style="text-decoration:underline;">Exhibit D</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.2<font style="font-weight:normal;"> Except to the extent already disclosed in the initial press release referenced in Section 5.2.1 above, and except as may be otherwise provided herein, neither Party shall issue any press release or make any public announcement concerning the terms of this Agreement or the transactions described herein without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that it shall not be unreasonable for any Party to withhold consent with respect to any press release or public announcement containing any of such Party's Confidential Information. This Section 5.2.2 shall not preclude any Party from issuing press releases or making public announcements if such Party reasonably believes that any such release or announcement is (a) legally required by Applicable Laws or (b) required by the rules of any stock exchange on which such Party&#8217;s securities are listed. Sangamo shall accord JDRF the opportunity to review and comment on any submission of this Agreement and redaction thereof required to be submitted to the Securities and Exchange Commission by Sangamo.  For clarity, Sangamo shall have the right to issue press releases without obtaining the consent of JDRF so long as such press releases contain substantially the same information as contained in Sangamo's Form 8-K filings made pursuant to the Securities and Exchange Act of 1934, as amended.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.3<font style="font-weight:normal;"> In each instance, the Party desiring to issue any press release or to make any public announcement shall provide the other Party with a written copy of the proposed release or announcement in sufficient time where practicable prior to public release to allow such other Party to comment upon such release or announcement prior to its public release. In addition, each press release and/or public announcement issued or made pursuant to this Section 5.2, where practicable, shall include JDRF-approved language acknowledging JDRF&#8217;s funding of a portion of the Research Program.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.4<font style="font-weight:normal;"> Except as may be otherwise provided herein, no Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logos of the other Party for any purpose.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.5<font style="font-weight:normal;"> Notwithstanding the foregoing or any contrary provision contained herein, in connection with: (a) any description by JDRF of its research portfolio and of its industry discovery and development program, and/or (b) JDRF's fundraising activities, marketing materials and/or reporting requirements, JDRF shall be entitled to use and/or disclose, and Sangamo hereby pre-approves </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">JDRF's use and/or disclosure of: (i) the names &#8220;Sangamo,&#8221; &#8220;Sangamo BioSciences, Inc.&#8221;, Sangamo&#8217;s logo and a general description of Sangamo, (ii) the existence and a general description of the nature of this Agreement in a form previously agreed upon by the Parties, and (iii) a general description of the nature of the Research Program in a form previously agreed upon by the Parties. In connection with: (w) any description of Sangamo&#8217;s intellectual property rights and drug pipeline; (x) Sangamo&#8217;s reporting requirements under the Securities and Exchange Act of l 934, as amended, and the Securities Act of l 933, as amended; (y) Sangamo&#8217;s fundraising activities or marketing materials; and (z) any description or acknowledgment of JDRF or JDRF funding as required hereunder, Sangamo shall be entitled to use and/or disclose, and JDRF hereby pre-approves Sangamo&#8217;s use and/or disclosure of: (i) the names &#8220;JDRF,&#8221; &#8220;Juvenile Diabetes Research Foundation International&#8221;, JDRF&#8217;s logo and a general description of JDRF in the context of describing the funding provided by JDRF, (ii) the existence and a general description of the nature of this Agreement in a form previously agreed upon by the Parties, and (iii) a general description of the nature of the Research Program in a form previously agreed upon by the Parties.</font></p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VI PUBLICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo shall have the first right to publish, publicly present, or otherwise make available the results of the Research Plan, including any data necessary for Third Parties to utilize any new discoveries and information regarding the surrogate clinical endpoints related to the JDRF Studies and identified by Sangamo during the Research Program (the &#8220;<font style="text-decoration:underline;">Surrogate Endpoint Data</font>&#8221;). In the event that Sangamo does not exercise its publication rights by submitting within twelve (12) months after the Research Termination Date a manuscript for publication, JDRF shall have the right to publish, publicly present, or otherwise make available the Surrogate Endpoint Data, but only to the extent that such publication, presentation or availability of the data would not have an adverse impact on any ongoing or planned development and/or commercialization of the Product. If JDRF is the publishing party, JDRF will submit a draft of any proposed manuscript or speech to Sangamo for comments at least sixty (60) days prior to submission for publication or oral presentation. Sangamo shall notify JDRF in writing within thirty (30) days of receipt of such draft whether such draft contains (a) information which Sangamo considers to be Confidential Information under the provisions of Article V hereof, (b) information that if published would have an adverse effect on a patent application which Sangamo intends to file, or (c) information which Sangamo reasonably believes would be likely to have an adverse impact on the development or commercialization of the Product. In any such notification, Sangamo shall indicate with specificity its suggestions regarding the manner and degree to which JDRF may disclose such information.  In the case of item (a) above, JDRF shall not publish the Confidential Information of Sangamo in violation of Article V of this Agreement. In the case of item (b) above, Sangamo may request a delay and JDRF shall delay such publication, for a period not exceeding an additional ninety (90) days, to permit the timely preparation and filing of a patent application or an application for a certificate of invention on the information involved. In the case of item (c) above, if JDRF disagrees with Sangamo&#8217;s assessment of the impact of the publication, then the program coordinator of each Party shall attempt in good faith to reach a fair and equitable resolution of such disagreement. If the disagreement is not resolved in this manner within fourteen (14) days of referral to the respective program coordinators, then the decision of Sangamo as to publication of any information generated by it, subject always to the confidentiality provisions of Article V hereof shall be final, <font style="text-decoration:underline;">provided</font> that such decision shall be exercised with reasonable regard for the interests and rights of JDRF. The Parties agree that authorship of any publication will be determined based on the customary standards then being applied in the relevant scientific journal. JDRF shall comply with the foregoing publication requirements in the event that pursuant to Section 9.5, the Interruption License becomes effective.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, (a) Sangamo intends to advance the body of general scientific knowledge of Diabetes and its potential therapies and cures, all in a manner consistent with its general scientific and commercial objectives in entering into this Agreement with JDRF, and (b) the Parties acknowledge that Sangamo intends to publish the results of the placebo data from the Research Program in a major scientific peer reviewed publication as soon as practicable, following the completion of the Research Program; <font style="text-decoration:underline;">provided</font> that Sangamo shall not be obligated to publish any information which Sangamo reasonably believes would be likely to have an adverse impact on the development or commercialization of the Product. Sangamo shall acknowledge the financial support of JDRF in all Research Program publications. In addition, Sangamo agrees to make available to requesting Third Parties the Surrogate Endpoint Data without charge but only after twelve (12) months have passed since the Research Termination Date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VII INDEMNIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.1 Indemnification by Sangamo.<font style="font-weight:normal;"> Sangamo shall indemnify, defend and hold harmless JDRF, its Affiliates, and each of their respective directors, officers, committee members, volunteers, employees, consultants, agents and representatives and their respective successors, heirs and assigns (including, without limitation, the JDRF Designees) (each, a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">JDRF Indemnitee</font><font style="font-weight:normal;">&#8221;), from and against any and all claims, suits and demands of Third Parties and losses, liabilities, damages for personal injury, property damage or otherwise, costs, penalties, fines and expenses (including court costs and the reasonable fees of attorneys and other professionals) arising therefrom (collectively &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Losses</font><font style="font-weight:normal;">&#8221;), to the extent that such Losses arise from:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) the conduct of the Research Program by Sangamo or its Affiliates or their respective directors, officers, employees, consultants, agents, representatives, licensees, sublicensees, subcontractors and/or investigators (each, a &#8220;<font style="text-decoration:underline;">Sangamo Party</font>&#8221;) under this Agreement and/or pursuant to one or more agreements between Sangamo and any Sangamo Party, or any actual or alleged violation of law resulting therefrom;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) the Product (not including any Product developed, manufactured or sold pursuant to the Interruption License) and/or any claim of infringement or misappropriation of intellectual property with respect thereto;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Sangamo&#8217;s breach of any of its representations, warranties, covenants and/or obligations under this Agreement, or the negligence or willful misconduct of any Sangamo Party in connection with Sangamo&#8217;s performance of its obligations under this Agreement; or</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Any tort claims of personal injury (including death) arising out of, or in connection with, Sangamo&#8217;s performance of the Research Program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above indemnification shall not apply to the extent that any Losses are due to the gross negligence or willful misconduct of JDRF or the practice of the Interruption License.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.2 Indemnification by JDRF.<font style="font-weight:normal;"> In the event that, pursuant to Section 9.5, the Interruption License becomes effective, JDRF shall indemnify, defend and hold harmless Sangamo, its Affiliates, and their respective directors, officers, employees, consultants, agents and representatives and their respective successors, heirs and assigns (including, without limitation, the Sangamo Designees), (each a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Indemnitee</font><font style="font-weight:normal;">&#8221;), from and against any and all Losses that arise as a result of (a) practice of the Interruption License or (b) JDRF's activities after the Interruption License Effective Date and before the Reversion License Effective Date to the extent that such Losses arise from JDRF&#8217;s breach of any of its obligations under this Agreement, or the negligence or willful misconduct of JDRF in connection with JDRF&#8217;s performance of its obligations under this Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above indemnification shall not apply to the extent that any Losses are due to the gross negligence or willful misconduct of Sangamo or a Sangamo Party.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.3 Claims Procedures.<font style="font-weight:normal;"> The Party claiming indemnity under this Article VII (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnified Partv</font><font style="font-weight:normal;">&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnifying Party</font><font style="font-weight:normal;">&#8221;) promptly after learning of the commencement of the relevant Third Party action, suit or proceeding (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Claim&#8221;</font><font style="font-weight:normal;">).  Subject to this Section 7.3, the Indemnifying Party shall have the right to assume and manage the defense thereof (with counsel selected by the Indemnifying Party and reasonably satisfactory to the Indemnified Party), including the right to settle, compromise and/or litigate with respect to any such Claim (but only after obtaining the Indemnified Party&#8217;s prior written consent with respect to any proposed settlement, compromise or litigation; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that the Indemnifying Party shall not be required to obtain the Indemnified Party&#8217;s prior written consent in connection with any proposed settlement, compromise or litigation if, in connection with and following any such settlement, compromise or litigation, the Indemnified Party (a) has no liability (monetary or otherwise), (b) has not waived any of its rights and has not admitted to any wrongdoing or guilt, (c) is not subject to any injunction or other equitable or non-monetary relief, and (d) receives a full and unconditional release of all applicable claims and liability).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.4<font style="font-weight:normal;"> </font>Participation; Assuming Control of the Defense.<font style="font-weight:normal;"> Notwithstanding Section 7.3 above, the Indemnified Party may participate in the defense of any Claim at the Indemnified Party&#8217;s sole expense, provided that, (a) the employment of counsel by the Indemnified Party has been authorized by the Indemnified Party; or (b) there is a conflict of interest that would prevent an Indemnitee from being represented by a single law firm in the defense of such action; in each such instance, the Indemnifying Party shall pay the reasonable fees and expenses of one law firm serving as counsel for the Indemnified Party, which law firm shall be subject to the prior consent of the Indemnifying Party, which such consent shall not be unreasonably withheld, conditioned or delayed.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.5<font style="font-weight:normal;"> </font>Advance Payment of Expenses.<font style="font-weight:normal;"> The expenses of an Indemnified Party incurred in defending a Claim shall be paid by the Indemnifying Party as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">undertaking by or on behalf of the Indemnified Party to repay the amount if it is ultimately determined by a court of competent jurisdiction that such Indemnified Party is not entitled to be indemnified by the Indemnifying Party. All costs and expenses incurred by an Indemnified Party in connection with enforcement of this Article VII also shall be reimbursed by the Indemnifying Party.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.6<font style="font-weight:normal;"> </font>Limitation of Liability.<font style="font-weight:normal;"> NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES, INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, IN CONNECTION WITH SUCH PARTY'S PERFORMANCE OR BREACH OF THIS AGREEMENT. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 7.6 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE V.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.7 Insurance.<font style="font-weight:normal;"> Sangamo shall maintain at its own expense, with a reputable insurance carrier reasonably acceptable to JDRF, full coverage for Sangamo, its Affiliates, and their respective employees that is commensurate with a reasonable estimate of the liability exposure associated with the Research Program, written on a per occurrence basis, which will name JDRF as an additional insured, including, without limitation, errors and omissions insurance encompassing claims relating to the performance and lack of performance of Sangamo&#8217;s obligations under this Agreement and comprehensive general liability insurance for claims relating to the performance and lack of performance of Sangamo&#8217;s obligations under this Agreement and comprehensive general liability insurance for claims for damages arising from bodily injury (including death) and property damages arising out of acts or omissions of a Sangamo Party which will be specifically endorsed to cover Sangamo&#8217;s indemnification obligations under this Article VII. Maintenance of such insurance coverage will not relieve Sangamo of any responsibility under this Agreement for damage in excess of insurance limits or otherwise. On or prior to the Effective Date, Sangamo shall provide JDRF with an insurance certificate from insurer(s) evidencing each insurance coverage and the insurer&#8217;s agreement to notify JDRF at least sixty (60) days in advance of any cancellation or modification of such insurance coverage.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the Interruption License becomes effective pursuant to Section 9.5, JDRF shall comply with the foregoing insurance requirements and shall maintain such insurance for as long as necessary to cover any claims that may arise from JDRF&#8217;s activities during the effectiveness of the Interruption License.</p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VIII PATENTABLE INVENTIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.1<font style="font-weight:normal;"> </font>Ownership.<font style="font-weight:normal;"> All inventions made and all data and know-how generated solely by either Party or its Affiliates (directly or through others acting on its behalf), as determined in accordance with United States laws of inventorship, prior to and during the term of this Agreement that relates to the Research Program shall be solely owned by the Party making the invention or generating the data or know-how, and all Patents claiming such inventions shall be solely owned by such Party. All inventions made and all data and know-how generated by both Parties jointly, as determined in accordance with United States laws of inventorship, prior to and during the term of this Agreement that relate to the Research Program (a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Invention&#8221;</font><font style="font-weight:normal;">), shall be owned jointly, with each Party having an undivided one-half interest in each Joint Invention and each Patent claiming a Joint Invention.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.2<font style="font-weight:normal;"> </font>Preparation.<font style="font-weight:normal;"> Sangamo shall take initial responsibility for the preparation, filing, prosecution and maintenance of all Sangamo Patents, JDRF Patents, and any patents and patent applications claiming Joint Inventions. JDRF shall have the right to review, and Sangamo shall deliver to JDRF, all patent applications for JDRF Patents or claiming Joint Inventions prior to their filing. With respect to such patent applications, Sangamo shall include in the Quarterly Reports delivered to JDRF pursuant to Section 3.2.3(a) the name of each patent application filed by Sangamo in the United States and other jurisdictions for such Joint Inventions and/or JDRF Patents, along with a general summary of the claims made and the jurisdictions of filing.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.3 Costs.<font style="font-weight:normal;"> Subject to Section 8.4, Sangamo shall be responsible for all costs incurred in the preparation, prosecution and maintenance of Sangamo Patents, JDRF Patents, and Joint Inventions.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.4 Abandonment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Notwithstanding any contrary provision contained herein, prior to the Interruption License Effective Date, before Sangamo (or any Affiliate, licensee, sublicensee, transferee or successor of Sangamo) abandons any patent or patent application for any JDRF Patents or claiming any Joint Inventions (including abandonment for failure to pay any required fees), Sangamo shall promptly notify JDRF, or cause JDRF to be notified, of such pending abandonment, whereupon JDRF shall have the right and opportunity to take title to such patent and/or patent application by agreeing to maintain the issued patent or continue prosecution of the patent application at JDRF&#8217;s own expense.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Following the Interruption License Effective Date, before Sangamo (or any Affiliate, licensee, sublicensee, transferee or successor of Sangamo) abandons any patent or patent application for any JDRF Patents, claiming any Joint Inventions, or for any Sangamo Patents (including abandonment for failure to pay any required fees), Sangamo shall promptly notify JDRF, or cause JDRF to be notified, of such pending abandonment, whereupon JDRF shall have the right and opportunity to take title to such patent and/or patent application by agreeing to maintain the issued patent or continue prosecution of the patent application at JDRF&#8217;s own expense. Sangamo shall reasonably cooperate with JDRF to obtain such consents, on JDRF&#8217;s behalf, as may be necessary, advisable and/or appropriate for JDRF to exercise its rights under this Section 8.4.</p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IX TERM AND TERMINATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.1<font style="font-weight:normal;"> </font>Term.<font style="font-weight:normal;"> This Agreement shall become effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this Article IX, shall terminate at such time as when there are no longer any payment obligations owing from either Party to the other Party under Article IV hereto.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.2 Termination by JDRF With Cause.<font style="font-weight:normal;"> Notwithstanding any provision contained herein, JDRF may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement if, after the occurrence of a Default (as defined herein) and Sangamo&#8217;s receipt of a written notice from JDRF identifying such Default, Sangamo fails to cure such Default within sixty (60) days after Sangamo&#8217;s receipt of such notice. The following events shall constitute a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Default</font><font style="font-weight:normal;">&#8221; hereunder:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Any material breach by Sangamo of any applicable foreign, federal, state or local laws, statutes, rules or regulations in the course of its performance of the Research Program;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any material breach or default by Sangamo in the performance of any of its material covenants or obligations hereunder;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Any representation or warranty made by Sangamo in this Agreement is not true in any material respects as of the Effective Date; and/or</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) A case or proceeding (i) under the bankruptcy laws of the United States now or hereafter in effect is filed against Sangamo or all or substantially all of its assets and such petition or application is not dismissed within sixty (60) days after the date of its filing or Sangamo shall file any answer admitting and not contesting such petition, or (ii) under the bankruptcy laws of the United States now or hereafter in effect is filed by Sangamo for all or substantially all of its assets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clarity, an Interruption shall not, for the purposes of this Section 9.2, be considered a material breach or default by Sangamo in the performance of any of its material covenants or obligations hereunder. JDRF&#8217;s remedies in the event of an Interruption are set forth in Section 9.5 rather than in this Section 9.2.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.3<font style="font-weight:normal;"> </font>Termination for JDRF Breach.<font style="font-weight:normal;"> Sangamo may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement upon written notice to JDRF in the event JDRF shall have materially breached or defaulted in the performance of any of its material covenants or obligations hereunder, and JDRF fails to cure such breach or default within sixty (60) days after written notice thereof was provided to JDRF by Sangamo.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.4 General Effect of Termination; Survival.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) If this Agreement is terminated for any reason, all of the Parties&#8217; rights and obligations under, and/or the provisions contained in, Sections 3.2.1, 3.2.2, 3.2.3(b), and 9.4, Articles V, VI, VII, VIII, and XI shall survive expiration, termination or relinquishment of this Agreement. If this Agreement is terminated pursuant to Section 9.2 and no Interruption License is in effect at the time of such termination, in addition to the provisions specified in the preceding sentence, the Parties&#8217; rights and obligations under, and/or provisions contained in Sections 4.2, 4.3, 4.4 and 9.5 shall also survive such termination. In the event that, pursuant to Section 9.5, the Interruption License becomes effective prior to termination of this Agreement pursuant to Sections 9.1 or 9.2, in addition to the provisions specified in the first sentence of this Section 9.4(b), the Parties&#8217; rights and obligations under, and/or provisions contained in Sections 4.4, 9.5(e), 9.5(g) and 9.5(h) shall survive such termination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Sangamo will retain sole ownership of the Sangamo Research Program Technology.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.5 Interruption License.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) In the event JDRF determines that an Interruption has occurred, it shall notify Sangamo in writing of such belief, stating in reasonable detail the basis for its belief that an Interruption has occurred (the &#8220;<font style="text-decoration:underline;">Interruption Notice</font>&#8221;). If at the time of receipt of the Interruption Notice, Sangamo (i) has not licensed or otherwise transferred rights to a Third Party to the Sangamo Research Program Technology in the Field; or (ii) has successfully terminated the rights it licensed or otherwise transferred to a Third Party to the Sangamo Research Program Technology in the Field, then Sangamo shall have sixty (60) days after the receipt of the Interruption Notice to avoid the Interruption License Effective Date by (x) responding to the Interruption Notice by explaining why it believes an Interruption has not occurred (the &#8220;<font style="text-decoration:underline;">Interruption Response</font>&#8221;); or (y) resuming Commercially Reasonable Efforts (either itself or through an Affiliate, collaborator, licensee, sublicensee, transferee, or successor); provided that, Sangamo may avoid the Interruption License Effective Date by any such resumption only once.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) If at the time of receipt of the Interruption Notice, Sangamo has licensed or otherwise transferred rights to a Third Party to the Sangamo Research Program Technology in the Field pursuant to an agreement that includes a provision that gives Sangamo the right to terminate such Third Party&#8217;s rights under the Sangamo Research Program Technology in the Field upon a final determination that an Interruption has occurred and not been cured within the applicable time after the relevant notice, then Sangamo shall have sixty (60) days after the receipt of the Interruption Notice to avoid the Interruption License Effective Date by (i) providing an Interruption Response to JDRF; or (ii) commencing and continuing thereafter commercially reasonable efforts to effect such a termination. If Sangamo successfully effects such a termination then it shall have sixty (60) days after the termination effective date to avoid the Interruption License Effective Date by resuming Commercially Reasonable Efforts (either itself or through an Affiliate, collaborator, licensee, sublicensee, transferee, or successor); provided that, Sangamo may avoid the Interruption License Effective Date by any such resumption only once.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) If Sangamo provides an Interruption Response within the sixty (60) day period set forth in Section 9.5(a) or 9.5(b) and JDRF disagrees with the Interruption Response, JDRF may resolve such Dispute in accordance with Section 11.2. Sangamo shall have sixty (60) days after a final determination pursuant to Section 11.2 that an Interruption has occurred (or if earlier a subsequent written admission by Sangamo that an Interruption has occurred) to avoid the Interruption License Effective Date by (i) resuming Commercially Reasonable Efforts (either itself or through an Affiliate, collaborator, licensee, sublicensee, transferee, or successor); provided that, Sangamo may avoid the Interruption License Effective Date by any such resumption only once; or (ii) if Sangamo provided the Interruption Response pursuant Section 9.5(b), commencing and continuing thereafter commercially reasonable efforts to terminate such Third Party&#8217;s rights under the Sangamo Research Program Technology in the Field upon a final determination that an Interruption has occurred and not been cured within the applicable time after the relevant notice. If Sangamo successfully effects such a termination then it shall have sixty (60) days after the termination effective date to avoid the Interruption License Effective Date by resuming Commercially Reasonable Efforts (either itself or through an Affiliate, collaborator, licensee, sublicensee, transferee, or successor); provided that, Sangamo may avoid the Interruption License Effective Date by any such resumption only once.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) The &#8220;<font style="text-decoration:underline;">Interruption License Effective Date</font>&#8221; shall be the first of the following events to occur: (i) the expiration of the sixty (60) day period set forth in Section 9.5(a) without Sangamo having taken any of the actions specified in Section 9.5(a), (ii) Sangamo&#8217;s agreement in writing, following receipt of the Interruption Notice, that an Interruption has occurred (provided, however, that none of Sangamo&#8217;s written communications pursuant to Section 9.5(b)(ii) or 9.5(c)(ii) shall be considered such an agreement), (iii) the expiration of the applicable sixty (60) day period set forth in Section 9.5(b) without Sangamo having taken any of the actions specified in Section 9.5(b), or (iv) the expiration of the applicable sixty (60) day period set forth in Section 9.5(c) without Sangamo having taken any of the actions specified in Section 9.5(c).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) Upon the Interruption License Effective Date, Sangamo shall be deemed to have automatically granted to JDRF with respect to the Research Program an exclusive (even as to Sangamo) worldwide license, with the right to sublicense, under the Sangamo Research Program Technology, to manufacture, have manufactured, sell, offer to sell and import the Product in the Field (the &#8220;<font style="text-decoration:underline;">Interruption License</font>&#8221;). Sangamo&#8217;s obligations pursuant to Sections 3.2.3(d), 4.1 and 4.2 shall expire upon the Interruption License Effective Date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) For clarity, prior to the Interruption License Effective Date, Sangamo shall be free to license to a Third Party the Sangamo Research Program Technology (including the grant of exclusive worldwide sublicensable rights under Sangamo Research Program Technology for such Third Party to research, develop, or commercialize the Product). In the event that Sangamo commences negotiations with a Third Party to transfer all of or certain of Sangamo&#8217;s rights under the Sangamo Research Program Technology to such Third Party to develop and commercialize a Product in the Field, Sangamo shall use best commercial efforts to include in the agreement a provision that gives Sangamo the right to terminate such Third Party&#8217;s rights under the Sangamo Research Program Technology in the Field upon a final determination that an Interruption has occurred and not been cured within the applicable time after the relevant notice; and solely for purposes of this Section 9.5, the term &#8220;Interruption&#8221; with respect to a Sangamo Third Party licensee or transferee shall be defined in a manner that is as close to the definition contained in Section 1.22 as Sangamo, by the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise of best commercial efforts, is able to include in the executed agreement with such Third Party. In the event that Sangamo does not successfully negotiate such a provision, then Sangamo shall so notify JDRF prior to Sangamo&#8217;s execution of the agreement with such Third Party and, upon receipt of such notice, JDRF shall no longer have any right to obtain the Interruption License with respect to the Sangamo Research Program Technology licensed or transferred to such Third Party.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g) In connection with this Section 9.5, Sangamo shall deliver to JDRF, within sixty (60) days of the Interruption License Effective Date, all materials and data generated in the performance of the Research Program and the Sangamo Research Program Technology and all other materials and data that Sangamo may Control that are reasonably required by JDRF to manufacture, have manufactured, sell, offer to sell and import the Product in the Field, provided that the foregoing obligations shall apply only to the extent such materials or data are reasonably accessible and available to Sangamo.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h) Notwithstanding the foregoing or any contrary provision contained in this Section 9.5, if, following the Interruption License Effective Date, JDRF ceases to conduct Commercially Reasonable Efforts with respect to the research, development and commercialization of the Product in the Field for a period of one hundred eighty (180) consecutive days then upon the expiration of such 180-day period (the &#8220;<font style="text-decoration:underline;">Reversion License Effective Date</font>&#8221;) the Interruption License shall terminate and, in accordance with the terms and conditions of this Agreement, JDRF shall be deemed to have automatically granted to Sangamo a non-exclusive, royalty-free, fully paid, irrevocable, perpetual, worldwide license (with the right to grant sublicenses), under the JDRF Interruption License Technology to research, develop, make, have made, use, import, offer for sale and sell the Product in the Field. In addition, JDRF shall deliver to Sangamo within sixty (60) days of the Reversion License Effective Date all materials and data generated by JDRF and all other materials and data that JDRF may Control that are reasonably required by Sangamo to manufacture, have manufactured, sell, offer to sell and import the Product in the Field, provided that the foregoing obligations shall apply only to the extent such materials or data are reasonably accessible and available to JDRF.</p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE X REPRESENTATIONS AND WARRANTIES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1 Representations, Warranties and Covenants of Sangamo.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) As of the Effective Date, Sangamo represents and warrants to JDRF that: (i) this Agreement has been duly executed and delivered by Sangamo and constitutes tbe valid and binding obligation of Sangamo, enforceable against Sangamo in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of Sangamo and its directors and stockholders; (iii) the individual executing this Agreement on behalf of Sangamo is duly authorized to do so; and (iv) no provision contained in this Agreement violates any other agreement to which Sangamo is bound or otherwise subject.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) In addition to the foregoing, as of the Effective Date, Sangamo represents, warrants and covenants to JDRF that (i) while guaranteeing no specific results, it has the knowledge, skills, expertise and experience to perform the Research Program or the resources to engage Persons to perform the Research Program who have such knowledge, skills, expertise and experience; (ii) it has and shall maintain all licenses, permits and other approvals and authorizations required for Sangamo to conduct work under the Research Program consistent with its obligations pursuant to this Agreement and shall do so in conformity with all applicable laws, statutes, rules and regulations, and the applicable policies of any and all medical research institutions at which Sangamo is conducting work under the Research Program (collectively, &#8220;<font style="text-decoration:underline;">Applicable Law</font>&#8221;); (iii) it shall abide by and comply with all of the applicable provisions and conditions set forth in the &#8220;JDRF Policies and Conditions Regarding Funding of Research Involving Human Clinical Trials,&#8221; attached hereto as <font style="font-weight:bold;text-decoration:underline;">Exhibit C </font>(the &#8220;<font style="text-decoration:underline;">Policies</font>&#8221;), and Sangamo hereby acknowledges that it is a &#8220;Sponsor&#8221; within the meaning of such Policies; (iv) it shall not enter into any arrangement, understanding or agreement that conflicts in any marmer with this Agreement and Sangamo&#8217;s obligations and responsibilities hereunder; provided that the foregoing shall not be interpreted as prohibiting Sangamo from entering into an agreement with a Third Party whereby such Third Party would research, develop, make, have made, use, import, offer for sale and sell the Product or participate in the Research Program; and (v) with respect to any Third Party to whom Sangamo subcontracts the performance of any aspect of the Research Program, Sangamo shall: (A) subcontract only with reputable entities that possess the knowledge, skills, expertise, and experience necessary to perform such services; (B) use Commercially Reasonable Efforts to ensure that each such subcontractor possesses and shall maintain all necessary licenses, permits, approvals or authorizations necessary for such subcontractor to conduct its work under the Research Program; and (C) use Commercially Reasonable Efforts to ensure that each such subcontractor conducts all work under the Research Program in conformity with Applicable Law.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.2 Representations and Warranties of JDRF.<font style="font-weight:normal;"> As of the Effective Date, JDRF represents and warrants to Sangamo that: (a) this Agreement has been duly executed and delivered by JDRF and constitutes the valid and binding obligation of JDRF, enforceable against JDRF in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">reorganization, moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles; (b) the execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of JDRF and its directors; (c) the individual executing this Agreement on behalf of JDRF is duly authorized to do so; and (d) no provision contained in this Agreement violates any other agreement to which JDRF is bound or otherwise subject.</font></p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XI MISCELLANEOUS PROVISIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.1 Governing Law.<font style="font-weight:normal;"> This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without regard to any conflict of laws principles thereof that would cause the application of the laws of a different jurisdiction.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.2 Dispute Resolution.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) In the event of any dispute, claim or controversy arising out of, relating to or in any way connected to the interpretation of any provision of this Agreement, the performance of either Party under this Agreement or any other matter under this Agreement, including any action in tort, contract or otherwise, at equity or law (a &#8220;Dispute&#8221;), either Party may at any time provide the other Party written notice specifying the terms of such Dispute in reasonable detail. As soon as practicable after receipt of such notice, the Chief Executive Officers, or their respective designees, of both JDRF and Sangamo shall meet at a mutually agreed upon time and location for the purpose of resolving such Dispute. The Chief Executive Officers, or their respective designees, shall engage in good faith discussions and/or negotiations for a period of up to thirty (30) days to resolve the Dispute or negotiate an interpretation or revision of the applicable portion of this Agreement which is mutually agreeable to both Parties without the necessity of formal dispute resolution procedures relating thereto. During the course of such discussion and/or negotiation, the Parties shall reasonably cooperate in order that each of the Chief Executive Officers, or their respective designees, may be fully informed with respect to the issues in the Dispute.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) In the event any Dispute is not resolved by the Chief Executive Officers, or their respective designees, pursuant to Section 11.2(a), then the Parties shall resolve such Dispute by final and binding arbitration. Arbitration shall be held in New York, NY, according to the then-current JAMS&#8217; Commercial Rules of Arbitration (&#8220;<font style="text-decoration:underline;">JAMS&#8217; Rules</font>&#8221;), except to the extent such rules are inconsistent with this Section 11.2. The arbitration will be conducted by one (1) arbitrator who shall be reasonably acceptable to the Parties and who shall be appointed in accordance with JAMS&#8217; Rules. If the Parties are unable to select an arbitrator, then the arbitrator shall be appointed in accordance with JAMS&#8217; Rules. Any arbitrator chosen hereunder shall have educational training and industry experience sufficient to demonstrate a reasonable level of relevant scientific, financial, medical and biotechnology industry knowledge. Within twenty (20) days of the selection of the arbitrator, each Party shall submit to the arbitrator a proposed resolution of the Dispute that is the subject of the arbitration (the &#8220;Proposals&#8221;).  The arbitrator shall thereafter select one of the Proposals so submitted as the resolution of the Dispute, but may not alter the terms of either Proposal and may not resolve the Dispute in a manner other than by selection of one of the submitted Proposals. If a Party fails to submit a Proposal in accordance with the terms of this Section 11.2(b), the arbitrator shall select the Proposal of the other Party as the resolution of the Dispute. The arbitrator shall agree to render its opinion within thirty (30) days of the final arbitration hearing. No arbitrator shall have the power to award punitive damages under this Agreement regardless of whether any such damages are contained in a Proposal, and such award is expressly prohibited. The proceedings and decisions of the arbitrator shall be confidential, final and binding on all of the Parties. Judgment on the award so rendered may be entered in a court having jurisdiction thereof. The Parties shall share the costs of arbitration according to the decision of the arbitrator. Nothing in this Section 11.2(b) will preclude either Party from seeking equitable relief in accordance with Section 11.3 or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.3 Equitable Relief.<font style="font-weight:normal;"> The Parties acknowledge and agree that, in the event of a breach or a threatened breach by either Party of this Agreement for which there is no adequate remedy at law, the other Party may suffer irreparable damage and accordingly, shall be entitled to seek injunctive and other equitable remedies to prevent or restrain such breach or threatened breach, in addition to any other remedy such Party might have at law or at equity.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.4 Waiver.<font style="font-weight:normal;"> No provision of this Agreement may be waived except in writing by both Parties hereto. No failure or delay by either Party hereto in exercising any right or remedy hereunder or under applicable law will operate as a waiver thereof, or a waiver of any right or remedy on any subsequent occasion.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.5 Force Majeure.<font style="font-weight:normal;"> Neither Party will be in breach hereof by reason of its delay in the performance of or failure to perform any of its obligations hereunder, if that delay or failure is caused by strikes, acts of God or the public enemy, riots, incendiaries, interference by civil or military authorities, compliance with governmental priorities for materials, or any fault beyond its reasonable </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">control. In such event Sangamo or JDRF, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.6 Severability.<font style="font-weight:normal;"> Should one or more provisions of this Agreement be or become invalid, then the Parties hereto shall attempt to agree upon valid provisions in substitution for the invalid provisions, which in their economic effect come so close to the invalid provisions that it can be reasonably assumed that the Parties would have accepted this Agreement with those new provisions. If the Parties are unable to agree on such valid provisions, the invalidity of such one or more provisions of this Agreement shall nevertheless not affect the validity of the Agreement as a whole, unless the invalid provisions are of such essential importance for this Agreement that it may be reasonably presumed that the Parties would not have entered into this Agreement without the invalid provisions.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.7<font style="font-weight:normal;"> </font>Assignment.<font style="font-weight:normal;"> This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that either Party may assign this Agreement, without the consent of the other Party, (i) to any of its Affiliates, if the assigning Party guarantees the full performance of its Affiliate&#8217;s obligations hereunder; (ii) in connection with such Party&#8217;s merger, consolidation or transfer or sale of all or substantially all of the assets of such Party; or (iii) to any Third Party to whom Sangamo grants an exclusive or co-exclusive license to develop the Product in the Field, </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">, that in the case of (ii) or (iii) hereunder, the successor, surviving entity, purchaser of assets, transferee, or Third Party, as applicable, expressly assumes in writing such Party&#8217;s obligations under this Agreement. Any purported assignment in contravention of this Section 11.7 shall, at the option of the non&#173; assigning Party, be null and void and of no effect. No assignment shall release either Party from responsibility for the performance of any accrued obligation of such Party hereunder. This Agreement shall be binding upon and enforceable against the successor to or any permitted assignees from either of the Parties hereto.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.8 Counterparts.<font style="font-weight:normal;"> This Agreement may be executed in duplicate, each of which shall be deemed to be original and both of which shall constitute one and the same Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.9 No Agency.<font style="font-weight:normal;"> Nothing herein contained shall be deemed to create an agency, joint venture, amalgamation, partnership or similar relationship between JDRF and Sangamo. Notwithstanding any of the provisions of this Agreement, neither Party to this Agreement shall at any time enter into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever, and all contracts, expenses and liabilities in connection with or relating to the obligations of each Party under this Agreement shall be made, paid, and undertaken exclusively by such Party on its own behalf and not as an agent or representative of the other.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.10 Notice.<font style="font-weight:normal;"> All communications between the Parties with respect to any of the provisions of this Agreement will be sent to the addresses set out below, or to such other addresses as may be designated by one Party to the other by notice pursuant hereto, by prepaid, certified mail (which shall be deemed received by the other Party on the fifth (5th) business day following deposit in the mails), or by facsimile transmission, or other electronic means of communication (which shall be deemed received when successful transmission is confirmed), with confirmation by first class letter, postage pre-paid, given by the close of business on or before the next following business day:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if to JDRF, at:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:13.61%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Insel, M.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President for Research</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Juvenile Diabetes Research Foundation International</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120 Wall Street, 16th Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10005-4001</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel.: (212) 785-9500</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: (212) 785-9595</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="text-decoration:underline;">rinsel@jdrf.com </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kenneth I. Schaner, Esq.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bingham McCutchen LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3000 K Street, N.W., Suite 300</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20007</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel: (202) 373-6518</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: (202) 424-7647</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: kenneth.schaner@bingham.com</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if to Sangamo, at:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:13.61%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501 Canal Boulevard, Suite A100</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richmond, CA 94804</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Executive Officer</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:13.61%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marya Postner, Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley Godward, LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Palo Alto Square</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3000 El Camino Real</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.6%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94306</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.11<font style="font-weight:normal;"> </font>Headings. <font style="font-weight:normal;">The paragraph headings are for convenience only and will not be deemed to affect in any way the language of the provisions to which they refer.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.12<font style="font-weight:normal;"> </font>Entire Agreement.<font style="font-weight:normal;"> This Agreement contains the entire understanding of the Parties relating to the matters referred to herein, and may only be amended by a written document, duly executed on behalf of the respective Parties.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> [Remainder of Page Intentionally Left Blank.]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first Written above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:5.5%;"></td>
<td style="width:44.5%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ EDWARD O. LANPHIER</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EDWARD O. LANPHIER</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Juvenile Diabetes Research Foundation International</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard A. Insel</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard A. Insel</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President for Research</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit B</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research Funding and Milestones</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I. Payment Schedule for Research Funding: Up to an aggregate amount of Three Million Dollars ($3,000,000), payable as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:540.6pt;;">
<tr>
<td style="width:270.5pt;"></td>
<td style="width:270.1pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment Amount($)</p></td>
</tr>
<tr style="height:46.5pt;">
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Upon the Effective Date, if FDA acceptance of phase 2 plan (102 patients in two treatment groups) has occurred; or upon FDA acceptance of such Phase 2 plan, if such acceptance has not yet occurred as of the Effective Date</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:13.6pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Enrollment of the first Qualified Subject</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:13.6pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Enrollment of the 25<sup style="font-size:85%; vertical-align:top">th</sup> Qualified Subject</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:13.6pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. Enrollment of the 50<sup style="font-size:85%; vertical-align:top">th</sup> Qualified Subject</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:13.95pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. Enrollment of the 100<sup style="font-size:85%; vertical-align:top">th</sup> Qualified Subject</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:26.5pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6. Receipt by JDRF of the final report of the Primary Statistical Analysis</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II. Payments pursuant to this <font style="font-weight:bold;text-decoration:underline;">Exhibit B </font>shall be paid by JDRF to Sangamo within forty-five (45) days following JDRF&#8217;s receipt from Sangamo of a written certification setting forth Sangamo&#8217;s achievement of the applicable Milestone unless the JRAC determines, in a meeting held within such forty-five (45) day period, that such Milestone was not achieved. If JRAC&#8217;s vote on such matter during such meeting is not unanimous, then JDRF shall make the applicable payment within forty-five (45) days following resolution of such dispute in Sangamo&#8217;s favor.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit C</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">JDRF Policies and Conditions Regarding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Funding of Research Involving Human Clinical Trials</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JDRF will fund research involving human clinical trials only if the Sponsor of the trial can assure JDRF, with a reasonable degree of certainty, that the following conditions will be met:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The research will be conducted in accordance with basic ethical principles as reflected in the Nuremburg Code, the World Medical Association Declaration of Helsinki and the Belmont Report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The research will comply with governmental regulatory requirements and guidance, as applicable;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The research will be reviewed and approved by an institutional review board to assure that risk is minimized and reasonable in relation to anticipated benefits, that voluntary informed consent is given, and that the rights, safety and welfare of the subjects are maintained;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The investigators will be qualified by training, education and experience to assume responsibility for the proper conduct of the trial and to comply with good clinical practices;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A qualified physician will be responsible for all trial-related medical decisions. During and following a subject&#8217;s participation in the trial, the investigator will arrange for adequate medical care to be provided to a subject for any adverse events, including clinically significant laboratory values, related to the trial;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Conflicts of interest will be disclosed and appropriate action taken;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Safety reporting, including serious adverse event reports, will be made in a timely fashion and in accordance with applicable regulatory requirements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Sponsor of the trial will implement and maintain quality assurance and quality control systems with written standard operating procedures in order to conduct the trial, generate data and document compliance with the protocol, good clinical practices and applicable regulatory requirements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The clinical trial will be registered in a public registry acceptable to JDRF, if applicable; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The investigators conducting the research, the responsible institutional review board and the Sponsor will engage in ongoing compliance and review activity to promote and assure the integrity of the research.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit D</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Press Release</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>sgmo-ex102_20150331594.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIRST AMENDMENT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH, DEVLEOPMENT AND COMMERCIALIZATION AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BETYWEEN SANGAMO BIOSCIENCES, INC. (&#8220;SANGAMO&#8221;) AND JUVENILE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DIABETES RESEARCH FOUNDATION INTERNATIONAL (&#8220;JDRF&#8221;)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This First Amendment (this &#8220;First Amendment&#8221;) to the Agreement of October 24, 2006 is made as of this 8<sup style="font-size:85%; vertical-align:top">th</sup> day of January 2010 (the &#8220;First Amendment Effective Date&#8221;) by and between Sangamo and JDRF. Capitalized terms used but not defined herein shall have the definition provided in this Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties entered into the Agreement; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties now desire to amend the Agreement so that JDRF may support Sangamo&#8217;s SB-509-901 clinical trial which is entitled &#8220;A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects with Moderately Severe Diabetic Neuropathy&#8221;.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, in consideration of the foregoing, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Confirmation of Terms</font>.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as provided in this First Amendment, the Agreement shall remain in full force and effect.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Acknowledgement</font>.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties hereby acknowledge that, prior to the First Amendment Effective Date, Sangamo fulfilled its obligations under the Agreement to perform the Research Plan as described in Exhibit A and to achieve the Milestones set forth in Exhibit B as it existed prior to the First Amendment Effective Date, and JDRF fulfilled its obligations under the Agreement to pay to Sangamo the amounts set forth in Exhibit B as it existed prior to the First Amendment Effective Date.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Amendment to Agreement</font>.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following amendments shall be made to the Agreement:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The term &#8220;Award&#8221; as defined in Section 1.5 of the Agreement shall be amended to substitute &#8220;Six Million Dollars ($6,000,000&#8221;)&#8221; in lieu of &#8220;Three Million Dollars ($3,000,000)&#8221; previously specified therein:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) The definiton of &#8220;Research Plan&#8221; as set forth in Section 1.54 of the Agreement shall be replaced with the following: &#8220;<font style="text-decoration:underline;">Research Plan</font>&#8221; means (a) the written protocol for Sangamo&#8217;s Phase II Repeat Dosing Clinical Trial of SB-509, that shall be attached to this Agreement as <font style="font-weight:bold;text-decoration:underline;">Exhibit A</font> upon approval by the FDA, which protocol was based on the Application, includes the JDRF Studies, and has been accepted &#8217;y the FDA, as modified from time to time by Sangamo in consultation with the FDA and in accordance with Section 2.4 and (b) the written protocol for Sangamo&#8217;s SB-509-901 clinical trial that is attached to the First Amendment as <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font>, which Exhibit will be updated to reflect any amendments to such protocol that are agreed upon by Sangamo and the FDA.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Section 3.1.2(a) shall be amended by increasing &#8220;Three Million Dollars ($3,000,000)&#8221; to &#8220;Six Million Dollars ($6,000,000)&#8221;;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Section 7. 7 (Insurance) of the Agreement is hereby deleted in its entirety and is replaced with the following provision:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Insurance.<font style="font-weight:normal;"> Sangamo shall maintain at its own expense, with a reputable insurance carrier reasonably acceptable to JDRF, coverage for Sangamo, its Affiliates, and their respective employees written on a per occurrence basis commensurate with a reasonable assessment of the risks associated with the research efforts being conducted by Sangamo, the following policies:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Comprehensive general liability insurance for claims relating to the performance and lack of performance of Sangamo&#8217;s obligations under this Agreement;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Comprehensive general liability insurance for claims for damages, including, damages as a result of bodily injury (including death) and damages to property, arising out of acts or omissions of a Sangamo Party;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Products liability insurance for claims for damages, including, damages as a result of bodily injury (including death) and damages to property, arising out of the acts or omissions of a Sangamo Party; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Clinical trials liability insurance for damages, including, damages as a result of bodily injury (including death) and damages to property, arising out of any clinical trials conducted by Sangamo in connection with its obligations under the Agreement, or arising out of the acts or omissions of a Sangamo Party. This insurance shall specifically include coverage for obligations and liabilities of Sangamo under any clinical trial agreement or protocol that is a part of clinical trials conducted by Sangamo under the Agreement and for liability arising as a result of allegations of the insufficiency or other defects in the informed consent provided to participants in the clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All insurance policies required hereunder shall name JDRF as an additional insured, be specifically endorsed to cover Sangamo&#8217;s indemnification obligations under this Article VII and be written with coverage limits approved by JDRF. Maintenance of such insurance coverage will not relieve Sangamo of any responsibility under this Agreement for damage in excess of insurance limits or otherwise. On or prior to the First Amendment Effective Date, Sangamo shall provide JDRF with an insurance certificate from the insurer(s) evidencing each insurance coverage and the insurer&#8217;s agreement to notify JDRF at least sixty (60) days in advance of any cancellation or material modification of such insurance coverage. At its request, JDRF may review Sangamo&#8217;s insurance coverage with relevant Sangamo officials from time to time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the lnterruption License becomes effective pursuant to Section 9.5, JDRF shall comply with the foregoing insurance requirements and shall maintain such insurance for as long as necessary to cover any claims that may arise from JDRF&#8217;s activities during the effectiveness of the Interruption License.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) Section 11 .10 shall be amended to replace the notice address for JDRF with the following:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Insel, MD</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, Research</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Juvenile Diabetes Research Foundation International</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26 Broadway, 14th Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10004</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel.: 212-479-7604</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: rinsel@ jdrf.org</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) Exhibit B shall be replaced with the Exhibit B attached to this First Amendment; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g) Exhibit C attached to this First Amendment shall be added to the Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signatures on next page]</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the undersigned have executed this First Amendment as of the First Amendment Effective Date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:53.33%;width:48.67%;">
<tr>
<td style="width:6.94%;"></td>
<td style="width:41.72%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Edward O. Lanphier</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward O. Lanphier</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:53.33%;width:48.67%;">
<tr>
<td style="width:6.94%;"></td>
<td style="width:41.72%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Juvenile Diabetes Research Foundation International</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Alan J. Lewis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alan J. Lewis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT B</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH FUNDING AND MILESTONES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I. Payment Schedule for Research Funding: Up to an aggregate amount of Six Million Dollars ($6,000,000), payable as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.81%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="RANGE!A1:B13"></a>Milestones</p></td>
<td valign="bottom"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment Amount ($)</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.&#160;&#160;Upon the Effective Date, if FDA acceptance of Phase 2 plan (102 patients in two treatment groups) has occurred; or upon FDA acceptance of such Phase 2 plan, if such acceptance has not yet occurred as of the Effective Date</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.&#160;&#160;Enrollment of the first Qualified Subject</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.&#160;&#160;Enrollment of the 25<sup style="font-size:85%; vertical-align:top">t</sup><sup style="font-size:85%; vertical-align:top">h</sup> Qualified Subject</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.&#160;&#160;Enrollment of the 50<sup style="font-size:85%; vertical-align:top">t</sup><sup style="font-size:85%; vertical-align:top">h</sup> Qualified Subject</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.&#160;&#160;Enrollment of the 100<sup style="font-size:85%; vertical-align:top">th</sup> Qualified Subject</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.&#160;&#160;Receipt by JDRF of the final report of the Primary Statistical Analysis</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.&#160;&#160;Initiation of patient screening for SB-509-901</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$250,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.&#160;&#160;First patient for SB-509-901 randomized by assignment of randomization number</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$250,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.&#160;&#160;76<sup style="font-size:85%; vertical-align:top">th</sup> patient, or 50% of the then planned number of patients for SB-509-901, whichever occurs first, randomized by assignment of randomization number</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.&#160;&#160;150<sup style="font-size:85%; vertical-align:top">t</sup><sup style="font-size:85%; vertical-align:top">h</sup> patient, or the last planned patient for SB-509-901, whichever occurs first, randomized by assignment of randomization number</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.&#160;&#160;Submission to JDRF of day 180 data analysis for SB-509-901</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.&#160;&#160;Submission to JDRF of day 360 data analysis for SB-509-901</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:84.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.&#160;&#160;Submission to JDRF of draft clinical study report for SB-509-901</p></td>
<td valign="top"  style="width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:4pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$500,000</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II Payments pursuant to this <font style="font-weight:bold;text-decoration:underline;">Exhibit B</font> shall be paid by JDRF to Sangamo within forty-five (45) days following JDRF&#8217;s receipt from Sangamo of a written certification setting forth Sangamo&#8217;s achievement of the applicable Milestone unless the JRAC determines, in a meeting held within such forty-five (45) day period, that such Milestone was not achieved. If JRAC&#8217;s vote on such matter during such meeting is not unanimous, then JDRF shall make the applicable payment within forty-five (45) days following resolution of such dispute in Sangamo&#8217;s favor.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:18pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;margin-left:19.73%;margin-right:15.19%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical<font style="letter-spacing:2.75pt;"> </font>Study<font style="letter-spacing:1.95pt;"> </font>Protocol</p>
<p style="text-align:center;margin-top:25pt;margin-bottom:0pt;margin-left:6.27%;margin-right:2.22%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:1.25pt;"> </font>Phase<font style="letter-spacing:2.2pt;"> </font>2b<font style="letter-spacing:1.65pt;"> </font>Repeat<font style="letter-spacing:3.05pt;"> </font>Dosing<font style="letter-spacing:3.05pt;"> </font>Clinical<font style="letter-spacing:2.55pt;"> </font>Trial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.27%;margin-right:2.22%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of<font style="letter-spacing:1.15pt;"> </font>SB-509<font style="letter-spacing:2.45pt;"> </font>in<font style="letter-spacing:1.1pt;"> </font>Subjects<font style="letter-spacing:4pt;"> </font>with<font style="letter-spacing:1.8pt;"> </font>Moderately</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.27%;margin-right:2.22%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Severe<font style="letter-spacing:2.1pt;"> </font>Diabetic<font style="letter-spacing:3.95pt;"> </font>Neuropathy</p>
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Protocol Number</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509-0901</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BB-IND</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12189</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sponsor</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo<font style="letter-spacing:1.85pt;"> </font>BioSciences,<font style="letter-spacing:2.1pt;"> </font>Inc.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Point<font style="letter-spacing:1.3pt;"> </font>Richmond<font style="letter-spacing:2.1pt;"> </font>Tech<font style="letter-spacing:1.1pt;"> </font>Center<font style="letter-spacing:1.35pt;"> </font>II</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501<font style="letter-spacing:1.3pt;"> </font>Canal<font style="letter-spacing:1pt;"> </font>Blvd.,<font style="letter-spacing:1.45pt;"> </font>Suite<font style="letter-spacing:1.05pt;"> </font>A100</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richmond,<font style="letter-spacing:1.75pt;"> </font>CA 94804</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phone:<font style="letter-spacing:1.6pt;"> </font>(5<font style="letter-spacing:0.05pt;">1</font>0)<font style="letter-spacing:1.2pt;"> </font>970-6000</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax:<font style="letter-spacing:1.1pt;"> </font>(5<font style="letter-spacing:-0.35pt;">1</font>0)<font style="letter-spacing:1.05pt;"> </font>970-6009</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Medical<font style="letter-spacing:-1.25pt;"> </font>Monitor</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ely<font style="letter-spacing:1.15pt;"> </font>Benaim,<font style="letter-spacing:1.5pt;"> </font>M.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phone: (510)<font style="letter-spacing:1.35pt;"> </font>970-7868</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: (510)<font style="letter-spacing:0.8pt;"> </font>970-6009</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Original<font style="letter-spacing:-1.1pt;"> </font>Date</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August<font style="letter-spacing:1.05pt;"> </font>18,<font style="letter-spacing:1.05pt;"> </font>2009</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:6pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:right;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amendment 1<font style="letter-spacing:0.5pt;"> </font>Date</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:55%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October<font style="letter-spacing:1.45pt;"> </font>9,<font style="letter-spacing:0.6pt;"> </font>2009</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:60pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality<font style="letter-spacing:1pt;"> </font>Statement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This<font style="letter-spacing:1.85pt;"> </font>document contains<font style="letter-spacing:2.5pt;"> </font>confidential information. It<font style="letter-spacing:1.35pt;"> </font>is<font style="letter-spacing:1.5pt;"> </font>intended solely for<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.7pt;"> </font>use<font style="letter-spacing:1.55pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.7pt;"> </font>principal investigator, co-investigators,<font style="letter-spacing:1.4pt;"> </font>staff,<font style="letter-spacing:1.85pt;"> </font>appropriate institutional review boards or<font style="letter-spacing:1pt;"> </font>ethical<font style="letter-spacing:1.35pt;"> </font>committees, and<font style="letter-spacing:1.15pt;"> </font>other<font style="letter-spacing:1pt;"> </font>required<font style="letter-spacing:1.8pt;"> </font>regulatory<font style="letter-spacing:2.1pt;"> </font>bodies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo<font style="letter-spacing:0.9pt;"> </font>BioSciences,<font style="letter-spacing:-1.9pt;"> </font>Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical<font style="letter-spacing:1.2pt;"> </font>Approval<font style="letter-spacing:1.7pt;"> </font>Signature<font style="letter-spacing:2.75pt;"> </font>Page</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:2.55%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:16.42%;"></td>
<td style="width:83.58%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Protocol<font style="letter-spacing:2.95pt;"> </font>Number:</p></td>
<td valign="bottom"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SB-509-0901</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Protocol<font style="letter-spacing:-1.5pt;"> </font>Title:</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A Phase<font style="letter-spacing:1.25pt;"> </font>2b Repeat Dosing<font style="letter-spacing:2.75pt;"> </font>Clinica<font style="letter-spacing:0.8pt;">l</font>Trial<font style="letter-spacing:-1.8pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>SB-509<font style="letter-spacing:-0.2pt;"> </font>in Subjects with<font style="letter-spacing:1.15pt;"> </font>Moderately<font style="letter-spacing:2.45pt;"> </font>Severe<font style="letter-spacing:0.5pt;"> </font>Diabetic<font style="letter-spacing:1.45pt;"> </font>Neuropathy</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Version:</p></td>
<td valign="bottom"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amendment<font style="letter-spacing:2.45pt;"> </font>1</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">October<font style="letter-spacing:2.8pt;"> </font>9,<font style="letter-spacing:-1.55pt;"> </font>2009</p></td>
</tr>
</table></div>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Ely Benaim, M.D.</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/09/2009</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ely Benaim, M.D.</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:49%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice Preseident, Clinical Affairs</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:49%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Shelley Wang, MS. M.D.</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/09/2009</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shelley Wang, MS. M.D.</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:49%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Associate Director, Clinical Development</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page ii of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:7.2pt;">
<td colspan="4" valign="bottom"  style="width:93.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTOCOL SYNOPSIS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VI</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="4" valign="bottom"  style="width:93.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="4" valign="bottom"  style="width:93.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SCHEMA<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VIII</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="4" valign="bottom"  style="width:93.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="4" valign="bottom"  style="width:93.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ABBREVIATIONS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IX</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="4" valign="bottom"  style="width:93.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:3.3pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INTRODUCTION<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.</p></td>
<td valign="bottom"  style="width:83.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Background</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr style="height:13.55pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2.</p></td>
<td valign="bottom"  style="width:83.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rationale</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:3.05pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:3.05pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OBJECTIVES<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:3.05pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.95pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STUDY DESIGN<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.95pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.95pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUBJECT SELECTION<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inclusion Criteria</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr style="height:13.55pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusion Criteria</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.9pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.9pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INFORMED CONSENT<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.9pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.5pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AUTHORIZATION TO USE AND DISCLOSE MEDICAL INFORMATION<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.5pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.9pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STUDY METHODOLOGY<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr style="height:12.85pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Screening Visit</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject Enrollment Procedures</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Baseline Duplicate Assessments</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule for Treatment Period</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:13.4pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule for Follow-Up Period</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.9pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.9pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CRITERIA FOR WITHDRAWAL FROM THE STUDY<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinuation from Study Treatment and Follow-up of Subjects</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td colspan="3" valign="bottom"  style="padding-left:2.25pt;width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ADMINISTRATION OF STUDY DRUG<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product Description</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description and Manufacturer of Drug Substance</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 and Placebo Study Drug Composition</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, Storage, and Handling of the Drug Product</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr style="height:13.55pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 Administration</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precautions</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premedications</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8.</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dose Modifications</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:3.9pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.05pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SAFETY<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.95pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential Risks</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.95pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EFFICACY<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:4.1pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.85pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential Benefits</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.5pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efficacy Criteria</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.5pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:4.2pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONCOMITANT MEDICATIONS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:3.5pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ADVERSE EVENTS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.15pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse Event Reporting Period</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr style="height:13.4pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.9pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.9pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recording of an Adverse Event</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page iii of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SERIOUS ADVERSE EVENT<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious Adverse Event Reporting</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:12.85pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.85pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recording of a Serious Adverse Event</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-0.5pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:3.8pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STATISTICAL METHODS AND DATA ANALYSIS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sample Size</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:13.4pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.9pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Randomization</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statistical Methods/Data Analysis</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.9pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intent-to-Treat Population</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.5pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject Disposition</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.6.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.9pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Demographics</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.7.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.8pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efficacy</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.8.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.85pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Baseline Values</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.9.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.45pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Missing Data</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.10.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.5pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safety</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.11.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.45pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory Data</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:3.8pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.1.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.9pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional Review Board/Institutional Ethics Committee</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:13pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.2.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.85pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Informed Consent</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:13.4pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.3.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study Amendments</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.4.</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study Drug Accountability</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6.35pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.5</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.5pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study Personnel</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.6</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.5pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monitoring the Study</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr style="height:12.8pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.7</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completion and Return of Case Report Forms</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.8</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.55pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deviation from Protocol for Individual Subjects</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.9</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.15pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quality Assurance Procedures</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.10</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.1pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences Policy on Fraud in Clinical Studies</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.11</p></td>
<td colspan="2" valign="bottom"  style="padding-left:1.75pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of the Study</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:6pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.12</p></td>
<td colspan="2" valign="bottom"  style="padding-left:2.45pt;width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Record Retention</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr style="height:12.95pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:5.75pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.13</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr style="height:13.35pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:5.75pt;width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.14</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publication Statement</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STUDY FUNDING<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:83.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:3.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td colspan="3" valign="bottom"  style="width:90.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REFERENCES<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 1:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE OF EVENTS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 2:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CTCAE<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 3:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AMERICAN CANCER SOCIETY (ACS) CANCER DETECTION GUIDELINES<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="top"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 4:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SB-509 DRUG PRODUCT AND PLACEBO DESCRIPTION AND INSTRUCTIONS FOR STORAGE, HANDLING, ADMINISTRATION AND DISPOSAL<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 5:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NEUROPATHY IMPAIRMENT SCORE- LOWER LIMB (NIS-LL)<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 6:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LOWER EXTREMITY NEUROLOGICAL SENSORY EXAM<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 7:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ELECTROPHYSIOLOGICAL STUDIES<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 8:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">QUANTITATIVE SENSORY TESTING (QST)<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 9:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SKIN BIOPSY<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td colspan="3" valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 10:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NEUROPATHY TOTAL SYMPTOM SCORE (NTSS-6)<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page iv of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 11:</p></td>
<td valign="bottom"  style="width:79.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VISUAL ANALOG SCALE FOR PAIN INTENSITY (VASPI)<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 12:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NEURO-QOL<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 13:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SF-36<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style="width:14.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 14:</p></td>
<td valign="bottom"  style="width:79.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GLOBAL ASSESSMENT<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="width:6.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page v of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROTOCOL<font style="letter-spacing:-0.35pt;"> </font>SYNOPSIS</p>
<p style="margin-top:0pt;line-height:14pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:29.99%;"></td>
<td style="width:2.09%;"></td>
<td style="width:67.92%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td colspan="2" valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:0.05pt;"> </font>Phase<font style="letter-spacing:-0.25pt;"> </font>2b Repeat<font style="letter-spacing:0.85pt;"> </font>Dosing<font style="letter-spacing:-0.25pt;"> </font>Clinical<font style="letter-spacing:-0.4pt;"> </font>Trial<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>SB-509<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:0.3pt;"> </font>Subjects with<font style="letter-spacing:-0.55pt;"> </font>Moderately<font style="letter-spacing:-0.95pt;"> </font>Severe<font style="letter-spacing:0.2pt;"> </font>Diabetic<font style="letter-spacing:-0.6pt;"> </font>Neuropathy</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sponsor</p></td>
<td colspan="2" valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo<font style="letter-spacing:-0.7pt;"> </font>BioSciences,<font style="letter-spacing:-0.3pt;"> </font>Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investigational Products</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Objectives</p></td>
<td colspan="2" valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Primary:</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:1.85pt;"> </font>compare<font style="letter-spacing:1.5pt;"> </font>the<font style="letter-spacing:2pt;"> </font>effect<font style="letter-spacing:2.1pt;"> </font>of<font style="letter-spacing:1.4pt;"> </font>SB-509<font style="letter-spacing:1.25pt;"> </font>versus<font style="letter-spacing:1.1pt;"> </font>placebo<font style="letter-spacing:2.1pt;"> </font>in<font style="letter-spacing:1.9pt;"> </font>subjects with moderately severe diabetic<font style="letter-spacing:2.75pt;"> </font>neuropathy (DN) on sural Nerve<font style="letter-spacing:-0.3pt;"> </font>Conduction<font style="letter-spacing:-0.2pt;"> </font>Velocity<font style="letter-spacing:-0.4pt;"> </font>(NCV)<font style="letter-spacing:-1.05pt;"> </font>at<font style="letter-spacing:0.15pt;"> </font>six-months</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.7pt;;margin-right:47.22%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Secondary:</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:2.55pt;"> </font>compare<font style="letter-spacing:3.1pt;"> </font>in<font style="letter-spacing:3pt;"> </font>subjects<font style="letter-spacing:2.45pt;"> </font>with<font style="letter-spacing:2.1pt;"> </font>moderately<font style="letter-spacing:2.7pt;"> </font>severe<font style="letter-spacing:2.5pt;"> </font>diabetic<font style="letter-spacing:-0.45pt;"> </font>neuropathy<font style="letter-spacing:2.6pt;"> </font>the effect of<font style="letter-spacing:2.85pt;"> </font>SB-509<font style="letter-spacing:2.6pt;"> </font>versus<font style="letter-spacing:2.55pt;"> </font>placebo on the<font style="letter-spacing:-0.4pt;"> </font>following<font style="letter-spacing:-0.9pt;"> </font>endpoints:</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Neuropathy</font><font style="font-family:Times New Roman;letter-spacing:-0.6pt;"> </font><font style="font-family:Times New Roman;">Impairment</font><font style="font-family:Times New Roman;letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;">Score -</font><font style="font-family:Times New Roman;letter-spacing:-1.2pt;"> </font><font style="font-family:Times New Roman;">Lower</font><font style="font-family:Times New Roman;letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;">Limb</font><font style="font-family:Times New Roman;letter-spacing:-0.35pt;"> </font><font style="font-family:Times New Roman;">(NIS-LL)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-weight:bold;font-family:Times New Roman;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">Motor</font><font style="font-family:Times New Roman;letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;">Nerve</font><font style="font-family:Times New Roman;letter-spacing:0.3pt;"> </font><font style="font-family:Times New Roman;">Conduction</font><font style="font-family:Times New Roman;letter-spacing:-0.8pt;"> </font><font style="font-family:Times New Roman;">Velocity</font><font style="font-family:Times New Roman;letter-spacing:-0.8pt;"> </font><font style="font-family:Times New Roman;">(NCV)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Quantitative</font><font style="font-family:Times New Roman;letter-spacing:-0.5pt;"> </font><font style="font-family:Times New Roman;">Sensory</font><font style="font-family:Times New Roman;letter-spacing:-0.75pt;"> </font><font style="font-family:Times New Roman;">Testing</font><font style="font-family:Times New Roman;letter-spacing:-0.75pt;"> </font><font style="font-family:Times New Roman;">(QST)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;lntraepidermal</font><font style="font-family:Times New Roman;letter-spacing:-1pt;"> </font><font style="font-family:Times New Roman;">Nerve</font><font style="font-family:Times New Roman;letter-spacing:-0.65pt;"> </font><font style="font-family:Times New Roman;">Fiber</font><font style="font-family:Times New Roman;letter-spacing:-0.45pt;"> </font><font style="font-family:Times New Roman;">Density</font><font style="font-family:Times New Roman;letter-spacing:-0.35pt;"> </font><font style="font-family:Times New Roman;">(IENFD)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Lower</font><font style="font-family:Times New Roman;letter-spacing:-0.3pt;"> </font><font style="font-family:Times New Roman;">Extremity</font><font style="font-family:Times New Roman;letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;">Neurological</font><font style="font-family:Times New Roman;letter-spacing:-0.95pt;"> </font><font style="font-family:Times New Roman;">Sensory</font><font style="font-family:Times New Roman;letter-spacing:-0.25pt;"> </font><font style="font-family:Times New Roman;">Exam</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Visual</font><font style="font-family:Times New Roman;letter-spacing:-0.75pt;"> </font><font style="font-family:Times New Roman;">Analog</font><font style="font-family:Times New Roman;letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;">Scale</font><font style="font-family:Times New Roman;letter-spacing:-0.45pt;"> </font><font style="font-family:Times New Roman;">for</font><font style="font-family:Times New Roman;letter-spacing:-0.55pt;"> </font><font style="font-family:Times New Roman;">Pain</font><font style="font-family:Times New Roman;letter-spacing:-0.15pt;"> </font><font style="font-family:Times New Roman;">Intensity</font><font style="font-family:Times New Roman;letter-spacing:-0.45pt;"> </font><font style="font-family:Times New Roman;">(VASPI)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Neuropathy</font><font style="font-family:Times New Roman;letter-spacing:-0.55pt;"> </font><font style="font-family:Times New Roman;">Total</font><font style="font-family:Times New Roman;letter-spacing:-0.55pt;"> </font><font style="font-family:Times New Roman;">Symptom</font><font style="font-family:Times New Roman;letter-spacing:-1pt;"> </font><font style="font-family:Times New Roman;">Score</font><font style="font-family:Times New Roman;letter-spacing:-0.55pt;"> </font><font style="font-family:Times New Roman;">(NTSS-6)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Quality</font><font style="font-family:Times New Roman;letter-spacing:-0.7pt;"> </font><font style="font-family:Times New Roman;">of</font><font style="font-family:Times New Roman;letter-spacing:0.45pt;"> </font><font style="font-family:Times New Roman;">Life:</font><font style="font-family:Times New Roman;letter-spacing:-0.1pt;"> </font><font style="font-family:Times New Roman;">NeuroQoL</font><font style="font-family:Times New Roman;letter-spacing:-0.7pt;"> </font><font style="font-family:Times New Roman;">and</font><font style="font-family:Times New Roman;letter-spacing:-0.3pt;"> </font><font style="font-family:Times New Roman;">SF-36</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:67.45pt;;text-indent:-30pt;;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;<font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Global</font><font style="font-family:Times New Roman;letter-spacing:-0.45pt;"> </font><font style="font-family:Times New Roman;">Assessment</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To compare the effect of SB-509 versus placebo in<font style="letter-spacing:-0.35pt;"> </font>subjects<font style="letter-spacing:0.3pt;"> </font>with<font style="letter-spacing:1.05pt;"> </font>moderately<font style="letter-spacing:0.9pt;"> </font>severe<font style="letter-spacing:-0.05pt;"> </font>diabetic<font style="letter-spacing:0.65pt;"> </font>neuropathy<font style="letter-spacing:0.5pt;"> </font>using<font style="letter-spacing:0.3pt;"> </font>a multi-endpoint analysis that includes Neuropathy<font style="letter-spacing:-0.65pt;"> </font>Impairment<font style="letter-spacing:2.95pt;"> </font>Score -<font style="letter-spacing:-0.6pt;"> </font>Lower Limb (NIS-LL),<font style="letter-spacing:3pt;"> </font>Sural Nerve Conduction<font style="letter-spacing:0.45pt;"> </font>Velocity<font style="letter-spacing:0.75pt;"> </font>(NCV)<font style="letter-spacing:0.2pt;"> </font>and<font style="letter-spacing:1pt;"> </font>lntraepidermal<font style="letter-spacing:-0.3pt;"> </font>Nerve<font style="letter-spacing:0.5pt;"> </font>Fiber Density<font style="letter-spacing:-0.4pt;"> </font>(IENFD),<font style="letter-spacing:-0.15pt;"> </font>as detailed<font style="letter-spacing:-0.5pt;"> </font>by O&#8217;Brien<font style="letter-spacing:-0.3pt;"> </font>(1984)</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font></p></td>
<td valign="top"  style="">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:1.15pt;"> </font>evaluate<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:1.5pt;"> </font>safety<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>SB-509<font style="letter-spacing:0.2pt;"> </font>as<font style="letter-spacing:1.15pt;"> </font>compared<font style="letter-spacing:1.25pt;"> </font>to<font style="letter-spacing:1pt;"> </font>placebo in<font style="letter-spacing:-0.25pt;"> </font>subjects<font style="letter-spacing:-0.8pt;"> </font>with<font style="letter-spacing:-0.15pt;"> </font>moderately<font style="letter-spacing:-0.55pt;"> </font>severe<font style="letter-spacing:-0.4pt;"> </font>diabetic<font style="letter-spacing:-0.45pt;"> </font>neuropathy</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subject Population</p></td>
<td colspan="2" valign="top"  style="">
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of 150 subjects with moderately severe diabetic<font style="letter-spacing:-0.45pt;"> </font>neuropathy<font style="letter-spacing:-0.15pt;"> </font>as<font style="letter-spacing:1.35pt;"> </font>defined<font style="letter-spacing:0.95pt;"> </font>by<font style="letter-spacing:0.9pt;"> </font>mean<font style="letter-spacing:0.7pt;"> </font>sural<font style="letter-spacing:0.65pt;"> </font>NCV &#8804; 45<font style="letter-spacing:0.65pt;"> </font>m/s,IENFD &#8804; 18 fibers/mm,<font style="letter-spacing:2.7pt;"> </font>NIS-LL &#8805; 3<font style="letter-spacing:0.2pt;"> </font>points,<font style="letter-spacing:0.05pt;"> </font>sICAM<font style="letter-spacing:2.9pt;"> </font>&#8805; 200 ng/ML,<font style="letter-spacing:3pt;"> </font>with measurable<font style="letter-spacing:-0.15pt;"> </font>lower<font style="letter-spacing:0.5pt;"> </font>extremity<font style="letter-spacing:-0.1pt;"> </font>nerves<font style="letter-spacing:-0.05pt;"> </font>(sural<font style="letter-spacing:0.05pt;"> </font>NCV<font style="letter-spacing:0.2pt;"> </font>amplitude<font style="letter-spacing:-0.65pt;"> </font>must<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:0.1pt;"> </font>&gt;<font style="letter-spacing:1.45pt;"> </font>1.0<font style="letter-spacing:0.3pt;"> &#181;</font><font style="font-style:italic;">V)</font><font style="font-style:italic;letter-spacing:2.85pt;"> </font>will<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:0.3pt;"> </font>enrolled<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>this<font style="letter-spacing:-0.75pt;"> </font>trial.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Study<font style="letter-spacing:1.9pt;"> </font>Design</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase<font style="letter-spacing:0.1pt;"> </font>2b,<font style="letter-spacing:0.3pt;"> </font>randomized,<font style="letter-spacing:0.6pt;"> </font>double-blind,<font style="letter-spacing:-0.05pt;"> </font>placebo-controlled,<font style="letter-spacing:-1.25pt;"> </font>multi&#173;center<font style="letter-spacing:-0.1pt;"> </font>study.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Treatment</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.7pt;;margin-right:0.19%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150<font style="letter-spacing:0.05pt;"> </font>subjects<font style="letter-spacing:-0.8pt;"> </font>will<font style="letter-spacing:-0.15pt;"> </font>be<font style="letter-spacing:0.6pt;"> </font>randomized<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:-0.35pt;"> </font>1:1<font style="letter-spacing:0.1pt;"> </font>ratio to<font style="letter-spacing:-0.25pt;"> </font>treatment<font style="letter-spacing:-0.65pt;"> </font>with</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Plan</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509<font style="letter-spacing:-0.5pt;"> </font>or<font style="letter-spacing:0.25pt;"> </font>placebo:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)&#160;&#160;&#160;&#160;SB-509<font style="letter-spacing:-0.3pt;"> </font>treatment:<font style="letter-spacing:-0.95pt;"> </font>60<font style="letter-spacing:-0.05pt;"> </font>mg<font style="letter-spacing:-0.15pt;"> </font>of SB-509<font style="letter-spacing:-0.85pt;"> </font>on<font style="letter-spacing:-0.3pt;"> </font>Day<font style="letter-spacing:0.15pt;"> </font>0,<font style="letter-spacing:-0.05pt;"> </font>Day<font style="letter-spacing:-0.15pt;"> </font>60<font style="letter-spacing:0.65pt;"> </font>and Day<font style="letter-spacing:0.15pt;"> </font>120.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)&#160;&#160;&#160;&#160;Placebo<font style="letter-spacing:-0.75pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>Day<font style="letter-spacing:-0.2pt;"> </font>0,<font style="letter-spacing:0.3pt;"> </font>Day<font style="letter-spacing:-0.15pt;"> </font>60<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>Day<font style="letter-spacing:-0.25pt;"> </font>120.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30 mg of SB-509<font style="letter-spacing:3.1pt;"> </font>or an equal volume of placebo will be injected intramuscularly (IM)<font style="letter-spacing:2.05pt;"> </font>into<font style="letter-spacing:2.35pt;"> </font>each<font style="letter-spacing:2.05pt;"> </font>lower<font style="letter-spacing:2.45pt;"> </font>limb<font style="letter-spacing:2.3pt;"> </font>for<font style="letter-spacing:2.5pt;"> </font>a<font style="letter-spacing:2.5pt;"> </font>total dose<font style="letter-spacing:3.1pt;"> </font>of<font style="letter-spacing:2.9pt;"> </font>60<font style="letter-spacing:2.75pt;"> </font>mg. Each subject will<font style="letter-spacing:2.8pt;"> </font>receive<font style="letter-spacing:3.05pt;"> </font>a<font style="letter-spacing:2.9pt;"> </font>total<font style="letter-spacing:2.7pt;"> </font>of three<font style="letter-spacing:-0.3pt;"> </font>treatments,<font style="letter-spacing:-0.45pt;"> </font>two<font style="letter-spacing:-0.5pt;"> </font>months<font style="letter-spacing:0.05pt;"> </font>apart.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page vi of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:29.99%;"></td>
<td style="width:70.01%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Duration<font style="letter-spacing:1.8pt;"> </font>of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Participation</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.8pt;"> </font>duration<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>participation<font style="letter-spacing:0.4pt;"> </font>will<font style="letter-spacing:0.4pt;"> </font>be<font style="letter-spacing:1.3pt;"> </font>approximately<font style="letter-spacing:-0.15pt;"> </font>15<font style="letter-spacing:1.15pt;"> </font>months: 12<font style="letter-spacing:1pt;"> </font>weeks<font style="letter-spacing:1.6pt;"> </font>for<font style="letter-spacing:0.65pt;"> </font>screening,<font style="letter-spacing:1.25pt;"> </font>5<font style="letter-spacing:0.6pt;"> </font>months<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.85pt;"> </font>treatment<font style="letter-spacing:0.1pt;"> </font>(includes<font style="letter-spacing:1pt;"> </font>one<font style="letter-spacing:-0.45pt;"> </font>month<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>last<font style="letter-spacing:0.3pt;"> </font>dose),<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>7<font style="letter-spacing:0.6pt;"> </font>months<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.2pt;"> </font>follow-up<font style="letter-spacing:-0.2pt;"> </font>after<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>treatment<font style="letter-spacing:-0.6pt;"> </font>period.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Randomization</p></td>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subjects<font style="letter-spacing:-0.45pt;"> </font>will<font style="letter-spacing:-0.45pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>randomized<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:0.5pt;"> </font>a 1:1<font style="letter-spacing:-0.3pt;"> </font>ratio<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:0.15pt;"> </font>SB-509<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>placebo stratified<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>study<font style="letter-spacing:-0.25pt;"> </font>site<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>screening<font style="letter-spacing:-0.05pt;"> </font>IENFD<font style="letter-spacing:-0.15pt;"> </font>(&lt;<font style="letter-spacing:0.7pt;"> </font>9, &#8805;<font style="letter-spacing:0.05pt;"> </font>9).</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sample<font style="letter-spacing:1.65pt;"> </font>Size</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">and<font style="letter-spacing:1pt;"> </font>Analyses</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:0.2pt;"> </font>sample<font style="letter-spacing:0.6pt;"> </font>size<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.35pt;"> </font>150<font style="letter-spacing:0.35pt;"> </font>subjects<font style="letter-spacing:-0.55pt;"> </font>provides<font style="letter-spacing:0.65pt;"> </font>93%<font style="letter-spacing:0.15pt;"> </font>power<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.25pt;"> </font>detect<font style="letter-spacing:0.3pt;"> </font>a<font style="letter-spacing:-0.75pt;"> </font>mean<font style="letter-spacing:1.1pt;"> </font>improvement<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>2.2<font style="letter-spacing:0.8pt;"> </font>units<font style="letter-spacing:0.8pt;"> </font>on<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:1pt;"> </font>sNCV<font style="letter-spacing:0.95pt;"> </font>in<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:1.15pt;"> </font>comparison between<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:1pt;"> </font>SB-509<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:0.6pt;"> </font>placebo<font style="letter-spacing:0.95pt;"> </font>arms,<font style="letter-spacing:1.35pt;"> </font>assuming<font style="letter-spacing:1.35pt;"> </font>a<font style="letter-spacing:1.3pt;"> </font>standard<font style="letter-spacing:-0.95pt;"> </font>deviation<font style="letter-spacing:2.1pt;"> </font>of<font style="letter-spacing:2.1pt;"> </font>4. The<font style="letter-spacing:2.3pt;"> </font>statistical<font style="letter-spacing:1.2pt;"> </font>test<font style="letter-spacing:2.1pt;"> </font>used<font style="letter-spacing:2.15pt;"> </font>will<font style="letter-spacing:1.85pt;"> </font>be<font style="letter-spacing:2.45pt;"> </font>a<font style="letter-spacing:2.5pt;"> </font>two-sided Wilcoxon<font style="letter-spacing:-0.25pt;"> </font>Rank-Sum<font style="letter-spacing:-0.6pt;"> </font>test,<font style="letter-spacing:0.1pt;"> </font>with<font style="letter-spacing:-0.5pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>Type<font style="letter-spacing:-0.3pt;"> </font>I error<font style="letter-spacing:-0.1pt;"> </font>rate<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>5%.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.7pt;;margin-right:34.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Primary</font><font style="text-decoration:underline;letter-spacing:-0.2pt;"> </font><font style="text-decoration:underline;">Efficacy</font><font style="text-decoration:underline;letter-spacing:-0.45pt;"> </font><font style="text-decoration:underline;">Analyses</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.1pt;"> </font>Day<font style="letter-spacing:0.15pt;"> </font>180<font style="letter-spacing:-0.45pt;"> </font>change<font style="letter-spacing:0.55pt;"> </font>from<font style="letter-spacing:-0.7pt;"> </font>baseline<font style="letter-spacing:0.35pt;"> </font>sNCV<font style="letter-spacing:-0.15pt;"> </font>will<font style="letter-spacing:-0.45pt;"> </font>be<font style="letter-spacing:0.2pt;"> </font>compared<font style="letter-spacing:-0.5pt;"> </font>by<font style="letter-spacing:0.3pt;"> </font>treatment<font style="letter-spacing:-0.55pt;"> </font>group<font style="letter-spacing:0.25pt;"> </font>using<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Wilcoxon<font style="letter-spacing:-0.3pt;"> </font>Rank-Sum<font style="letter-spacing:-0.95pt;"> </font>test<font style="letter-spacing:0.25pt;"> </font>at<font style="letter-spacing:-0.25pt;"> </font>an<font style="letter-spacing:0.15pt;"> </font>alpha<font style="letter-spacing:-0.3pt;"> </font>level<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>0.05</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.35pt;;margin-right:31.48%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Secondary</font><font style="text-decoration:underline;letter-spacing:-0.35pt;"> </font><font style="text-decoration:underline;">Efficacy</font><font style="text-decoration:underline;letter-spacing:-0.45pt;"> </font><font style="text-decoration:underline;">Analyses</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.3pt;"> </font>Day<font style="letter-spacing:0.5pt;"> </font>180 change<font style="letter-spacing:0.9pt;"> </font>from<font style="letter-spacing:-0.35pt;"> </font>baseline<font style="letter-spacing:0.6pt;"> </font>sNCV<font style="letter-spacing:0.25pt;"> </font>will<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:0.6pt;"> </font>compared<font style="letter-spacing:0.25pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>treatment group <font style="letter-spacing:0.25pt;"> </font>using <font style="letter-spacing:-0.15pt;"> </font>the Cochran-Mantel-Haenszel test<font style="letter-spacing:-0.45pt;"> </font>stratified<font style="letter-spacing:-0.5pt;"> </font>by<font style="letter-spacing:-0.15pt;"> </font>IENFD<font style="letter-spacing:0.05pt;"> </font>&lt;<font style="letter-spacing:0.75pt;"> </font>9<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.35pt;"> &#8805; </font>9<font style="letter-spacing:0.2pt;"> </font>at<font style="letter-spacing:-0.25pt;"> </font>an<font style="letter-spacing:-0.3pt;"> </font>alpha<font style="letter-spacing:0.3pt;"> </font>level<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>0.05</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:0.2pt;"> </font>following<font style="letter-spacing:-0.6pt;"> </font>measures,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>Day<font style="letter-spacing:0.15pt;"> </font>180<font style="letter-spacing:-0.1pt;"> </font>change<font style="letter-spacing:0.15pt;"> </font>from<font style="letter-spacing:0.1pt;"> </font>baseline measures will be compared by <font style="letter-spacing:1.2pt;"> </font>treatment group using the<font style="letter-spacing:-0.4pt;"> </font>Wilcoxon<font style="letter-spacing:-0.7pt;"> </font>Rank-Sum<font style="letter-spacing:-0.6pt;"> </font>test.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Neuropathy</font><font style="font-family:Times New Roman;letter-spacing:-0.85pt;"> </font><font style="font-family:Times New Roman;">Impairment</font><font style="font-family:Times New Roman;letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;">Score -</font><font style="font-family:Times New Roman;letter-spacing:-1.65pt;"> </font><font style="font-family:Times New Roman;">Lower</font><font style="font-family:Times New Roman;letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;">Limb</font><font style="font-family:Times New Roman;letter-spacing:-0.25pt;"> </font><font style="font-family:Times New Roman;">(NIS-LL)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Lower</font><font style="font-family:Times New Roman;letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;">Extremity</font><font style="font-family:Times New Roman;letter-spacing:-0.25pt;"> </font><font style="font-family:Times New Roman;">Neurological</font><font style="font-family:Times New Roman;letter-spacing:-0.3pt;"> </font><font style="font-family:Times New Roman;">Sensory</font><font style="font-family:Times New Roman;letter-spacing:-0.25pt;"> </font><font style="font-family:Times New Roman;">Exam</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Motor</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">Nerve</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">Conduction</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">Velocity</font><font style="font-family:Times New Roman;letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;">(NCV)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Quantitative</font><font style="font-family:Times New Roman;letter-spacing:-0.5pt;"> </font><font style="font-family:Times New Roman;">Sensory</font><font style="font-family:Times New Roman;letter-spacing:-0.3pt;"> </font><font style="font-family:Times New Roman;">Testing</font><font style="font-family:Times New Roman;letter-spacing:-0.65pt;"> </font><font style="font-family:Times New Roman;">(QST)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;lntraepidermal</font><font style="font-family:Times New Roman;letter-spacing:-1.15pt;"> </font><font style="font-family:Times New Roman;">Nerve</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">Fiber</font><font style="font-family:Times New Roman;letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;">Density</font><font style="font-family:Times New Roman;letter-spacing:-0.05pt;"> </font><font style="font-family:Times New Roman;">(IENFD)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Neuropathy</font><font style="font-family:Times New Roman;letter-spacing:-0.55pt;"> </font><font style="font-family:Times New Roman;">Total</font><font style="font-family:Times New Roman;letter-spacing:0.35pt;"> </font><font style="font-family:Times New Roman;">Symptom</font><font style="font-family:Times New Roman;letter-spacing:-0.65pt;"> </font><font style="font-family:Times New Roman;">Score</font><font style="font-family:Times New Roman;letter-spacing:-0.65pt;"> </font><font style="font-family:Times New Roman;">(NTSS-6)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Visual</font><font style="font-family:Times New Roman;letter-spacing:-0.1pt;"> </font><font style="font-family:Times New Roman;">Analog</font><font style="font-family:Times New Roman;letter-spacing:-0.15pt;"> </font><font style="font-family:Times New Roman;">Scale</font><font style="font-family:Times New Roman;letter-spacing:-0.05pt;"> </font><font style="font-family:Times New Roman;">for</font><font style="font-family:Times New Roman;letter-spacing:-0.55pt;"> </font><font style="font-family:Times New Roman;">Pain</font><font style="font-family:Times New Roman;letter-spacing:-0.05pt;"> </font><font style="font-family:Times New Roman;">Intensity</font><font style="font-family:Times New Roman;letter-spacing:-0.45pt;"> </font><font style="font-family:Times New Roman;">(VASPI)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Quality</font><font style="font-family:Times New Roman;letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;">of</font><font style="font-family:Times New Roman;letter-spacing:-0.65pt;"> </font><font style="font-family:Times New Roman;">Life</font><font style="font-family:Times New Roman;letter-spacing:0.35pt;"> </font><font style="font-family:Times New Roman;">(QOL)-</font><font style="font-family:Times New Roman;letter-spacing:-1.6pt;"> </font><font style="font-family:Times New Roman;">NeuroQoL</font><font style="font-family:Times New Roman;letter-spacing:-0.6pt;"> </font><font style="font-family:Times New Roman;">and</font><font style="font-family:Times New Roman;letter-spacing:-0.3pt;"> </font><font style="font-family:Times New Roman;">SF-36</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.37%;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Symbol'">&#183;</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Global</font><font style="font-family:Times New Roman;letter-spacing:0.15pt;"> </font><font style="font-family:Times New Roman;">assessment</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effect of SB-509 versus placebo in subjects with moderately<font style="letter-spacing:0.2pt;"> </font>severe<font style="letter-spacing:-0.4pt;"> </font>diabetic<font style="letter-spacing:0.25pt;"> </font>neuropathy<font style="letter-spacing:-0.45pt;"> </font>will<font style="letter-spacing:0.25pt;"> </font>be<font style="letter-spacing:0.2pt;"> </font>compared<font style="letter-spacing:0.7pt;"> </font>using a<font style="letter-spacing:0.5pt;"> </font>multi-endpoint<font style="letter-spacing:-0.1pt;"> </font>analysis<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.65pt;"> </font>includes<font style="letter-spacing:0.55pt;"> </font>Neuropathy<font style="letter-spacing:-0.5pt;"> </font>Impairment Score -<font style="letter-spacing:-1.35pt;"> </font>Lower<font style="letter-spacing:-0.2pt;"> </font>Limb<font style="letter-spacing:-0.35pt;"> </font>(NIS-LL),<font style="letter-spacing:-0.25pt;"> </font>Sural<font style="letter-spacing:-0.2pt;"> </font>Nerve<font style="letter-spacing:-0.5pt;"> </font>Conduction<font style="letter-spacing:-0.65pt;"> </font>Velocity (NCV)<font style="letter-spacing:2.85pt;"> </font>and<font style="letter-spacing:3.15pt;"> </font>lntraepidermal<font style="letter-spacing:1.35pt;"> </font>Nerve Fiber<font style="letter-spacing:2.4pt;"> </font>Density<font style="letter-spacing:2.5pt;"> </font>(IENFD), as detailed<font style="letter-spacing:-0.1pt;"> </font>by<font style="letter-spacing:0.4pt;"> </font>O&#8217;Brien<font style="letter-spacing:-0.75pt;"> </font>(1984).</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Safety</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safety<font style="letter-spacing:0.4pt;"> </font>assessment will<font style="letter-spacing:0.2pt;"> </font>occur<font style="letter-spacing:0.25pt;"> </font>on<font style="letter-spacing:0.9pt;"> </font>all<font style="letter-spacing:0.4pt;"> </font>subjects<font style="letter-spacing:-0.15pt;"> </font>who<font style="letter-spacing:0.25pt;"> </font>received<font style="letter-spacing:1pt;"> </font>any study medication. Terminations/premature withdrawals, adverse<font style="letter-spacing:1pt;"> </font>events,<font style="letter-spacing:-0.35pt;"> </font>concomitant<font style="letter-spacing:0.05pt;"> </font>medications,<font style="letter-spacing:0.35pt;"> </font>and<font style="letter-spacing:0.65pt;"> </font>laboratory<font style="letter-spacing:0.55pt;"> </font>data will<font style="letter-spacing:0.8pt;"> </font>be<font style="letter-spacing:1.15pt;"> </font>tabulated. Adverse<font style="letter-spacing:0.1pt;"> </font>events<font style="letter-spacing:0.7pt;"> </font>will<font style="letter-spacing:0.65pt;"> </font>be<font style="letter-spacing:0.95pt;"> </font>coded<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.95pt;"> </font>a<font style="letter-spacing:0.9pt;"> </font>standard set of terms using<font style="letter-spacing:3.15pt;"> </font>the<font style="letter-spacing:3.1pt;"> </font>MedDRA<font style="letter-spacing:2.25pt;"> </font>dictionary. Frequency of adverse<font style="letter-spacing:-0.2pt;"> </font>events<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.45pt;"> </font>be<font style="letter-spacing:0.2pt;"> </font>compared<font style="letter-spacing:-0.1pt;"> </font>using<font style="letter-spacing:-0.3pt;"> </font>Fisher&#8217;s<font style="letter-spacing:-0.1pt;"> </font>exact<font style="letter-spacing:0.1pt;"> </font>test.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page vii of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEMA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201504281926018191269.jpg" title="" alt="" style="width:720px;height:420px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page viii of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ABBREVIATIONS</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32Ep65</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Engineered<font style="letter-spacing:2.1pt;"> </font>ZFP-TF</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACS</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American<font style="letter-spacing:2.05pt;"> </font>Cancer<font style="letter-spacing:1.3pt;"> </font>Society</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADA</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American<font style="letter-spacing:1.75pt;"> </font>Diabetes<font style="letter-spacing:0.1pt;"> </font>Association</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADR</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:15.37%;text-indent:0.7pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:15.37%;text-indent:0.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse<font style="letter-spacing:1.7pt;"> </font>drug<font style="letter-spacing:0.65pt;"> </font>reaction</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AE</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse<font style="letter-spacing:1.65pt;"> </font>event</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALP</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkaline<font style="letter-spacing:1.6pt;"> </font>phosphatase</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALT</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alanine<font style="letter-spacing:1.5pt;"> </font>aminotransferase</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARI</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aldose<font style="letter-spacing:1.45pt;"> </font>reductase<font style="letter-spacing:1.05pt;"> </font>inhibitors</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AST</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aspartate<font style="letter-spacing:1.8pt;"> </font>aminotransferase</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BMI</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:18.52%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:18.52%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Body<font style="letter-spacing:1.25pt;"> </font>mass<font style="letter-spacing:-0.25pt;"> </font>index</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BOCF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Baseline<font style="letter-spacing:2.15pt;"> </font>observation<font style="letter-spacing:1.1pt;"> </font>carried<font style="letter-spacing:1.9pt;"> </font>forward</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BUN</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blood<font style="letter-spacing:1.45pt;"> </font>urea<font style="letter-spacing:0.9pt;"> </font>nitrogen</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CBC</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complete<font style="letter-spacing:2pt;"> </font>blood<font style="letter-spacing:1pt;"> </font>count</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFR</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Code<font style="letter-spacing:1.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Federal<font style="letter-spacing:0.95pt;"> </font>Regulations</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cm</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centimeter</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CPK</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Creatinine<font style="letter-spacing:2.1pt;"> </font>phosphokinase</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CPKmb</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Creatinine<font style="letter-spacing:2.05pt;"> </font>phosphokinase,<font style="letter-spacing:0.1pt;"> </font>mb<font style="letter-spacing:1.05pt;"> </font>fraction</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Case<font style="letter-spacing:1.7pt;"> </font>report<font style="letter-spacing:0.8pt;"> </font>form</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CTCAE</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common<font style="letter-spacing:2.55pt;"> </font>terminology<font style="letter-spacing:1.55pt;"> </font>criteria<font style="letter-spacing:1.7pt;"> </font>for<font style="letter-spacing:0.65pt;"> </font>adverse<font style="letter-spacing:1.15pt;"> </font>events</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DN</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:23.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:23.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diabetic<font style="letter-spacing:2.05pt;"> </font>neuropathy<font style="letter-spacing:1.15pt;"> </font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DNA</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deoxyribonucleic acid</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ECG</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Electroc<font style="letter-spacing:0.3pt;">a</font>r<font style="letter-spacing:-0.2pt;">d</font>iogram</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENFD</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:16.11%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:16.11%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epidermal<font style="letter-spacing:1.95pt;"> </font>nerve<font style="letter-spacing:0.75pt;"> </font>fiber<font style="letter-spacing:1.05pt;"> </font>density</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENFDR</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epidermal<font style="letter-spacing:1.95pt;"> </font>nerve<font style="letter-spacing:0.75pt;"> </font>fiber<font style="letter-spacing:1.05pt;"> </font>density<font style="letter-spacing:1.9pt;"> </font>regeneration</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food<font style="letter-spacing:1.45pt;"> </font>and<font style="letter-spacing:0.75pt;"> </font>Drug<font style="letter-spacing:1.05pt;"> </font>Administration</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOBT</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fecal<font style="letter-spacing:1.3pt;"> </font>occult<font style="letter-spacing:0.95pt;"> </font>blood<font style="letter-spacing:1.35pt;"> </font>test</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HBV</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hepatitis<font style="letter-spacing:1.75pt;"> </font>B<font style="letter-spacing:0.65pt;"> </font>virus</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HCV</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hepatitis<font style="letter-spacing:2.05pt;"> </font>C<font style="letter-spacing:0.6pt;"> </font>virus</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hg</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mercury</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIV</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human<font style="letter-spacing:1.8pt;"> </font>Immunodeficiency Virus</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HPV</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human<font style="letter-spacing:1.75pt;"> </font>papillomaviurs</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ICH</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International<font style="letter-spacing:1.65pt;"> </font>Conference<font style="letter-spacing:2.15pt;"> </font>on<font style="letter-spacing:0.8pt;"> </font>Harmonization</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IBC</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional<font style="letter-spacing:2.3pt;"> </font>Biosafety<font style="letter-spacing:1.65pt;"> </font>Committee</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ICAM</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intracellular<font style="letter-spacing:2.3pt;"> </font>Adhesion<font style="letter-spacing:1.8pt;"> </font>Molecules</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IEC</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional<font style="letter-spacing:1.7pt;"> </font>Ethics<font style="letter-spacing:0.85pt;"> </font>Committee</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IENFD</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lntraepidermal<font style="letter-spacing:-0.7pt;"> </font>Nerve<font style="letter-spacing:0.25pt;"> </font>Fiber<font style="letter-spacing:1.6pt;"> </font>Density</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IM</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intramuscular</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INR</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International<font style="letter-spacing:1.5pt;"> </font>normalized<font style="letter-spacing:3.05pt;"> </font>ratio</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRB</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional<font style="letter-spacing:2.05pt;"> </font>Review<font style="letter-spacing:1.85pt;"> </font>Board</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kb</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kil<font style="letter-spacing:0.3pt;">o</font>base</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.96%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">kg</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kilogram</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liter</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LDH</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lactate<font style="letter-spacing:1.45pt;"> </font>dehydrogenase</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.41%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LDL</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Low-density<font style="letter-spacing:2.25pt;"> </font>lipoprotein</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LOCF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Last<font style="letter-spacing:0.7pt;"> </font>observation<font style="letter-spacing:1.1pt;"> </font>carried<font style="letter-spacing:2.25pt;"> </font>forward</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mg</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:49.81%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:49.81%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milligram<font style="letter-spacing:1.9pt;"> </font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mL</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milliliter</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mm</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Millimeter</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mM</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:49.81%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:49.81%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Millimolar</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MRI</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Magnetic<font style="letter-spacing:1.45pt;"> </font>resonance<font style="letter-spacing:1.55pt;"> </font>imaging</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCI</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">National<font style="letter-spacing:0.45pt;"> </font>Cancer<font style="letter-spacing:0.7pt;"> </font>Institute</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCS</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nerve<font style="letter-spacing:1.25pt;"> </font>conduction<font style="letter-spacing:0.75pt;"> </font>studies</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCV</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nerve<font style="letter-spacing:0.9pt;"> </font>conduction<font style="letter-spacing:1.45pt;"> </font>velocity</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.56%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:31.85%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:31.85%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">National<font style="letter-spacing:1pt;"> </font>Formulary</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NTSS-6</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuropathy<font style="letter-spacing:1.05pt;"> </font>Total<font style="letter-spacing:0.8pt;"> </font>Symptom<font style="letter-spacing:1.9pt;"> </font>Score</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.41%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nanogram</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NGF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nerve<font style="letter-spacing:1.2pt;"> </font>growth<font style="letter-spacing:0.6pt;"> </font>factor</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page ix of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NIH</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">National<font style="letter-spacing:0.9pt;"> </font>Institute<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.55pt;"> </font>Health</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NIS-LL</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuropathy<font style="letter-spacing:1.4pt;"> </font>Impairment<font style="letter-spacing:2.5pt;"> </font>Score<font style="letter-spacing:0.55pt;"> </font>-<font style="letter-spacing:-4.65pt;"> </font>Lower<font style="letter-spacing:1.15pt;"> </font>Limb</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.33%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NLS</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nuclear<font style="letter-spacing:1.85pt;"> </font>localization<font style="letter-spacing:1.65pt;"> </font>sequence</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOAEL</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No<font style="letter-spacing:1.05pt;"> </font>observed<font style="letter-spacing:0.95pt;"> </font>adverse<font style="letter-spacing:1.55pt;"> </font>effect<font style="letter-spacing:1.6pt;"> </font>level</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NSAIDs</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-steroidal<font style="letter-spacing:1.25pt;"> </font>anti-inflammatory<font style="letter-spacing:2.6pt;"> </font>drugs</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.41%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P188</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poloxamer<font style="letter-spacing:0.95pt;"> </font>188</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCR</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:33.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:33.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Polymerase<font style="letter-spacing:0.8pt;"> </font>chain<font style="letter-spacing:1.8pt;"> </font>reaction<font style="letter-spacing:1.25pt;"> </font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PSA</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate-specific<font style="letter-spacing:1.7pt;"> </font>antigen</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PT</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prothrombin<font style="letter-spacing:1.2pt;"> </font>time</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTT</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partial<font style="letter-spacing:0.3pt;"> </font>prothrombin<font style="letter-spacing:1.45pt;"> </font>time</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pV-32Ep65</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plasmid;<font style="letter-spacing:1.5pt;"> </font>the<font style="letter-spacing:0.15pt;"> </font>active<font style="letter-spacing:1.2pt;"> </font>drug<font style="letter-spacing:1.7pt;"> </font>substance<font style="letter-spacing:1.95pt;"> </font>in<font style="letter-spacing:0.45pt;"> </font>SB-509</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QOL</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quality<font style="letter-spacing:1.2pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>Life</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QST</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quantitative<font style="letter-spacing:1.3pt;"> </font>sensory<font style="letter-spacing:1.75pt;"> </font>testing</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.7pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ribonucleic<font style="letter-spacing:1.7pt;"> </font>acid</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.56%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAE</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious<font style="letter-spacing:0.9pt;"> </font>adverse<font style="letter-spacing:1.1pt;"> </font>event</p></td>
</tr>
<tr>
<td valign="top"  style="width:11%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plasmid formulation containing the 32Ep65 expression<font style="letter-spacing:2.25pt;"> </font>cassette, an engineered transcription factor that induces<font style="letter-spacing:2.05pt;"> </font>expression<font style="letter-spacing:2.3pt;"> </font>of<font style="letter-spacing:0.35pt;"> </font>VEGF-A</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sNCV</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sural Nerve<font style="letter-spacing:0.6pt;"> </font>Conduction<font style="letter-spacing:2.75pt;"> </font>Velocity</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STZ</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Streptozotocin</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SV40</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simian<font style="letter-spacing:0.85pt;"> </font>Virus<font style="letter-spacing:0.4pt;"> </font>40</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transcription factor</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.93%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TSH</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thyroid Stimulating Hormone</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tris-HCI</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tris-(hydroxymethyl)-aminomethane<font style="letter-spacing:-1.35pt;"> </font>hydrochloride</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unit</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#181;m</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Micrometer<font style="letter-spacing:1.2pt;"> </font>(micron)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USP</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United<font style="letter-spacing:0.85pt;"> </font>States<font style="letter-spacing:0.7pt;"> </font>Pharmacopoeia</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VPT</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibration<font style="letter-spacing:1.2pt;"> </font>Perception<font style="letter-spacing:1.35pt;"> </font>Threshold</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VA<font style="letter-spacing:-0.05pt;">S</font>PI</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Visual<font style="letter-spacing:0.5pt;"> </font>Analog<font style="letter-spacing:1.05pt;"> </font>Scale<font style="letter-spacing:1.15pt;"> </font>for<font style="letter-spacing:0.5pt;"> </font>Pain<font style="letter-spacing:0.9pt;"> </font>Intensity</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VEGF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:23.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:23.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vascular<font style="letter-spacing:0.8pt;"> </font>endothelial<font style="letter-spacing:-0.4pt;"> </font>growth<font style="letter-spacing:1.8pt;"> </font>factor</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.41%;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.25pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VEGF-A</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vascular<font style="letter-spacing:0.8pt;"> </font>endothelial<font style="letter-spacing:1.2pt;"> </font>growth<font style="letter-spacing:1.8pt;"> </font>factor-A</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.63%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WBC</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:23.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:23.89%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">White<font style="letter-spacing:0.6pt;"> </font>blood<font style="letter-spacing:-0.45pt;"> </font>cell</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.41%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHO</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">World<font style="letter-spacing:0.75pt;"> </font>Health<font style="letter-spacing:0.65pt;"> </font>Organization</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.41%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ZFP</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zinc<font style="letter-spacing:0.55pt;"> </font>finger<font style="letter-spacing:1.1pt;"> </font>protein</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11%;">
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ZFP-TF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zinc<font style="letter-spacing:0.65pt;"> </font>finger<font style="letter-spacing:1.45pt;"> </font>protein<font style="letter-spacing:1.05pt;"> </font>transcription<font style="letter-spacing:2.25pt;"> </font>factor</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page x of 66</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INTRODUCTION</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VEGF-A is well known as a potent angiogenic factor, but it has also been shown to be a potent neurotrophic and neuroprotective factor. Studies have shown that plasmid-mediated delivery of hVEGF-A can reverse neuropathy in diabetic animals (Schratzberger <font style="font-style:italic;">et al</font>. 2001). Another study showed that gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy (Price <font style="font-style:italic;">et al</font>. 2006). A Phase 1 clinical trial testing hVEGF-A<sub style="font-size:85%; vertical-align:bottom">1</sub><sub style="font-size:85%; vertical-align:bottom">65</sub> cDNA suggests that this approach may be beneficial (Simovic <font style="font-style:italic;">et al</font>.2001).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The VEGF-A mRNA is alternatively spliced to express three major protein isoforms, VEGF-A<sub style="font-size:85%; vertical-align:bottom">1</sub><sub style="font-size:85%; vertical-align:bottom">89</sub>, VEGF-A<sub style="font-size:85%; vertical-align:bottom">1</sub><sub style="font-size:85%; vertical-align:bottom">65</sub>, and VEGF-A<sub style="font-size:85%; vertical-align:bottom">121</sub> Recent studies suggest that the combination of all three isoforms provides a more potent angiogenic response than any of the isoforms alone (Whitlock <font style="font-style:italic;">et al</font>. 2004). The same may be true for the neurotrophic and neuroprotective effects of VEGF-A.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences has developed a plasmid SB-509 that expresses an engineered transcription factor (TF) that binds the endogenous VEGF-A promoter and activates transcription of the endogenous VEGF-A gene. The transcript produced undergoes alternative splicing, naturally producing the three major protein isoforms. This TF is based on the Cys<sub style="font-size:85%; vertical-align:bottom">2</sub>-His<sub style="font-size:85%; vertical-align:bottom">2</sub> zinc finger DNA binding domain. Treatment of disease via localized gene delivery may mimic local autocrine/paracrine mechanisms by which VEGF-A works. It has been shown, in side-by-side comparisons, that activation of the endogenous VEGF-A gene, using engineered TFs, produces non-leaky vasculature with normal vessel architecture (Rebar <font style="font-style:italic;">et al</font>. 2002) in contrast to vessels produced in response to a single isoform, which leak and have defective architecture (Elson <font style="font-style:italic;">et al</font>. 2001).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 is an investigational product that has not been approved or marketed in any country.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Background</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Epidemiology and Treatment of Diabetic Neuropathy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is estimated that diabetes affects nearly 23.6 million patients in the United States, of which 5.7 million are undiagnosed (CDC 2007 National Diabetes Fact Sheet). The incidence of diabetic peripheral neuropathy ranges from 10% at the time of diagnosis of diabetes to 50% after 25 years of living with diabetes (Poncelet 2003). The severity of neuropathy in diabetes is related to the duration of disease, glucose control, hypertension, and hyperlipidemia (Feldman <font style="font-style:italic;">et al</font>. 1999; Stratton <font style="font-style:italic;">et al</font>. 2000; Malik 2000). In addition, neuropathy is an independent risk factor for further morbidity in diabetes due to foot ulcerations and limb amputation (McNeely <font style="font-style:italic;">et al</font>. 1995; Potter <font style="font-style:italic;">et al</font>. 1998). The pathogenesis is related to hyperglycemia, which affects both small and large nerve fibers. The WHO definition of diabetic neuropathy (DN) is &#8220;A disease characterized as a progressive loss of nerve fibers leading to sensation loss, foot ulceration, and amputation.&#8221; Symptoms and signs are directly related to the type of nerve fiber damage. Thinly myelinated small nerve fibers mediate pain and altered cold, heat, and light touch. Large myelinated fibers mediate vibration and proprioception. Symptoms and signs include the stocking and glove distribution of sensory loss, pain and eventually motor loss resulting in weakness of the muscles in the feet and are directly related to the type of nerve fiber damage (Thomas and Tomlinson 1993).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no treatment for diabetic neuropathy that has been shown to modify disease onset or progression; current treatments are limited to the relief of select symptoms (i.e. pain). Intensive glucose control can stabilize or improve diabetic neuropathy (DN) (UKPDS 33 1998). Medical treatment for pain symptoms associated with diabetic neuropathy includes anti-depressants, anti-convulsants, opiates, anti-arrhythmics, and topical agents (Poncelet 2003). Duloxetine and pregabalin have recently received FDA approval for the symptomatic treatment on Diabetic Neuropathy pain (Argoff <font style="font-style:italic;">et al</font>. 2006). Additional treatment strategies have included attempts to protect or regenerate neurons and thus interfere with the primary disease process in neuropathy. Aldose reductase inhibitors (ARI) and growth factors such as Nerve Growth Factor (NGF) have been evaluated in clinical trials. Phase 3 trials with these agents have proved unsuccessful in detecting significant improvement in neurologic endpoints and have been limited by side effects (Boulton <font style="font-style:italic;">et al</font>. 2004). These studies did provide significant insight into the natural course of progression of DN and the need for a composite endpoint combining measurements of the signs and symptoms of DN, neurological examination, and electrophysiological testing (Feldman 2002). Epalrestat (Kinedak&#8482;, Ono Pharmaceuticals, Osaka, Japan), approved in Japan in 1992, is the only ARI currently available commercially.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Rationale</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.2.1. Pre-clinical Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biological activity of the 32Ep65 transcriptional activator (also known as VZ+434) was evaluated in both in vitro multiple cell lines and in vivo in multiple species. In vitro studies demonstrated that the transcriptional activator can 1)upregulate the major </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 11 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">isoforms VEGF-A mRNA and conserve their relative proportions and 2) increase VEGF-A protein and 3) the secreted protein can protect neuronal-derived cells from growth arrest in response to serum starvation. The therapeutic potential of SB-509 was assessed in a validated experimental model of diabetic neuropathy in streptozotocin (STZ)-induced diabetic rats (Schratzberger et al. 2001; Calcutt <font style="font-style:italic;">et al</font>. 2003; Biessels <font style="font-style:italic;">et al</font>. 1999, Price <font style="font-style:italic;">et al</font> 2006). Single and repeat administration of the formulated plasmid encoding 32Ep65 (SB-509) showed a significant and dose-related protection against losses in both motor and sensory nerve conduction velocities. Please refer to the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Single administration pre-clinical toxicology and biodistribution studies of SB-509 were designed to support the Phase 1 dose-escalation clinical trial of a single treatment of SB-509 in subjects with diabetic neuropathy. Single administration toxicology studies included both toxicology and biodistribution studies in rats and rabbits. The single intramuscular injection treatment of SB-509 was, in general, well-tolerated, with no treatment-related effects or biologically significant differences among treatment groups for body weights, clinical observations, laboratory tests, and microscopic histological evaluation. SB-509 plasmid persisted up to 30 days and was localized to the injection site. A NOAEL of 1.0 mg/kg SB-509 was determined from the study</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A repeat SB-509 administration study in rats was designed to support the Phase 2 repeat administration clinical trial in subjects with diabetic neuropathy. Rats received monthly SB-509 intramuscular administration for three months. In general, rats tolerated three doses of SB-509 given at monthly intervals at up to 1.0 mg/kg/dose SB-509 without any toxic effects. Specific ocular histopathology revealed no evidence of retinal arterial proliferation or other lesions related to SB-509 treatment. Proteinuria was observed at 5.0 mg/kg/dose SB-509 at Study Day 60 in 1/5 males and at Study Day 90 in 1/5 females. Proteinuria was also observed at a similar incidence at Study Day 120 for both the low (1.0 mg/kg) and high (5.0 mg/kg) dose groups in both male (1/5) and female (1/5) groups. This finding was not supported by protein serum changes in creatinine and blood urea nitrogen levels or by histological changes in the kidney. The only microscopic histology findings were local inflammation and muscle damage at the injection site. The incidence of these findings generally correlated with the volume administered and was a transient effect. No significant changes in body weight gain were observed during dosing (Study Days 0-60); however, during the recovery period (Study Days 60-120), males and females in the 5.0 mg/kg dose groups showed significant changes in body weight gains and were considered to insignificant and were not toxicologically relevant. One mortality was observed in a PCR (biodistribution) satellite group (5 mg/kg/dose SB-509), and the cause of death was undetermined. At all study time points (Study Days 30, 60, 90, and 120), plasmid DNA was detected at the injection sites in all rats given SB-509 at 5 mg/kg/dose. SB-509 plasmid was not found in heart or gonads at Study Days 30, 60, 90, and 120. The NOAEL was 1.0 mg/kg/dose for repeat administration of SB-509. For additional information, please refer to the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.2.2. Clinical Rationale</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials of SB-509 in subjects with mild, moderate, or severe diabetic peripheral neuropathy have identified the following effects of SB-509: improvement in sensory and motor nerve conduction velocity, improvement in quantitative sensory testing, decrease in the neuropathy impairment score-lower limb, and a strong trend for re&#173; growth of nerve fibers in the skin. Subgroup analyses by baseline disease severity show that subjects with more advanced disease (i.e., low nerve conduction velocity, low intraepidermal nerve fiber density and poor vibration perception) tend to respond better to SB-509, as indicated, for example, by a greater decrease in the neuropathy impairment score. Thus, this protocol will be conducted in subjects with advanced diabetic neuropathy who have a mean sural nerve conduction velocity of &#8804; 45 m/s, NIS-LL &#8805; 3, an intraepidermal nerve fiber density &#8804; 18 fibers/mm, and serum Intracellular Adhesion Molecule (ICAM) &#8805; 200 ng/ml.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further information is provided in the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure</font>.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">OBJECTIVES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The primary objective is:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy on the sural Nerve Conduction Velocity (sNCV) endpoint at six&#173;months</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The secondary objective is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">To compare in subjects with moderately severe diabetic neuropathy the effect of SB-509 versus placebo on the following endpoints: Neuropathy Impairment Score - Lower Limb (NIS-LL), motor Nerve Conduction Velocity (NCV), Quantitative Sensory Testing (QST), lntraepidermal Nerve Fiber Density (IENFD), Lower Extremity Neurological Sensory Exam, Visual </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Analog Scale for Pain Intensity (VASPI), Neuropathy Total Symptom Score (NTSS-6), NeuroQoL, SF-36, and Global Assessment</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy using a multi-endpoint analysis that includes Neuropathy Impairment Score - Lower Limb (NIS-LL), Sural Nerve Conduction Velocity (NCV) and lntraepidermal Nerve Fiber Density (IENFD), as detailed by O&#8217;Brien (1984)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">To evaluate the safety of SB-509 as compared to placebo in subjects with moderately severe diabetic neuropathy</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STUDY DESIGN</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 2 trial is a randomized, double-blind, placebo-controlled, multi-center study of SB-509 given by intramuscular injections into the lower limbs in 150 subjects with moderately severe diabetic neuropathy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150 subjects will be randomized in a 1:1 ratio to treatment with SB-509 or placebo stratified by study site and screening IENFD (&lt;9 fiber/mm, &#8805; 9 fiber/mm):</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1) SB-509 treatment: 60 mg of SB-509 on Day 0, Day 60 and Day 120.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2) Placebo on Day 0, Day 60 and Day 120.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30 mg of SB-509 or an equal volume of placebo will be injected (IM) into each lower limb for a total dose of 60 mg. Each subject will receive a total of three treatments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duration of participation will be approximately 15 months: 12 weeks for screening, 5 months for treatment (includes one month after the last dose), and 7 months for follow-up after the treatment period.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SUBJECT SELECTION</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inclusion Criteria</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. </p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written informed consent signed and dated by study subject</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Male or female between the ages of 18 and 70, inclusive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Clinical diagnosis of Diabetes Mellitus Type I or II for at least 12 months. A past history of Diabetes Mellitus and/or the use of anti-diabetic medications for the treatment of Diabetes Mellitus are sufficient.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Clinical signs and symptoms of moderate to severe diabetic sensori&#173; motor polyneuropathy of the lower extremities for at least 6 months that are not otherwise attributed to an etiology other than diabetes, as determined by a an internist with neuropathy experience, neurologist or endocrinologist and excluding subjects with only diabetic autonomic neuropathy or mononeuropathy.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mean sural nerve conduction velocity &#8804; 45 m/s as confirmed by the Neurological Core Laboratory</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Measurable sural response (amplitude equal or greater than 1.0 &#181;v) and a measurable peroneal response (amplitude equal to or greater than 500 &#181;V) bilaterally</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuropathy Impairment Score Lower Limb (NIS-LL) must be &#8805; 3 points</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">lntraepidermal Nerve Fiber Density &#8804; 18 fibers per mm</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum Intracellular Adhesion Molecule level (ICAM) &#8805; 200 ng/mL</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Hemoglobin level &#8805; 10 g/dL</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HgbA1<sub style="font-size:85%; vertical-align:bottom">c</sub> level &#8804; 9%. Subjects should be treated according to ADA guidelines and goals for dietary intervention and/or glucose control therapy and have stable glycemic control for 3 months, as determined by the investigator</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">WBC count &#8805; 3,000/mm<sup style="font-size:85%; vertical-align:top">3</sup>, an absolute granulocyte count &#8805; 1,500/mm<sup style="font-size:85%; vertical-align:top">3</sup>, and a platelet count &#8805; 100,000/mm<sup style="font-size:85%; vertical-align:top">3</sup></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum creatinine &lt; 1.5 mg/dL</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Total bilirubin &#8804; 1.5 times the upper limit of normal</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AST and ALT &#8804; 2 times the upper limit of normal</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INR &lt; 1.5 times the upper limit of normal or PTT &lt; 1.5 times the upper limit of normal</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Normal or elevated serum levels of vitamin B12</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Normal thyroid function (as determined by normal TSH and free T4 levels). For subjects on thyroid hormone replacement therapy, an elevated TSH level that is no higher than 7 mU/L is acceptable if the investigator feels the subject is clinically euthyroid.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Random urine sample albumin/creatinine ratio &#8804; 300 &#181;g/mg creatinine. Normal urinalysis, with the exception of glucose and protein. If other abnormalities are present, the urinalysis may be repeated within the screening period at the discretion of the investigator.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If subject is female and of childbearing potential, she agrees to use a medically acceptable physical barrier method contraceptive during the treatment phase through 30 days after the last dose and have a negative serum pregnancy test prior to study entry.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A female subject is considered to be of childbearing potential if she is postmenarchial, has an intact uterus and at least 1 ovary, and is less than 2 years postmenopausal. A male subject must agree to use a medically acceptable physical barrier method contraceptive during the treatment phase through 30 days after the last dose. The following are acceptable physical barrier methods: Male condom, Female condom, Diaphragm, Cervical cap.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subject must not be breastfeeding. Subjects who become pregnant during treatment must inform the investigator of their pregnancy, be withdrawn from treatment, and agree to provide follow-up information at time of delivery.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Complete screening tests for malignancies of the colon, breast (females only), cervix/uterus (females only), and prostate (males only) at the time of screening based on the American Cancer Society&#8217;s current recommended guidelines (see <font style="font-weight:bold;">Appendix 3</font>). Documented evidence of negative screening tests is sufficient. Any subject found to have cancer by these screening tests is excluded from the trial.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Negative mammogram, if female and over age 40</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Have a PSA (&lt;4 ng/mL), if male and over age 45</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Normal Pap smear documented within a year of screening, if female, unless the subject has had a hysterectomy</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Be willing and able to participate in the study as an outpatient, make the required visits to the study center during the treatment and post&#173; treatment periods, and comply with study requirements</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">LDL cholesterol &#8804; 130 mg/dL. Subjects with hyperlipidemia should be treated by diet or medications according to ADA guidelines and goals. Modification of treatment during the screening period is allowed at the discretion of the investigator. Subjects with elevated LDL in spite of adequate stalin therapy (at least 3 months) or intolerant to statins, will be discussed with the FDA for eligibility approval.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood pressure &#8804; 140/90 mm Hg. Subjects with hypertension should be treated according to ADA guidelines and goals, as determined by the investigator.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subjects should have a body mass index (BMI) &#8804; 38 and should be receiving medical care, education, and counseling for obesity according to ADA guidelines and goals, as determined by the investigator. BMI is obtained by dividing the body weight (in kilograms) by the height squared (in meters squared).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:30.25%;">
<tr>
<td style="width:5.67%;"></td>
<td style="width:3.42%;"></td>
<td style="width:21.17%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BMI</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">=</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weight (kg)</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">height (m) x height (m)</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exclusion Criteria</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unable to comply with the protocol evaluation requirements</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Require surgical intervention within 4 weeks of treatment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Moderate to severe ischemic heart disease or any history of congestive heart failure, or have had a myocardial infarction within the previous 6 months</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evidence of cardiac enlargement and/or congestive heart failure.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Current diabetic foot or leg ulcer, gangrene in the lower extremity, or any amputation of the lower extremity</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Bleeding diathesis (e.g., hemophilia due to Factor VIII or IX deficiency) or require treatment with warfarin 2 weeks prior to and including the dosing period (up to 24 hours after dosing)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6. </p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Hemorrhagic stroke</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Gastrointestinal hemorrhage</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any other condition that, in the opinion of the clinical investigator or sponsor, might compromise any aspect of this trial</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Participation in another clinical trial concurrently or have participated in such a trial within 30 days of screening</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Received gene transfer agents within 6 months of screening</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">History of malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inflammatory angiopathy (e.g., Buerger&#8217;s disease, etc.)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Have an active infection requiring systemic or oral antibiotics. Subjects with prior infection must have discontinued such treatments at least 2 weeks prior to administration of the investigational agent.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Be expected to require immunosuppressants (such as methotrexate, cyclophosphamide, or cyclosporine) for 30 days prior to, during, and for 30 days following administration of the investigational drug product</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Known immune or immunodeficiency disorders (e.g., HIV positive, sarcoidosis, tuberculosis, rheumatoid arthritis, autoimmune disorders &#8211; e.g. psoriasis)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Chronic active viral hepatitis (HBV, HCV) or other active liver disease</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">History of clinically significant hypersensitivity reactions to any component of SB-509</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Current history (within 12 months of start of study) of alcohol or chemical dependency (excluding nicotine), as assessed by the investigator.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">History of or current proliferative retinopathy, macular edema or retinal neovascularization based on a dilated retinal examination with fluorescein angiography and retinal photographs performed by an ophthalmologist</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-cancerous conditions (e.g. Barrett&#8217;s Esophagus, dysplasias) or benign tumors which have the potential for clinically significant growth due to VEGF stimulation.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">History of or current benign colon polyps that have been removed that meet the following criteria: 3 or more adenomas, any adenoma &#8805; 1cm, any adenoma with villous features, high-grade dysplasia or sessile adenomas.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Family history of inherited neuropathy (e.g. Charcot Marie Tooth, Hereditary Predisposition to Pressure Palsy).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Known or suspected spinal pathology such as spinal stenosis, or a history suspicious of claudication (neurogenic and/or vascular).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INFORMED CONSENT</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to entering the study, the investigator or designated assistant will explain to each subject the nature of the study, its purpose, the procedures, the expected duration, alternative therapies available, and the benefits and risks involved in study participation. Subjects will be given an information and consent document, will have the opportunity to ask questions, and will be informed of their right to withdraw from the study at any time without prejudice. After this explanation and before any study&#173;specific procedures have been performed, the subject will voluntarily sign and date the informed consent document.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a subject is re-screened for study participation, the subject should be re-consented if outside of the acceptable screening window. The subject will receive a copy of the re-signed and dated written informed consent form and any other written information provided to the subject.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AUTHORIZATION TO USE AND DISCLOSE MEDICAL INFORMATION</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under federal law, subject study records cannot be used or disclosed for research purposes unless an authorization to use and disclose medical information is signed by each subject prior to participation in the study. The investigator or designated assistant will explain </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 15 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to each subject the purpose of the subject authorization, and the disclosures will be agreed to by signing the authorization document. Subjects will be given an authorization document and will have the opportunity to ask questions. The subject must also be informed of the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">They may not participate in the study unless the authorization is signed; however, they have the right to revoke this authorization (in writing) at any time.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If subject discontinues from the study, they need not revoke the authorization to use and disclose their medical information.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If subject discontinues from the study and does decide to revoke their authorization to use and disclose their medical information, the information that has already been collected in their study records may be used and disclosed as necessary to protect the integrity of the research project.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After this explanation and before any study-specific procedures have been performed, the subject will voluntarily sign and date an authorization document.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to participation in the study, the subject will receive a copy of the signed and dated written authorization.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STUDY METHODOLOGY</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following sections describe in detail all study procedures. A detailed flow chart of all study procedures is presented in the Schedule of Events (<font style="font-weight:bold;">Appendix 1</font>).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STUDY VISIT PROCEDURES</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Screening Visit</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The objective of the screening visit procedures is to identify subjects who meet the stated inclusion and exclusion criteria and who are willing and able to participate in the study. The following screening information and procedures must be obtained and completed within 12 weeks prior to administering the first treatment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blood tests including CBC with WBC differential and platelet count, Coagulation tests PT/INR and PTT and Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub> , Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, vitamin B12, T4/TSH, direct LDL, and total protein must be performed and reviewed for eligibility within 12 weeks prior to administering the first treatment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Procedures that were performed as standard care (e.g., chest X-ray and ECG) may be done prior to written informed consent and may be used for screening eligibility, but they must be completed within 12 weeks prior to administering the first treatment. Sigmoidoscopies or colonoscopies and pap smears may be used for screening eligibility if these procedures have been completed within a year of screening. Mammograms may also be used for screening eligibility if the procedure has been completed within 3 months of screening.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary table of the study procedures can be found in the Schedule of Events, <font style="font-weight:bold;">Appendix 1</font>. The following study procedures will be performed at the screening visit:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Obtain a signed and dated subject informed consent form and authorization document to use and disclose medical information prior to performing any study-specific procedures</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assign a subject number</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Review the inclusion and exclusion criteria</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collect subject demographic information</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A complete medical history; and perform a general physical examination, including evaluation of lower extremity edema, height, weight, vital sign measurements (temperature, blood pressure [systolic and diastolic], and pulse rate), assessment of concomitant medications and <font style="font-weight:bold;">a digital rectal exam for male subjects only</font>. If the subject is not normally seen at the study center and reports having a condition listed in the exclusion criteria, it may be necessary to obtain medical records to confirm study eligibility (i.e., document stability of a clinically significant abnormality or disease)</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 16 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Coagulation tests PT/INR and PTT</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, C0<sub style="font-size:85%; vertical-align:bottom">2</sub> , Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, total protein, and vitamin B12</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">T4/TSH</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Direct LDL cholesterol (subject should be fasting from midnight on)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HgbA1<sub style="font-size:85%; vertical-align:bottom">c</sub> levels</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HIV serology</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum pregnancy test if female subject is of childbearing potential</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Urinalysis - test for presence of glucose, protein, bilirubin, blood, pH, and specific gravity</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection: 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for serum Intracellular Adhesion Molecule (ICAM) level, cytokine assay, immunogenicity testing and detection of inflammatory markers, which should be collected and stored frozen until ready to be shipped to the laboratory. Collection, handling, and shipping instructions will be provided in the <font style="font-weight:bold;">Study Reference Manual</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination for NIS-LL and Lower Extremity Neurological Sensory Exam testing. (See <font style="font-weight:bold;">Appendix 5 and Appendix 6</font> for details).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves (See <font style="font-weight:bold;">Appendix 7</font> and the <font style="font-weight:bold;">Study Reference Manual</font> for details of testing requirements)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Review of waveforms for nerve conduction velocity by the Neurological Core Laboratory.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing (QST) of bilateral lower extremities (<font style="font-weight:bold;">Appendix 8</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">3 mm skin biopsy to determine lntraepidermal Nerve Fiber Density (IENFD) (See <font style="font-weight:bold;">Appendix 9</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuropathy Total Symptom Score (NTSS-6) (See <font style="font-weight:bold;">Appendix 10</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Visual Analog Scale for Pain Intensity (VASPI) (See <font style="font-weight:bold;">Appendix 11</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuro-QoL(lSee <font style="font-weight:bold;">Appendix 12</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SF-36 (See <font style="font-weight:bold;">Appendix 13</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrocardiogram (ECG)- standard 12-lead</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Chest X-ray (2 views anterior-posterior and lateral)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retinal examination with fluorescein angiography and fundus photos, performed by an ophthalmologist</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">PSA blood test for male subjects 45 years of age and older</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mammogram for female subjects 40 years of age and older; A mammogram performed within 3 months of screening can be used for screening eligibility.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pap smear for females who have not had a procedure within a year of screening</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Flexible sigmoidoscopy for subjects 50 years of age and older; A sigmoidoscopy or colonoscopy performed within a year of screening can be used for screening eligibility. Subjects with a history of benign colon polyps removed that do not meet exclusion criteria, must have documented evidence of a normal colonoscopy within the last 12 months. Subjects who have benign colon polyps removed during a sigmoidoscopy performed in the screening period that do not meet exclusion criteria need to have a colonoscopy performed and any additional polyps removed.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fecal Occult Blood Test (FOBT) for subjects 50 years of age and older; (Note: It is acceptable to perform the FOBT test without altering the subject&#8217;s anti-platelet medication. If the subject tests positive, anti-platelet medications should be stopped for 3 days and the test should be repeated.) <font style="font-style:italic;">Note: Only a sigmoidoscopy is required at screening, however if a colonoscopy is performed during screening, the FOBT test is not required</font>.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 17 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subject Enrollment Procedures</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the subject to be enrolled, the clinical site must fax all required documentation, signed by the investigator, to Sangamo BioSciences at (510) 970-6009. The Medical Monitor will review the enrollment form and supportive clinical documentation to confirm eligibility. If the subject meets the enrollment criteria, the subject will be approved for entry into the treatment phase of the protocol and will be randomized to one of the two treatment groups. A product kit number will be assigned to the subject. Please refer to the <font style="font-weight:bold;">Study Reference Manual</font> for additional details.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Baseline Duplicate Assessments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a subject is enrolled and randomized into the study, baseline duplicate measurements will be performed within 14 days prior to the Day 0 visit.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE:<font style="font-weight:normal;"> Duplicate assessments cannot be performed on the same day (there must be a minimum of 1 day and a maximum of 14 days from the other assessment).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following duplicate assessments must be performed in enrolled and randomized subjects within 14 days prior to the Day 0 visit.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing (QST)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Schedule for Treatment Period</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.1</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 0 - Baseline Evaluations (to be completed prior to treatment)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Review eligibility (inclusion and exclusion criteria)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Vital signs: blood pressure (systolic and diastolic), pulse, and temperature</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Weight</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment for ischemic ulcers (present, absent, location, number, size), gangrene (present, absent), and lower extremity edema</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Coagulation tests PT/INR and PTT</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub>, Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Urine pregnancy test &#8211; must be negative prior to drug administration</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection - 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for serum Intracellular Adhesion Molecule (ICAM) level, cytokine assay, immunogenicity testing and detection of inflammatory markers</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination, including gait</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">3 mm skin biopsy</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuropathy Total Symptom Score (NTSS-6)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Visual Analog Scale for Pain Intensity (VASPI)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NeuroQoL</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SF-36</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 18 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subjects counseled to remain compliant with ACS guidelines and follow&#173;up</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Drug administration</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.2</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 0 &#8211; 2 hours post-treatment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection. 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.3</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 60 - Evaluations to be completed prior to treatment (visit window may be &#177; 7 days)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Vital signs: blood pressure (systolic and diastolic), pulse, and temperature</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Weight</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment for ischemic ulcers (present, absent, location, number, size), gangrene (present, absent), and lower extremity edema.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub>, Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection: 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global assessment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Drug administration</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.4</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 60 &#8211; 2 hours post-treatment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection. 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.5</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 90 (visit window may be &#177; 7 days)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Vital signs: blood pressure (systolic and diastolic), pulse, and temperature</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Weight</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment for ischemic ulcers (present, absent, location, number, size), gangrene (present, absent), and lower extremity edema.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub> , Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HgbA1c</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood Sample collection: 6 mL blood (3 mL plasma) sample for PCR assay and 10mL blood (5 mL serum) sample for cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 19 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing (QST) of bilateral lower extremities</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuropathy Total Symptom Score (NTSS-6)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Visual Analog Scale for Pain Intensity (VASPI)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NeuroQoL</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global assessment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.6</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 120 - Evaluations to be completed prior to treatment (visit window may be &#177; 7 days)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Vital signs: blood pressure (systolic and diastolic), pulse, and temperature</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Weight</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment for ischemic ulcers (present, absent, location, number, size), gangrene (present, absent), and lower extremity edema.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub> , Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HgbA1c</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection: 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global assessment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Drug administration</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.<font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 120 &#8211; 2 hours post-treatment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection. 6 ML blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.8</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 150 (visit window may be &#177; 7 days)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">3 mm skin biopsy</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global assessment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Schedule for Follow-Up Period</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5.1</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 180 (visit window may be &#177; 7 days)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Vital signs: blood pressure (systolic and diastolic), pulse, and temperature</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Weight</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 20 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ischemic ulcers (present, absent, location, number, size)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Gangrene (present, absent)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessments for lower extremity edema.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub>, Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HgbA1c</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Urine pregnancy test</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection: 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for serum Intracellular Adhesion Molecule (ICAM) level, cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing (QST) of bilateral lower extremities</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination, including gait</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">3 mm skin biopsy</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuropathy Total Symptom Score (NTSS-6)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Visual Analog Scale for Pain Intensity (VASPI)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NeuroQoL</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SF-36</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global assessment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retinal examination with fluorescein angiography and fundus photos, performed by an ophthalmologist <font style="font-weight:bold;">(Visit window for the retinal</font> <font style="font-weight:bold;">examination is &#177;14 days)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5.2</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 180 &#177; 14 days: The following <font style="font-weight:bold;">duplicate</font> assessments must be performed &#177; 14 days of the Day 180 visit. Duplicate assessments cannot be performed on the same day (there must be a minimum of 1 day and a maximum of 14 days from the other assessment).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5.3</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 240 (visit window may be &#177; 7 days)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Vital signs: blood pressure (systolic and diastolic), pulse, and temperature</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Weight</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment for ischemic ulcers (present, absent, location, number, size), gangrene (present, absent), and lower extremity edema.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub>, Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HgbA1c</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 21 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection: 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global assessment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5.4</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 360 (visit window may be &#177; 14 days)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">General physical examination for all subjects, including a digital rectal exam for male subjects only.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Vital signs: blood pressure (systolic and diastolic), pulse, and temperature</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Weight</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment for ischemic ulcers (present, absent, location, number, size), gangrene (present, absent), and lower extremity edema.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CBC with WBC differential and platelet count</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Coagulation tests PT/INR and PTT</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serum chemistry: electrolytes (Na, K, CO<sub style="font-size:85%; vertical-align:bottom">2</sub>, Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HgbA1c</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Direct LDL cholesterol (subject should be fasting from midnight on)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Spot urine test for microalbumin/creatinine</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Urine pregnancy test</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Blood sample collection: 6 mL blood (3 mL plasma) sample for PCR assay and 10 mL blood (5 mL serum) sample for serum Intracellular Adhesion Molecule (ICAM) level, cytokine assay, immunogenicity testing and detection of inflammatory markers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing (QST) of bilateral lower extremities</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination, including gait</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">3 mm skin biopsy</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuropathy Total Symptom Score (NTSS-6)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Visual Analog Scale for Pain Intensity (VASPI)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NeuroQoL</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SF-36</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global assessment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ECG &#8211; standard 12-lead</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retinal examination with fluorescein angiography and fundus photos, performed by an ophthalmologist</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">PSA blood test for male subjects 45 years of age and older</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mammogram for female subjects 40 years of age and older</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FOBT for subjects 50 years of age and older</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subject counseled to remain compliant with ACS guidelines and follow&#173;up</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AE query and appropriate medical evaluation if positive</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 22 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Assessment of concomitant medications</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5.5</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Day 360 &#177; 14 days: The following <font style="font-weight:bold;">duplicate</font> assessments must be performed &#177; 14 days of the Day 360 visit. Duplicate assessments cannot be performed on the same day (there must be a minimum of 1 day and a maximum of 14 days from the other assessment).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing of the sural and peroneal nerves</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower extremity neurological examination</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CRITERIA FOR WITHDRAWAL FROM THE STUDY</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Discontinuation from Study Treatment and Follow-up of Subjects</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subjects will be strongly encouraged to continue with follow-up safety evaluations if they withdraw consent from the study. If a subject discontinues from the study a conference between the investigator and medical monitor will take place to ensure that all subjects will comply with the follow-up safety evaluations of the protocol. Participation in this study will not prejudice the subject&#8217;s future medical care.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subjects will be assessed for treatment-related adverse events and disease status. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subjects who discontinue during the post-treatment follow-up period will not be replaced; therefore, study centers are encouraged to carefully select subjects who would be likely to complete all study procedures.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ADMINISTRATION OF STUDY DRUG</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Product Description</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SB-509 drug product is a clear, colorless, and sterile liquid supplied in single&#173; use glass vials. Each 3 mL glass vial is filled with 2.2 mL of drug product that contains 2 mg/mL of pV-32Ep65 DNA plasmid, 2 mM Tris, 150 mM sodium chloride and 5% (w/v) poloxamer 188 at pH 8.0. It is intended for intramuscular administration.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description and Manufacturer of Drug Substance</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug substance containing the active ingredient, plasmid pV-32Ep65, is manufactured under cGMP at Althea Technologies, Inc., San Diego, CA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pV-32Ep65 is a typical eukaryotic expression vector bearing the CMV immediate early enhancer/promoter and a polyadenylation site from the bovine growth hormone gene. The vector backbone, pVAX-1 (3.0 kb), has been specifically designed for use in the development of DNA vaccines.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pV-32Ep65 is a 4106 base-pair DNA plasmid that encodes an engineered ZFP-TF. The therapeutic gene encodes a 3-finger DNA binding ZFP with a transactivation domain and nuclear localization signal (NLS) and was cloned into a pVAX-1 vector backbone. The ZFP-TF is a 378 amino acid protein that is composed of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the NLS of the long T antigen of SV40</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a designed 3-finger ZFP (32E) that binds to a 9 base pair target present in the human VEGF-A promoter region (GGGGGTGAC)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the transactivation domain from the p65 subunit of the human transcription factor NF-KB</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 23 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key features of pV-32Ep65 are illustrated in the plasmid map shown in <font style="font-weight:bold;">Figure 5</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 5. Circular Plasmid Map of pV-32Ep65</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201504281926168661270.jpg" title="" alt="" style="width:432px;height:342px;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SB-509 and Placebo Study Drug Composition</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 is a purified, double-stranded bacterial DNA plasmid. It is formulated as a sterile, injectable solution and is filled 2.2 mlin 3-mL vials. The drug product composition is described in <font style="font-weight:bold;">Table 1</font>. It consists of pV-32Ep65 DNA plasmid (2 mg/ml), Poloxamer 188 (5%&#160;w/v), NaCI (150 mM), 2 mM Tris-HCI, pH 8.0, and sterile water for injection.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table 1. Composition of SB-509</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:50.09%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Component</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unit Formula (mg/mL)</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pV-32Ep65 (plasmid DNA)</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 mg</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sodium chloride, USP (150mM NaCI)</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.76 mg</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poloxamer 188, NF (5%w/v)</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50 mg</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tromethamine, pH 8.0, USP (2 mM Tris-HCI)</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.242 mg</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sterile Water for Injection, USP</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">q.s. to 1.0 mL</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The final drug product is tested for appearance, identity, potency, concentration, purity, pH, conductivity, endotoxin, and sterility.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Normal saline (0.9% NaCI) will be provided in identical 3-mL vials and will serve as the placebo.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inventory, Storage, and Handling of the Drug Product</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Labeled product will be stored at Fisher Clinical Services for distribution to the clinical sites. Sangamo BioSciences requires its sponsored investigators to maintain adequate drug inventory and security at all times (Appendix 4). Therefore, SB-509 and placebo will be supplied as a frozen liquid "to deliver"</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0 ml. Upon receipt of labeled product, the investigator or designated individual (e.g., pharmacist) will check the details of the supplies and document receipt. As a double-blind controlled trial, the clinical supplies will be in a blinded packaging configuration containing 18 vials per kit. One kit will be assigned for each dose.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 24 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator will store both SB-509 and the placebo in a locked &#8211;20<font style="Background-color:#FFFFFF;color:#222222;font-size:9.5pt;font-family:Arial;">&#176;</font>C freezer and will monitor and maintain a log of the temperature. Immediately before use, vials will be thawed at room temperature and allowed to equilibrate to room temperature for at least 10 minutes. Once thawed, vials will not be reused on subsequent days.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Empty vials and any remaining product in the used vials will be stored at room temperature at the clinical sites and must be kept with original carton. Vials should not be discarded until the Sangamo BioSciences monitor reviews the drug accountability log.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accessibility to labeled product should only be to those individuals authorized by the investigator to dispense this study drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator or designated individual will maintain an inventory. A drug accountability log will be provided to the pharmacist. This inventory will include the description and quantity of labeled product received during the course of this study, as well as a record of the labeled product that is dispensed. This inventory record shall indicate the quantity and description of labeled product on hand at any time during the course of this study. A Sangamo BioSciences monitor will review this inventory during interim monitoring visits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the conclusion or termination of this study, return or destruction of all drug supplies must be coordinated with Sangamo BioSciences. Please see the Study <font style="font-weight:bold;">Reference Manual</font> for additional details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator agrees not to supply labeled product to any person other than study personnel and subjects in this study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Good Clinical Practice, it is Sangamo BioSciences policy always to investigate suspected cases of fraud.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.11 Termination of the Study</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences retains the right to terminate the study and remove all study materials at any time. Specific instances that may precipitate such termination are as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Completion of the study at an investigational site</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unanticipated adverse medical experiences in this or other studies indicating a potential health hazard caused by the investigational drug</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Significant protocol deviation and/or lack of compliance and cooperation on the part of the investigator; such as failure to obtain signed informed consent prior to initiating study-related procedures, unsatisfactory subject enrollment with regard to quality or quantity, deviation from protocol requirements without prior approval from Sangamo BioSciences, or inaccurate and/or incomplete data recording on a recurrent basis</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Investigator withdrawal from participation in the study</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Withdrawal of investigational drug from investigational use</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Termination of this study by Sangamo BioSciences</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.12 Record Retention</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator should retain essential documents according to 21 CFR 312.62(c) and ICH Guidelines for Good Clinical Practices (E6), until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period, however, if required by the applicable regulatory requirements or by an agreement with Sangamo BioSciences. It is the responsibility of Sangamo BioSciences to inform the investigator as to when these documents no longer need to be retained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Records to be retained by the investigator include, but are not restricted to, protocols; amendments; investigator&#8217;s brochure; Investigator agreement (including financial agreement); IRB/IEC/IBC applications; approvals and composition; copies of the Form FDA 1572; pre-study and follow-up financial disclosure; completed, signed, and dated informed consents; subject medical records; case report forms;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">monitoring log; serious adverse event reports; IRB notifications; subject screening/enrollment log; study personnel signature log; drug accountability record and logs; clinical laboratory normal ranges and accreditation certificate; and all correspondence between study monitor, study sponsor, and IRB/IEC/IBC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 25 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject files and other source data must be kept for the maximum period of time permitted by the hospital, institution, or private practice, but not less than 15 years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.13 Confidentiality</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject medical information obtained for the purpose of this trial is confidential, and disclosure to third parties, other than those noted below, is prohibited. Upon the subject&#8217;s request and receipt of written permission, medical information may be given to his/her personal physician or other appropriate medical personnel responsible for the subject&#8217;s welfare.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data generated for this study must be available for inspection upon request to representatives of the FDA, other national or local health authorities, Sangamo BioSciences, and the associated IRB/IEC/IBC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release of research results or data that reveal subject names or other identifiers, such as photographs, audiotapes, or videotapes, must be carried out in accordance with the Department of Health and Human Services&#8217; proposed Standards for Privacy of Individual Health information, 45 CFR 164.508. Written authorization must be obtained from the subject and the IRB/IEC/IBC prior to the release of such information. Identifiable subject data may not be used for the purpose of promoting the study drug.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.14 Publication Statement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is intended that the results of the study be published in scientific literature. Results may also be used in submissions to regulatory authorities. The following conditions are to protect commercial confidential materials (e.g., patents), not to restrict publication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All information concerning the labeled product under study (such as patent applications, formulae, basic scientific data, or formulation information supplied to the investigator and not previously published) is considered confidential by Sangamo BioSciences and shall remain the sole property of Sangamo BioSciences.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is understood by the investigator that the results of this clinical trial may be used by Sangamo BioSciences in registration documents for regulatory authorities in the U.S. or abroad, or for public dissemination in the form of papers, abstracts, posters, or other informational materials to be presented at scientific meetings, or published in professional journals, or as a part of an academic thesis by an investigator.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All proposed publications, papers, abstracts, or other written materials related to the study, or an outline of any proposed oral presentations, shall be submitted to</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences for approval at least 45 days prior to (1) submission for publication or (2) any proposed oral disclosure to a third party. Sangamo BioSciences shall have the right to review and comment on such written material or outline, and to confirm the accuracy of the data described therein by comparison with that collected during the course of this study. In the event that Sangamo BioSciences determines that an enabling description of patentable subject matter is contained in such written material or outline, it shall notify the clinical site(s) within 1 month after receipt by Sangamo BioSciences, and Sangamo BioSciences will have an additional 90 days for review.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of publication of multi-center data, the number of subjects enrolled by each investigator will usually determine the order of participation, unless otherwise agreed upon by the investigators and Sangamo BioSciences.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17<font style="margin-left:24pt;"></font>STUDY FUNDING</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs necessary to perform the study will be agreed to by the investigator and/or the management of the study facility and will be documented in a separate financial agreement. All financial agreements will be signed by the investigator and Sangamo BioSciences.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18<font style="margin-left:24pt;"></font>REFERENCES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Cancer Society (2009). <font style="font-style:italic;">Cancer Facts &amp; Figures 2009</font>. Atlanta, Ga: American Cancer Society.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Argoff, C.E., Backonja, M.M., Belgrade, M.J., Bennett, G.J., Clark, M.R., Cole, B.E., Fishbain, D.A., Irving, G.A., McCarberg, B.H., and McLean, M.J. (2006). Consensus guidelines: treatment planning and options. Mayo Clin. Proc. <font style="font-style:italic;">81</font>, S12&#8211;S25.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 26 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bastyr, E., Price, K., Bril, V., <font style="font-style:italic;">et al</font>. (2005). Development and Validity Testing of the Neuropathy Total Symptom Score-6: Questionnaire for the Study of Sensory Symptoms of Diabetic Peripheral Neuropathy. Clinical Therapeutics. <font style="font-style:italic;">27</font>:1278-1294</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biessels, G.-J., Cristino, N.A., Rutten, G.-J., Hamers, F.P.T., Erkelens, D.W., and Gispen, W.H. (1999). Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats. Course of development and effects of insulin treatment. Brain <font style="font-style:italic;">122</font>, 757&#8211;768.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bril, V. (1999). NIS-LL: The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology. <font style="font-style:italic;">41</font>(Suppl 1):8-13</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boulton, A.J.M., Malik, R.A.M., Arezzo, J.C., and Sosenko, J.M. (2004). Diabetic somatic neuropathies. Diabetes Care. <font style="font-style:italic;">27</font>, 1458-1486.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calcutt, N.A., Allendoerfer, K.L., Mizisin, A.P., Middlemas, A., Freshwater, J.D., Burgers, M., Ranciato, R., Delcroix, J.-D., Taylor, F.R., Shapiro, R., <font style="font-style:italic;">et al</font>. (2003). Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy. J. Clin. Invest. <font style="font-style:italic;">111</font>,507&#8211;514.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elson, D.A., Thurston, G., Huang, L.E., Ginzinger, D.G., McDonald, D.M., Johnson, R.S., and Arbeit, J.M. (2001). Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. <font style="font-style:italic;">15</font>, 2520&#8211;2532.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Feldman, E.L. (2002). Diabetic Neuropathy, Presented at May 16, 2002 Anesthetic and Life Support Drugs Advisory Committee, FDA. (http://www.fda.gov/ohrms/dockets/ac/02/slides/3864S1_01_Hertz.ppt).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Feldman, E.L., Russell, J.W., Sullivan, K.A., and Golovoy, D. (1999). New insights into the pathogenesis of diabetic neuropathy. Curr. Opin. Neurol. <font style="font-style:italic;">12</font>, 553&#8211;563.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Levin, B., Lieberman, D.A., McFarland, et al. (2008). Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology . Published online March 5, 2008. <font style="font-style:italic;">CA Cancer J Clin. 58</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Malik, R.A. (2000). Can diabetic neuropathy be prevented by angioensin-converting enzyme inhibitors? Ann. Med. 32, 1&#8211;5.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McNeely, M., Boyko, E., Ahroni, J., Stensel, V.L., Reiber, G.E., Smith, D.G., and Pecoraro, R.F. (1995). The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care <font style="font-style:italic;">18</font>, 216&#8211;219.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O&#8217;Brien, P.C. (1984). Procedures for comparing samples with multiple endpoints, Biometrics, <font style="font-style:italic;">40</font>, 1079&#8211;1087.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poncelet, A.N. (2003). Diabetic polyneuropathy: Risk factors, patterns of presentation, diagnosis and treatment. Geriatrics <font style="font-style:italic;">58</font>, 16&#8211;30.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potter, P., Maryniak, O., Yaworsky, R., and Jones, I. (1998). Incidence of peripheral neuropathy in the contralateral limb of persons with unilateral amputation due to diabetes. Rehabil. Res. Dev. 25, 335&#8211;339.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price, S.A., Dent, C., Duran-Jimenez, B., Liang, Y., Zhang, L., Rebar, E.J., Case, C.C., Gregory, P.O., Martin, T.J., Spratt, S.K., Tomlinson, D.R. (2006). Gene Transfer of an Engineered Transcription Factor Promoting Expression of VEGF-A Protects Against Experimental Diabetic Neuroapthy. Diabetes. 55, 1847-1854.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quattrini, C et al. Reduced vascular endothelial growth factor expression and intra&#173;epidermal nerve fiber loss in human diabetic neuropathy. (2008). Diabetes Care.31(1):140-145</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rebar, E.J., Huang, Y., Hickey, R., Nath, A.K., Meoli, D., Nath, S., Chen, B., Xu, L., Liang, Y., Jamieson, A.C., <font style="font-style:italic;">et al</font>. (2002). Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. <font style="font-style:italic;">8</font>, 1427&#8211;1432.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Saslow, D., Boetes, C., Burke, W., et. al. for the American Cancer Society Breast Cancer Advisory Group (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. <font style="font-style:italic;">CA Cancer J Clin. 57</font>:75-89.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 27 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schratzberger, P., Walter, D.H., Rittig, K., Bahlmann, F.H., Pola, R., Curry, C., Silver, M., Krainin, J.G., Weinberg, D.H., Ropper, A.H., <font style="font-style:italic;">et al</font>. (2001). Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. <font style="font-style:italic;">107</font>, 1083&#8211;1092.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simovic, D., Isner, J.M., Ropper, A.H., Pieczek, A., and Weinberg, D.H. (2001). Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch. Neurol. <font style="font-style:italic;">58</font>, 761&#8211;768.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skyler, J. (1997). Diabetes Mellitus, Types I and II. In Textbook of Internal Medicine, 3<sup style="font-size:85%; vertical-align:top">rd</sup> Edition, Kelley, W.N., ed. (Philadelphia: Lippincott-Raven Publishers), pp. 2238&#8211;2252.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stratton, I., Adler, A., Neil, H., Matthews, D.R., Manley, S.E., Cull, C.A., Hadden, D., Turner, R.C., and Homan, R.R. (2000). Association of glycaemia with macrovasclar and microvasclar complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ <font style="font-style:italic;">321</font>, 405&#8211;412.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas, P. and Tomlinson, D. (1993). Diabetic and hypoglycemic neuropathy. In Peripheral Neuropathy, 3<sup style="font-size:85%; vertical-align:top">rd</sup> Edition, Dyck, P. Thomas, P., eds. (Philadelphia: W.B. Saunders Company), pp. 1219&#8211;1250.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UK Prospective Diabetes Study Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet <font style="font-style:italic;">352</font>, 837&#8211;853.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vileikyte, L, Peyrot, M, Bundy, C, Rubin, RR, Leventhal, H, Mora, P, Shaw, JE, Baker, P, and Boulton, AJ. (2003) The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care. 26(9):2549-2555.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whitlock, P.R., Hackett, N.R., Leopold, P.L., Rosengart, T.K., and Crystal, RG. (2004). Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol. Ther. <font style="font-style:italic;">9</font>, 67&#8211;75.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 28 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">APPENDIX 1:SCHEDULE OF EVENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Visit Number</p></td>
<td valign="bottom"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VO</p></td>
<td valign="bottom"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VI/V2</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V3</p></td>
<td valign="bottom"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V4</p></td>
<td valign="bottom"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V5</p></td>
<td valign="bottom"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V6</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V7/V8</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V9</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V10/11</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dose 1</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dose 2</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dose 3</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr style="height:18.4pt;">
<td valign="bottom"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Visit</p></td>
<td valign="bottom"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day-84 Screening</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day 0</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day 0</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2 hours post-tx)</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2 hours post-tx)</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day120</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2 hours post-tx)</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">360n</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Informed consent</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eligibility</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical history</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physical exam<sup style="font-size:85%; vertical-align:top">a</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vital signs<sup style="font-size:85%; vertical-align:top">b</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Height</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weight</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ischemic ulcers/Gangrene</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lower extremity edema</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CBC with WBC differential and platelet count</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PT/INR and PTT</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serum chemistry<sup style="font-size:85%; vertical-align:top">c</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HgbA1c</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIV serology</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serum pregnancy test</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Urine pregnancy test<sup style="font-size:85%; vertical-align:top">d</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Urinalysis<sup style="font-size:85%; vertical-align:top">e</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spot urine test for microalbumin/creatinine</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blood sample<sup style="font-size:85%; vertical-align:top">f</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug administration</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Electrophysiological testing (sural and peroneal nerves)<sup style="font-size:85%; vertical-align:top">g</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QST<sup style="font-size:85%; vertical-align:top">g</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lower extremity neurological examination</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XX*</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 mm skin biopsy (IENFD)</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NTSS-6</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VASPI</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuro-QoL</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SF-36</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global assessment</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12-lead ECG<sup style="font-size:85%; vertical-align:top">h</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chest X-ray<sup style="font-size:85%; vertical-align:top">h</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Retinal examination and photos</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PSA<sup style="font-size:85%; vertical-align:top">i</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mammogram<sup style="font-size:85%; vertical-align:top">i</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pap Smear<sup style="font-size:85%; vertical-align:top">k</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 29 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.67%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Visit Number</p></td>
<td valign="bottom"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VO</p></td>
<td valign="bottom"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VI/V2</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V3</p></td>
<td valign="bottom"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V4</p></td>
<td valign="bottom"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V5</p></td>
<td valign="bottom"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V6</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V7/V8</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V9</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V10/11</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dose 1</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dose 2</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dose 3</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr style="height:18.4pt;">
<td valign="bottom"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Visit</p></td>
<td valign="bottom"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day-84 Screening</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day 0</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day 0</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2 hours post-tx)</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2 hours post-tx)</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
<td valign="bottom"  BGCOLOR="#BFBFBF" style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Day120</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2 hours post-tx)</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">360n</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOBT<sup style="font-size:85%; vertical-align:top">l</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sigmoidoscopy<sup style="font-size:85%; vertical-align:top">l</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AEs<sup style="font-size:85%; vertical-align:top">m</sup></p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assessment of concomitant medications</p></td>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject counseled to remain compliant with ACS guidelines and follow-up</p></td>
<td valign="bottom"  style="width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">*</sup><sup style="font-size:85%; vertical-align:top"> </sup><font style="font-weight:bold;">Duplicate assessments (XX) must be performed in enrolled and randomized subjects within14 days prior to the Day 0 visit, or performed within &#177; 14 days of the projected visit day (Day 180 and Day 360).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">a</sup><sup style="font-size:85%; vertical-align:top"> </sup>Physical examination for all subjects to include a digital rectal examination for male subjects only.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">b</sup><sup style="font-size:85%; vertical-align:top"> </sup>Vital signs to include systolic/diastolic pressure, pulse, and temperature.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">c</sup><sup style="font-size:85%; vertical-align:top"> </sup>Serum chemistry: electrolytes (Na, K, C0<sub style="font-size:85%; vertical-align:bottom">2</sub>, Cl), CPK, CPKmb, troponin, creatinine, BUN, glucose, uric acid, total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and total protein; In addition: <font style="text-decoration:underline;">On screening day</font>: vitamin B12, T4/TSH, direct LDL; <font style="text-decoration:underline;">On Day 360:</font> direct LDL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">d</sup><sup style="font-size:85%; vertical-align:top"> </sup>Urine pregnancy test: result must be negative prior to drug administration on Day 0.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">e</sup><sup style="font-size:85%; vertical-align:top"> </sup>Urinalysis: test for the presence of glucose, protein, bilirubin, blood, pH, and specific gravity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">f</sup><sup style="font-size:85%; vertical-align:top"> </sup>Blood samples will be used for PCR assay, cytokine assay, immunogenicity testing, ICAM assay, and detection of inflammatory markers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">g</sup><sup style="font-size:85%; vertical-align:top"> </sup>The screening (Day -84) disease activity assessments may be done in stages, but they must be completed prior to Day 0.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">h</sup><sup style="font-size:85%; vertical-align:top"> </sup>If none available in the preceding 12 weeks.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">I </sup>PSA blood test for male subjects age 45 years or older.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">j</sup><sup style="font-size:85%; vertical-align:top"> </sup>Mammogram: for females older than 40 years of age. A mammogram performed within 3 months of screening can be used for screening eligibility.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">k</sup><sup style="font-size:85%; vertical-align:top"> </sup>Pap smear for females who have not had a procedure within a year of screening.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">l</sup> FOBT for subjects 50 years of age or older. Only a sigmoidoscopy is required at screening, however if a colonoscopy is performed during screening, an FOBT is not required. Sigmoidoscopy for subjects 50 years of age or older. A sigmoidoscopy or colonoscopy performed within a year of screening may be used for screening eligibility.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">m</sup> Query for AEs and appropriate medical evaluation if positive.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">n</sup><sup style="font-size:85%; vertical-align:top"> </sup>Day 360 or early termination.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:35.73%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:35.73%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 30 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.67%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SB-509 Administration</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.5.1. Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150 subjects will be randomized in a 1:1 ratio stratified by study site and screening IENFD (&lt;9, &#8805;9) to treatment with SB-509 or placebo:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1) SB-509 treatment: 60 mg of SB-509 on Day 0, Day 60 and Day 120.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2) Placebo on Day 0, Day 60 and Day 120.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30 mg of SB-509 or an equal volume of placebo will be injected (IM) into each lower limb for a total dose of 60 mg. Each subject will receive a total of three treatments. The drug will be supplied in 3-mL vials and will be injected in 0.5 or 1 mL volumes each injection in the lower leg and thigh, respectively. See <font style="font-weight:bold;">Appendix 4</font> for detailed pharmacy preparation and subject injection instructions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Injection Procedure</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The injection site in the muscle will allow the deposit of 0.5 mL and 1.0 mL doses of study drug by inserting a needle along the long axis of the muscle fiber (i.e., parallel with the femoral artery) up to its hub (the needle&#8217;s full insertion point) and depositin 0.5 mL doses to the lower leg injection sites or 1.0 mL doses to the thigh injection sites.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.5.2. Injection Needles and Volumes for Each Injection Site</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Needles (25 gauge; 1- to 1.5-inch or 27 gauge; 1.25 inch) with 1 mL syringes are to be used. Care should be taken to avoid injection into any area of skin ulceration.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Precautions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 is an investigational drug, and there is a possible risk of anaphylaxis. SB-509 should be administered in a setting where emergency treatment is available for anaphylaxis. If any serious allergic or anaphylactoid reaction occurs, administration should be immediately discontinued and appropriate therapy initiated.  Subjects must remain in the clinic for 2 hours after administration of SB-509.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Premedications</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NSAIDs or acetaminophen may be taken prior to or after injections for pain. Diphenhydramine, oral or topical, may be used for pruritus.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dose Modifications</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No dose modifications will be allowed.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SAFETY</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Potential Risks</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1.1. SB-509</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 has been administered to a total of 164 subjects with diabetic peripheral neuropathy in four clinical trials. Twenty-seven subjects received SB-509 as a single treatment; 75 subjects as a repeat dosing (Days 0, 60, and 120), and 30 subjects as a repeat dosing (Days 0 and 90). For the single treatment, separate groups received increasing doses of 1 mg, 5 mg, 15 mg, 30 mg, or 60 mg. For the repeat dosing, the dose was 60 mg. The length of follow-up was 180 days after the single dose, and 360 days after the first dose of the repeat dosing schedule.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 was well-tolerated. Most of the AEs were injection site reactions, which were mild to moderate in severity. There were no drug-related SAEs, dose-limiting toxicities, deaths, or discontinuations of study drug because of AEs. Immunogenicity was not triggered by SB-509. There was no evidence of retinal neovascularization or tumorigenesis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further information is provided in the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 31 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1.2. Vascular Endothelial Growth Factor</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 induces the production of all isoforms of VEGF. Clinical studies have been performed with recombinant human VEGF and VEGF plasmid DNA gene therapy. A review of the previous human experience with VEGF is in the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure</font>. The major potential risk is the augmentation of growth of tumors and a reversible leg edema with VEGF plasmid DNA gene therapy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1.3. Poloxamer 188</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poloxamer 188 is being used as a delivery enhancer in SB-509. It is a complex polymer that is commonly used in stool softeners and foods. It has an effect on red blood cell elasticity and has been used parenterally for the treatment of Sickle Cell Crisis. A review of the previous human experience is in the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure</font>. The major risk is an idiosyncratic allergic reaction that would be associated with any component of the formulation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1.4. Gene Transfer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a risk that people who receive gene transfer may develop new tumors. This risk is primarily associated with viral gene transfer vectors that integrate into the cellular DNA and may induce carcinogenesis. This risk with plasmid DNA gene transfer is extremely low.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1.5. Skin Biopsy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin biopsies will be obtained during the trial for the analysis of intraepidermal nerve fiber density to see if treatment with SB-509 will affect the number of epidermal nerve fibers in the skin. The size of the biopsies is 3 mm in diameter. Side effects include pain, bleeding, low rates of infection (1/500 biopsies), and, rarely, depigmented skin at the healed biopsy site.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">EFFICACY</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Potential Benefits</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is likely that the subjects receiving this treatment will not derive any benefit from their participation in this trial.  However, based on the results to date, subjects receiving SB-509 treatment may have improvements in nerve conduction velocities and vibration perception threshold.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Efficacy Criteria</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.1. Clinical Evaluation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A neurological evaluation, electrophysiological test, and quantitative sensory testing will be performed at screening, on Day 0 pre-treatment, on Days 90, 180, and 360. Duplicate measurements will be completed within 14 days prior to the Day 0 visit, and &#177;14 days of Day180 and Day 360 visits. <font style="font-weight:bold;">Note</font>: Neurological evaluation must be performed by a qualified medical doctor</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.2. Disease Assessment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diabetic peripheral neuropathy will be evaluated by using the following scales and modalities based on the neurological examination data, electrophysiological testing data, skin biopsy data, subject neurological questionnaire, subject pain assessment, and Quality of Life questionnaires.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Electrophysiological testing using nerve conduction velocity (NCV) studies (<font style="font-weight:bold;">Appendix 7</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Signs using Neuropathy Impairment Score &#8211; Lower Limb (NIS-LL) (<font style="font-weight:bold;">Appendix 5</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lower Extremity Neurological Sensory Exam (<font style="font-weight:bold;">Appendix 6</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quantitative sensory testing (QST) with the Vibratron II instrument (<font style="font-weight:bold;">Appendix 8</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">lntraepidermal Nerve Fiber Density (IENFD) (<font style="font-weight:bold;">Appendix 9</font>) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuropathy Total Symptom Score (NTSS-6) (<font style="font-weight:bold;">Appendix 10</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Visual analog scale for pain intensity (VASPI) (<font style="font-weight:bold;">Appendix 11</font>)</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 32 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neuro-Qo(<font style="font-weight:bold;">Appendix 12</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SF-36 (<font style="font-weight:bold;">Appendix 13</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Global Assessment (<font style="font-weight:bold;">Appendix 14</font>)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CONCOMITANT MEDICATIONS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator will record all concomitant medications, including those given for treatment of adverse events on the concomitant medication page in the subject's case report form. Any medication taken by the subject from screening throughout the course of the study, including over-the-counter medicinal products, dietary supplements, and herbal medications, should be recorded on this form. Medications may be adjusted as needed throughout the course of the study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subjects will be evaluated for pain, and use of pain medications will be recorded from the time of the first treatment throughout the course of the study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If required after Day 0, antibiotics must be completed at least 2 weeks prior to the dose and the subject must be asymptomatic prior to dosing.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ADVERSE EVENTS</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Adverse Event Reporting Period</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The screening period is defined as starting with screen procedures and ending with the first treatment. The treatment period is defined as starting with the first treatment and ending 4 weeks after the last treatment.  The follow-up period is defined as starting 4 weeks after the last treatment until the Day 360 visit.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the screening period, study procedural related adverse events will be reported. During both the treatment and follow-up periods, subjects will be queried and events will be assessed at each clinic visit. All adverse events will be reported. Subjects will be reminded to immediately report any Serious Adverse Event to the investigator.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Definitions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An <font style="text-decoration:underline;">adverse event</font> is any untoward medical occurrence in a patient or clinical investigation subject that is temporally related to protocol procedures, including the administration of a labeled product at any dose, but which does not necessarily have a causal relationship with the treatment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term adverse event also applies to laboratory findings or results of other diagnostic procedures that are considered to be clinically relevant (e.g., that required unscheduled diagnostic procedures or treatment measures, or resulted in withdrawal from the study).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An <font style="text-decoration:underline;">adverse drug reaction (ADR)</font> occurring in a clinical study is an untoward medical occurrence in a patient or clinical investigation subject that is possibly or probably causally related to the administration of a labeled product. Such ADRs are a subset of the adverse events defined above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;adverse event&#8221; could include any of the following events which develop or increase in severity during the course of the study. Examples include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any sign, symptom, or physical examination finding that worsens in nature, severity, or frequency compared to baseline. Whether thought to be related or unrelated to the condition under study</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any clinically significant laboratory abnormality or laboratory abnormality that requires medication or hospitalization</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All reactions from study drug, including those occurring as a result of an overdose, abuse, withdrawal phenomena, sensitivity, or toxicity to study drug</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Concurrent illness</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Injury or accident</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 33 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A pre-existing condition is one that is present prior to or at the start of the study and is to be reported as part of the subject&#8217;s medical history. It should be reported as an adverse event only if the frequency, intensity, or the character of the condition worsen during study treatment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An unexpected adverse event is one not identified in nature, severity, or frequency in the current protocol or the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Recording of an Adverse Event</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal investigator is responsible for evaluating all adverse events, obtaining supporting documents, and determining that documentation of the event is adequate. He/she is responsible for determining the severity and relationship to the investigational drug.  The principal investigator may delegate these duties to sub&#173; investigators and must assure that these sub-investigators are qualified to perform these duties under the supervision of the principal investigator.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All adverse events will be recorded in the subject&#8217;s case report form (CRF).  The detailed description of the event will include appropriately graded severity of the adverse event and its relationship to the study drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severity will be categorized by toxicity grade according to the revised NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE) (<font style="font-weight:bold;">Appendix 2</font>).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse events not listed in the NCI CTCAE will be evaluated by using the following criteria:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Grade 1, Mild</font>: Subject is aware of signs and symptoms, are easily tolerated; usually transient and requiring no special treatment; does not interfere with usual daily activities</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Grade 2, Moderate</font>: May be ameliorated by simple therapeutic measures; sufficient to restrict; should not prevent usual daily activities</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Grade 3, Severe</font>: Incapacitating; inability to perform usual daily activities</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Grade 4, Life-threatening/Disabling</font>: Subject was at risk of death or significant disability at the time of the event</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The relationship of the adverse event to the investigational drug will be determined by the principal investigator and will be categorized as:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Not Related</font>: The adverse event is clearly related to other factors, such as the subject&#8217;s clinical state, environmental factors, or other modes of therapy or concomitant drugs administered to the subject.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Related</font>: The adverse event is temporally associated with the use of the study drug, and/or a causal relationship between the study drug and the adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled out.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Grade 3 and 4 clinical laboratory results that represent an increase in severity from baseline will be reported as adverse events. A Grade 1 or 2 clinical laboratory abnormality should be reported as an adverse event only if it is considered clinically significant by the investigator.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of death, the cause of death should be recorded as the adverse event and reported as an SAE (see <font style="font-weight:bold;">Section 14</font>). &#8220;Death&#8221; is not the adverse event; &#8220;death&#8221; is an outcome. A copy of the death certificate should be obtained. Because the long-term effects of gene transfer are not known, the NIH would like an autopsy in the event of death. If an autopsy is performed, a copy of the autopsy report should be obtained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 34 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SERIOUS ADVERSE EVENT</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Serious Adverse Event Reporting</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Serious&#8221; events, whether or not unexpected or considered to be associated with the use of the labeled product, must be communicated to Sangamo BioSciences upon discovery of the event, either by telephone or fax within 24 hours.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td style="width:17.53%;"></td>
<td style="width:52.47%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Medical Monitor: </p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ely Benaim, M.D</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phone Number:</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(510) 970-7868</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(510) 621-8533, mobile</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fax Number:</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(510) 970-6009</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator is responsible for promptly notifying the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), in accordance with local regulations, of all serious adverse events.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The National Institutes of Health (NIH) requires that all investigators participating in gene transfer research report all drug related serious adverse events immediately to the FDA, NIH, and Institutional Biosafety Committee (IBC). Sangamo BioSciences will assume responsibility for NIH and FDA reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All &#8220;serious&#8221; events must be followed with appropriate medical management until resolved or stabilized.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Definitions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A "Serious" Adverse Event (SAE) is defined as any event that suggests a significant hazard, contraindication, side effect, or precaution. An SAE is also any adverse event or adverse drug reaction that, at any dose, results in the following outcomes:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">death</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">life-threatening condition</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">in-patient hospitalization or prolongation of an existing hospitalization</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">persistent or significant disability/incapacity</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">congenital anomaly/birth defect in the offspring of an exposed subject</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important medical event that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, it jeopardizes the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A life-threatening adverse event is defined as any adverse experience that places the subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Recording of a Serious Adverse Event</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious Adverse Events reported by telephone must be recorded on a written Serious Adverse Event Report Form, provided by Sangamo BioSciences. The SAE report form must be faxed to the medical monitor within 24 hours.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The medical monitor will then advise the investigator regarding the nature of any further information or documentation that is required. Follow-up reports must be submitted in a timely fashion as additional information becomes available.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STATISTICAL METHODS AND DATA ANALYSIS</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Sample Size</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results from SB-509-601 showed a treatment effect of SB-509 in patients with baseline serum ICAM &gt; 200 ng/mL. The change from baseline in sural NCV for treated patients showed an increase in m/s of 1.06 compared to a decrease in placebo of -1.18. With 150 patients (75 per group) the power to detect a similar difference with a standard deviation of 4 and alpha=0.05 is 93%, using Wilcoxon&#8217;s rank-sum test.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 35 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Randomization</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150 subjects will be randomized in a 1:1 ratio to treatment with SB-509 or placebo stratified by study site and screening IENFD (&lt;9, &#8805;9):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SB-509 treatment: 60 mg of SB-509 on Day 0, Day 60 and Day 120.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Placebo on Day 0, Day 60 and Day 120.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Statistical Methods/Data Analysis</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The statistical analyses will be reported using summary tables, figures, and data listings. Statistical tests will be two-sided at the alpha =0.05 significance level. All analyses and tabulations will be performed using SAS&#174; or SPLUS. Continuous variables will be summarized with means, standard deviations, medians, minimums, and maximums. Categorical variables will be summarized by counts and by percentages of subjects in corresponding categories. All raw data obtained from the case report forms as well as any derived data will be included in data listings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All efficacy analyses will be performed on the intent-to-treat population. All safety analyses will be performed on all subjects that received any study medication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All tables will report summary results by treatment and dose group.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Intent-to-Treat Population</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All subjects enrolled and randomized will be included in the intent-to-treat population and analyzed by the treatment received at Day 0.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subject Disposition</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summaries will include the number of randomized subjects, the number of subjects receiving study medication, the number of subjects completing the study, and the reasons for discontinuation.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.6.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Demographics</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Demographic variables include age, sex, and race. Other baseline characteristics include medical history, physical exam, duration of diabetes, duration of neuropathic pain, resting ankle-brachial systolic pressure index, and baseline assessments of diabetic neuropathy by symptoms, by neurological examination, by lower extremity electrophysiological testing and by quantitative sensory testing.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Efficacy</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary measurement of efficacy is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Sural Nerve Conduction Velocity (NCV)</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The secondary measurements of efficacy are:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Neuropathy Impairment Score-Lower Limb (NIS-LL)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Lower Extremity Neurological Sensory Exam</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Motor Nerve Conduction Velocity (NCV)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Quantitative Sensory Testing (QST)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">lntraepidermal Nerve Fiber Density (IENFD)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Neuropathy Total Symptom Score (NTSS-6)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Visual Analog Scale for Pain Intensity (VASPI)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Quality of Life (QOL)- NeuroQoL and SF-36</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Global assessment</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 36 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Primary Efficacy Analyses</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Day 180 change from baseline sural NCV measurements will be compared by treatment group using the Wilcoxon Rank-Sum test at an alpha level of 0.05</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Secondary Efficacy Analyses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Day 180 change from baseline sNCV will be compared by treatment group using the Cochran-Mantel-Haenszel test stratified by IENFD &lt; 9 fiber/mm and &#8805; 9 fiber /mm at an alpha level of 0.05.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the following measures, the Day 180 change from baseline measures will be compared by treatment group using the Wilcoxon Rank-Sum test.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Neuropathy Impairment Score-Lower Limb (NIS-LL)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Lower Extremity Neurological Sensory Exam</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Motor Nerve conduction velocity (NCV)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Quantitative Sensory Testing (QST)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">lntraepidermal Nerve Fiber Density (IENFD)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Neuropathy Total Symptom Score (NTSS-6)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Visual Analog Scale for Pain Intensity (VASPI)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Quality of Life (QOL)- NeuroQoL and SF-36</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Global assessment</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy will be compared using a multi-endpoint analysis that includes Neuropathy Impairment Score - Lower Limb (NIS-LL), Sural Nerve Conduction Velocity (NCV) and lntraepidermal Nerve Fiber Density (IENFD), as detailed by O&#8217;Brien (1984).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exploratory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The efficacy variables will be organized by clinically meaningful groups of 4 or fewer endpoints and analyzed by treatment and dose group with a multiple endpoint analysis defined by O&#8217;Brien (1984). For each grouping of endpoints, subjects will be ranked separately by each component of the multiple endpoint and the sum of the ranks will be obtained for each subject. The sums of ranks by treatment group will be compared with a Wilcoxon Rank-Sum test.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.8.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Baseline Values</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The baseline value for each variable is the last value recorded before the start of dosing. For NCV, QST, NIS-LL, and the lower extremity neurological sensory exam, the two measurements prior to dosing will be averaged for the baseline value.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Missing Data</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physically undetectable NCV measures will be imputed with the 1st percentile value of all measurable observations by nerve. For all other measures, no imputations for missing data will be made.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Safety</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safety assessment will occur on all subjects who received any study medication. Terminations/premature withdrawals, adverse events, concomitant medications, and laboratory data will be tabulated. Adverse events will be coded to a standard set of terms using the MedDRA dictionary. Frequency of adverse events will be compared using Fisher&#8217;s exact test.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 37 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.11.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Laboratory Data</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory data will be summarized for each time-point that specimens are collected. Change-from-baseline values may be calculated for selected laboratory parameters. (Baseline refers to blood drawn prior to the first study treatment.) Shift&#173; tables (change-from-baseline relative to the normal range) may be constructed for selected laboratory parameters.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator will ensure that the study is conducted in compliance with the protocol and according to ICH Guidelines for Good Clinical Practices (E6), the Declaration of Helsinki, and all regulatory and institutional requirements, including those for subject privacy, informed consent, IRB or IEC approval, and record retention.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A final study report will be prepared as part of Sangamo BioSciences&#8217; commitment to Good Clinical Practice.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Institutional Review Board/Institutional Ethics Committee</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An Institutional Review Board should safeguard the rights, safety, and well being of all study subjects. In performing this study, both the investigator and sponsor endorse, as a minimum, the standards for conduct of clinical research activities as set forth in the Declaration of Helsinki and local country regulations. As such, this study must have the approval of a properly constituted IRB or IEC, with the investigator responsible for providing the IRB or IEC with all necessary documents for review.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This study will only be undertaken or investigational drug supplies shipped when full approval has been obtained from the appropriate IRB or IEC and a copy of the IRB or IEC approval letter has been received by Sangamo BioSciences. The approval letter must contain sufficient information to identify the version of both the protocol and subject information/informed consent, the date of the committee&#8217;s approval, the chairperson&#8217;s signature, and identify all study documents reviewed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol amendments must also be reviewed and approved by the IRB or IEC and must be received by Sangamo BioSciences before implementation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until written approval by the IRB or IEC has been received by the investigator, no subject may undergo any procedures solely for the purpose of determining eligibility for this study.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Informed Consent</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to 21 CFR Part 50.20, no investigator may involve a human being as a subject in research covered by these regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative. An investigator shall seek such consent only under circumstances that provide the prospective subject or the subject's legally authorized representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence. The information that is given to the subject or the representative shall be in language understandable to the subject or the representative.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences will provide the investigator with a template for the consent form. State and local laws and/or institutional requirements may require the disclosure of additional information in the informed consent. The proposed consent form must be submitted to Sangamo BioSciences prior to submission to the IRB or IEC to ensure that it meets Sangamo BioSciences&#8217; standards for consent forms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The IRB or IEC must approve the consent form. A copy of the approved form must be submitted to Sangamo BioSciences prior to the initiation of the study. Prior to the initiation of any procedures or treatment relating to the study, informed consent shall be documented by the use of a written consent form approved by the IRB and signed and dated by the subject or the subject's legally authorized representative at the time of consent. A copy of the signed informed consent will be given to the person signing the form. The investigator must keep each subject's signed consent form on file for inspection by a regulatory authority at any time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 38 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Study Amendments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any changes to this protocol will be initiated by Sangamo BioSciences. Approval of the amendment by the investigator&#8217;s IRB must be obtained before implementation, with the following exception:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">When necessary to eliminate apparent immediate hazard to the subject</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All amendments must be signed and dated by Sangamo BioSciences. Sangamo BioSciences will notify other investigators using this protocol.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Study Drug Accountability</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator must ensure that subjects receive study drug only from personnel who fully understand the procedures for dosing and administering the drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator or designated individual will maintain an inventory. A drug accountability log will be provided to the pharmacist or designated personnel. This inventory will include the description and quantity of labeled product received during the course of this study, as well as a record of the labeled product that is dispensed. This inventory record shall indicate the quantity and description of labeled product on hand at any time during the course of this study. Empty vials and any remaining product in the used vials will be stored at room temperature at the clinical sites and will be kept in the original carton. Vials should not be discarded until the Sangamo BioSciences monitor reviews the drug accountability log. A Sangamo BioSciences monitor will review this log during interim monitoring visits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug accountability records must be readily available for inspection by representatives of Sangamo BioSciences and are open to inspection by regulatory authorities at any time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return or destruction of all drug supplies must be coordinated with Sangamo BioSciences. Please see the <font style="font-weight:bold;">Study Reference Manual</font> for additional details.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.5</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Study Personnel</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator should maintain a list of appropriately qualified persons who are delegated to perform significant study-related studies. In addition, the investigator should maintain a signature sheet to document signatures and initials of all persons authorized to make entries and/or corrections on the case report forms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator is responsible for informing the subject's primary care physician that the subject is participating in a clinical study. This should only be done after agreement from the subject.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.6</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Monitoring the Study</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, as sponsor of this study, is responsible to regulatory authorities for ensuring the proper conduct of the study as regards protocol adherence and validity of the data recorded on the case report forms presented to the regulatory authorities. Sangamo BioSciences has therefore assigned a clinical monitor and a medical monitor to this study. Their duties are to aid the investigator and, at the same time, Sangamo BioSciences in the maintenance of complete, legible, well-organized, and easily retrievable data. In addition, a Sangamo BioSciences study monitor will explain, interpret, and ensure the investigator&#8217;s understanding of all applicable regulations concerning the clinical evaluation of a labeled product (whether licensed or unlicensed) and ensure an understanding of the protocol, reporting responsibilities, and the validity of the data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to perforrn their roles well, the Sangamo BioSciences monitors must be given direct access to primary subject data (source documents) that support data entered onto the case report forms (e.g., hospital and general practice charts, appointment books, original laboratory records). The investigator must exercise judgment regarding information in a subject's chart that is not relevant to the performance, observation, or conduct of this study. The investigator must make available such records to Sangamo BioSciences, Quality Assurance, Institutional Review Board, and Regulatory personnel for inspection and copying. Because this enters into the realm of subject confidentiality, this fact must be included in the information signed by the subject.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 39 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator or designated person should agree, as a minimum requirement, to record the following information in the subject notes:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Protocol identification number, brief description or title of study</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Date and statement that subject has given written informed consent</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">All visit dates</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">All Adverse Events</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">All concomitant medications</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Primary efficacy details (as defined by the protocol)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">All labeled product accountability information</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entries in the subject notes must contain the signature or initials of the person making the entries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical study monitor will perform source data verification at each monitoring visit.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Sangamo BioSciences representative will monitor individual sites at appropriate intervals. The frequency of interim monitoring visits may vary depending on enrollment rate and the quality of data collected. Telephone contact will be made with each site Study Coordinator to keep abreast of subject status and to answer study-related questions.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.7</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Completion and Return of Case Report Forms</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator is responsible for the quality of the data recorded on the case report form. The data recorded should be a complete and accurate account of the subject's record collected during the study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator and Sangamo BioSciences study monitor will identify any data that will be recorded directly on the case report form and considered as source data (i.e., no prior written or electronic record of the data). The Sangamo BioSciences monitor will document this on the study initiation report and document the use of case report forms as source documents as necessary during the course of the study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Detailed instructions for case report form completion will be provided in the <font style="font-weight:bold;">Study</font> <font style="font-weight:bold;">Reference Manual.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigator agrees to complete case report forms in a timely fashion, and make them available to the Sangamo BioSciences study monitor for full inspection. In addition, all data queries should be resolved promptly.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before acceptance, the Sangamo BioSciences study monitor will review the case report forms for completeness and adherence to the protocol.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.8</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Deviation from Protocol for Individual Subjects</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Digressions from a written protocol for individual subjects are inherent to clinical research and will be categorized by Sangamo BioSciences as deviations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Examples of protocol deviations include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Informed consent improperly obtained</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Violation of inclusion/exclusion criteria</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Error in product randomization</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Major drug injection errors that may compromise subject safety or efficacy assessments</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Administration of an excluded concomitant medication or treatment during the course of the study</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Vital signs were not measured at study visit</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 40 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Missed, delayed, or rescheduled visit</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Missing laboratory results</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investigators are encouraged to adhere to protocol procedures in that the deviation does not affect the evaluation of the data for the subject or compromise statistical analysis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When a significant deviation occurs, the investigator should contact the study or medical monitor by telephone. The medical monitor will decide whether the subject is to continue on study.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.9</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quality Assurance Procedures</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quality Assurance activities undertaken during this study include monitoring and source data verification by the study monitor. It is possible that Sangamo BioSciences personnel or their agents may audit this study center.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.10</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Sangamo BioSciences Policy on Fraud in Clinical Studies</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 41 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>2<font style="font-size:10pt;">: </font>CTCAE</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc. will provide the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 to the clinical site.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 42 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:31.73%;text-indent:-31.73%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>3<font style="font-size:10pt;">: </font>A<font style="font-size:10pt;">MERICAN </font>C<font style="font-size:10pt;">ANCER </font>S<font style="font-size:10pt;">OCIETY </font>(ACS)<font style="font-size:10pt;"> </font>C<font style="font-size:10pt;">ANCER </font>D<font style="font-size:10pt;">ETECTION </font>G<font style="font-size:10pt;">UIDELINES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following cancer screening guidelines are recommended for those people at average risk for cancer (unless otherwise specified) and without any specific symptoms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">People who are at increased risk for certain cancers may need to follow a different screening schedule, such as starting at an earlier age or being screened more often. Those with symptoms that could be related to cancer should see their doctor right away.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cancer-related Checkup</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For people aged 20 or older having periodic health exams, a cancer-related checkup should include health counseling, and depending on a person&#8217;s age and gender, might include exams for cancers of the thyroid, oral cavity, skin, lymph nodes, testes, and ovaries, as well as for some non-malignant (non-cancerous) diseases.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Special tests for certain cancer sites are recommended as outlined below.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Breast Cancer</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Yearly mammograms are recommended starting at age 40 and continuing for as long as a woman is in good health.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Clinical breast exam (CBE) should be part of a periodic health exam, about every 3 years for women in their 20s and 30s and every year for women 40 and over.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Women should know how their breasts normally feel and report any breast change promptly to their health care providers. Breast self-exam (BSE) is an option for women starting in their 20s.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Women at high risk (greater than 20% lifetime risk) should get an MRI and amammogram every year. Women at moderately increased risk (15% to 20% lifetime risk) should talk with their doctors about the benefits and limitations of adding MRI screening to their yearly mammogram. Yearly MRI screening is not recommended for women whose lifetime risk of breast cancer is less than 15%.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Colon and Rectal Cancer</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning at age 50, both men and women at <font style="font-style:italic;">average risk</font> for developing colorectal cancer should use one of the screening tests below. The tests that are designed to find both early cancer and polyps are preferred if these tests are available to you and you are willing to have one of these more invasive tests. Talk to your doctor about which test is best for you.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Tests that find polyps and cancer</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">flexible sigmoidoscopy every 5 years*</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">colonoscopy every 10 years</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">double contrast barium enema every 5 years*</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">CT colonography (virtual colonoscopy) every 5 years*</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Tests that mainly find cancer</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">fecal occult blood test (FOBT) every year*,**</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">fecal immunochemical test (FIT) every year*,**</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">stool DNA test (sDNA), interval uncertain*</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Colonoscopy should be done if test results are positive.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**For FOBT or FIT used as a screening test, the take-home multiple sample method should be used. A FOBT or FIT done during a digital rectal exam in the doctor&#8217;s office is not adequate for screening.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 43 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">People should talk to their doctor about starting colorectal cancer screening earlier and/or being screened more often if they have any of the following colorectal cancer risk factors:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">a personal history of colorectal cancer or adenomatous polyps</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">a personal history of chronic inflammatory bowel disease (Crohns disease or ulcerative colitis)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">a strong family history of colorectal cancer or polyps (cancer or polyps in a first&#173; degree relative [parent, sibling, or child] younger than 60 or in 2 first-degree relatives of any age)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">a known family history of hereditary colorectal cancer syndromes such as familial adenomatous polyposis (FAP) or hereditary non-polyposis colon cancer (HNPCC)</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cervical Cancer</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">All women should begin cervical cancer screening about 3 years after they begin having vaginal intercourse, but no later than when they are 21 years old. Screening should be done every year with the regular Pap test or every 2 years using the newer liquid-based Pap test.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Beginning at age 30, women who have had 3 normal Pap test results in a row may get screened every 2 to 3 years. Another reasonable option for women over 30 is to get screened every 3 years (but not more frequently) with either the conventional or liquid-based Pap test, plus the HPV DNA test. Women who have certain risk factors such as diethylstilbestrol (DES) exposure before birth, HIV infection, or a weakened immune system due to organ transplant, chemotherapy, or chronic steroid use should continue to be screened annually.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Women 70 years of age or older who have had 3 or more normal Pap tests in a row and no abnormal Pap test results in the last 10 years may choose to stop having cervical cancer screening. Women with a history of cervical cancer, DES exposure before birth, HIV infection or a weakened immune system should continue to have screening as long as they are in good health.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Women who have had a total hysterectomy (removal of the uterus and cervix) may also choose to stop having cervical cancer screening, unless the surgery was done as a treatment for cervical cancer or precancer. Women who have had a hysterectomy without removal of the cervix should continue to follow the guidelines above.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Endometrial (Uterine) Cancer</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The American Cancer Society recommends that at the time of menopause, all women should be informed about the risks and symptoms of endometrial cancer, and strongly encouraged to report any unexpected bleeding or spotting to their doctors. For women with or at high risk for hereditary non-polyposis colon cancer (HNPCC), annual screening should be offered for endometrial cancer with endometrial biopsy beginning at age 35.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Prostate Cancer</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The American Cancer Society (ACS) does not support routine testing for prostate cancer at this time. ACS does believe that health care professionals should discuss the potential benefits and limitations of prostate cancer early detection testing with men before any testing begins. This discussion should include an offer for testing with the prostate&#173;specific antigen (PSA) blood test and digital rectal exam (DRE) yearly, beginning at age 50, to men who are at average risk of prostate cancer and have at least a 10-year life expectancy. Following this discussion, those men who favor testing should be tested. Men should actively take part in this decision by learning about prostate cancer and the pros and cons of early detection and treatment of prostate cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion should take place starting at age 45 for men at high risk of developing prostate cancer. This includes African American men and men who have a first-degree relative (father, brother, or son) diagnosed with prostate cancer at an early age (younger than age 65).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion should take place at age 40 for men at even higher risk (those with several first-degree relatives who had prostate cancer at an early age).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, after this discussion, a man asks his health care professional to make the decision for him, he should be tested (unless there is a specific reason not to test).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 44 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">References</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Cancer Society. <font style="font-style:italic;">Cancer Facts &amp; Figures 2009</font>. Atlanta, Ga: American Cancer Society; 2009.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Levin B, Lieberman DA, McFarland, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Published online March 5, 2008. <font style="font-style:italic;">CA Cancer J Clin</font>. 2008;58.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Saslow D, Boetes C, Burke W, et al for the American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. <font style="font-style:italic;">CA Cancer J Clin</font>. 2007;57:75-89.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Last Revised: 05/21/2009</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 45 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>4<font style="font-size:10pt;">: </font>SB-509<font style="font-size:10pt;"> </font>D<font style="font-size:10pt;">RUG </font>P<font style="font-size:10pt;">RODUCT AND </font>P<font style="font-size:10pt;">LACEBO </font>D<font style="font-size:10pt;">ESCRIPTION AND </font>I<font style="font-size:10pt;">NSTRUCTIONS FOR </font>S<font style="font-size:10pt;">TORAGE, </font>H<font style="font-size:10pt;">ANDLING, </font>A<font style="font-size:10pt;">DMINISTRATION AND </font>D<font style="font-size:10pt;">ISPOSAL</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Product Description</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 is a bacterial DNA plasmid (pV-32Ep65) that encodes an engineered zinc finger protein transcription factor (32Ep65) that up-regulates endogenous VEGF-A gene transcription. SB-509 is formulated as a liquid in 5% poloxamer 188. Sterile injectable saline (0.9% NaCl) serves as the placebo.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">They are supplied in 3 mL glass vials filled with 2.2 mL of product, to deliver 2.0 mL. The SB-509 drug product is supplied at a concentration of 2.0 mg/mL. Each vial is prepared as a direct injectable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to the <font style="font-weight:bold;">SB-509 DN Clinical Investigator&#8217;s Brochure</font> for additional information on SB-509 and the placebo.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Storage and Administration</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-509 and placebo are shipped to the clinical site by air courier on dry ice. Upon receipt at the clinical site, the vials should be immediately transferred to a locked -20&#176;C or below freezer. Accurate accounting logs of all investigational drug received, dispensed, destroyed, and/or returned to Sangamo should be maintained at the clinical site.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Injection Preparation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time of injection, the vials are removed from the freezer, allowed to thaw at room temperature at least 10 minutes. First draw the study drug into 1 mL syringes with <font style="font-weight:bold;">19 gauge, 1&#189; inch needles</font>. Syringes will be filled with either <font style="font-weight:bold;">0.5 mL</font> or <font style="font-weight:bold;">1.0 mL</font> according to the table shown on the next page. Once the syringes are filled, replace the <font style="font-weight:bold;">19 gauge needle</font> with a <font style="font-weight:bold;">25 gauge needle</font>, with either <font style="font-weight:bold;">1 inch</font> or <font style="font-weight:bold;">1&#189; inch</font> needles, as indicated in the table. A <font style="font-weight:bold;">27 gauge 1&#188; inch</font> needle may also be used for the lower leg and thigh injections. Follow the same injection technique as described on the following page. Additional syringes may be filled as back-up if necessary. The syringes are then released to the appropriate medical personnel for intramuscular injection and kept at room temperature until the drug is administered. All injections should be given the same day the study drug is thawed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Injection Volumes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lower leg (injection 1-14): 0.5 mL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thigh (injections 15-22): 1.0 mL</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Injection Technique</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use standard aseptic technique for preparation of the skin at the injection site. Cleaning of the sites with alcohol wipes, with a second alcohol swipe at the site prior to injection is recommended. Administer 0.5 mL and 1.0 mL doses of study drug by inserting a needle along the long axis of the muscle fiber (i.e., parallel with the femoral artery) up to its hub (the needle&#8217;s full insertion point) and depositing 0.5 mL for the 0.5 mL volume in the lower leg or 1.0 mL volume in the anterior and lateral thigh. The needle will be pointed toward the foot and inserted at an approximate 30&#176; angle to the surface of the skin. Needles (25 gauge) with 1 mL syringes are to be used as follows: 1-inch needle for the lower leg and a 1&#189;-inch needle for the thigh. If a 27 gauge needle is used, use the 1 &#188; inch needle for both the lower leg and thigh injections.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 46 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Injection Site Summary</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Dose level: 60 mg (30 mg per leg)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Total volume: 30 mL(15 mL per leg)</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:102.06%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:11.45%;"></td>
<td style="width:11.45%;"></td>
<td style="width:11.45%;"></td>
<td style="width:11.45%;"></td>
<td style="width:11.45%;"></td>
<td style="width:11.45%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Syringe</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fill</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Needle Gauge &amp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Length</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Syringes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">per Leg*</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Syringes</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Muscle</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Injection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sites</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peripheral</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nerve</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lower leg</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5 mL</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 gauge:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 inch or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27 gauge: 1 &#188; inches</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1-14</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peroneal, sural, tibial</p></td>
</tr>
<tr style="height:48.1pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thigh</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0 mL</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 gauge: 1 &#189; inches or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27 gauge: 1 &#188; inches</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15-22</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sciatic and femoral</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201504281926445851271.jpg" title="" alt="" style="width:456px;height:583px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 47 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dose Level Injection Instructions</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lower leg injections</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Anterior leg injections</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identify the bony landmarks of the anterior tibia and the fibula in the anterior lower leg. The muscle between these bones is the tibialis anterior. Identify Injection site 1 as the distal tibialis anterior muscle, 2-3 inches above the lateral malleolus of the ankle. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning at site 1 as described above, identify 5 ascending injection sites in the tibialis anterior separated by at least one inch. Inject 0.5 mL into injections 1-5 (see <font style="font-weight:bold;">figure</font>).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Lateral leg injections</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palpate the lateral fibular head and then extending inferiorly to the lateral malleolus, the peroneus longus muscle. Inject five, 0.5 mL at least one inch apart, moving inferiorly along the leg for injections 6-10 (see <font style="font-weight:bold;">figure</font>).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Medial leg injections</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palpate the medial gastrocnemius muscle. At the top of the medial muscular portion of the muscle inject 4, 0.5 mL injections at least one inch apart moving inferiorly along the medial curve of the gastrocnemius for injections 11-14 (see <font style="font-weight:bold;">figure</font>).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Thigh injections</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The upper leg or thigh injections will use syringes filled with 1.0 mL and will <font style="font-weight:bold;">deliver one dose of 1.0 mL at maximum needle length</font> (needle&#8217;s full insertion point).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Anterior thigh</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palpate the body of the rectus femoris muscle above the patella approximately 5-6 inches above the knee. Injections 15-18 (see <font style="font-weight:bold;">figure</font>) should be placed at least one inch apart, extending superiorly along the rectus femoris.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;</p></td>
<td valign="top" style="width:95.46%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Lateral thigh</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palpate the body of the muscles of the lateral quadriceps, anterior and superior to the iliotibial band at approximately 5-6 inches above the knee. Injections 19-22 (see <font style="font-weight:bold;">figure</font>) should be placed at least one inch apart, extending superiorly along the lateral quadriceps.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 48 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>5<font style="font-size:10pt;">: </font>N<font style="font-size:10pt;">EUROPATHY </font>I<font style="font-size:10pt;">MPAIRMENT </font>S<font style="font-size:10pt;">CORE- </font>L<font style="font-size:10pt;">OWER </font><font style="font-size:11pt;">L</font><font style="font-size:10pt;">IMB</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(NIS-LL)</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adapted from Bril, Eur. Neural. (1999). 41 (supp. 1):8-13</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A. Muscle Group Testing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Groups Tested</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following muscle groups are tested for power (bilaterally):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Hip Flexion</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Hip Extension</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Knee Flexion</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Knee Extension</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Ankle Dorsiflexion</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Ankle Plantar Flexion</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Toe Extension</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Toe Flexion</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Scoring</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each muscle group is scored according to the following scale:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:50.07%;"></td>
<td style="width:50.02%;"></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Muscle Power</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NIS-LL Score</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Normal</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25% Weak</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50% Weak</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75% Weak</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paralysis</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Muscles groups are scored between 0 and 4 points per side per group (bilaterally) for a maximum total of 64 points.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">B. Sensory and Reflex Testing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Sensory Testing</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following sensory modalities are tested:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Touch pressure</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Pin Prick</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Vibration</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Joint position</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Reflex Testing</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deep tendon reflex testing is done at the following sites (bilaterally):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Quadriceps (patellar)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Ankle (Achilles)</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 49 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Scoring</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sensory testing and reflex testing is scored according to the following scale:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:50.11%;"></td>
<td style="width:49.98%;"></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sensory/Reflex Activity Grading</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NIS-LL Score</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Normal</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreased</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absent</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sensory modalities are scored between 0 and 2 points per modality (bilaterally) for a maximum total of 16 points. Reflexes are scored between 0 and 2 points per reflex (bilaterally) for a maximum total of 8 points.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 50 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>6<font style="font-size:10pt;">: </font>L<font style="font-size:10pt;">OWER </font>E<font style="font-size:10pt;">XTREMITY </font>N<font style="font-size:10pt;">EUROLOGICAL </font>S<font style="font-size:10pt;">ENSORY </font>E<font style="font-size:10pt;">XAM</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lower Extremity Neurological Sensory Exam includes distal to proximal examinations to evaluate sensory changes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pin Prick, Vibration and Touch Pressure will be evaluated at the Toe, Mid-Foot, Ankle, Mid-calf, Knee and Above Knee locations. At each location and for each leg, the sensory testing is scored according to the following scale:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:50.11%;"></td>
<td style="width:49.98%;"></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sensory Grading </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Score</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Normal </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreased</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absent </p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sensory modalities are scored between 0 and 2 points per modality (bilaterally) for a maximum total of 24 points per modality and 72 points overall.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 51 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>7<font style="font-size:10pt;">: </font>E<font style="font-size:10pt;">LECTROPHYSIOLOGICAL </font>S<font style="font-size:10pt;">TUDIES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nerve conduction studies (NCS) will be done at the sural and peroneal motor nerves. All NCS studies will be done bilaterally using standard surface recording techniques. Procedures for the recording of NCS are briefly outlined below and presented in full detail in an accompanying <font style="font-weight:bold;">Study Reference Manual</font> for NCS Studies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The temperatures at the beginning and the end of the NCS will be recorded. Hard copies of all nerve conduction studies will be printed and saved (see <font style="font-weight:bold;">Study Reference Manual</font> for details).</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sural Sensory Nerve</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conduction velocity and sensory amplitudes will be measured using antidromic procedures. Surface electrodes will be placed adjacent to the lateral malleolus of the ankle (active recording electrode); the stimulating cathode will be applied to a more proximal segment of the nerve (12-14 cm distance).</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peroneal Motor Nerve</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Motor nerve conduction velocity, distal and proximal baseline-to-peak compound muscle action potential amplitudes will be measured using orthodromic procedures. The active recording electrode will be placed over the extensor digitorum brevis muscle; the distal stimulation cathode will be placed at the ankle. The fibular head will be used as a proximal stimulation point.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 52 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>8<font style="font-size:10pt;">: </font>Q<font style="font-size:10pt;">UANTITATIVE </font>S<font style="font-size:10pt;">ENSORY </font>T<font style="font-size:10pt;">ESTING </font>(QST)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SCHEDULE</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See<font style="font-weight:bold;"> Appendix 1, Schedule of Events.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">DEFINITION OF TERMS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THRESHOLD - minimal energy required before a subject can just detect a stimulus - in the present study, the last correctly identified intensity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TWO ALTERNATIVE FORCED CHOICE PROCEDURE - VPT testing algorithm in which two potential stimuli are presented in each trial and the subject must select which stimulus is actually vibrating.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.0</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">EQUIPMENT</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Vibratron II, manufactured by Physitemp Instruments, Inc. (Clifton N.J), is a QST device to quantify the ability of human subjects to detect vibratory stimuli at the distal extremes of their upper and lower limbs. It consists of a controller and two vibrating posts. The frequency of vibration is fixed at 120 Hz. The power supply, switches and digital meter are encased as one unit, while the vibrating rods are located in separate units with adjoining cables. Each vibrating rod protrudes through a metal case and can be contacted by either the hands or the feet. The tandem vibrating surfaces are manufactured from hardened rubber and are identical in appearance. Vibration is achieved by driving the transducers with a variable voltage source. A dual position switch connected in series with the vibrating units, controls which rod vibrates, while a "dummy" switch is used to imitate the sounds and motions of switching. The amplitude of vibration is proportional to the square of the applied voltage and is continuously available on a digital display accurate to the nearest 0.1 units. A switch sets the maximal level of the vibration, which ranges from 0- 6.5 vibration units or 6.5 - 20 vibration units.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.0</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">TESTING PROCEDURE</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Methodology</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thresholds should be measured bilaterally, on the great toes. The methodology of testing is a "two alternative forced choice procedure." For each trial the subject is required to determine which of the two rods is actually vibrating. The position of vibration is under experimental control, determined by a randomization sequence. The intensity sequence is similarly under the control of the experimenter and is determined by a testing algorithm (see <font style="font-weight:bold;">Section 4.6</font>).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Temperature Control</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to testing, each subject should be seated in a comfortable chair and allowed an adaptation period of approximately 10 minutes, during which time they can become acclimated to room temperature. Subjects should then remove all footwear, including pantyhose. A surface thermometer should be used to determine skin temperature at the arch of the foot. Skin temperature at this site must be at least 30&#176;C, otherwise the subject should be warmed using a circulating water bath, an insulated thermal wrap or a heating pad. Radiant heaters should not be used.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Adaptation Period</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the subject is warmed, they should be given an opportunity to become familiar with the testing apparatus and with the expected vibratory sensations. During this period, the experimenter can instruct the subject as to the appropriate length and force with which to contact the vibrating rod. An ideal duration for contact is approximately one second and the force should be the minimum necessary to detect vibration. This adaptation period will also allow the experimenter to determine the appropriate voltage level at which to begin testing. A number of vibration intensities should be set and sampled by the subject. For the initial trial, the experimenter should set the intensity at a level detectable by that subject 100% of the time. For many subjects in the 20 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 53 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to 50 year age range, an initial intensity setting of 10-12 units is sufficient. This level should be increased for older subjects. For each trial, both the intensity setting and the subject's choice should be recorded in the appropriate columns on the data sheet.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Foot Support</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throughout testing, the subject should rest his/her feet on the elevated platform provided by Physitemp. Thus, the subject should only be required to pivot his/her foot to contact each vibrating rod.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Instructions</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the beginning of each testing session, the subject should be issued the following instructions:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"Please press your toe lightly against each rod in sequence for approximately one second. During each trial you will be allowed to touch the rods only once. Only one of the rods will be vibrating; please decided which rod (A or B) is vibrating or please let us know if you no longer can tell the difference. The task will become increasingly more difficult."</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Testing Algorithm</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The starting intensity, in vibration units (vu), should be entered on the left hand column of the worksheet. The location of the stimulus (A or B rod) is indicated by the first column in the A/B matrix. If the subject correctly identifies which rod is vibrating, circle the "A" or "B" - then decrease the intensity for the next presentation by approximately 10%. If the subject <font style="text-decoration:underline;">incorrectly</font> identifies the vibrating rod, cross out the "A" or "B" on the sheet with an "X" and increase the intensity for the next presentation by approximately 10% (ie., return to the level immediately prior to the error). The A/B matrix should be followed diagonally to the right (up one level and to the right one column).Testing is complete when a subject responds that there is "no difference" (mark with a single line on the A/B matrix) <font style="font-weight:bold;">OR</font> if the subject makes two errors before responding "no difference." The final lowest "correct" intensity is entered as the VPT value. Ideally, the subject should have at least 10 correct responses before they report "no difference" or make their first error. If the subject reports "no difference" or if there is an error in the first 10 trials, the test must be restarted at a higher initial intensity level. If the test was started at 20 vibration units (vu), simply report the last score correctly identified. If the subject reports "no difference" or makes an error at the 20 vu level, check the circle "intensity &gt;20" on the worksheet. For sample worksheet see <font style="font-weight:bold;">Study Reference Manual</font>.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">TECHNICAL CONCERNS</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine accurate vibration thresholds, the experimenter must be concerned with the following details:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">The subject should be consistent in the location and duration of touch, as well as in the approximate force applied to the vibrating surface. Instructions such as &#8220;please don&#8217;t press so hard&#8221; can be issued during testing to ensure trial-to-trial consistency.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">Throughout testing, the sounds and motions associated with changing the stimulus position should be presented between each trial. For the conditions where the stimulus position remains unaltered, the "dummy" switch must be used. Both the active and "dummy" switches can be used between trials to mask the actual positioning of the stimulus.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">The rods should be visually inspected prior to every test to ensure that they are "free-standing" and not in contact with the metal covering.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">The subject must take care not to contact the metal casing around the vibrating rods during the trials.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">The subject should be carefully screened from viewing the instrument settings or the data sheet.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">All testing should be conducted in a quiet room with minimal distractions.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;">Each Vibratron II should be factory calibrated at an interval appropriate for the study.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 54 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>9<font style="font-size:10pt;">: </font>S<font style="font-size:10pt;">KIN </font>B<font style="font-size:10pt;">IOPSY</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.0<font style="margin-left:24pt;"></font>INTRODUCTION</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Rationale</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 mm skin biopsy punches will be obtained for the evaluation of intra-epidermal nerve fiber density (IENFD). Epidermal nerve fibers are C and A-sigma small caliber unmyelinated nerve fibers that are relevant to diabetic neuropathy. These fibers are not directly assessed by conventional testing measures such as nerve conduction velocity, amplitude, or most forms of quantitative sensory testing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the figure below, epidermal nerve fiber axons can be seen extending to the dermis in a normal subject (panel A). Decreased numbers of epidermal nerve fiber axons are evident in a skin biopsy from a diabetic subject (panel B).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201504281926540221272.jpg" title="" alt="" style="width:296px;height:184px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin section (50 &#181;m) stained for PGP9.5+ IENFDs in a nondiabetic subject (A) and in a subject with established neuropathy (B). Original magnification X600 (Quattrini et al. 2008).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.0<font style="margin-left:24pt;"></font>SCHEDULE AND GENERAL PROCEDURES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The schedule for skin biopsy collection is located in <font style="font-weight:bold;">Appendix 1: Schedule of Events</font>. The method for obtaining this analysis requires a 3 mm skin biopsy on the distal lateral thigh. The sample will then be processed with fixative and shipped to Johns Hopkins University. The samples will then be further processed by the laboratory and analyzed to determine intraepidermal nerve fiber density.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A manual with detailed instructions will be provided to you in the <font style="font-weight:bold;">Study Reference Manual</font> for obtaining, processing and shipping the biopsy samples.  In addition, each investigator will be provided with a video clip presentation on CD that will further illustrate the specific procedures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 55 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>10<font style="font-size:10pt;">: </font>N<font style="font-size:10pt;">EUROPATHY </font>T<font style="font-size:10pt;">OTAL </font>S<font style="font-size:10pt;">YMPTOM </font>S<font style="font-size:10pt;">CORE </font>(NTSS-6)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bastyr, Clinical Therapeutics (2005) 27:1278-1294</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instructions for the Health Care Professional (HCP)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Each of the 6 questions is scored by marking an X in the box on the grid corresponding to the symptom frequency and intensity.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Grading of the symptom frequency and intensity should be according to the definitions provided below for each category level.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The symptom evaluated should be due to diabetic peripheral neuropathy in the feet or legs, in the opinion of the administering HCP. The symptom question should be evaluated taking into consideration what would be normal for a healthy person of comparable age and sex.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Symptoms are graded based on the experience of the patient during the past 24 hours.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Each symptom question can be assigned a maximum score of 3.66 points. The NTSS-6 total score is the sum of the 6 individual symptom scores and has a maximum of 21.96 points.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The HCP scores the symptom question based on the patient's response to the question and the definitions of symptom frequency and intensity provided to the HCP (see below).</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Definitions for Grading</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Frequency</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Never or occasional</font><font style="font-family:Times New Roman;"> means that the symptom does not occur; occurs a normal amount; not beyond normal; not noticeable.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Occasional, but abnormal</font><font style="font-family:Times New Roman;"> means that the symptom occurs or is present less than a third of the time, either in total frequency or duration. It also applies to symptoms that may have a duration of only seconds and occur only during a portion of the day and/or night.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Often</font><font style="font-family:Times New Roman;"> means that the symptom occurs for one third to two thirds of the time, either in total frequency or duration. It may also apply to symptoms that may have a duration of only seconds and occur throughout the day and/or night.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Almost continuous</font><font style="font-family:Times New Roman;"> means that the symptom occurs for more than two thirds of the time, either in total frequency or duration. It may also apply to symptoms that may have a duration of only seconds and occur throughout the day and/or night.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Intensity</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Not present</font><font style="font-family:Times New Roman;"> means no symptoms noted.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Mild</font><font style="font-family:Times New Roman;"> means that the patient notices the pain or other symptom but it does not interfere with or restrict daily activities, and the patient does not need any treatment to control it.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Moderate</font><font style="font-family:Times New Roman;"> means that the pain or other symptom sometimes interferes with or restricts &#8805;1 of the patient's sleep, work, social, or family activities, or the patient needs treatment to control the pain or symptom.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Severe</font><font style="font-family:Times New Roman;"> means that the pain or other symptom usually interferes with or restricts &#8805;1 of the patient's sleep, work, social, or family activities, even if the pain or symptom is treated.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Symptoms and Questions Evaluated by the NTSS-6</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Aching pain: "Do you experience a deep, aching, tightness, boring, pulling, or squeezing pain in your feet or legs?"</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Allodynia: "Do you experience unusual sensitivity or tenderness when your feet are touched or are used in activities such as walking?"</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Burning pain: "Do you experience burning pain in your feet or legs?"</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Lancinating pain: "Do you experience sharp, stabbing, or shooting pain, electrical shock-like pain, or surges of pain that last seconds to minutes in your feet or legs?"</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 56 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Numbness: "Do you experience numbness, lost sensation, or a &#8216;dead feeling&#8217; like an anesthetic, without prickling in your feet or legs?"</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Prickling sensation: "Do you experience a prickling or tingling feeling, with or without an &#8216;asleep&#8217; feeling, in your feet or legs?"</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NTSS-6 Sample Scoring Sheet</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Symptom Intensity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Symptom Frequency</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mild</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moderate</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severe</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Never or occasional (normal amount)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Occasional but abnormal (less than 1/3 of the time)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Often (1/3 to 2/3 of the time)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Almost continuous (more than 2/3 of the time)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 57 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>11<font style="font-size:10pt;">: </font>V<font style="font-size:10pt;">ISUAL </font>A<font style="font-size:10pt;">NALOG </font>S<font style="font-size:10pt;">CALE FOR </font>P<font style="font-size:10pt;">AIN </font>I<font style="font-size:10pt;">NTENSITY </font>(VASPI)</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please rate your pain by circling the one number that best describes your pain from diabetic neuropathy in the last 24 hours.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:9.27%;"></td>
<td style="width:9.28%;"></td>
<td style="width:9.28%;"></td>
<td style="width:9.28%;"></td>
<td style="width:9.29%;"></td>
<td style="width:9.29%;"></td>
<td style="width:9.29%;"></td>
<td style="width:9.29%;"></td>
<td style="width:9.29%;"></td>
<td style="width:9.29%;"></td>
<td style="width:9.18%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr style="height:41.35pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No <br>Pain</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Worst Possible Pain</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 58 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>12<font style="font-size:10pt;">: </font>N<font style="font-size:10pt;">EURO-</font>Q<font style="font-size:10pt;">OL</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vileikyte, Diabetes Care (2003) 26:2549-2555</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NEUROPATHY-SPECIFIC QUALITY OF LIFE</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Questionnaire Instructions (UK Version)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">These questions ask about the effect your FOOT PROBLEMS may have on your daily life and well-being. By foot problems we mean lost or reduced feeling in your extremities, pain, discomfort and/or ulcers (open sores) on your feet and, in some cases unsteadiness while walking or standing.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Please note that many questions have two parts. Answer every question by ticking one box for each part (tick two boxes per line). Please make sure you answer all questions.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Please concentrate on how you have felt IN THE PAST 4 WEEKS for all of the questions.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">There are no right or wrong answers. If you are unsure about how to answer a question, you can ask the person who gave you the questionnaire. Please DO NOT ask a relative or friend to help you.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">All of your responses will be held strictly confidential.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:28.05pt;">
<td rowspan="2" colspan="2" valign="middle"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:1.6pt;"> </font>the<font style="letter-spacing:2.5pt;"> </font>past 4<font style="letter-spacing:0.4pt;"> </font>weeks how often<font style="letter-spacing:-0.5pt;"> </font>have you experienced<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:2.5pt;"> </font>following<font style="letter-spacing:0.35pt;"> </font>symptoms?</p></td>
<td rowspan="2" colspan="2" valign="middle"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.1pt;;margin-right:0.74%;text-indent:-0.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All<font style="letter-spacing:-0.15pt;"> <br></font>the<font style="letter-spacing:-0.15pt;"> <br></font>time</p></td>
<td rowspan="2" colspan="4" valign="middle"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.25pt;;margin-right:0.56%;text-indent:0.1pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most <br>of<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>time</p></td>
<td rowspan="2" colspan="6" valign="middle"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.55pt;;margin-right:0.56%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>of<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-1pt;"> </font>time</p></td>
<td rowspan="2" colspan="5" valign="middle"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.5pt;;margin-right:0.56%;text-indent:3.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Occa- sionally</p></td>
<td rowspan="2" colspan="3" valign="middle"  style="width:8.96%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Never</p></td>
<td colspan="13" valign="bottom"  style="width:27%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;margin-right:9.63%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How<font style="letter-spacing:0.1pt;"> </font>much<font style="letter-spacing:0.7pt;"> </font>bother<font style="letter-spacing:1pt;"> </font>did this<font style="letter-spacing:1.15pt;"> </font>cause<font style="letter-spacing:0.45pt;"> </font>you?</p></td>
</tr>
<tr style="height:22.3pt;">
<td colspan="4" valign="bottom"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">much</p></td>
<td colspan="5" valign="bottom"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.65pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bother</p></td>
<td colspan="4" valign="bottom"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:16pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr style="height:16.95pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Burning in your legs or<font style="letter-spacing:-0.1pt;"> </font>feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:21.9pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Excessive heat or<font style="letter-spacing:2.5pt;"> </font>cold<font style="letter-spacing:1.5pt;"> </font>in<font style="letter-spacing:0.8pt;"> </font>your<font style="letter-spacing:1.45pt;"> </font>legs<font style="letter-spacing:1.2pt;"> </font>or<font style="letter-spacing:0.4pt;"> </font>feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:22.35pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Pins<font style="letter-spacing:1.4pt;"> </font>and<font style="letter-spacing:1.5pt;"> </font>needles<font style="letter-spacing:1.9pt;"> </font>in<font style="letter-spacing:0.3pt;"> </font>your<font style="letter-spacing:0.9pt;"> </font>legs<font style="letter-spacing:1.5pt;"> </font>or<font style="letter-spacing:0.75pt;"> </font>feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:22.8pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. Shooting or stabbing<font style="letter-spacing:1.6pt;"> </font>pain<font style="letter-spacing:1.75pt;"> </font>in<font style="letter-spacing:0.65pt;"> </font>your<font style="letter-spacing:1.1pt;"> </font>legs<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.4pt;"> </font>feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:17.4pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. Throbbing in your legs<font style="letter-spacing:1.25pt;"> </font>or<font style="letter-spacing:0.85pt;"> </font>feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.95pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6. Sensations in<font style="letter-spacing:2.2pt;"> </font>your legs<font style="letter-spacing:1.25pt;"> </font>or feet that make them<font style="letter-spacing:1.25pt;"> </font>jump</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:34.5pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7. Irritation of the skin<font style="letter-spacing:1.05pt;"> </font>caused by something<font style="letter-spacing:1.45pt;"> </font>touching your<font style="letter-spacing:2.7pt;"> </font>feel,<font style="letter-spacing:2pt;"> </font>such<font style="letter-spacing:1.45pt;"> </font>as<font style="letter-spacing:0.7pt;"> </font>bedsheets<font style="letter-spacing:2pt;"> </font>or<font style="letter-spacing:0.55pt;"> </font>socks</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:26.1pt;">
<td rowspan="2" colspan="7" valign="top"  style="width:43.12%; border-top:solid 0.75pt #000000; border-bottom:solid 2.875pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A. Have these <font style="font-weight:bold;">painful symptoms</font> reduced<font style="letter-spacing:2.7pt;"> </font>your<font style="letter-spacing:1.05pt;"> </font>quality<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:0.4pt;"> </font>life?</p></td>
<td colspan="7" valign="top"  style="width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very <br>much</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite a <br>lot</p></td>
<td colspan="4" valign="top"  style="width:11.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some<br> what</p></td>
<td colspan="6" valign="top"  style="width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A little</p></td>
<td colspan="6" valign="top"  style="width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not at all</p></td>
</tr>
<tr style="height:24.3pt;">
<td colspan="7" valign="top"  style="width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:11.28%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:29.7pt;">
<td rowspan="2" colspan="2" valign="top"  style="width:29.88%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:1.5pt;"> </font>the<font style="letter-spacing:2.5pt;"> </font>past 4<font style="letter-spacing:0.4pt;"> </font>weeks how often<font style="letter-spacing:-0.55pt;"> </font>have you experienced<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:2.15pt;"> </font>following<font style="letter-spacing:0.8pt;"> </font>symptoms?</p></td>
<td rowspan="2" colspan="2" valign="top"  style="width:8.02%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All <br>the<br> time</p></td>
<td rowspan="2" colspan="4" valign="top"  style="width:8.2%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most <br>of the time</p></td>
<td rowspan="2" colspan="6" valign="top"  style="width:7.9%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the time</p></td>
<td rowspan="2" colspan="5" valign="top"  style="width:10.04%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Occa- sionally</p></td>
<td rowspan="2" colspan="3" valign="top"  style="width:8.96%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Never</p></td>
<td colspan="13" valign="top"  style="width:27%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How much bother did this cause you?</p></td>
</tr>
<tr style="height:25.95pt;">
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">much</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 1pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bother</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 1pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr style="height:17.45pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8. Numbness in your feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 1pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 1pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 1pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:31.35pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9. Inability to feel the difference between hot and cold with your feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.2pt;">
<td colspan="2" valign="top"  style="width:29.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10. Inability to feel objects with your feet</p></td>
<td colspan="2" valign="top"  style="width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:10.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 59 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:26.1pt;">
<td rowspan="2" colspan="7" valign="middle"  style="width:43.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. Have these <font style="font-weight:bold;">last three symptoms</font> reduced your quality of life?</p></td>
<td colspan="7" valign="top"  style="width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very <br>much</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite a <br>lot</p></td>
<td colspan="4" valign="top"  style="width:11.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="6" valign="top"  style="width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A little</p></td>
<td colspan="6" valign="top"  style="width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:4.85pt;;margin-right:0.74%;text-indent:0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not at all</p></td>
</tr>
<tr style="height:22.7pt;">
<td colspan="7" valign="top"  style="width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:11.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:29.15pt;">
<td rowspan="2" colspan="3" valign="top"  style="width:32.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.7pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>past<font style="letter-spacing:1.2pt;"> </font>4<font style="letter-spacing:0.45pt;"> </font>weeks<font style="letter-spacing:0.9pt;"> </font>how<font style="letter-spacing:1.15pt;"> </font>often<font style="letter-spacing:1.8pt;"> </font>have<font style="letter-spacing:1.3pt;"> </font>you<font style="letter-spacing:0.75pt;"> </font>experienced<font style="letter-spacing:2.45pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>following<font style="letter-spacing:2.05pt;"> </font>symptoms?</p></td>
<td rowspan="2" colspan="3" valign="middle"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All<font style="letter-spacing:0.4pt;"> </font>the</p>
<p style="text-align:center;line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</p></td>
<td rowspan="2" colspan="5" valign="middle"  style="width:7.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.4pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of<font style="letter-spacing:-1.05pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>time</p></td>
<td rowspan="2" colspan="6" valign="middle"  style="width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of<font style="letter-spacing:-1.05pt;"> </font>the<font style="letter-spacing:0.15pt;"> </font>time</p></td>
<td rowspan="2" colspan="4" valign="middle"  style="width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:2.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Occa- sionally</p></td>
<td rowspan="2" colspan="3" valign="middle"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Never</p></td>
<td colspan="11" valign="top"  style="width:24.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How<font style="letter-spacing:1.25pt;"> </font>much<font style="letter-spacing:1.2pt;"> </font>bother<font style="letter-spacing:1.7pt;"> </font>did<font style="letter-spacing:0.75pt;"> </font>this<font style="letter-spacing:1pt;"> </font>cause<font style="letter-spacing:1.9pt;"> </font>you?</p></td>
</tr>
<tr style="height:28.65pt;">
<td colspan="4" valign="middle"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">much</p></td>
<td colspan="5" valign="middle"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bother</p></td>
<td colspan="2" valign="middle"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr style="height:41.2pt;">
<td colspan="3" valign="top"  style="width:32.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11. Weakness<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:1.2pt;"> </font>your<font style="letter-spacing:1.7pt;"> </font>hands</p></td>
<td colspan="3" valign="top"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:41.2pt;">
<td colspan="3" valign="top"  style="width:32.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12. Problems<font style="letter-spacing:1.35pt;"> </font>with balance<font style="letter-spacing:1.55pt;"> </font>or<font style="letter-spacing:1pt;"> </font>unsteadiness<font style="letter-spacing:0.3pt;"> </font>while<font style="letter-spacing:2.4pt;"> </font>walking</p></td>
<td colspan="3" valign="top"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:40.3pt;">
<td colspan="3" valign="top"  style="width:32.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13. Problems with balance<font style="letter-spacing:1.55pt;"> </font>or<font style="letter-spacing:1pt;"> </font>unsteadiness while<font style="letter-spacing:0.25pt;"> </font>standing</p></td>
<td colspan="3" valign="top"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:25pt;">
<td rowspan="2" colspan="6" valign="top"  style="width:42.72%; border-top:solid 0.75pt #000000; border-bottom:solid 1.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Have these <font style="font-weight:bold;">last</font><font style="font-weight:bold;letter-spacing:0.45pt;"> </font><font style="font-weight:bold;">three</font><font style="font-weight:bold;letter-spacing:1.4pt;"> </font><font style="font-weight:bold;">symptoms</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduced<font style="letter-spacing:-0.35pt;"> </font>your<font style="letter-spacing:1.75pt;"> </font>quality of<font style="letter-spacing:1.05pt;"> </font>life?</p></td>
<td colspan="9" valign="middle"  style="width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:1.1pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very<font style="letter-spacing:-0.2pt;"> <br></font>much</p></td>
<td colspan="6" valign="middle"  style="width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:2pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite<font style="letter-spacing:0.55pt;"> </font>a<br><font style="letter-spacing:-0.4pt;"> </font>lot</p></td>
<td colspan="3" valign="middle"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:2pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:-1.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="6" valign="middle"  style="width:12.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:0.05pt;"> </font>little</p></td>
<td colspan="5" valign="middle"  style="width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:0.15pt;"> </font>at<font style="letter-spacing:0.25pt;"> </font>all</p></td>
</tr>
<tr style="height:27.9pt;">
<td colspan="9" valign="top"  style="width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 1.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 1.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 1.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:12.46%; border-top:solid 0.75pt #000000; border-bottom:solid 1.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 1.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.8pt;">
<td colspan="35" valign="top"  style="width:100%; border-top:solid 1.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:1pt;"> </font>following<font style="letter-spacing:1.85pt;"> </font>questions<font style="letter-spacing:2.25pt;"> </font>ask<font style="letter-spacing:1pt;"> </font>about<font style="letter-spacing:1.2pt;"> </font>how<font style="letter-spacing:1.25pt;"> </font>your<font style="letter-spacing:0.7pt;"> </font>FOOT<font style="letter-spacing:1.85pt;"> </font>PROBLEMS<font style="letter-spacing:2.2pt;"> </font>affect<font style="letter-spacing:1.6pt;"> </font>your<font style="letter-spacing:0.85pt;"> </font>daily<font style="letter-spacing:1pt;"> </font>activities,<font style="letter-spacing:2.5pt;"> </font>relationships<font style="letter-spacing:2.5pt;"> </font>and feelings.</p></td>
</tr>
<tr style="height:32.75pt;">
<td colspan="9" valign="middle"  style="width:46.5%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Are<font style="letter-spacing:1.7pt;"> </font>you<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.55pt;"> </font><font style="text-decoration:underline;">PAID</font><font style="text-decoration:underline;letter-spacing:0.9pt;"> </font><font style="text-decoration:underline;">WORK</font>?</p></td>
<td colspan="4" valign="middle"  style="width:5.8%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes</p></td>
<td colspan="5" valign="middle"  style="width:7.76%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No</p></td>
<td colspan="17" valign="middle"  style="width:39.94%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:1pt;"> </font><font style="font-weight:bold;">YES</font><font style="font-weight:bold;letter-spacing:0.85pt;"> </font>please<font style="letter-spacing:0.1pt;"> </font>go<font style="letter-spacing:1.35pt;"> </font>to<font style="letter-spacing:1.4pt;"> </font>Question<font style="letter-spacing:1.9pt;"> </font>14.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:1pt;"> </font><font style="font-weight:bold;">NO</font><font style="font-weight:bold;letter-spacing:0.6pt;"> </font>please<font style="letter-spacing:0.65pt;"> </font>go<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:1.4pt;"> </font>Question<font style="letter-spacing:1.1pt;"> </font>15.</p></td>
</tr>
<tr style="height:38.75pt;">
<td rowspan="2" colspan="3" valign="middle"  style="width:32.96%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.25pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>past<font style="letter-spacing:1.2pt;"> </font>4<font style="letter-spacing:0.45pt;"> </font>weeks,<font style="letter-spacing:0.8pt;"> </font>HOW<font style="letter-spacing:1.35pt;"> </font>MUCH<font style="letter-spacing:2pt;"> </font>have<font style="letter-spacing:1.5pt;"> </font>your<font style="letter-spacing:0.1pt;"> </font>foot<font style="letter-spacing:0.65pt;"> </font>problems<font style="letter-spacing:2.25pt;"> </font>interfered<font style="letter-spacing:2.05pt;"> </font>with<font style="letter-spacing:1.15pt;"> </font>your:</p></td>
<td rowspan="2" colspan="3" valign="middle"  style="width:9.76%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.25pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very<br>much</p></td>
<td rowspan="2" colspan="5" valign="middle"  style="width:7.64%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-2.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite<font style="letter-spacing:-0.25pt;"> <br></font>a<font style="letter-spacing:0.1pt;"> </font>lot</p></td>
<td rowspan="2" colspan="7" valign="middle"  style="width:9.7%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-1.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some<font style="letter-spacing:0.25pt;"> <br></font>what</p></td>
<td rowspan="2" colspan="3" valign="middle"  style="width:7.04%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<br>little</p></td>
<td rowspan="2" colspan="3" valign="middle"  style="width:8.34%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:2.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:-0.15pt;"> <br></font>at<font style="letter-spacing:-0.15pt;"> </font>all</p></td>
<td colspan="11" valign="top"  style="width:24.58%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:1.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How<font style="letter-spacing:1.15pt;"> </font>important<font style="letter-spacing:2.2pt;"> </font>is<font style="letter-spacing:0.55pt;"> </font>this<font style="letter-spacing:1.05pt;"> </font>aspect<font style="letter-spacing:1.6pt;"> </font>of<font style="letter-spacing:0.65pt;"> </font>your</p>
<p style="text-align:center;margin-top:0pt;line-height:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">life<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:1.15pt;"> </font>you?</p></td>
</tr>
<tr style="height:39.65pt;">
<td colspan="4" valign="top"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:1.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very<font style="letter-spacing:-0.65pt;"> <br></font>much</p></td>
<td colspan="5" valign="top"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-2.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some<font style="letter-spacing:0.25pt;"> </font>what</p></td>
<td colspan="2" valign="top"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:-2.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:0.35pt;"> <br></font>at <br>all</p></td>
</tr>
<tr style="height:25.9pt;">
<td colspan="3" valign="top"  style="width:32.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="letter-spacing:1.85pt;"> </font>Ability<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:1.2pt;"> </font>perform<font style="letter-spacing:0.45pt;"> </font>your<font style="letter-spacing:2.45pt;"> </font>paid<font style="letter-spacing:2pt;"> </font>work?</p></td>
<td colspan="3" valign="top"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="top"  style="width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:37.1pt;">
<td colspan="3" valign="top"  style="width:32.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="letter-spacing:1.85pt;"> </font>Ability to<font style="letter-spacing:1.2pt;"> </font>perform<font style="letter-spacing:0.1pt;"> </font>tasks<font style="letter-spacing:0.35pt;"> </font>around<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:1.55pt;"> </font>house or<font style="letter-spacing:0.55pt;"> </font>garden?</p></td>
<td colspan="3" valign="top"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="top"  style="width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.75pt;">
<td colspan="3" valign="top"  style="width:32.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16. Ability to<font style="letter-spacing:1.3pt;"> </font>take<font style="letter-spacing:1.5pt;"> </font>part<font style="letter-spacing:1.8pt;"> </font>in<font style="letter-spacing:1.8pt;"> </font>leisure<font style="letter-spacing:0.4pt;"> </font>activities?</p></td>
<td colspan="3" valign="top"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="top"  style="width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:7.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:40.65pt;">
<td rowspan="2" colspan="6" valign="top"  style="width:42.72%; border-top:solid 0.75pt #000000; border-bottom:solid 1pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="letter-spacing:0.05pt;"> </font>Have<font style="letter-spacing:1.45pt;"> </font>these changes<font style="letter-spacing:1.3pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">daily</font><font style="font-weight:bold;letter-spacing:1.55pt;"> </font><font style="font-weight:bold;">activities</font><font style="font-weight:bold;letter-spacing:2.75pt;"> </font>as<font style="letter-spacing:1.95pt;"> </font>a<font style="letter-spacing:1.7pt;"> </font>result of your<font style="letter-spacing:0.2pt;"> </font>foot<font style="letter-spacing:1.65pt;"> </font>problems<font style="letter-spacing:1.9pt;"> </font>reduced<font style="letter-spacing:1pt;"> </font>your<font style="letter-spacing:2.4pt;"> </font>quality<font style="letter-spacing:2.5pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>life?</p></td>
<td colspan="9" valign="middle"  style="width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:1.1pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very<font style="letter-spacing:-0.2pt;"> <br></font>much</p></td>
<td colspan="6" valign="middle"  style="width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite<font style="letter-spacing:0.15pt;"> <br></font>a<font style="letter-spacing:0.25pt;"> <br></font>lot</p></td>
<td colspan="3" valign="middle"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-2.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="6" valign="middle"  style="width:12.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:0.1pt;"> </font>little</p></td>
<td colspan="5" valign="middle"  style="width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:0.55pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>all</p></td>
</tr>
<tr style="height:27.1pt;">
<td colspan="9" valign="top"  style="width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:12.46%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:2.5pt;">
<td colspan="21" valign="top"  style="width:67.08%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:8.34%; border-top:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="11" valign="top"  style="width:24.58%; border-top:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:36.9pt;">
<td colspan="25" valign="middle"  style="width:77.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:1.5pt;"> </font>the<font style="letter-spacing:1.35pt;"> </font>past<font style="letter-spacing:2pt;"> </font>4 weeks:</p></td>
<td colspan="9" valign="middle"  style="width:22.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:1.95pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How<font style="letter-spacing:1.95pt;"> </font>important<font style="letter-spacing:-0.45pt;"> </font>is<font style="letter-spacing:1.8pt;"> </font>this<font style="letter-spacing:2.4pt;"> </font>aspect<font style="letter-spacing:2.6pt;"> </font>of<font style="letter-spacing:1.5pt;"> </font>your<font style="letter-spacing:1.85pt;"> </font>life<font style="letter-spacing:1.85pt;"> </font>to<font style="letter-spacing:1.25pt;"> </font>you?</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 60 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:39.45pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:1.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very <br>much</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-2.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite <br>a<font style="letter-spacing:-0.75pt;"> </font>lot</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-1.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:-0.6pt;"> <br></font>little</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:-0.05pt;"> <br></font>at<font style="letter-spacing:-0.9pt;"> <br></font>all</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:1.1pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very much</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-2.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:2.9pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not at<font style="letter-spacing:-0.95pt;"> </font>all</p></td>
</tr>
<tr style="height:54.35pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17. How much have your<font style="letter-spacing:-0.25pt;"> </font>foot problems interfered with your relationships<font style="letter-spacing:-0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>people<font style="letter-spacing:0.05pt;"> </font>close<font style="letter-spacing:-0.55pt;"> </font>to<font style="letter-spacing:0.15pt;"> </font>you?</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:73.45pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18. Have you felt more physically dependent<font style="letter-spacing:-0.55pt;"> </font>than<font style="letter-spacing:1.25pt;"> </font>you<font style="letter-spacing:0.7pt;"> </font>would<font style="letter-spacing:0.7pt;"> </font>like<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.75pt;"> </font>be<font style="letter-spacing:0.3pt;"> </font>on<font style="letter-spacing:0.15pt;"> </font>people<font style="letter-spacing:0.4pt;"> </font>close<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>you as<font style="letter-spacing:-0.3pt;"> </font>a result of your foot<font style="letter-spacing:-0.2pt;"> </font>problems?</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:73.45pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19. Have you felt more emotionally dependent than you would like to be on people close to you as a result of your foot problems?</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:48.95pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20. Has your role in the family changed as a result of your foot problems?</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:26.45pt;">
<td rowspan="2" colspan="5" valign="top"  style="width:40.84%; border-top:solid 0.75pt #000000; border-bottom:solid 1pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E. Have these changes in<font style="letter-spacing:0.1pt;"> </font><font style="font-weight:bold;">relationships</font><font style="font-weight:bold;letter-spacing:1.75pt;"> </font><font style="font-weight:bold;">with other people</font> as a result of your foot problems reduced<font style="letter-spacing:0.85pt;"> </font>your<font style="letter-spacing:-0.5pt;"> </font>quality of<font style="letter-spacing:-0.1pt;"> </font>life?</p></td>
<td colspan="7" valign="middle"  style="width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:1.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very <br>much</p></td>
<td colspan="8" valign="middle"  style="width:15.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite<font style="letter-spacing:-0.1pt;"> </font>a<font style="letter-spacing:-0.75pt;"> </font>lot</p></td>
<td colspan="5" valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-1.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="2" valign="middle"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">little</p></td>
<td colspan="7" valign="middle"  style="width:15.82%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:0.35pt;"> </font>at<font style="letter-spacing:-0.95pt;"> </font>all</p></td>
</tr>
<tr style="height:23.75pt;">
<td colspan="7" valign="top"  style="width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="8" valign="top"  style="width:15.02%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:37.6pt;">
<td colspan="25" valign="top"  style="width:77.12%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="9" valign="middle"  style="width:22.82%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.35pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How<font style="letter-spacing:1.5pt;"> </font>much<font style="letter-spacing:2.35pt;"> </font>bother did<font style="letter-spacing:1.55pt;"> </font>this<font style="letter-spacing:2.7pt;"> </font>cause<font style="letter-spacing:1.75pt;"> </font>you?</p></td>
</tr>
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0.7pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How<font style="letter-spacing:-0.65pt;"> </font>much do<font style="letter-spacing:-0.4pt;"> </font>you<font style="letter-spacing:-0.75pt;"> </font>agree<font style="letter-spacing:-0.3pt;"> </font>with<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>following<font style="letter-spacing:0.9pt;"> </font>statements:</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-9.35pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completely <br>agree</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partly<br>agree</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:2.15pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither agree or</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partly<br>disagree</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-4.3pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completely<br>disagree</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:1.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very<br>much</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:1.1pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some<br>bother</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr style="height:49.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:-10.8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21. People treat me<font style="letter-spacing:0.35pt;"> </font>differently from other people<font style="letter-spacing:1.95pt;"> </font>as<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:0.65pt;"> </font>result<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:0.6pt;"> </font>my<font style="letter-spacing:0.15pt;"> </font>foot<font style="letter-spacing:0.1pt;"> </font>problems.</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:42.5pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22. I<font style="letter-spacing:2.4pt;"> </font>feel older than my<font style="letter-spacing:0.15pt;"> </font>years<font style="letter-spacing:2.6pt;"> </font>as<font style="letter-spacing:2.2pt;"> </font>a<font style="letter-spacing:2.1pt;"> </font>result<font style="letter-spacing:2pt;"> </font>of<font style="letter-spacing:2.05pt;"> </font>my<font style="letter-spacing:0.15pt;"> </font>foot<font style="letter-spacing:0.1pt;"> </font>problems.</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:37.1pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23. My<font style="letter-spacing:0.5pt;"> </font>self -<font style="letter-spacing:2.55pt;"> </font>confidence<font style="letter-spacing:-1pt;"> </font>is affected<font style="letter-spacing:-0.5pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font>result<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>my<font style="letter-spacing:0.65pt;"> </font>foot<font style="letter-spacing:-0.25pt;"> </font>problems.</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.<font style="letter-spacing:2.1pt;"> </font>My<font style="letter-spacing:2.2pt;"> </font>foot<font style="letter-spacing:1.2pt;"> </font>problems<font style="letter-spacing:1.8pt;"> </font>make my<font style="letter-spacing:0.45pt;"> </font>life<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font>struggle.</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25. I generally<font style="letter-spacing:2.2pt;"> </font>feel<font style="letter-spacing:0.45pt;"> </font>frustrated<font style="letter-spacing:1.8pt;"> </font>because of<font style="letter-spacing:1.35pt;"> </font>my<font style="letter-spacing:1.1pt;"> </font>foot<font style="letter-spacing:1.15pt;"> </font>problems.</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.<font style="letter-spacing:2.2pt;"> </font>My<font style="letter-spacing:2.2pt;"> </font>foot<font style="letter-spacing:1.75pt;"> </font>problems cause<font style="letter-spacing:1.75pt;"> </font>me<font style="letter-spacing:1.35pt;"> </font>embarrassment.</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 61 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.<font style="letter-spacing:0.9pt;"> </font>I<font style="letter-spacing:0.3pt;"> </font>feel<font style="letter-spacing:1pt;"> </font>depressed<font style="letter-spacing:1.95pt;"> </font>because<font style="letter-spacing:2.45pt;"> </font>of<font style="letter-spacing:0.8pt;"> </font>my<font style="letter-spacing:0.65pt;"> </font>foot<font style="letter-spacing:0.7pt;"> </font>problems</p></td>
<td colspan="4" valign="top"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="6" valign="top"  style="width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 1.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:8.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:35.3pt;">
<td rowspan="2" valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F. Have these <font style="font-weight:bold;">feelings about yourself</font> as a result of your foot problems reduced your quality of life?</p></td>
<td colspan="4" valign="middle"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very <br>much</p></td>
<td colspan="11" valign="middle"  style="width:16.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite<font style="letter-spacing:-0.15pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>lot</p></td>
<td colspan="4" valign="middle"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="7" valign="middle"  style="width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:-0.45pt;"> </font>little</p></td>
<td colspan="7" valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:-0.75pt;"> </font>at<font style="letter-spacing:-0.35pt;"> </font>all</p></td>
</tr>
<tr style="height:35.3pt;">
<td colspan="4" valign="middle"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="11" valign="middle"  style="width:16.4%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:11.56%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very <br>much</p></td>
<td colspan="11" valign="middle"  style="width:16.4%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite<font style="letter-spacing:-0.15pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>lot</p></td>
<td colspan="4" valign="middle"  style="width:9.12%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <br>what</p></td>
<td colspan="7" valign="middle"  style="width:17.74%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:-0.45pt;"> </font>little</p></td>
<td colspan="7" valign="middle"  style="width:15.82%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<font style="letter-spacing:-0.75pt;"> </font>at<font style="letter-spacing:-0.35pt;"> </font>all</p></td>
</tr>
<tr style="height:48.95pt;">
<td valign="top"  style="width:29.26%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28. Overall, I would say problems with my feet<font style="letter-spacing:0.8pt;"> </font>reduced<font style="letter-spacing:1.6pt;"> </font>my<font style="letter-spacing:0.3pt;"> </font>Quality of<font style="letter-spacing:0.2pt;"> </font>Life:</p></td>
<td colspan="4" valign="middle"  style="width:11.56%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="11" valign="middle"  style="width:16.4%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:9.12%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="width:17.74%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="width:15.82%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:11.56%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excellent</p></td>
<td colspan="11" valign="middle"  style="width:16.4%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very<font style="letter-spacing:-0.65pt;"> </font>good</p></td>
<td colspan="4" valign="middle"  style="width:9.12%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good</p></td>
<td colspan="7" valign="middle"  style="width:17.74%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td colspan="7" valign="middle"  style="width:15.82%; border-top:solid 1.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poor</p></td>
</tr>
<tr style="height:35.3pt;">
<td valign="top"  style="width:29.26%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29. Overall, I would rate my quality of life as:</p></td>
<td colspan="4" valign="middle"  style="width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="11" valign="middle"  style="width:16.4%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="7" valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 62 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>13<font style="font-size:10pt;">: </font>SF-36</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities. <font style="font-style:italic;">Thank you for completing this survey!</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the following questions, please mark an <font style="font-size:10pt;font-family:'Wingdings'">&#120;</font> in the one box that best describes your answer.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. </p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>In general, would you say your health is:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr style="height:19.3pt;">
<td valign="top"  style="width:17.72%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excellent</p></td>
<td valign="top"  style="width:24.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very<font style="letter-spacing:0.3pt;"> </font>good</p></td>
<td valign="top"  style="width:21.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good</p></td>
<td valign="top"  style="width:21.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td valign="top"  style="width:15.1%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poor</p></td>
</tr>
<tr style="height:23.75pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;text-decoration:underline;">Compared to one year ago</font><font style="font-weight:bold;">, how would you rate your health in general </font><font style="font-weight:bold;text-decoration:underline;">now</font><font style="font-weight:bold;">?</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr style="height:48.95pt;">
<td valign="top"  style="width:17.72%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Much<font style="letter-spacing:1pt;"> </font>better</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">now<font style="letter-spacing:1.4pt;"> </font>than<font style="letter-spacing:0.7pt;"> </font>one</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year<font style="letter-spacing:0.95pt;"> </font>ago</p></td>
<td valign="top"  style="width:24.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Somewhat</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">better<font style="letter-spacing:0.65pt;"> </font>now</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than<font style="letter-spacing:0.65pt;"> </font>one<font style="letter-spacing:0.7pt;"> </font>year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ago</p></td>
<td valign="top"  style="width:21.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">About<font style="letter-spacing:1.4pt;"> </font>the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">same<font style="letter-spacing:1.2pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>one</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year<font style="letter-spacing:0.95pt;"> </font>ago</p></td>
<td valign="top"  style="width:21.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Somewhat</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">worse<font style="letter-spacing:1.1pt;"> </font>now</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than<font style="letter-spacing:0.65pt;"> </font>one<font style="letter-spacing:0.7pt;"> </font>year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ago</p></td>
<td valign="top"  style="width:15.1%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Much<font style="letter-spacing:0.9pt;"> </font>worse</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">now<font style="letter-spacing:1pt;"> </font>than<font style="letter-spacing:0.3pt;"> </font>one</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year<font style="letter-spacing:0.95pt;"> </font>ago</p></td>
</tr>
<tr style="height:23.75pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SF-36v2<sup style="font-size:85%; vertical-align:top">TM</sup> Health Survey &#169;1996, 2000 by Quality Metric Incorporated and Medical Outcomes Trust. All Rights Reserved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SF-36 &#174; is a registered trademark of Medical Outcomes Trust.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(SF-36v2 Standard, US Version 2.0)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The following questions are about activities you might do during a typical day. Does <font style="text-decoration:underline;">your health now limit you</font> in these activities? If so, how much?</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr style="height:48.95pt;">
<td valign="top"  style="width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:47.78%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:16.66%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limited</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a<font style="letter-spacing:0.25pt;"> l</font><font style="letter-spacing:-0.15pt;">o</font>t</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style="width:16.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limited</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a<font style="letter-spacing:0.65pt;"> </font>l<font style="letter-spacing:0.1pt;">i</font>t<font style="letter-spacing:0.05pt;">t</font>le</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style="width:16.66%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No,<font style="letter-spacing:0.1pt;"> </font>not</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limited</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:0.1pt;">l</font>l</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">a</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vigorous</font><font style="text-decoration:underline;letter-spacing:2.15pt;"> </font><font style="text-decoration:underline;">activities</font>,<font style="letter-spacing:1.3pt;"> </font>such<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.6pt;"> </font>running,<font style="letter-spacing:1.35pt;"> </font>lifting heavy<font style="letter-spacing:1pt;"> </font>objects,<font style="letter-spacing:1.6pt;"> </font>participating<font style="letter-spacing:1.45pt;"> </font>in strenuous<br>sports <font style="letter-spacing:1pt;"> </font></p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:5.85pt;;margin-right:0.56%;text-indent:-5.85pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">b</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Moderate</font><font style="text-decoration:underline;letter-spacing:1.8pt;"> </font><font style="text-decoration:underline;">activities</font>,<font style="letter-spacing:1.3pt;"> </font>such<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.9pt;"> </font>moving<font style="letter-spacing:1pt;"> </font>a<font style="letter-spacing:0.75pt;"> </font>table,<font style="letter-spacing:0.8pt;"> </font>pushing<font style="letter-spacing:1.65pt;"> </font>a<font style="letter-spacing:0.55pt;"> </font>vacuum<font style="letter-spacing:1.1pt;"> </font>cleaner,<font style="letter-spacing:1.25pt;"> </font>bowling,<font style="letter-spacing:-0.2pt;"> </font>or playing<font style="letter-spacing:1.65pt;"> </font>golf</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">c</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lifting<font style="letter-spacing:1.2pt;"> </font>or<font style="letter-spacing:0.7pt;"> </font>carrying<font style="letter-spacing:-0.4pt;"> </font>groceries</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">d</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Climbing<font style="letter-spacing:2.2pt;"> </font><font style="text-decoration:underline;">several</font><font style="letter-spacing:1.25pt;"> </font>flights<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.5pt;"> </font>stair</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">e</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Climbing<font style="letter-spacing:2.4pt;"> </font><font style="text-decoration:underline;">one</font><font style="letter-spacing:1.05pt;"> </font>flight<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>stair<font style="letter-spacing:0.6pt;">s</font></p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">f</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bending,<font style="letter-spacing:2.3pt;"> </font>kneeling,<font style="letter-spacing:1.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>stooping</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">g</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Walking<font style="letter-spacing:2.05pt;"> </font><font style="text-decoration:underline;">more</font><font style="text-decoration:underline;letter-spacing:1.1pt;"> </font><font style="text-decoration:underline;">than</font><font style="text-decoration:underline;letter-spacing:0.7pt;"> </font><font style="text-decoration:underline;">a</font><font style="text-decoration:underline;letter-spacing:0.15pt;"> </font><font style="text-decoration:underline;">mile</font></p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;letter-spacing:1.2pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">h</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Walking<font style="letter-spacing:2pt;"> </font><font style="text-decoration:underline;">several</font><font style="text-decoration:underline;letter-spacing:1.15pt;"> </font><font style="text-decoration:underline;">hundred</font><font style="text-decoration:underline;letter-spacing:0.9pt;"> </font><font style="text-decoration:underline;">yards</font></p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">i</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Walking<font style="letter-spacing:2.15pt;"> </font><font style="text-decoration:underline;">one</font><font style="text-decoration:underline;letter-spacing:1.05pt;"> </font><font style="text-decoration:underline;">hundred</font><font style="text-decoration:underline;letter-spacing:1.25pt;"> </font><font style="text-decoration:underline;">yards</font></p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
<tr>
<td valign="top"  style="width:2.22%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">j</sub></p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bathing<font style="letter-spacing:1.65pt;"> </font>or<font style="letter-spacing:0.4pt;"> </font>dressing<font style="letter-spacing:1.65pt;"> </font>yourself</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></font>&#8230;&#8230;&#8230;</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></font>&#8230;&#8230;&#8230;.</p></td>
<td valign="bottom"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;&#8230;&#8230;.<font style="font-size:12pt;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 63 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. </p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During the <font style="text-decoration:underline;">past 4 weeks</font>, how much of the time have you had any of the following problems with your work or other regular daily activities <font style="text-decoration:underline;">as a result of your physical health</font>?</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:486.35pt;;">
<tr>
<td style="width:10.75pt;"></td>
<td style="width:205.3pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.1pt;"></td>
</tr>
<tr style="height:48.95pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:0.55pt;"> </font>little <br>of the<font style="letter-spacing:0.55pt;"> <br></font>time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of <br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">a</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cut down on the <font style="text-decoration:underline;">amount of time</font> you spent on work or other activities</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">b</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Accomplished less</font> than you would <br>like</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">c</sub></p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Were limited in the <font style="text-decoration:underline;">kind</font> of work or other</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activities</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">d</sub></p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Had <font style="text-decoration:underline;">difficulty</font> performing the work or other activities (for example, it took extra effort)</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. </p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During the <font style="text-decoration:underline;">past 4 weeks</font>, how much of the time have you had any of the following problems with your work or other regular daily activities <font style="text-decoration:underline;">as a result of any emotional problems</font> (such as feeling depressed or anxious)?</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:486.35pt;;">
<tr>
<td style="width:10.75pt;"></td>
<td style="width:205.3pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.1pt;"></td>
</tr>
<tr style="height:48.95pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:0.55pt;"> </font>little <br>of the<font style="letter-spacing:0.55pt;"> <br></font>time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of <br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">a</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cut down on the <font style="text-decoration:underline;">amount of time</font> you spent on work or other activities</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">b</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Accomplished less</font> than you would like</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">c</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Did work or other activities <font style="text-decoration:underline;">less carefully than usual</font></p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. </p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During the <font style="text-decoration:underline;">past 4 weeks</font>, to what extent has your <font style="text-decoration:underline;">physical health or emotional problems</font> interfered with your normal social activities with family, friends, neighbors, or groups?</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr style="height:19.3pt;">
<td valign="middle"  style="width:17.72%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not at all</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:24.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slightly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:21.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moderately</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:21.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite a bit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extremely</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.75pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">How much <font style="text-decoration:underline;">bodilv</font> pain have you had during the <font style="text-decoration:underline;">past 4 weeks</font>?</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr style="height:19.3pt;">
<td valign="middle"  style="width:15.4%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:21.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very mild</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mild</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moderate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severe</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very Severe</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:23.75pt;">
<td valign="top"  style="width:15.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:18.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="top"  style="width:15.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></p></td>
<td valign="top"  style="width:21.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></p></td>
<td valign="top"  style="width:18.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></p></td>
<td valign="top"  style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub></p></td>
<td valign="top"  style="width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
<td valign="top"  style="width:13.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">6</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 64 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:24pt;"></font>During the <font style="text-decoration:underline;">past 4 weeks</font>, how much did <font style="text-decoration:underline;">pain</font> interfere with your normal work<br>(including both work outside the home and housework)?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr style="height:19.3pt;">
<td valign="middle"  style="width:17.72%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not at all</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:24.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A little bit </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:21.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moderate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:21.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quite a bit </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extremely</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.75pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">These questions are about how you feel and how things have been with you <font style="text-decoration:underline;">during the past 4 weeks</font>. For each question, please give the one answer that comes closest to the way you have been feeling. How much of the time during the <font style="text-decoration:underline;">past 4 weeks</font>&#8230;.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:486.35pt;;">
<tr>
<td style="width:10.75pt;"></td>
<td style="width:205.3pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.1pt;"></td>
</tr>
<tr style="height:48.95pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of<br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:0.55pt;"> </font>little <br>of the<font style="letter-spacing:0.55pt;"> <br></font>time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of <br>the time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">a</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Did you feel full of life?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">b</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Have you been very nervous?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">c</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Have you felt so down in the dumps that nothing could cheer you up?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">d</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Have you felt calm and peaceful?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">e</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Did you have a lot of energy?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">f</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Have you felt downhearted and depressed?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">g</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Did you feel worn out?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">h</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Have you been happy?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">i</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Did you feel tried?</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During the <font style="text-decoration:underline;">past 4 weeks</font>, how much of the time has your <font style="text-decoration:underline;">physical health or emotional problems</font> interfered with your social activities (like visiting friends, relatives, etc.)?</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr style="height:25.9pt;">
<td valign="middle"  style="width:17.72%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the <br>time </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:24.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of the <br>time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:21.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the <br>time </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:21.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A little of the <br>time </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the <br>time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.75pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="top"  style="width:17.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub></p></td>
<td valign="top"  style="width:24.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub></p></td>
<td valign="top"  style="width:21.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub></p></td>
<td valign="top"  style="width:21.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub></p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:24pt;">How TRUE or FALSE is </font><font style="text-decoration:underline;">each</font> of the following statements for you?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:486.35pt;;">
<tr>
<td style="width:10.75pt;"></td>
<td style="width:205.3pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.05pt;"></td>
<td style="width:54.1pt;"></td>
</tr>
<tr style="height:48.95pt;">
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitely true</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mostly <br>true</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Don&#8217;t<br>know</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mostly<br>false</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitely<br>false</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:15pt;font-family:'Wingdings 3'">&#113;</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">a</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I seem to get sick a little easier than other people</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">b</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I am as healthy as anybody I know</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">c</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I expect my health to get worse</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;margin-right:0.56%;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">d</sub></p></td>
<td valign="bottom"  style="">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">My health is excellent</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">1</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">2</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">3</sub>&#8230;..</p></td>
<td valign="bottom"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;..<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">4</sub>&#8230;..</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8230;...<font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font><sub style="font-size:85%; vertical-align:bottom">5</sub></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 65 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sangamo BioSciences, Inc.</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Protocol SB-509-0901 for Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:10pt;">PPENDIX </font>14<font style="font-size:10pt;">: </font>G<font style="font-size:10pt;">LOBAL </font>A<font style="font-size:10pt;">SSESSMENT</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following question will be asked of the subject according to the schedule outlined in <font style="font-weight:bold;">Appendix 1: Schedule of Events:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:49.96%;"></td>
<td style="width:4.12%;"></td>
<td style="width:45.92%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">How have you felt since your last visit?</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font></p></td>
<td valign="top"  style="padding-left:3.6pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Better </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font></p></td>
<td valign="top"  style="padding-left:3.6pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Same</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Wingdings 2'">&#163;</font></p></td>
<td valign="top"  style="padding-left:3.6pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Worse</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 66 of 66</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Version date: October&nbsp;&nbsp;9, 2009</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sgmo-ex311_201503319.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CERTIFICATION </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Edward O. Lanphier II, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Sangamo BioSciences, Inc. (&#8220;registrant&#8221;) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &#8212; 15(f) and 15d &#8212; 15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 28, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Edward O. Lanphier II&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward O. Lanphier II</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sgmo-ex312_201503316.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CERTIFICATION </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, H. Ward Wolff, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Sangamo BioSciences, Inc. (&#8220;registrant&#8221;) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &#8212; 15(f) and 15d &#8212; 15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.47%;margin-left:4.53%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 28, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ H. Ward Wolff&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H. Ward Wolff</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive&#160;Vice&#160;President&#160;and&#160;Chief&#160;Financial&#160;Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sgmo-ex321_2015033110.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Certification Pursuant to 18 U.S.C. &#167;1350, as Adopted </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the undersigned hereby certifies pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 in his capacity as an officer of Sangamo BioSciences, Inc. (the &#8220;Company&#8221;), that: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended March 31, 2015, as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Edward O. Lanphier II&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward O. Lanphier II</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 28, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ H. Ward Wolff&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H. Ward Wolff</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive&#160;Vice&#160;President&#160;and&#160;Chief&#160;Financial&#160;Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 28, 2015</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g201504281926018191269.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201504281926018191269.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`'H`T0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#U[[1KNH:G
MJD-A?Z=;0V=RL"K<:?)*QS#')G<)E!YD[`=,=>:L"V\2[OFU;22-I&!I<@^;
M=U_X^.F.,>O.>U)HC;M6\2#Y?EU%!P<_\NMN>?3K6U0!AFU\5>7@:SHP?U.D
MRX[=OM/^]W[CTY&M?%61MUG1AQSG293S@?\`3SZY/TX]ZW**`,(6GBO;SK6B
M[L=?[(EQW_Z>?I^1]>`VGBO(QK6B@;<'.D2\MZ_\?/3V_6MVB@#":T\5\[=:
MT4<<9TB4]_\`KY]/\?:FM:>+MQVZYH@7/`.CRD_^E5;]%`'/_8_&'_0=T/\`
M\$TW_P`E4JVGB[<-VN:(5SR!H\H/_I56_10!S_V/QA_T'=#_`/!--_\`)5'V
M/QA_T'=#_P#!--_\E5T%%`&`MIXNW#=KFB%<\@:/*#_Z54GV/QA_T'=#_P#!
M--_\E5T%%`&`;3Q=@8US1`<<YT>7G_R:H^R>+MI_XGFB;L\'^QY<?^E5;]%`
M&`;3Q=@8US1`<<YT>7G_`,FJ=]D\5X;.M:+DJ`O_`!*)>&XR3_I/(Z\<=1SQ
MSNT4`8`M/%V?FUS1",'IH\H_]NJ3['XP_P"@[H?_`()IO_DJN@HH`Y_['XP_
MZ#NA_P#@FF_^2J/L?C#_`*#NA_\`@FF_^2JZ"B@#G_L?C#_H.Z'_`.":;_Y*
MH^Q^,/\`H.Z'_P"":;_Y*KH**`,#[)XNVC_B>:)NSR?['EQ_Z54GV/QA_P!!
MW0__``33?_)5=!10!A/:>*RS^7K6BJI;*!M(E)"^A_TD9/3GCZ4C6GBW`VZW
MH@/?.D2GL/\`IY]<UO44`<_]C\8?]!W0_P#P33?_`"51]C\8?]!W0_\`P33?
M_)5=!10!@-:>+MQVZYH@7/`.CRD_^E5"VGB[<-VN:(5SR!H\H/\`Z55OT4`<
M_P#8_&'_`$'=#_\`!--_\E4IM/%V!C7-$!QSG1Y>?_)JM^B@#G_L?C#_`*#N
MA_\`@FF_^2J7[)XNVC_B>:)NSR?['EQ_Z55OT4`8<EKXJ+-Y>LZ,JG.T-I,I
M(YXS_I(SQQVYY]J9]D\7;1_Q/-$W9Y/]CRX_]*JWZ*`,*.T\5@_O-:T5AG^'
M2)1_[<GVH%IXK\H@ZUHIDSPPTB7`_#[3_6MVB@#"-IXKW<:UHH7!X.D2Y[X_
MY>?I_P#6IOV3Q=M/_$\T3=G@_P!CRX_]*JWZ*`,(VGBO?E=:T4+M`P=(E)W8
MZY^T],\X].,]Z%M/%8CD#ZUHI<@;"-(E`'/.1]IYX]Q6[10!A"T\5[4SK6BE
M@Q+$:1+@KQ@#_2>#UYYZCCCEOV3Q=M/_`!/-$W9X/]CRX_\`2JM^B@##:U\5
M;P5UG1@N>0=)E)QQW^T_6D%IXKR<ZUHI&W`QI$O#>O\`Q\]/;]:W:*`,(6GB
MO(SK6BXR,_\`$HE_'_EY_P#U>].%KXHV_-K&CDX/(TJ4?P_]?'KS]./>MNB@
M#&^S>)=P_P")MI.W'(_LN3/_`*44DEMXG(;R]7TA3QMW:7(V.!G/^D#/.?T_
M':HH`Q!:^*-QSK&CD8X`TJ7CYO\`KX]./KS[4Q;3Q;@[M;T0GMC2)1V/_3SZ
MXK>HH`QGMO$I8>7JVDJN!D-I<A)Z9_Y>![_F/3E@M?%6>=9T8\'II,O7''_+
MSZ\_3CCK6Y10!@_9/%O&=;T3H<_\2B7KV_Y>?I3A:^*LG.LZ-C/'_$IEZ9'_
M`$\^F?S'ISN44`8?V7Q5Y9`UG1M_&#_9,N/?C[3]>]'V7Q5Y@)UG1MG.1_9,
MN?;G[3].U;E%`&$;3Q7MXUK1=V.O]D2X[?\`3S]?S'IRKVOBHR$QZSHRIS@-
MI,I(ZXY^TCV[<X/3MN44`8AM?%&?EUC1P-P/.E2GY?3_`(^.OO\`I1]E\4;3
M_P`3C1]VW`/]E2XW>O\`Q\=/;]:VZ*`,1K7Q1Y9"ZQHX?/!.E2D=?3[1Z>]+
M]F\3[U/]KZ1MW@D?V7)DKW&?M'7W_2MJB@#$%KXHW<ZQH^W/3^RI<]_^GCZ?
MD?7A1;>)]ZDZOI!48W`:7)D],X/VCC/S>N,CKCG:HH`Q!:^*.^L:/]W'_(*E
M^]@\_P#'QTSCCV(SSD.^S>)=P_XFVD[<<C^RY,_^E%;-%`&(+7Q1L(.L:.7Q
MP1I4N!QZ?:/6G-;>)>=NK:2/FR,Z7(?EST_X^.N._P"..U;-%`&1]G\1?-_Q
M-=+ZC;_Q+9...<_O^>?RZ<]:3[-XD\M!_:VE;QC>?[,DP>N<#S^.W<]#Z\;%
M%`&.UMXD_>[=6TH9_P!7G3)#M^O[_P";OTQ2BW\18.=5TLG'&--DX_\`(]:]
M%`&1]G\1>:Q_M72_+(^5?[-DR.O4^?SV[#_!&MO$A'RZMI0//73)#_#Q_P`M
M_P"]S]./>MBB@#(^S^(N/^)KI?W<'_B6R?>SU_U_3';\<]J0VWB3'&K:4.!U
MTR3KGG_EOZ<?7GGI6Q10!C-;>)<G;JVD@8XSI<AYV_\`7Q_>Y^G'O0EMXE#'
MS-6TEEP<!=+D!'7'_+P?;\CZ\;-%`&+]F\3[P?[7TC;L`(_LN3);N<_:.GM^
MM+]F\2X7&K:3D$[O^)7)SUQC_2..WKT/KQLT4`8GV7Q1A?\`B<:/D#YO^)5+
MSTZ?Z1QW_P`]7?9O$ODD?VMI/FXX;^RY-OY?:/ZULT4`8PMO$O?5M)Z?]`N3
MU/\`T\>F/R)[X""V\3^6`=7TC?GDC2Y,8X[?:/KW[CTYVJ*`,7[-XGRO_$WT
MC'\7_$KDYY/_`$\>FW\CZ\*;;Q+MXU;2=V[.?[+DQMXX_P"/CKUY]QQQSLT4
M`8GV7Q1AO^)QH^2/E_XE4O'7K_I'/;_/1QMO$N[C5M)"[B<'2Y,[><#_`(^.
MO3G]!6S10!CBV\28.=6TK.>/^)9)TP/^F_KG\QZ<J+?Q%ORVJZ64W$X&FR`[
M<],^?UQW_2M>B@#(^S^(L?\`(5TO.#_S#9/;'_+?Z_F/3E5M_$.#NU32R>V-
M.D'8_P#3?UQ6M10!D_9_$/R_\332^V?^)=)SSS_RW]./KS[4L5OKX(\W4],8
M;0#LTZ1?F[G_`%QXZ\?K6K10!DFW\0[`!JFE[NY_LZ3'?MY_T_(^O"&W\1=M
M5TOK_P!`V3T'_3?US^8';)UZ*`,EK?Q#A]NJ:6"<[,Z=(<<'&?W_`#SCTZ'U
MX<8->R,:EIN,\_\`$O?ID_\`3;TQ^1]>-2B@#):W\0G[NJ:6.3UTZ0\=O^6]
M(]OXB,;!-5TL/D[2VFR$#DXR//YXQW['UXUZ*`,OPUJ4VL^%=(U2X6-9[VRA
MN)%C!"AG0,0,DG&3ZFBJ7@,$?#OPUEB?^)5;<G_KDM%`%G1FSJOB$8C&-00?
M*V2?]%@^\.Q]O3![UL5D:.'&J>("V<&_0KE0./LT'Y\YZYK7H`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`YWP#M_X5WX:VKM']EVW&W'/EKG]:*=X$_Y)YX9
M_P"P5:_^BEHH`FT0H=6\2;65B-13<`N-I^RV_!X&>,'//7&>,#:K'T8N=5\0
MAFR!J"!1Z#[+!Q^>?SK8H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*:TB)]YU7@MR<<#J:=
M7E?QN\,Z++X$U?7I+"#^U8Q;HEXP.Y1YR+_(D=.]`'J88,,J01DC@^E+7DWB
M&;5O#/B_0/!7@=K#2;?4HII3YL&]4906)'7LI_&LC6_B7XO@\5:W:Z7&L]KH
MDMO"\$>F2R-<DG#DNN1'DAMN<9&`,G)H`]PHKQ;XA?$W7])F^TZ%-'!%;6EO
M<7-A/8R230M+T6X;&V$X9<+N))!Z9&8?#NN>)_MOQ#U]-4A:VLX99TM)5,C1
MD0M)"%)Z*.A'0D'IS0![?17B`\7?$=VTN!=4T4-JVC'5$D^QMF!50/@<X+'.
M.01R:FD^)GB2?X=^$+VV\E=7UNZFBDF2SDF54C=U^6-`26("\>QP.X`/::*\
M.7XA>.[F3P[I82WL=1O[^\LGGNM/D1)5C$>R15;!'+,"/5>1VJ#Q!XE\3:[\
M-7,VH017]CXC_LR[>&/"3[7&TC!^[DKD=\?F`>\45A:UJ]SX7\%7.JWB#4+J
MPM/,F$0\L3.H&XCKM!.3WP/6O-;;Q[XQT2;0GUZXTR^A\16,MQ:K:IL:T8(L
MBENS+A@,?7GCD`]GI"P498@#(')]:\B\+>+O&T][X0O=8N],GTW7S(A@@@*2
M1[8V93G_`(#D_E[C;^+=I:7]AX5L[V(2PS^);*)HR>&#;PP/'(*EO3Z]B`>A
MT5Y#JEMIGP_^*'AJW\,PPV::C!=?VE:"<I$T2(&21MV0@4JYW`9PI'3-4?"O
MC_Q?J/BRQTR]O+:XM=9MK@V5S%ITL$0E2,L"C2*"Z#'7!//(Z4`>V45YGX8\
M>:IXGU?PSIUN8$F6TGF\01_+OA>,B-5Q_`3)D[2/ND8-3>)].TWQ!\4].T;7
M[>.XTM=&GN(8I92%,_FH"<#'(3/)/<],4`>C4FX;@N1N(R!GG_/-<1\'KJZO
M/A1H,UY(\DHCD0,_78LKJ@^@4*!["H/&FBZ;K_Q!\(V.JV<=W:FVU!C%(.,@
M0X-`'?T5XS:7J^"=2^(EAX?FM[2PL192VXN?,>WM)YAM8`*'=MQ((`&,@+@"
MJFB_$CQ=+H_BR"ZQ-J6B0PWL+S67V9I(<AI0Z'I\G*G`]3VH`]QHKC?"WBV7
MQ7XJUIM.F@G\.V4<,4$Z+S+.PW/@]P`0#TY]>M>5^/)I6\8^*-9U7P\;^QT6
MYM$\]=4:&:UC94*>4%Z;F.XG&?F]B:`/H:BO`?%D&E^(]4^(FJWCLUWIEA92
MZ469E>W5HA)N4*?XFV\]1GWQ7L$^JRV/@-M5>YMHIX].\X3WA;RA)Y>07V\X
MW8SCGTYH`WJ*\9\%^/O$]]KNI6.I7\%]`NAR:G;SK8/;J6#*HV;PI>/D_,1S
M^!JII?Q%\9V-WX4U#6Y].N],UZ&9Q;6\)1X_+7KN/<Y4]QU''6@#V]Y$CV[W
M5=QVC)QD^E*6"C+$`9`Y/K7@UMK/B_69O`>L:WJFGSZ?J>L)-#;6\0C:!@K)
MC<>HP6R.3DXSTKJOC]_R2^;_`*^X?YF@#TV.6.9=T4B2*#C*L"*?7D.N:)I/
M@KXE^"_^$;C_`++:_EFBO8+=F"3PJH.7!./ER>W?.?E%5/#7COQ;J?CK3+.?
M4;>?3-8^TB!X=-D2WCV1NRF*614:3!"@Y'8].I`/::1F"J68@*!DDG@5Y-X.
M^(6N>(M4T30I7B75X+B\&NJ(/]5'$<)@?P[BRKGU!^E;GQ9T6]U7PC>SQ:W/
M86%G874UU;0@`W;"/,:ENRAE.1SN!Q[@`[UF"J68@*!DDG@4M>?>(+;PY>?#
MK0KWQ49&L;:*WG6TBDS]IE,>%CP/]83DX`Z]^,UPEOX7O]&T7PMX=U]-FGZK
MXB>>33O-)6.(H#'"Y''W@QV@X)/<T`>]JP90RD%2,@@\&EK@_AGBV;Q1I-LD
M@T[3]9EAM`SDK&I52T2@]`K$G_@5=Y0`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`'/>`P%^'?AH#/_`""K8\G/_+):*/`>[_A7?AK<`#_95MT.?^62T4`6M'+G
M5/$&Y"H%^FTD`;A]F@Y]^<CGTK7K&T48U;Q'\X;.HIP"#M_T6WXXZ>O/KZ8K
M9H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@"AKC,N@:DRDAA:RD$'D?*:\_P!*\#>'9M(TZ:>RU`O+;Q/(7U"\#R,4W$`"
M0`L1@_+P,-Z5W^O?\B]J?_7I+_Z`:YC09MN@6$2E%(M;7(=60`F)#T'(`R21
M\NW()4?>(!57X>^&5E\F:VN1(`03_:EV"QP<$)YQ8Y*.0.X'7CF,^`/#J`))
MI][YSAMB+J-X6.W!/RF7I@]0<9QR20*Z&6/*O&BQ(N^,"$M&P7YTPIC+;01\
MJ#![$@D[04EV0!,-(8VE+85799,*<$[1E<[3@E2&)`!+%#0!@?\`"O?#^^11
M873"/(8IJ5XQ5N#MV^;[C&<9SG@#YHD\#^%KC=]GAF9=_D[_`.U;K"2!S&0P
M\_M(KC'?;@$FNDVS/M42I(JHI5)I8V!8[QZGJ5P!VV\');#_`#'B:,M&TTJ.
M&`B5F=P<;<=ON*NYR=NXD9'-`$'PXD:7X>Z,[N9"83ARY<L-QP<GKQBNIKE/
MAJ4/P\TCRV+H$<!C('S^\;G<.#^'Y#I75T`%9?B+0+'Q1H5SHVI+(UG<[?,$
M;;6^5@PY^JBM2B@#&O/#&FWWBC3?$4ZR'4-.1XX"'PH#@J<COPQK,U?X;^&-
M<\10ZY>V&;Q"C.$;;'.4.5,BCA\>_4``\"NLHH`X[Q#\,/#'BC59]1U2VN'F
MGB6.01W+HK%00K$`\L,\9X]J0?#'P[]JNKDB\,EW8"PN-URQ$D8B$0)!ZL%`
MY]>>M=E10!SR^"]'CN=.GCCF1]/L#IUOME/RPE0N/<X`YJE+\-O#<W@VU\+2
M6\K:?:2&6W;S3YL;%RQ(?KU8CZ&NNHH`Y*U^&_AJQ;1&MK62)M&EDFMB)22T
MDF-[.3RQ.T=?H.,"K%QX$T.YT35-(EAF-KJ=Z]]<?OFW"9F#EE/\/*C@?U-=
M+10!3@TRUAT:+26C^T6:6XMBEQ^\\R,+MP^?O9'7/6N:T+X8>%O#LUW+I]G(
M'N(6MP99FD,,;9RL9;)4'<?\YJ'Q]X[F\--8Z1HEFFI>(]2?R[2TS\J],M)@
M@A>?4="<@`FN!\->-?B)H]MK.H:S%#XALM,U%[34((`$N;;;C,L850&CY/&/
MX<_*,F@#U2V\%Z/:6VA011R>7HC%K,,^[!*E3NR.>"?IUJ?Q1X6TSQAHYTO5
MHY'MO,63]V^U@PSCG\34GAOQ)IGBS1(=7TB?SK:7(((PR,.JL.Q'^!&00:UJ
M`.3\,_#?POX3@O(]+L&#7D?E3RRRL[LG/R@Y^4<]L9P,]!5/1OA7X:\-:E%J
MVCVTZZE;"3R'FNI&7#(5"$<_*,^F?K7<44`<+X`\%7OA_5-?UW5VL_[3UJX\
MUXK128X%RQVAB`226YXY('7K6KXN\":#XWAMH]:MG=K9BT4D3['`/49]#QQ[
M"NEHH`Y6X\$VK:WX4NK,QVUGX>CF2&$`LQ#HJ*N2>@`)).3D#D<FG^+_``%H
MGC<V9UA;@FS$@B\F4I]_;NSCK]T5T]%`'+6OP[\,6?A&Z\,6^G!-,NAF==Y+
MNW'SECSN!4$=A@8%4HOA]9>';'49O#%K$VIWELMLW]HW,ACE&[YB[#+Y(+<C
MV'`Z=M10!ROP[\'+X&\'V^CM-'-<[VFN98UVJ\C>G<@`*N3UVYP.@9K_`,-/
M"GB?7H=9U73!-=QJ%8B1E64#[N\`_-C^6`<@`5UM%`'*>(_ASX:\5:M;ZEJM
MB7N80%8HY43*""%D`^\.*Z'4M.M-7TVYTZ_@6>TN8S%+&Q(W*1SR.1]1R.U6
MJ*`.,T+X7>&?#MQY]A#=!S!);.7N&;S(WQE3[#:,#MUZU;C\`:%%_P`(]MCG
M_P"*?W_8?WIXW8SN_O?=%=110!Q&G_"CPIIFJ0:A;6LXEMKG[3;JT[,D!RQV
MHIX"Y;./]D>E;WB?PQIOB[1FTK55D:U9UD(C?:<KTYK9HH`Y3PO\./"OA!I)
M=*TQ!<2+L>XG8RR%>>`6^Z.<':!G`SG%4].^$WA'2M7M]5L[&:.[MIS-`WVA
MRL8.3L5<[0F6)QC/O7;T4`<+X+\(:MI?BKQ#XEUUM-6^U4QJL&G%S%&B#!)+
M`$L<`GCJ">^!V&I:?!JVE7FFW08V]W`\$H4X)5U*G![<&K5%`'*Z_P##W0?$
MFA:=HVH)<FRTX*(%2<@C:NT9/4\=S5&V^$GA&V\,77A\64LEE<S"=C+*6=)`
M``R-_"<#&1U!(.1Q7<44`97AWP[IOA;1X]+TJ$QVZ,SDLVYW9CDLS=6/N>P`
MZ"M6BB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.>\!L&^'?AHC/_`""K8<C'
M_+):*7P)_P`D\\,_]@JU_P#12T4`3Z+G^UO$>0`/[13&#U_T6WK9K%T0@ZMX
MDP^[&HID<?+_`*+;\?U_&MJ@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`,_7O^1>U/_KTE_P#0#7-^&PD>@:<P614-I;DL
MT84.ODPY()?'95)_`#()/2:]_P`B]J?_`%Z2_P#H!KFM#8_\(YH\K>:%&GP[
M054-*!&C%B>IPVYLKLR<<8P2`;2+/M>,SO/(B,KL8P!(P5@0V-Q`+9(&"!G&
M#P*C>-@=R[PPR&4Q!$8;20">=B\(<D9^3'4@4,R":22X"QNX=&VQAMO&&\L\
M@X)!)9>[$X`($4D?F?-Y:*L*-Y;,IS&NTC*G#%N'P<Y4<''&"`*Q40^9<1+O
M*N`'<C@8*ABN2`06ZG*E\`,#4T(S?)'Y7RJX.#YA,>""<C)V_,.!]W;@@G`%
M0K*H1]D4(,BJ65F;=U?[[9Y3D$=03OX]'*J32Q+)%^Y!"-&ZJ000B]0>5((Z
MLW#\YX``*OPT:5OA[I)F*&3;(#L(Q_K&_N\#Z#..F3U/5UR7PR3R_AWI*9<D
M+(&WXR&\Q\@X5>AR,X&<5UM`!1110`4444`%%%%`!1110`5Q/CSQQ_84<>C:
M(%OO%-^?+L[*-=YC[F20#[JA<GGKCT#$2^-/'MOX::+2M/@.I>)+T;;+3HP2
M23_&Y_A0<GDC.#V!(A\!>`AX;6;5]8G&H^)[\E[R^?DKG'[M/11CL!GZ```#
M_`O@1O#/GZIJ]_)JOB2]0"[OI&+8'!\M,\A`0/3.!P,`#-T.0:+\;_$>E$[(
MM8L(-2B4L,;D_=MMYZDY)XR=OH.?1J\L^*'_`!)O&_@3Q,`5CAOVL;B0$\+*
M`!Z]!YAP!DT`:?B'X<!;^X\1>#;IM%\1,,_NB%MKDYR1+'@@Y]<=<'KS4GA7
MXA/=WJ:#XNLO["\2?PP2#;#=<X!A?)#<\8R>>A/..\K&\3^%M)\7:-)IFKVP
MEA8$HXP'A;!`=#V89^GJ".*`-FBO+;.Z\2_"Z%K358KGQ!X80_N+Z`;KFRC&
M`%E7^)0.A'3![8`]%TG5]/UW3(=1TN[CNK.8926,\'U'J"/0\T`7:***`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`.?\"?\`)//#/_8*M?\`T4M%'@3_`))YX9_[!5K_
M`.BEHH`GT5LZMXC&7.W44'S$X'^BV_3/;Z=\]\ULUBZ)_P`A;Q)^\5O^)BG`
M/W?]%M^#Q^/?K^`VJ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`S]>_P"1>U/_`*])?_0#7,>'MBZ%8.(Y8KAK"$32QPE3
M*WEQ_,),<C;Y*EP2"!@XV';T^O?\B]J?_7I+_P"@&N;\-[9/#U@28E,=C;J!
M+EUB/DHVT,!Q][/#MUZ\8`!L%YOMUW(&`;D$J"P*#.$&WDO@,<#)7=G'.#`)
M6!:1X9&8*'=G1BV`P9.JX+`XPGRL,D@9/+HQ)(J%DDE9@N'==Q60YP64JI`5
M@.=HQE3@8.UK!$D:)<K&0P.U'*QKU4,#]TL1DG!&%_V@:`)6,L,(19XXR#*.
M)%49P/\`:Y8DDY.<$Y([U#'!Y/V41*Z;W,L0$.-C.=Q=D'?=(P;D,1N))^8U
M*9G:+>C_`.D!09(^CQAP@`;'4Y'KG@@;B,4KQQFX6!8W8;E1C&YC(QM4YW<@
M]P5/(&0<XR`4_AOM'@'3`@4(OFA0I!`42N!TXZ8X'`Z#%=57)?#)]_P]TL@.
M!F8`/C(Q,XQPS#'IR>*ZV@`HHHH`****`"BBB@`KB_'WCY?"*6EA863:EK^H
MDI96*'KVWOCD+G\\'D8)%KQQXQ7PIIT4=I;_`&[6[Y_)T^P4_-*Y[D#G:.I/
MT&1G-1^$?"%QI5U<:YK]Y'J7B2\`6:Z5<)#'VBB!Z(#[`GJ:`*_@KP)_8ES/
MK^N3+J/BF^^:ZO".(\@#RXQV4``9[X[#`';444`%<1\7-"AU[X9ZQ'(J>99P
MF]A=OX&B!8X]RNY?^!5V]1SP1W-O+;S+NBE0HZYQD$8(XH`H^'M537?#FFZL
MFW%Y;1SD+_"64$CJ>AR,9[5I5P'P=FD7P*=)G<O/HU]<:=(2I!RCY&1]&'3-
M=_0`5YM>_#J[\,W\^N?#VX2QNY"&N-)F/^B707/RCNC<G!SCG^$9->DT4`<=
MX*^(FG>,)+BQ:UN-+UFT`^TZ;>#;(O')7."R@\$X!'&0,C/8US?BOP3I/BV&
M-[E9+;4K?!M-1MFV3V[#D%6'.,D\'CGL>:Y.W\7ZY\/[^/2_';->:3(=MMXB
MBA(7ID),BYVMV![]>>2`#U"BHK:Y@O+:.YM9XY[>50\<L3AE=3T((X(J6@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`.?\"?\`)//#/_8*M?\`T4M%'@3_`))YX9_[!5K_`.BE
MHH`DT(,-8\3[D50=33:1_$/LEOR?QR/PK<K%T1)$U;Q(SC"OJ*,G7D?9;<=_
M<'I_C6U0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`&?KW_`"+VI_\`7I+_`.@&N8T"2WE\.Z8;>(310V<"2'<!YF^!6&"H
M!^[L4,>N-N.<UT^O?\B]J?\`UZ2_^@&N9T#CPYI<@?)DL[:0NL[.<;$"8+$D
M`L@`53ASEN2S4`;'E1M<202M<3XW,V`4=@!R#M&#D\_PC#*,'G*[2(Y('CDE
MP"!&'PK$,N2%Y*@$\#)X!_&O;(D,4=I;E%6%!%'%(5D9%"D;23EG;:A7.6Y1
ML[L$4YB29)0\*M$/M$A8*_E/DH3W"@8<Y&.5.<?-D`7S(TAA,SF5%!E)!(RW
M`!7^$=&^4DD97D$\M0&*[4M(D4,1CD=6R&1=NYMS'W([`!5QQVEE654B!5U8
MNX4!%!8>6.-N`&X'W3Z'@[01'F13YRV]P[0,7D02.[9),A`^8GG^%21A7"X`
M)%`%7X9)-%\/-*CG$8D02J1$,*,2N,`9./IGCVZ5UM<E\,I$E^'NF/')'(I,
MP#QA0IQ,X_AX_*NMH`****`"BBB@`KE/&OCFR\)6B0HIO-:NQML-.B&Z29R<
M+D#D+GO['&31XZ\<6W@NPM<6LE]J=_+Y%A91?>FDX'X`$J.,G+#CFL[P5X#F
MT[5+CQ5XEECO?%%[G>ZDF.U0_P#+.,'T``SZ<#C)8`9X"\"7>EW<WB;Q3<C4
M/%%X,M(W*VB$?ZN/MZY(P,<#C);OZ**`"BBB@`HHHH`\K\+D:)\>_%VE;5CA
MU6TAOXLD?.RX#8_X$\A_"O5*\Z\?+_97CSP+XABB`9K\Z5,ZJ,NLZX16Y!(4
M[F`Y`))^OHM`!1110`4R6*.XADAFC22*12CHZ@JRG@@@]0:?10!YA>>$/$'@
M;4EU7P)(;G2-V^[\/32':03EVA)/RMC&!ZC^(';77>%/&>E>+[:9[`S175J5
M6[M+B(QRV['.%8'Z'D9'%=#7'^,/!USJ]U:ZUH%^NE^(++=Y4^W]W<*=N8YL
M#++\H]<<\&@#L**\_P!&^(QLM1C\/>-[9=&UPG;%+R;6\'9HY.@SZ-C!('7@
M>@4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`'/>`\#X>^&P'+@:9;#<1C/[M?8<>E%-\`2"3X=^'"K(
MVW38$)1MPRL84\_444`6-#D1]7\2JJD%-216))Y/V2W/KZ$=,?UK;K"T$DZS
MXH!Q@:F@&&S_`,N=M^5;M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`9^O?\B]J?\`UZ2_^@&N<\.HLGAO3V,JEC9P`KRQ
MSY:^S?>^]CCA\E022>CU[_D7M3_Z])?_`$`US7AY-VA:8MP6,9T^V\O`4'R?
M+3Y6/(;YBQW#:?D`QQN8`UH]\DL\,H\PEG5I%R%+!&S@<D$Y(&0<!<?W2S4,
M7VAI-R[D&4"%L1')7Y>"2P)"D8`&YASAA3X$FPJSAC=-'NF`4(97QEAMW-MC
MX*\[OO##<9,<SE+=$,TQ+AE`DD61<;<[BI`R`0Q`&&.WTS@`:D>0L:%-\Q,8
ME1%!;!S@C!&SI]T_QG*\-1"V\6[8#.'+1QR!E"-GCJ3A<E5^4LO0@8Z3,(#$
M6+[5XB$2.<<;<KD)N)(QGJ?EP.]-C$<JPBYCDE5F\O#($20;BF=N/NX)P,G*
M[<YS0!5^&X8>`=,W;LGS3\RD'F5^H(!SZY`KJJY3X;8_X0#3"I)R9B27W'/F
MOGG`SS75T`%%%%`!7+^._%X\(Z(DMO;?;=5NY!;V%DI^::4^PY('?'L.,YIW
MC/QIIW@_2VDFE674IAMLK&/YI;B0\*`@.2,]3_7`.3X&\&7UI>S>*O%DD=UX
MHO<DA>8[&,@`11]LXX+#Z`GEF`'^"O!MY:WC>*?%4BW?BBZC"L<#99)C_51X
MXSR<D>X'&2>YHHH`****`"BBB@`HHHH`X?XNV#WOPUU2:!<W5CLO8'V[MC1N
M&+8_W=W7CFNMTN_CU72++48@!'=P).F#D890PY[]:??V<.HZ=<V-PNZ"YB:&
M08!RK`@]>.AKS_X(ZE=7?P_&G7QD^UZ1=RV$@D;<RA<,!G)X`;:.@`7`Z4`>
MD4444`%%%%`!1110!E:_X;T?Q/I[6.LV$-W"0=N]?FC)[HW53[BN$FN_%/PP
MVO?3S^(_"8?:;AE+7MBG)RY`Q(@'\1_08!]0HH`HZ3K.FZ]8)?:5?07EJ_22
M%PP!P#@^AY&0>1WJ]7GGB'P%?:9=G7OA]);Z5J@!,]CC;:WHP.&3[JMQP0!D
MGDCK6OX9\=VVMWTNCZE9R:-X@@SYNFW+@LPY^:-N!(N!G*_RY(!UE%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M<_X%_P"2?^'/^P9;\=A^[7@>H]#W'<]:*;X!`'P[\-839_Q*[;CC_GFO/'KU
M_&B@"30`O]M>*MIY.J)NY[_8[;V],>M;U86@E3K/B@+G(U-`V0.OV.V_ICK6
M[0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`&?KW_(O:G_UZ2_^@&N8\-(S>'M-!;SC-96S2#YFD#"!0S-M(ZJ$.,_Q#@=^
MGU[_`)%[4_\`KTE_]`-<UHC/-X?TMY%9O^)?;B(RH2RY5#C(Z-YFT$L$(V'^
MZ6H`T8G29?M3&11*%=U4)L!.6V;ACS-S,B@#&X*O4$[G,6MW58T6W_>KO&X@
MF,;B`221U"@L>S$#G&7I/]I(NXW))#,FY7#K&PW%"F1(K$#IC((^[\M$<LBV
MTBPI*HBA81JF[:5#CD`9P,9Q@`D?=SC@`8NY+'R<.LB(3Y\@5"K.!T*C8A(W
M<8X(4GKR.9E+0VB+;S<%'E9@2Q.",'.$W(J\?P_=X(J/:%S.(241W$3`;RC-
MEB05&X$Y4$JQ#'(.&/+HIU=$\JYDMH4^4C<L?E!%P2%;`VC!((&TCG#+C(!#
M\-V5O`.F,D7E(?-V+C'R^:^/S&#755ROPW9W\`Z8SG+'S<\,/^6K\?,2?SY]
MAT'54`%9'BC7!X9\,:CK36YN!9PF7R0^W?[9P<?7!K7KDOB<N[X:Z\N`<VV,
M$'!^8>G/Y4`9/@GP1=?VK)XR\6R0WOB*[`:%4R8K",@XCC![X."><=B<L6]#
MJEH[*VB6#)G8;:,KD`'&T>G'Y5=H`****`"BBB@`HHHH`****`"O./#-N/#O
MQD\4:/'$!:ZQ:QZS%B3.Q@VR7(/.6=B?08P/;T>N(W-_PO(J`X4^&\MP=I(N
M>/8D9/7IGCJ:`.WHHHH`****`"BN5\:7-S;W7A5;>[EMQ-KD4<HC<KYJ>5*2
MAQU!P#@^GKBNJH`****`"L#Q7X.T;QCIQM-5M0SH"8+A#ME@;!`96'IG.#P<
M#(-;]%`'`>`]1UNSU_6/!VM7J:F^E)'+#J+2`2R1R#Y5=>I88.6R>V>H)[^N
M$\/A$^,'C(%"DDEK8L,.`'`1@6*@\]@"02-IY`(SW=`!1110`4444`%%<K\.
M;NYOO!5M<7=Q+<3&YNU,DKEV(6YE4#)YX``'L!754`%%%%`!117*ZE>NGQ-T
M&R6XN1')I]Y(\*%A&S!HMK/SM.`7`X)!/N*`.JHHHH`****`"BBB@`HHHH`*
M***`"BBN7^(U]=:;\.M>N[*>2WN8[1MDL9PR$\9!['GJ.1VH`ZBBL/P9/-=>
M!?#UQ<2R33RZ9;/))(Q9G8Q*223R23WK<H`****`"BBB@`HHHH`****`"BBB
M@`HKF_"5Q<SS^(OM$\LJQZQ+'"))-VQ`D>%7T&<\'U/8BNDH`****`"BBB@`
MHHHH`****`"BBB@#GO`>[_A7?AK<03_95MT&/^62T4O@3_DGGAG_`+!5K_Z*
M6B@!^@@C6?%&7#`ZFF`#G;_H=MQ[>OXUNUB:'(7U?Q*I5`$U)%!4\G_1+<\\
M]>?;C'UK;H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@#/U[_D7M3_Z])?_`$`UR^B6Y7PYIY91MDL8/*("JQ_=I&<XR&P%
M)!R<[P,C`-=1KW_(O:G_`->DO_H!KD_#:QIH>E+YJB0V=KG8V3*3!&`).ZL"
MH8;<#!&>O(!OK.DN9%WGS@2J[5D;#+GJ'*L`#G'.0.,G%0RO(LV$1A:OAI<C
MGC[H5>!Q\BY#'GJN.:<ES%.[3"-)(9SO3Y0F>C!LY!&`$?)!()..<"EB#;S)
M"%,BG<B*6!8`!.F1\NX@G=G[IZX!4`9$9))%7='F-%<-$3(58CYB0<`)\@92
M3DD]!MYEM\QSVR&1EW2;R)&++&2-VQ3[;@HX`QZD8,4P.WE(DA"F3"R$ACMP
M<X)P,-%@#GAAT/,(MTB"QR//&AD+R2.RH54X8L7P,`E9&XZ9/"G&T`9\-`5^
M'NE`KMXDQTY'FO@\>HP<>_4]:ZRN4^&N_P#X5_I?F$F0B4N2`"6\U\Y`[YSZ
M?0=*ZN@`KD?BAS\,]?&%/^C=&.`>1U-==7D'QH^'[:W#'XAL;>2>>U4?:+=&
MP)5!7#$=<!=X)!S@C'0T`>IZ2,:-8C&,6\?&,8^4>P_D/I5RN7^'_AYO#7@^
MSLYF+7+KYLQ*X*LW.WGG`SCYB3[UU%`!1110`4444`%%%%`!1110`5P)8?\`
M#0*KCD>%B<\?\_0_PKO64,I5@"I&"".#7@D/P@F7XL>1<M+<:/Y9N1*20C0[
MS^X<!N3R$P-J[1G!Y6@#WRBD50JA5`"@8``X%+0`4444`<?XZ_X_O!W_`&,$
M7_HF:NPKYH^-W@_6M.\61:KISW<VFZC.AB1)&(ANSQM`R<%C\P/'+$#I7N_@
MGP\WA;PC8:5+,T]S&A>XF8Y+RL2S'/?!.`3S@"@#H****`"BBD90RE6`*D8(
M(X-`'!^'5/\`PN/QHR,646M@'P>%;8V`<-UP,\KGW'\7>U\]:/\`"*Z_X6?<
M6]PDW]E6LK2-.\TFZ:!B/+CR,9&T;<Y'.[J%VU]"*H50J@!0,``<"@!:***`
M"BBN"^+OAS4/$'@B9]'ENDU*Q;[1"EN[!I@!ADP.I(Y`ZDJ`.M`%WX8?\B%:
M_P#7W>_^E4M=A7C/[/>@7EMX<NM>OI)6%Z_EVB.Y(6-22[`9Q\S_`/H/O7LU
M`!1110`5RNH<_%#00SL`NEWQ0;."?,M\\_3G\!ZUU$B++&T;C*L"I'J#7RM/
M\,?%`^*Z>&UU.YRT9FCU+S&8I:;B-QY!SG@J#C<>N#F@#ZKHJII>GQ:5I5K8
M0L[1V\2QJSL69L#J2>235N@`HHHH`****`"BBB@`HHHH`*X_XJ?\DO\`$/\`
MUZ'^8KL*\N^.WARZUGP*VH6,LPFTLM+)$CD++`<>9D#@XP&YZ!6]:`.Q\"?\
MD\\,_P#8*M?_`$4M=!7F7P2\*W^@>#EOM5>8WFH!72*60MY$`'[M0,_*3DL0
M/500"M>FT`%%%%`!1110`4444`%%%%`!1161XGT*/Q)X=O-+:5X'F0^5.APT
M3_PL#V_#L2.]`&=X-4+/XF(G63=K<Q*@#]W\D8VG\L_\"KJ*^9OA+X+\0O\`
M$FY34IKN"VT6Y,EXOF,%FG_A'HV2`V>Z@>HKZ9H`**RM<\2Z-X:ABFUG48;*
M.9BL;2D@,1SBG:+XBT;Q%`\VCZG:WR(0'\B0,4SG&X=5S@XSUH`TZ***`"BB
MB@`HHHH`****`.?\"?\`)//#/_8*M?\`T4M%)X#8-\._#1&?^05;#D8_Y9+1
M0`OA[_D.>+/^PJG_`*16M=!7/^'O^0YXL_["J?\`I%:UT%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`9^O?\`(O:G_P!>
MDO\`Z`:YCP]+Y/AFQW72,L=E!'*L[C;;.84P)"V0&.\OR=S>8N1C%=/KW_(O
M:G_UZ2_^@&N>T%-WAS1T:ZD206%N`A1U*@1+P/E!P<C(/.01GC``-"7$TY0"
M2&:0K,8XROF@"0'G80Q4G`)R5_O%ESD+K$TK3KM"1`LC!B-HPV67&U5PA`Z8
M.[')-);QJ;1876T(94^:'_4*Y&4^\,%<LI`&3DKQWILSM$S;8IW;<7D6,JBG
M[S!F#D$`$*.`>2GS;=Y``TQ&SE2'<_FD*`3(W[TIUVQD_,1N8EMIR`F22HVR
MI#-#);A(;J2.$X7(()(]0<!NFT%LXPK9YR3S1`K(Q$<:J"(PFTL3N!!'W""!
M&1N((W?-C(%(D?F7D42H44HI%PGRC(PHQN!+<J6&1M("G)S0!2^%R+'\.=)5
M`0F)2N9"^097(.X]<]<].>.*Z^N4^&S%_`&F,Q!),Q.%9?\`EJ_9@#GUSS75
MT`%9OB'4GT7PUJNJQQK(]E9S7*HQP&*(6`/UQ6E7/^._^2>>)O\`L%77_HIJ
M`&1'QH8E,JZ$KD9*CSN/:G'_`(3''RG0@<CJ)C6]$`(8P&=@%'+_`'C]?>GT
M`<__`,5A_P!0/_R-2'_A,<C!T(#/.1-S70T4`<V@\;!CYDGA]AV"I,.P]SWS
M^8],F3_BL/\`J!_^1JZ"B@#G_P#BL/\`J!_^1J/^*P_Z@?\`Y&KH**`.?_XK
M#_J!_P#D:HW'C8_<D\/KS_$DQXQ]1WP?IQ[UTE%`'.$>--W#Z!MSTVS9[>_U
M_,>G*X\9[%&[0=W&3MFP?7C-=%10!SI'C/YMK:"./ERLQP??GGM3<>-O^>GA
M_P"_G[DWW?3KU]_TKI**`.=`\9_+N;03Q\V%F&3[<\=Z3'C3#?/H&2/E^6;C
MKUYY[>G?\.CHH`YIXO&,C@2?\(\\(.[8R3$[@05.<]B">GITQRCKXY)?9+X=
M7.=FZ*<XX&,_,,\Y/;CCCK7344`<TR^-^=LGAX<<9CF/?_>]/\?:@KXWV\2>
M'MV.OES8[?[7U_,>G/2T4`<VP\;%OED\/@<\%)CVX[^O^>]!'C;M)X?'(ZI-
MTSSW]./KSSTKI**`.:9?&Y4;)/#P;`R3',1[_P`7TIV/&F&^?0,D?+\LW'7K
MSSV]._X='10!SF/&FY?GT#;D[AMFR?3'/']?:D(\;<XD\/CTRDWO[_3\CZ\=
M)10!SF/&F%^?0,@?-\LW/3ISQW]>WXM=?&YW^7)X>7(^3=',<<=_F&><>GI[
MUTM%`',B+QG'&J0GP[&`3P(YL8YQ@`C'./K@],\)M\=;F_?>'-NT!1Y,^0W<
MGYN1[=O4UN:;J=GJ]D+RPF$UNSO&'"D`LCE&Z^C*1GOCCBK=`'-!?&^1F3P]
MC(S^[F_'^+_]7O1M\;^:I$GA[RP3N7RYLGKC!W<=NQZ'UXZ6B@#G`/&FP@OH
M!?'!"S8''IGU_P`]Z3R_&'VCS<>'_N;<[)MW7U]/:NDHH`YO'C;#?O/#^<G'
MR3<#''?UH(\;<XD\/CTRDWO[_3\CZ\=)10!S2KXWS\TGAXC(Z1S#TS_%_O?F
M/3D"^-]B@R>'B^T!B(YL%L')QNX&<<?K72T4`<UM\;[C^\\/;=V0/+FSM]/O
M=??]*0+XYYS+X=]OW4_H/]KUR?H0.V3TU%`'+R)X\.[RY_#:YSMW0SG'IGYA
MG]*=M\<[CB7P[MR,#RI\XR,_Q>F1]>?:NFHH`YDKXY\PD2^'0F.`8I\YY[[O
MIV['UX>H\:8&Y]`)W$G"S#Y><#KUZ<]\'@9XZ.B@#G_^*P_Z@?\`Y&IDJ^,7
M0J/[`P000ZS,#QZ9KHZ*`.:5?&_F`M)X>*8Y`CF!Z>N[U]J4#QM@YD\/YQQ\
MDW7`]_7/YCTYZ2B@#G_^*P_Z@?\`Y&IN/&?EXW:#OQUVS8S],_UKHJ*`.=QX
MSW?>T'&>FV;ICZ^O^>]-(\;;EQ)X?V\Y&R;)Y&._ID?4@\8P>DHH`YIE\;D'
M9)X>!SQF.8^O^U]/R/KP%/&Y;"W'AX`D?,8)CCYO3?SQQU&3SQTKI:*`.:9?
M&Y9MDGAX*1\H,<Q(^OS<]_2CRO&^_'VSP\$)!S]EF)7DY&/,^;C`SQW..U=+
M10!SJQ^,S)#ON=!1,CS<6\S$COM^<>YY^GO49C\<\8N_#O/7_1I_EX/_`$TY
MY(].%/\`>^7IJ*`,K1XM9CDN3JS:8=[!D:RB="W&,MN)YP`/_P!5:M%%`'E?
MQAGAM=9\!7%Q+'#!%KL3R22,%5%#*223P`!WK'O-7TIOBKJ.O^&I-^GZ;X<F
M.HWNF(LD:OEV7C`5WX!&20=O8*37KVI:+I6M1QQZKIEG?I&=R+=0+*%/J`P.
M*++1=*TRTDM+#3+.TMI,[X8(%1&SP<J!@T`>&>`]>UG6_$>IZ);^(-1,.K:%
M));RWNIQW4D5P>`Z^4?W&-Y/E_>&T9[;7Z3XQ\5:GIEY+'J,]A/X5T9K:_:Z
M1Y@;QI"F^1$#%]J1EMQ!"MDD8SGV-?"ND65M-_8NFZ=I5Z8I%@N[:QB#0LRX
MW`8P>B\'@X`-5O"7A)?#-G?"YOI-3OM1N&N;V[EC">:Y`!`4<*OH.V<4`>=_
M"?Q-*GB>70+_`%K4-1N+BT$Z&74HM0A)7[S+*N&CSS^[(^O8GVBL[3=`T;1F
M=M+TBPL6<88VMLD18>^T#-:-`!1110`4444`<_X$_P"2>>&?^P5:_P#HI:*/
M`G_)//#/_8*M?_12T4`'A[_D.>+/^PJG_I%:UT%8.@.6UKQ4"%PFJ(!A0/\`
MESMCSZ]>I^G:MZ@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`,_7O\`D7M3_P"O27_T`US.@2E/#FCQJ8XY(;2WC\Y2/+?$
M:%F/!*\N<9XY#<@\]-KW_(O:G_UZ2_\`H!KF/#303:!HL*&-E6QM9&2,;Y"O
MEQ_-V9E(PF06X7!R20`#8#+!(,H8=W[J.,LL)B!PJJ#T)&>QQ@#`8@$PS7=G
M:1!IY(K:,!06DG7=O+)L"L?EZ+WZX'3FG^5.$^SSEFGEA/FE4R'95Q(5'RL`
M<M@J0`6!Q\W/SAXJTVY\5Q>-_%&I7TD=UHEXEM'8``JBF41C//'\1X4`L&-`
M'T8TQ>(F!A&JQK,N[#9SGYP592>-R\G#``@G!!FN97BFFN%M[B9EC618EQO+
M*H/S8R03\JXQZGGMXSX2N+JQ^,NJ:19WDT]O?6IDF@6/R_(?:I"CEB"HPNX'
M/J002/7K-8X9`P,A!NAO+H<([R%BI#DE3N?L1PPQQL6@"+X:)&GP_P!-6%8U
MA!F\KR_N[/.?:1R<Y&.>_:NLKE/AM";?P#IT;!P0TY.]V8\S.>2W/ZGZGJ>K
MH`*Y_P`=_P#)//$W_8*NO_135T%<_P"._P#DGGB;_L%77_HIJ`-R`YMXCY?E
MY0'9C[O'3\*DJ&T*M90%'WJ8U(;=NR,=<Y.?KD_4U-0`4444`%%%%`!1110`
M4444`%8NDOK#>(-?%^&_LY)X1IV54?+Y*%\8Y/SEN3]!TK:K!T>VU:'Q-XDF
MO6E-A//`;`/-N4*(5#[5S\OSALC`R>:`-ZBBB@`HHHH`P/&>ER:SX8FL(;J&
MVDEGMRLDSE5RL\;;<CNV-H'<D"M^L;Q3H;>)-`ETM;@6YDF@D\PINQY<J28Q
MD==F/QK9H`****`"BBB@##TG1KFP\2>(=2EFC>'4I8'A52=R!(50@\8Z@GCU
MK<K$TG1KC3_$7B#4))4:'4IH98D#$E=D*QG(Q@9VCIFMN@`HHHH`****`,'P
M<^D/X<C_`+#65=/%Q<;!*#D-YSE^O4;]V/:MZL3PD^D2>'86T*)XM/\`.GV*
MY;._SG\S[Q)Y?>:VZ`"BBB@`K!OK%9/'&C7QN8%,-E=QB!I<2/N:`[E3'(&T
MACQC<O6MZL6\T'[7XOTK6VE55L+:XB"!?F9I#'@D^@"-QZF@#:HHHH`****`
M"BBB@`HHHH`****`"JNI0?:M*O+?>L?FP.F]NBY4C)JU5;4;9KW3+NU5@K3P
MO&&/0;@1G]:`*GAK3WTCPKH^FR21RO9V4-NTD9RK%$"DCV.*U*SM`TQM%\.:
M7I32B5K*TBMC(%P'V(%SCMG%:-`!1110`4444`%%%%`!1110`4444`9&A:3/
MI4FK--+'(MY?O=1[%P55E48;U.5//IBM>LC0M&;2)-6=IA)]OOWO`!GY`RJN
MWG_=_6M>@`HHHH`****`"BBB@`HHHH`****`.>\![O\`A7?AK<`#_95MT.?^
M62T4G@$;?AYX;&U5QIEOC;T/[M>?QZ_C10!)H'_(:\5<J?\`B:)T&,?Z';=?
M6MZN?\/?\ASQ9_V%4_\`2*UKH*`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`S]>_Y%[4_^O27_`-`-<QX<:.Y\/:7$8]K&
MRMU"K&4#LT*'=O90VT*=N<$'8%)W94=/KW_(O:G_`->DO_H!KE]"GB7PSI)C
MC.5L+<D2H8UE'E(0Q'.>-B$D#H<9P%H`UXW$PEF5D\N<EE0NNUBRX`SP,DNJ
M[D)&>,YYKQR\\,^`_B3XOU%+2[OM/UB*5_M2#:HD*`AGVN>Y')#9SU'.ZO7'
M$[6:RQ,+@H`'97=E*+ELAB<D$<X;(^;JPP#X-I7P\N?$6J>,-1L[NXTK5=/U
M-VT]N8QGS&R&8<(?N;2&X.[J!D`'8^$;/P7X+\7W7AW2K;4;C7Y+,>;=WI38
M$90[*JH=RMR/E*[N._?TJX9D$CR%RL<?RNJ2?*I3($:IR[8`XC)+'(^7(%>#
M?#NZU?4OC5-+XA66+4VMO+N<QX;Y41<D'CE0">W.0,<5[O*CI%*T[;D,6Z>0
MN,#?\S*-^%/50`V/E'(PH#`!\/&5O!-F5#`>;<#YO43R9_6NHKF/A[N_X0JS
MWQA#YMQP,]//DP>?4<_C73T`%<_X[_Y)YXF_[!5U_P"BFKH*Y_QW_P`D\\3?
M]@JZ_P#134`;L6[R8]RE6VC*EMQ'MGO]:?45L`+6$+C:$7&.G3ZG^9J6@`HH
MHH`****`"BBB@`HHHH`*Q]+LM3M]=UVXO+GS+&ZGB>RB\PMY2B%%<8/"Y<$X
M'N>];%8NDV6IV_B#7[J\N&DLKF>$V41E+>6JPHKX7HN7#'`Z]:`-JBBB@`HH
MHH`Q/%FE0:UX>DL+F]2RA>>W<S.!@;)D<+R1RQ4*/=N_2MNLCQ-IVGZMH,MG
MJMT;6S:6%VE$BIADE5U&6!'+*H]\XK7H`****`"BBB@#$TC2([+Q#X@U&.]2
M=M0GA:2%5`,#)"B;2<G)(`;H.&'UK;K$TC3+6T\0^(+Z"^2>>]GA:>%2,V[+
M"BA3@YR5`;G'#"MN@`HHHH`****`.>\$3Z=<^%8)=*LWL[,SW(6%W+D,)Y`Y
MR2>K!C[9Q70U@^#;ZRU+PS#=:?8K8V[SW`^SJ1A6$SAR,>K!C^-;U`!1110`
M5A7^FV4WC/1=2EO88KNVMKJ.&V;`></Y>YASDA0O/!^_V[[M9%WIUA-XJTO4
M)KD+?V]M<1V]N7'SJQCWL%//R[5&1_>Y[4`:]%%%`!1110`4444`%%%%`!11
M10`55U*%+C2KR"2984D@=&E;H@*D$GZ=:M5!>P1W5A<6\S%(I8F1V!`(4C!.
M30!2\-6<.G^%=(LK>[CO(+>RABCN8\;9E5``XP2,$#/4]>M:E9^A6MG8^'M,
ML].N/M%C!:116\V\/YD:H`K;EX.0`<C@UH4`%%%%`!1110`4444`%%%%`!11
M10!CZ%I<.ESZP8KJ.=[O4'N90J@&)F1/D;D\[0IR<<$<5L5D:'I]E8S:NUE=
M).;J_>><*RDQRE$#(<=QM!YYP16O0`4444`%%%%`!1110`4444`%%%%`'.^`
MF=OA[X=,BLKC3H`0R;<80#I@?R_/K12^`V#?#WPVRD'.F6Q.#QGRUR/;GMVZ
M44`+X>_Y#GBS_L*I_P"D5K705S_A[_D.>+/^PJG_`*16M=!0`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`&?KW_`"+VI_\`
M7I+_`.@&N8T-KE=!TK>7AE^R6[,^=NUC&N<L4YZ@#.1^Z7))W+73Z]_R+VI_
M]>DO_H!KF-$C2'PYHJ31OL338"A1"X&V-"-NTG:"50`97<R'`SC(!A>+M&\5
MWMYHTF@:M):"TEV:BUS(B/+O*_,5B0#.W=N(P,#(Z9KD]:T?XFC5;J2'QCI\
M%JLTDEK%+>*CHFXJN$V?*=I/`'0$=>#ZY#<2/8B:W%RL3(SC"X9RV[YN.&.2
M[G8/X>`05)\(LO!-AXR\<>+7\5:\]IJ5M=GR[8RB,S1'(1D>7)*;0F.#\NWD
M;@:`.O\`!>G^-;?Q)$FN>*M*U6T$+J;&"]\R09!*,%4`XW+V/\)]*]!8`)M'
MF2!D"^9)&'+'NS*,[@RM]WT954*<UPOA7X8^&O#>N->Z;KK7-P89(A#-=0E2
MAPK$A>2""!CM^5>@&Y,K.;>64RG9'YB-G!!^5=X!!`:3;DAONMP2&H`A^&[!
M_`MDRN74S7)#$=?](D_3TKJZY7X<SFX\#V;GM/<IW_AN)%[D^G_ZNE=50`5S
M_CO_`))YXF_[!5U_Z*:N@KG_`!W_`,D\\3?]@JZ_]%-0!N0$M;Q,49"4!*L2
M2..A)J2HX,_9XLLK'8,E22#QV)ZU)0`4444`%%%%`!1110`4444`%8VE:3=6
M.O:]?37(DM]0GBE@B!/[K;"D;9!X!)7/'M6S6)I&ARZ=XA\0:G),CKJD\,D:
M*#E%2%(^3ZDJ?PQ^`!MT444`%%%%`&!XSM]-NO#$T6KWCVEEY]NSS(N2"L\9
M4`8/5@J].];]8GBVWTJ[\.S0ZU<FVL&F@+S"0)M83(4Y/`&\+G-;=`!1110`
M4444`<]HEI90^*O$]Q;WXGN+B>W-S;[,&W80(%&>^5PWXUT-8^F66EV_B#7+
MBSNUEOKF2%[Z$2JQA81A4RHY7*@'GKU%;%`!1110`4444`8'@R^L]2\,QW5A
M8)86[W-R%MT.0"L\BLW08W$%L=MV*WZPO"&H_P!K>'5O/LEO:L]U=*T=N04W
M+<2*S`C@EB"Q/<L36[0`4444`%<[J5K8OX\T&ZEO5BOH[2\6"V\G)G4F+<=_
M\.WCCJ=Q]#715A7L6DOXUTB2XN'758[2Z^RP[AM9"8O,.,?>'RXP1QNZXX`-
MVBBB@`HHHH`****`"BBB@`HHHH`*J:HL+Z1>I<2&.%H'$C@9*KM.3CV%6ZJZ
MEY']E7GVK=]G\A_-V]=FTYQ^%`%/PO%:0>$=%AT^X:YLH["!;>=E*F2,1J%8
M@\C(P<>]:U9?AI;%/"NCKI;R/IZV4(M7D^\T6P;">!SMQVK4H`****`"BBB@
M`HHHH`****`"BBB@##\.06$,NMFQN6G:34Y'N,JP\N7:F5YZX`7D<<^N:W*R
MM%ATV&;51IUR9F:^9[H>9O$<Q1"5'IQM./4FM6@`HHHH`****`"BBB@`HHHH
M`****`.=\`J5^'?AH$Y_XE=L>_>-?6BF_#Z99_ASX;=0P`TRW3YACE8PI_44
M4`2>'O\`D.>+/^PJG_I%:UT%<_X>_P"0YXL_["J?^D5K704`%%%%`&5K'B+3
M="EM8KY[CS;HL(8[>TEG9]N,\1JQ_B'YUG#Q[H3=%U<X&[C1;SISS_JO]EOR
M/I4/B$J/&WAXD2;OLE_L*RA-IVQ\G*GMGG(QUYJ:+SFF%P7#1A0D;>8#(&!8
MMN?!W*-R[1CC+\D$4`(OC_07*!1JS%P"N-%O#NSTQ^ZYSF@>/]!8X4:L3@GC
M1;SM_P!LJ:IO9$&90USP08QDLO`0_,V,D!G`;H77/0Y1+DI#YC2%IF'EJZ@$
MJ7VH&^8Y^^Y_B7A<'D'(`'XB>'%"EGU,;L[<Z/><X.TX_=>O'UI\GQ`T"(D2
M?VLA#!3NT6\&"<8'^JZ\C\Q3C/.93,UQ)]C3"R1,3OR0NTE@3CA6R,8)E'(*
M9,"RR@-';7($[2E(G#`JO/"L%P2<DGKCY@>A"@`4?$;PVR[EEU,C!.1H]WV7
M=_SR].?IS1_PL;PWY@C\W4]Y.`O]CW>>F>GE>AHGDG8$1W4K0;T39(&WXWK@
M8,@R=GRX;DL22&^X71S,85>YDWKR'1"8U7*G!`8L>1O&<C@CY2<&@"(?$SPL
M4+BYU`J.K?V3=X[?],O<?F*D_P"%B>'//\C?J?G?-^[_`+'O-W&<\>5VP<_0
MU*][+$8LO<@+&21YVYV.<CMC`^8'(S\OH/FD2XDQ(8YIFA4.8G\PL-NS`)YR
MX^7(.0?FZG[Q`*G_``LCPSA3YVI88A0?[(N^21D#_5>E2'X@^'U"ECJH#$JI
M.C7G)`R0/W7I2^9=QW`)NT`!5YE`92XQL(SN.WYV5LXX"%><Y#`\R646R4!]
M[C./+"':OR\,,989QGID<M\U`"GXA^'E3>S:H$VA]QT:\QM(SG_5=,<T'XA^
M'ALRVJ#>`4_XDUY\V1D8_=<\<TZY=MKK!/\`9KA@S>?<@2")]I^8@[<A3\_7
M&U5`P&&'B:>2:8R,94=#Y<:DA_,+!\*Q/!51]T#G83@=*`&'Q_H(9U(U8,A`
M8'1;S*YSC/[KCH?R-._X3O1,J-FL98X4?V)><].G[KW'YT2D/@PH=C90N0I9
MD+#."<'(4M]X'_6YSU%(V)&9=/"V]S(^X-*AE16+!LE1M+#<6;AAD#()&!0`
M@\?Z">G]K')Q_P`@6\]"?^>7H"?P-)_PL+PX'C62;4(A(X17FTJZC3)('+-&
M`!EEY)P,BIANDBEC*;4VJ(PY)X!3*8]0<C/OR&P<\WXSDQX<9?,=]US:L&:8
M@`"Z@(SDKN/.=WR[<*O\7S`'HU%%%`&?KW_(O:G_`->DO_H!KD=`,<&A:7LD
MCDDDM[990AVLA-M$/O,`=H`WY'/)^7Y3CKM>_P"1>U/_`*])?_0#7+:'+$OA
MC1_*#+OTNW+2;@0P"(<GY0&+*%7=T[8.W%`&E)%;$OLAAC@\Q=A=`.BY7*D9
MX.V/&-PZ`#`->%:;X>\':OXU\40^+M95;U=3=(I3?QPQ"'+'?N8\G@*%!8J2
M`5P&(]WN)1'-<!I$C`D<&3Y2!NW*!MR/[P)Y.=N``3@>'>.+GX8Z+K5Y!/X>
MFU'6)&DEN&@O)5CBD9MX5LL,L,X8+P,=CD``ZWPEX=\!Z+JJ7OA[5$N=3:%M
MD%MJ<;R*#@E3SV##IT",23TKTH[KFZB02`J=JNP=U/`PQW'!Y)&""2<J>AR/
M*?AFOP]U"Z^W>'+&XLM6MD/G)++(TD<1"JS@;BK`_-\PQMS@C&`WI*NDEN)`
M<*"?,83E(\`L,`_>0;E!R-VT(P!P%)`$^&G_`"(=GF02'S[K+#.,_:),CGTZ
M8]NIZUUM<C\,]W_""6FYLG[3><YSQ]IEQ^E==0`5GZ[IG]M^'M3TGSO)^W6D
MMMYNW=LWH5W8R,XSG&16A7+>*_B#H'@VXM[?59IOM%PC2)%!"9&"+U8XZ#@_
MD?0T`=0H"J%&<`8Y.3^=+5;3]0M-5T^WO[&=)[6X0212IT93_GI6?X:\4Z5X
MMT^:^TB=Y889VMY-\90JZX)'/L0<CU]<T`;-%%%`!1110`4444`%%%4=9U:U
MT+1;S5;UF%M:1-+)M&20!T`]3T%`%ZLVPT2VT_5]5U*)Y6FU.2.297(*J4C$
M8V\9'"C.2>:YC2OB=8WD.I/J>CZMHQL+0WKB]@VAX>""K`X+<K\O!R<#.#BW
MX6\>P>)=5DTV32-2TNY^S"\A2^C"F:`M@.N"?5<CL3CM0!UU%<EJ7Q!TFR\1
MZ'HUL\=_)JLTD/F6TZ,(&3;][![[OTKK:`"BBN<\4>.-$\(&W34Y)FGN`S1P
M6\)E?:O5B!T4>I_H:`-;5M*M-:TZ2PO4+V[LC$`X.58.I_`J#5VN4UCXC>&=
M$T;3=4N+UY;?4UWV8@B9WE4`$D+C(P",YQC..M;FBZS8^(-&M=6TV836ETF^
M-Q^1!]"""".Q!H`OT5EZ#K]CXDL)+S3VD:&.=X&+IM.Y#@_K6I0`45B^)O%>
MC>$-+.H:S=K!$3M11R\A]%7J?Z54USQUHOA[3].NK][C=J*[K:WAA,DKC:&/
MRKGH",_6@#2L-%@T_6=6U*.1S)J;Q22J>BE(P@Q^"BM.N&NOBYX1M=-L+W[9
M<3?;@YBAAMG:4;,A]RX^7:1W^HR.:[#3]0M-6TZWU"PG6>UN(Q)%*O1E/3_]
M1H`LT5DZ#XBT_P`1QWTFGF4BQO)+*82QE")4QN&#SW%:U`!16'JGB_0]'U>P
MTF[OH_[0OIU@AMT.YP3T+`?='3D^HJAXD^(6A^%M7BTJ^6]EO)(!<".UMFE(
MC+%03CW!H`ZE(TC7;&BJ"2Q"C').2?Q))IU<=K7Q-\.Z`UDE^;U);NT%[Y2V
MCL\,)_BD`'R]P?3!KHKG6;&VT";7#,)-/BM6N_-B^8-$%W[E]<CD4`7Z*JZ;
MJ$&K:59ZE:EC;W<"3Q%A@E74,,CMP:-2U*RT?3I]0U&YCMK2W3?++(<!1_CV
M`ZDG`H`M50GT>TN-<L]7D#FZLX988?F^4"0H6./7Y`,^A/MC'7Q]H+>"8_%O
MGRKI<A*H6C_>.P<IM"]2=P/%167Q'\,W>D:GJ;W<MI#I947J75N\<D.[A<IC
M/S'IC.:`.LHKG_"WC/1_&$%S)I<DNZU=5FBGC,<B[AE25/.",X/?!JY8Z_8Z
MCKNK:-;M(;S2O)^TADPH\U2R8/?@4`:E%%%`!1110`4444`%%%%`!45S;QW=
MK-;2Y,<R-&^#@X(P:Y*\^*'ABP\1?V)/<SB<7*VC3"!C"DS8^0R=`1GGT[]#
M6OX@\6:/X8?3X]4N3'+J$XM[:-$+L[$@$X'.!D9/N/44`:&EZ=!I&D66F6Q<
MV]G`EO$7.6VHH49/K@5;KD]=^(_AOPYK7]EZC=2I,H1IG2!GC@#G"^8P&%S6
MOX@\0Z?X9\/W&MZ@[_8H`A=HEWGYF"C`[\L*`-6BHK:XCN[6&YBR8YD61,C!
MP1D5+0`4444`%%%%`!1110`45RWBGX@Z!X0N4MM3EN&N&A^T-';P-(4BW;=[
M8X5=W&3WHUOXA>'M"@TZ6>XFN3J,+7%K'9P-,[PA=YDP!PH7G)[9]#@`VM,T
MF#2GOF@>1C>W374F\@X=@H(&`./E'K5^N5U/XA^'],TG2M1::>XBU5#)9QVL
M+222*%W,=HY&T8SZ=ZV]%UFP\0Z/;:KIDXGL[E=T<@!&<$@C!Y!!!!^E`%^B
MLSP_KUCXFT2WU?36=K2<N$+K@G:Q0_JIK3H`****`"BBB@`HHHH`****`.:^
M'N/^%<^',2&0?V="`QZXV#`_#I12?#L`?#OP^`&!%E&&W`@EL?,>0#R<GGUH
MH`F\/?\`(<\6?]A5/_2*UKH*Y_P]_P`ASQ9_V%4_](K6N@H`****`.(\5R1K
M\1/!R,9&EEBU&.*-'P&/DJ?F!X(PI'((R1Q5P$W-M<P?:BL,:XD\L8\IE))9
MI>NXC&02"`.>N:K^*VF3QUX-$;A%E>^B=LX.#;LPP><<H#GKP/>KDA9(8B8)
M9(UBX5YE'EDC[IR002&C7ABH)Y``R0",7,?FG[->0?ZYWC,TA9?.9F`1N2V0
MP*%<D#8VT+L`5&<QO]D8@231,%ADDVRR#!&<<L&QN.['S'C.,&IYFC\P)<-Y
M\(8>;*7#)U^<')S@?O<Y&T+D=1MJ"49D\N>+S$F=4\PJ-OF94AB/O?ZUD7IV
M.1@"@#*\4I>W.@7PL)X(]3:%S`X*C:W/&3DIS&W`P/E??S7EG@F"ZT?QKI=G
MJ"^)=*FOT>.>WU(F:#49`N,(X";<?)AOFVY'(QSZSJ^D66N6DNE:C;R307D+
MH[#:'&PKC#'D]GX!^Z,[6"HV%HG@""VU:PU"^UG5M072HRNGPZA(GE1G:`IR
MA).WYP.!S&3D+M+`&1IGCO6_$.IMJ>BZ$U]H_P!O,#2QS+%._P`B^8_E,678
M`PX;/WARI+&JVH?$;6X]3UV9=&@FT?1B8;V=;I5RDA7R@$!7.2N%8!B`1AA\
MV[=NOAIHMUJ]Q<)J&J6VF7%^M\=.A8)%YXS\Q!&]0#]X`?+NX(`.V]%X.TJ6
M#Q%#=7!>WUR<SSQNX4(0N-T>W=U+$Y."IV`KS@@'%:+\6//6^BU.U4&VL'NH
M9;:Y\]B"5+(6QD,#T)Y4ECD#&;'A;XE/XFUS['=V$"W%[;M-`+*5IBKARV#&
M3G</O9&2%!Q@<#<T[X;Z?86VH1WUQJNIM<6ILDMYGB4[-J@F-!N7<&&"QP<Q
MLPS]YK?A_P"'^F>&;FY5+W5[^*..2%8)9%5(X\,3_JRNYOE4')`Q)@@$G`!R
M>G?%'4;N30YM2T6SM]/UDS6UO<0W*AD<,JLQ4`;2`VWG!P^0><%NA>+;_1O`
M/@R'2+,2S:E-=Q1K>W*C:5D.9"^T9`W=\@;%XR*ZF#X>:;:6WA.`7U]GP[)+
M/;@;0\SO()"A'W000<;<@A6R0!3[7X?Z=IFDZ'!%<W$T>@2W,\4C,H,SN>4*
M`XP<I@YXR<[3P0#F5^*C0>%[C49M+M1J4%\-,^S23;HY/E4'<SG[NU6R>WMN
M)/3>$_$WB#5?$VKZ!K>F6EE>Z;!"TRP(LV[?MQT'0!@V!GD#T(.#XM^'T<?A
MC5[?2HIM7GU#53?-"LRQ-$P9E(0M]X@EU^Z<C)XR,W?AEX=UJ'6-:UO7K:_M
MYM12",+JD_F3.5QN8X4?+N,:J"!@$C^&@#T!;:Z^T?:@C[V7"Q&)MBMA<@`@
M@9&U>W^K//S&HGBCO$:VEF:XM)%\MGCF;<R^5RH*L6+^6QX4\EBPP>:E"*T?
MF22K'.R%0DGWHBH#\[5SN&XGK@`\9R<O:+[-<LX0JD2^:S-A4ZEPK'&1\W5B
MO0<G=G(`P^9,BS>8$BF"$RHA`ES\H"GC!9F5@PPWRCVQRGC2.!_!\UNMP\<M
MS+9-'*TI4F-;B%`Z$G((\U/G4=0,_>&[J8AY\0=XUA96+@,H9E`(4*=O1N>H
MW8#,"!D5A>+RO_"-2L]PD8,]L[)",,P2YC&X``YY#88D8R,X)!0`U?\`A7EK
M_P!#'XK_`/!W/_C1_P`*\M?^AC\5_P#@[G_QKL**`.!UKX?VT>A:A(OB/Q22
MMM(0&UF9APIZ@G!^AJ3P]>)+X>T7%W%*RZ?:>8$=,H_EQD*"JYZM&V,?QKQA
M@*ZG7P3X;U0!BI-I+R.H^0UR/A6Y7_A&-$@MXIT"6%M"9GF7G%M$V5P2>CJ`
M%'WMQQCD@&I)*L44+WKW"LWDNGFR&'=*VP#Y`1]Z0QJ5!(RS`\.P;QOP[XFT
MCX>^+_%<.OF[BU.?4#-;WL47$L>YP<HIQ@AR=N,!L9PR#':^.-7\::=]C_X1
M&Q-XDAE-TT]LA(/\)8$C#$%\C`XQD#D#S"[U+QSXOU6YMI_!NFZC>:=B*4?8
M]QM_EP$+;_;."3@@^]`&WX.U&V\5_&^[UO1[8PZ;!9MYP>-1Y[$",9+9^9I&
M#98EFV^^![+/<02/<-<R(D?E[;N=V,#(BK\[;LJ8PN=V\8(RG;;7E7PV\1^)
M1XH;P?J&D:?HUM;PF:6"*U,3*QP`Y`/S9W#GD<+T%>K0R%Y4<!X-J^:H,>[8
M<<C&=S#<``%)R"H4D9V@')^!/!L&J^%(KU];\06S2W=WF*TU26&)<7,H^5%.
M!TR?<DUTG_"O+7_H8_%?_@[G_P`:=\,\_P#""6F=N?M-Y]W'_/S+Z5UU`!7D
M?C?7-.\)_%E=6UU)%TV^\-26,3A6*R2B;>4RH)'!`SCC<*]<J&YM+:\C$=U;
MQ3H#N"RH&`/K@_6@#YON[:&W7P!I7C>YN['P[_8[S*R93]^69L-M!/"^3]"1
MTR:[_P#9[F:7X<3;PF5U&4;ALRV50Y;:`<\_Q9.`.<;0/4YH(;A`D\4<J@A@
MKJ&&1T/-+%%'!&(X8TC0$D*B@#DY/'UH`?1110`4444`%%%%`!7,_$+1;CQ#
MX`UK2[2/S+F:W)BCW;=SJ0P&?<KWX]>*Z:B@#YV\/>#]?NK#Q7:Z;I^NVNEW
M>B[!#JZ^6\U]\C$JK8ZXD^;IEN>U;ZZ;X@\8WC7%EI6J:'+8^&9-.$E]!Y)E
MN6XV*2?F3`/S#ID'KBO:J8LL;R21I(C/&0'4,"5R,C([<4`?._AW0+H^*/A\
MUKX+U/39=/#)JEW)8F-)''\3-CGN=Q/.X`=*^BZ**`"O)/BO=P^'_%.B^((=
M6.D:A]EFMENYK`W$+)P=A*Y(?+$@$$=>G?UNHKBV@NXO*N8(YHR<[)$##\C0
M!\ZZ-&_@9_AGKWB".XM-,@AODEF>$MY1E,K1A@H)!97#8Y/WO0XKP:7I'_".
M>&)O'-W>VF@7\^I7UO$JR8A#^3Y2?+G`($CC`YW].2:^DYX(;F%H;B*.6)OO
M)(H93WZ&B6"&?9YT4<GEN'3>H.UAT(ST/O0!YU\#E"_#UE43!1?W``G'[P?-
M_%_M>OO7I--2-(UVQHJ@DL0HQR3DG\22:=0!YG\<M)L+GX=WVKW$"O>6$82V
MD8;O+\V6)7(!XR0`,]1DXIWQ&\76OP\\/Z,#%%>ZV4-O8W5XC/Y>U5625FY;
MH5R`<MGOS7I)4,,,`1D'D>E0W%E:W;1M<VT,S1G*&2,,5^F>G0?E0!\WZ%>Z
M'X.\1Z)XECNKR_T$Z5/:RZE-;R!9KTO*[1GY25SD8SG@YYP35J]TNUL?#?PX
ML_&MY<6F@BTN9I?*1E*S'YXPP0'!"L`/XLANF37T*+"S%LEL+2`0(=RQ>6-J
MG.<@=.O-3/&DB[9$5@"&`89Y!R#^!`-`'EGP$BDA\(:TDJW".-;G#+<_ZY2$
MC!$@[/QR#WKU6FI&D>[8BKN.XX&,GUIU`'E_C7PWI]EX^\,Z[!9;KS4=;A6Z
MG8!C\D+*@!/W0`I.!U(R<[5KD/B\]EI7C+4M4;Q#K>C:L=,C6Q%HC*EU\S90
M.I&%!"DYQZX/`/OKQI)MWHK;3N&1G!]:1HHWDCD>-&>,DHQ4$KD8.#VXH`\$
MO_$C>'-8U:\\91M#>ZSX4A6.)XB5GGV$-&=J_(2V<AA@9/;&>,U;38;&6^T[
MQK-?Q7]IH$!T6"&)E&_R!N!V@C"L"')Z[6YXKZNDBCE*&2-'*-O3<H.UO4>A
MY-*8T9U=D4LN=K$<C/7%`&#X$_Y)YX9_[!5K_P"BEJSX@\.Z9XCMK6/5;87$
M5G<K=Q1L"5,BJP7<H^\/F/R]#WK7HH`\"M<G]EC3U,)>%IB)I`K$P)]L<F4;
M><KC/\^*YVXL9=6^'WCJ32KNZU^UAN[2Y_MJXBD6:Y5%^=#O))\I2#T'!8]-
MHKZ>50JA5`"@8``X%,@@AMH5AMXHXHE^ZD:A5'?H*`/FOQMJS^*;C6O%.CR7
M(\,RRV%E?7*AD)CP3(I&,\,T8.,\D=0:[;X,1:+#XL\;)X=>=](_T$VK3A@Q
M4I(?X@&QDG&1TQ7K\44<$8CAC2-`20J*`.3D\?6G*H50J@!0,``<"@!:***`
M"BBB@`HHHH`****`/"/&/C3PWK7CQ?#EY?2:;H^EWRS7*VMHSR:A>!]NWY`<
M*O<D9)!P"=IK/\>Z'XGA\5S^(]4T2UN/,U>WM]/N6O(U6*W67]VNQ@0"YQEV
MSCYL@`FOH>B@#P3QM<-;:OX]TBZTV1M6\2Q:<-,M@C2"Y9$57VL%V_NVR<G&
M<5Q/C&RL;&P\2V^NM>CQ=%=0I;@%S$UBH0*<CY<'C.?X@NW'(KZO,:,ZNR*6
M7.UB.1GKBEVC<6P-Q&"<<_YYH`H:#_R+VF?]>D7_`*`*T***`"BBB@`HHHH`
M****`/)OC;XBL(-#G\.W]S?Z>;JT:ZM[F*,M'=2(2/LQ(Y&258YX`QSS7(>)
M?MFEZCH&I:W?7WA*"Y\,)8F7382S1RQR[Q#P=R`C8>H/&TG&ZOHBD*AAA@",
M@\CTH`\16_N]#U/P;\0_%2S1PR:,]C>&.%G,3C<\3-_%F0-CI@,.3@\<7X>T
M*+3H_#</CFSU.'1Y[*>338[82&1KUY1M`6/Y@Y3:5SC)Q[BOJ)E#*58`J1@@
MC@TM`'GWP3B,/PHTE'61)`]P)%DW?*PG<8`/3IT'?/?->@T44`%%%%`!1110
M`4444`%%%%`',_#O=_PKKP\&7&+"+;\N,KM&T_B,'/&>N!THI/AT-OP\T,'.
M1:KDE2,GG)YYP>HSSZ\T4`3^'O\`D.>+/^PJG_I%:UT%<_X>_P"0YXL_["J?
M^D5K704`%%%%`'*>+_#VKZQ>Z1?Z+?6EM=:>TW%W$9$82)L/`P00,\@CJ?4U
M@1^&/B3'*9%\3:+NP,?Z&X`P6.<`]]P!]0B^ASZ510!YLGAGXD1R+(GB/0U=
M2<,+)P<9X7KR```,]ASDDDK_`,(S\1A&8T\0Z&B9!`6SD&`"3M^]R,L<@YS7
MI%%`'G`\-?$,(R#6_#_EL<E392'/ISNSP.!SQUZ\U*V@?$1VD9]:\/NS$D%K
M68[`0`0OS\`@8QVR<8->A5E^)-3GT7PSJ>J6UM]IFM+:2=(<XW%5)_I]?2@#
MDWT'X@/,TC:GX:R6W8^R3X!W;P?]9V8`_ASD<4QO#OC]U8-JOAXLQ^9_L]SD
M_7]YC\>N"1T)!I?#7XCZOXLU6:SU./2)85T]+TW6FM(%MV9L>3*'S\^,G@X&
MWOGB7PQ\4)?%7Q-NM#L;1/[#2T>:WNS$Y>X9'"%P<[1'G<`<')4<@G``++Z#
M\17;)UKP[@EBP^Q2_-D$8^__`+3'C^\?08/^$>\?[C_Q,O#(C_AB%G-L3IC'
M[SMA<>FT8KH_$_C'2/"26O\`:<DQENV98(+>%I9)-HRQ"CL`1GZUQVA_&/3;
MG3;^_P!3=6A;5[BSTM+*WD:6XAC5&#E#DYVN"3QUZ"@"Y+X=^(,KJQU7PVI!
M);;8RC=D8_O\8&>F/O'.<TYM`^(;ONDU?PZXR64&TF^5B<DC#Y'./R^N=.R^
M)7AR_;1A#-<!=7ED@MG>$@>:F`R-W4Y('/7-+/\`$GP[!I$NIM+<M`FH-IL:
MI;LSSS#M&H^\/?V(Z\4`9:Z!\0P`)-7\.2CHP>RE`<8`*D*X!&`!CVIC>'?B
M&RNHUKPZH=&1L6,A)RP;<26))&,#/]X]\$=5X9\5Z3XNL);O2IG80RF&:*5"
MDD3CLRGD?Y]ZVZ`/-F\-?$MHS&WBC13'A`J&Q8A=OH,]\`'/IQC)RUO"OQ%9
MF*^(=#0$D@)9R#!.>1\W7DG/7))SGFO2Z*`/,Y?"GQ'FCC1_$NBDQNSJQLW)
MW$$9/.#@''.>*0>"?&U[<V\>KZ_I4^G"YAEG@BM74LB2(Y13GC.S'L&8=":]
M-HH`****`,_7O^1>U/\`Z])?_0#7)>'&$OA71U+1[#IMFL:&7<(U\E=PX`7=
M\V<CL$;!`VCK=>_Y%[4_^O27_P!`-<GX:DB?PCH<89G(TRV62;>2ROY"$G!8
M@@1G/`(RW?)R`:WG;C)</'.@N)%7RW8H^&*#:P(//S;1T`S@8P7KQ6ZM_B#X
M#\0:U_8>A#5=.U*[:ZB*V[731$EL-E"'5L$KD]><5[9(S1B96(>9F<!Q'@+\
MI#,H;J,EF(.['(Y^45XH++Q_X_\`%/B%].\22:-I]A?/:-;FZEB"*'(QMC!#
M-CKN(ST'`X`-3P/X>\7:M\0)?%_BFS^P!;3RX;16\MVW(41!'DLJ@`G+]QGG
M!QZDAMMZM*)(XI&9P7D$90;CN?/!QC)4D`X);<6/'`>$_!/C71O$#7FL^+/[
M5TR&"0F"2\G?,C(>0LBE"P.X\Y[$@9KT576!$D\B$1HQE(0>66`RQ8[G"]1U
M).[!;I0!3^&+%O`=J6))^U7@Y/I=2UU]<C\,P!X$M`!C_2;P_>!_Y>9?3_(K
MKJ`"L'QO(\7@'Q')&[(Z:7<LK*<$$1-@@UO5S_CO_DGGB;_L%77_`**:@#6T
MUMVE6;;V?,"'<S[RWRCDM@9^N!FK55M.;?IEH^`-T*'`4@#@=CR/QJS0`444
M4`%%%%`!1110`4444`%8>CV6GV_B+Q%=6M[YUY<W$)NX<C]P5@15&.O*X;/O
M[5N5A:/9Z=#XD\1W-I>&:[N)X?MD!_Y8.L*!0/8IM/XGZ``W:***`"BBB@#,
M\07]IIFB7%Y?0336T93>D*Y<Y<`8&1T)!^@K3K$\77UCIGA>]O=2L1?6D(1I
M+8A3YGSK@8;@\X//I6W0`4444`%%%%`&787UA<:WJ]K;(PN[5XENVQPS,@9>
M_P#=([#M6I6)IEYI\_B?7K:WMC'>VYMQ=2G_`):[DRF/8#(_/UK;H`****`"
MBBB@#!\(76H7FAO-JDTDUR;RY0,T(C'EK,ZQ[1@?*4"D$Y)SUK>K%\+7.J7>
MCR3:NC)<F\NE16C\LB(3N(^,#^`+@]Q@\YS6U0`4444`%8][J%C!XJTBPGAD
M-[<P7+VT@/RJ$\O>#SW##''8UL5A:C>:=%XQT.TN+,R7\\%TUK<#_ED%\O>/
M^!`K_P!\T`;M%%%`!1110`4444`%%%%`!1110`56U&:.WTR[GE0O''"[N@."
MP`)(JS5>_D2+3KF22'ST2)F:+&=X`.5QWSTH`K:!=VVH>'-+O;.)X;6XM(I8
M8W.61&0%0>O(!'>M&LOPU<6MWX5T>YL;;[-9S64,D$'_`#RC*`JOX#`_"M2@
M`HHHH`****`"BBB@`HHHH`****`,G1-1L+^75DL8I(VM+][>YWC&Z4*C$CDY
M&&7_``K6K#\.W]E?3ZXEG9_9C:ZG)!.>/WTH1&+_`(A@/PK<H`****`"BBB@
M`HHHH`****`"BBB@#EOANNWX<:`N(QBT48C!P/SYSZY[YHI?AR6/P]T3>[.W
MV?DMUZG@_3IQQQQ10!8\/?\`(<\6?]A5/_2*UKH*Y_P]_P`ASQ9_V%4_](K6
MN@H`****`"BBB@`HHHH`*QO%FCS^(/"6JZ1:W(MYKRV>%)3G`R.AQS@]#['O
M6S10!XWX5^&.LQ-,E[#;>'X'T0:9*VEW&Z6ZER#YS_+@=#T^;G&<&K'A?X3Z
MGX9^(MKJ46M7,FDVVGB$.&57D(;B%E`^Y@!L]R*]<HH`XKQAX>UFY\4>'?$N
MAI;W-SI1GC>SNIC&CK*FW<&P=I'?`R1].>)M_`GQ$LM*F47\8FN=9NK^_ATZ
M_-J;D2)%L*R["5`=7R,`D''N/:Z*`/!]=\/-X*^$136]0L[77]/U0ZEI4L<W
MFM)*'4C:'`+_`'CD$'LQZ5T5[\.+FZ^$FC:#':VUY=0R)>W<5W(\32RL&,F)
M!RK9<@%@>!@BO3[FRM;P(+JVAG$;!T\V,-M8=",]#4]`'%?#?0O$>@Z7=0Z_
M>/*C2C[';R71N7MXP,;3(0,\]`!P,?0=K110`4444`%%%%`!1110!GZ]_P`B
M]J?_`%Z2_P#H!KDO#2)+X8T5A;+(YTJUB=$3:RAHE*Q$]&QG)!&`N"1W/6Z]
M_P`B]J?_`%Z2_P#H!KF/#Z`^&=$.V251IMJPE;:5F7RD!(4A@IY&`.I)X&=Q
M`-&"Y^TQK<6TLQ:XA#K,P8%X]K,I?.-AVDG'`5F4D#(%>57?PX^(;>*M:U/2
M?$^DV?V^ZWO&9I$8JCXBW*8NHXPW.2<Y.<GU-$2>(J[Q2P[0[-$=P.QAA_F.
M7&1O))/W<?/FOFKQ1I4WB%_&6NW%^6U+2=2*-9O)G9:^88\(",X5B@'0``YY
MP"`>M^&/"_CO2M=BF\1>*=+O[1HY!';1SY=Y"5<%=R+_`!;6)!ST/7!KO2/M
M<O[J1HVG(@\R,%'R!B0JQ&[H@.X\,!&0S`@5X=X,TO0_#/Q=2STG4'U""[TI
MIK.0RJ3&[1[RLFP$9`4GC&`1UZ'W)8B9S;$QP[CA(Y(OW95@22T?3<2VT@%0
M>2#D[:`*?PP_Y$*U_P"ON]_]*I:["N/^&'_(A6O_`%]WO_I5+784`%<_X[_Y
M)YXF_P"P5=?^BFKH*Y_QW_R3SQ-_V"KK_P!%-0!JZ6`ND607.T0(!E<'[H[<
M8JW532R6TBR)8,3`AW`Y!^4<YX_E5N@`HHHH`****`"BBB@`HHHH`*P-%@TN
M/Q/XEDL[J26^EG@-]$RD+"P@0(%.!G*`'J>O:M^L/2%T<>(_$)L96;43/#_:
M",3\K>2FS`]"F.G<'TH`W****`"BBB@#"\8WEGI_A:[N[_3QJ%M$T3/;G^+]
MXN#SP"#ALG`&.2!R-VL3Q=JUKH7A6^U.\LA>V]NJLUN0#YF6``P0><D8K;H`
M****`"BBB@#!TB^LI_%/B*T@L5@NK:2W^TS@C_2-T0*D]^!\O?IUZ@;U86E:
MA:7'BKQ!90VABN+4VYGG+Y\[?'E>.V`,5NT`%%%%`!1110!B^%Y-4ETJ9]7:
M4W/VVZ5/-C5"(EF=8^`!P4"D'G(.<G-;58GA:YU&ZTNXDU,7`F%]=)&+B$1-
MY(F<1<`#(V!><<^_6MN@`HHHH`*YW4M2M(?'>@Z?)IRS7=Q;73Q7;9'D*OE[
M@O&#NXS@@C:/6NBK#U#58;7Q?HFF-8QRS7L%TZ71(W0B/RR0!CG=N&>1]T=:
M`-RBBB@`HHHH`****`"BBB@`HHHH`*K:C((=,NY6@$ZI"[&$]),`_+WZ].E6
M:K:C(L.F7<KQ),B0NS1N0%<`'@D\8/O0!2\+W,%YX1T6ZM;1;2WFL()(K96W
M"%3&I"`X&<#C..U:U9/A>^BU/PII%]!8K80W%G%+':J5VPJ5!51MXP!C'`XQ
MP.E:U`!1110`4444`%%%%`!1110`4444`8?AW4+:^N==6VTZ.S^S:F\$CH`/
MM+B.,F4X`Y.[;SG[HY[#<K!\-WUO?7.O"WTV.R-OJCP2LA_X^7$<9,IX')!`
M[_=ZUO4`%%%%`!1110`4444`%%%%`!1110!S/P]W_P#"`:*9(VC=K<,R-)O9
M223ACW;USSG/`Z44GP[V_P#"`Z1L<.GE-M8$$$;VYX)'Y&B@"?P]_P`ASQ9_
MV%4_](K6N@KG_#W_`"'/%G_853_TBM:Z"@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`,_7O^1>U/\`Z])?_0#7->'%9/#^
MC(]J2\MA:H%E7`D`B0ER!C#$[5((.!'G&.*Z77O^1>U/_KTE_P#0#7*:$L*>
M%M(BDDV$:=;^?O'E.&-NJ\DX8C8'Y.<8;G*_*`5O$/BS2_">D176KZC<8EEB
M*,%4S3\`MM**4.4)W8`'S_*R_)CE?#&M>`/%U]KE[;+/:ZG>Z=]GO8ITCC#P
M*5WR<!@"1][;V3=M4\UC?&Z/[1KG@^QO"KAIY1+'C#-N:(,Q(5<[L'#`#IVK
M)^)7A_3=3^*NBZ7H<VGZ<-1B2V9[4J(E!=HU.$/4IA<<9X&.]`&C\.6\&:/\
M0[NP\.B]U622"5$O;MPL:(IR0JJN6)P!N)4$''?!]G?;\RQ+$3(`(U7(_>8;
M)!)4Y))(.<-N4@@DM6+X5\.^&/!NBQP:&L;?:"WFWT[(9+@#&[)/5!SD*,+M
M)(Y).Y&?)N$<)(YC"Q,TC[FW?*X4[B%#'*("WS'C+4`4OAA_R(5K_P!?=[_Z
M52UV%<?\,/\`D0K7_K[O?_2J6NPH`*PO&H8^`_$01BKG3+G:1G(/E-Z<_E6[
M6%XU$9\!^(A*Q6,Z9<[B.H'E-F@#2TL`:19`,[`0)R_WC\HZ^]6ZI:.6;1+`
MMC<;:,G#9'W1WYS5V@`HHHH`****`"BBB@`HHHH`*Q]+?1VU_7!8+C45EB&H
MG#<MY2E.O'W"O3TYK8K"T8Z2?$?B/[$L@U`7,/V\OG!;R$V;>V-F/?.?:@#=
MHHHH`****`,GQ+JL>AZ!<:E+927JVY1O(C`+,=Z@$9XR"0?P[5K5C>*]6_L/
MPQ>ZF;6.Z%LJN897"*XW`'YCP..YXK9H`****`"BBB@#"TJ_6X\5>(+(6$,#
M6IMRUPF-]QNCSEN_&,`^WM6[61I^LK>>(]9TH6PC;3Q`S2;QF7S%)SMQD`;<
M9[X/I6O0`4444`%%%%`&+X8@U.#3)QJ\LCW+WMRR!VSLB\UA&`?38%(SSSS6
MU6+X8MM2M=,GBU-]TGVVY,(+%BL)E;RP6/+?+CD\X(SS6U0`4444`%8&HZK!
M;>-M#TQK*&6XN[:Z=+DD>9`J>62!QG#9&>1]P=<5OUB7^N2V7B_1=&$*-%J,
M%U(TA)#(T7ED8]0=[9_#\0#;HHHH`****`"BBB@`HHHH`****`"H;N?[+93W
M&%/E1L^&;:#@9Y/;ZU-5>_N&M-.N;E%5FAB:0!C@$@$\GM0!3\-7_P#:GA71
M]1\B.#[790S^3']V/<@;:/89Q6I69X<U*76?"^DZI,B)+>V4-PZ)G:K.@8@9
M[<UIT`%%%%`!1110`4444`%%%%`!1110!C:!J<FHS:S')8BU%GJ+VR$`CSE"
M(WF=.^XCO]VMFL?0M=_MJ?6(_LWD_P!FZ@]EG?N\S:B-NZ#'W\8YZ=:V*`"B
MBB@`HHHH`****`"BBB@`HHHH`Y?X=`+\/]'4,S@1$!F`!/S-R0**?\/VD;P)
MI+2Y\TQ$R`C&&W'(_//_`-:B@"7P]_R'/%G_`&%4_P#2*UKH*P/#Y!UOQ7\H
M&-53)'?_`$.VK?H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@#/U[_D7M3_`.O27_T`UR_AMU7PUH*)`88C86W,NV-I5$"_
M.0I.T?=7.,@H>-N&'4:]_P`B]J?_`%Z2_P#H!KF?#;2V_AO2_.G#3BQM=\<$
MC(8L0+PP.[IAVX`^\`5)^9@#'\7_``^T3QF+`:CJ4]K!9K(L.QA$69U0*&#)
MM7_5\@`8)VX&!7*_\*"\->88VU/5XFP"-YC)!(/!"H>AQSG:>`"2V1ZQ"C6L
M(AE+/*,>9+"W+L."VT;W"E\<$MP#N)^;+,"*/:H&(I7D\Q0/N<9V@<A]I"YX
M`#,1QQ0!P/A;X4Z1X3U_^V;"[O;K9$1&LK1M&V\,"FX`'>/EZA`=P&3\V.Y0
M.0?W121W<+;ABI8%A@[@2%SPY;[^/FP"=JRHQ?:K.ID\O/F%,(S$G+X"Y/\`
M#P&],XX9FRSPOYC3QG:=WR3'8F,GESC&W;L4_+]TGEP0:`*GPP_Y$*U_Z^[W
M_P!*I:["N.^%P"^`+11G`NKP<G)_X^I>]=C0`5C^+`6\&ZXH94)T^X`9@2!^
M[;D@5L5C^+`#X-UP$L`=/N,E2`?]6W3(/\J`+6BG=H6GMN9LVT9W-U/RCDU>
MK/T'_D7M,_Z](O\`T`5H4`%%%%`!1110`4444`%%%%`!6)I#:0WB'Q`+*,KJ
M"SPB_)+'>WDH4//`^0@<>G-;=5+;3+.SO;V\MX0EQ?.LER^XDR,J!%Z],*H&
M!_,F@"W1110`4444`8'C75!HOA&_U+[%'>M;A&2WD3<';>H7C')R01[@=.M;
M]%%`!1110`4444`8.DW_`-H\5^(;/[!%`+4V_P#I"IA[DM'G+'OCA1WX/M6]
M110`4444`%%%%`&+X8358]-N1J\TDLYO[KRRX`(A\YQ'T[;0".O!%;5%%`!1
M110`5SVIZD+;QSX?T_[';R-=VUXPN'7]Y%L\HX4]@V>1WVKZ5T-%`!1110`4
M444`%%%%`!1110`4444`%07K.EA</'&DCK$Q5'("L<<`D\8-3T4`9/A>^?4_
M".BZA)%%$]U803M'"NU$+1JQ"CL!G@5K444`%%%%`!1110`4444`%%%%`!11
M10!A^';ZXO;G74N+.*W^RZF\$;1IM\Y/+C8.?4_,1G_9]JW***`"BBB@`HHH
MH`****`"BBB@`HHHH`YGX>DGP'I18L28VR6()/SMUP2/R)^M%+\/]O\`P@NE
M[(TC38VU$QM4;VX&.,?2B@"7P]_R'/%G_853_P!(K6N@K`\/X_MOQ7@$'^U4
MSD]?]#MJWZ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`S]>_Y%[4_^O27_`-`-<EX?1(_#>BQV_F[6TRVV@7#DL#$F-@5\
M@8BX"XY5R1\Q8];KW_(O:G_UZ2_^@&N:\/,Y\,>'S#A1_9EIY7EAF60&,;2J
MD+R"2>1P`I.,D4`:TD@EN7>!/M`2?RF,3*Z@%LE<!<`]0=PR,]0&+4L)9L^1
MM=W;SF.[SMP;:%8$\`$C(QA<*0!D9"!"K!-D4*QGR\`@H,@?(F_&1DJAQCK@
M8/2*1E29(590TA#J'B^9BRLHPI'WN3D<$#EB`,$`8J?Z4)`&$FWR"@4(IPA8
MC8#RW);:P/#94=:<[M'<"-70W0=FCC3'S-DOC82H)^<$C`(X+$X5ZDRLUOY*
M^8N`)(P4V+ES@#+`*6^63*#D`\XR,LN%.R3AV,H6/8DB2/(I&.AX8[=O##:"
MQ.2!F@"E\+@1X`M`6+$75YR>I_TJ6NQKC_AA_P`B%:_]?=[_`.E4M=A0`5E>
M)[:6\\)ZS:PH\DLUC/&B)G<S%"`!CO6K10!R^F>*;&#1[2.:VUSS(X$5]VB7
MF[(`!_Y9'N??OZ59/C#3%.#:ZWT!XT*]/_M*M^B@#G_^$RTO_GUUS_P0WO\`
M\9IK^-M(C7=)!K:@D*"VAWHY)P!_JNY(%=%10!S_`/PF6E_\^NN?^"&]_P#C
M-'_"9:7_`,^NN?\`@AO?_C-=!10!S_\`PF6E_P#/KKG_`((;W_XS1_PF6E_\
M^NN?^"&]_P#C-=!10!S)\>Z$L<,C+JX28A8F.BWF)">@4^5SGMBFR?$'P_%Y
MWF'54\C;YN[1KP>7NZ;OW7&>V:ZBB@#EY/B#X?BN/L\AU5)_D_=MHUX&^<L%
MX\K/)5L>NT^AIT7CW0IV"PKJ\A(W`)HMX<C`.?\`5>C*?^!#UKIJ*`.5/Q$\
M.""*<OJ8BF++'(='O-KD!F(!\KG`5B<=E)[&I(_'NA32-'$NKR.I965=%O"0
M5QN&/*[9&?3(KIJ*`.7_`.%@^'PSJ3JNY$9W']C7F5520Q/[K@`@@GL14P\;
M:09&C$&MEU`8K_8=[D`YP<>5WP?R-=%10!S_`/PF6E_\^NN?^"&]_P#C--/C
M;2!(L9@UL.P+!?[#O<D#&3CRNV1^8KHJ*`.?_P"$RTO_`)]=<_\`!#>__&:/
M^$RTO_GUUS_P0WO_`,9KH**`.?\`^$RTO_GUUS_P0WO_`,9H_P"$RTO_`)]=
M<_\`!#>__&:Z"B@#G5\;:0[.JP:VQ0[6`T.].TX!P?W7'!!_&FGQSHJS"%HM
M9$IQA#HE[N.<D<>5_LM_WR?2NDHH`Y__`(3+2_\`GUUS_P`$-[_\9H_X3+2_
M^?77/_!#>_\`QFN@HH`Y_P#X3+2_^?77/_!#>_\`QFC_`(3+2_\`GUUS_P`$
M-[_\9KH**`.?_P"$RTO_`)]=<_\`!#>__&:/^$RTO_GUUS_P0WO_`,9KH**`
M.?\`^$RTO_GUUS_P0WO_`,9H_P"$RTO_`)]=<_\`!#>__&:Z"B@#G1XTTWS&
M7[%KP``(?^PKS!SGC_59XQZ=Q[X4^,],!'^AZZ<GDC0KWC_R%70T4`<XOC73
M6(S8:^O'4Z%>>WI%[_H?;+AXSTPCFSUT<G@Z%>__`!JNAHH`Y_\`X3+2_P#G
MUUS_`,$-[_\`&:/^$RTO_GUUS_P0WO\`\9KH**`.?_X3+2_^?77/_!#>_P#Q
MFF'QKIH7(L-?)R>!H5YGC/\`TR[_`-:Z.B@#F_\`A-M.W8_L_P`08_O?V%>8
MZX_YY?C]/?BD/C?3@N?[-\0DXZ?V%=Y[?],_?]#[9Z6B@#F6\<:>I(&E^(FQ
MT(T.[YY/K'[`_P#`A[X3_A.;#;(?[*\1Y4G`_L.ZR^,]/W??`ZXZC..<=/10
M!S3>-].!XTWQ"W)Y&A7?O_TS]A_WT/?"_P#";:=_T#_$'W]O_("O.G][_5=/
MU]JZ2B@#FO\`A-].RO\`Q+?$/)Y/]A7?R].O[OW[>A]J1?'&GD$G2_$2X['0
M[OG@_P#3/\/QKIJ*`.7/CJP^7_B4>(SG.?\`B1W7&,?['?/Z'VR?\)U8;0?[
M(\1Y.>/[#NN.2/[GX_C7444`<I_PGMGA2-"\3'(RW_$EN!MZ=<KSU[9Z4Y?'
M=B68'1_$B@#@G0[K!Z=/D]S^1]L]310!R@\>6SG":!XF/S%>='F7\>0./\^E
M//CFT!8C1/$;(O\`$-&GY^;;P"N>V>G3\JZBB@#ECXYM@0#H7B3<3@@:1,<'
MMSC'/J#@=\4#QS;=3H7B0)C._P#LB;IDCH!N[=,9Z'H:ZFB@#FHO&<,R$KH7
MB$$'&U],D4GD#OQW_($TO_"8Q9_Y`7B#&2N?[-?J`2?Y8!Z$XP>17244`4--
MU1=25S]CO;5E/W;J`H2/4'H?SS5^BB@#ROXS)-=W'@[2UO;NU@O]8CMYFMI2
MC;6(4D=L@,<9!ING'5O`/Q!T[PK9W^I:WI&H64UPD5](LDT,L:DX63"A5;:J
M@'@%NV<UUOC3P3#XQ332^HW5A<:=<_:8)K<*2'`X/([$`_A5*R^&FGI+>7FJ
M:IJFJZG=V3V#7ES,`T43!@PC"@!<[B><\_4Y`,#0OBU?ZQJ]YI2Z/82WOV*6
MZM8['41<*709\IV5<9/JN1_.K-K\6_[2M;&;3-#>Z:71Y]6NH5GPT21LT>Q<
MK\Y,BD9XX&0#P*L>'/A=;^$]3@UJ+4;S4;NRM&MX+?RXHD9-H`4``#<2.6)Y
MSSZU3\$_#UXHO%%QJ=A<Z'_:TYCMK2UO`&M+<$N-CQ'"Y=F.T<<8P02"`7_`
M'Q'F\9W\MM)8V$2>29TDM=225E&1\KQ$+("`P^;;MSQP>*]!KA/#/PPLO#WB
M1=>DU2\OKV.`VT1DCCC4)_M;%!9O]HG^E=W0`4444`%%%%`'-^`=Y\#Z89#E
M]C[CC&3O;/%%,^'>3\/]%<H$WP;P@.=H))`ZGD9Y'4=#S10!/X>_Y#GBS_L*
MI_Z16M=!7/\`A[_D.>+/^PJG_I%:UT%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`9^O?\B]J?_7I+_P"@&N7T'!\+Z%^Y
M;[/_`&5:I&[!<NOE=@O&>0-H89^;T7/4:]_R+VI_]>DO_H!KFO#KH_AS0SY*
M-<OIMKYH221O);RU)7:#Z<@9!X)Y)Y`-971)1BX+PNK2R,I7]Z`,Y"_=8,N<
MD`?0=50*(YGB(V;1\V%^5P"%!\OW))RI_A7^\5I([L89TB<&<,Q1R?,#-G`*
MKSQNP0`<8))R,TQ(]@\B225XR2KK^Y.Q=ZD[L`8)QM(7IE3C=\U`#2/WBF0.
MF4<EC@[<#&-C=\'<WL0!NP&$A&ZZ18)'"IL4G`95=<*H(W<J&SD9SD$<]58I
MC*FWE"*Q.^1F(4%=S;4!/(7[V/EZ$X.X$U)&1!*'8EB")2AP'&2#C"JNX(K!
M%"Y/(W!BV:`,_P"%Q)\`6A*E2;J\X/4?Z5+78UQWPN`7P!:*,X%U>#DY/_'U
M+WKL:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`***:9$7=N=1M&YLGH/4_D?RH`=13?,09RZ\$*>>A.,#]1^=-6>%P2DL
M;!2%)#`X)`('X@C\Q0!)13/-CW*OF)N8D*-PR<=<?2FBY@*[A/&5QG.\8[_X
M'\C0!+14)N[8('-Q$%/1MXQW_P`#^1I?M,&XKY\>X-L(WC.[T^O%`$M%0?;;
M4E!]IAS(VQ/W@^9O0>II1=VS#(N(B#GD..PR?R%`$U%0+>VK[=ES"V\X7$@.
M><<?B"/PI?M=L,YN(N`&/SC@'&#^H_.@":BH/MMKC/VF'&`?]8.^<?\`H)_(
M^E+]KMMZI]HBW-C"[QDYZ4`3457-_9JF\W<`4$+N,@QD]!^-2+/"[E%EC9@=
MI4,,@\\?H?RH`DHJ+[3!M5O/CVL"5.\8..N/I49U&R$:2&\MPC@%&\U<-DX&
M#GGF@"S14'VVUVEOM,.T'!/F#'^>*#>VH`)N80&&1F0<T`3T57:_LT$A>[@4
M1';(3(!L.,X/IQ3C=VP(!N(AGI\X]"W\@3]`:`)J*C,\(1W,L85#M9MPPI]#
M2"Y@/2>,_-L^^/O9(Q]<@C\#0!+135D1R0KJQ'4`].2/Y@_E2>;'A3YB8<97
MYASTZ?F/S%`#Z*:)$9V174LN-R@\C/3-.H`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@#FOA_@^!=+Q(9!L;YSU;YVYHI?`
M))\#Z82&!*/D,"#]]NN2?YT4`3:`A76O%1)7#ZHA&&!_Y<[8<^G3H?KWK>K`
M\/X_MOQ7@$'^U4SD]?\`0[:M^@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`,_7O^1>U/\`Z])?_0#7+^'-DG@SPM;.4EMS
MH]JYAEP%8!$))!X)P,8/U'0D=1KW_(O:G_UZ2_\`H!KF?#'S^"_#(C95=])L
M\1$D*?W8`ZXZ9)^]GC@$@9`-4232P,)7>7SHV4[F#1-^Z)W=`I0YY;`4DC@'
MBI9&_>2!I7,D46WS(SYA7YP2HQ\V>@Z@MC@$BH_.Q+YT5O,6:5BLJ[5V@\%B
MK8X4."<\_(PZ[0T0WAX$90S!L2AFR\>0WS-@@_>QP-_S,N,#Y@`2!YA;,%D\
MN(!CNB<Y9F922,#'4\L"P&YLD8J!]DT*V<D<DL$H$9M'B(1E8$+&Z@$*A`;(
M(X0#<,GF5H08TD41S328#,!A8\?/NR=IQ\V3R2,G"G+4NY!.DL]S"55U8;@P
M"H,D'../DVD]@2>@H`H_##_D0K7_`*^[W_TJEKL*XSX59/P\L24=#]IO/E<Y
M9?\`2I>"<G)_$UV=`!1110`4444`%%%%`!1110`4444`%%%%`!1110!YGXE\
M+:#XF^)MV-=TU;U+;1+8Q;I98PA:>=3DI_,],9]2$7X3_#]'79X73,A4)OOY
MB"<@G)WD#@J0,DMD\8!K7NMH^)FJL,&4:#:E5&=S#[1/D#MR<#)(QD=LXTGV
MK9*B2QAHVW&.,,I8\'D''='`8D#Y>W8`Y3_A5W@&.-)CX4CV_P`(%W<,?NX^
M9<Y!RI&",YQ_$=M!^%G@$RS1/X:MVD+8D<7LL0+\8V*9.`6.,`X&0.H('6D*
M85R!''"^T!HR1(H+-D$`@@C!R/4Y]*81\LLB7*72L&.-^&<%2-P.`H.P,?[O
M3H",`'(GX7_#P74<?_"*2"5F&P-/=!=O&"><`G(X/^U_<?:I^%/P^B@)D\-0
MD8\PL-4D&54')&9..0>,XZ9(YQU)PUPT+PJ@8?-<%?DC^X0NTY8;OF/8?N1G
M`(S'#)(UR^R%@YEB43Y#*[;8AN*[]V/NDY5,A>"<@L`<X_PO\"6[&,^%4'F`
MHRB6YE9@H;D8.4'R_?(^;@#)9<A^$_@01DR>%H.F3LU&<D;0>,*Q)."HXSDD
M\=,\ZGQ)U_6IKX^&?!MSJNF02^2\R/M1MI#$*%!!.`.0>C9P,@5T'A7QI8>)
M]#DU%%%L8`+>^2:4%X3AOO#CY1OD96QR%8'!4`@#G^$W@01A8_#-NA^;#2:C
M*1T'/^LR1CYO8$'J<4VX^%G@(7$R_P#",VY9IB/FO9X1G/&T[BO.[``QD@C`
MVG;MIK>E3W,,$6HVD[&-9(XTD!\Q`P5CMSGC$>3C!&6`["OXDUB'PWHMY?7%
MPWV>R0[BW,DF'6/:<9&^3+88C^(D[>P!F-\-?`X'GQ>';0VMNC`N'F=EYP-R
MAV+,""<E6##N!UC3X<>![R:2#_A&K5%B?8&WS+P44DE@X'!+G/H$Q]Y2>7M?
MBGKGGZ7J>N>&9+/2=1G$<.HK([)'O9<G&#N`"`A3S\G'0@]1!X[TT?$&;PLD
MH0PQCSKB:<+&L@*8CC3AG.#RO!#;SCJ:`);?X:^"I',K>&+,,\3.J+)-(,LF
M_C:Q#*.1N``SPISQ0_PQ\"6Y`D\.6^Y=JA5DG?&0Q()#G<1L(]<C&/F&=2UU
M[2O[&BN'OK3[/`\<4C1R(HCD#*"?F`51N^;;D,`<*-V%I)=?L+.WMWEO;9(;
MQ2T:FY15G)7Y`K`_.O.U<-@D-P5^90#/_P"%:^"9_P#6>%K.-HU957SG3)5L
M$G]X-P`)Y(Y*$Y`VDPR_#KP"ENTTGAJ!+1(?-9F-PDJQ!<\INW^9M!^4#=DC
M(!ZYWACXD?V[_;;ZBEO96^ERI;BX2;B5G:7#-N('5"1MR<L,`]*[.\OVCU"&
MTDNH+*^NFE6U225<>;W\O/+@,$W``X#]!E@H!B'X;>#([H0C0-,65F\L8=CN
MP<8&6*JV,'D$D!L9).U5^'7A%E+/X6MU5,2#SE$.X87"\G.03R>!SCKE12^(
MOB]_!^@PWUE''<))=_9_L[.1\A5S\W!5@0O0\_.<\CC)T[Q-X\GU"SEN/!JV
M=E-)$)KUI`4CCW<R$CL`<@9V\#CKD`Z*+X;^#$9C_8FGM;Q2GS&(P0.6;)9C
MT^8';D?*0-N"`R'X=^$'VI'X9L&E*'!82*0,KCACC.6`YYZYY4J=EM>T6:PN
M+]=3LGTRU1`T\DP,/"`-&S+G!Y12&4'Y\;3D`U[OQ7H=NMN9M5MHX[G#+*;^
M-$*?WURZEE`W<+ELR*0`0=@!0/P^\$[Q&?#5OR`6=HF57!&W(.<?>5B=A^48
M8\,&+_\`A77@YFC>'P_82H^`L>-K,W`Y&"P&[=NXRNTGCI6;\0/&MSX/T:"\
MAM(;M9YT526P&#*S;AGG9\B`97DJ_..O13:]I1AU*9=3M9/L,FV['VA=T6QF
M4%F1CM)1"0=RMG.0#E``9S?#GP@OF[/#FGNQ3>$`+'D$Y7&0Q``PJ]<C/WLT
MU?ASX/GCF*Z#:;8FV.IA(8]\J0<N,9/`&<#!R#G4N=<T:VT?^UGUC39;.5B\
M<_F`+(V[;E6/R[@P8@#&"G4#)&7KGC?3-)\,3:U;7,-_9*J@Q0W096?Y0L98
M`@.1Q\I;'/!`+*`(O@+P7-*6_P"$=MH8<#EH'&-P4J264`9WA<C<!M;/*MMD
M'PW\*&1@_AO3UF6,&1&7:(\@]/F(W81FP2<9`R`2U9S^.O,T;PQ>:>;6[.I3
MP03*EZD;6K,J[DW':&D!+$CJ/,Z`$$[MWXCTK3+P:8^JV=K<)+^ZB62*-BX;
M!`0N."R@`$_=8KG.<`%)?AWX.\X$^'K'#+R?);RQMVDXDSL'+[<9);!Q]QJ6
M+X?>#9BP3PY8?Z,RQSMLPK-@.<,2`<HRD$9'S$'!!QM7FJV&F/!'?ZE;6;2R
M#RC<3/&T[AB"JEN21D[L*.9!TQ@U['Q#I6KVLMS::G#+]EC;=Y4Z..07+DJQ
M"]2#N*\H3]W!(!0/PX\'B4V@T"P)#+'YOE9DY)!.`2I(ZGCCJ5`-(OPZ\(.4
M<>%(F7<#^[A^4\D`$G^$D=5SC@YVG)MZ7KVBZQ"]CIM_9W06VS)%;3^8!'M`
M$>5)<G!5<E/;[PQ6N'M_M,1D$C%Y2FY90-@^9BS8P"IVD@`$\AL+@LH!SK?#
MCP>N'/A_3E0X"$896QG<=WX#J%&6`R2=H0?#GP@2L0T#3A*S;5;:'&[>0V0I
MX48P.A.`"0QQ72[I&A1E@$CDN05V_*<($4`L,!OE&>2,C.W)PK2GS`LJM=08
MVR*J!]X'R]"=QRJEL;<$$X+<9`.8?X>^#1'E_#=G$#$79O+.Z+OEU[<$`+]X
MGMU(E?X;>#CO"^';!)"VT1M(F1RVTCW8@KSG[OU-=%)',GE[8W8(N2)'.44`
MA5`#+R6VD9P`!E@I`J25,8,TMNT;;4#R`N2Z[C@OMZ<C'INDH`Y7P_X=TKP_
M\4[5-)T^TM(I="F+^0PW2,);<Y8!C@?-QQZ\GMZ57"6#,_Q.T]I$$4IT6[W1
M>7L*_P"D0<GY0#N.YL@D9)QQRW=T`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110!S?@'_D1],^;?\C_-NW9^=N<]_K11X!(;
MP/IC*VX%'(;GGYVYYY_.B@";0/\`D->*N%'_`!-$Z'.?]#MNOI6]6!X?Q_;?
MBO!)/]JIG(Z?Z';5OT`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110!GZ]_R+VI_]>DO_`*`:Y;PRZKX'\-!U60-HEHI1GQQL
M3G/1>@R3UR,$$<]3KW_(O:G_`->DO_H!KF_";2'P;X42%/,9=*LG=0>G[L!2
M<=OO=0>F1R"0`:LBQ1,Z=9-L@<RX+'.07QA<C'S':PXR!TQ4<BW9=51S;ER5
MP\)Q@Y(^;>&^\8@3C)^;@9S&EM)Y=M'"BM#N:-%61%R-P4^44`^0E%^8#&-Q
M;&.:6V:2XB,ZQB=9,G?$J.C@9R3_``G)_N\Y5<Y`.`!?E5%)(7)"B/<-NW:=
MRX&/FQDEL*/G7[VT"B25%(874BHK*&O#(I*K\P.2!@8(P=P8?)S@G-#HTS%H
M@Q?YD>-4("GY6Y`QAF^7[V1@>A.Z*1$,<T44S2"<%V>.X<Y)0N51P2RDAF*[
M/F"[<?*J@`%7X7;O^$`M-P`;[5>9`.1_Q]2UV-<=\+MW_"`6FX@M]JO,D#`_
MX^I:[&@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`XNZ,G_"Q]7\I?F_
ML*T*DL-N?M$^`1C)S[$=_4$7@)FA*B0,K.TBEEX"L`50_-DG[I8\`AB.IR,^
MZ91\3=31]H5M#M,G(#?\?,PPI^\"<X&T]<=\5KQL[`;2OG2%P(Q$C`.,*Q!`
MR`&89/S?=`)!X(!&@=/*8!F9L!C$^>!RR@<.,L),?,?JWW0!;=#M>`H.4'ER
MY2-AP1PN0!M4=,;,DC&138S_`&BKAT2Y4`%#!(N2I7&`R=!N#CD=06!&``]5
MDNY)7"A904#,+?@;=L@^1@=A/S'H2-ZYR0*`(E6XDF$;@-;[,,/+*MN4ED`.
M<<+N^4Q\]<KPI@O(#=:3-#'<QP7#Q>4+HR9^SY3[^`RLF%W,`'&/E;.XDBR\
MT44GV>18HY'E5HX9"0S`Y`'S<'KA58_PM@#:`'F&;8OD12LL7RH)(COW+@KS
MA203ALEL$E@3Z`'CG@/Q7HO@_P`+7?AWQ+-/8ZIIMS*S0L.N02K)\IYYX(Y^
M[_"6K/TC2KZY\)_$'Q5Y,EE8:P9GM$=3EX_WLA(Z<<JH;OEA7N1LH'*?:=.\
M_;PIDM!(<<R8RPX'!4`<`N!Q4;2_:9$@22!Y,(1$NS9(CAP#MSN*$(PY!!"!
MA]TT`?/NDZ=9V.@?#+4K.S2/4+G5RUQ/&I\R;_22JC=T``3&,'.?KGV#Q5>W
M-IX2O[B&P_M&$0.K6D2D*(3Q*H)`("J=N``?D<?(6&.B=H[=%,MM;0VEF^\`
MK&/)(8$')7"LPP=HY_>=1Q@\M[<01E9"<B)6!,8=@NPL@7&%V%W"J>H.,'D@
M'S:^HZ;I,%K?>`/$>JVVH7+0^?H21RL&DPV[YA\KJ#@!3N)!SGJ!U5E;V>F?
MM":@NHVUI9RN(GLUFMPZ>>QAPRC`W,3O^9=I+9(QTKVJV-M&TES:V-@UXDFU
M3'"JN'*LS)G@E@.H'.!SU.(9=.C2W07$,LT><+),@,B,6(RCM\P)(SC.<LH'
M44`?-4%U%H/PW\6>&M1;R=:_M"*-K4J6("L-S9''!3&<D<_[0-:EHFGV_C'P
MM)XN")I+Z!&T/VM2T.#"P!*@$GGD`$$G'(Z#Z"/V:VA;[38V#R&/9*1"I3:A
M1#SCE%<C.3\JH,C-#+:W;F,-!*I3,5ILCD4JHP&6/!^X)(OF`Y#C.05P`>"_
M#C1(?$GA;Q_I5JGE+</;?98Y020P\]HU.&R#N"@_>[\'K5CX:/=>*=6M]1DE
M>+_A'M%:T2=^4CG<R)$P`90,1GJ2.8^HR"/;-3^TS:9<1Z7>V.F7<^)([P01
M28?)?S65B!@JDF#SQ\V6.0,3P3X-'@VTDTZ*]DN]1N96N)IIUV2%BN`=@+84
M'C<=Z[LGG"B@#D_CLGE^`K3*C<VIQ98-U`CG(&W&.`V,]\#@=!G>'I?ADGB'
M2IK'Q3XBN-1$L8B@F=V661^-K9AP3T7'"D;>?O8]@-O:RR!'@6X62,R0))$)
M0^#NR.JXPQ&5XY`S]T416<$$L872[19@2PVVB"9=N"67@`\D`'&`1WR*`/G_
M`%KP_J=CXFNO`&G,GV+Q#?0W=NPB*+#'E]X"[C@`@=SN6-2.HI/'?V)?$&K:
M1#;:1IZV&GQ6\4]S;O)<W2A%,:1J-Z*_W4W`*<9)(Z#Z$MKJVB$=Q$T$D-NW
MD/<9,LB%0JM'QNV-N&"G4G/?DM$40-O=/';2LJA[=Y%0EOF`&TD%MNY]P"^J
M!>N"`?/WB9YG_9X\)2.5*O>NI8C+ML:X51GLJCH.^X].ZW&I)HMQ\4=)OE:V
MO+^Y+PV[Q$NZAIF^7`P!MD5]W`VYQP:]\,=I-=_94M;"22&-9&TP;#Y(8G#F
M//5@0-Q'&QL=:LO$_GJ]S']HE;]WN>WC#2(VYO*7(&0%R#T[DX&:`/G>_O\`
M[)\)?`<,FG64\<\UP1<WL<AC@9;E\9VG#`ACE2",`\-QMIZ.;:?P3\1-.%U!
M=21M;7=L4@\M65)&5Y8X\84$.HZ#`8'MBOHZX:V$2Q726D*(H3RGA(C`)/.P
M@]/F8$C^!N5&XU+#-$)HC#!:>8^8&V1+N"J03%QG&%7[AR?FXP%-`'@][?Z-
M=:1\.X="BM=]O?6<=VL,(C#77EQ%RY!4,3E1DG.4?D5A))I&E^%_$VG^+K!9
M?%RW,@+76][@L54(RR!L85]SDY.X$=1BOI&VLP8H3!;6[1-(DT#16J!%)11N
MSMR#E6((!ZKSCBEDFMUD5Y(;("W95A,L49-O\P"H,'[Q?]VH!^\O&2#0!X'X
M@TN[-O\`"_3M:C9I99/+GB<`/AY(L*<Y_P"6;(,$=0?<5!K&G6%MXU^(=E%!
M-!8#2Q*L>G0*?)_>VSC"9`V@D@D8^4L:^A;ES-<[W@CFD65FA=H4+1.,%4VD
M;LLH#9!R`H)XYIRGRD2XBAA!>/)G6%1YA!(C&[&&!PH`&"<J10!\\?#^1K?Q
MOH^G6$>BZR;B)DCNH+)]]M&589F4;`V"?F#;B1D!A\K#Z$;S"20&B5^6+`.Q
MR0,$XW.H)3C*G@_,W2GPS6LA>:UBA>"[S*QA@5A=1$DE\@?.NTY!&<[UZYY9
M<J\,4LUU*+98R2TJ%H0QV%#\P*[LE\C=D9'`R`0`-$MN6V(\RE5#;]^_"L7^
MF&^1R2.`=I.X#`6>-+H&(6L3!T\EDWAD*D[`I<+N!RH&>2,,!CAJD>,^84C;
M/GRA`00$W+]Y!@<``*"!D'RVRH`;,=Q-!]E>YF*0VGDNYE<1A74HS,<L0AR`
MS[B#C<<[1N%`$RJK,IE57944_P#`]P7*DY(R"<]?O8W#NR+$1\XS7"+(_EJ7
M(0KMZ9.#N&XL,<`#/RY!--FE_?KDAW,VYU64[0S+)&$.#M/S?+A@5RI.-^,J
MT\<;BU5[>*?"C$Q422!M^P;6R5RRRA<X7!(&<$``R;)C_P`+2L8]BJ$T2Y!`
MD#\B:W4\C'0*`>/O!ASBNZKA;&59?BG:;&<[='O`P,>P*QGMV8$8'S98_4%3
MDYR>ZH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@#G/`98^"=-+9W%7SGK]]O8?R%%)X!Q_P@^F85E&Q\!E`(^=NH'2B@"3
MP]_R'/%G_853_P!(K6N@K`\/@#6_%?S`YU5,@=O]#MJWZ`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`S]>_P"1>U/_`*])
M?_0#7*>'0&\"^&,ACMT:US@@<&+G!+#!P,<C!+#/`.WJ]>_Y%[4_^O27_P!`
M-<MX::Y;P=X:\K_EKHEH%`B``DV`@YR`0/[O';!YH`U[N7RI74'SO](4&-""
M$#2#YMKE<D'G*DL&.`K<"B41Q;]ZB10OE[5#DX7DA<@`_.N!D@?,/8%D;S,`
MT<P0@;F$D;O@`#<&;(8':&`8C=EE)4[2&:ZRB2%5V>69<^4BD,P$;'!PP4G=
MSG83A?ND_,H`\KR&,;&*1A&985#;OEVL22>$7+X[DL<+@<O='D(!G\FYD">6
M9/G:,,/EZ##;6QW(..3GDAP[0-M7#2KM1@!M.!D;QU+;LYZ84`*#S5:X)CM)
M/L\IA7R6,<;D8WXSYFX.O&#NQ\C$G)9>P!!\+F#>`+1AG!NKP\C!_P"/J6NQ
MKC_AA_R(5K_U]WO_`*52UV%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0!S6M>#(-8UHZM'J^K:;=M:BT9K"=4W1AF89RIYRY.?8527X?;+=(5\6^)?E
M.X.;F(MD``'F/'`7`P.YKLJ*`.+/P\W!`WB[Q.54J0/M470`C'^KZ')XZ<X&
M!1'\.DCCCC'BKQ)MC^X/M$0"CH0`(L`$<$=/QYKM**`./_X0`>2T7_"5>)=I
MZ9O$.T_-DC*=]QSG.>G3.6#X=6^\F3Q'XAE1FW-$]TA0\8Y79@\<<]N!P!CL
MZ*`.0'@+:^Y?%/B,98L1]IC.23DG/EYZX/\`P$4Y?`B"&.,^)-?.P$`FXCS@
M]?\`EGCGV'>NMHH`Y0^!_G##Q/XA4!54*+F/`P"./W>>Y_/C%1)\/;=(A&WB
M#7'0`##318R``#@1CD;5Q_NCTKL**`.3;P(C1[/^$C\0#IAOM:[@1GG.S.<D
MG/7)XQ3?^$`@"@+K^N(02Q9;A!DD$'/R8.1@?\!%==10!R?_``@</FR2'Q#X
M@9G+$EKT'J,?W><#(`.>IH;P(CC#^(_$#'.X-]K4$'#<\(.[$_6NLHH`Y)?`
M4*322KXB\1!I#ER+_D_=[[<]$4=>@]231)X!MY68MX@\0C+%L+?D8)]#C([X
M]-Q(P:ZVB@#EO^$&MP&`US7P&()`U!@.,8P,<8P.GI3?^$"LAC_B<:WT`/\`
MII^8#H&X^8#L#G%=710!RR^!K<.CG7-?9D.5+Z@S=R>XYQN./3M33X#M")`=
M:UW$H`<?;VP<=.,<8Q75T4`<N?!$!8M_;WB#GL-0;;G).<=,Y).>O3T%1+\/
M[(1M&=9UUT8899+]G!&0<8(/'`X]!CI76T4`<H/`=J-W_$[U\AB20=08@DC!
M/UP3S3CX&MRKK_;FOA7`!`U!@,#/'3@<GCI74T4`<G_P@-GMVMK6O,/]O4&;
MMCO^)^I)ZDFI/^$(MQ*\O]N:]O<[F;[>V<X(]..":ZBB@#DA\/[,(4&M:_L*
M[2O]HMC&<]/K_,^II3X!M&9B=<\0$MU_XF+^F/ZG\R>YKK**`.4;P':O*)&U
MO7RX<2`G4&X8'/\`D>@`Z``5T^&NFH3MUCQ#R!UU.0]._/0XR,]P2.A.>SHH
M`XQOAMI[1E&USQ(5)R?^)M+D\YY.>?\`ZP]!3F^'-@\QE?6_$;,PPV[5)"''
MHPZ,/8\8XZ5V-%`'&CX<6*G<NO\`B<-S\PUB8'DY/.<]>:9_PK/3?+$?]M^)
M`@&,#5Y0#SGGGGH/R'I7:T4`<SH/@;2_#VK2:G!<ZE<W;PM#YE[>//M5F#MC
M<>,LH)-=-110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`'.>`RQ\$Z:6SN*OG/7[[>P_D**3P#M_X0?3-OW=CXZ=-[>G'Y
M<44`3Z#G^V?%'R%?^)FF"1][_0[;GI^'?I6[6'H2XUCQ.<J=VIH>,<?Z);]<
M?UY_#%;E`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`9^O?\B]J?_7I+_Z`:Y3PXKOX)\+_`+SRXUT6UWX"Y8&(#)R#TZCM
MD\Y'%=7KW_(O:G_UZ2_^@&N:\+%QX&\,$3RH@T:T+A&Y_P!6N#@$$#.,M].0
M,D`&BI10XFB-QY1"LLLWF,I&XY4[0>,?>)SA`<;CR+Y7F'>P/E`C=))L+'*@
MA@.<C=U7Y06!QTQ)&TRP^:MR[E4W*L5SYO&W<H`Y+@A<9QN.[/7HLC/F2"63
M='*'@\N9VPP`^;EA@'!W<YR%.,@Y`!75XBH@VJI6)<[W!D7.XL=GW01@MDJ%
M.5X^3%+'(T"X>%#)&QD;]RZ,[9&,JO7+'&X*<GD+BIVCV0Q*-ABB*LJ^<JJ`
MFUD&,[1RV.!_=[`8J*8[:`MMD2.WEE?_`$>%RZR$L&<)MR6;#N#M(<R$#=N!
M8`A^&""/P%:HK;@MW>@-DG/^E2^O/YUV%<C\,T,?@:WC8J2MY>@E6##BZEZ$
M<'ZBNNH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`YKX?^8/`NEB5R\FQM[$8+'>V3C`Q^0HI?`./^$'T
MS#,PV/@L02?G;J1UHH`FT`$:UXJRFW.J)@\_-_H=MS_3\*WJPM!_Y#/BCD'_
M`(F:=`./]#MO3^O\L5NT`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110!GZ]_R+VI_P#7I+_Z`:YGPSF7P;X7$F\1G1K4[HUP
M5.U,X'0_3J#MP#VZ;7O^1>U/_KTE_P#0#7+^&B?^$'\+'RRZKH]H67&X-^[7
M"D9[MMY`_A[C(H`U8#%<@2J\9#*9V8*.'`[#<5(W98'/!48)ZA'6)7<&*,I@
MB(NQ7L`,D#Y<#<I;/`(X)?;3X7\@*QNI[B,?+]I*IF5F"J#E,`@@AN-ISPO!
M"4V47$QD02M".)G=6RO.5(&01M.[=E@W<=@5`!1`'??*6C7#;Q&W+`DLS`X`
M;)(P.<`9)RN'/#MF\P13+M(\H@;WRR@@G<V`V[Y1D;1@9XQ@:1&8(NT;"W[L
M2_<5@K*<!LG.T@;6`Z_@QLH&DEBF=40*$B5C(<+D`;=N'(`.!D*<8Q@D@%7X
M9A!X&MQ&S,@O+W:67!(^U2XR,G'YFNNKC_AA_P`B%:_]?=[_`.E4M=A0`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110!SO@4L?!FG%QAB'R,8YWM[G^=%,^'^T>!=+".738VUB`"PWMS@``
M?@!10!+X>_Y#GBS_`+"J?^D5K705S_A[_D.>+/\`L*I_Z16M=!0`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`&?KW_(O:G_
M`->DO_H!KG?#B&+POX;LFR)(--MT16;#,_DC#`#E>/,'4$X;L*ZZ>".YMY;>
M9=T4J%'7.,@C!'%<E'\.;"&&.&/6_$:Q1H(T0:I)M5!@;0/3Y1Q_B:`-19)'
MN$=XIDF>-B@=BWW\`XX#JH8IGCC`+!3S4;QQ1><Q@=(V3)<H1@J?,R68`#!W
MG<V.3D')-4C\/K-AAM<\1'.,DZFY)('!)[D=0>H(!'(!IW_"`V8#8UK7ER<_
M+J##'(;`QT&5!P..OJ<@%V2%FN5D90UP%"*C`NX"D?.`S`$;BAR.,@$D\8A6
MQC,D4#6QA625@J\(Q!;>S=LLY42$C#`DGDBJG_"NM/#[QK/B`';MXU)P,?-Q
MCT^=OSIR?#VR1U==:\0;E8,I.HN2,$'`ST'`XZ':`>`,`#/A<P;P!:,,X-U>
M'D8/_'U+78UGZ)HUIX?T>#2[$2"WAW;?,<LQ+,68DGJ223GWK0H`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`YKX?M(W@72VESYA1B^1@YWMFBF?#EVD^'NB2/NW/;[R6.<DDG/X]>IZ]
M3UHH`L>'O^0YXL_["J?^D5K705S_`(>_Y#GBS_L*I_Z16M=!0`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110!S'PZS_`,*[T'(`S:(0!TQVQR>/QHH^'2A?AUH`
M`(!LHSDALOD9W?-S\WWOQXXHH`G\/?\`(<\6?]A5/_2*UKH*Y_P]_P`ASQ9_
MV%4_](K6N@H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`YGX>9_X5YH(/&+-!
MC85QQZ$#^0^@HI?AZJ+\/=!$9=E^Q1_,X`+<<DX)')YZGK10!%$-<TG6]<DM
M]%6\M[Z\2YBD%VD>`+>&,@@CUC-6O[7\1?\`0K_^5"/_``HHH`/[7\1?]"O_
M`.5"/_"C^U_$7_0K_P#E0C_PHHH`/[7\1?\`0K_^5"/_``H_M?Q%_P!"O_Y4
M(_\`"BB@`_M?Q%_T*_\`Y4(_\*/[7\1?]"O_`.5"/_"BB@`_M?Q%_P!"O_Y4
M(_\`"C^U_$7_`$*__E0C_P`***`#^U_$7_0K_P#E0C_PH_M?Q%_T*_\`Y4(_
M\***`#^U_$7_`$*__E0C_P`*/[7\1?\`0K_^5"/_``HHH`/[7\1?]"O_`.5"
M/_"C^U_$7_0K_P#E0C_PHHH`/[7\1?\`0K_^5"/_``H_M?Q%_P!"O_Y4(_\`
M"BB@`_M?Q%_T*_\`Y4(_\*/[7\1?]"O_`.5"/_"BB@`_M?Q%_P!"O_Y4(_\`
M"FG5_$OS;?"JGCY<ZC&,GWXX[444`)_;'B;C_BE4Z\_\3)/7_=]/\/>F+K/B
MLK\WA*(-@<#5$(SCG^#UX^G/M110`XZQXHR,>%(\9Y_XF:=,G_9],?F?3EO]
ML^*\-_Q246?X?^)HG/`_V/7=^0]>"B@!QUCQ1SCPI&?3.II[_P"S]/S/IR#6
M/%&3GPI'C/'_`!,TZ9'^SZ9_(>O!10`T:SXKQSX2B!YZ:HGIQ_!Z_P"32+K/
MBP[=_A&$9/S8U5#CGM\G/&/3T]Z**`$.M>+MC$>$(-P'RC^UDP3[G9Q^M!UK
MQ=YC!?"$!3^$G5D!/U&SCMWHHH`<NL^*RY#^$H@O&"-40D],\;/K^0Z9X4:Q
MXIWJ#X3C"Y&XC4TR.#GC;SS@?3GVHHH`E_M?Q%_T*_\`Y4(_\*/[7\1?]"O_
M`.5"/_"BB@`_M?Q%_P!"O_Y4(_\`"F/K'B8!MGA5&.!MW:D@SZ_PFBB@!6U?
MQ+D;?"JD=\ZC&.X]O3--_MCQ1Y@!\*1[.<G^TTSWQQM^G>BB@!)-8\4ACY?A
M.-EP,%M30'OG^$^WYGICEC:UXN#D+X0@*YX)U9`2.>VS_=_,^G)10`'6/%_.
MWPC:8P<;M7`.0`><1GJ<C\/?A1JWC$JO_%*6`)`R#K'0[2>T/3.!^?'J44`'
M]J^,2W'A73@N6&6UDYXZ'B$\'/X8/'3*/JGC5`2OA;2GP,X76FYXZ<VX^E%%
M`##J_C8+D>$=,)R>!K9SQG_IAW_K3O[5\:Y_Y%32^IY_MMO;_IAWR?R/MDHH
M`:VK^-@./".F-P>!K9]_^F'L/^^A[X7^UO&VQ6_X1/3,G&5_MLY'_D#M110`
MCZOXV5E`\(Z8X8\E=;.%^N8/Y4\:IXU,P3_A%M*"G_EH=:;:.G_3OGN>W8^V
M2B@!1J?C0J"?"^D@DG(.M/D=?^G?O@?]]#WQ-]M\8;@/[!T3!'7^V9<#_P`E
M:**`%^V>,/\`H!:'_P"#F;_Y%H^V>,/^@%H?_@YF_P#D6BB@!IOO&(#G_A']
M$.WH/[9E^;CM_HWX<TIO?&`(_P")#HAR>2-9EX_\E:**`!KWQ@%)&@Z(Q`Z#
M69<G_P`E:07WC$A#_P`(_H@W=1_;,OR\=_\`1OPXHHH`%OO&))!\/Z(N.YUF
M7GD_].WX_C2?;_&/F!?^$>T7!/WO[:DP./\`KVS[444`*;[QB`Y_X1_1#MZ#
M^V9?FX[?Z-^'-(M_XQ.,^'M%7)[ZU)QQG_GV_#_ZW-%%`#7U'QFF_;X:T=]H
MXVZT_P`W!/&;8?3G'7TYIQO_`!C@_P#%/:*>#Q_;4G;_`+=N_P#^O%%%`"/J
M'C)=V/#FC/CIC6I.>GK;>_Z'VRQ]3\:*C,/"^DN0!A5UI\GCWM\>U%%`"/JG
MC5>GA;2GZ?=UIN_UM^W].]!U/QJ4ROAC2`01P=:<Y'?_`)=_\Y[T44`']H>-
MPQ_XIW1"#AEQK$GRC`RI_P!'Y.<\CCD>A-*VH>-@&4>'-%+8;##6),#KCC[/
MGT_/MV**`%-_XUR#_P`(]HA'7']L29Q@\?\`'OUR.O3D>YI%O?&X5@V@Z$6)
M^4C5I0%Z#D?9^><GZ<=>I10`Y[[QH%9U\/Z(P4']V-8EW-C/0_9\<\8S^/L?
MVCXSP_\`Q36C_*>!_;3_`#?3_1OYXHHH`7^T/&6&/_".:-P2`/[:DYXZ_P#'
MMWZ4\7?C')SH>A$9XQK$W'_DK110`@N_&?R[M$T$\?-C5YAD^W^C<=Z47OC`
MD_\`$AT08/!.LR\_^2M%%``M[XP*@G0=$4D=#K,N1_Y*TOVSQA_T`M#_`/!S
M-_\`(M%%`!]L\8?]`+0__!S-_P#(M'VSQA_T`M#_`/!S-_\`(M%%`!]L\8?]
M`+0__!S-_P#(M'VSQA_T`M#_`/!S-_\`(M%%`!]L\8?]`+0__!S-_P#(M'VS
MQA_T`M#_`/!S-_\`(M%%`$;77C8@;-&\/@Y.<ZM,<C!Q_P`NWKC\CTSPYKOQ
MGD;=$T$#OG5YCW'_`$[>F:**`&-=>-_*(71_#PDQPQU68CIZ?9_7GKTX]ZD^
MU^,=P_XD>A;<<C^V)L_^DM%%`#1=^--A!T70"^."-7FP./3[-Z_Y[TXW?C'(
MQH>A`9YSK$W/_DK110`"[\8Y.=#T(C/&-8FX_P#)6@W?C'(QH>A`9YSK$W/_
M`)*T44`,%UXVWN3HWA_:2-@_M:;('?)^S<]_3'O2)=>-QL\S1_#S8'S[=5F&
M>!T_T<XYSZ^GO110`W[1XZ\P?\2SPYLV\_\`$PGSNQ_UQZ9_Q]J!+XZW'-EX
M<*@K@_;)\GIG_EEQ_%CKU'IR44`)YOCSY";+PV<[=X^USC'3=@^7SWQP/\7A
M_&Y7F'P\K`?\]IB#U_V1CMZ]S[444`.4^-"1O30`,<X:8^GM]?R'KP[_`(K'
J<>-"VXX.9LT44`6_#&D2:#X7TW29IUGDM+=(FD5=H8@=AV'I1110!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g201504281926445851271.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201504281926445851271.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`)'`<@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#M-8?QMK?Q
M#U72=`\41:39V-K;R^6]E',6:0-R"RD_P]S]/:>+PS\3%R7^(-NYQ@`Z3#@<
MCG@#_:_,5;T:,GXQ^*)/,PJZ?9*4QUSOYS[8_6NYH`\\'AGXF`*#\0K5L,,G
M^QX@2/?_`.MCIU%-?PM\32IV?$>#=G(']C0@?3O7HM%`'GG_``BGQ)VL/^%E
M1YR-I_L.#.,<_K_+\*%\*_$DC#_$B-<`89=%@.>3G(/X?ET[UZ'10!YT?"OQ
M+#87XDPLI'4Z+`"#]*>OA?XD@#/Q%@)&/^8-#@\DG/Z#MQ[\UZ%10!YXWA;X
ME$#'Q&@'R@'&BP]?7ZTH\*_$C&#\2HQVR-#@]>O7K7H5%`'GG_"*?$@[?^+E
MQCL<:'!^?6C_`(13XD%L'XEQA1T(T.#)Y[C/I7H=%`'GO_"+?$C:O_%R(<JY
M_P"8)#\R]L\]?8?G2_\`"+_$?J?B-"<MG;_8L(`'H#Z?KQU&<UZ#10!Y[_PC
M7Q+\O'_"P;7=M`R='BZ]S_7ZYZ4C^%OB420OQ'@```4_V+#D]>OIVKT.B@#S
MS_A&/B65?/Q$MU)7C&C1'!Y./IT&>>.WJX>&?B3E_P#BX=MRIV_\26+@Y^O^
M/05Z#10!YT_A?XFD87XBVPP!S_8T.3ZTX^&?B69&8?$&V56/"_V3$0H_+GT_
MSQZ'10!YP/"_Q/P@;XBV_7+$:1#G'IT_IW-._P"$;^)V[/\`PGMGCL/[+CQG
MWXZ?X#WSZ+10!YTOAKXG#)/CZT8DYQ_946`.P''\^WIUH_X1OXH;%4>/K+*D
M$L=*CRWL>,8^@S[UZ+10!YTGAGXGA0K?$*T.&#%O[(BR>F1Z8Z^]+_PBWQ+,
M;?\`%QX`_&W&BP^_\^.Q_P`?1**`///^$5^)+(0?B3$#P01HD/;\>]'_``B?
MQ)Y_XN8G3C_B1P=?\YKT.B@#ST^$OB*5Q_PLX9/7_B10#^M+_P`(G\1LC_BY
MPQSG_B0V_P#C7H-%`'GB^$OB.%4'XFKP<?\`(#@/'USUI!X/^(H`_P"+G?=/
M&=$@Y'OS7HE%`'G?_"(?$8+L'Q-&W.,_V)!G'Y]:/^$1^(X!"_$T'N,Z'!US
M]>G_`.JO1**`//&\(_$9A@_$T?=[:'`.?3KT]Z:?!_Q%+!O^%G<@9_Y`D.-W
MIUZ?YQ7HM%`'G?\`PAWQ$RP/Q/.UN_\`8D.?_0N._2D_X0SXA9!/Q.8YSD?V
M+#@9';YJ]%HH`\Z_X0[XB9/_`!<\\DD_\22'_'T_SWH/@SXAEN?B>V,XXT6$
M<8_WO\]:]%HH`\Y;P7\0VY/Q/?.>@T6$#'_?7I_GO2_\(7\03Q_PM"3&`/\`
MD"P__%5Z+10!YW_PA?Q!PH_X6A)P,#_B20__`!5+_P`(9\0>/^+H/QG_`)@D
M/?\`X%7H=%`'G/\`PA7Q!R!_PM"3&.O]BPY_]"H_X0SXAYW?\+/;(&0/[&AQ
MGW^;I7HU%`'G)\%?$$\?\+0DQG/&C0^G^]^E-/@GXA%0#\3Y.3N.-(B&#QWW
M=/\`/<UZ110!YL/!'Q##;A\3Y,D98'2(L`^PW4]?!WQ&C+%/B=DG`^;183QD
M^I/^?I7HU%`'G"^#_B2H_P"2F+TQSH\)_K2_\(A\1QG'Q-!Y`YT6'H.G?K7H
MU%`'G2^$_B0L:I_PLF,@'DG1H22/3.?\YH7PG\2D0J/B3&W&`6T6$D?C7HM%
M`'G9\)_$G<<?$R,C/!.AP4T^$_B6<'_A9<>1R/\`B2P"O1J*`/+#_P`)YX<\
M9>&8-6\6)JMCJ%PT,L*:=%"!B,GE@,]<?YXHK;\;;O\`A,?`VT'_`)",NXC/
M3RFZ_CBB@!-&W?\`"X_%&,;?[/LL],Y^?'?/KV_$<9[FN&T8/_PN7Q00PV#3
MK,%<<D_/@_S_`#KN:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.)\9OM\7^"1G&_4)%Q
MC.?W9/X=/_K=P4OC,[?%O@KY@-VH2+@J>?W9/7H.G>B@"'1Q_P`7G\3G8A_X
MEMG\QSN'+\#M@]_H/>N[KA-'=A\9_$Z93:=-LR0?O<%^GMSS^%=W0`4444`%
M%%%`!1110`4444`%%%%`!1110`44UG5`"[!<],G'O_2HC=(,`JP8D`J0,KD@
M#/XGMZ&@">BJ37<F4.P)G`*L><G:2,?CCU_D8%9W0([ER(U?9U8]PP(X)SM&
M>GRD]Z`(?$/BG2_#.A7.KW\N8+=<E$*[V/'RJ&(^;GIFM'3K^#5-,M-0MB3;
MW4*3Q$C!*LH8?H:\L^-SO_PKF^;>JAY(0=PW;QO7`1L9[;B3Q[@G!]/T=!%H
MEA&'#A;:-0RG@X4<B@"[1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`&<VNZ8GB&/0&NT75)+8W26Y!RT0;;N!QCJ#QG/!.,"K45U'(VT_*Q
M)V@_Q#J"/7(Y_/T->2^-;N33/V@/!UQ#@M<VPMG5LD;2\BYP".0';!KTJ0YD
M5E3Y=S!/X0Y+$X![$XSGIP#D="`:RL'4,IRI&0:6LM'8?*7;RPWWB^-JC`/3
M'HWIC`R.M3QWCR+PJ[B0N`<D$YYP#TXSUZ<Y[4`7:*KI>1ML#`H6P!N(P<@'
MCUZX^M2K(C-M##<,\=^.O\Q^8H`?1110`4444`%%%%`!1110`4444`%%%%`'
M$^--_P#PEW@DKNV_VA(&PN1_JCU/;D44[QFH/BOP4Q`XU%\$_P#7)NG^>W7L
M2@"MHZY^-GB5]IXTNU&[/`R6X_3]*[VN#T<?\7J\3-Y><:9:#?GIRW&/?^E=
MY0`4444`%%%%`!113#-&%W%AMR%SVSG&/SXH`?15.2^`#*JD.>%W=FS@9'IR
M#]#VR,M^TRG,@91&"6.02``H/)[#_'VP0"Z2`0"0,\#WICSHD?F<LN1RH['O
M]*H&5OE$C`;9%8^86!`YR>HXP./;.>]9&L:A=:?`)+;2FO'(+2#SUB")M+%B
MQ)']['!SSG')(!O->;O]6I&&P22/7`XZ^OH<KCKQ41N)&*ABT1R7(;@JN=P!
MP>X5AP#C^?,Q^)I;F339&TJ[6SU`6Z17>\;OWJ;E'D\G:.`Y)'1CR%)&^A<9
M**!("-B(0,X^]C/.WA?ESD8QQ0`IV.S1_*&"ABVW(SR6/KCAAZ@L>N3A"K2;
MHV@*R`%@`<E>>P],C!/?<><4[@0E2WFC)^5U(!(8`<8'S%L9Z\@],TUB`!\A
M,0D?AGSAL<CC'.,COU).>I`%R#(R!HROWDW;N<Y`(Z@Y!QGN23SP*5!YJLVX
M_P"KX!.[/&-WUP0>QZ=.<\IK'B+5;"]UX;+58[6P,UL"SOY\N9%P0,<DA0$Y
MQZGC%KPKJ5WJNFW:ZF^^\M;GR?->U^SO(C1JZ.T89B/O%1R=PXQ\QP`<O\;/
MD^&MXP)7S9XLJ23T921TP3G'/^SCKFO5M.3R]+M(]S-MA1=S').%')KR/XUW
M`;PUIFE%"7U.[C12"=IPP/09)/S>I'/!))KV"U!6TA4F-B(U&8_NGCMR>/QH
M`EHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#R3Q8D4G[1/
M@I9]IC%G*P#<?,%E*\_4#C_&O09(W5I#N<AN'`4_.".`P/)Y&,@@'IQDX\V^
M)J2V7QC^'NHI($$]Q]F&TX;_`%BA@>V")<?G7IERB1S7`$<84G+%CC&X?>/L
M3N'/^UR.`0!,G=(RL8R<`L[]\'.=N"1QR3T(/84K1EF7]WRR[6CP1E3@<=.H
M48R?4'IPW+,WS!E,HR``"S@\$#((.<J3DG&!SQPUD&T!@CJXR"5*Y&0.`1T&
M%^N%X.>`!ZEMSD2LCL&W,1@@>K?0$<D<!E]#EVV9U"%W&S^'R^G=&`]!COS\
MOJ2"UV:,;&($@'[M2VW.<A0.^.3W'7G'0-;!#!U*?>5VV#`4``9]?ER>W!;`
MY%`%F.^;#.Y3`(+@D\#';_ODG^6<@U92[C=@HSN*[L`?P^N.N.U9TGF;&+#8
M,DN=H!'&>?<<MD'U.,X%/#,^QG"O^]!+'.U3QM].3P,\XXZYR0#4$BMT(^\5
M!R.2.O\`7\J=60DNR(M&S(-P#*22<+P1Z9//?@`<#M+#=2$A&;E,EB3TQG<&
MY]P..A&>F!0!I456CO%?;N0I\A9L]L8R/PY!]"/<5/O7?LW#=Z9Y[?XC\Z`'
M4444`%%%%`!1110!QOC*/?XF\&-G&S4V;IU_=./ZT4_Q@BMXD\'DDY34F(P.
M_E,/ZFB@"AI!;_A=WB0!OE_LNUR,]3DXX_.N^K@M'W?\+L\2X#;?[+M<X/&<
MMC/OU_6N]H`****`"N%\&^.KSQ+KWB[3[FRBMXM$O1;0R(22R[Y%)?)QQLR<
M=C[<]U7COPJ`/B#XAE&"-_;3`.@Y&7E`"Y]SCGU[4`>FM/(5+.5=5=7*@\*!
M@YSV!.2,GCCMG#$'F,GRKO((Q@GY/3&.4(`_0=3FF,WS!B%W##!0.JJ1MVDC
M[IXX[L!CKD#?.NPRL=X.7R"IX&<G')R=F0#QQUXH`=OC8QQD!L!L`G)520.A
M['.1QSM`ZFG1[7E3!8;BH5D.<@$@KUQ@`]1TY[\E-WG3;`=O``=%W?,W.<=1
MR,@CTR>U-;S7Y6)F#C!#/RY)R1GME=IZX&0.@X`$!7R<"-&&<)CN/XRI/<D@
M8(QD@<\UC^(=$GUE8K6+53:1[LSH(%=+CML/S`D%NH.`Q4YZ$5LHKC:0^P*S
M`.R\KZG.`..<C/\`!W[BC:PW)Y6Q2`)0-J@\$D#!&['!R>2>..0#G$TC5)/$
M]IK4^N+(8T14MWM1C(4!R@SA7D!Y;L"`"0,5T@7Y#F((I.PH$XY/`Z8&"<CU
MR,XZU&761R27+#8GS$$@EC\K#)]QUR!CJ<TY-JKN.$C(Y+#+'J%S@;=I!P"/
MH.F:`'^:'3YMC*WS$,^[)('4#`Q@%@?;@`\4V3<#]XQ,P4[&4`YR<#OR3SU)
MSD\8.55-XC8J&5G(*M@@DJ6R`,\$G/!)P`>Q--C<_.H"Y`S(H8Y`)/!Z]#R1
MVR>3R*`*-YI4-X\[W]N7:9%M9G=R`4#9"=>F6)SP>^<\4^STRVT^,K;"=O-<
MRR2W$CS/*.@9I6W$KMXP/N@XX!S5D(%`!@B0YVKG'`4Y(XXZ9S]3R3D4]-R(
MKI$H8#!P#\@&06!YS@'&#C'H.:`/+?BT&N?$O@:%2GF3:JH49'S$NAZ]A\Z\
M9/7/?)]K50JA5`"@8``X%>->+XGU'XR_#_32(W2V,ESM7(564[SV'/[H''TX
M'?V:@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#R+XUK+
M::OX%UF/!-GJP7:>Y9D8>^/W9_/Z5Z1<,RW4R1G:?N*$8`Y(W<'L21C'OGG%
M<;\<-,GO_AI<SVPS-I\\=XK!B&3:2"R^X#$_3/>NML[]=6TK3-5MQ((KRWBN
M%9QT5@&`8`]?F'KWZ=:`$<C/"#;N\IL'[Q)&?O=S\XSZ@YZ\,8(4EW?>Y!)"
MH)&Y//OP5)]`W-*1L1L)&,)\RY"@$XR#QU(7.2,>N1@T,2C,7`9-N&4<8!ZJ
M<#H`,$\GY>_(``K*52029BC`()8#!R`N<=.H."2./;@.#`2",$1&0`A@Q!;(
M'R9'3[P`QR!S]6EE$;OM+YDW>2N,2$\<]#SD#W!&0<TY)'2-D59F!+LK1G#,
M3G&<#O@'H2,CJ,X`$()@WGRW0*0&56XYV]QMQCD]!Q@\<T961<(5=6!3!.>0
MP4#G^'YR..Q]>B)D'>NXN"?+V\[AW"\]``!TSTY'9V'2Z&Y]NX(I8`AR6X!Y
M'NWIT/!QB@!PQNW[6)VX4$\8((`(XX/0'GG([DL@<X\V5F;**6QR1\I.1CJ"
M0WL,<<&H@(MI"G,;[]H\M1P?O8X.1R0<GM_P(*IWNI56B=@/ECQD,!C'4],G
MC'`/K@``4MEMJNC2;"Y(<=L'C.3CCJ>O'H"'#(G9Q"N-C%$;*[0#D<=N-O7I
M\O3G"JY:3:I81J2<D]<').W/7*D9X/?DY(CCV/#F/RO+V-\N/<D`<8(&UL$]
MR>,T`78;MMW#,ZD#'R[B?F^]QZ@Y/ID?2I8KT;,S;%`7)="2ON<XX&,'/_ZS
MGKD_,<M&<!9`H.2<DDCCJ&Z`_P`7`SG$5]#'>V4T%RX99XFA^5_O9!!(;']U
MN.,=>`#F@"UX>\2Z5XIL);W1[DW%O%,T#L8F3#KC(PP!Z$?G6M7E/P"3RO!V
MLQ!2BQZW.BH3]T".+BO5J`"BBB@#B_&IQXE\%C8&)U0@'/(_=-R/\^M%)XX/
M_%2>"EP3NU4C@D8Q$Q_'I10!6TAC_P`+N\2+D\Z7:G&>.">WXUWU<%HY7_A=
M?B4$+N.F6A![XRV?Z?I7>T`%%%%`!7C/PH$O_"5?$_>LKQG4B%4]2WF3Y]>?
MNY_"O9J\B^&!4^,OB1'F$?\`$Z4Y4\@F67Z\Y_#.>U`'H$A+I(%B5%<)U4E3
M@`#/7C)XX.<?F$HXPQ#B3A5C;G&2,G/`.3CN"3Z$FF-NV%ML1CBQG<<`9V]L
M=&Y/J?J<5._#E&?!*%W5TRR@Y!8@G!&.^2>`.>:``!Y-OF-(Q,A(8H2,C/IS
MD8`]L#'0DQAGP'!5BY`!5N-WIGCYOF;//4_6GO'F95VAG`!V=3R!\AXP`=N,
M\G'7H:1YT"LQG=I<'N,L@X!!'3C=[\G)&,@`5EB8!&`Y`''S<<<D'@C.P@#G
MH,=J0,OG#`52O`*L>_&`2,\A>.G?!^Z:&8I*TA;8N`=R#'!ZD9YX!<Y[G)Y[
M5=5G@MM)OO[1\[[.(&$D$+N6:/!R%"D'.",`$'GIPM`%HECN+F9=Q4;0=V6Y
M4XR<\';SU!P/:G[I3*0Q?S,H[JIY#'.1^61QV`YY)'FL5K!>_#'Q"^G1-:B6
M.69=.LA)`L+"`JB8"C<7/+!<`DA>1DGT^[D!NVCS\P4L-QRO`R,>C#)[8Y'H
M*`*ZF,$,N71E^7(X)).1D=3DE>N,-U.3E7*,WER2^81(0@9MRLV>!R.W/OR!
MEJ02('5C(&8@,"!DDD=R3NP!G!`Z=SDBFS0I-;S6\Y_<M"(YD):/Y6XP2IRI
M.X@`<#'`&:`,ZZU_1[)8&OM8TNW65F9)'O(T#NK%7(WD`L#D'`R#D''!&D&5
M_P!_\IC<"1"YR#C.TAN_\(!SCD^HSPUCH,T7@W2]!DTLJC:C/#,K1*6M[9KF
M:0^R;T54!7_GH",8!KM[BX%I9SW#")52`NVTGE$4]<<;3ZXQC/0XH`\T\$0Q
MZK\?_%.I&6:<6=ND<4DC#*DJBD'''9ORKVFO*/@I9S7R>(_&,T/E)KU^\ENK
MN7=8U=^,^@+$?\!^E>KT`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`8_BO3&UKPCK&F(NZ2ZLY8D&<?,5.W]<5P_P<OCJ_P`)M-BW-YEE
M-):NSH.3O)7;V("2`<CG!'O7J%>+_#P+X:^+'C?PJ`UO;W'^F6PXVQ+R<CG`
M&)5]_E'H:`/2]B$QCRPC`-M8K\N2V0/4YP<$<\]SR&JRCYDDP%.,1L.HQGN.
M,9)YXSGC)`F5@6&R`97I$#_#][(P>&.`<'OCTS0LH22/9MDF(W`)NPQ!/0^I
MR,G&!\V>]``%9G+HH4EAL?:21D'./XB"=_Y#'7((XPRH?*=8Y2045,C'U)ST
M+=!SEL9XI`J"9(CDE<C:\1!?U/J0%V].O0].&`JCB5\F4$[ED(W$C!&3_",@
MX)]LYQP`+@,I2:24AUY=B,`$$;CSZ<GMA3CBG+B)V4R2JP4N.,!3C`&#U;[G
M'3L#SRFU][KEI&QC>XP=V.`3C"L<J1G_`&>!@`I\C1O(8&SA5*[3@YR`,YZ?
M3)P1ZXH`$"O#N9RJJY8G&1N[\]-V<8Y'7\`K>;(Q8D[51C(02</P"&[9`ST]
M.G04Y6E8ER6+(%.]LC*DM@G'.`._K^)+#,S>6Y$AD(W!BV,*>_&<`C)XY&"/
M<`#UC!D94\Q75P=C1C]V"2<?+GCY5Y[<$4B%V@5Y#(^-Q*L1\WR]R.#@#KW!
M_"F'#32$A5X)8KAB&.<C`/'?.3U&.0":=&V601Q89?F0+DX!49P0>0/E],\<
M@&@`/S?(K>8RL?G90!\QZ@#(PP]<9SD9.<T]6O#INF7=Q%ND\B"2[2-VX.U6
MD`^4G/*X)'/)QGM;4N/XMP,84`<J`?[O'/!&1@=1@'@5'?6@OK*ZL&C9HY;<
MQNB@@HKILZ<C(!(Y^O.,``XWX$%G\(ZS*X&^76[AVQTSMCZ>U>I5YA\"HS%X
M)U!/,$D:ZM<"-\<LH"#)XZYS^E>GT`%%%%`'#>/<GQ)X'`56SK'1ES_RR<YZ
M'G_.1UHI?'B!_$/@MC)M*:N&`XRWR,,?K^GXT4`0:0?^+X^(QQSI5KV]S7?U
MP6D,W_"[?$B@C:=+M21QG.6Q_,UWM`!1110`5XU\.B?^%A_$RW,.\-?QR8W;
MSQ)+TR.>N<'@=.E>RUXU\,)B?$_Q-F9CY+:MPQ)&099N.?;'Y]NM`'HZJSL"
M\9"A#N=NB)W]>#\P`'&`._(:.4VB38I);&5/RY.3^&6RHXQD9S2NRX0D%6B5
MU;9@$G.2<`X#`?-P."><4Y@HVA4WL?X"AP6''KG^$_*.``>N.0`+,N'9'2)V
MWG*@J"#]X<YR>O7."?0$N3<""&DC+#*D`'J1@*3U&=HZ8YY)X-(N%92T;QX8
MEW*]-N"O?ORQQR::H8(KJ7)9MG[Q^O/RCI]XYR#GC`&?4`7Y'8?*A(!D^5N&
MY)R23\N,>H&6(SU-)L?;)E&!W*-P!`ZG`R>>AVX(QT^M"HQ@*-D9YW'G@_=!
MX[\C(&00?6D&T'YG;YAPN"2>.OS'&%#<<^]`"A<-A5RJJ"NXXX().".V$([Y
M&,$=2[<P!:-CO.4=PQWD*<$MG.!SGU&<<8S3%SR5DV<X(0CJWIZJ<'!Y.``!
MZJL9#*P5EPIR!_=Z$=?3.[)X)XYZ@#L_,Y1RJC`E0L`$&3A<^F3TX.`1UXI=
MCH0P(.!LX4CY1@'CD;1\PP<D9!/S<5&`HB=2"-K94;N3@CY<@C('?/(Z]>DD
M@9Y')5LE\C:I!/).=O4].A!Z=3RP`!(PJ@Q@E<,``%`"`$\D=CD<'N?KGB?B
M;XCB\/>![B-4DDGOD^QVJQ*K`.VXYP&Z?*W3.#MZG-=L61Y,+O._<Z@KC<<L
MPP1G=@XZ_+@9]*\H\=QW/B_XH^&_"EK!,R6#K>WS/&ORQDK@G'3"\>GSCC-`
M'IOP]T:3P_\`#_1-,F39-%;!I4*[2KOEV!'J"QKI:**`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"O'/BFW_``B7Q#\)^,X(VC@DG-GJ
M,RG@I\N`<G'W?,(Z?=KV.N<\>Z"OB3P/JVFBW6:X>V=K967)$H4E,>ASQGW-
M`%R[CC\MO*$31.!*"22O0_-WX''0=QVJ%_N.V%C3!W[C@$G<I+<$9(4\^IQS
MFN4^&FO+X@^&^G?O':_T]197"R)RKKPN<\'Y<=B>?6NJ9<(.9`2-W4$[>5R<
MG&.A^C8SC((`.F54JD<L8(VJ@X?Y@!NW#`).>GJWXJ0R*,;G`(*DI@D-C'?@
M9`'3/'RGBC`+E2R`GYT9P!\N,DXP<Y(ZG.!G//5N4;[OECAF)0E=V`!MSVXS
MG)P-V><9``JR)%N92<H!@_="CG+9Z<G&,\\GY22<@;9*[>8(P(Q\V3A2XXYY
M[L>3TY(ZFE1&;Y"9QN)R%4'/)&[UP"1E<#&<8SFFH"%5@X+$[!\VX#=U.#P2
M<GUY7`SV`%11(_DQHO42F,#(QWXS^';J,'T5"9%"LN7D3>2')9AMZ`C[Q`.>
MW7`X-("&+[F\S<0%&]MI^\",X&,\#T)&.W"JVZ,NP)5C\KXW`_,V>0<9]2/;
M`^4&@!I(`PHVDJ""C#YMK#'M[Y```/3D`/D,;NPF=6&[[S`DCI@]AGC&..01
M@X&&*PSN*C<%`=78M@C/WL?Q=>1SQ_#SF2,LP4$L@"G<#R0S9!]>>,#N22.N
M:`&F1GD<B/>S?*64G<S'.1]!@\'MZU1UBXDL=`U":&0F6"T>9=R@88#`&`>.
MZ\9XW#L,W$58P'(#1[%0YPVTX(!(/8YSD9Y&!D=8-5^S_8+U;Z4QVT<;^?G+
M$1D;68XRQ!7/')^[@T`<]\#5C_X5A:3)&$\^YGD90H`!\PCCVP`.U>CUYI\#
MIQ+X'O(U15BAU2XCCV@`%<JW0`8^\1T'3I7I=`!1110!Q'CO_D8/!1\O>1K`
MZ?P_NV^;T]OQHIGCXD>(O!"Y8*VL@$*2,_NV(S[9`_*B@!FC@?\`"[/$I^7(
MTNUZDYZMT]O_`*U=[7!:.?\`B]GB49'.EVIQSGJWX?Y^M=[0`4444`%>-?"I
MPVK_`!$=W7:=9SN)`7_62=,`_P`B.GO7LM>0?"T>7XV^)T**0ZZH'4E<X)DG
MQP,]#_\`JH`]!VD'<N0P";@.H8G`]<'(Z#C@CG&"LBY&TIR@^96`((XSN!/&
M1C/OSP#DM"G:&9F`#;HC&"^U2<YS@9R<$#D]N>14BJ4*?Q@@D(B$@<DC`^7(
M///).3VS0!&59(EDS\Q8_?"MP`,_>(RO?(Z<\CI3U0/E`'*[#T.2PQD\9]=O
MO\V`<`4X;0%E9LY+9=5W$+@!CSQM&<^WIU`9L)(50QE.YUV+@9ZJ<GL2.F`.
MO8"@`0&1O+=-V5,C`<LP],<!E[<\8.`>N,H>)M&:>:U_M6%'M!))*RG@B/[X
MW,`#M"MN&>,8[8&F2"#(@)(;"B,G;N&,;23U.!P1V/!S\W#ZEI6MZY?ZHLVG
M&TCA2:'3RMQ'Y>3DM(X7+;I,$8X"@D8SN-`'7Z??V>HVK7-E,)-C>4XC#*8\
M@'HX!R5.>1@CD$5:0!F2,9DD4%B-H&X@<@$\\8^Z0!]!BL;1DOI=3U75[_3O
ML,EY)%$EFTJR;-BD98KT9]^0`>BJ>#FMIP`)&61UC.TE^2#DYP3ZX.,@\YY/
M(-`&?JFLZ=I4NG6]]<-']MGCMK9&!+O)\L9(4'/!90?X1QU)&766L6&HW]Q:
MVS3;XV<>8D+>0Y0G='YF-F5S@X/4=20<1Z]I;ZG;0P1-;@V][;39=2IV13HS
M`8XR5B.,8[\J,BL71/"MUH_B$7B0VR+'-<3O<H7-U?><S'R95(&44L6#9.?+
M!P#N%`'333P6]JS32(D47SMEB&`!R00I.>G3!/XY*^??!>&_\0:UKOCS4((X
M?[0"6MNB=-J8#8YS@;5'/4@FD^,FJ72:'8>'M,N7_M+5[M;4"-BC/&<JZMM;
M.&8H,,#P6!).<>H>&]`L_"_AZST6Q+FWM4VJS@;F))))P`,DD]J`-6BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\@TJ%O`7
MQMNM+R&TCQ6'N(E;`$<PRQ`]LEUQ@?>7TKT.:/:D\>-CA@Y!R<@+][/=1[YX
MP.VVN:^,7A^76/`\U_9JQU'2&%[;,C;6&T@OANH.T$C!!R!WQ6EX7UZ+Q/X0
MT?5HB)WFMPLZ`DXG0?,#]"'QD_-D=0<@`T&#&!OD=\AL[#@KG^$'UZGTP>A&
MVAG=Y%8N,YQA#@L5/&!R-P!''0G/ME8U5]H;Y6+`]`,#.21@=>1A>AW`D?-2
M-PCR$R;%15<D9!]1G(*GU&[OCD#D`4(P&(U5CP55FPKD'OGURN,>H'&X@M;*
MMY15^2!N+8(R2N"H]0??(`[\AY4@+A%)8;4+YY)(&[!PN.1S@GIP3F@*ODJ0
M2@;,H(W$D8SU^Z1SP<C;QSDF@`W$$>8\*94X8C&<X('RXR.G;N><?>:<<!T3
M*.XR&`)QC((7'&0.?SQT(&$,C#>4`/+9)`Y;@`]<G(YQCWY-&XC9'Y6^3`0X
M?<0!@8'8D?Q=.3QV(`')@L)9)D+'^)R3P<D9X`QTQQ].!2*K>6DAB<[5/W02
M!@\#)Y[<YY'0`'.%WJ(>/F\QE5&#G+@'&1SC^+[H&!C!["G2+A-ZF/;@KEE*
M*_3!!Q@YYX^Z?0]2`,<%7"IE`N6#)M"D<D'C@[L<X`ZGL,5'>K%]CG$L06(A
MU*-MY10<_>]5P<DYY/3^*9\&XD"EL'(7YB5SZ>H8_*#GKN(ZXS7O;>&YTJYB
MO/*$$UNZEP2IVX))'`'0]0.F2>F"`<3^SZJ#P9K!B1HHCK,VR$G/ECRXL#/7
M/;\*]:KS'X%VK6?@K4(P=T/]KW'DN>KH`JY)[G*GFO3J`"BBB@#A?'^/^$B\
M#_,RG^V1C`SG]VW'Y9HH\?C_`(G_`()()#C65QR`,;&S]>,C'OGM10!'I`/_
M``N[Q(VT\:7:C=V')X_SZ5WU<'HZD_&KQ,VS.-,M!OSTR6XQ[X_2N\H`****
M`"O'O#,`L_C9X^@C+@2QP/M[L7"L>G;YC[XSWKV&O*M`59/CWXZC.TN;.T95
M/.2(X^V1D9QWH`[89F5TA.&*%,)ALL5'?L2`03QC)]S2G;(DB[L,752<GH1@
M$'@D@'@'&>>IY+3^\@&__4L#D[<KUQW('!'0^YZ9+2#=+,J"7"CC.0.IW*,'
M^(Y`!W9ZGKG``.Q\U9$;RY&5$V85MIP,<G.#G('0';U[T@3S`L>!&K$*/F.W
M[W7''7/8'&5'R\4C$!&+1M'((\#L<<C)!QQG!+8]0>*7=Y:A&8'R]S@R$8<'
MA22W1>,<>V,Y!H`2+]Z$9OE61C']]BH);D<$8)SVZ].!G*LI\MBRF-%P65P>
M#G(`/.,Y&3G/3@8Q1&624%MXRH*D9<C.<<=\9&.">#Z8IJ%/+5BD6-Y3*\MG
M.#@=\G;R.?F;D=P"3R_+8E8GP`-Y9.Q&1O\`?)))!X(SCYCF-`PBCV`&3)`+
M!<D'')(Z[L]1D_-U)/+HP^`L30[@I.X[2#C.=K8Y![_W<B@LI8F,8R3L103E
M6QR`>N01D8.!Z4`(S;2%+L,')5CC:F<J2#C!/''LHX'%*5$8VR+(K%4)!?!Q
MD87TQ@$]<_*1GC)3YWVK&H;Y5DVA2``W.1_$1G'!!'KC%<9\4_$DOASP7<RV
MJ++<:B_V*"-LMM+`[C@'=OVYR#P3UST(!E>!-GCOXL:MXT2`OI-C"+.RED0#
M=-@%B![9<@\'#KGG->S5R_P]\)#P5X-L]':433J6EGD48#2,<G'L.![XS744
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M5X]X3A;P5\6M;\)W*;;/Q`6U#3GC).PC>2O3@@!O^^!SR,^PUYA\:M)F7P[;
M>+M-FE@U?0)!+`\:*V5=U5MP(.0.#Z8SD<T`=C)@2<%A*IYB8D[3E1@_[)XY
M!SAL8/8"M]H5E0R#:&&QBP93G&,D9&!T)]@,9S#:77]J:+IVK1[XX+ZU2YP6
MSY6]0YQQDC!;((YZ>F)DC<CY@ZN6*J&8@#J<<_Q,<=0>/8@$`1>'R78L`-TG
M3:HR!C@'&W<3T)P,>M.5$CPSQD1%MY;80IYR6&#_`,"![?,<=!2(P*[M_P"Y
M+9+%RJ[N?R((/0C.>PQ3`PRP8O&VX..",#OD8&T]2.>V?EH`D(1%*-N4*0QW
M<,-W3JW7Y<X__9H.Y<1YR=HYC(4;\%<`'N<D'@?=XYX!LQ&59MJY8`.@C!?&
M<DX&TDXXZ'WYH;DG!(9CM902`K#@J.I[D`C`R0.00``*F%?!/E9<@*.02<XZ
M>C``#`XW#')`18V7:I2120&8.,A3D<>F>G'&<@8QPJ;`NU3&RN(L[3U``Y)_
M->>.0>,\%S)DE3NP5!^51MP0.01T!P/FXQC(QS@`0*TK;I)"`!\W`9LGMG'7
M<5'MS]WBL3QC-+!X%UN=6.Y-/N),;<+S&<<CM_=S_=QVXVQN;,>UMJI\Q*D,
MJ_PYZ<Y7OT'.2.:PO&-L+_P3K5NI5)GL9F;)Z?(W"C'.,,,8X`QU`-`%?X((
M$^$>BL.KM.Q_[_R#^E>A5P'P3)/PAT(DD_Z\<_\`7>2N_H`****`.(\?!3K/
M@_*Y(U>,J<D;3TS^1(Y]:*E\=9_M#PL0<?\`$WA!!Q@\C]?_`*_O10!4T<M_
MPNSQ*-@*_P!F6F7QR.6XS[_TKO:X/1RW_"ZO$PYV_P!F6F?EXSEN_;OQW_"N
M\H`****`"O*8K;[%^TE>F0[!J>A9C.1\Q#(#U'_3(\>WI7JU>2_$)H]+^,GP
M^U-L#[3))9L5)R<E54'VS+_.@#NV`8-EQ\P'F8`W*I&3US@`8YX'S#ICA6=T
M=3*6CW9)`Z@;F'W6X(QW/0"GS1KYLJ85V+,P5&R>IZ#/)`#9XR"<#L0Q95"B
M?=M7=B1BQVGEAT/48'0#U`P:`%19(U0I"%F61?DC8\C.0`>ZD;LG\.W"*`@$
M;$K(XVJI0C!X`Y/U'!!XS@;3R&-=FPJ`6&S<F1M)...1\Q_B!QVX.#2I'YB%
M&&=S%#B/<!@'MTSTRISP`!]W@`XG4'U$Z=J%K+J=Y([Z]&@^R,+:8PFWA/EP
MDMA?G93@MEAGG<=U;7A&_N[[PS!<WK2,5GN8%>>96=XHY2B,64X8[54,X)!V
MYR03G5NK6UOX9;>>"SN([ALF*2,;9F`4?,>Q`5!]>.@J2-50+%$$"IPHV8/!
MVA>P'.U<<;0<\\$`&=XE^TC1K\VEV+:Y2T9UE*`LBB(DD+V.1[XZXZ!N4U2?
M4_[<TW4S?F:QM;.P-Q8QZI)%-([L<N8@I\TG@`$C.TXY)KO9(T=6MS&C1`$`
M.@4X/J,?*.!Z9`Y&,D5S96$]S%,;>*1X%"Q3OMW``D`!NW\(X]3URI(!8<"%
M_FFR=[1+\NYG/3J!][#>W(YZFO,[BTC\<?&VTTM[A+C1=!M1<RQQ.2CS`[0"
MRG!8,1G.#\C#`KT>\OELK&ZNY_W<4*F2222,H.NY@Q/W1QQW&1R*XOX`V<O_
M``AE_K%X6DOM2U"2:2>0DO(,+R<]<MO.>^:`/6****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*ANK6WOK66UNH4F@E4
MK)&ZY5@>Q%344`>/_!QIK?PWK/AR4Q&31=6DAW/D87GYCSU!5CP1T_&O06P"
M?W?\#9#%MK>@P#U!RN>N2,\FO/XK-O#7Q^NK2R61++7=.DO&BWDQ_:`Q8R;>
M<MN0GID;SCT/H`*><_R.%C1F9D^\I[\9P#@<'KP,Y(-``%D.[[Z2+N<J'*`?
M[Q_A!Q[9SV`!H5U49#J77+A\#I]X\=P.><'!7H>E&&VHRJH^8B,%?E#'!'4#
M)R1R?8\X)H1L2;]QB`7(('S;1R<?@`!VZ<`'#`"QIE2R*7&YD)5=Y49/('UW
M8.>,?Q8%-)9)&.TY";E?<6X.<'C@@_4\`YSR2_*,N]]IA(WO@*-I"GGKR/EY
MSQ\OU%-`1E&2SN1@[U`W<CMG[Q(Z<Y(/3YA0`;%7#94J2"`@+)A<`L".N,]^
MNXY]`\1DRM&1T.UB'R2VULD`_>P<_4;LY(IHQ@21+D'A94DQO)[DDD@Y)PN<
M\XYRV#;'+(WE8(R%0(G!4=2,=,;3@=]H]6H`$<2,9'1$3RU?O\IR.F>O\/&>
M`<8]<CQ3.MEX.UEV9CLL[@N78_-A&SMSP6X)],XZ_+6PTB$!T3+R`*`"VU3P
M>N>!MR<<$`C(Q7-?$5X(?`.O;IS@6+@-D<[E^1>XZGJ.>H```H`L?!NW-M\)
MM!C+;LQR29P1]Z5V[_6NZKEOAO;?9?AKX<CW%MVGQ29(Q]]0W]:ZF@`HHHH`
MX[QU@:AX6)+`'5X1P>IST/MQG\**9X\)&I>$P%1LZQ#DF3!49Z@?Q=A^.:*`
M*ND'_B]WB0;C_P`@NUX['D_Y_&N^K@=(;'QN\2)CKI=J<Y/8G_&N^H`****`
M"O)OC?,VFCPAK6Q#%8:S'([,0,'A@/7G8>GI7K->4_M!S)%\.H`S;3)J$:+Q
MGDQR>Q[9H`[N_4+<38"')Y3)P3@'DCD,3T`QFH\!BV7<X?!90<*-W!4KQGV'
M<8P3R&V3QG2M-N7D7RY+>%BS<DY4<9ST(SR>^,DC@`8#)8LAC0,^W).X=^O.
M/<<[<?*`:`'['=65H8\!<,W.W@;A\P]>23QU&3T%'EEU3<LFUMQQ&,YXX&.#
MP!QW.20>Y0Q?O-^)(=AR=N6VMC('KDY4@'N<=CE/W3KGY8\X^9C\HYS@DG'4
M'GD]B.-I`'AQY32*B$@_>/SA@#P,,3M'/)[9'X(08=P=<-M!^=CGD8R><]@!
M_O$=\4Q,,W``RR_)\Q##)(ZCU(SG^\!D`TY1F)`RL"",-M7+G^$]C@[>FW!S
MW/0`2-]@VQDKC+`[02JY(]"64Y]QVR."7+N.U5DPW&"K@JR+Z-W.!SVY[9.8
MFW89W=@JX)&X\8S\V=N<X4Y]P<XQ5'0M7L=>L)+K3[AYH4N7MF(0JK,N-S+N
M`+<L`.,9)`P30!Q_QFU%M.^'UT(3M-W.D*N5)!5LO@=A\H)QU'X9'I'A31H_
M#WA32]*2)8VMK:-)`H`S(%&XG'&2<DUY'\27C\0>-O!OA9;F,QSW(N9PT>["
M@[0>1T.V4!?IP._NM`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110!Y1\3;E_#OQ"\&>*/LHGCBFDL2-X3)E5E
M&3R>,DXP<\\COW,XD#R);IND0E4B8[3Q]T;@,@'CGL,D!B":X#]HM-_PZM&R
M!LU.-N>_[N4?UKOI-TEE;3$ON:V1B3DKG'J>"<X)).<+W&:`*UI<)J-C;W!M
M[B$R/Y3PR@J8W#!64X.-V1R>A`X(ZU8VD39.TR.IP[L5(7.<Y'`(!S@_=XQU
MK"UA)])N/[=MEEDMXR8]2@63@PCYFE"C@RH$4X89*[@!DD5ONKH3C&6<(<88
M$YX7G*C!SS@GG)QT(`CH[2$D;-V3_JRNS!)_/`''MZ'++NS\P*;<*2,8`#'*
M]CMXP./Q/0U&-H^;^'[P.>,9.1SUP3C@YYQD'&'Y*E(PI!^\-ZY(''][(X!&
M!U&3D@9)```!2D8,;#&7<;2`<X!SG&1GGV7N12H(O-8,'"A3\K1X;CYLMTQZ
M\'GGL`*1"/+;/R,H8;B?E"D-G.<#L>HXQC_9H8;753G>YPX9L\]#MYPV"6]\
M]>30`@#!]C89U79M4Y(X(VG`/0YQW^7)Z9'%?&+<GPOUD`[>8OO,2?\`7QA@
M"<Y)ZGGCD?7MW(\D9PJR,1E'WG`(;@]6YZY/&#BN(^+Z`?"O7%7`13"Z)NS@
M>?%A@W?((R.0,Y],@';^"-O_``@/AS9G9_9=MMR<\>4OL/Y"MZN>\!L&^'?A
MHC/_`""K8<C'_+):Z&@`HHHH`XKQZY34O"2@#Y]9B!.S/OC...GZ44_QR#_:
M/A<C=@:M%G"Y'WAU]/K^'>B@"GI#8^-WB1,#G2[4YQR,$_XUWU<!I!/_``O'
MQ&,G!TJU)'XFN_H`****`"O%/VBI'N-,\.:1$[&2ZO698D&2Q`"@XZD_/C\:
M]KKQ_6`OB?\`:!ALW*FW\.::;AHV"G=(V#R&QD8DC[X&.H)X`.L\+W!N_!&C
M21QD%=.CAVIAFW*I3KC)'RGIVYXQ6HSDEOF5%1P-@<;E7C)!(STYR.!G//4<
M_P"#)K9O!]AM0QP6DUQ:E=^[:(YG'/3D@*<'!YZ-6[+EH@`^4(VL03@]#N]!
MCG(]CR>30!(V4RK,JO@EH]N6P<YZ8(!W#`]<`8P33TW1G>(W/&]0@.22,C&.
M!R3D<G:%XP.(3\K@AP=H8'?P.H'L%.>#GU'WLG+CB-6"@&09!#H!CIV(.&8Y
M/?)`X/8`4C]TTB;7`;)'RMG/3W7)!XZ=N>A50&;;'\Z%CF1ASP,'YN1Q@D#(
MXQ]1&X^1P6)(SQG;@<@YPQVD_P`@20<$#G_%^IW,=O;Z7:S;=0U>Z2R@9&`,
M0R=TI'\.U"<$<A@.^,`&=J?F^,]1DT6"X:/1+>0?VK*#G[425VPQR#!7!&)6
MX((`]178*L<<:P0PI#;KM5(XTV848"J%'`.01_(?>%5]*TV'1-*M-.LE/V.T
MC""5E&YV'WF?C&]F).3SECP3Q5L!85"[1&0QSN.QMAVD?5O4`YY/]Z@#S.8R
MZA^TKX?)12+/3'+G/4%9N1^,@[DGKWKVRO$IR8OVEO#6S"^=IDGF``#/R7'7
MWRH].G0=![;0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`>3?M`VS7O@O1[56"M/K4,88]!F.49_6NXP\:QP
MAX_W<2HI*EL@8'W>@/&/KA1T-<+^T%-]C\(:+?*NY[?6(G52>#B.0\_]\BN^
MO-@3,<B%&57B=\<YQCD]5Z>F,Y.:`(98U*M&_E[3A0')X3(/))`*GD!A@<!<
MG-9OAJ>66PN=/G:9I],NFLY7\HEC$1OC'!.=J.%R<GJ>N<ZLN0I53A0%*G.&
M48'/!XZ#K@X7ZD5EM(8M0N+R,&.XNTC\U(Y"%.T8#E<$9(91]WG[IS@4`3C=
MD;BJ@1B5]N",<X8-_$N"Q^ON<TXA8PH;KN0[\``AB2#U(Q[=..3TPC9106'E
M1[F7[QR6.2.3U^Z01U&2.^`[<^YBP5(&R26'RAN<!!C@]1GKG&1VH`9"5=D!
M,9C9<JG7'HPYXQ_,#)X)"Q%<1D[65V9EV-GIGGI@8RN<@8YXP2*#,)2_F$+G
M;G8`N6SU;WSC_P`>&0,D/*N99MN#(Q+$2+\I4<C()&TXS_#SUZ9-`#8SG?(V
MW<JGDC`R.!G.>F?N]B>V>.!^,]_;P_#?4H)[C9+>/"+=%/\`K,RK)\WOM5R0
M>!@8Q7?ER&5IE0.HX)3;E2`.5(XX&/3YCCT/F_Q8TR?7X-"TZSA::XGN)90J
MQ.YPL)R0O!(R5^;(/S+GMD`[SX93R7/PS\.O(06%C&@P,<*-H_0"NKKSSX*Z
MB;OX;V=G(X:ZTZ26TG'&5*NQ`Q_NE?\`.:]#H`****`.+\=\ZGX4&0,:M$>6
MQGD#`'<\_H:*=XZS]O\`"V`#_P`3B$G@Y'/7^G/K]**`*.D?\ER\1_\`8*MO
M_0C7H%>?Z1_R7+Q'_P!@JV_]"->@4`%%%%`#)98X(9)I6"1QJ6=CT`')->-?
M"$3ZK:>(O%]]S<ZWJ.(]V6V1QG=M!Y(&6VA?1!P<`5TWQD\12:+X&EL+/G4-
M8;[#`N.S\/ST'RDCDCDY[5JZ+HUIX>T&QT6UX@LX/)+-,%RQ.7)('=FY;'48
M[T`8?@J#['H&I02Y41:U?@H[D%@)<]<^V,\]?IGJ?F?>^67&0'(/RGD<\#`!
MP=W;!QCHK$CCBB98T$>X,^=JQY##YL@<L3GE\8ZGCO(TH#*V261@FU_F.X'Y
M<8'.`1VRIQU).0!I?RU8E(T(8%5W<=6'S#@@<X[#)(/`"T]XV1E`$Y!``;J2
M3T&[&W&3^(/(X%(KI#('(`B1<DF0.V.`1CH1U'Y`<Y!:J_OE'S),!G9DD@Y^
M]MX[+GN3QUX#``OF.`,N2BY5&0L=I.`>>6&`.<''7!S63-HR3>*K;6;J17%I
M:O#!ALE&=TRX()/&W9Z<]0<XU=R@QODG.YV`88ZC[IZ=SD'''7@9I^Y!A00Q
M8LX97"D]R..@`!XR?<#(H`;EE?:^WS`6W*&W?+UVYZ=%((/8<#J*%W;UC168
M`\\$\9`&,\GHV5/88[$U3U;5+70-)N[[4;A;>V@&Z5V7=CDC"XSC)P,`9R,#
MU&9X/AO5T2XOKQ[B1-7OY]0M8IB<6]O*1Y<8.2%.P;ATVDXP.30!QNJP_;?V
MD?"B[B=FG^8[+G'RB=AU`P#P,>A%>Y5XS\.YV\3?&3Q3KC3)<0Z;#]B@D$6S
M(:1CG!Y!^1^>.OOBO9J`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@#S'X]V7VKX6W,VT'[)<PS9XXRVS_P!G
M[5T,,EO>>&K*6Y:1$NM-1F,?(53$/F4]L9/0^^1@5T.JZ79ZUI=SINH0)/:W
M*%)$8`@CUY[@\@]B`:\H^%EW+I*7WPYU3,>L:9/)-#&RAU>V8*XPX)`8E]V.
M.#V.2`#I?#VI2-!%X?U25X]7@MS)%.R$17ULH51,C#Y<X9<KN!!)X`)K<E4`
M2QR*V6ZIVY&3N].IQZ#)]16=:Z#I>DW$MU8:=:6]P8Y`'C4*P7(/R^B_+DE0
M,D?0UIEX8G8L[(JA3U)(#9Y('7DC!'(SV.*``N=[`9/(!^3ISM`VJ>"01CW4
M9[X25/*9E*DQA=@\QN1C/!XZ<CGH#C[W&52-MX1U*R!1D`%L9Y/'4@],<=SC
M&0`&3(=@T?=@0=VX;<\$Y(QU]L$DT`*P,LZA\$LI+888/&>!]WD<DCH2/3EB
MM&QWA2_R,=ZG=C)SW!)`SR<@\C(R!3L@,WEE@!E@"#P#P3D<9^\-H'!'/"T@
M?,19<.C.0.IPXXX;G.<DXZY/!-`$IRF3B4+]Y6VA\YQ\V1C(PO/UY)S648U_
MX2FV9HP/)TV9`I&_F1XMC!QC_GFW;KCG)K2()8LB_*2I4[<J>N!P``<^G7(Z
M_P`7/:+!N\0^(]5^T^;#=3PV42-'Y?E-#'EQG.!F1L$<?</4T`8WPH!TOQUX
M\T-F0(MY'>0JI!&V3<2>"1C!CX[=*]9KQK7I?^$8^-/AC65)CAU@-8W@VE-[
M<*A<9)SEEP3U"=>N/9:`"BBB@#C/';;=0\*CNVL0CIQC.?SX_G13?'R*VI>$
M6(Y36H2#^8_/_P"O10!5TDD_''Q$"2<:3;`>WS&N_K@=));XX>(LMG;I-L`#
MZ;B>/\]Z[Z@`HHJ&\NHK&RGNYSB*"-I'/L!DT`>1ZU"OBWX_V<*L[V7ANT6:
M;)^07&2R8QUY>//3[I'U]`&YI2<APW#,C'(!ZX[8VEO;)R<'IYQ\%K3/A35?
M$-Q'(MWJNHRL'R5\R-0&RH_W]_(Z8]B*](;E2'/F1NPVG<.><;0.JC!8$#GH
M,<X(`*S%@!A=PWC(."2#ST'3<?E^H)P*3<8(T8!`5VL/F)`R<KT!..AV_7`[
MA48;"<A<R!AA1@-T!VY&,8_'@GT+HP0ZLP(8]61BI5=NW@'O@#DX_`8-`"1@
M+*%5B=S[U^8J<@9R<DC'<YZ8.!DD4;OW8)6+`9FSP!@'@%!@\@>O)&#VH!W#
M'EG;(YPJ'`8]`,;<#J`3T//!I<[0)(\'HJMC=DC/\/.2"1@CWY`(P`*@R%4C
MF1O]7O&2`"!EA]TDGT!P2#DTT+N1FD"EFX^4Y&,'KGOTSSWZ`XR]5VS+(S=6
M4G<ZL3MY!Y."""1G(QUX.`*-SJ^GZ<T,-_J5K:7$JA85N)T0LH[?,06!QTZ=
MSG(R`8>O^$8_$&KVFJ+=RV]_9QM#`7B#QQ9(&[:X(#@`D'.0<9SMY?.MGX%\
M*ZI?-<3S,B_:Y9+F4&220`C[W&5+%0JC`Y`&-P)OZGXBT;2[-YKF]M9)%55B
M@@G1YI.#M1$#$MG((`YX)Y(!K@?B!?3>*_$?A3P?";R"+6A%>:C%)'LF$)PX
M4C!VLNV3CD`J.V<@'2_`G2+C3OA[]LO(R+C4[E[OS&8,TB$*%)/7L3@^I]:]
M.J*VMH;.UAM;=!'#"BQQH.BJ!@#\JEH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"O%_C=:'P[J>@>/-/WI
M?6MW';S%7(5T&YPK`8R#AE//((%>T5Y3^T(`?AHI(!Q?Q$>W#4`=7IT]_<VL
MHOH(8;R.X8-]E5GC=&),<B-SGY>O0\#A>`+;XC5FF22%-W[SS`=H4]6W8`R<
MY`['(]JJ7%C!=V:VEQ`)XI;18WPY0,-J@@-CICD^G7CDG&T3X?\`AO0-1M=2
MTO3U@N+<,;=TN9)6&Y6!^5G(Z,PQCJS8YP2`;&F7L>J6*7L(;RY6<1&1=@<#
M.YQNY5>^"!D!2"0`:MA0LBJQ^;`;`7W)Z?S7MC'3Y@@=S&N!A`#M!&.H.1G'
M!('(]<G!/`5,)#Y>"JLX4Q@8`],@]"<-SSC`SDC-`#CN5/W98A64[2/F'&#_
M`!$X`)XP<8Y[TTONG\X')=2F\H0K$G!.WH#C/7@]>,$4J@LZ[WVRA#@A0`2,
M84<X"\#![Y)&#S2`QG*A6`.T#=Z'/8@=\8/`QMSMP#0!E>)]072-$NKA75[A
ME,-MNR&EF*X"]>&)88[GD$'FK>EZ6-$TRSTB.XDO&LP`TTO!E8G+LQ'JV3SG
M&.<]L-[>V\3^(8)IXO.TO192\+))E);[$9#8'WU0-RQX+$CV/2C8-V\,S+DD
MA\`<-@\'D<GWYY+$\@'%?%/0GUWX?73PQC[58@W,)"X"A`&;!/(RH..A)*CN
M2>X\$:XOB/P5I&J><LLLUJGGE>TH`#C_`+ZS0NP8#F13\V`%^4<'`'/IG`)X
M#<=0:\]^"UU!I.M^+?!R2KLLKTW-JA8DF,_*V,C.%Q'U[M0![#1110!QGCM<
MZAX5.W<%UB$YW`;3GKCOW''K11X\Q_:'A,$OG^V82,+D?CZ=:*`*>DC_`(OC
MXBY!SI-M^'S&N_K@-*8GXX^(1QQI-L!@?[1KOZ`"O//C9K`TKX97\:N5N;UX
M[:`#J6+!C_XZK?CBO0Z\<^)L3Z_\6O!?AKSY5A*O=.B\KD;B&QTR!&W/;)H`
M[C1=,30M`TO1DCEV6\(\P9W9=@688Z<DD@'TP/6L[Q#?ZBESI=KI[7$C7<DA
M:2)XL^6JM\N9`RX!/)*D]L*,D;\C"1R96`9R53=@\<YR6Z#H1D=^%.!6?JNE
M6.M6+6]_9B>-2C8GW2;'&2",X8\$G(Z?-@8)H`=I=PVI:+9W`S-)<VT3/Y@$
M7F,4`.Y1PO(&`"1SP>0:M*@+NHP[,R@!E#*<^HQR1NP.@]<``"-8UBB2&.()
M`J"%%5L*$&T*!MXVXR"`<>]/?+1KOQE8^%/)4;NY/)ZX"X&X8^@`'-E]R;T)
M8%=F_`)SR3CJ<'YB!G&>S`TK(7F^95+&-07,>-HP`.G&.2?<#!``S37!>+:S
M;%.YBH?Y<<9(P>">1C'<\$YR`;I596VE6+'8I3<.>A_ASC!('J<]*`%4*LVY
M20-RLW7D[LY)S@GO@]#[9(K7=C::A9M:75LLEO,K!D((!4\XR1U.2&'&<@<#
M-3XCD";DZ'Y$<@#&<EF4CC).<9&<X[`T]L-)O>,,NT;O0G`&,`<$$\'V/`Y(
M`,G2?"NC:(SG2K*"WW(JNT(*E\%FXYPI^4\CKUY&!7"6=T]Q^TQ;(T:(L%A)
M$FP\,NUSG`X'+$8&>G4]3Z8J,T2^:F3@,#M&<GIUXY)!.>HZXP17E^FSQ7'[
M3,+1H0ZV4B2LP.YG"-U)&20,+GGA1]``>Z4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7EO[0$>_P"&
M,C9QLO(6Z=>H_K7J5><?'*)IOA;?HI`(EC;GT5LG^5`'0V;,;>SE4`$P1+C'
M0[0&RPY7`S@X_O8XY,SH2S*=K[]J,&DW%S@#UYQ_D@Y-9FARB7PKI-U>`)(U
MLH?=']U5;Y=P&"V0!GMQD8[Z+D+;EB"N/DP<,QP?[P^\/]GI@>F*`%+`%=K*
MH4L`A?[ISRW3ID*<X`!QCU"D2Q$,-JX15())&#M&!@\CWY/`!&.JJ5C55!VH
MKD%BN[!Z<]L<MWQR3SC):$"3>6$"N%;**V=@.=W3@_3@\`#U``H5XR.5.%4'
M:,G&`>W7@].!C..,X8A*Q;6Z$9+KD[FR.2<`D?,W&<\X..M*K,T2*02H8L00
M2W..2#SC(W8Y!P>PIX'EE%(B!\ML84+USD'NOWON^HP.O``UPL38&$`[`9"J
M22#@=>IZ<?-@X'!)0SRL&/SJ`#ECU&0<$G_$D#GK2*S,%5?+7(^4<!<X)SM'
M`)Z<GO@YP0<*UBN?^$IU3_396BN-/B,8=E$<3B5\E%8#G@'+;LG&>.``=$Q6
M4)(S/DD@H"5SW!`XP2><XYZ\'`KS/4)AH'Q[\.:IYJQVFKV;V4[9"[G4'`(S
MP.8.#Z?2NH\()(=%DCFDEN9H]1NXO-G8[W5;J4?,<<G`/.%Q@>PKC_C?:J_@
M^PU2(1M<V-Y&XD>,A@AW*1SD\D(2,@<9YSF@#W&BJ]A>1:CIUK?0,&AN84F0
MJ<@JP!&#WX-6*`.)^(#,-2\'JID`;7(=P4'!&&^][9QU[X^H*/B`SKJ'@\*V
MU6UV$-\Q&X;6./?D`X]L]J*`*ND?\ER\1_\`8*MO_0C7H%<!I((^./B(D$9T
MFV(]_F-=_0`5XSX>E;Q)\>]?UW[.XMM"MGLE(D.#,',8!R!@$"0XZ#@YKV:O
M%O@S)'-8>,M3A9F2?5F.`.J<D;>X/S=?;I0!Z2!EP%9E8Y)D1=IP21QW(SM&
M/;@=,(V9!\@5V"[$^;<<$_*5/89QQ]X<=!S3R7Z%BY3.P9)R=Q^X,`=`<<Y&
M,#JK53@OK.Z9XH[NUG=`Q>&"6,,,_*6*JQP?FVY(^NV@"T,&5.55B0^%QGAA
MR>H&._4@8[96D4C,9RP0X(53D[MH(.#G!!!X(SQ@`@8I`"TB9\L))RQ<#!],
MY`&XCDL<\A@,]`Y6\Q.=BAF)V,H!8X;!8\9&1MR>#GJ#P`!/NQB4%,Y_>;^2
M<YS@8QT#9SDG`Z\95B5M\;%8;OF;AEY'4@Y);OD@YQQG/+"(VC'REBRF,=P2
M%!VE>"6.T#/^[R3BI`P4K)(=A!5LGY@._.T<DG:>"<]R,`T`-E+-&0)$5BVW
M&#C.0"WIGD?-G/WN2,8"-K%W5<^8.P;=CKGG&3GCKT;W-!=PB[@6&W"DJ#C`
MVG/J`#G;CN>XK.T;6HM:M6NM/@OH@-BQS7%J\0E1P2&C8@"1<#.<G:`#GD4`
M:)D,8+,KAP=C.W/3CYCU()!/WB.F-V"!Y?X6MWG_`&D-;7RI#'96VY6+_P"K
M'EJN#V)_>'\C[UZ<!T9'$8S\F"0%!/;WY!P,'G[I&`//?A9++J7Q9\>WWEJD
M4$B6@`QG",R)TZDK%R?6@#V6BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*Y3XEV":A\-]?1R1Y5C-./
M0E$+#/Y5U=9WB"R&I>&]4L"NX7-G+#MW;<[D(QGMUZT`<7\.[L7GPU\/W*.)
M6-J8CQEF9696&#@''3'.>V.IZ5Y`KLT1X'SL#G)QTQG`PK9P.,XZ8P:X;X,W
M'G_"?31&")+:ZF@^5<$[G+=?4[L9^GI7;*Q9@Q$I.=ZC?@;@,[0O/S`C'TQV
M(H`>$9W6-"N<2'+'KG!)R.1GW/L>AR;F;:H<LI(D7)^Z2<Y.#PW4]AD-C.<4
MPQ*TF')VX&`1^1/S<CCC']0"KC[00T@8O@R?O,C"D;N<'D\<=.@SV```["B[
M59022F$P1G!QP!M/W>@[C!ZL57#M))DC>1N(;:?7H...?F]2",<TI)\V0GCY
M@"S#Y",DCY?XNY!`'7/?A%9P3A'+E<@.=S#`.=QXSC@X/NOJ*`%.7D;<2^3E
MBW<D8&2"1]XG'88QP>2L@;S&9G)5BKB39NSGL1UQ@]<8QD8YQ2%?N@*6R`4`
M<AT&<@YX&WC..V<\=D&W8LJ1Y"QD8\Q6P-NT'*C)&#C`)SZ9Z@#L9<1YVILV
M'>H)3&/E/<@%<`CNW4FL'QSHP\0^#M4LQMC\V$R$L=^UE)8=P#SC&"<9S@YY
MW2-^Q97)BSM(W]\<`;?E`R%XZ#&3UY9<+N1EFCY?=YD>1M9L'@DX7/.">,CC
M&,9`,GX/ZJ^K?"S1)961I8(FM6"_PB-BB@^^P*?QKN:\B_9_,UGX;US1;@EI
M=/U5T+9.W[J@@`@$#*$]!UZ5Z[0!Q'Q!"?VCX-+YS_;T(0#UVOU]L9_3\"E^
M(1_TWP:#T/B&#MWV2=_IFB@"KI'_`"7+Q'_V"K;_`-"->@5P&E8_X7CXAP"#
M_9-MG)Z_,:[^@`KQ3]G^%?\`A6^IR@\G5&#Y'0+'&1@]<C.<\^PS7M=>*?L_
MR?\`%N-0C4J6.KMN0C.X&*+`QWR1^6>1UH`]*.&#;N-P'EL`,8'&#_>XR,G`
M..>#6%I5FAU75+R2P2W)D%E;K]G(+Q@!BY`Y(9V89''[M<8(P=T,1%N)<;@&
M8[><$YR#U`X//KM.#R6&?;&P9L*5"GRUR&_NL2!@CG:1DYVGTH`9RTFYWX8D
M`.N_D[3M8<ELXQG'IT(P'LS%V<NSNN&#<DJ?E.?0J#@[>V#Z$E58Q%5#D9/)
M7'R@M@E>>"<CY1@Y[#H4CD6)5*.APX9?+4?-R1\O'7!`P3U!4`]*`&KE8W89
M.Y26.U_F&<YQT;[W<]QVSE[`)(N%8LV</&_."<G#'G.<9&,\G`P>(]JB0[FC
M7[SEMV0<<Y/S#!^I'WN,<T+L".F6VGY64%@-S'I@G.[@].N?^`L`*Y?R#&I5
M6*,XVJ0H?J&(7)&#SP1UQVP.9\*^&SH+7`^SV>GVEQ%"@LK2222(S(S9EW.H
M*LVY5QSPO+'@UTT@8IG//)(==R$YXR.@;'<^_((-/.?-#+&C%C@G:#D#YLD^
MW)QC)VG."!@`AN+M;*TEN[B1E@B#S3.%+`@')^5<X/!'0Y!/..*X;X!Z?C3_
M`!+K)^]?:FT8^4KE8\D'!Y',C=>>*ZSQ&RGPSJLNYF<VDC.Q[@IR-H!^;@8.
M"!TS\HK!^`O'@2]CVQ@Q:K.A\H_+T0\<GCGM_P#7(!ZC1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`'BWP6O)(O#6O^'I-RR:/?A@'SPKD\'IR"C=`.>17I&X%R'9QDJBXVC:`<
M?,1UQC@]NOH#YS\.SYWQ!^)06-I5^WQR*\;`\AYL`>Y!.",XQZXSZ-N*CYB3
MM?>S1MC`X'7^'('W1S@<`=P`*[AMDV2`#`9=J$CJ`3UXP,=CWYZ#,6E,V0^0
M<%G^?J=O7C;C.1QCJ1BE)D145E4L"3E1@9XS@#HN,$CG(Y'<TF`./*$C[BQ5
MB%X4YS\QX./4Y..>A!`%<CYML<97=\Q51]WDD;CSGALYYR.@P,H5=8]NUP<Y
MD7=RK'HW8J/O?-S]W.>,TI.V4F-LL5*.TG)V\]<X8?Q=?0'H/E5&^10&P"[,
M`?F"DG\R1UW>W&<XH`;O13]UMS'."HR!@;2IQ@''3C@>YY9++%`8Q<S*GF,(
MH]\BIB1CA0N\YW$D#CYB>^<@2JP,)WN=Q.2'&XG!&%<8R3D\9(Z'MG/.>)]!
M6_DT.>.P,MWI^J6\L9RBF&/S8FE)!QV3&X=<>_(!LQZI9W5])9V]]:O<P2;W
MMMP,B-NY9E'(.<<G`&>0`P%6D4VY&U/O*%12=Q&.O#8P.6YP.`W3.:YK3)KN
M?Q/?^?HMQI\$#3+:R&.)8G\QP9)'VON+OMZ!..6)RWR](#&B311@HAPHW<@@
MD?+U.X`$DXXY/4'D`\T^$C36/Q/\;:4[LRM,UT,-\I!?*G`.,E7'(_,\5[77
MB_PON6O_`(Q>.+J25VD5C`0S%\!'"#+=#PN/PXXKVB@#BOB"$-YX.W,5(\00
M%?\`:.R3C\B3GV]Z*9\0_P#D(>"^%(_X2&#D]1\DE%`$&E#'QQ\0GGG2;8\C
M_:/2N_KS_2/^2Y>(_P#L%6W_`*$:]`H`*\6^"R1V]EXOL(5(-IJQ(1!\I7E0
MN,C(^4\?2O::\5\!F3P[\8?&?ANYA1/[19M1MOW@4N!(61$]<K(3V(V'Z@`]
M*1W^8!B.=^UI`"/X<CI^)!ZG'?Y8\`QYW11A22<C;D]20?X3QU/&<=MM*V[9
MG)=2K/A0=IP,?D1@=N,K]ZN2O?$6H1^/+;3X+EVTU9(H9C]F4QK)('(5Y&(9
M9LE-FT%277/+4`=<CB0[0PC;>=H4>5O;'\)Z!N0/4^N*1F9P1M4X&%!P/X<8
M)]^#R>0N#DCAV2`3*"P9L,RDDD+P0W)ZC/\`P$9'<5'CAF#KC&&<GKR!@[3E
M@1QP/3MR0!Q9E'FH`2@.TLN[!'/?H?3KG`'\(R[<^<*S1Q[2,R890/?@CID$
M]AP<4V1<1D2`/G*$M(I*J,'`'<=2,`G/TY'0+)YIR&7D;`#MVG.,X(/0`<DC
M(SF@`XW`^6P)R"03N7`!"D_AC/0$$C&TY"RH<,<D@*RKGYAD8Z\''/N,YP-N
M*P/%6LW&D:=:P6+M!<73E4NX[.2Z%M\H9I"B!L@<!5(/S@9.`36CX?NC>>'-
M'O%D?$UJDA<N59V9$W-C`;`89.>N1ZB@!NN@?V!>[E4LMFRG]WU39@<'((]0
M>2#T&.,#X"EO^$'U!64@KJ\XYQS\J?YY]*W-?&WPQJ,PE4JMI-D\@`JF[*C&
M5X_`X`X^6L3X"1+'\/[DJ"`^ISGE0.RCMQV[<4`>HT444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M!XI\,(A_PE_Q#11EA>P%"%8\YGY`ZCU`[=N@%>DKM79)&ASD;5P"PXR2%['I
MC/=>><"O-_AXC6_C?XD02-AUOH-VX?>7=,">GHP(&/H*])(5`5:,A6<>9D+R
M@/0KW/)^8>V.2:`#Y6;:556V<[E/*@<#)]2<@>V,_=(4E`S,WWL$*`I7!7[O
M0`C!V@<#HWK3'W[51A)M!&X,,@$XQD>P#8(_/@$K*R[&_=E8R5#JRY7'\(;C
MD#GIZY[#(`N?+VJS1MG:$^4@$E=V"".G3G``X';(3S&0DQ;F8;E`8DA1D9#9
MP,DALC&>!W!RF_8'!8JV22W4$-@<D$@C/)[].N#E06C&3O+1(2%#G*KSNQZ#
M@#;G=C/L:`&[O,0(8R`&VJ"`P`&`>F<C:.3T//N"%L1+(P9,$;5VDD%@!DX^
M\2",_F1C-.R0?)D9W"J47;UQ@@,O7'`R?JO0=45VFD&_A54D>6>`"".,D[1T
MXQU(!ZX``\!@PVL@C0G`1/O?,-P!4#/51R,'/?&:!\ZEOE!:,,4(X"\84'G;
MT.!VRN.<Y:Q=URR[>-QAVC";0,GD\<$\=1@CMD1WDLEM%/<+]ZU4E2!G)4]S
MD9Y89Z`@GI0!P/P%:+46\7:[';/&+[4LJS9^[\SA?3(\SG'J/:O9*\L_9^L3
M:?#%9R''VR]FG&[H<;8^/;]W^>:]3H`X;XB?\A#P5\W_`#,,''K^[DHI_P`0
M_P#C\\&<'_D8[?G/'^KEHH`KZ7_R7#Q!P?\`D$6W\./XC^==]7`:40?CCXA]
MM)ML\8_B/YUW]`!7BWCF6WT']H+PCK,NV**>V,,CE>,GS$SQWQ(OY"O::\N^
M.^AK?>`SK$"HE]I,\<\<P4>9L+;2H;J!E@W_``&@#L94:*7`7'EDL6)_NX`S
MDY/7'&,]O?.DT>PGU5M1FMV-QN1U=F8EG3(1B/N,P&0#C=S@$'-7+*YCUG3=
M,U=)M\=[!'.KJH!165<]>F"?S/;!RY6D\E767_5J1C&W;V`7T`&,X&>>0<8H
M`:T:J""JEA@JP4,N,8X&""!QD<XVG'M(WRR@LS?.6P\;<IDCCJ#R<G`YY(/)
M%"#"``NR*"`@&SD9PR\=L=3P!@=B:$W)+L@?'F-N(CRH)!QCG!S[$\\^HP`+
M&BHT0CB`<*0OED[MI7(V$'U.3D?Q`X&:2,KN7Y.2,AHP0#P!D$<YPQX!!SG&
M,_,U%C=5&P-%D@[R,,1R1T!!.`"<@9_`4X-N+(7.2&!WXS@!MQ.!SP21@?Q9
MYQ0`A#.ZJQ1F[!_N#/WB3G(Z\\]1WZ!D4,,2+!'"L<"HD<:%3@`+@#:F",=!
MP`O/H*D?:RNI:!6<;B><<#/S*?O8SUYRQYZ8+CL7Y<L&W'<2P(P,``D+R?F.
M,=,C.1Q0!B>+%7_A#M:D#1\V$P!=`<#RFQP.>,\]`#C'`(JC\";80?"C3I`,
M&XFGD/OB1E_]EI?B"TEOX`UMT=E86;?,A7;T^[WZ`D#Z'D\@7O@Y;M:_";08
MV.28Y)/P:5V'\Z`.YHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#Q?P81%\8?B):K\T4@69E`RN
MX-D$@]<%CV/?VSZ,=H9U)8_*[,ZJ22N<[>O())[YZYQ7`:5]HM?VB/%UO"66
M.YTR*<*C'DKY`S@=>K^^"<=:[]`',<+.HCPI"[?E&#M).>,@`8'3@\<C(`1@
M(V[Y259MNP$$-M/W>N`1U_B&1D\"C8%AVHT94[1C=A<<MT)'`/KT([DFG/(L
MG#`E20Q#/DY`QT/3..,\_*W48%-X^4.=CJ,DC@`@X0?[.`.-WJ>01P`*5:8+
MN7[REAYA`VD_.3Z*3UYR"0>!C%*H)82+)M89)89')`/`(R"?4]0IS_>H!V!D
MV+\SK\^=C=>`>0,CC&?3IG(#4`9EW_NSM8%=N#DX"Y(X'0`CI@8.!\H`$E53
M\OENV%)V$[F)`QGG!#="3^>/F-<^^OZK=Z5>W+:=';/!=%;F&YE>9(XQ&'+%
M8U9F.2,*I(Y`!(&:WPX2,N%=0<#8%QA"20N``3^!Y[\'G/N=%24S1P:A>6MT
M]P)O.M)MA5PACP,[E8!5/RL#COCJ@!-HNHG5M!T_5'M1$U_`EP83*6\LLN3N
M/.?N\$_=P,@8`',?%C4?L7PQU%R-[3(L`+K@MN8?,>O0,WIR#R>E=;I>FVVE
M:=;V=@OEVT6=IF)#<DN=Q^\6+,6X/4@C`QGSCXH0OXD\4>%?!`V^;>W9N[L`
M`M&B@@,"#_=\[())^0<T`>G^!=+CT;P'H5A%&B>591%Q'G!D90SL,^K%C^-=
M!2*H50J@!0,``<"EH`XGXAY^U>#?3_A([?\`]%RT4OQ#_P"/GP;_`-C';_\`
MHN6B@"'30@^-VN%<;CH]L7P<\[VZ^G&*[NN$TY=OQNUPX'S:-;'@8_Y:,.?7
MI7=T`%4-;TR+6M$O=-F166XB9!OS@'L>/0X/X5?HH`\>^"5Y<W/PZN=,N3M?
M2-1DB3:`IVGYL;NQWL_/I@=,UW5U=6]O:R7EU/#%%&IEDEDX,87DL,?=&/FY
MW=0>>37GGA>UB\._'CQ3H"18LM2M?M<08EOFPKGC.>K2=QT'M7H6H6_]H6,E
MK-&J^?;NLBN?ED1@<AAGD'J<''7/6@"GIFKP:Q:R311WEM)$R%XKN$12`-@(
MXZ@*VP@'/4#(R#6GLC<A9&/EALON`/`;H<=<`$#'J.1P*Y_P]I<NEI>2W+XF
MG@@@D5+V6XVQPANCRDX!,K#;T&.=S'GH9=P;:8PDBJ-CNQRHQR0&[`=/0C+'
M).`!NYW+#Y\E=NTL.!D#'`Y'`!QUXP3C)E4,Q780"Z^6XD88;.`,JO;D@?KC
M%1JRHZMY#*R@L"C;2%SZD\*2>OIW)SA'4!"?W:G!*X4Y`."<=BN#D@YZG'!%
M`$4]_:07%O!+?QVL\XVVHNIE0O\`]<P2N[J.G3;WR,S@%<1Y<R(I(08.T,,M
MSC&/;GV]3Q?C:SN;J%[>PTJY:\EB1H[BV,($C)(62.?<0RQ`D.<$@\X((KM3
M*[7+;3\^3M`Z_,<[E`Y'`^G()Z$D`XSXJ7)M?AIKS;_W@ACA5<C8RM*B$J?I
MC@]AZ].M^'MD=/\`AWX>MF)W"PB9@>Q90Q'X$XKSGXPR_:=`T708)Q&VJZG#
M$8U.-Z!>>,'D,Z9(]CCFO9+.V6SL;>U3)6&-8QDY.`,=>/Y4`3T444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110!X_((K?]I:9)D9A?Z/Y:,`3L;`R>!Z(>O'->@_O"8T<%<2`GDXP
M#\N>N.`?F&.!G`&,<%\1F70OBQX&UJ*?[/\`:II+:YD=FV;/W8QCD`D,1P!G
M`R>..]DMV:1K7RL*C$J2N1CC"@`$[0,=,?P\CI0!#O);<R>8",MO!/W<\D9R
M>AP>V><`C$GF,9WSYT@4*?F'SJ>/IGMG&<%1GIRY=Y(*PDL3D97)0\9?'4YS
MGCI@>M-!380B?NR0R^4?N@$X(;GC[QZ9SNZ8Q0`J%E"HP+Q`D`!CU!VYXY(Q
MU`[#L#@MB"+$ORQ[0I.PY]-W;MG:,8+$CVIP^\(V+?*J/M0D;",@]<XP<`GG
M&./0,52T4:^7$5YVL$^4Y8?,N#U]L>@QDX(!)\RF12QD`R$92"1DY)&,Y4X&
M0?Z$TDAD2,(DIQD(P5LJ>,<8&/;!R<8SCK2!3*BOOW,#DLN#\^<Y&.,[F(XS
MU_X%3591&&C,13&4&W`)[CCOSSCH`"2><@#RZ/*\Q+8*EAY1QCDD<$9Z\^[8
MX`(SYMX(MY?$WQOU_7)HX%M]`4Z?!L#8WY9,KDGL),_[PXYKO]3O38:9?7C!
MIEM8&NGP02R(I(!]>`,8XR<Y(-<W\#=.N(?!MYJ]W&JRZQ?R7B,'+$QD`#)/
M?<'H`].HHHH`XKXA<77@[C.?$5N/I^[EY_SZT4OQ!&ZY\'=<_P#"1VY``S_R
MSE_I10!6TQ`OQOUXX8;M'MB<]_G8<?E7>UPFG(4^-VN,490^C6S`D<-^\89'
MMQC\#7=T`%%%%`'CWC1TT_X_^$K^9F$-S:?8&``Y,GG*O7C[SC(_0UZ%(CK(
M1\ZRD$"-EW,P.<X`.",\X).<9/OP'Q\2>STCP_KL*L1IVIH[E&*L.,J<]N5Q
MGL2/6O0+S9]NE1/E5\;E0`%B1Z=2QS].1GJ:`$W8=797<1L0C!B-OL&)PN1@
MGCH3R.!3%08.UT`&`&4/@G&<CC(.0?E&1D],@TP2;=Q9D#+G.U>@&3RHY&#U
M_,#.&IV2YV*JK\P#@\AB,##>^>0/0$#GH`.P[GR\$%6#8VD[B`1D8[C;CGT.
M".M`XW&14=MF"Q7'RD<`XY``S[$9]!33E02#MV'Y#,0<$'&"?PXQCZY7A2VT
M#<63Y<,6*X/4`'/Y#/`Y!'#4`#$AE4O&QWD`'J6Y*JW(Y!!Y&.6)_O&E.UD.
M4Q\WW22<\87@'KPN..V!P?E!N``!VF4A2&4*&X`7//(&<]\Y[#:*0&/RY!A1
MC:<;L[1D@'H1@G=CH<YR>IH`\S^(,?\`:?Q3^'^G)&A$=XUP_4AL2(S*1CL(
M\9(YZFO;J\2TB.3Q!^T2S>>9+30+,NF!NC):-5VC@;3F0GG)^3VS7MM`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`'DWQ]\JV\+Z'J;QEVL]8B8D'G9M<D#MR57_.:[N])$TA
MD#X.6'RXXZ$C)Y&.HXZ#!QTP/C)I0U7X7ZL,#?:J+I,_[!Y_\=)J;PKJLFM>
M#=#UDW,<DTUG")YV)`>8?(^2-O(96SZ=NIR`:H(4<&/>`PVD9+`_Q*5'`R6X
M.!QR!R:#Y;$LI5G1MJ,H&2H/WA@8R`,]<#CY>1D5AA1N*J'R5)5=K#')'8YS
M@^W0G.43?(A?>^]@`6('(YY(R3R.^>A.`<4`/W2))C?OQ\Y,+%>2>HS_`+)/
M)SD#KG)I$4;7:9F:0#896^7)P3C/]X<`C.#TQWJ/<H^\PP,#RV89ZC`QGIQT
MS_"!D'K("^W<ZO(06C:5^6&!TX[<DX&<XQVH`QK[4;ZU\2:/`;>$:;<K,MU+
MG++LBD<`\;5`VKSGJ5&!@YH>%O%\7BO5=7BAN[>33X(K>2VS*&=@3,C-(%;(
MY2,@?>`*9P6..BGL(Y;BWG>`R7%GYAAD<$>7E&4MM'&-KG"XSSU&:BMM+L-/
MO+NZ@M`DUU&D+RP$*"BDL.`.G+Y(7GGJ,!0#G/B?/''\-M=GS",PB,8P?O.`
M%!]@2!C'3C/2NL\`6(T[X>^'K;8R,NGPLZMU#L@9OU)KS'XTR/>P^'=#2Y91
MJ%^L7ECE70E<$*.@!9<?@.QKVNTMUM+*"V3[L,:QCZ`8H`FHHHH`XKXA_P#'
MSX-_[&.W_P#1<M%+\05W7/@[D#'B.W/)_P"F<M%`%72@H^.'B`ALDZ3;$C'0
M[CQ_GUKOJX33F)^-VN`@\:-;`97'_+1NG//Z5W=`!1110!Y[\;;+[9\*-6()
MW0&*9>G.)%!_0GI6II5_;:MX>L-2C<&"ZMHY`TI..F""`,\[`>N<CT!K2\9V
M9U#P/KUH`FZ;3YT7?T#&,X)^AQ7`_":]:[^%6DM,6`MFGMR['(VARP^G#!<#
M)(7CTH`MSZCK37MU837XM6EU2UM(IK6)0]M%(#D`L""Y\O&2,?/C'"XUO#]Y
M/<:7=17EP+B>SO+BU-RRJC2I%(5!8!=A.`$S@<CW(J>YTC3+Z&ZMY[.$I<%!
M,C*K&1U'RL!W.<8/4<8([6K.SM;6VAMK6&."W50L4<:@*J,3T'<'YNARWKG<
M2`3_`#(N,B/:O^L5&!"GD8*D':<-ZD<DGO2>:$V^68E<+\@0G/3;@#G@D8X.
M1C&>X:"%B1T(VD-(K1<$D#J&/'`+<=/O>HIZ_=C`=!&[%=N!ST&X#`'`^7'(
M[`''(!DQ:U`?$46E_9+P&7S(X)F@5(9F"ERB,3N^ZISE=K&,Y)(Q6IO`<;=L
M('SHR-C<"2-PSDX/'`Z_RPK73-0_X2J6]O&M9+0;5MO*=D:$%?OA"N"[,/O'
M)"L0N>]OQ)>)9>&-5G8LB06;3[`0&R(V8CL">.H].,\T`<G\'4&I>,O'/B#R
MMBS7H@CQG!P6+=><GY#SZU[#7FOP)M(X?A?9W2A/.NYII)7'WF(D91N]3A?R
MQ7I5`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`%'6;!=4T._L'C61;FW>+:XR#N4BO,?@S>17
M7POLK0.C36-U)!.B`[E5I&8!O7.\\CL>.<Y]<KQ;X>_:-/\`B)X\T!(%\I;_
M`.V0F)/F0LY*]3C:%([?C0!Z/)(5VR`LAP%3?@\C;V&,@X4\$8]?NBG@EF"I
M&<%,H"2[)C.T@#&54D=N><$TT/"JLR,@`&THK?-LX)()[=R&]^A!R@C&U8UB
MRQ+`*$]"%)7_`.OTQDY.*`'$JKX13D855#'<4)^[SC"AN,'G.1QC)80T:!5<
MN,`IR`1CE2.,8`8^AZ<"GX9MH9F/49085FX&X$\;B">_(.<=F;\DH,HC4QR8
M&(_7GC)X+#\^3CKP`++RP",`H^Z><'C!P?H/0#'?&"&["<KNVE-V[#C.[G([
M_-UR<8(!],TI=)&8M)'(W/F/CAQG`YR<9Q]!D8P:!(/*>64-Q@[BQ4@Y'+G)
M!^[@$8Z=N"`#SSQS`-:^*?P\L$4YCN9+LKG@(HCDP`>`,1'@'OQGC/LM>3Z)
M8Q7?Q]U&26"2-]+TR,Q?,<;G55Y['@O[98GW/K%`!1110!QOC\;KCPASS_PD
M-N0-N<_NY?RXR?PHIGQ"&;KP;_V,=O\`^BY:*`(=-<O\;M<4L2$T>V4`G./G
M8X'/'7VZ].Y[NN%T]@?C;K0#`D:-;`CT_>/7=4`%%%%`#719$9'&58$$>HKQ
MCX&.TG@6_P!/D_>S6.I2*T(4$K&R(1TZY96[_E@$>TUXA\,-NG>./B)I(292
MEW&8=[%B%2210<DYW$,A':@#TV-]PC4,S$*I"1`-NR,[P,CYN^<#J#CJ*0*'
M"!(X)MY(&YL[SSN/4Y(V_-CD$#\5V>8SKYH1I)/F*+_JVYX/'WL=#R2>XZE!
MB<%P$)Y1@%R#R,*WIP`!CDXSUP*`'?/C+REBSAF5<DD\$9SM&>`!SSSCH,)C
M=&9=J%%!4NQR">0`2<`9!V^P8YP:8[%-^]`)4`<M)@G:W)4KZ9)'OGJ,U(Y#
M$!?G=#E`%);C!P`/X<;>?O=.*`!E;.TI@E`7+-C;G[RL/?J6)((!(KGO',ZC
MP+KYG&7_`+-GQO.2,H5'(]?E(/YGIGH1&_)A217)(5@O*'(.%(SD')_`$XYY
MY/XE3M!\-]=>$!0UOMVJY"C<V"1D^G'N21R!P`:?P;MVM?A-H,;=3'))^#2N
MP_0UW5<K\-+=K;X:>'(VQDV$<G&>C#<.P]?_`-?6NJH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`*\:TD@_M%>-+0K&(&TV*=]PP-RI!@]/]HY^M>RUY!I:>5^T[KSH7R^D*
M[*`/G.V$8Y^@_*@#OV$A^?S,A6*A#\JA@#C''WACI_LG)]6A`^56%2S-N(V=
MQD*..F`#CKR/09(A&_>69T^ZI!ZGG(YP!\H`.#T'?J(4**NUC'ED1L8QG'8_
M@<`^W&T4`3?-M\]$X8?,WW<YQG)QCG).#QD<=>45DRLK-LW*4=_NECW!&,G)
MP?7)Y'04X`/(LN"K$D;7&,`$YY';KGJ1QGJ6IJ!FCC4_W-Z$`9(`]\#!7!(Q
MGIU[`#F,RA_/.V4#,C!P">"<'CIC\...`31\J.RHVU2642`=!C&W'4@'L0<=
M<D9I'W11KQ,C*,@'"L!P,]3M'8=SP,GLDOFJA&6CX*QX8D1E3DD`YZ8Z#/(^
MAH`X3X8()_BKX]N55"L3PQ*5.0H);@>QV_ISS7KU>2_`ZWD>/Q7JT\L=S+?:
ML^;J-0%GVECN!'&"68X[9]Z]:H`****`.+^(0!N/!WS`8\1V^`>_[N6BD^(1
MQ=>#?^QCM_\`T7+10!'8,K_&W6,'E-$MU.#W\US_`(5W-<+IV/\`A=NMX<L?
M[&ML@X^7]X_`P?QYP>?3!KNJ`"BBB@`KQCP]$MM^T3XWMH44E],$H14&"Q$#
M'CIG+>AS_/V>O&;)_P#C)'Q4'60)_9$2D@$Y7_1LGJ/EZYQZ'O0!Z(6'F#?O
MCB4=6)RJYX)/9?3!SD>VZB3<S+YK$8!`C7YL\@;5!((SCD9XZ=>`J[MZ>2,'
MD(5ZG.[..O/!Z=QG:V*8"(G7RD9`V%`B8(2<?+@'@.1Q@X!R>0.:`%PPC+_*
M\:.H1A@!=N>A"@@`!<\9..#Q0[B6,QKEL(<2,5XQD`=>,_,.>`/QRHV^>-DB
MMO4*CN,`D-]TGJ,<#C(Z'@@&EW[T+R2OM$GWRPPK!L9.>-P`^[VQC&22`#&T
M&YN9]/O#?SQR7,=W-$SJJQJ%`'`4,><$#!)SM7)P><3XJJA^'&MB1(F<HK*&
M/1@Z@@9'51]>B^F:[&*&WLQ*UNG#N9)8MN%SCEG&?O$#IGH#G'0<?\4HI/\`
MA6.KB.9HL1J&;G)^=6VG'`!&0,==_(Y.`#M/`G_)//#/_8*M?_12UT%8'@4Y
M^'WAHG'.E6O08_Y9+6_0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5Y/9+G]I+5MZJT9T?!!
M3GI#GZ_3GOQS7K%>66HV_M%W1!^9M.<,"1TVP8QSUS0!V+88A6"/L&Y<'[P'
M8#/3Y<$GD<9/7`R8W[?F5ES&Q&=PSDGG`.>">N,9X^7*?NW#.(QY6_Y3_",G
MG&>C>Q_N]>U$:A?W<BC>9`<$Y1V'!X&"6.1P<?ATH`4R(00&B6%F/E?.2RK]
MW<HZ=,]>O(]J8Q1OW?DE#DJJ`+@=/N\_?Z<'(SC/2G"0>4&DF=-Q8ONP%(/1
MC@_*Q!..QQZ9-.+R#S1*664XWN7QN!R-IX[CD<?CQ0`URJK*"%)7*;22@8C`
M!'8MC'R]%P.F!6?XBD\K1-:DBV>:UM(Z!5&'<`D-CGC'/S'!&>G;0,FYW=W*
M,S;6<$#G(X/.<9SP1T['!Q3U1"VD7:R!D*P?,'.-@PV%Z'`].O;WH`PO@,BC
MX6V;A0&:>;<0.3AS7IE><_`Q2OPFTL_-\TDYYZ?ZUAQ[<?SKT:@`HHHH`XOX
MA(S7'@[:/N^([<DXZ#RY:*3XB,%E\'DH&/\`PDEJ!E]N/EDY]_I10`RQQ_PN
MO6,9_P"0+;YS_P!=7KN*X+3`/^%X:\5V\Z/;;L$DYWMU]./Z5WM`!1110`5X
MS#'*W[3&L1QN`TND#;SP#LCQGZ,`?P!KV:O'8V5?VF=19F7:NCY.0"`-J=<=
M?Q_EB@#O3AHFC1EW$9D0D@G&<ALY`(&WU`[8`S3I'4C:Y(1QP6"@[?EXYXR1
M@\]/EZ#HGF*B@>9M9!M(<A<]]V><G'\0Y(]"1E?F2-=HG#-\P3`#=<=>C*21
MC(/!_`@#0%61?,599&`!!;!()``QUQCICW'.14P219%#>8-B[3)M(P[#I[8^
M49'J."*C"@RE0C3MMRT>W((W9Z9Y7G//HOO2G`*%6^[L;S%4>GW\C/89YQN!
M/`()H`3<YQ*LDF?N`J5!105W8.>1]X\G`]!D8Y3XCVK7'P\UW8`P6U\PE4^Z
M`VX@>V0W/M]:ZA4#"1D*>9N"`JQSU/(/')QP#W/05A>-H$F\`^()!(`5LKCY
MR/E(\LG:IV]>`,$?3%`&U\-;@W7PT\.2%=N+"*/&<_=7;G]*ZFN!^"LK3?"/
M0RS;F43+]`)I`!^6*[Z@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KRBUEW?M'7]NY5HSI;'
M83ZK!G(]"%_2O5Z\CD98/VC61<^==:=(BG+8/[N,@$CI]TG/7GZ4`=UB3>H5
M\E>"V"2OW<9'3<2,8XP1[`B`21K&WEA-RJ<AB",D\*.3E<\Y]1GD\5,H\HHY
MWJH!P#P$R/KR&RP'<[0,CDAN"O5V&8PX`&3@C(`[L!C&3G&!SZ`#MKEV96+$
M?>8MN)!'"DXY!ZKC@G`QT`C5"@/"A0J@GC"@X9O7Y.I!Y^Z3SP0YT"7!1&\P
MHQ!WJO!SMX`SD9YY'L,9`H*N8T=B=P(V*1U8`'(;I@#)V]".1C&``.<NSR@2
MR"8*%))W9YVX/L2>1STXSFLOQ*RQ^&-8E@S(5L)PA*@!3Y9Z'/S!1VY&!Z$F
MM(J!&'`D"JH"-N.0O)'/3))`.>/F&.*R/%[;?!.NF$QR!K*X"#)"L`APHY&,
M`\*1CZX`H`C^"(`^$.AD`#/V@GW_`'\E>@5Y_P#!+_DD.A?]O'_H^2O0*`"B
MBB@#@_B;CS/!>[;C_A*+/[W^[)11\3?O^"_O?\C19_=`/\,GK10`^P;=\;-8
M&!\NBVX^[C/[QSU[]>OX=J[FN&T\_P#%[-:X<8T6V^\<@_O'Z>@_KFNYH`**
M**`"O'X/E_:<OS+Q&=(SEV!&W:F?H.OZ^M>P5XU8*;C]I3Q4J;MT6C+@*,%O
MEM\CKR<-P>QQP<<@'9ZQJ0TC0+R_>W>=;>VDGVQ,`Q0+N9ESQC@_S&22:GLK
MU+_2['4+8M]GOH8[F((1G#`<'/+$;L;3D<GIVL/E3(,J?O/MQC(!Y[<'(/JO
M;H,5S'@"=O[%O])$4RS:/J5Q8`S$[BC2,\;#H%.UPH!]%Z4`=-\I8CY"IRN%
MYW<XPN1UY/'`YQR.*>K-\LA0,JNP&TC!SP,8Z-@YZY.,$Y`I!'L1G`=7+#;C
MD/P2.>N3QZ$9]N'!`D@4'H$`+`,&R"4#8Y).2.AZYR2`:`(UYE7#_P`9",%4
M8.5SCITZ@#DY.>N*I:Q%&^AWT?DK)&;:563!<KO&54C.!V^O&"W(J^ORNQD+
M(F-KR*1_M;6/^S@_CG&#S3"GG+C;)\D8+JASM)P?FSV(QSD]#USD@'*?`:=C
M\.DM&!S:W$L;GJ`Y<DC/3H0?QKU"O&_@I(++Q/XXT9MJF*^$\0#[B5+..N3T
M&SOGGFO9*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"O(0L%Y^TM)#/"KM:Z>TL9V]"T<:Y/
MKP6&#TS7KU>-V#2R?M,Z_.L#,EIIL:%@<#+)#C)]]QX&3QP#0!Z`"K`A61T(
MW#8Q.1R"R]SQG.>.`.G%/`=F8.$PYYD0<.QX.#@'/\0Q@$G/I3(B,D*R$L&?
M;D9]QT)!`]R/?CEXA4[Y/-^6,;'(4D*0-Q/08(;U(X/8#!`&Y4K,695?=ATY
M"=2!MQT/48(`.>1G)JGJNHVNAZ?<ZC>;_L<3B&8QC>RNS!!@#&#N<<Y`^8'`
MQQ<,)"XZ@+M(`R3CL<\>O/'0YY&*P-8U&VN?%^C:+/;,9#NU`L"-J+'N`1@Q
M_P">A49`_A.,#H`;[;?.=&)W*[!Y`V-WS$98CH,\@`'G@^IQ?&1=O!&O&-?-
M!TZ8X?\`ARIP<<X8]CGD#L>NTP3C+,%D^3+X##D_>/.XY#?GP,@@4]=@-YHF
MHP[#\]K-DOAF0,I4E@"`1UR,Y&6'3@@&=\$O^20Z%_V\?^CY*]`KS[X(-N^$
M6BCCY3../^N\A_K7H-`!1110!POQ*R9/!@&[GQ-:9"D_W9#^7%%'Q+.)/!G7
M/_"3VF,?[LE%`"63+_PO+50#$3_84&<.2P/FMV/3Z#C[IZDUW=<18N'^->KJ
M'+;-$MU(/\/[USCK[Y[=?Q/;T`%%%%`!7B?@@2ZE\9/B!K1,<BPJ+)<#[P9P
MJ8QC/$/X\<C.:]HGFCMK>2>9U2*-2[LS!0H`R22>`/K7BWP0M5'@[4M6FC59
MM3U!]S*Y),<:C:,9Z!F<9R,9!]"`#T@<-(2%`3*L6<X&<9W$<@]N!SSDGOQO
M@'*^*?'<!4QG^TH0OF#?@E&'`SSTZ?3C.!7;<NRQB6,.%V^;O`**.I]#T8YQ
MU[@\#D?A_;R2V_B'4KB%7MM5UB=[;R!O+01,8N@]UQSZYH`ZIB-@C4KE^@SE
MCD%??C)]<Y`X'(J65BN(SM)<#:A'][!R,>IX]1C@4TL[`,'!+-QY;`D@X50"
M>".,8X!YSGDA\>)&RL@C#$DE5V<#.YE/'.1WXYR?2@!JKNEVJ6+L>&0<8).2
M.H/3[IZ\X`Y`:TF6V9+J1D?-R!DC(^AZC/\`"!D@9IV8Y5W8`BW*K$L43/0]
MQCIGY<9QSR0"YB[J1)DDME1T^8<;<C@'`&%[X&0.<@'E?C%I?!/Q&T/QI;*Z
MVEVPMM6D5V<",B,`-VP%VD8P-R_3/M]O<175M%<P2"2&5!)&Z]&4C((_"N5U
MW1K;6='O-*U!-T%U$4+[BV",#/4`%3TX/)P.F#Y]X(\977P\UC_A"?%\Y&G!
MV_LO59FPGE=%4GLOH2?ES@\8P`>WT4V.1)8UDC=71P&5E.00>A!IU`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4456O]0L]*L9;V_N8[:VB`+RR-@#)P!]22`!W)`H`?=W=O86<UW=S)!;
MPH9))9#A44<DDUY%\-8+G6]1\0>/KIPJZU/Y=I&\>=D,9[DJ1P%"9`/*'\*>
MKWNH_&6_^R:?-/IW@RV+,]XHQ)=R``%2N[(7YNI&!U/85Z59VD,$$4%K;QV4
M44>$M[6':(U)(RJ@`D9P<COSQW`'%QL*#Y2BX.9.1V`*\]R>>H.!\O%-:0!U
M)E4X&!N')&>#CN",>X[#BI-GF,8QG"@MMB.XJ/5<8W#*X/4]NIHC<.(][JQ9
MR=PPQ)')P0!GEAQTX&,T`#*5=W<!=Y;:3DE>>@XQC.%R>1D=,`#'TB.UN?$.
MOZI%(DQC>+225"NT?E)YC#(Z$-,003QY0Y-:@7[J$@>83D8!))]\=1G&WCH,
M=<UQ_P`,S-'I7B-&A??/XDNY4RA.Y1L4E?7#`]\<')]0#M(UD1/+VF3*@*[<
MAN>S%0<9`Q[E<>M9^LVLEWX<U.W@(<SVL\4;$#!+*0&'XD<`C!X]CH,HRV/W
MJ;@%DEXY_P!KL._!Y)ZCD4V0*[.NU2>!()L_=;@@DC*G`&.??)SE@#E/@-,A
M^&T=ITFM;N:.5<@X.[/;ZUZ=7D7PMA72/B3X[TF.,PV\LL5Y;Q$!%",7.40<
M!2'7'H``:]=H`****`.$^)>/-\%Y_P"AGM.V?X9**3XG,$?P622/^*HLQD>X
MD%%`$MD`/C5JWWN=#M_O)M'^MDZ''S#WYYR.V*[>N(LO^2U:MS_S!+?_`-&R
M5V]`!1110!QWQ4UG^P_AGKMTNWS)+<VT8+[3F4B/(]P&+8_V>W6L_P`#Z2=#
M\!:+I)S%/#`9IR.2C.=[L?H'&#U[#!&*P_CC.VJIX=\(02%9M3U&(R<$?)DJ
M.>G4YQU^6N_N,I)*(]PPQ11C[IS@8`&1C=QCT4\[A@`R?$>J#1/#VHZDR1L;
M>"6=87)0.RC[N[J3D#@>O/()+/#%J+3P7HD"QHKO9I-(I.Q0[@RO@],99B3W
MQUR#AOB[3+C6O"&KV%LB++/;-$J-L3#\[<C'&<`D_7MC#_"^HP:AX5TRXM,.
ML-LL$RR(,QRQX1T;@XY7J>PX(!S0!J2,B6[EPJERV.JY/1B<_P!W@].N0*<S
M_O'),P4*0XP.F,,>^#C<1SQ@C^\!'+<1P7-O!YI2>XW)$NT$OA2S87!R-J'#
M8&<@9Z9EDWJN,NJ[`RX`![#<#CC(P2<G:>V<&@!"X8>:9`<,4`1AGY<<$]0.
M3\W4#!YXPD*B.1@(]S`<.P)Z]_0@9'//!!]!0[,C*7!W?,P+,>>>G3!3^0S^
M+GC?:/,4CYE)52`&[DC/W@,\\8P>W(``U$6)55&S@*^\J68ID\X/&/PX[D8!
M.3X@\-:3XCTN33M6A$Y>,LDCD;X@0?G23!YW,,=CM`([5L[6W$?O"069MPQN
M'=B#SZG'&-W!&1367.TB7);$F6E"]<')/8GKC^>*`/,+32_'OPZN6/AZY/B7
M1CE1:7LFQXQV\O+<_*J],]?N]Z[#P=\7/#WBRZATUC+I^M2$J;&=&)W!<L`^
M,<8(YP>.E=!O/R$DL3M7LI8<[1@<;L@\=]H'?%<UXI\!:'XOB:&]LU6Z4D"Z
MAVK,<9!`8J2<'G;TQT`[@'HE%>(06WCSX:07;Z1<Q^)=$C7>Z7TC)+"%QG:"
MV`.<8!)]5%>@^"_B3X>\=B5-)DN$N85WR6US%M=5S@-D$J1]"30!UU%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`54U/4[+1
MM-GU'4;A+>T@7=+*_11T[5R?COXFZ/X*3[(WF7FLS(?LUE`FXEB/EW\\`G'O
M@\`UQ+>`M>\::A)J/Q!O&1,*;;3-.N,I&#]X-P1D?)PK9;(Y]0#3O/C.VM:H
MND_#_1I-;O/*:5Y)OW,:J-O0,03U(YQSMQG-9:?#C5?$\XO_`!QK]U+(SF5K
M"TF!@CPQ(7DD$`'!`"X'<]3Z7:6,-C;K:6EG%#&L;"%($V!44$$$*.I(`(ZC
M)Q@U([!P0PVY`.Y"#@\C*X/#9]#SCV((!7AM[2R@6"&&VLK<<B.&/:J#DY`[
M]5XZ<GC.,R,D>TJ=L;#UEVYX8,=_4-VP>!D<5(CN`'9D96?!?&['<\@97`(X
M&/N]L',;.4RH!$H0@`H0V20.<<YY&#@<^N3@`5LM*H=!))G(7;G/3([X(XX&
M"/F'`P:Q[/7H9?$,NA:A`;:^D_>V`<_N[R#"G=\O"."6^7C@CKDUL.%C<K,=
MB["""6!9NJYQC&,CD<^O6DNX+>[26&]@CDWO^\CD52`2>!M.1@$CY\<Y/([@
M%;5KZ#1M/DU&_DDAMXPOF94]<@A=J+DL=V.`.,^^*?AK1Y=#TB*RN2&O)W\^
MX65MVV:1M[H".HW.PW>PZ<-3-&\*:/HM_<7UI9CS)\2@-EO((+#$0ZHF&(W+
MUP,UK0M&5V"1C,PW,I&=H&2<'@;3GICI^&0!Q4[04D4Y&T.7'S<MR3UQD8R<
MC)..V9)%D+L`"C(F5Q'C&%W$G@#T'8C/\/0I(V+>/*JNQP2<%N"%Z'G(^I].
MGRTYMHG\H[8W$A8JH/J.,9Y&2,9P,XQUVT`<$\Z^'/CIIMUPUMXALGL\H<JK
MQE<$=SRH&3UW$\5ZW7B?Q@D&CR>$];995_LW5$?."Q\OY6YS_%\@!7IR.F:]
MH@GCN;>*XA;=%*@=&QC((R#S0!)1110!POQ+SYO@O!Q_Q4]I_P"@R44?$H_O
M/!HXY\3VF<C/\,AHH`6SP?C?JGJ-"@`P#_SV?J?7Z8_2NYKB+38WQMU-E;E-
M!@5E"E029G//]XXQR/7':NWH`****`/'+R5=;_::@A\LL=#TPE4)P'<J6'_H
MY?RKT-'+*4+*5;(7+`$L<\#&."6()Y/7H>GG-FC6?[36O&>(_P"FZ0#;L%W'
MB.($@?\`;-Q7HPWQJ?E<JI!8E#EVY"CH<J<[<CJ`!0`QV3R\*^\D!@6`^4CM
MG^[GGTZYYX.+?^%=/NM0%_'-=:5>@EGN;)@'D`7;EE92LJX*\L"1MX/!)VRX
MA5@2K-C?@H&^7`^;Z@=O3DTY8V#1,VTJSC)4XP6;(`P."1GT^\">>:`,C2/#
M^EZ%&[6<0>\F#237EQ(7FE^4;F9CGC*Y*@`9W`+R0-4L<_*P"@^8#'UR2,'G
MC)QT!(..!C#4]MX4,S9P1G``*XXP"!C/^SD'@=*0#)4DOG?@Y9MI;=CKP0^>
MW`Z'H,T`)Q&KJI.=VX'`!"D<8QT//"^PQC!%*JE':,_*V<83D?>P<,.XX^4\
M?,/I0OENN[S5(4;2^.@.<@D_=Z8R,9QSC(-(=J[EF&UP,*QZX]#TP<\YQD^X
MZ@"285RXC5<@-A)`1GY2?4`988!ZAOI4\I/GR<;<N6"L.0!DGOW]<GC&,?+F
M.(N74?-OV\Q`!6)P>2N!P,GMR,YSP"1D!8UCW?+NY;(X.,GO\IY`.>`">2,@
M`"!Y909D7=Y:.Y*D#:1DX'!`!Y//0G&!4AW23.V"R8^5E&T2#)Y.0!CN2/7U
MVXBV^4.'*%@`JB3.0W0#&=PY/..?U68(WGK\JG'S*W'[S&64@XRW...<=>O-
M`#&9%)W2+@*&?#9QN'`'8J"1CW`Z=:X7Q?\`#+1?%$T6HHS:=JB`%;BV(C&!
MG82`,$[L_,,$X'3(%=RK(JQHI5-X.Q@QZ':<X/4@$]<@9QT)PCR`MY[,Z@%@
M`58*N`>@XS_=QCL,C)P0#S>T^)/B;P&;>U^(-FMY82Y2VU;3P&,C9SEU)&!@
MD#Y5)VG`;!->H^'_`!-H_BC3TO='OX;F)AEE1AOC]F7JI]C5>X3>OE-"IR0C
M*Z[@^YL$'<&!]S[@$\`'S_5O@UX5U"]-Q:BZTJ>/]X'L92!)GG<-V0,`'`7'
M0\^@!Z]17BR>%_B1X>MX_P"R_'T$BQD*8-3B`0)C=\S'>0?KM)P>>F8;/Q!\
M4[[<+?7O",S`[<17"2;3[[<XYR.<<T`>WT5Y!;_$WQEH,0'B?P@][&L(=[K2
M,OLP>6=>0.,'J!D>_&UIOQM\'7\S12S75@R<2?;8@GEGN&`8D8/'IGB@#T6B
MH+.]M=1LXKRRN([BVF7='+$P96'J"*GH`****`"BBB@`HHHH`***Q_$/BK1/
M"UB]UK&HP6P"%TC9QYDN.R+U8_2@#8HKQ^W^->J:Q&9?#_@+4+^##$2-<!"<
M$#A0K9Y(Z'KQ2:EJ7Q<_L^+5K>?2$=(][:7:VK2&4YQ@$Y))P3@,,#=UP*`/
M8:*\6@^)'Q/D4POX&MHYT;8\LA=(PV.."WJ#WZ?G5F\\/>.?&Q>+Q7K$6EZ7
MO$;:?HR%FG'WCEF)((V]\C((P.:`.LU[XJ^$/#TC17&JQ7$R@$Q6CK(P).`#
MS@'CN>.^,UQL_C7QK\0A)9^%-,?0],>+]YJ&H1,)'4D@^40"I."O`R<D<CK7
M2Z!X'\-^&8772=.BW.HS)*Q=Y&'(Y/3OPN/FZ#*YKHWPH(?[L@7"XR6Z<]CD
MDG!'7=C.<``'*>#O`^E>$(/M4(DO=4E3;>:A),V^1R`VQ>>!GT^;UST/4"1_
M,"Y1L!R,G:`0.1_LX)/<=CZ4]PR*P(12?X2P`VGOD<E<=2/H=W.$XF?".DIS
M@@D+R<C!P>@.WG/!`V\$"@!%,>1`"IRXSN/SYSZ<@'YP/YG`(",X:&1V`('R
MNH!&"`3RHY'(//UZ<@NX.5#LP+`.B_*V.I`49W9&/FR>O7&30^Y3CS'/RYWO
MQ@<9..G./]WY3CY<X`&\$2;C\JE5<)CD\GD9X`&2#W'.0>:1G0$)*8U[D;B.
MO&.",KC."?QP&R45HP4VN,[QMR"6*[L$=,D=`1D[OP-*6$9"F;Y`JR[8R&;:
M1DL#R#V&,XQDXP!0`NXK\I0QJ0V`O)7J2<#KGCG/UR#EG_-D`1A-C%2%`94/
MIG^(X7DGI2-M\U47:[$_P+N.#@<8/('S<]BO/6F;!')&H#[B#PZD``$8&#T(
MX)SVSG<#0`A=0$!98]S^8/FP".#\N1AN#]WJ,^YI1L"!',9!;(W#'3GGG(.?
MX1C!SG@BGH&6*/$;E5=RI93M`!!(.><C'3V(R:?\R;EROF8/\(&`%.[YE'N0
M.!RA/K0`SYCRH;:3M#><5+'CY3_M8Y(_O#I][*HS?+&S#>-RC(QSM(;G..,=
M^@Y]!05V-^\PK;BI8KDGD8!STZ@9R.N=QII.$5]W&%4#<2<J!PPQV&3TZCGL
M*`.:\>:='JWP]UR#"O&+,NK$E5#)AU^;UW#OSR`W<C8^&%^=2^&7AZX))(LU
MA)/?R_D_]EINOJ[^%]6;Y`YL9MIW*>L9.%&?X0<CKD`#(Z5B_`FVN[?X66)N
M0@26:62`+U\LMCYO?<&/T(H`])HHHH`X7XE@M)X,4!CGQ/:$A3Z+(?RXS^%%
M+\22!-X,R,_\5-:_^@2T4`+:_+\;]1`0@/H$+,VT@$B9P/KQ].G3O7<5PUIC
M_A=^I`@!CH,&,.#D><^>.H^GX]Q7<T`%%%%`'D'Q7-SX3\9>'?B!;K))#:XL
MKR-!]Z$EB>^,_.V/?![5Z(YMUB\^%XI(''F(Y*D$<#(.T_U[=2W%[5])L==T
MBZTO4H%GL[F,QR(P[=B/0@X(/4$`CI7B]AJNO?!RX71O%$5SJ7A9YP+'5(B2
M;?I@$9.`!SL/H=N[F@#UA=QDC4.N59?D9]K=1D\_>(.0/3@8ZT$$?.@!;Y5"
M@<`-C`.#U/')_$8XKF+#XA>#-15FM/$VG@[@0+R4P97/.?-`Q@$`8STSCTN_
M\)=X5CVL?$FA%5ZXU&$[5[_*#\QQ_(>N*`-GY$W88Y`4M+(QPF0=@]0,G!/L
M.G&';%64"52N-IYP&`SQ\HY/7&<C)QP>E<W<^./"]G;%W\2Z3A1]Z.^CF(/^
MZK%F!`YX[\[J@G^(?@Z!%9_$FEO@9^5R^2&X!"KG'7MD\9XPU`'40E_,V%V`
M!)*H-YY."=O<$=\8'OFFJ4B.2Z;0&PYSRW(P`1\PW;?7&W/>N4F^)O@91-"W
MB.T=@H)4I*4(VG/(3!^@R??+52?XQ^!DD\P:T\G&,?8I3TR!U7IT_P#KGD`'
M<[EX#Y<YWJR\\]S_`+0')&>V,GYC4DF(R[;F&TG[S$@G(!PV.1D@$8Y[G(./
M-3\:/#S//%'8WUU*CJ"\2,$=3R"#M+#G'^]U)/2@?&OPU(5D@T_6987D`W"W
M!)).`,@\MCH#G)!Y'4@'I60LY7;OVG_>9@01C.,,>#GCC#=3S2JS98NJG>HS
M(B;5D8]>2.G&>!ZG@5Y]#\8?"1A5YVO[61TRT#VCOY9.><XP,GC@?EV<GQ@\
M%8</J=U'LSYK"RDYSQM88X'`X]\#&,T`=[M&Q8S@;1O`(,9P,DCG)!''J3R3
MP<TTJ^P<A'RH*<*3G^1(Z#GOUR:X9/B_X"()?76+DC@V<^!S_NXX&0../3I6
MS:^.?"%];^=;>)M)4,"=MQ>"-AN![2;6/!Z'ICN>*`.C=3]MD&1R[9!<J"/F
M/!YP>OH#R.QSB:SXA.AW$(/A[Q%J23@G.G6ZS!>JX9=P*'A3DC!P<=.([SQS
MX0M(&GE\3:1Y:#)$5VDC8&2`$BR3R1GKGGCI6+/\7/`L;3`:X9I9.T=K,X)R
M..4`///'K@CC!`->?Q=:VSQW>H>'?$UG`Z$O<O`DT:!AG=(D,CL!P,';P1QC
M)I3J]S'I<6J:)H\&L:<P8AM.N@TA'0D(T>UFPJYRRGJ`"<YYFS^-?A:20_;;
M+5K*)F):65#(JHRC8_0\-T]_<&N"U/5M%TFXN;_P3XLN[J_N+_[9:Z=:V\\>
M9&*@AMV%=>'^3;D@J,D`Y`-_Q#XZL;&S,ECXHU:*\50USHVJ6LT4OS8;:LR@
M&)N^0W(/4D<^:W2SW=L\)DA@BU%VNH//19TBW+O*>>X+JYQT').,YW9'>^)=
M6F\77&H)I_PXUZ/4[UECF:5I$B+C"IYJ@!6VX4C><`UJZ7\*/&/B6#3-.\9:
MD;/1=-B"1VEJ4W/G)(^7*\849(/`X`ZD`[3X)6,]G\-K6:=RWVR9[E1@`*"`
M./Q4GMU_$^BU4TS3K?2-*M-.M%*V]K$L,88Y.%&!D]SZFK=`!1110`4444`%
M%%%`!7S1X=TM_B#XU\3^+M0M8]9M=/N-L>G/+@2QL6"[7!``15!&1AO;K7TE
M<Q-<6LT*RO$TB,@D0X9,C&1[BOG'PMJ^N?"<SZ-JOA"YFMA=M+/?PQL=\9PJ
ML&`(X*\<C&\\`\T`>BQ^$-/M?$=K<Z;HEEH<.CW6Z*XC(\Z\0(5(^5>$.]@6
M9F8[<8Y!KLIW7+M*24#,6'!(4-\PXY4_,,8//\N:T_XB>"M6B,UGXDLXU7:G
ME7DPMBO7M(!N'N,_>/7H;6J>,O#.BPR7%UK^GH"`Z+]I260J>X5,N>_(.<@<
MX^Z`;;F0(R[68R-Y3;P!N8DDA<#CD$YR<$_0A&VB-@68@@(N%V\!`<%N@X.>
M<\#U''E.G_&71+7^V;O4KJ];SV5;.P^S%,1(&8$'D;I-P.<_*"H'W1GT?0M1
MM?$F@VVH:=<I=0SPKYAA=7,,A"GRV`;AE#<@X()SW(H`OR&0'J`LBX8'H,?>
MSSZ@^A'/("T+MC$K',3X"D.F?E.!G#8SR!D].3]:C"LQPQ=))`#@\AB?[N<9
M4#'`Z<9QBE3YI$BB,H:1=YVY+9(SNSD$<D?*>V#P:`%#*$:8'RRA)4A=W3[Q
MQ_'C`&1P"<^Y$8QE9"PWQDXY#(,DX/!/'RGKCD$Y'6N6\0?$7PUX=E\G4=7M
M?M:L=]M`AG<;3T(7[C=!M8KP>O&!P.H?$#QWXG#IX9\+:E'IA9L7D<+>;(BX
M`VR;=J'`Z#)&>Y&Z@#UG4=4TW2+:)[^[AM$E1GVSOEI./F(3!9P.?E&1@9/7
MB!O$5N8/,CL]:DR?,40V,@:0$#!1L<\=AP.`<8S7G&G6'Q/M;F"[L?`6CQ3<
MLMY?W7GW`+$G+.TV_///&>,=.*V/LWQCF5,0Z79,3A_*CCEPN"!S)(Q/!/''
MZF@#K(_$UO+;1N;+6ED?&,Z<[JOR_<RI*D]CACD@#GO-8>(M*U9BMCJ'F*O/
ME-OBF`8<$(X!W#![=AC&:X@Z7\;&DW/?Z6<!>!!`0?NY'*Y_O?D/7BEJFF?$
MV2,_VCX1TC6U6)L7'[N&XC..2I27@\X&WGCC!/(!ZLVXOL8QA?+V[LE5W?W<
M]%;@Y/7IQ2R;=C=48E0/-C\O`).,XZ'CJ.#CD`5YEH_Q,AT33Q8>,=+\0:?J
M4:RA9+F)I@\?(!W$!F5>!N^8GJ2<UO67Q5\#7UR(8M?BC=SN3SHGC51@\'?&
M$!&`>HSGJ<"@#K0RRH2@8"2,M\Y]!R,<'@-D$=L<<4\X&9$"[,I@LRXY!"L5
M`^7.<YP.3C'<4-,U"QUR&233+RVU!(RHE>UN1+M8G('?(ZG#=,]N2=-;:\C9
MG6$H,[L,XD(R3NZ]>.@Z\GGJ"`0LHC9599%ACY5=ISDCN3W[G@XQQZA7(C=%
M3>`"/NL6)!VXP?XEZ]<`],YR*9&@DA4C>"%Z'(Y&T=,C&3V/S9VY&>#B>)O%
MVC>%X]NK7\$$DCCRH`"TKCJ"(U!*\#J0`2>3Q@@&1\2M=AT;P+=6D:^9J&J(
M;*U@C.69I.&QGDJ%)([9QR3@CM?!.CR:!X)T;2Y@!-;VJ+*%'`<C+?J37`^$
M-%U/Q[XC@\8^);.2WTFUVRZ%92.IW9Y\V0`9)X4@GJ<'IC/KE`!1110!PWQ*
M.)/!HP,'Q-:#D9_ADHIOQ+&9/!?_`&,]I_Z#)10`MKD?'/405`!T"$CY0"?W
MS<YZG]?T%=U7#6H(^..H?*V&T"$[BO`_?OQG_P#5T/I7<T`%%%%`!45S:V]Y
M`8;J"*>)NJ2H&4_@:EHH`Y6]^&G@J_WF?PSIP+G+&*$1'/U3%56^$G@-U*GP
MW:X)SPSCU]&]Z[2B@#C4^$_@2-<+X:LSSGYMS?S-.7X5^!E7:/#-CC&.5)/\
MZ["B@#GH_`?@^(`)X6T7@Y!-A$3^96KEOX7\/VA4VVA:9"5&`8[2-<#\!6K1
M0!5&FV"G(LK8?2)?\*3^R]/_`.?&V_[\K_A5NB@"E_9&F?\`0.M.>3^X7USZ
M>M-.B:2<9TNR..G^CI_A5^B@#(E\*>'+A"DV@:5(AP"KV<9!QTZBL2^^%'@7
M491+-X;LT8,&_P!'!A''LA`Q[8KLJ*`.,M/A+X#LBGE>&K1MC;AYS/+[\[R<
MCCH:V[?PEX;M&5K;P]I,+*<@QV4:X[]A6Q10!3GTC3+J,QW&G6DR,`I62!6!
M`Z#!'L*IV7A/PWIMRMS8^']*M;A?NRP64:,/H0,UL44`%%%%`!1110`4444`
M%%%%`!1110`4V2-)8S'(BNC=589!IU%`'*:G\-/!NK%WN/#]DLKC!DAB$;=O
M3Z5#IWPK\%:7<+<0Z#;R2KT:X)FQTY^8GGCK78T4`47T;2I(3#)IMFT3+M*-
M`I4CTQCI7$ZA\%O"MW?&\LGU'2)CS_Q+;GR@#QD@$'&<#./2O1**`/,)/@M;
M%AY7C+Q6HQR&OPW_`+**</@GI4B;+WQ+XFO(S]Z*:^4QM]5V<UZ;10!SFB^`
M_"^@0+'8Z)9*PQF5X59V(X!+$5T2JJ(J(H55&``,`"EHH`****`"BBB@"*:W
M@N`!/#'*!R`ZAL?G63>^#_#6HQR1W>@:;*),[B;5,G)SUQG-;=%`'!7WP;\$
MWMR)TTH6K#D"W.U<]0<$$?AT]16<GP+\,0.7M-1URTD)&7M[P(>.@^[C%>G4
M4`>;-\&-*?S0WB;Q4RR?PG4@0OT^3G\<UJ^'?A5X2\-N9(-.^US<!9+X^>8P
M#D;01A>1U`S7:44`(JJB*B*%51@`#``I:**`"BBB@#A_B3@-X/)!X\36?S9^
M[P_\^GXT4?$@?O?!I/0>)K3^+'\,@_&B@!L2E?CM=%4PK>'(RQ)/)^T,!@?3
M^5=U7#6Y_P"+Y7P/7_A'H<=_^6[]_P"'Z=^M=S0`4444`%%%%`!1110`4452
MU?5+?1='O-4NRPM[2%II-N,[5&3C/4^U`%VBH+J^M+%%>\NH+=&;:K32!`3Z
M#/>J@\0:0;^_L3J-LMSIZ+)=QO(%,*L,AFST&,'/O0!I45475-.=(76_M66=
MS'"1,N)&'!5>>3["J=[XDTRTL9KI+J&Y6">.WE6"56*.\@C`//!W'H?2@#7H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBN;N_&5I9^/K+PG)!)Y]U9M=B?<`B@%L+]2$<_A^0!TE%
M<EHOQ"T74]#_`+5NYETV(W4EJ@NG`WLHW9'J"O/TJ?6_'F@Z-&J_;K>YNG\L
MI;PR@LRNP`.1D#C)&>N*`.FHK"?Q;I%K;R3ZA>06D2W<EKYDC_)N1MIRV,+[
MYX'K4NDZ^FJZUK6G)#M_LR6)!*'W"421+("../O8[],]\``V****`"BBB@`H
MHHH`****`.(^([A'\'Y(!;Q+:*"5![2?E]:*7XC!B?")&>/$EF2`V./G_/\`
MSZ44`,M6Q\<M04D.3H$)4[2"@\]_E]\YSQCZ=Z[FN$BVM\=[DAB2GAN-2"<8
MS<,>G?MSSCU&:[N@`HHHH`****`"BBB@`K%\7:3<:[X/U?2K1HUN+NU>&,R'
M"[B,#)P>/PK:HH`X/QOX>U_Q7I5O;"ULD39.);<RA_G:,"-_,9,@*Q;("\\5
ME7GP\UF;4?$\D4ML(]4BT\QD28WFW4+)$^5/RN!U'MD'FO4:*`//5\`3K=Z-
M?6A6":Q>]N62[E$O^D3)A6`50N`V6X`['DU1M/`_B>26^N;Z:Q6XO$L_/V2D
MK++#=F9GP$4!2A(`ZYSD<UZA10`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7!^,OA_<^)M0O;^TOX
M[*\>UMK>UN2I9H=DDIEX&.&60#\".!7>44`<%J?P]:1;=["2$&UE8PP/))"C
M1M;1PLA:(AADQ@]^N*J77PTO(+C5(M$O+&STW46LR]NUN28Q;X^56ST.,\YP
M1_M$UZ110!YQXJ^'NLZY8R6EIJ\<4,TMZ\J2/(J'SV4H2JG#E`&`#<?-D8Q7
M2>&?#4N@WNJW,ERDOVTVV%52-GE0)%U[Y*D_E71T4`%%%%`!1110`4444`%%
M%%`'%?$7);PB`.OB2T[D#HY_'\:*3XC$*_A`GG_BI+08V@]1(.IZ=>OX=Z*`
M&0'/QSO0X^8>'H@A5L@+]H?.>.#GMSQSGG%=S7#0$'XZ7F6+%?#L0`VX"_Z0
MQQG]?Q]J[F@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#BOB*0'\(_O&0GQ):`;?XN'X/
MMC-%+\0\F3PCA]H_X2.USAL%OEDX]_IZ9HH`CA!7XY7F>`WAV(C;P#_I#CYO
M4^GM7<5P48_XOY.P8\>&D!`)(_X^3U[`^WOGUKO:`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`.*^(@R_A$^8J8\1VG4<MQ)P/?\`^OVHH^(K,O\`PB9!PO\`PD=F&)7/
M!W@?F<#/O^-%`%>(+_PORX)BVM_PC28?CYA]I/X^@_#Z5WM<)$=GQWN4R1YG
MAN-]H'!Q<,,GCK7=T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<5\1GVIX5^5F+>([(#
M#`8Y;DYZCZ<T4_XA'CPL,9SXBL^?3[W^?_KT4`0:_P"$?$-SXY'B70-;M;!S
MIHL7CN+<S!L2E\XR`.H_(^M*FC?$56^;Q;IDBEQ_S#=N%SSW///Z>^:**`$_
ML3XC$MGQAIJ_-E<:8#QQP>>F,_CZ4U-$^(ZK\_B_3G)&T_\`$N5<<GYA[X(&
M".V?J44`(N@_$<%#_P`)I8X)^8-IB-C\1C/(]!P3T(%.&A_$7^+QC8':."--
M7YO3</YX(HHH`:NA?$9.?^$RL9<1X`;3D7+=B<#\_7G&WLJ:#\1<;&\:6&,L
M=_\`92[N0<#KC`)_'`]Z**`$_L+XC9W'QC8GY?N#3T'//4X/J.PZ=#2'0/B,
M&39XVL\*.=^F(=QP.N,<$YZ=,CKC)**`'?V%\1>!_P`)E8_>P6&G)PN<YQZX
MXZXH_L'XBY/_`!6EC@D?\PM?EP?KSD=??IQQ110`?V!\0V+Y\:VB`KA<:;&V
M#CKTYR?\\\..A_$1DY\8V"MMQ\FF+USU&2>PZ8/4^V"B@`&A_$-593XQLI.5
MVO\`V:BD?WLCD?0?KW")H/Q#5-LGC.SD(4J&7340D[<;B,'G/.!@=?7`**`$
M&@?$,+@^-K1FY^;^RT'ICC\^_8>M._L'XAX7_BM;/Y<G!TM#NSV)ST'L.HST
M^6BB@",Z!\1F((\:6:`'[ITY&R.N"<#GMD`<=J4:#\10>?&=F>2<G3X_;`^[
M]<_ATQR44`+_`&%\12B`^,K-6')/]GH<\YP>!QVXQQZ'FG'0_B&T13_A,+%6
MSPXTY20..HZ$]?3K^-%%`#6T'XB,"/\`A,[-0SGE=.3*J<8QD$$CGJ.A_$']
M@?$0KQXTLU81X_Y!J'+^O08'MS]:**``:%\0U9C_`,)C:,#D!6L(^.F&R%],
M\>O.<?*#_A'_`(A9V_\`":P%22"PT^($#G!`V]1D#!],]\`HH`0>'_B)@$^-
M;7=L(XTZ/;NQP<;<]?>D'ASXBB.(?\)W;LP3]XQTJ+EO;`Z=_?IQUHHH`;_P
MCOQ&\HC_`(3JW\S>""=,B("YS@\#/<9XX]#4A\/_`!"^<CQO;G<!@'38OEXY
MQQ]<9[]00<`HH`1_#OQ#;:!XZ@7#$';ID62O.#R#SD].GRCIDTT^'OB*968>
M.+9$(X4Z;$VTY)_NC/8=NF>***`%7P]\1/D+>-[?*C#`:=%ACSS]WCJ/R'7G
M*#P[\1-BJ?'$)(^5G&GP@D8'S8V'G.>.GN>Q10`?\([\1-BC_A.(BP7:S?V?
M"-QY^;[G!Z<<]3S2?\([\1L,W_"<0;R0P7^SXMHX.5^YGGCGVZ=J**`%/AWX
MB"1=OCB(H&)^:PAR1CH<1^N#D8[\<C:S_A'/B09HF_X3J`1J<NO]GPDL,YQG
M9Z<=.^>V"44`+_PCOQ'"X'CB`DK]YM/B.&SGL@R,<'IU[8Y#X<^(X=L>.X2N
MX,N=.AR.F5/R=/O<]>1Z8)10`I\-_$0O(?\`A/$4$_(!IT'RC'NG7(_7VYC7
MPU\25#$^/(W."%!T^`#V/^K_`,^]%%`#AX;^(XG#CQY#Y8+9C;3H3D=N0@(_
M6G?\([\1BISXX@!V`#;80C+<\\H<`\<<]/?@HH`/^$<^(BOA?',;IW9K"$-[
M](\<=OKD@]*:/#?Q'Q@^/(_NXW?8(.N>N/+].***`%D\-_$4["GCI%P/G'V&
M#GIR/W7'?CGMZ'(_AKXB%<1^/-K9R"UC;GCGC'E#VYSZ\444`$WASXC.&$7C
MF*+YB5/V"%N"1P1Y?89Y]_;E3X;^(NY2/'<>,LQ7^SH?;"_<Z>_4>]%%`#7\
M-_$=E.WQW&C%4Q_H$#88?>/^KY!_#'Z4O_"._$;?G_A-X=IQ\IL825Q[^7SG
MIT'KWP"B@!$\._$@??\`&]N<JP.+"(8/.&'R?3@Y^OJ'P[\2=KJ/'%L20`'&
MGQ*0<YSC8>W&.>W(QR44`#^'OB4R*%\<6B-@`L--C(ZDDX*^F!U_4<O.@_$;
M>K?\)E:;=O*BRC'./78>_.?J,=Z**`(9?!?B[4]1TN76?%,=S:6.H17WD+;(
2I8H>%W*@/'//?/0=0444`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g201504281926540221272.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201504281926540221272.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"X`2@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UCQEX\T?P
M+#8S:P+GR[R;RE,"!MF.2S#(.![9/M73*RNBNC!E89!!R"*^??C-CQ)XYN=+
MDNTCM="T.:^\IV"^9,>RG/)P8C@]E/K7K'PTU`:G\-/#UR'WXLDA+>IC_=G\
M<J:`.KHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N-\5_$_PWX-
MU>+2]6EN1=20K,JPPEQM)('3OE3Q795X1\0[Z2R^-\$B>&#XG)T4(=/*!@`7
M?+8VOP/I_%^8!Z]X:\4Z/XNTS[?HUV)X5;9("I5XVQDJRGD']/3-;->0?`V6
M*>?Q=+]A32[E]05I-+6,I]D7#;5P0,?Q#H.5/`XKU^@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`/'[/X1KXD\9>*=9\:63/%<W@_LX)=$-Y2E
ME!.T\`J(\`\C!X%=1\+?#FJ^$_#M_HNI&0P6^ISC3V=U8M;':5;Y2<9;><'D
M$FNV9U3;N8+N.!DXR?2F-<P)MW3QKN+!<N!DKG(_#!S]#0!+12;EQG<,9QG/
M?./YTPSQ`2$RH!&<.=P^4X!P?3@@_B*`)**8)HV+`2(2IPP##@^AI%GB<@+*
MC$XP`P/49'Z<T`2444@8$D`@E3@X/2@!:**;O7"G</F^[SU[\4`.HHHH`***
M*`"BBB@`HHHH`*\;^(&E^-H/BE;>(/"]A+*@TY+-IP48+EW)P"#@#Y2>">3C
MV]DHH`\X^%/AC7-(;7M;\1HD6I:U<),T:E<JJAB,A0`#EV!QZ5Z/110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'.^*'6-K%R9$PY_>(1E>G3
M(/S9QC^1.!7)Y`>0%`Z+N616^50F0%5R"!Y>=P!QP?HI/5>+20EF(Y&CF+L%
M8#.,@*3T]_;(R,X)KE6>)BCQ;I)!GRS"`VT`8/E\`;<?WL=<8]0"VDYS&"B1
MM$P>1Y6#>6IR%9NN%(&`2N>6'U6YGMU8PL9)WC#.%A`R%#$9&.2"23C`QCKU
MS3Y?[.09)@K!@$P5)*G<RYZ#[F<DG.>5'-/M&(;<$$3%3<`R.!\HP"0W!4@@
M9!S]P\]!0!:LW+3B-+"*`$*!OD^5,'@C(/R^S#.`?6K$<(ND9PCNLK+M19?D
MY9<%&VYQD;>I'S=?2A%*9KF(LIE64AXP%W`X'"IC(#8.2>1P>O`J4JD\;!+F
M)&G9<,#PS8Z*>F<`<]/EZ<B@"41VT*$6^T9;S(FB<JLF`#\AZ;N`>H&%/0<"
ML7M9/+C=0$B.Q2XWI(6QP1C<&`).0,;<9]#/%*SV7V6XF%O(K*`7)#-@Y8-C
M^(*&&`.?4]*A9S#&))GEAB4`.QP0,\`$#H3@\C'3G'2@!\K21R*0%N"O0J[)
M'(=@X)X.3D<C`SUYSNKI+'*LEPSK,'D(F-P`V%/.UF&,?KC/7G(;-<K+*R6L
MKJQ)61VQN!P04(/0D]#E>G7GA\LUTT_S37(D52(=@!="%8@(,`8`SGIQT89.
M0"62\<*X,;#9L"%I.`0.2[=E(['&!Z\`N50VFFW,+.L<&"'CSE.,DH.,'<?E
MZ_-@\]*SWLC10@J7B"*L6S:B,!U*\DD`@X4<Y'U%3EA-@JBS%C\K1D88_+AU
M&,AB2W08PQX!X``ZZL)Y&D3+6\>1P`,E3N#`;AG&1D[LGH!CG#6MW$Z0M=F9
MY?NK&N&Y.#Y9P"%RIR"2<`@`;<BLELF?-5MR2R;C$(V4LP(P@/(\S<H!(R/F
M4<<EGW2-"LTGG`3.WF;EVA#(Y`!^8@DD\<@9QDXS0!:(3RDGM2HMTE64+%]Y
M^3E\XR9`N1D>N1FJY=C-'O!>-&=`Q0%7/`)4*!AQDDG./E/XP"5;D-Y2+Y,C
M[F<JV'3H2RXZ]AMZC'RG&1)+(T:MF+YD;YY9$*;`#G;(H'4]1R.">A%`&C#+
M)<KOG4$E-\C-G&\C;D?-\K#.,].HZMSO^'XUC$J[VE8=9&QQDGJ.Q/'3K@=.
M%'(F9G0B=&%U#A)(I.1C:2`Z]2I'&!SVR1UZSPW)+)]HWAU5"`H9@<Y)/;MZ
M<`\G.>#0!O5S/CF41:+`"57S+E4W/]T?*QYXZ'&/QKIJY#XAR&/1[$@RJ3>8
MW18RH\J3/!Z@C((]":`.&:29Y61,"3=AA*Q?;VZ<90AC@#GGZ9NP>3.SVX>1
M'F48#R&3RPW)R0,[#CH,D#'//&6K/#Y>QG(W;HO+<Y&0=S(#P$&T9#8/XYQ=
ML^J[9A,5+"(0S!2Q7@2(2,C&WH>ZCI@8`)=0GOK?<DD<K2!-JD.&9D<=$!ZJ
M2>A.>1GJ2,*9;J[N<2I)-/CS(E@0,SJ`1NCR<;5Y)#`^GKC>GEN<H&^8HV!L
M<(6W=2."-Y!.21P67`Y&<B\N2'=UDAG+RN00<+(1T!(4C=U)/;!&TYR0"G->
M7TJQR)!,P)RC(Y.0""S1EL@''J>,=QBD^UL\)260F.5]P4/@$[>J]]Q&<\GU
M`%9VI^)9(TG!"JDF<EL!@0"3N<D;F!QV`/?@G%8>([?>HDMMX5LR3,K%!D?\
MM.`=_'RD<=SG`H`DE>>W=;:6=W8L-N93^0VG&[[JGL>,==U5(9[E`JQW9D\Y
M=XVL0A?/((Z@_,!\OOC.<UJW4;S!9LN48$LTK?,@/.U^[?48_P!K/&(&LLLZ
MQ+(ZNA#PQLOF)CCEL;2HSTQ@[A@@8%`'-W\H/F1S2N"XPHG4;5`[D*?]6`Q.
M.V[)Z@5:L[!UC!BN)HY!@E0?WB`X!)8Y!'(Q@9.1G<>*F^QW$DP;.&9`^4+$
M;E(7*<G*@\<@_=R,$4D$>)T@@60K_K/E*D*VT8=..,<=00>V<\@&C:V,5K!-
M<6C3>;\VWRI688;[X4<?+GD@DGYC@DC-5[FVOC*PC:4,5S"8'9=RGJ4/WM@'
MWO49'H*T;6&2VB\Y@!\X)8!2"2!Q\V?WI#\DY`^7Z&U-%?SP&VC^S^2"K2^<
M,@MC('S``,!D'@@[?XN30!0TB._EF5[:ZE$[2+Y!W,3N[[.>6SV/<<`CIO:5
M.GG#`<8<G*L27<_>"\@!VPW4CD'&,54AM3`IGF0K&OS&8@;#QT+<%BN,C)QU
M!!R2!X(`YD,$HC=@92^5429)"R$=7)SM((QAO4E0#1U*W-S.4@N&:24A,&9U
M1L8PO3`;D<\#KD#.:SI8IWO%@DN9&WGYLR$!C@84GDAAR!M!Z$'J36I!<7/D
MB*\7(51'*98P0$8<!\<MQD?EZL3G7*SS)+YA3>H)D9I?G3'`+`'A,Y`(Y/`Q
MT``.B\%Z<T^O6EPQFD"-O,A;)!(9B),$@,2..V!CBBJW@<*GB>PCEN9F>,/@
M<;ER."Q'&&Z``9Z^IP4`=[XO-R#9?9XTD+%TVXRY)VD;1C!/!.#Z5S*10B%)
MIO+D:9B[>2>)'S\VQ_[^#R3G/UP:Z/QI]H$-J8(T(^?=)*V(XS\I!/!YR./H
M<\9KFS:S>7*C3R/(A`=9.6(`P-PV_4="1MYX&*`'R7$.$5756+E7!RJL^<]`
M!\V#QCKWSG-4IY@+0RQB,%2N]I54+-P=I<<[6.<#!P0V.A)J1(7S]FS$K*F!
M&PW;"R_<;G[N0"&!Z]0>,*4&V>/RH8]K]1(?W<6[!SZ1\`<!CT'7J`-FN$E&
MTA$5U(E61F4E<YVR=?FP!M/8#/48%Z68FVD2/9,`NU@X*DDJ,(XYRN2&!&>`
M.A!!K"&6.WD-J[O(%,850NY0%8@$DMSW`(^ZISW!<+6U\L0AH@"1Y?E%F8+N
M!V@L2-F'R0<YSGGC(!*THN!]H>7?<`^:5(W,J]3DMR4"X8>HVDG/!K7#1?:(
MEGAD$J*K!X_O`%<948Y4DYZ=OP:94E@=#`JAPIECY.Y2&8_(OH0N-O`^4GM\
MK!:W#Q$RJPW?ZIM^54="5#`!CC<IW<'''#`@`(@AB2%Y3+"R9A.5W%3U7:`%
M91MP2!N'3W#9YEVD1@31S+B(0R%B[#G:@W8\P97&?4<=,3317$]LJM*\6)23
M$`TC.QW*-IX(;JR@#ID8JA>VMVKQR70BF"$$[OF#J3@(^U00_+'Y2<'HS9X`
M'R:R_E+%M=7\YY))(G.1,O8OTSW)QV')`JQY<(NIMXB:--@:6X0JLAQSO]&*
M[5!!QC`R.33+J16A>PFCC@@8QCRKEU\J10%"HR!L*@(`#`@<],XPB!T2,PW4
M?F(X2216RL<6TO@\A0A8#``YZ_+DY`)GL[B"Z:"54\E-GG&1508Z`28"[5Y;
M#<]`,@<@9#=&9HV>9_+&Y6*MB,@$(Q4'Y.A'KQCW:B+`JNQ17CWL2KL7B4H"
MW&.0<_4[SGI0US%*T(^QHK*H";6.(]S;@8\D94C/3WX."Q`".WF:20FV\J6-
M\BX2+<74=WP`-IPN`.03Z4DD:M&UO<%1))$S'R\ETCZL22#D9^AQGTIR2)<[
M"9)"(U#P+#AU,>3GRR#@CGH<#@$8.#3/G6U*>;)),A/^K1<],NZX`PQ)&01C
MYL#C&0">*WECBA+&1FZ*J)MQ&>NS=SMR"<,4//USM^#KRXDN[RV>U,<*J"KA
M"JC!*A1Q[$'GJIZCIS4-O.F\)-N\Q64*`3F7/"H.I<')ZE<@\G.3V'A63_CX
M4;"A^ZR.#N()W$C@YR>O?\<4`=)7'_$5$DT?3T;;O:^41_,5;=Y<GW2/XL9'
MXFNPKD/B,$.@6PD\K9]J&?-5F7_5OC[O.<X(QWH`X"11Y#HWG31F4'9T\UP&
M]/N2<D#C!R><#YH5O/(F):4DMDRF<$;QDD^81\H;C`QQR<D_-EH\J)/.N$(D
M50)LG:=NX`(Q./DX#9QZ=*5ILXC\X!5BWGS3AEP<#=SCR@S<$@\'@8QD`NW%
MZ)@0\BEF<"3SA_$3@*X4=3_"02>QZ87%F@M_*6/8N\9#@K@@<9C?:#@$=UYX
M[9`%TV;RQNUV6WHI4;^1'&V2!_M(P(QUP```>K3K9J(HG:.14*R2((SD*IS]
MTDXVDMR>>&)Y^;(!STB0F5$D1HXUC0"Z*@",=0K\\(,K@J.<C&.,32Z;;+(+
MJUM0_P`FR1/+``C.,=<Y3YL`CL>G3.Y,&0,JR3B14#0E7)8`9^5&.,+U#9]_
M2JUO#=^1)'&?,B=]T(4;&9A@%AGOTX)SS@9.``!D-HEF&6VB;RW1RMO"_*H-
MS-)'D#*G!W=-I?H1FDDTN*2,3Z:1,C$Q6XA)VY;G"<$=1TY.?6E@N938QP"X
MD;9,3$`@'S@`%E88S)U!&0`%'KQ(C-"[C?'%O8+*-C;'..0W<,`0./PQQ0!A
M>>YO!"#$ASC/_+.60]`>/E8'KM&TD'G.36]::3;7,$9N);0QR2;G+,2CN-V[
MS,'&\$<'C.>I&:L2P6\BDW6PPA0TDCDG@\B.1L'"<9W=]J\]!31)%:G9&T4;
MJAR9<LFPA1\QSPF`2#Z#_:&`!3I4=O:(\-^'7`CF>95786)*B0X^]DL`%X.`
M>",#$N6O!(9`=P7:CKN.$PRA5DQD@=!D>P.,J:V?M"M$C.KQF-<,FUDS%DC@
M=2AP,8P0,\&I&D:11'$T<2HI)F1L$(W&(P2`58-SNYPW7(Y`,QKYHV6.2X,E
MTAP450&`^7Y6`P/+&XCC&<'H<863^T'021W$D)@#CHSR+'MY&,$&,]`0"<;B
M1R`6J)0^+&%I9\_ZT$,&!^\8P0,I@<@D''`!(&+#:9=WMLQ^UO%)%'YD0#@*
MI!!#*#P"/O$8`SS\V02`5K'4);>X`N0P*R'9LVC"YR=H4<*VXY).5//.3F>Z
M.FS%7@AW3<_NX(SD*%)+18SE``"QZXY]16'_`&F`_P!GOH7)5CB,8Y8D8*GH
M'P#Z#&2.@%6K!D,K+;!E61F*S;/OL.<#!YDZ=QQW`Q0!VG@J"T_X2>W^R@1*
M@<1^7"?+;`^8KDAAG)^\HZ_0T55\%"\A\3V"B<2J2REM@"DA3N!``)(!X(R.
M<Y&"6*`._P#%<MLD=LL^=WS.#MW#8"N\,,YVX/.,GCBN3ME6-CY11?,4#8?F
M"QL2`N3U7J.>?FYX.:ZGQ9N)L$1`[R2,H4'YCQG@=^F?PXYQ7)0Q^7O,0&%'
MS,J*DAW9W.!D$MG&0PQP>^#0!+(WF>0L:)';+@^5&V,HQ!(7(.Y<GD\9W$8Q
MRU0-/<W2_P"F,KD&:W*;NQ^9D('*J=HP2!D'N%%7YKI[5H[MV=%9MX,&=TC$
M8!#D?.>"0<=O2LJ='-VKQW'VB"X1S\K;$D;;@?+CKE5/`]-W!9:`-&SMRRPE
M9(Y+4.K#RP/FPV-WH2!U!P/N]<96."U$I4D/L#H'9$Q^\88XQAB^2>#C.3T^
M6I%,GF22L'>2,[G9_N2,QY#[3\K98#CCY@>&YI`421C-"@E616<;-S`C/RL.
MBR<9&T'(#=,8``YWC-@@B9D:<!8Y9B""_)`RIX.>>F#Z]J)4NXK13+)(%B=Q
M-ER$$@X7S!DE3L4`8R`",\C-#L2TQ?YFCC8SQ3Y0CE<JXQG:!M'!QC9U*C"B
M.)))RI`*I\[2P@;$'R!6.#\F%'(ZG.,]"`3?97CDE10H=QM8'C<N-K;AD8.#
MC!]/J!"UBPM8@6=C.%7>7#",_>90#\K`8`R1DAB<#;4OF)L?RI@3O(2(R%,`
M`<'!Y)&XCJ0#T(XI;1S=))$H.(SQM.Y4)902#R,_[)&3CIG`H`J/$\<486Y"
M^=PSEF;:N`?DP<MG))(Y('Y2P0*XDF@F6X@`WQ/'#A47:2&3=C()##@'.WC.
M2`^0V\H6.&20,^X9X)`(!&W#`;L$GN.`=V.37N(F=28&).\L0#\@DYX#8X8'
M&"`%.3N/WJ`'2PBW\J0@EV*O$P.&9ESEA_M?+@]/8C!J:=8A\TT`W(QAC!FV
MG<2.!QP^.3DCH/7%5_.6^D,LLB,IE)F$\05P,-EG`S@8+$8'!/<9-7"GF/L=
M`BE0AG8KYV,;1NP>&P3@J2,'&5QP`5A;Q//<-;EC&Y#!2&))7D9S]UC@<=!Q
MS@TAM)D@9(V$JR!U<LPVMC/S':#R"6&".K9Z9)>!)N4R"1_+81^=+&A(Q]U6
MZ$(26(=2/O[<Y/!;6L<2PPJ8Q'(3*5V<NA7'SXPS(5/'4X`Y^[D`K&WN(X))
M[F&)X(<6\ZE\E7"[B).,EN<Y`Q@_WLYZWPI%;1O<%'\V;`3>6Y"`#"X[#!&`
M.G?WYF>ZNK>-OW\$TB1A_-DD=FC3H=P;[V6..,D$]SFNJ\*-(R7)<A5+!EC4
M_*H/3'S$]NXSVZ#D`Z.N4\?231:19/"7&+P;F5@-H\N3KGC!.!^(XKJZY?QT
MI;2;,JFZ1;M2@`R0=CC('J,Y[=*`.!:$+(B-&<RLP00K\P4[L[,]4/(.>01C
ML<P+;&&Z149F"`_+%\I3`(9H^2`H'7@'@\CYL27?[VZ**MNI&%4(,AG(!/7/
MS9P#U'49Q@F-HG_L][C"%7/+,N%>0#@CYB<CG(^Z>1_O`%AXUE8_8XY'5UW*
M8\-(HZF1`1G(Q@Y]/^^8!FXLU$4<<DK2YB**S[G)!R&_OGL/;UV@5Y3+<)#-
M!(N_<N]O,VAGZYD.?E<`Y`'!SR3R2LHCB+0F0;.1+'-\B$YRHD*CY7]`/NGL
M3D``L0L#:2S2$R!@!A(L"5OX1C^^.XP<XSSGFK;W,LKS$(TT;2`'S#@.!D98
M`?>564+C).??F*>*W6X6,R(4=`&67=M.2N$?:X&/<<G.1FIU6.VN%4O(%4'+
M$M\HP!M8`<QK@@D>AX`44`,:W8P&[E=IE3&9)"=C=2`Y+?>X5@`3T^M8DES-
M9RRPO/+`L<9,YF&7C7J%?;@#(^;<.WIBMD7#0SJ.@>,;I)"1A<'(.<?+C'OZ
M<<F[:&UC<136Z??W!`OSPR>J#N>3UZD`'ID@'+-<RH48+.Q=1F-/X`?O;.<8
M;J2#G)R>36GHUQ/+=`NTG.]D\DKA"%Y*X/(XYW8XSTQQ,VAPQ28MO)$;<QQ/
MG!8G.4QR'.[=DX'7UY:-/U>6?99)%'!+N#E@RK,ZYP#D<,,=OEQ_$<#(!KW=
MM;Q0J;IFB42`Q^03CGG>AP"&*X)7KCIN^45A3+!?B6.-@MKD*@0+^\8_*S(`
M,ECS\IP">.I%:4.G>6R2:G.\Y(^<LQ*L=Q8!@3PX)XP0,$MSSE;E=/6Q,4-K
M$(7($CA<F7DE=X`^\>3D@X]NP!K6%KILUDB6TL%P'^6-B0!N"+N`X(#],]0/
M3U@8W%NTD-W+&9@<"27)5U.>'/4$<XZ@\U3.G6\]]'//&+;<")I<E58D`A6/
MW@#G/R[N@X7BF><%NA%/<D6[`L9)SG9G&`<C[@ZYP3C'7L`8NM6UO+*TTJM(
M0"DKN,$G'!?;G:2%XVDD!1GIBJDUC;FXC>4R"0`!0+A0%`R=I`&>,_>''L.*
MZ;4K4X6>=1&=N5:*(ED7@\9(#H1LQ_%S[9K*MK&-)EE66-'B*M&>\8.6&T'[
MR-D$D^^!UP`='X`1F\36B`^68T.4>3>^%3!4;3M"#*X)Y.116UX0@C76[62.
M*+&PCF3<5(5A^[.,E>#DDC.>F5-%`&[XR,>ZQC>$3F02JD<F-A;:""?0\<'W
M.>M<PK!XTRLLD*L5DDN%554'DAP#PV#QVZ9SCCK?%@0BS\UE\I2Q96P`WW>I
MZJ,9.1T.*Y(DQ3S(WD(=I8/(GW.0`6`&-I&<$$GY<]P*`&-.!9/;OGS;=]DA
MG9<E.ZODG!!QT!)Z<8(%"[EF1@\NV,I*&="0&;#+B-F_NX*X92,X'?%:%S*D
MD8S"O"F0`M\ZQ\@DA059>!@D'ANX%4[MX`8XS%"&".ZQL`%(#$$J&&&4D`$,
M./3@F@#1&RYPB@),Z[B#EEVLV.6ZB/GMDDE<TP/,KR(S&-F#.Y+X;[A.<L?F
M!.[J0<C)'7.=J1EM;)(;-50O$9$=3][!P0K$_,,9&20,#J"*MB2.4V]S`Z-,
M'+`1OEV.`6(4@#AE'RG`PV<=J`+)B8"(&/RDVDA(3DJFXDA`><9SSN'Y\B&:
MZ4Q0H+>`1%0N=^!(``"T9/\`"/F!SMS\W04QS<%(8R["3(C:&'&XN3\I4J,9
M!89Y')'4-RYX"]N9TMX2'(V%!MWMS\I/\+``C:."1D9(R`"6)Q(/W8$^2JX8
MX,9P.4QDEB>-IP>>.O,C7NGO')%!/;H'`#A5"H&)R=Q(&[[O^T"0,\<UDN8A
M+YT\\K0AO,9M^U7+9QO"\H3A<;<C[N,CK/OD5UBN@S*B@'[2%(1<XRV`<+DC
MGDY&!UY`+\]U/]D?S"8%C8F4DX(8$823OR<D;<GIG.>*]U=RQI-&T$996#21
M/,OS#`!5RO)3@'(SGY<=,"G),EDWVK[5(80N619`[VH'60``@@\9RQ.#QP,%
M(K]%A2$1NTDC,WE1@,T0(W?)R2XR23N`QG&3R:`+`NF2_5X(Q):+\LHD.]<%
M0-SD`L(SSU)Z^IP;(O(6MGG$1C4;3&FTCRQ\J[0_(V\MSC[O3G.8`ENMS;-#
M$GEQL'WA6<LOR@,H.,C`Y4_X9F2XE6WDWP1F,*I;]YD=FW!@`">N1E5.5/(Q
M@`FCV-!%+;C:2=HC5PN`V2%7.[Y<+R1R..H!--EN&=?]6RJP;:S'RP&Y^9>2
M"./FW`8PW&1PR%8\^?;QYC*DJJ$#RS@<#/\`'W_N\#@Y&9946(?92IGF*$;`
M"A$A)"\C!#'E<=.2.IX`(@Q;Y(V#H$+@V^-WR<*T9##Y\XZ_*-@[88=5X23R
MVO%5-D>[("H0/3+9`.XX)XR.>O0#FY$BBNYXT(7,OSB4$9<C*[U^\#@'H#P"
M><XKH_"$4*+<E71I%P&"D97/4-C'S9&2,?CS@`'3UROCP`Z1:9$9`NU.V1MJ
MM\C\$_Y]^,UU5<YXTQ_8\*D?*T^"QZ)\C_,?IUR.G!P<8(!YV8O-)WP.YVX*
M,S!FX;`;&?FQR"IZ$<#D+GSW"I;-$R'H(Y&90<\J`K#N,_7ISU%6I(0KVY4I
MF3=(S+'Y@5.>3GAEV]#C/RJ,]ZHQ.#82((R?-D8QHAR0H##:-Q`9>,,6.00Q
MY`((`P7;"^$#INBPN&DC921MZ$@Y*#`P<`G`.!DBGERFU!)MER9ED"[GP3G.
M<X*G(P3\RY'?&1?LTC/Y1`DC<NI`^\,MG8""6CR`""!@CM@D#EI(UD@N)B<.
M4$;;U7&0SH223T`VL5488T`4H[22&2.:53]H$;$&&125C)).U1]Y2#DGJ`QZ
MD\RQSW"SY\O>$R\:J,-@<8C#?PJ%7).,XZ>C5:::=(Y0RB23*Q0M\I]U.-P<
MGDCIT(Z85\CF^BDC$Y8Q39/[S;O8'.`P^Z1C)`&T]`<X)`)YF$4<4B`,LP#H
M0H9,A1\R<\MPO7!R"<XQBO&?.T]7BC,14DL&8LOU./\`EH2#D``'!Y&*2Z\V
M.4^=(TS,X9T90-S=#QM&UA@#`P#\Q/3-6,O8B6*1$.Q0`]Q&JA<CK(JYV9P"
M"F.`>A&*`'02I-:E;X-%DF.7S!MW9;`#G!!).&`7TP>>#+:3_9Y85>50Z-MD
M>?*@`D#:V.>P/R$\J.^W%:+$6H%))9@0H9PB@NB\?,"<!E)8`'/`/&<`4U+,
M2W*&2[:81JQ@5RIR,GA,\.G!W''`)[]0"\M^NIP,)3,TD:\R%0`J]<_>(V;B
M,8&<YX!ZQ_>9F!N(S&F$18P61.P'4%`.YXPWW>M0I>E6*10NJ%<JT9$JRXZE
M"3DCC!#'^%NG4-9HTN%DBR?.'F1"+.]^GW0<%B.G/?Z4`69I(7**2P7.V.>/
MH`<D*K8^X^&!S[D@8R6RF.6)19RNTNW<KQ8;;M/SM'G)"Y7).`/4#:*@M[>!
MRZ1"8";A1&S*KY(^X_7<2>5.%Q@XR1M<(HVC\PLL@E8A,8V@@],X^4YQE>`-
MHZY!H`F-TS)##/:@ON#Q>4`=K=VCSSG.>,YXX&0,.:32WO`L:"-1G(V#!Z_.
M/FR'.&)&-O7J?EJN75K>6/;\Z2;&)0;20=Q^4_=89&,'H??E\2XF0RLH:-6'
MFLQC&#\N&`P5?(&"N<[FSUQ0!V7@NYB;6HX@?F*DEL[@S@-GGC#`,N3W!'7&
M:*J^#<CQ)"WD/'(JL)(\J7`89&X>V[)(P26/J:*`.I\6NXGL%01%G655#NP.
M?D[#@CKG(..#CJ1RQ88CD3?+"QW1KM4[L?*QQP&!(P<C'(`QSCJ/&"+)-8H)
M9$F*2^4D6-SM\HP#USSG'3CGH`>0)5U,*X0J0!&K[-['<0C$YVX'0*0#GKU%
M`"R[7D7,9E7'FJ0PW.>"9$(SENH*'@`#VVP21C9*X@1G4>6(8D<M(I(R$'9S
ME/E/`X&>U76E<W1>%R9(#N!=0=SOR=Z@$*1D8'*Y'^SQ'Q)#(OD1SN^T8G!"
MK\Q&UW&=K%@1D')&<G(((!4BU&.XC>7>Q8[ED20KRZ`@@D<HXR,@'!SDGC%2
MQH@M&")EU(7O$S,5S\^.`>,#:`,D=#TD>2)W^TM/.JH=Q!RHW-C`)'"C&2&&
M>3SR1FM$9H[Z,(%<@;U8Q@$GL^.1@@D!AR#CC.#0!`UVW]L+M!DM?)/FQO$6
MP_S!=RJ,*W`&<?-N;@GKK2S*B/#<M*(BJ!Q+&K!>F%8_PY#$AD////W:P7EE
MMM4A8%6M)$?)F.9%!`P00.<G(+=0!QGC&I>M.ELJ["IVEU,;,'"G<3@D88?*
MV21GTR0QH`I6,RR7;7*(JLK-&DLF[Y1T);L4QCG&>AQNQC1VK9VH6/*?)O96
M`;(&"57/+*-H^4Y&"<YYJE8^4UB/,E#B.,<!1D^K(>A3(Q\W&,CO@RPSQPE9
M`8_E.5:.5BLK]3N9S\KG`/\`"IXS@4`#O<+#M!#HPPDD3$DY4#Y?[V.1M^4#
MKS@"LK3]22^OI;52YDD4J(@Y!9CC(4@9#Y;MQG:<X.!KR02,KVQ?S92=C^?D
M;6(P"V1E6ST!_N]<D@X]G:PQ>(+@.'53"#(74*Z[FPRMSE'&'.Y?FQP<#.`#
M?\P_+((U<IE(C')MW/U&`!A#M&=HRA^4<A13Y[N$Q2+),R`;<.1M:4Y?<&V_
M=;H..#@Y;&34"W$)E=W6%ALS(6)(4_+A"0<;<@$,.GS$=L)-<7EM<I:HT#1L
M"S3O$$>('&=Y7G;]T_WOND8`Y`+"A&ME5O/9-XR%_@4E?]9S\K9(`/)P?QJ\
ML"3V]Q]I1L!6CV3(0>^(6"XPIVXR"2>?;'/P2*+A(HRXN`QDVH%WGC[R9^\O
MS#DG(!S@]MRY\IKN-\HLA9UC9%8*_<JH/7@.QR!TX)/0`;]ECD$02S^SNB*K
M+G*+D@@MURN0!D[CP"/X:ZGPO#<0HXE=G1AE,J%\OGE>I+#=NQGH![US1BAD
MLHIEE\Q\AAY:'GG'&.J]<Y.!M(ZXSU/AM7,<LI#"(?)%DY&T=OJ&W#!SCZDT
M`;U<KX\F>#2+1HU+'[4,KM!!&Q^N01CN<CH#Z5U5<OXZFCAT:V:7:0;H`(W\
M9V/Q_4Y[`_0@'G!N&>^DDBC<-*2D4:LI4Y&TD,PZ\_<;Y<#/)PH@+A+68[FR
M57#ABQ!&"Q4D$[\G)'W>3@8`HO[1A(LD<\81V82,_P`J;P3A2!C:<],'G=@\
M9`;,B+/),TKF*-`H$A(Y!.`W.5<Y8+L/UZ<@$"P*?WT(C,3@%P1LRP''RMR"
MN0,+@9`/S<9:L,4<4L+22,=P<'YER<GKT*,I"GC@YZ]08Y$-W=R+<1Q&.".-
M'Y`R7/RY_N[L'YAR01R>"KH+=H[8-O#!5R2T;OL1MNTGCY@,KAL$]>:`*\YN
MA?QR6[1,B!`=BY^?YN`%P%=L$*1G))!Z9JS<"6!W;S`A.=X=.4^0$*V!W!P2
M!S@%C@`DL46,+!<-\GEL1N8,0A`^9S]TJ5'#$;@%)Y&,71:V[PQF"11&>JI\
MXB7&T-CDG(ZD@[<`X'0@&=+/*98_D=#Y8=O,8';C!VMP?DY^\%).X=MHI+7?
M/=)%F25D3?YQ?:\:G!R1RKJ<Y&XY('.!UA&;.5"08U+!@J/@J.GR9/SJ.=VX
MC[QZ\U)9J;F\FFBMX)5=',+1*W[S!&=ORYSD\!C@;CN/()`+VG1!9IG^9XI&
M#IY:[Q@8SM4D%C\W"G(P#R.!4/E7)=HX9G,@)P!)Q\W7:W#%B<D@<$]QA*I0
M.)()9$D:7>5W`G86X*\G^]TQMXW>@R:N2QO;/Y:LR*&4J9`%4,>5#C'R,6SA
MEXYY[X`)'$8D4%861PHW2A@C=@H_N''!'`/R^QI[PQW,CC#`K%L<'`&X$=23
M\C#(P!V[\J3FW33+*-Q",D8##YEW_P!U'(R<MTW+DA@>!FD2[=YY'<%UA0&0
MG!.T]'V]-BYP&Z@@="<4`:>T0M<8BV1!VCE4_,V6.%#A1E2VTL"""!UY!V,%
MQ<[(I4CC.PA78$`G&,*PP=N57.X'=EL]<U5,\$2R.[$2D[C'@.T:\[C\X*F,
MXZ$,0<<>C'EN/WQ7<J(/G@4!MJ]<C<2"N=Q.[C&>F,4`70MN;R17"%R-C`@<
M`8RK`\E0<$'AL8//R@6/-\Y@R*KM$A<K,`2$/0L22&7!.&SG'7&*IJ_G2^3$
MR2/+*&&]2Q*#D;2?O+\WW3UX'3BF0F9_(EB:)EEF/EIN!WCY273(!;`.=IQR
M3UW<`'8>#YO)\1VD;(43;N6/``&X/RIQSDMSDYZ>G)4/@62*[\1P3Q3E][-*
MZY.W[K#*GKG).5^Z!Z=**`.Q\7F`7.F^?.8M_F1CKM;<4!!]#C.".<\#K7(E
MC'Y22LL*R(`^20<Y4%3S]T$YW9SD\GH*Z?QR[+-IX4*0R3A@2<@83G'(*@XR
M3P,YZC!Y:WNOWT8`VW*%E9,ME1GA4R0&&>,DDCYN>30`L7FA%2.$;$"E5`+9
M!)^8DY^3[H!QN].M*KDXD#K(D08A48L53@_-D`,/0L00`<<96F8?]X8C'*\C
M`H0H920`I;T92>""."/NX.:>ORPQRY+.1O0I)M8DY(903AF^3.SD`,>.":`&
M27$45E#YZQ0%%*[XBQ*C=G$?),B<X^;L>G`Q7B1BWGC;*)AY<+QNTBMP`<.0
M,K]XX8=N!4URZB-@Y(+8+$RE<8`W;&/S!C\I*E?8#%5[;=#9I,F]V,HDCQE$
MF;`/']T@`?(.XQUS0!GW1:Y\06%LXP64NC1DY)`!\T<$$CD%>1@<9QQI'?+9
ML?O/,`BF$[MC\'"L2<,>21]T!1UR:S5GDEOY;YY(2L8\I96E9?-!8L[,3Q&>
M-H7@$+GT(N1W(\@JS[2V%D21M@YY`90`J,WX8!/7-`"H(?L2)OW;"<<\2%0>
M"Q'`&0=H^4_+G(S4Z1))+>AMDC8*[L%F+;ONL`,*HYQLSR2,_=J.Q,I+*",$
M[7);`^7&$D^[M7_;)S][!])V'D*C/-,X90I9HPK(1\QVCG>!CEB!D4`0WCI:
MI<RNK+;10K.\V0J=!AF[A#MZY)R`1R0#0T:W5=.GO7A5)+D^<[9!>)"%"X."
M2F<#.<@A<`\BK6I7`NT@LX]RM-+D!$#Y49WE"/OKPRD$\#=@#%2PP!(8RC*X
ME9R4CRI/W1NC`R68DC]V,@8/I@`&%')/93!4B("AE2.-^!%G+&(YRR@ANHR!
MT&`2ME/$-N-1M+"V6:2620%BB!A&P8+PKX!!SNV'&""<8)IFNP-)#*;-K9))
MH]L?V>,ELG&2@S_K,'.T9Z'(X%<UH"W$>JB2Y#RV;LB&)5(177&7)R?F4_-M
M8<YQP#0!W[!Y;:REA62:Y&V0;2Q>0JRY(`'SN`#D9'7H*UH8E?E2WV)L+&I`
M09*KR"HQNP3G!P"1SZ97F,'EFE@1BK8RB%,KCDN>J,`<`8[9SR=\T%[##9$N
M#,D+"+:ZX*C'W&*_ZON<\DY'0L,`%ZYG6VG5X_*,>",-($4N#PN[J.C]]NX`
MD>O5>&)(S]I0A3,9&R0H4X&/O#L<%<`#&T+WR*XYYXYP$!7Y$Y+Y9>%ZR8Z)
MEQ@XP<Y'H.N\(0K!:R(CY4*F5)S@@$<<YQD'D\MUZ8H`Z6N1^((!T>U!7I<9
M+%`RCY&X)/*Y)'(KKJY7QUSIMF/,$?\`I!)88W8V-G`/X<]N#[@`\[N(G6:Q
M.X`LREGPHV+V+]057)`8;B0!D9-9]Z)K7SE*[8]HD/&["\MN;=U7G([X(Q_"
M3;:UFBDM9)MS&28;57]X,CHR`9\Q1@[L\'+9P=Q.?>WRV:3O,FR`Y:-(E8C`
M&XD<G+').WDC))[X`,^&:]O)I88XFV;CAUSE0`=P7>,$$<$L>OL#G3AMW1RT
M<+2RY+#:-Y;YN-@8Y<`$GYR/3J"%S],<&*V2*(QM+,C'RV;$C%L#:>SEB!MX
MZXV]<Z<5M]KN&,9Q$R&)5C0@$C/3&2",_,!@=/04`1W*Q*(;A)HD9<2Q,">!
MWVL1T')VL,<'KDFK:HO]FQJP*VKGY"'SYCJ!@*?4]-G3E>@857U*W\W3+D3[
MFC"L'=F*K(5!Y(`^4@#@<_3'#,TF)K.T=48C?(=KME>#@C=S\K#!`P<?>SZ4
M`07\C1PMYH7:X#)AP@W#C8N#T`(R!A?<Y44R*Y61))+@1O&4VMYK`!VYW*X.
M0GIA.W==HS>OH2K&4'S9"/E=%*E@0=NX?P\#[W<D9/(K(M&1O/E!9B@.-N"6
M``.&X"[`".2I'S9QS@@%P"$^5%,BL=IRLB[DV]`TH&<@%MN0-^>G8&&YD,#[
M06S`AY5E9H8\G<Q'.\$]"<D#CLHJ:"2&'R46&%HPI=_+!(7'&$_OJ0<$-NP2
M>_!8TC,]O&KNWFMO\N)MPR,`D;3EB`?N<=^Y.`!L#+<Q*[1K')L("L,DJ6/K
M@,O(SSE>`.,BHK945HUC!#,#M7[S%5ZM'S\R\8;)X))..HFCMS=7\<;O@YPR
MJ[8XQC&!D2$$\*<8R<$'BW:6UO+)O'E'YRBQQ<!2.>H'##)^4#G(!R`,@%;3
M4,TZ0JY<,YDCV#YB1R73^\.!@<<$G`)&+C0Q6\Q5';#J4"C`#G@!E]7)_AY!
M/0'M=2W4MUCPK;3DE8I&_P!H`C8PR<`]NG7+1F%H9]CHH7(R#E>3[KC:QP<-
MD9X)/.*`,BYMGAG*QQ1RV[XV*>$9P,@`G!5LGG^'U+`9,0U.2WF:U0F1BS92
M1Q&<DD-R.58<8`X8DY/RYK3U"W,TAD9=S;A$Y.U5XX"MR,9)(+9!;.<@YQ"-
M/B-Q%<#(8C;EH\,,`;2PX&.@#]2,'/J`;O@6>63Q=:R.B.)-P,[QJ,M@\,.0
MK\'&T]=PZ="E\"V:)XCTTQO\D6_+\]"#P<D[E)QM/.,@`XVT4`=CX]E@2?2T
MD&Z5O-,>.73E`75<C<>=NWH=_/J.,L8YEOHWA90DV=J*Y'FD9.Q,#A\MNP/8
MXX`KI_B3:M=WND+NV8$HC+8VLY:/@D]#@''KD@<UR,*KI\+22L85BC\DB1SO
M!!)82+QA@/XQC=C!/&``:L-Q!/:A8Y8Y)';9G)P_8C/1&XX4\'#?>Z'&U-[C
M3K+[8<,R2+YA(55E!8+F3'^J?!P"`#P/<MNEI7`EN9)`58KLD.0K#:</CHF"
M&W`<D=L"J5[;1SVMQ:N+@#RMSJ6!7@GM]X@9/S#)R<D_+P`,,TCPB2:-Y8P(
M]\;_`"?*HSL?Y<J^%;G@D%N13;BXFMK^2#RS)E'#NR@$Y`PC`X"J>H;UQ@Y/
M&)87%QHET+6_Q)Y67C\QB'B0<8<8PV<CG.``""0,5I),]Y>6]M.GE%2&<%FD
MV';NVH!D.#RQ;!Q@],G(!+96QM(Q!(A5BI<%P<.."I?'50<$/G/0YXX@<&WO
M?,=RHBQ'*H4DA6&5P",2`@9#'C'?CFPWFC4;9X=K1K\K?>??R`67*X<=25((
MSSWRHD49DD>26-@S,R-')T1<`E#@;BI."HZ<>^T`+>8*T,JS2.K2;HV8;F[G
M"*0?,R<YSG:-W.`*AO+GSY%@M1,)2.,,[+N'4QDYY&?7G*9&!5CS$>"59PH(
M;:XBD^7H#G).=YR3L.!UXZ53BLXIKNXN&BB00JJD*QPR[N`P(^1B?3`X.#P1
M0!%%!<12&74IAYLG[L)MVJ.,X']PX&<#)XZ<DG769?.DVK$K;,/YC=R3\S`'
M]VV0%SQD9QWI$2=3DX$>44!U=4!^7Y&)/R+CG=UY'(R=M>2+RUC>60.Z`$MG
MY0?[V!U!./FSGD<\4`-NWGEAFAN7*3",AA(W^U@*V!E7XSG[W7\%TJT1[MKF
MQ4,Q@2-HP^`_*E=Z\;5PR_O`1T7!^;(J7,431K;PL\0FC#.RL&_=Y!&"0V\8
M7[V3A?H`UV_FM].C=Q:3+\WEI$0)#&N,#`!RRY`/.X`[L8H`>KRQ,6N'386$
MD))8X5E/#`CE,8&0,_-WY-7;RS\S>\7F.QC=UDB;Y@F3AR2#N7/\;=,#D``5
M2BU""18S:H]R;L&6(`YC5L#!3).]#M4?.3U/8$B9S;0:<[S(66&(RJZ$[]H4
M?,H8\G&<@?=(!XP<`&;?'48I5=;DYVB3S(E((E!497)VO'@Y/'RE#@8YKT/X
M?7_VW2I)7"*6957#`YP#P/7&"/P^M>?"S37KB)HWEDAD7?P^UARNW9T^9BP!
M4'C([9QZ1X,'EV\XWY\P[E!4J2!@9P3\O4<``<\9`S0!U5<7\2BXT&V*ND:F
MXVEL_/DHV`H_B)]._%=I7$_$R4+HMI$=S>9<8,>#M==K9!8?=!'?K^>"`>;O
M>R*\2OY1=UW*JMM)XW#!Q\I&>1C'XCFM<[;\RS-;."I"X;Y=[<_.=N-I&WCG
MG;UZY?JT>^=I5:)Y!*D14E5.\CD$CH<G[_&3@D\UG2WDLZFW>WB2%0'9]I!Y
M[/\`W>".?O#`/0$4`:.AQ2WD]S).L3PVZ[3$6V`$@`A^!M/S$=L\@\@FK\LE
MS#(_[MUD*^61(=O7'!`Y3KS(.3Q[[9M(B,41@+^4@4[W95+?4C'/J'P<?*=W
M%:48CDN##E`JE0L(<D!B!C`!^9&!RS<XQSG'S@%>Y_Y!P9BJR1H-\DBKS@\;
MU=L;1E2'P.IYX(JA$K0HKQ*4BB4+\ZY8*RYQD@[@W56YXP<X)SKS$013Q!0Z
M)&'"HP/'(^7U7@;NN#QC@U''+;PSVV)5=VB#!(R)"%(&67^]CG@DXST')`!F
M,\+VQFA$!A3=M;Y72+)YVY/S*>[<C)..E<IJ+2VVHA$AC1I!DQLXP/\`91CR
MW)(`Y7ZG('?,(VLFN>5!!)2+')(^\I)^9B1DIC`].U<S>6C7*[XDC/G289N-
MIQD'&0-IR<'!`^4=,4`8$VLW<@;$J_:E`&>/WBKD`DX^3@9*@<D=\@U;@D_?
M_,Z;,EF9QU^4\OT"'YMNP\\``G%44TVX@,_F(=V5!E8!DX&.6VC:O<L/F+!1
MD'%:=G;/9R.KK'E`25FR.<;&+C!^0`8W'YN>,$[@`6$:51)(J(5.47>VS#[N
M5..4<-T(&?N\D,:N6ZK+Y[&09?8KC;G<<+A'&/E4?*,C`_W>=J6UI,D9&YUC
M"?)(8QOA5N5.&!W(21@G/&W[P(J^1);-L:/`.=K*N3'GH5Q]]."=W..HZ4`7
MT51"P8E)%VJP=R=F!P#_`+.=N'X/.<YZQ&.11Y)B2%8%+KN7><'G/<,A&,''
M'7/3-O3EDF=%C548DRM&&4AB%YVC^-#SN'3@C/!J24#[`DH*[G8LC?>P>!\I
MR,YP?DR1G/3!H`S)K2<0RL#N\M=Q93G"\X4="P..I)Q@GI5:P1TC0_:96CBW
M#;M!'RX'R\X?'\7X]@:W(56[(501G+,JRJ,9/S,I!^]ZIT4C!'/RLOM/B0%T
M8H[@[F7;'N(./EVY*D=",<GH.E`%CP7"R>)[;:D>P!R-JC!(#`L&ZGKT!(^=
MCZ"BK7@M$&OQN2?.V_,`H'9@0W/R[>0%'49..E%`%KXE"0:AH<Z+_J1/(&);
M:K`QE<@'!Y'?'L<X!YMBT(5=T2N+<ML4$M"&!_B`^=<XPQS@+VP*Z#XF3I;:
MMH#R1>8CI<QGOC)BSQD;A@$$>GXD823QV[>;YQ-JXS))M#'(QEUX`9^!^['3
MYOI0!+:S;H8/.PMO&'ZKDQCG*Y&?,3GD]CQTV[G#$<T4@A90Y(01C<'QCD*I
MR1C)YSMSCTJ&)Q'%#)PT;N!MMR&&,DD!B#L<G)V8`.!D=!4S[3*T9B@<EP%#
M1;`[;?ESV4X(^08&!@<Y#`'-^)5WVEC(93%*;M)8]J_=`(#/&=N23O\`F4#O
MD#KMZ*&"U8S1B*=V><@1[RQ0Y_@/.7^Z?J<<EL'&UM[B"XLY\0K&\FR3,>TR
MKD?PX`0C[H`(SQD\\V;[6K/1Y+CSX&+(WEI')EY8Q@85SU5@N3G'))R2:`-$
MYE$<C1J=\GSH5\I9&+`')Y"G(`*\`D$#/`--HBEJ\HW*\VU@V.&*C:2RC[K+
MM//!8J#@GDX=YJ@NP1&6D`55<G:0P(SL8G`08_C!YYY7.:SKF\O)M-D:"X-L
ML95M\@(=NWS``[@!T;KD#'3(`-O6(IA$T8,D:&4`R!F4MV&[!!#9Y!!!^4YP
M<@6K6T5=T`=)KJ/:2\2&-@,X'^\V[[S<@`C)YJA8&6[NI&N(G6*-1*DC)ND'
MR#GT89Z,2#@>ZXT#:FU\AE1XW,?F*%D#E5.W)C)_UC=!LP<@@Y/8`TP@*QB2
M1ON,`R@.6R0=J[OO*,D]SSWYJ*,HL$<OFE83B1)`^XMZLG&6!')!_O'@=X+6
M<R'?"I97?:T43$995&0I7DO@KE`#]X<=`)O,C\AYEW2*C98[]OF#GNH^4C/0
MGKSQG#`%8M`UQ"5D"..<0L,CI@@#&[)QE<$=!Q@`)<0K=!0L<#11C,^`5+8Z
M%=F26.5&%X'UP32U"UDU*WCF6X15'S)YI&".Y=.JGMMX)P>W)TM*LI["4Q,!
M).5"AI'4[&&T;'S]PGIGCD')^\"`7[:"&*-8A#`%E?"LZ8X!P1ZCH,J`!G:,
M=*D9([B`W(`:/"LTD^/+8Y[X^XW?&/F&[CH3681_*5,;2+&&3><=4SAL=`0W
M^LQG)/'/#9I8FC*RRHC%#*6DFXQCD/D@,G(&[L=F.1R`9UI&\>NRL/.^RI"(
M0HC"C`!VJ1GY7)#$8^\!ZGCTOPAM\NZV$,H*Y?D$MEB<@]\$'.3G.:\ZT5KN
M:XN;R>T:W0(&78I=DQG#%B<$'LS=,=N*]$\'.6@N2_RR.P;9NW*!U^0Y.Y?F
M'/J<<X%`'3UQOQ$M!=Z;9)B0L)R5*`$CY3S@JWYX./R([*N8\:2S1VMAY61_
MI()<)O*84X95QRPZ@9'0_@`>=G1[U+V.-E5K9Y"QPYD\I?F`5`?O+@C.>%W8
MZ$`UH=$DD#&.,9B)57@.[*JW5>&X^7!5@3UZX)&Q']G`CD58]Q?#2*X!3J"R
ME<_.<YVXZG.,@TMU>>4T*(T,BX)PW[L-@G@'`"X.[(Z'IEN"0`^P?8-.6$3E
M0P$BR"13P!DNN0=Q[D<C)/'`-8!M[ZS*&V5I%DD(>*!W)9CC[O!^<\_+V.1W
M&-J19#'(Y,0=G1@6^56`8\L1E5=1P`.#SGU-#4&<0N98/+M8WRX(P6P`=KY^
MX6"G'T;GG(``7DETT7F$E7?EGD6)'&#D8_A/W<J.HY["MF(PR7+I#GD8?(,9
MSG'S`$!"N#@9X&?O9.[ETB9I61X3,LZ(I=B(B0<?*PRN`0/]9G@XZ;JOV]U;
MF%$E;RS">`_RD@=2W]T#<,-CD%<8[`&G(L&]B)L$_*K!=@P3R7^;"'([$<@]
M<D5)':A5E>>2Y7RT(E3&'4=B1@'(P1N([#CK43R!;ME4\K&Q))$B+Z`9^^OH
M^>!W&`:JK<RS:;Y46YTC7/[L'="3G@8PSCT&>V/<@"7-@TLKQLB,1C:3M8[>
M0P3`RX)#98@[<GOR7V>E_O/)50<*TBR(C2!5&,[3_$H^Z1R!@@=\"7`ND+99
M5.`I0$AN,_(1P&);.P''J.!5D:C,(O,Q&8XY.<MY1/4@@`<$;>4Z8`P,=0"I
M#I@B6(P@><Q+1C=R"0"9$8XW'GIGCM_LRWT*EV=6$(8KA8,[F.!C;D@YSC*\
M#!'`XIFI7\"VSRES&T@Y+,H4X[MR-K*0`H`SC'K\U:Y@E>=W-P-J%4=94*Y/
M+!7`^XQ&<<CC)[D@`NVKV<3EF2%E8,CGI%(0`QP?X2,\J.""N`V0#-'+DS,C
ML\A8HRK*$/RDCG;C8ZD'"@'<3T/?*B@#7*%XED$6Q&4_NQC@JKD\J.<;LC.1
MR.:@@)MKS?:SM&%W9BD8XR""3M/\(.!R"2"`..*`-"[F.\M$Q.`BX''IRYZ*
MQY!P1T]SBQ!=I/;;YBJ+%A,^7@G((VL.-O`QNP.IZ$FL;4]0MA9R,%2.907;
M"GS%#9R0I^\N.A(X///!KG/#NKD7$<LCEU<,`O=5P,@+C+9)&[(RH*G@YW`'
MJWA:W@EUZ&6)2"J[M\C%F&1G;C&"!M(#YYSW.`"K'A5!)J<;AHBR_,J[C@#:
MRG:W\?J<YP<#@\T4`5OBG:I<_P!F><ADC"S851M.?D/W\\=!QWYK@X-5NK>R
M$MU`QMMVT3",@`#.>HS&<=!WP#]?1_&VGQS:[I]V[`,D)C7<_P`G+#/F`C"K
MZ-]<\#GCRP+B=64Q(@*M(AW%6W8WIW!SU/?/&5%`&9I5Y%&UPB+)`CJ+>:)E
M4'@C"C=]UNF6)YX!YYK<@\NZ0/"P).`&D0J5!()5F;!0<Y#G&<=,#C,?2[4_
MZMI8!"H`,1\PQJ><L<8?*X&>!\O&,#,,?VZQNXUE!DR_R%?F^89X4Y)=3\Q)
M!/OD88@$OB&"-;1/)6*/;\RF9CAER>2`""O3!)]3V!I@T*T2X\^Z6263!*&9
MMVQ3@@DJ,NOO]>^*M74QN;)K:$,&904,)S\^><#'*`[@5!QU/0'+]-$+64#6
MDQ-HL;2(Q]AC*YZD9^9.<8/7G`!!-I\%K,9Q:&%R@!C,@?"_W"HSO0E6)/&W
MU((SCO'@73!S"D9)=CEE9>1GMYH#`_*",=.<9K=<W#0O"C)(Y!RL+$9P0<(1
MCDC'`Z<X/-8CW5Q')?6\ZM'9Y6:,J5196!R#NP0G&%*]>YX.V@#6L[>,):G:
M0R8*E$\SG`)*[L98%ON'U)W`DXDCA6:-]R!=QSO6X!VC(&X'_ECG=]T9[@8Y
M-+'(UU;B9YE5]I0LY*Y*[B&P,[&XP!_%SCKDA(@O0\:1)(J>8,Q,K=<%V3)W
M*02-QQSD\D"@"*Q1%N7D=`T;(L<N]"I(#`8.X$HV2WSG!.1P?FK3(97;!B4A
MA$V3@\L."Q.5ZY\P\'ICN,34Q%:7<<L;F-L`!,AG5<`C&!^\)P/F';'`P`=2
M20!2#(ID3#%`^5`(^[ZR+SN)X[G!R10!7@95OE/F2!0WS,0"4R%.3D]"&&&(
MYSTQ@U%<ZK:6CW#P.K?9LJ"5)`(Y^888L",`/V&<<9J*UU6V-XT,@6*2$Y1\
M?/N8KNV#.&`!8[.`-Y/&6RVXC$!1841,@RNRG>ZC@ED!'S</RISP><]``:%O
MK*M;0K<1M`[\QJY\QDYRPQP7`P26[<]N3#?W`Q%;0-&MSO(C6)"XD/4L`0`R
M<`$#D<=@0*5MY-T^R/[D8`(3G)Z`*#SGE25('3KU`L#['<+))');R31,2"Q&
M-PY'3(7!P"HSGGC@"@#3L)"MM&[JJA5$CLK!R'&"S!MO4;P<?0>N.X\%L'2[
M*'"JX!Q&0&]"">G\65YP3R237%P7*F69GG,>&+*SJ%QMZ9'S!&ST`R3@\'&:
M[+P5`\+ZEOD9V9H^&(!48.`5'0_SR/>@#K:Y7QPKM9V(!C$?GGS"[;,#:?X_
MX?YGH`:ZJN6\>VYGT&,K<&`QS!@Y!*CY6QN`(XSCID^G6@#C;2>$W+_:3(L*
M.0';Y&3N%W<^6V5;J><=@`#0O+T^>8V^SJFX+),ZE`A#A4#'@H!D9;CD\_Q&
MJES+=6CL7V`Q@%991N,>[G+#HR@<A@<!=H`Y%3264D1AOR\JR0H0FP`JI<9`
M`_Y:`A>6P-IR>.I`-Q4N6M_+N-@DV*D:$AF'_711DD`\;R#P<<<5DW-NJ*K^
M4C,$WH2!)M7&>A&64D+ACPO([#&GY]L%MXYI8_-(WL-I9]NW)=><LB\DCT'U
M%0I%-?6Q1;EHED=B&BQ)SCEE8';M)`P.,`]\'(!SMP]U8RVY,<4TL;J5@C_>
M$+G)+98AU(`)/1<^YW4;^+4;G5H+J"/[-%&69OO.[@`C<,8#*,'C'=AR!@]'
M_83-"?LUS=,K`1DA@=K?*04(!.\Y`*=0<<Y-5H_#MBMIYLLANY993EED.)77
MH%4G@\@$8.<C'&T4`5K:VN+F*)I;M)#M\X+&@)RW4JPY<?[)Z=<_>Q5:YO;3
M:"OF-,3)&7D(C!;D?/R=V",Q\$>O0+K6MG:^?(OFM]G:%CYP.W:>>>OR,<'C
M!+8'/(4WH=/C1[JZ6=F4*"\LBD1\9.YU!_=GKR#V.!QP`9BR:A<)ON4BA4$(
MT2)_#P/G+']TV1QCW!R"28I;%KV\6VDFD=PRPE.(U;.,;MO*CYA\Q/(VUM6T
M,`FPTDJ21INC?DX#<`C&-PR!@CGY@"!@4ES!)#>L\99%#*<1+O)SQRN/G'3)
M'"\]\$@%1+:*TMF\N4;A$,DKRA)&=PQD^SX!X&0,BII=DJL(@ZK`F0Q8_)D'
MJ>=X.,@XXP.G47+4W?RG]X[`E@K`2D!!@XSD,!CD#'3/);)F+@VPC$[Q[RKA
M2/,8\@ETP<MT;"YR!M.X<F@#)-LVZ+RXBB*2HV`OMR!G"\>:#CDYPH_O9`:U
M!;6,D<4@D9Y5PX9=S#)`Z8'SH/3/''O2A$DC4.-TC/N!@W#<S8("G&?FW<J!
MQC/.>+,`E-JGG7`VRJ<NH8%L\*`0<@?,GRGL#R.H`,*\1#L86;Q[CDE3N+#_
M`&0/O_[ON"/4Y$NG6QDA66S98PYE25<!BQ!^Z_<EB3L&.H!.2`.Q66&.U=+@
MNXW$*SED.!G/S$Y!&"`IY.!]#0BL]H+EI5MF=E=UCVHN6.">2$8C@\GG/`[@
M'0>!;^&^NK>151+F,-#/&JAER%_A;HI'=>_7L`"H?"&EB#Q#;R2LYD0,OF;_
M`+Q"GY2N,YZG<3\PVYSFB@#L-?TB\U.XMY+;[,#`C%&E9@0Y(]!TX_SQC$N?
M`T]U-&7>W$>T%AG=M8DY'*_.N.@RO4^E%%`"P^";R(H#<VY0,"1\QP<DY]QD
M]#US][@57O/`5[=600W%KYX<-GYAN(SSNQD9XR,'H`"`***`,\?#?5T?<+RR
ME#X,HDW<X7`"_+\BCY>%P/E[;L"]9^`]1M;R:1KJU:-U(8*67>PSM<<$HV=H
MR"3@MR:**`'0>"]69L7+VFQ3A2)V<XYPV#&,-@D9Y/)P1T)>^!M2GCG59;%S
M(H.6W1[F`P,[5XZM\W)^8]2`:**`*FF_#S5[*U$4MY:2F,$(I>0J1V&,<8]>
M3SG((&+8\"ZCM=1=6Z@9\L,S.,Y'WOE!9<9^7/![\G)10!6;X<WLDMN[W405
M)B[)YK':?[^0H+'MM.!WS5G_`(06^=9%=[,([`[`['&.A#;00/88!Q@]MI10
M!%<_#Z]ED>1&L"T@Q*,LJMRV,`*=HPV,#@CTP*6Z\!:G<V\D?VFS!;&64LOF
M=>3@?*>??H.F***`*=I\-]6MK<1FZLR1\O[MW3Y<#H=N0V>_.<\]]T[_``]U
M(W9*SV?V;8T>W>X)4G('"\'EOFR?IT(**`&Q^`]>M+E)+*XL(U*!)1YT@$G=
MMP"8;D#&?S'2NM\/:+=:1)<B>6&6.0*8RH.\'+;@3CD$;2/0DCH`:**`-VLW
M6K"?4;-(K>18Y%D#AF/'`/MSR1Z?6BB@#D#X&U0W+E;BV2%CD9GD9@>I[#C/
M09X&/?+KCP;KLRLHN+`(SA]@EE&TC/W2.@/4J..<<@"BB@"Q#X+N8TE+?9?,
MD5&.)"<NIX_@&!@+VSU[<5=A\*SI-AG@-L2"\0+8+#HP[COD`_-GD^A10!7N
M_"-V9)GM?L0+G81(6PRX^]C!`;@=FSU)Z@P_\(?J<SYN)K4L5"%U=ON8&%V[
M0,CGYL^^,YHHH`IMX#U03"2-]/RRE7W,WS#GK\G)`)&[OZ=<JG@C5TY#V)*#
M$9:>1L#_`&LJ=_;KUQCIT**`);?P?K0"I,VG>6K[E"RNQ)X^9B4Y[_+[#GO5
MH>$+_P`P-Y\$:99BB2/\I.>5.`5ZY(Z=?Q**`'-X2OH64V\UNRL,RH7:/<PZ
M'A2,8`!&,$$C@\TV;P;=,Z[6MBA8,XWLG(.0RX7@@\XZ$X]\E%`%2?P3J<KJ
MQ.GMQAOG90P/7"[3@D]P>W2K:^$;XL#*UJZF(1R1K*RJP&./NGD]VZ\9QR:*
M*`(IO!VI;(UBF@;:>AE90`1@CA?88/7\N9W\*ZB;9(E:T.%*YDE=B`<9&=OS
H>V>F!QR:**`-#1-`N-+O&=WB^SJ-L,:2,64<]20-W4_3M1110!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g201504281926168661270.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201504281926168661270.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`%6`;`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V"6YUN[UV
M^L]/N]/MH;58C_I%F\S-O!)Y$J`=/2I/LOBC</\`B<:/CC(_LJ7UY_Y>/3_)
MHT[_`)&O6_\`KG;?^@O6W0!C_9O$G_06TK[W_0,DZ>G^OZ^_Z4@MO$O\6K:2
M?II<@_\`;BMFB@#'^S>)/F_XFVE?[/\`Q+)./K^_YI/LWB7+8U;2<?P_\2R3
MCZ_Z1S6S10!D?9O$>3C5=*Z<?\2V3K_W_I#;>),<:MI6<?\`0,DZ_P#?^MBB
M@#'%MXDYSJVD]./^)9)U_P#`BC[-XD^7_B;:5Q][_B62<_3]_P`?K6Q10!C"
MV\2[>=6TG..O]ER=?_`B@6WB7C.K:2>><:7)S_Y,5LT4`8PMO$O?5M)Z_P#0
M+DZ?^!%!MO$VS`U?2=V>O]ER8Q]/M%4_B!JUWH7@75-3L+@6]S;HK)*4#A?G
M4$[3UX)KRS6/$=]J6GZ9<WU_%J6E:/XQMF.LI&J(T"@'<VT;>#(1D>@Z]:`/
M6Y8_$<$32RZWHT<:C+.^F2``>I/VBGBU\3]]8T@_+VTJ7KQS_P`?'3KQ^M>6
MM?Z-=ZU_:FJM#/X3NO$%T[3S(&MI'^R0K&S9X9=R2@=1N`]*]+\$MH[>%X3H
M$4\>E>;-]G$V>5\QN4S_``$YV^V*`)_LWB?_`*"^D?\`@KD_^2*!;>)\+G5]
M()V_-C2Y.3Z_\?'3VK:HH`Q?LOB?'_(8TC.#_P`PJ7KSC_EX^E(;7Q1SC6-'
M^[Q_Q*I>#Z_\?'3V_6MNB@#%^S>)LC.KZ1C//_$KD_\`DBC[+XGR/^)QI&.<
M_P#$JEYZ_P#3Q]/R/KQM44`8HMO$_P#%J^D'GMI4HXS_`-?'I_GM2FV\2XXU
M;2?QTR3_`.2*V:*`,;[-XEQQJVDY_P"P7)_\D?2@VWB7G&K:3TX_XE<G_P`D
M?6MFB@#&^S>)MX/]KZ3L[C^RY,]N_P!H^M'V;Q-E?^)OI&.-W_$KDY_\F*V:
M*`,-+7Q2!^\UG1F//W=)E'_MR:%M?%6T;M9T8MW(TF4`_P#DS6Y10!B_9?$^
M1C6-(QW_`.)5+_\`)%)]E\49_P"0QH^/^P5+_P#)%;=%`&)]E\4\_P#$YT?J
M,?\`$IEZ?^!'UH^R^*,'_B<:/G/!_LJ7_P"2*VZ*`,3[+XHP?^)QH^>W_$JE
M_P#DBC[+XHSSK&CX_P"P5+_\D?2MNB@#$^R^*-O_`"&-'S@<_P!E2]<<_P#+
MQZTOV;Q/_P!!?2/_``5R?_)%;5%`&)]E\4X'_$YT?..?^)3+U_\``BE^R^)^
M/^)OI'O_`,2J7G_R8K:HH`Q?LWB;`_XF^D>__$KD_P#DBC[-XG_Z"^D?^"N3
M_P"2*VJ*`,7[-XG_`.@OI'_@KD_^2*7[-XE[:MI/3_H%R=<?]?'K6S10!C_9
MO$?'_$UTKH,_\2R3KW_Y;TOV?Q%\O_$UTOC[W_$MDY^G[_BM>B@#(^S^(L+G
M5-+S_%_Q+9.?_(]+]G\09_Y">F8_[!TG_P`?K6HH`R/L_B+Y?^)KI?'WO^);
M)S]/W_%-^S>)<M_Q-M)QV_XEDG'_`),5LT4`8XMO$F.=6TDG/;3)/;_IX^M-
M^S>)L'_B;Z1GM_Q*Y/\`Y(K:HH`QC;>)LG&KZ2!VSI<G_P`D4S2[S4EURYTO
M5+RQG=+6*XC-M:M"3N9U;(:1\@;5_P"^JW*YY'(^(L\8)VG28V(R.<2OCCKW
M-`$VG?\`(UZW_P!<[;_T%ZVZQ-._Y&O6_P#KG;?^@O6W0`4444`%%%%`!111
M0`4444`%%%%`%+5]*MM:TN;3[O=Y$NW=M.#PP8?J!5H0Q+"81$@B((*!1M.>
MO%/HH`9Y,7D^3Y2>5C&S:-N/3%17DTMO&LL:!T5AYJA26V]RN.I'7&.<58HH
M`;'(DT22QN'C=0RLIR"#T(IU9Z@Z==;=S&TN'^4;2?)<]L_W2?R)QW`&A0`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%<CX@\1
M:XOB`:%X8L;&YOH;3[;<M?2LD:H6*HBE0?G8ACS@`#WXYJ^^+-WIOB35-*OM
M*BMFM-&^W1Q.Y9_M/EAQ"Q'!ZD9'I]<`'J=%>9>&?B5JNI76E2ZOIUK;:5J&
MFO=+<Q%N)4+DQ\_[$3MCT[]JZ#2/&>?`6G^)-?@^QR7P!BMK=&E9R['RD0#E
MF9=O0=30!UM%<JWQ$\.K'I\OG71M[T?+.+23RXB9/+`D./D)D!7![@YP.:Q]
M5^*FFVU]:1V"R30+J$EI?RR6\@$819"VPXPY_=G@9X([F@#T*BLS3M?T[59[
MF*RF:8VT<4DC"-L;9$WI@XY)7!P/4>M<T?B=HU]H%[>Z297NH[03VT5S`T8F
M+MY:$9QN7S"%.W)SQUQ0!W%%86D>+](US5+C3["29Y(0Y61H&6.;8P63RW(P
MVUF4''3</6MV@`HHHH`****`"N?5@/B'(O!9M*4]>1B5NH]\_H>G?H*P<_\`
M%P`,_P#,+/&/^FH[T`/T[_D:];_ZYVW_`*"];=8FG?\`(UZW_P!<[;_T%ZVZ
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!DL231/%(H9'&&![BJMI(\
M$OV"8LS*NZ&1FW&5!@'/?<,@'/7(/<@7:@O+;[5;E%?RY%(:.3&=C#H??W'<
M9'>@">BJD%Z#;R-=!898#B9020#C.0>X(((^N.H(K%O?%\*%%L8UGWY`=GPI
M],8SG/(Y((ZX.#0!TM4+G6K"T<I)."X!)"*6Q@X.<=_;J<<`UQ>H:I?7GF"Y
MF4ID@0G]V",'/;,9`#9R201C.,@U3&(V$9.6!PBRIM+D=21QM<`D;>_S<T`=
M+/XNSG[-;#;CY6D;EF[*`.">O\7&,'!Z5)/$]](#L>W12P3=&`<95NYR`P^7
M@]R`0.AK0:%J5P@9(I,.NW]\=N#QR0P)7URJ\D\@]*TH?"ES]Z2\C1QA"53>
M'0`@`YQC.02>3G/)H`RVU?4954O?.`26)9P@P/O9VX*XP>#@G&,'+9?I-Y<3
MZI&IGFD?S5$BS3$A`#DC!Y7IQQS@<G)QMCPI;DYDN9?N[2JJNUOJ&#`XQQ^.
M<@U:MO#UI:S12I+.QB^Z'8$'G.2,<GT)Z<8Q@4`:U)\VX<#;CDYYI:*`"BBB
M@`HHHH`****`"BBB@`HILDB0Q/+(ZI&BEF9C@`#J36<89-6*M<*\5DK*Z1;B
MK38Y!<=ESCY>^/F[K0!BZSX9?Q!J,6N:-KEQI=T]J]E)/%`KB:'<2,!QQALE
M6'7.1D&L'4O@[9ZEJ,5W+K%R?*DLB!)&'9DMT9"K,3EB^XDGMZ&O2Z*`.$NO
MAG;77PZL/"#:G.D=FP*W2)AV'S;AC/0J[*>>AK:\6^$K;Q3H$>EF1+98)HYX
M#Y*R1JR'@-&>&3'!7N*Z&B@#R^Z^#B7$]@XUSRTM8U_=I81H@E64R[XU0JL>
M2<$`9(XW=<Z\OP^ACBLY6NY)_L6J7.JM%'"`;@R[SY>-P`^]@'V[5W-%`'"?
M#3PMJ/AGP$]GJ,3+J,[R2/%).)&0;0D:&1>#A$0<<#MBL/PG\+=0CT?1)-<U
M.5+BRCA0V1B1E2-)Q.8RRDALNB<]@N/>O5Z*`.+\+_#RT\+^(;O4X+F*6.7S
M?*C-E$LL?F.';=,!O?&,`$\`]^*[2BB@`HHHH`****`"L#_FH7_<*_\`:M;]
M8&?^+@@<?\@K_P!JT`2:=_R->M_]<[;_`-!>MNL33O\`D:];_P"N=M_Z"];=
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5E:IKMOIX*+^]N/[B]%&>
M23[>G4]A67K7B1/+FMK.9$V@K).7`"G(`&0<KGYN>O`QUR.>CB>:?!@9VD8`
MQF3!8D_=/((!YVMP">>.6``Z^OIM2GEENY",+M`!"A4&<MC^!OF8#D@X/W@,
MTZVMKB]NV2.*2209!S']T]2''`0]OFY..N:W=*\-.8TEU!NP_=(2`>._3G\.
MAQZUTL,$5O$L4,:HBC``%`'/V/A545#>3>80H#1H,@X(X+$9(&.#@'UYYK<M
M;&ULP?L\"(2,,_5F^K'D_B:L44`%%%%`!1110`4444`5;[4;3385EO)EAC9]
M@9NF<$_T-26]U!=)O@E20=]IY'U'8\'@^E<9\1;Y473K%B55W:<L$!QM&!SV
M^]GIVR.F#RJ2B"9664^=&-Y`YVJ.O`ZQD]#C(P.N#@`]CHKSG3_%6I6/R28N
M(]H.QG,C+P<;3]YE..6);'7G(W=5IGBFPORD4K"VN')`1CE6(SG:_1@,'D4`
M;E%%%`!45S<1VEN\\I(1!V!))[``<DD\`#DDXJ.[O8;,1B0DR3-LAB49:1L$
MX`^@)R>``22!4=O:2/-'>7VQKI5(58R2D6>H7/4]MV`3Z#.*`$%J]W,LUVN(
MEYCMF`(!SPS>K>F.![GD7J**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`K!_YJ`#Q_R"SZ9_UHK>K!(_XK]3SSI9'3C_6B@!^G?\C7K?\`USMO_07K
M;K$T[_D:];_ZYVW_`*"];=`!1110`4444`%%%%`!1110`4444`%%%%`!7(:[
MKXNM]C92($91B0C=YASZ9!"<?>YSVX/,OB75V.ZQ@W!%!:5_+#A\?PA?XES]
M[I@@#GY@,*RMGNFAA5?,9L.I5LJ[9^8ACRZ[3T/*D^XR`-MK1[JX2*'>\K`D
M`R9YYY60'+`X(\S'MR%%=II&BIIR!Y"KSG!.!\L9Q@[>_KR?TZ5-I>F1Z=;X
MR7G?!ED+$[C_`"'X`5?H`****`"BBB@`HHHH`****`"BBB@!&574JZAE/4$9
M%86H^$-)OPICB:RE5@RR6A"8(_V2"AR"0<J>*WJ*`/.=1\%:E:#S;5X[Q`IW
M!<H_08(7)#<;N,XY'')KFXY3%N,RA91D;6=D*,1^:NN1D'KD$CC)]JK,U;P_
MIVLIFYAVS`86XB.R5?HPYQ['(/<4`<3HWBFZL'VM,MS;L&958[0V.20<8CQT
MV]/IG<>T@\06%ZBBRE$]PY*B#.UU(SG<#RH&.I'TR2`>`UK0K[0&,EQ(;BS=
M@BW(4;?]A9%_A;)VA^1T[MBJ>GZC=6,_G6LQ6>%0,#)`0Y'S+D[E.WAR<#`!
MQE<`'J]M;/&S2SRB6=\`L%VJH]%&3@=^IY/T`LUD:%KL6LVY^7R[A`"\>[<,
M'."&``;H<XZ$$5KT`%%%%`!1110`4444`%<1XQ\1>)]$U_2+/2[?2)+34YA;
M1/=-)O67:S'<%XVX`Y'//2NTFFBMX6FFD6.-!EG<X`'UK%U70K?Q%=:)J!GF
MB_LVZ^UQKY94N=I7!#8(ZT`9=GKOB@^/1H=Y9:3]A\E[EI()W,R0Y*HQ4C&6
M;C_@+>U=C65::'%:>(]3UKSG>:^BAA*,!B-8]V`._)<DY]JU:`"BBB@`HHHH
M`****`"L,_\`(](<#_D&-SW_`-:M;E8C9_X3F/@8_LUL<_\`35:`#3O^1KUO
M_KG;?^@O6W6)IW_(UZW_`-<[;_T%ZVZ`"BBB@`HHHH`****`"BBB@`HHHH`*
MYK5_$5SI^H7%B(HRYCWP$L%8*0!NYR&P=W'7CICFNEK#\0Z5<7R126G,H8*R
MD@87GE2?XLD>V,\&@#CDCD+!6#2,6.\Q?,6;K@'&<],ID_>`SRJGM]#T@:;;
M*\G-TZ_O#V'L/0>V2,DXZUD6.@:E:75O<".U=H>-LDC`%<'@<-@YYSR?7)X'
M6T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`UT22-HY%5T8%65
MAD$'J"*\_P#$?A-M,#W^F@M8H3++"Q9V@_O,N3\ZX_@/3MQP/0J*`/'K*XEB
MGAE1WB((9629BS'*J=G7<3G!3KC&>G'I>@ZW%K-FKY43`?,%^Z?<?F,CJN1G
MJ">5\5^'5TZ5]2L85%I+_P`?$2X0(<Y+;OX5/.>,`\DXR*R--OKO3KE)T,BL
MFV(F7Y-N"%*.I^Z<9&]B<G/(VL2`>KT56MK^WNK**[5BD4F`/-&P@D[<$'OG
MCW[59H`*YRXU^^U*2XL_#=F)I896@FO;P-';PNO#8&-TI!&,+QD8+"NCHH`X
MVU\91Z-=76B>(YIFU*SB>X6=;<XO(!R'0*,;L9!4=/+<_=&:Z.&ZN=1@BFMD
M6"VFC5UED.7(//"C@97H2>#U4UQWBSP+K%YI,T?A_7)5E5F>&VO\2HNX,KJL
MA'F`%78`$D#)X'&.]BB6&&.)/NHH5?H*`(4L(!,)I%\Z<$$22_,0<8^7LOX`
M59HHH`**\KAUBXEU'7-8L[-[MI9I7LHUM)E:,1(J+)NZ,A(D;:!DEAUXV]!#
MJ?B.36HH8GDN;1KB,QNUB80UNWF%V=F[J`BC&W)YQAA@`[2BO*+$:G9WVNW%
M]9W@L[B/4([%K>&9Q-ODW*)%P3PBKL(&W!<9Z"NG+2RP>#XY69+>5<.)`03,
M+<E`RGKC#'#=U4]0,`'845YYJ.KZ_H.F:G.=0O;Y&:1;:=[`2B$0H?,9A#&,
M%I,J-_R@)NSGY3?M]2UJY\2?99A(UF;V9+FVFMPL:6?DDQR!BH)W/M!Y;DL,
M#:<`':45B>$)I+CP=I$TC2N7M4*M,279<?*6)Y)(QDGFMN@`K$;/_"=1]<?V
M:W_HU:VZQ&_Y'B/_`+!K_P#HQ:`#3O\`D:];_P"N=M_Z"];=8FG?\C7K?_7.
MV_\`07K;H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`&NB21M'(JNC`JRL,@@]017DFM
MZ?%HNN3644K31H%="7+M&K9)5AGYNA8^V"<Y&?7:S[C0]+N23)8P[F8N71=C
M$DY.67!Y/7UH`XSPCI_VC5(WR3!;YDVAV*9Z+M/1\<9/8C'I7H=4-/T>RTMI
M&M$=?,QD,Y;&/3//_P"H>@I^J_:O[*NC93I;W(C)CE>/S`I'/*Y&:`)[FZ@L
MK9[BZFCAAC&7DD8*H_&N93Q=<ZP6'AO2Y+J)6^:^O-UO;;>Y1L$R8/H,#!YR
M,'D(#>:[.MSI&C76LW65;^T]<?%LN<!C%$/E!X(``RO7!W'.X?!`N8%NO&OB
M":\;.3`DOV>T3_9"C&<`=>">30!W-M<P7ENEQ:SQSPN,I)$X96^A'!J3'.<G
MZ5S6C:EX5NG^R:7'`4MEV>9]G(0``='88;J.03WYSFMP:98`Y%C;`C_IDO\`
MA0!:HJJVFV3$L+6)')SO1=K`^S#D5&-)M@%'FWORG(_TV;_XKGI0!>HKFO%4
MS>&_"NL:W8M,UW:VLDL8GN))(]P'&5+8KA1\5M6NED6.V@MI[>QM6NX)(FWP
M7+7HMY4(STV\@=>1S0!Z_37C21=LB*P!#`,,\@Y!_`@&N'^)/B;6?#<&F/IC
M0VUO/(ZW5]/:O/'!@#:&"<@,2><'&VNH\/ZA+JWAW3M0G-N9;FW21S;/OCR1
MSM/I0!>^SP?9S;^3'Y!4J8]HVD'J,=,4YT22-HY%5T8%65AD$'J"*=10`444
M4`%8C?\`(\1_]@U__1BUMUB-_P`CQ'_V#7_]&+0`:=_R->M_]<[;_P!!>MNL
M33O^1KUO_KG;?^@O6W0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!S&L-
MXNEO+M-/;3['3X4WQW+!IYICM!(\O@+SN'4]0>Q!X&32;6YO1<:I+)JDZ/A)
M;UA-Y9;J`NT+@XZXR%P,#(->RUYG<V\=I>W-K&(XH;9V\M0<>4F[@8.-W;Y<
MXV[30!Z%IKA],MB$C3$84K&1M4@8(&.,<<8IWV01JWV:1H2>@'*`_P"Z>@^F
M,UC^%;HM8_9I%`F4EF*K@'IGWSD]#S704`5A/-%N^T0$A?\`EI#\P/\`P'[V
M?8`]>M3I(D@)C=7`."5.:=43V\<D@D*XD48#J<-CTSW'L>*`*FN:1#K^A7VD
MW$DD<-Y"T+O&1N`88.,@BN7UGX8:5JNJ:QJ,=U<V=QJL<"3F`+@&*5)`Z@C[
MQ\L`YSZUV9\U",`2*`<]FZ<>QYSZ=:D5MPZ$'N"*`.3N?!VI736EP_C'6/MU
MJ[^7<+%;K\C@!D*",*>@P2"0>E;F@:):>'-!L]'L3(;:TC$:&0@L?<D`#)//
M05HT4`%%-$B,[('4NN"R@\C/3-.H`**0D`@$@9X'O2T`%8C?\CQ'_P!@U_\`
MT8M;=8C?\CQ'_P!@U_\`T8M`!IW_`"->M_\`7.V_]!>MNL33O^1KUO\`ZYVW
M_H+UMT`%%%%`!1110`4444`%%%%`!113'FBCD2-Y$5W^XI8`M]/6@!]%%%`!
M1110`4444`%%%%`!1110`45YU:>*=9\0V6GV.I:>NE1>)=/<Z;=V-Z6EBD\G
MS,MP"OR_,I&<;<'K4ECXGN]?_P"$.T^VDGCN;@-=:HZ?\LQ;C:\;8_O387Z`
M^HH`]!HKG8=3TWQKIUU::=J&IVRKL\V6*"6TE`.2`K2(#@X/*\^XK`\(BYUF
MQ\0:;=:GK%K:P7:I##=3,E];Q[%8AY3SACEE().T_>SP`#T&BO';B]U1?!-X
M\.I:U<:7)K]O!IUQ'<G[7/;&2-'"29#$,V\*2>1CG&*Z.UU.?P]I<1T_3==N
M)KN_BM5CUR]8L2RL<JS,^!QS_6@#OZ*\ZUKQ3KS:1'IWV0V^M-K$6FW"Z;(L
MA*&+SV>%I=H!,8(!;H<^F:=<QW6I^%XK31X_$ADL]5":A;/J'EWJ*%W,OFM*
M`00Z,,.00PQ0!Z'17.>"Y[*?1YELGU8F&Z>*>/59GEGBD7&5)9FXQ@C!(YR.
MM='0`4444`%%%%`!1110`5PGB>W>/Q$60+LD2.;,DF%5QE6(SPIVHF#QW.<+
M7=UR'C2$FYL9(\!RDBL6&Y<94#*Y`X+=>W7T(`*GA5@NI0;4E5=K1?,Q`&`2
M$*8QN``RV3W&/3NJ\YTX22:E%&P)B#['19,.H(P<R`CS,`XS^O`KN(].DMXM
MEM?7*A1\BS/YPS[ELN1_P+\10!>HJ@)-4A.)8+>Y0=7@<QN?HC9'YO\`X4XZ
MG%&X2XAN+<GG+Q$H!ZEURH_$C^5`%VN3\2QRSZ]8R)837-O96TSW&V%L[7:,
M?NSC#.%#G8,DCI\VVNHAN(;A2T,T<@'4HP/\JDH`X][O44^WP:&&6WMUE2"-
M;4*D9$2[%3"]?-W`@YP`<XX-3645Q<^,(;B]M9'>WBO4AGDML>6ADA51OV@9
M;:Y&#RM=);6=M91M':6T,$;.TC+$@4%F.6;`[D\D]ZFH`XC5K>:_MECB0>>;
MVY2=WMC.%_U@B\Q%&[&W;M;C`QSS@O6_\5-'$T5G<1W;.,6DX5H1%]G#9,H&
M=PD(7DY)!XQ\U=I10!R`OKZ6X);[1):^98&T:^MQ%-YID83@+M4\1[3T_B?M
MP.OHHH`*Q&_Y'B/_`+!K_P#HQ:VZQ&_Y'B/_`+!K_P#HQ:`#3O\`D:];_P"N
M=M_Z"];=8FG?\C7K?_7.V_\`07K;H`****`"BBB@`HHHH`****`*NH74MI;;
MX;=YG)P`JDA>"=Q`YQQV!/2N"NKZ:\O);F2;YP/,7:6R@!QE3@'H<[00WWLX
M))KT>O+ID`O9(1'O=9B0`NT.RDX8=E;@`Y`R?7H0#N=&U::^B5+FWD23A1((
MVV.<$GG&!C'KC/'7BMBL[00PT.UW,K?*<%5V\9../7&,^IK1H`****`"BBB@
M`HHHH`****`.)\(>#+FPL?#UUK6H7=Q>:78I%;VD@B$=H[1*D@!11O(P5#$G
M@GKDDZF@^#=.\/ZYK&K6LUU)-J<IE=)I-R0Y8LP08X#,Q)_#TKHJ*`*6JV5Q
MJ%@T%KJ5QIT^0R7%NJ,RD>H=2"/48_*N;O?A]!?Z+JME/K6IFYU62-[R\#1A
MY`@`";0NT)@8V@<CJ3DYZQ;B!]NR:-M[%5PP.2,Y`]Q@Y^E03ZK86]I+=27<
M7DQ-L=E;=\V<!0!DEB>`HY)X`S0!B7'@^6[T?^S[KQ!J,OE3PW%K-Y5LC6[Q
M-N3:%B"D9"Y!!Z=LU5UGPSJ]S::=#'KNHW<L>HPSO<2);*\"*&!*`1!3U'#!
MJZ2?5(+>:R219%6\)6-V3:%(4MALX*D@'J.QJXK*V=K`X.#@]#0!S,G@N&;2
MVMY=5OVOFO4U`Z@#&LOVA555;:%V;0JJNW;@@8.>M2Q^%YK73I(K/7=0AOYK
MO[9/?$1NTTA4(0RLNW9M"@*`,;5P>*Z*B@#.T;1X=%M)(8YY[B2:9IYIYRN^
M61NK':`H[<``<=*T:**`"BBB@`HHHH`****`"N5\:NL45G(Y902\:N#P&;&,
M@<L.#P/KVKJJXOQ2=4^T1I<+`;<,S6\L2LK`_P"T2<`A??YN?]V@#%L.;RU1
M2&/F*Z1^6?E8='!.`F",[?0$9YKTZO+[6655B6T<RDL&C4@219[?N\_*W0?=
M'MU%>CV37;P;KQ(TD)R%3^$8'!Y/.<]"10!9HHHH`JW6G65\0;FUBE91A79?
MF7_=;J#[BN/U[6]=\.>+O#NGP?87T6_N%LU6>21IV.UB[-*YP",+M7YBY)'7
M%=U7*:QX%MM9UY-3FU744B$D4[62R+Y+31?ZM\$9&,G(!&[C/3D`X;7OB#XR
MT1M2M[D:4)H9+;,MM#),EH99&7R6YS(VP*_`!YZ<BO0?!.J7>KZ&]S>:A#?/
MY[*LL5C+:#:`O!23DG)//3D>AKF[;X1PP:7+8-XFUB2-[M;P;O*.V8/OWX*<
ML3C).>AX].WTFPO+"V:.]U>ZU.1FSYMQ'$A4>@$:*,?7/]*`-"BBB@`HHHH`
M*Q&_Y'B/_L&O_P"C%K;K$;_D>(_^P:__`*,6@`T[_D:];_ZYVW_H+UMUB:=_
MR->M_P#7.V_]!>MN@`HHHH`****`"BBB@`HHHH`*\TU(%=1U`.P:(W#YR-P(
M#$[2O))^8X.,#L>#GTNO/?$$"IKEX3$"_6-W!X#*,DC!+)RXPO\`=;C/W@#J
M_#;*VD*%ZJ[!@<Y!SW)^]QCGN,=>M:]<[X1D7[)<6Z!P(G!P[A^HY(.3QD'&
M><5T5`!1110`4444`%%%%`!1110`56U".[EL)H["=(+IEQ'*Z[@I]<59HH`X
M#PYX8U%=$TZ*>VM[.:UOM083*S"6.*5YPNS()Y\Q6Y(X5>_24^";R5M->9K1
MEL(K.$6^]O+G6$2`ECM!'^L.%Y'!!R&X[JB@#E+OPS<W7AW1=.N4LM2>R),R
M7N2D@\B2/&=I)P7')&2`>]8?A7PS=6_BN\DDC<+I]Y"?MTT#(]X!8)"X&5P5
M,GSD@]4'7@CT>B@`HHHH`****`"BBB@`HHHH`****`(KF!;JTFMW9E65&0E3
M@@$8X]Z\8UOX>W^A/;VFG^([IHY58_O80``N.K*PVX'0[<`\_3VRO/O$MPES
MXFG5.?)B6WDPQ'0>:0PQ\PPX^49!V\].`#D=,TSQ@M_"MEXFEGN&8JOGR%BR
MDG]Y\X)V_P"[D=2,\BO3O#=IXCL;)U\0ZC%=SEE$;0J"%&,<_(I(R?KP,GJ:
MQ/#4"R:W&KI`7ARS*Z;W!V_>23D%>1\NX\Y//6N\H`@`NEY+0R>VTIWZYR>W
M;'XTJO<;27ACR"<!)"<CCU`YZ_I^$F-B_(HQDDJ!U_\`KYI<@YP>G6@"!KED
M56>VG"G.<`,5_!22?PS4J2+(H89&>@92I_(\T^N&\3VTVH>*/+73IIEAL!%%
M*+9L.\LRE@LH&(RHB0[OX=V1R*`.YHKB+76?$=W(4:VO89/,C1P;,JB[KG#;
M69?F"Q*<G)SN!&.R7LFJZEI&NV%]:W4H?2\Q1R6FY3*[S!5!5?F90(L\X'!X
MYH`[BD+*&"D@$]!GK7G>IZ3-=7OB">33GG:\FTUH9([)D9MCJ2<G/W1R<XQS
MTKIK]KL:]<[2RXTMOL;I&"PD+'S,9!YXA('.<'B@#?HKDX=0U^6X&^&Y#G[*
M\,:0A8I(V7,N]F3*,#O&TD$;4_O$5DZ"+S3+!I;A-1`,=NA$5A*LF\!R5D`5
MB[`L"TRC#[57']X`]!!!)`(..#[5BM_R/$?_`&#7_P#1BU%I3S/J-COD$UQ_
M9O\`Q,)A"8BTN8]A9#@KG]Z0",@5*W_(\1_]@U__`$8M`!IW_(UZW_USMO\`
MT%ZVZQ-._P"1KUO_`*YVW_H+UMT`%%%%`!1110`4444`%%%%`!7'>,HE2]M;
M@DG?&5(4$-A3D[7'W.'.<9S@#!XKL:QO$]HMWHLA*@M"PD7=C'<'.>/NLW7@
M=3QF@#!\,7AM]0C@94)F.UI`N!C:2#UX)P%QG)QTXS7;UYG;.T-PDY.&3:&R
M<8P>,_3H&4%?F!^8[C7I4;B6))%^ZRAA^-`#J***`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*\NN9H[Z^FNU##S)3("?
MO%=V4*MD8P,$J>/3D''>^(;S['H=RRG$LJ^3$`P!W-QD9].3]`:X"*$+L0!$
M;'W0I^;Y<8YQM;U)"CH*`.P\*682T^ULPW-N0+$W[O!()*K@%.<_+^.!G`Z.
MJNFP/:Z;;PR?ZQ8QOY_B[_K5J@`IKJ6'RL5;L>WY4ZB@!AD"L!(54L<+SU_^
MO[4^BN6UOQ-/I?B2VTBW6W9KJWWIYPDR)6E5$!*@_*<MZ8VYYZ4`=317-?\`
M"=:,59D-Q(NQI8V6+Y98UWEI$)X*CRVSW^[Q\RYHZGXTFL/&%MHT45K=1W0M
M7A".WFNDSR*SK@$$((F<G@$,!P1R`=G17.Q^(;E-`U'4+BVC,MM=2VT<<3'$
MA5_+4DGIENO7`]:)?%UI:W5U820W,U]:RV\#1Q1J/-DFSMV`MPORL<L0.#R2
M#0!T5%<U;>-]-NIK>);>\0R"/SS(B@6K/,T"I)\WWC*CIA=W*G/'-6$\1&9=
M,N([.5+>[O);*19@%DB=2X#$`D$;HR,#GYE/&#0!NUB-_P`CQ'_V#7_]&+6W
M6(W_`"/$?_8-?_T8M`!IW_(UZW_USMO_`$%ZVZQ-._Y&O6_^N=M_Z"];=`!1
M110`4444`%%%%`!1110`4R6))X7BE4/&ZE64]"#U%/HH`\PN[9K74)H&?YK=
MMCO*JY9,?@"F#DCC)SZ5UOAC48W@%@8_+D4%P"`-P.#D`''))/;Z5!XNL6/D
MWZ1&38`C[6VL`#E<$D`#.0<YSD<9P1SEE<M%=(\&_:&+J008@WWCQC((YZX&
M.><@D`],HJ*WN(KJW2>!P\3C*L.A%2T`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!11534[Y=.TZ:Z8;BHPJ^K'@#Z9_2@#D_%E
M_P#:=0%HF#':D!]R@KO89SUX(&`#ZMCOQ'X=LQ/J2A&9HXV)=25X51A01MP>
MW([>GW5RA),]P\A<L\BDM+&"<!L@DD=4.<XZC/7!.>Y\.V0M=,20H4:500I_
MA4?='Y'TSS@]*`->BBB@`HHHH`*R+GPY876I3:@SW:7,R1QRM%=2)O1"2J8!
MX&68\8SN.:UZ*`,&V\&Z)::=#I\-O,+2*.6%8C<2,OE2?>CY;[IXX]A4MWX5
MT>^OGO;FU+SLL*AA*Z^7Y3,T93!&P@NW*XZD=":V:*`,@^'+$:3?:=&TZQ7D
MCRLQE9F1V.=RDDXPPW?6H7\+6-R\MQ=F1[V9HY9)XW9-LL8PKQKD[,9/'.02
M&W"MVB@#GY/".GF[LI(46&&VD\UE7<9)F$AE&]RV2/,)<@@DMSGJ#*OAJVCG
ML=DLGV:TNYKY8G8L6FDW<EB?NCS)#CGDJ<C;@[=%`!6(W_(\1_\`8-?_`-&+
M6W6(W_(\1_\`8-?_`-&+0`:=_P`C7K?_`%SMO_07K;K$T[_D:];_`.N=M_Z"
M];=`!1110`4444`%%%%`!1145Q<P6D)EN)5C0<98]3Z#U/M0!+2,P52S$!0,
MDD\"J9N+JX21;6`Q<82:Y7"Y(ZA,[C@]0=N>Q[TO]G12'==LUTV[=B7[@/;"
M=..Q.3[F@"*XG74+<P6]N]Q',I'FGY(P.H;<>3GL5#<XZ=:X2]M)K&XDBN2#
M*#MED&"&3J"X.,\8RP`X`X/(/IE96MZ.FIVV^,;+R,AHI%(4\=LX/!R>W>@#
M)\-:L?,6SFD^610T2,<LG)[C((/&#GL?;/5UY>LIMIEC`V.K_=4E3O'#!/0#
M"DCG!SCG@=GX>UQ=1@6*5P90N4D!&)1W..Q&.1SVYZX`-VBBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KA/$&J/J&H1I`H-O#DQ[3
MAYB<@E&SCI@C'..AY(K6\3:V8,:?9O\`OW.)=HRV#C$:_P"VP/&,X'/&0:Y6
M*'S_`-S`BS!R/N.`LIR!P<?ZS/.X_+QCB@#3T/3?M][$`%^SQ'S&*_<<9X*#
M&54D''NI]`*[RJ6F:=%IUKL1%$C_`#2N,9=O<X&?R'T%7:`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"L1O^1XC_`.P:_P#Z,6MNL1O^1XC_`.P:_P#Z,6@"
MNLCPZUXEEC.'2VA93CH0CXKBO`/Q!U;Q1LFNI72'3-)6YN8F@59M1E(8%TX`
M$:E"/EQ\W7CBNYM85N/$7B"!R0LD,"$CK@JXJDWP\T8Z7IVGI)=Q0V5A+IV8
MY%#3P2)M=9#MYR0&XQAAD8Z4`8=I\7K.^LK=[/1KFYO9M0_L\6L%S"_[PQ[U
M(D#;"IZ9SQ@^G,S_`!<TE#H#FPNA;ZPL124R1@QL[E,;"VYMI'S%00..YQ5[
M1/ACH>A7=O<P3WTTL%P+E3-(N#((C%D[5'\)Z#O5-/@YX7BFLI(VOU-I'$B`
M3C#&-]ZL?EZ\D=A@],X(`(G^*X"))%X7U66*5+J2&198,2);L5F(R^1C'0C)
M[`U>?XH:.DLD;07.Z%IS*NT;DAB@$YEQG[I5E`[Y8"KT/@#2(;>S@$EVR6D-
M[#'F1<D73;I"?EZ@]/3/.:S=,\#+_P`)CKNHWUC;)I]UI\>EQ1K,SO/$%`=W
MX`4E5C7CLGXD`CF\;7MY#H$XT_4M%6\U:W@"W$$<GVF&6)W`SN^7H"<?,I`&
M.35SPC\0HO%E_%;+I%W8K<V1OK669T831JX1OND[2&(X/UJ2P^'.CV$-E&+K
M4I_L5W#=0&>XW;/*1DCC`Q@(JNW&,GN35W0_!>E^'Y=/ELWN6:PL7L(O-D#9
MB:17.>.H*C'M0!P.E>,_$,WCUK$ZY]J676[FS727TLH%MHW93(MP``Q4`$CD
M^M>M&UMVNUNV@C-PB%%E*C<JGJ`>H!K!_P"$(T<>4X$PGAU*34XIPP\R.61B
MS@''W#G!7N,9]:Z2@`HHHH`****`.9\1Z&90U_9Q,TH.Z6%.LAQ@%?1\<9Y&
M,\&N9AO6BNFN(YRQWES)DDJXR?WF>02HP!SPA/7<1Z97)>(-"^SG[?8Q9"+M
M*`9$2CG@?W>/NCN<_0`VM(U:/48S&0Z7$0Q+&XP4/H>V>F?K6G7F,%S]ED#V
MTK!(5W1R8#-''@<KG((QNZ\]NW/:Z7XAM[YOL\SQQW6XKL#<.>?N_D?R/H<`
M&S1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%86NZ]]A5K:S(:\[
MDC*Q].ON0>.PZGT,6M^)(K9)+:RFA>=24E<MD0_7!&3P>`<C!/.,'DW#.\A,
M@-P\C*78Y*^SG^('/R@'=EAG/2@!'R[RL^223O5P7*MDY+CKD@$#/3)!X!QU
M&BP6VFW(DOGD@N+AMMNEP`!@]%#="YYXR&('*CFGZ!H0BQ=W4'EN-HBC)Y0#
M.#].>%/3OZ#H9H8KB%X9HUDC<89&&010`^BLTP7U@SO;2->6Y#-]GF?]XI]$
M<]>_#GJ?O`#%6;:_MKJ1XHY,3Q@&2%QMD0$D`E3S@X.#T..":`+-%%%`!111
M0`4444`%%%%`!1110`4444`%8C?\CQ'_`-@U_P#T8M;=8C?\CQ'_`-@U_P#T
M8M`!IW_(UZW_`-<[;_T%ZVZQ-._Y&O6_^N=M_P"@O6W0`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`<SKGAUG=K^PWF96\WR01_K,Y,B9_CZ#GC@>G/)
MX6.48D\E0V,%20SC("_,,B12S$Y[-TYY]2K*U30++4P[F-8[AN&E5>7''#?W
MA@=^G:@#%TCQ28D6&]82`DXEWCY,'E6)[C(R3QWS@BNJAN(;A2T3AL'##H5/
MH1U!^M>?7VF7NEO_`*0H9,?+/G"L><!B,8'5L]<GICHMC<W5H?\`1I9(W7!.
M!\B#!4!@1DIGH<9YX]*`/1:*@M/.-I&;@YE(RW&*GH`****`"BBB@`HHHH`*
M**H6VLV-SI+:F)A%:+N+O,-FS:2#G/3I0!?HK,;7K"*TCGFF"%HQ(T:G>R`C
M/.W..A&3QQ6%>^+II'$5I";?<F[,P!DZ]=HR`O!YR?H<8(!U%Y?6UA"9;J41
MH`2203P.O`KD=4\13:BABM_,MH'0%@P&Y5(SO<_=V$'@`Y.#Z\89N)KJ5;B2
M9WD(&T[][8&<F,]PN23D\`G_`&@+VE:+-JFUXK>/[+N!60D"-6_B9`!SCH`?
M1N5[@%>"%Y[M(X5D\PXD15PQ0'D,/9L\]3R3Q@UUVB>'UL0LMRJ&5!B)`2PB
M&>@)R?3C)QZGBM#3=)MM+1A`IW/]YCU/?^=7J`"BBB@`JO=64%YL,JL)(\[)
M(W*.N>N".<'C(Z''-6**`*-JNHP2+#.8KF$<?:2VV0^FY`NW/J01]!TI=6U?
M3]"TZ34-4NXK6TBQOED.`,\`>Y]JSO&\CQ>`?$<D;LCII=RRLIP01$V"#7D`
MT;Q'?:;'>6=KXC@TJ)]/GEB:02W3S*K":6#>6YP5.>`3C`XP`#UJX\>>%K63
M3HYM:M@VHHKV@&6\U6.`1@>O'-='7@MCH'BY-3T*_?3-6M-82VM[9)K80K:^
M2+IF=)D`^4[-K\'!;/%=+\3(O$DWB.U.CZ?J,BP0P2PW%MYK*'$Q,BD*ZJIV
M#DE7W`X`'4`'I]W=V]A9S7=W,D%O"ADDED.%11R234U>(:CH&O:AH7BK3KS1
MM8NM8GCN6DO#<$6\ZB9'@$:[L,=J\``8&5(YQ7IT-U->>'=0L]+T_4+%[>S$
M=FURA0L6A!7;D[LJ2%.>00>M`&LNI6;:K)I:W"F^CA6=X1G(C)*AOS!JW7@%
MMH/B5(9Y[/1]>MT:ST^/44FE8SW05V^TK&Y;.6SGCJ,X`W5I-X9UZ^AOS)9Z
MS':QZ1J,FE0O<2+)%)YJFV1BK9+`9(5B>,9SB@#VVJMOJ5I=7]Y90R[KBS*"
M=-I&S<-R\D8/'/%>*:OH_BJWM]3TR'3]8N[&6_WPRM+-*R[K;DX#JS9D)Y+!
M589-.L=#\7:IJ\$>K)K7V66YT9IV,LJ?*ME(+GD$$?O"`V,<F@#W.BN<\!V^
MH6G@NPMM46=;J$RQD3N6<()&"9)Y/R!?PKHZ`"L)R/\`A/(1D9.F2<;N?]:G
M;_/ZUNUS\C?\7"MUW'G2I3M[']['S_GUH`ET[_D:];_ZYVW_`*"];=8FG?\`
M(UZW_P!<[;_T%ZVZ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M:Z)(A21593U5AD&L@>&[*/4(KJ!1$$.[R\$@$'/R\_*/;D<#`!YK9HH`0@$8
M(![\T@4@L0Q.XYY[=.!^7ZTZB@!!NR<@`9XP>M5-1U2STJS>ZO)?+B7/\)RQ
M'8#N?:KE8_B/1$US3&B4(+N,%K:1B0%;T)'\)Z$8/K@X%`'+P>-[C^TYKJXB
MVVRJ8U@WE/*).0).#^\(4X.0O4<88C3_`.$_L`?GL+]57`=BJ?(3Z@MG&.1Q
MS@]\`\;::=J=W&WE6=T'B!CD0JI,?S$;.^5Z_3D$'%66T/5EV/\`9+HNO*>7
M&Y:+J=H+8RI)YSR,YY^;<`=3_P`)]8L6$=E<_*1DR%%`4_Q'#'CD?7\1FK<>
M/W`/DZ6PPH<F64`@'&"5]#D<Y[Y],\[%H.ISQ1O%9S.KC(95`3:><Q^S#C!Q
MUYSR1:B\+:R[AA9,L>[<K;DRA.#O4,<[N""&QU7GC(`.V\/ZU)K$4YFA6&6-
MA\J-N!4Y`.?J&[#IBN1\Z33Y=?T*`2^7#J?VLNH"XCF'FD`$XP&\P\D`[#GO
M72^&M%O=(+FX^SJDB8,<3,0I&,'D`9.6SVR!CJ0(+VTC@^(-M-)$LEOJM@]M
M*CC*[XCO7(Z$E6;\%]J`.1Y,:DH(PN60.VTY[/&".HX&#CJ`..1K6^@:A<N-
MD;1J&SDJT84GJZE@&S]1T)X[5U=OX?M+34S>0#:K`EHF&X%\Y#`GH1S_`-]&
MM:@#$T_PS:V>&E=KB0$')&U<CO@=_7USS6W110`4444`%%%%`!1110!%=6T%
M[:36ES$LMO/&T<L;C(=6&"#[$&G11)!"D42A(T4*JCH`.@I]%`!1110`4444
M`%%%%`!1110`4444`%<])M_X6);<G=_9,N.!T\V/_P"M70USTC'_`(6);+D[
M3I,I(S_TUC_QH`GT\?\`%5:W[QVW\GK:K&T__D:M:X`_=VW0]>'K9H`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@"*.WBBE
MFECC"O,P:0C^(@!<GWP`,^@'I4M%%`%#1CC3%C#!EADD@0[<?*CL@'0=E%7Z
MSM.4Q7NIPG(7[0)8UYP%9%R1]7$A^N:T:`"HIXVDB(1BK@AEPQ&2.0#CMZ^U
M2T4`-1BT:LR[20"5]*=4$7[JXDBZ*^9$Y_[Z'YX/_`O:IZ`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KGI`/\`A8EL<C/]DR\=
M_P#6QUT-<[+(!\1[6+S""VD3-LQUQ-%S^&?UH`LZ><^*M:&.D=L/T>MFL73P
M1XJUHD$9CMB/?AZVJ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`*49`UNY!(R;:+`W<G#29X_$?G5VLVY5U\0Z?+\
MWE&">$X'&\F-A^B/6E0`4444`13CY`X&6C.X?+D^^!ZXR/QJ16#*&4@J1D$'
M@TM0P#RVDAR#M.Y1G)"GI].<@#T`H`FHHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`*YB:1A\4;&,8V-HMPQYYR)H<?S-=/7,3_P#)
M4K'E?^0+<<9.?]?#VZ?Y%`%[3\?\)5K6.OEVV?R>MFL:P!_X2G6<[N8K?&1[
M/TK9H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`H:BRQS:?,^`B70!)4G!9&1?IEF`S[U?K+\0_)H5S<9`^R[;H[F
M(!\IA)@GWVXK4H`****`"JFHF6*QN+FV2`W<4#F%IA\H.,X)X(!(&>>WM5NH
MIX([A`DJEE#*^`Q'(.1TZ\CI0!S9\6J;/2;^)DFM;Y'N"BQ$2+`D)9FQNX(?
M8"O)&[&,YQ=F\2V[P7@L\M/'!<2VY896?R2%D*@')"NRJ<XSGC(YJPWAW27#
M!K)/F,I^\W'FR+))CGC<ZJQQW&:?%H>FPK<+';;5N`ZR#>V,.2SA>?ER22=N
M,F@!B:A<,^FPA8VEN(6GD8+@!5VY`4MG)+@=3BLF?Q@!!#<1VS1QND^X2+N,
M<L4HCV2%21&"=PWD[1M.3QSMMI,&_3VA9X38_+%L.<IMVE&SG((`/KE0<^L:
M^'M*6-4%K\JH\9_>-\ZN2S*_/S@DDX;/4T`4G\76")=2L"((1.%D9PH=H9!%
M(IW8V_.P`)X/7.*N6NJ2SW-B'B1([NV>0!6#[74KQN4D,"&)&!_#[X#+C08I
M-0EU"&9K>[?8%DC11@*ZNP/&6W[%5LG[H`&.M3V6DQ6<L<BNS,BR@#&`#))Y
MCX]L@8'8"@#0HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*Y:<'_A:M@=
MF1_8ES\W/'[^#C\?Z5U-<I<?\E9T[_L!W7_H^WH`T=/Q_P`)5K>/^>=MG\GK
M:K%T_P#Y&K6N<_N[;\.'K:H`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`CG@CN;>6WF7=%*A1USC((P1Q7('XDZ#8
MZD=*U":Z2Y@G2SFN?LDA@\\@?+O`P,DCKCKZ5V=>%:]X"\57'B36[BPTJ]<7
M&K1WMKOU"$6#A2AS/!NW/T;L#TH`]+G^(GARVU9M/DNIAMN_L+W0MG-NEQC/
ME&7&P-ZC/'?O5M?&6BM8P7BSR&"?4?[,C;RFYGWE,8]-P/->?W/A[QG:1QZ/
MIMI=1K'K$UT+R&>`6]Q!),'+2ACYF]02-H'.<Y.!4<'PWUF./3+TMJ(NH?$P
MO9;(WX-L+?[07\SR]VW=MP>/FY/%`'L=07MY#I]A<WMPQ6"WB:60@=%4$G]!
M7C?C71KS7OBAK%G8::UW>_V3:_9KCSE06<GG$B4AB,@#=R`6[`?,:GU+PAXA
MDO-7VZ(9+R1]3EDU3[0I6[MYH)%A@"EM_#,@VD;4V9!.Z@#U^VGCNK6&XB),
M<J!T)&,@C(JAI'B'3-<N-1@T^X\V33KEK6Y7:1LD7J.>OIGV->8Z?9:C:?$&
M;2[.&&Y73K!=:-IYBY6^:V%NL9Y`R0"W)Q\V<CO=^'?@;Q)X,\0V\UX]O<VE
M]IQ2^>%L,ER)#(&DW,3(3YDB[AZ=!W`/5:***`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`*Y6?'_"U]/X.?[#NN__`$W@KJJY:X7_`(NMI[9'
M&B70QGG_`%\%`%N>QUJ#6KR]TYK!X[F.-=MRS@J4#?W1TYI0WBOY=T.BCCY@
M)93@^WR].M%%``&\6?+F+13_`'L2R_F/E_3WZ\<F?%?=-%^[_>EZ^O3I[444
M`&?%F?NZ+U_O2]/R^E`/BSC*Z+[_`#2_X?2BB@`!\6<971??YI?\/I29\6X^
M[HF<?WI>OY444`+GQ9AOET7G[OS2\?7CFC/BS/W=%QG^]+T_*BB@`!\6<971
M3QSAI?\`"C/BS;]W1<^NZ7_#Z444`&?%G/RZ+[?-+Z?3UI,^+?E^71/?YI>?
MTHHH``?%O&5T0\\X:7I^5+GQ9M^[HN?7=+_A]:**`#/BO=]S1L>F^7U^GI03
MXK[)HH^K2^_M]***`%SXIW?ZO1MN.F^7.?RI0WBG)S'H_M^\E_PHHH`"WBG(
MQ'H_O^\E_P`*3/BK/W-&]_GE_P`***`$SXKX^31NV?GEY_2DSXMQ]W1,X_O2
M]?RHHH``?%O&5T3KSS+T_*D/_"78X&B9[Y,M%%`"Y\6Y^[HF,?WI>OY4`^+>
MZZ(>>S2]/RHHH`,^+<?=T3//\4OX=J4'Q9W713]&E_P^M%%`$(M_$RW+7*V^
M@"X9`CR@2;F`/3.,XZ\5-GQ9Q\NB].?FE_PHHH`B2W\2Q3S3QVV@I+,<R.OF
M!GP,+N..<#CG]*ESXKP/DT7/?YI?3Z>M%%`"9\69^[HN,_WI>GY49\69^[HN
M,_WI>GY444`!/BW'"Z)V[R_CVI2?%G.U=%'IEI3Z^WT_ST**``GQ7N.$T7'8
M;I?\*,^+./ET7W^:7T^GK110``^*^,IHIYYPTOI]/7_/>D!\68&5T4GOAI?\
M***`%!\5Y&4T4COAI>?THSXLP/ET7J,_-+T[]J**`#/BO'W-%ZG^*7I^5(3X
MMVG"Z)NP,'=+@'OVHHH`4GQ9DX710.V6E_PI2?%63A-&QCCYY>OY444`)GQ7
MW31?N_WI>OKTZ>U&?%?=-%^[_>EZ^O3I[444``/BO(RFBD=\-+Z?3UI,^+=O
M"Z)GUS+_`(?2BB@`)\6]AH@^IE_SZ5#9Z1K$GBZ'6M3DL52&QFM$CMBY)WR1
--D[N./+_`%HHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>11
<FILENAME>sgmo-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Instance Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-04-28T18:51:15.9825191+00:00 -->
<!-- Version            : 2.0.4.0 -->
<!-- Package ID         : EFBAF9CDBCE805F8860901001F3B60C6-0001001233-001503 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:sgmo="http://www.sangamo.com/20150331" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="sgmo-20150331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_sgmoProgram">
    <measure>sgmo:Program</measure>
  </unit>
  <unit id="U_sgmoProduct">
    <measure>sgmo:Product</measure>
  </unit>
  <unit id="U_sgmoTargets">
    <measure>sgmo:Targets</measure>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <context id="C_0001001233_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20140424">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2014-04-24</instant>
    </period>
  </context>
  <context id="C_0001001233_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ShireAgMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommercialPaperMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommercialPaperMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommercialPaperMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommercialPaperMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_sgmoContingentConsiderationLiabilityMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ContingentConsiderationLiabilityMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_sgmoContingentConsiderationLiabilityMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ContingentConsiderationLiabilityMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel3Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel3Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CashEquivalentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CashEquivalentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommercialPaperMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:InvestmentTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommercialPaperMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AvailableforsaleSecuritiesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:StockOptionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:StockOptionMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20140101_20140131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-01-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoBetaThalassemiaMember_20140131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BetaThalassemiaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-01-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoSickleCellDiseaseMember_20140131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SickleCellDiseaseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-01-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoBetaThalassemiaMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BetaThalassemiaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoBetaThalassemiaMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BetaThalassemiaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoOtherProjectsMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:OtherProjectsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoOtherProjectsMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BiogenIncMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:OtherProjectsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ShireAgMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120601_20120630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ShireAgMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-06-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_us-gaapRangeAxis_us-gaapMaximumMember_20120131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ShireAgMember</explicitMember>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ShireAgMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ShireAgMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:ShireAgMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20070701_20070731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-07-01</startDate>
      <endDate>2007-07-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091001_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoUpfrontLicenseFeesMember_20091001_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:UpfrontLicenseFeesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:SigmaAldrichCorporationMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:DowAgroSciencesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:DowAgroSciencesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-10-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:DowAgroSciencesMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:DowAgroSciencesMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:DowAgroSciencesMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:CounterpartyNameAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:DowAgroSciencesMember</explicitMember>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20091001_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicenseAgreementTermsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140501_20140531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20130501_20130531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
        <explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BetaThalassemiaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
        <explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BetaThalassemiaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</explicitMember>
        <explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:BetaThalassemiaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">sgmo:CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001001233_20150101_20150331">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001001233_20150101_20150331">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001001233_20150101_20150331">2015-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001001233_20150101_20150331">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001001233_20150101_20150331">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001001233_20150101_20150331">SGMO</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001001233_20150101_20150331">SANGAMO BIOSCIENCES INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001001233_20150101_20150331">0001001233</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001001233_20150101_20150331">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0001001233_20150101_20150331">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000010" contextRef="C_0001001233_20140424" decimals="INF" unitRef="U_shares">69582797</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">25256000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000012" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">6030000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000013" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">170647000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000014" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">172932000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:InterestReceivableCurrent id="F_000015" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">398000</us-gaap:InterestReceivableCurrent>
  <us-gaap:InterestReceivableCurrent id="F_000016" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">423000</us-gaap:InterestReceivableCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000017" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">6638000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000018" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">10368000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000019" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">587000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000020" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">623000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="F_000021" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">320000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="F_000022" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">320000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsCurrent id="F_000023" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">100000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000024" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">183000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000025" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">203946000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000026" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">190879000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="F_000027" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">29822000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="F_000028" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">47260000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000029" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">2995000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000030" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">1479000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000031" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">1870000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:Goodwill id="F_000032" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">1585000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="F_000033" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">1585000</us-gaap:Goodwill>
  <us-gaap:OtherAssetsNoncurrent id="F_000034" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">157000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000035" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000036" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">238505000</us-gaap:Assets>
  <us-gaap:Assets id="F_000037" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">243212000</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000038" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">6806000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000039" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">8704000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000040" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">1703000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000041" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">2853000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <sgmo:EscrowLiability id="F_000042" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">275000</sgmo:EscrowLiability>
  <sgmo:EscrowLiability id="F_000043" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">275000</sgmo:EscrowLiability>
  <us-gaap:DeferredRevenueCurrent id="F_000044" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">11184000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000045" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">9050000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000046" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">19968000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000047" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">20882000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000048" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">11049000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000049" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">13149000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent id="F_000050" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent id="F_000051" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">748000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000052" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">31017000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000053" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">36579000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000054" xsi:nil="true" contextRef="C_0001001233_20150331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000055" xsi:nil="true" contextRef="C_0001001233_20141231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000056" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">695000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000057" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">690000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000058" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">540637000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000059" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">534518000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000060" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">-333869000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000061" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">-328550000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000062" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000063" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">-25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="F_000064" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">207488000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000065" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">206633000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000066" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">238505000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000067" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">243212000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000068" contextRef="C_0001001233_20150331" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000069" contextRef="C_0001001233_20141231" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000070" contextRef="C_0001001233_20150331" decimals="INF" unitRef="U_shares">160000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000071" contextRef="C_0001001233_20141231" decimals="INF" unitRef="U_shares">160000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000072" contextRef="C_0001001233_20150331" decimals="INF" unitRef="U_shares">69497256</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000073" contextRef="C_0001001233_20141231" decimals="INF" unitRef="U_shares">69062394</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000074" contextRef="C_0001001233_20150331" decimals="INF" unitRef="U_shares">69497256</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000075" contextRef="C_0001001233_20141231" decimals="INF" unitRef="U_shares">69062394</us-gaap:CommonStockSharesOutstanding>
  <sgmo:CollaborationAgreements id="F_000076" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">12671000</sgmo:CollaborationAgreements>
  <sgmo:CollaborationAgreements id="F_000077" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">7568000</sgmo:CollaborationAgreements>
  <us-gaap:RevenueFromGrants id="F_000078" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">820000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants id="F_000079" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">548000</us-gaap:RevenueFromGrants>
  <us-gaap:Revenues id="F_000080" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">13491000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000081" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">8116000</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000082" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">14980000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000083" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">12083000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000084" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">4732000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000085" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">3644000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000086" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">19712000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000087" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">15727000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000088" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-6221000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000089" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-7611000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestAndOtherIncome id="F_000090" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">154000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome id="F_000091" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">39000</us-gaap:InterestAndOtherIncome>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000092" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-6067000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000093" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-7572000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000094" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-748000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000095" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-5319000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000096" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-7572000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000097" contextRef="C_0001001233_20150101_20150331" decimals="2" unitRef="U_iso4217USD_shares">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000098" contextRef="C_0001001233_20140101_20140331" decimals="2" unitRef="U_iso4217USD_shares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000099" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_shares">69283000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000100" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_shares">63199000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000101" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000102" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000103" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-5269000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000104" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-7563000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000105" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">147000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000106" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">123000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000107" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-241000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000108" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-295000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:ShareBasedCompensation id="F_000109" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">2953000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000110" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">1907000</us-gaap:ShareBasedCompensation>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 id="F_000111" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 id="F_000112" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">50000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill id="F_000113" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1870000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000114" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-748000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet id="F_000115" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-25000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet id="F_000116" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">45000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000117" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-3730000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000118" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">2205000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000119" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-101000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000120" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">71000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000121" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-2477000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000122" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">1732000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000123" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-1150000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000124" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-1723000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000125" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000126" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">18888000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000127" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-2393000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000128" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">11379000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000129" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">39423000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000130" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">16773000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000131" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">58955000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000132" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">20786000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000133" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1084000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000134" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">126000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000135" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">18448000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000136" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">3887000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <sgmo:NetProceedsFromIssuancePublicOffering id="F_000137" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">93786000</sgmo:NetProceedsFromIssuancePublicOffering>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000138" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000139" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">3178000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000140" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">7585000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000141" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">3171000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000142" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">101371000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000143" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">19226000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000144" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">116637000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000145" contextRef="C_0001001233_20131231" decimals="-3" unitRef="U_iso4217USD">10186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000146" contextRef="C_0001001233_20140331" decimals="-3" unitRef="U_iso4217USD">126823000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000147" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">579000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="F_000148" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 1&amp;#8212;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (&amp;#8220;Sangamo&amp;#8221; or the &amp;#8220;Company&amp;#8221;) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December&amp;#160;31, 2015. The condensed consolidated balance sheet data at December&amp;#160;31, 2014 were derived from the audited consolidated financial statements included in Sangamo&amp;#8217;s Form 10-K for the year ended December&amp;#160;31, 2014, as filed with the SEC. These financial statements should be read in conjunction with the financial statements and footnotes thereto for the year ended December&amp;#160;31, 2014, included in Sangamo&amp;#8217;s Form 10-K, as filed with the SEC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&amp;#8217;s product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements prior to the adoption of ASU No.&amp;#160;2009-13, Revenue Recognition&amp;#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)&lt;font style="font-style:normal;"&gt;. For revenue arrangements entered into before January&amp;#160;1, 2011, that include multiple deliverables, the elements of such agreements were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements after the adoption of ASU 2009-13.&lt;font style="font-style:normal;"&gt; ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: &lt;/font&gt;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (VSOE), if available; third-party evidence (TPE), if available and VSOE is not available; or the best estimate of selling price (ESP), if neither VSOE nor TPE is available; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&amp;#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG (Shire), in January 2012 and Biogen Inc., formerly Biogen Idec Inc. (Biogen) in January 2014 were evaluated under these amended accounting standards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company&amp;#8217;s performance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo&amp;#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred to the extent such amounts have been agreed to with the respective collaboration partner. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2014 the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-15, &lt;font style="font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt; (ASU 2014-15). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting ASU 2014-15 on its consolidated financial statements will be material.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014 the Financial Accounting Standards Board issued ASU 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with&amp;#160;Customers&lt;/font&gt;&amp;#160;(ASU 2014-09). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&amp;#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&amp;#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. &lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000149" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 2&amp;#8212;FAIR VALUE MEASUREMENT &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for sale-securities and the contingent consideration liability.&amp;#160;The fair value of these assets and contingent liability was determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value measurements of our cash equivalents, available-for-sale marketable securities and contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,266&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,266&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,558&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,374&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generally classifies its debt instruments as Level 2. Instruments can be classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingent Consideration Liability &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2013, the Company acquired Ceregene and recorded a liability for the estimated fair value of contingent consideration payments to former Ceregene stockholders, as outlined under the terms of the merger agreement with Ceregene. These contingent payments are owed if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. The fair value of this liability is estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. &lt;font style="letter-spacing:-0.1pt;"&gt;The Company has classified this liability as Level 3.&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subsequent changes in the fair value of this contingent consideration liability are recorded to the research and development (R&amp;amp;D) expense line item in the Condensed Consolidated Statements of Operations as operating expenses. During the three months ended March 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of the in-process research and development (IPR&amp;amp;D) assets acquired from Ceregene (see Note 6). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value as of December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value as of March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="F_000150" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 3&amp;#8212;MARKETABLE SECURITIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Sangamo generally classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value, with the unrealized holding gains and losses included in accumulated other comprehensive income. Investments that have maturities beyond one year as of the end of the reporting period are classified as non-current. The Company&amp;#8217;s investments are subject to a periodic impairment review, and the Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&amp;#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&amp;#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below summarizes the Company&amp;#8217;s investments (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,266&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,558&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,831&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,374&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had no other-than-temporary impairments of its investments for the three months ended March 31, 2015 or the twelve months ended December&amp;#160;31, 2014. &lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000151" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 4&amp;#8212;BASIC AND DILUTED NET LOSS PER SHARE &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of stock options, which are anti-dilutive. The total number of shares subject to stock options outstanding excluded from consideration in the calculation of diluted net loss per share for the three months ended March 31, 2015 and 2014 were 7,624,600 and 7,302,366, respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000152" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 5&amp;#8212;MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Collaboration and License Agreement with Biogen Inc. in Human Therapeutics &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2014 Sangamo entered into a Global Research, Development and Commercialization Collaboration and License Agreement (the &amp;#8220;Biogen Agreement&amp;#8221;) with Biogen, pursuant to which Sangamo and Biogen collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&amp;#8217;s zinc finger DNA-binding protein (ZFP) technology for hemoglobinopathies, including beta-thalassemia and sickle cell disease (SCD). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Biogen Agreement, Sangamo and Biogen jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP Therapeutic developed under the Biogen Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (IND) application for ZFP Therapeutics intended to treat SCD. For both programs, Biogen is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Biogen Agreement. At the end of specified research terms for each program or under certain specified circumstances, Biogen retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any&amp;#160;licensed product to treat beta-thalassemia and SCD&amp;#160;developed under the Biogen Agreement, and Biogen agrees to compensate Sangamo for such co-promotion activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo received an upfront license fee of $20.0 million upon entering into the Biogen Agreement. In addition, the Company will also be eligible to receive $126.3 million in payments upon the achievement of specified research, regulatory, clinical development milestones, as well as $167.5 million in payments upon the achievement of specified commercialization and sales milestones. Biogen reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. In addition, Sangamo is eligible to receive contingent payments upon the achievement of specified regulatory, clinical development, commercialization and sales milestones. The total amount of potential regulatory, clinical development, commercialization and sales contingent payments, assuming the achievement of all specified milestone events in the Biogen Agreement, is $293.8 million, including Phase 1 contingent payments of $7.5 million for each of the beta-thalassemia and SCD programs. In addition, if products are commercialized under the Biogen Agreement, Biogen will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Biogen Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All contingent payments under the Biogen Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Biogen Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&amp;#160;that can be achieved based in whole or in part on either the Company&amp;#8217;s performance or on the occurrence of a specific outcome resulting from the Company&amp;#8217;s performance, (ii)&amp;#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&amp;#160;that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Biogen Agreement, assuming all other applicable revenue recognition criteria have been met. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subject to the terms of the Biogen Agreement, Sangamo grants Biogen an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Biogen Agreement. Sangamo also grants Biogen a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, of Sangamo&amp;#8217;s interest in certain other intellectual property developed pursuant to the Biogen Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Biogen apart from the research services to be performed pursuant to the Biogen Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a forty-month estimated initial research term during which the Company will perform research services. As of March 31, 2015, the Company has deferred revenue of $14.1 million related to the Biogen Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized under the agreement with Biogen for the three months ended March 31, 2015 and 2014 are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Biogen Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,056&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,083&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related costs and expenses incurred under the Biogen agreement related to the beta-thalassemia project, which is co-funded with California Institute for Regenerative Medicine (CIRM), were $1.4 million and $1.3 million during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses for other projects including sickle cell disease under the Biogen agreement were $1.1 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Collaboration and License Agreement with Shire International GmbH in Human Therapeutics and Diagnostics &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2012 the Company entered into a collaboration and license agreement (the &amp;#8220;Shire Agreement&amp;#8221;) with Shire, pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&amp;#8217;s novel ZFP technology. Under the Shire Agreement, the Company and Shire may develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets will be used for treating or diagnosing hemophilia. In June 2012, Shire selected a fifth gene target for the development of a ZFP Therapeutic for Huntington&amp;#8217;s disease. Shire has the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo&amp;#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. The initial research term of the Shire Agreement is six years and is subject to extensions upon mutual agreement and under other specified circumstances. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Shire Agreement, the Company is responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimburses Sangamo for agreed upon internal and external program-related research costs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement. In addition, the Company will also be eligible to receive $33.5 million in payments upon the achievement of specified research, regulatory, clinical development milestones, including payments for each gene target through the acceptance of an IND or CTA submission totaling $8.5 million, as well as $180 million in payments upon the achievement of specified commercialization and sales milestones. The Company will also be eligible to receive royalty payments that are a tiered double-digit percentage of net sales of licensed product sold by Shire or its sublicensees developed under the collaboration, if any. To date, no products have been approved and therefore no royalty fees have been earned under the Shire Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All contingent payments under the Shire Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Shire Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&amp;#160;that can be achieved based in whole or in part on either the Company&amp;#8217;s performance or on the occurrence of a specific outcome resulting from the Company&amp;#8217;s performance, (ii)&amp;#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&amp;#160;that would result in additional payments being due to the Company. Accordingly, revenue for the achievement of milestones that are determined to be substantive will be recognized in their entirety in the period the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Shire Agreement, assuming all other applicable revenue recognition criteria have been met. In 2014 Sangamo recognized a $1.0 million milestone payment related to our hemophilia program.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a six-year initial research term during which the Company will perform research services. As of March 31, 2015, the Company has deferred revenue of $6.8 million related to the Shire Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized under the agreement with Shire for the three months ended March 31, 2015 and 2014, were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Shire Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,979&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,064&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related costs and expenses incurred under the Shire agreement were $4.5 million and $4.8 million during the three months ended March 31, 2015 and 2014, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2007 Sangamo entered into a license agreement (the &amp;#8220;Sigma Agreement&amp;#8221;) with Sigma-Aldrich Corporation (Sigma). Under the Sigma Agreement, Sangamo agreed to provide Sigma with access to our proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (DAS). Under the Sigma Agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using Sangamo&amp;#8217;s ZFP technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company&amp;#8217;s ZFP technology in the research field. Sangamo has transferred its ZFP manufacturing technology to Sigma. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2009 Sangamo expanded the Sigma Agreement. In addition to the original terms of the Sigma Agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the Sigma Agreement as expanded in 2009, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock and a $15.1 million upfront license fee. The upfront license fee was recognized on a straight-line basis from the effective date of the expanded license through July 2010, which represents the period over which Sangamo was obligated to perform research services for Sigma. Sangamo is also eligible to receive commercial license fees of $5.0 million based upon a percentage of net sales. As of March 31, 2015 Sangamo has received the entire $5.0 million of commercial license fees and is eligible to receive royalty payments of 10.5% of net sales and sublicensing revenue.  In addition, upon the achievement of certain cumulative commercial milestones Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized under the agreement with Sigma for the three months ended March 31, 2015 and 2014, were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Sigma Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalty revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fee revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related costs and expenses incurred under the Sigma agreement were $0.2 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Agreement with Dow AgroSciences in Plant Agriculture &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2005 Sangamo entered into an exclusive commercial license agreement with DAS (the &amp;#8220;DAS Agreement&amp;#8221;). Under the DAS Agreement, Sangamo provides DAS with access to our proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP transcription factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic, therapeutic or prophylactic purposes. The DAS Agreement provided for an initial three-year research term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company&amp;#8217;s ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&amp;#8217;s ZFP technology to third parties for use in plant cells, plants or plant cell cultures. Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended the DAS Agreement to extend the period of reagent manufacturing services and research services through December&amp;#160;31, 2012. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The DAS Agreement also provides for minimum license fees each year due to Sangamo every October, provided the Agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years. The Company does not have any ongoing performance obligations under the agreement with DAS. DAS has the right to terminate the agreement at any time; accordingly, the Company&amp;#8217;s actual license fees over the term of the DAS Agreement could be lower than $25.3 million. In addition, each party may terminate the DAS Agreement upon an uncured material breach by the other party. In the event of any termination of the DAS Agreement, all rights to use the Company&amp;#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted access to Sangamo&amp;#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&amp;#8217;s ZFP technology. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no revenues or related costs and expenses recognized under the DAS Agreement during the three months ended March 31, 2015 and 2014, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Funding from Research Foundations &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;California Institute for Regenerative Medicine - HIV &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2009 CIRM, a State of California entity, granted a $14.5 million Disease Team Research Award to develop an HIV/AIDS therapy based on the application of ZFN gene editing technology in hematopoietic stem cells (HSCs). The four-year grant supports an innovative research project conducted by a multidisciplinary team of investigators, including investigators from the University of Southern California, City of Hope National Medical Center and Sangamo BioSciences. Sangamo received funds totaling $5.2 million from the total amount awarded based on expenses incurred for research and development efforts by Sangamo as prescribed in the agreement, and subject to its terms and conditions. The award is intended to substantially fund Sangamo&amp;#8217;s research and development efforts related to the agreement. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo resulting from sales of a commercial product resulting from research and development efforts supported by the grant. As of December&amp;#160;31, 2013, all revenues under the award had been recognized and all funds had been received. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no revenues attributable to research and development performed under the CIRM 2009 grant agreement during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM grant agreement were $0.2 million and $0.3 million during the three months ended March 31, 2015 and 2014, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014 CIRM agreed to fund a $5.6 million Strategic Partnership Award to fund clinical studies of a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of its ZFN genome editing technology in hematopoietic stem progenitor cells (HSPCs). The four year grant provides matching funds to support evaluation of the Company&amp;#8217;s stem cell-based ZFP Therapeutic in a clinical trial in HIV-infected individuals conducted at City of Hope. The Company expects funding for this grant to commence in 2015.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no revenues attributable to research and development performed under the Strategic Partnership Award during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM Strategic Partnership Award were $0.3 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;California Institute for Regenerative Medicine - Beta-Thalassemia &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2013 CIRM granted Sangamo a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its ZFN gene editing technology in HSCs. The four-year grant provides matching funds for preclinical work that will support an IND application and a Phase 1 clinical trial in transfusion-dependent beta-thalassemia patients. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo, or its collaborators, from sales of a commercial product resulting from research and development efforts supported by the grant, in accordance with Title 17, California Code of Regulations, Section&amp;#160;100600. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue attributable to research and development performed under the CIRM grant agreement for beta-thalassemia was $0.7 million and $0.4 million during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM grant agreement were $0.7 million and $0.4 million during the three months ended March 31, 2015 and 2014, respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:IntangibleAssetsDisclosureTextBlock id="F_000153" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 6&amp;#8212;INTANGIBLE ASSETS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Intangible assets for IPR&amp;amp;D consist of two clinical product candidates from our 2013 acquisition of Ceregene. IPR&amp;amp;D is an intangible asset classified as indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of these intangibles assets are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;CERE-110 for the treatment of Alzheimer&apos;s disease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,640&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;CERE-120 for the treatment of Parkinson&apos;s disease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March 31, 2015, the Company received clinical data demonstrating no statistically significant difference between the control group and the group treated with CERE-110 for Alzheimer&amp;#8217;s disease. Subsequently, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. Given these results, the Company does not believe the programs have an alternative future use for itself or other market participants. Accordingly, during the three months ended March 31, 2015, the Company recognized a $1.9 million impairment charge related to these assets. The impairment is recorded in R&amp;amp;D expense in the accompanying condensed consolidated statements of operations. &lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000154" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 7&amp;#8212;INCOME TAXES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&amp;#8217;s history of losses. Accordingly, the Company&amp;#8217;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March 31, 2015 the deferred tax liability of $0.7 million that was recorded upon acquiring the IPR&amp;amp;D assets in 2013 was adjusted due to the impairment of these assets. This resulted in the recognition of a $0.7 million income tax benefit. &lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000155" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 8&amp;#8212;STOCK-BASED COMPENSATION &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,073&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,262&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;834&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,907&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000156" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (&amp;#8220;Sangamo&amp;#8221; or the &amp;#8220;Company&amp;#8221;) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December&amp;#160;31, 2015. The condensed consolidated balance sheet data at December&amp;#160;31, 2014 were derived from the audited consolidated financial statements included in Sangamo&amp;#8217;s Form 10-K for the year ended December&amp;#160;31, 2014, as filed with the SEC. These financial statements should be read in conjunction with the financial statements and footnotes thereto for the year ended December&amp;#160;31, 2014, included in Sangamo&amp;#8217;s Form 10-K, as filed with the SEC. &lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000157" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000158" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&amp;#8217;s product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements prior to the adoption of ASU No.&amp;#160;2009-13, Revenue Recognition&amp;#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)&lt;font style="font-style:normal;"&gt;. For revenue arrangements entered into before January&amp;#160;1, 2011, that include multiple deliverables, the elements of such agreements were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements after the adoption of ASU 2009-13.&lt;font style="font-style:normal;"&gt; ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: &lt;/font&gt;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (VSOE), if available; third-party evidence (TPE), if available and VSOE is not available; or the best estimate of selling price (ESP), if neither VSOE nor TPE is available; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Symbol&apos;;font-size:10pt;"&gt;&amp;#183;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:96.67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&amp;#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG (Shire), in January 2012 and Biogen Inc., formerly Biogen Idec Inc. (Biogen) in January 2014 were evaluated under these amended accounting standards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company&amp;#8217;s performance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo&amp;#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred to the extent such amounts have been agreed to with the respective collaboration partner. &lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000159" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In August 2014 the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-15, &lt;font style="font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt; (ASU 2014-15). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting ASU 2014-15 on its consolidated financial statements will be material.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014 the Financial Accounting Standards Board issued ASU 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with&amp;#160;Customers&lt;/font&gt;&amp;#160;(ASU 2014-09). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&amp;#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&amp;#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. &lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock id="F_000160" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The fair value measurements of our cash equivalents, available-for-sale marketable securities and contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,266&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,266&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,558&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,374&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000161" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value as of December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value as of March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock id="F_000162" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The table below summarizes the Company&amp;#8217;s investments (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,266&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,558&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,831&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;220,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,374&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock id="F_000163" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues recognized under the agreement with Biogen for the three months ended March 31, 2015 and 2014 are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Biogen Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,056&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,083&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock id="F_000164" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues recognized under the agreement with Shire for the three months ended March 31, 2015 and 2014, were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Shire Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,979&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,064&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock id="F_000165" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues recognized under the agreement with Sigma for the three months ended March 31, 2015 and 2014, were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Sigma Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalty revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fee revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock id="F_000166" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The carrying values of these intangibles assets are as follows (in thousands): &lt;/p&gt;&lt;/div&gt;&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;CERE-110 for the treatment of Alzheimer&apos;s disease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,640&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;CERE-120 for the treatment of Parkinson&apos;s disease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000167" contextRef="C_0001001233_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,073&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,262&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;834&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,907&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000168" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000169" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000170" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000171" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:MarketableSecurities id="F_000172" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331" decimals="-3" unitRef="U_iso4217USD">31148000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000173" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331" decimals="-3" unitRef="U_iso4217USD">31148000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000174" contextRef="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">23266000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000175" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">23266000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000176" contextRef="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">146055000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000177" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">146055000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000178" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">200469000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000179" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20150331" decimals="-3" unitRef="U_iso4217USD">200469000</us-gaap:MarketableSecurities>
  <us-gaap:AssetsFairValueDisclosure id="F_000180" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">217558000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000181" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000182" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20150331" decimals="-3" unitRef="U_iso4217USD">200469000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000183" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000184" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000185" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000186" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:MarketableSecurities id="F_000187" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231" decimals="-3" unitRef="U_iso4217USD">33748000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000188" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231" decimals="-3" unitRef="U_iso4217USD">33748000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000189" contextRef="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">22813000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000190" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">22813000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000191" contextRef="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">163631000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000192" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">163631000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000193" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">220192000</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000194" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20141231" decimals="-3" unitRef="U_iso4217USD">220192000</us-gaap:MarketableSecurities>
  <us-gaap:AssetsFairValueDisclosure id="F_000195" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">223374000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000196" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000197" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20141231" decimals="-3" unitRef="U_iso4217USD">220192000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000198" contextRef="C_0001001233_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_sgmoContingentConsiderationLiabilityMember_20141231" decimals="-3" unitRef="U_iso4217USD">1800000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000199" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_sgmoContingentConsiderationLiabilityMember_20141231" decimals="-3" unitRef="U_iso4217USD">1800000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000200" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">1800000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000201" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20141231" decimals="-3" unitRef="U_iso4217USD">1800000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000202" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">1800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="F_000203" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-1800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000204" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000205" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000206" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000207" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000208" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000209" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20150331" decimals="-3" unitRef="U_iso4217USD">17089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000210" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20141231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000211" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331" decimals="-3" unitRef="U_iso4217USD">31121000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000212" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">23261000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000213" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">146062000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000214" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">200444000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000215" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">217533000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000216" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231" decimals="-3" unitRef="U_iso4217USD">33715000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000217" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">22831000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000218" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">163671000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000219" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">220217000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="F_000220" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">223399000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000221" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000222" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000223" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000224" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000225" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231" decimals="-3" unitRef="U_iso4217USD">33000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000226" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">33000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000227" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">33000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000228" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000229" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000230" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000231" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000232" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">40000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000233" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">58000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000234" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">58000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecurities id="F_000235" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20150331" decimals="-3" unitRef="U_iso4217USD">31148000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000236" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">23266000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000237" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">146055000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000238" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20150331" decimals="-3" unitRef="U_iso4217USD">200469000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000239" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">217558000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000240" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20141231" decimals="-3" unitRef="U_iso4217USD">33748000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000241" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">22813000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000242" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">163631000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000243" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20141231" decimals="-3" unitRef="U_iso4217USD">220192000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="F_000244" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">223374000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities id="F_000245" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities id="F_000246" contextRef="C_0001001233_20140101_20141231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000247" contextRef="C_0001001233_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20150101_20150331" decimals="INF" unitRef="U_shares">7624600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000248" contextRef="C_0001001233_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20140101_20140331" decimals="INF" unitRef="U_shares">7302366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <sgmo:NumberOfResearchProgram id="F_000249" contextRef="C_0001001233_20140101_20140131" decimals="INF" unitRef="U_sgmoProgram">2</sgmo:NumberOfResearchProgram>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000250" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140131" decimals="-5" unitRef="U_iso4217USD">20000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved id="F_000251" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140131" decimals="-5" unitRef="U_iso4217USD">126300000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive id="F_000252" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140131" decimals="-5" unitRef="U_iso4217USD">167500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
  <sgmo:MilestoneRevenueReceivable id="F_000253" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140131" decimals="-5" unitRef="U_iso4217USD">293800000</sgmo:MilestoneRevenueReceivable>
  <sgmo:MilestoneRevenueReceivable id="F_000254" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoBetaThalassemiaMember_20140131" decimals="-5" unitRef="U_iso4217USD">7500000</sgmo:MilestoneRevenueReceivable>
  <sgmo:MilestoneRevenueReceivable id="F_000255" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoSickleCellDiseaseMember_20140131" decimals="-5" unitRef="U_iso4217USD">7500000</sgmo:MilestoneRevenueReceivable>
  <sgmo:MilestonePaymentsReceived id="F_000256" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</sgmo:MilestonePaymentsReceived>
  <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement id="F_000257" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331" decimals="INF" unitRef="U_sgmoProduct">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
  <us-gaap:RoyaltyRevenue id="F_000258" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RoyaltyRevenue>
  <sgmo:InitialResearchTermOfAgreement id="F_000259" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331">P40M</sgmo:InitialResearchTermOfAgreement>
  <us-gaap:DeferredRevenue id="F_000260" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150331" decimals="-5" unitRef="U_iso4217USD">14100000</us-gaap:DeferredRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000261" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1523000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000262" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">660000</us-gaap:LicenseAndServicesRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000263" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1533000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000264" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">423000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <us-gaap:ContractsRevenue id="F_000265" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">3056000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000266" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">1083000</us-gaap:ContractsRevenue>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000267" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoBetaThalassemiaMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">1400000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000268" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoBetaThalassemiaMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">1300000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000269" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoOtherProjectsMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000270" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoOtherProjectsMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
  <sgmo:AggregateNumberOfGeneTargets id="F_000271" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="INF" unitRef="U_sgmoTargets">7</sgmo:AggregateNumberOfGeneTargets>
  <sgmo:NumberOfInitialGeneTargets id="F_000272" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="INF" unitRef="U_sgmoTargets">4</sgmo:NumberOfInitialGeneTargets>
  <sgmo:NumberOfGeneTargets id="F_000273" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120601_20120630" decimals="INF" unitRef="U_sgmoTargets">5</sgmo:NumberOfGeneTargets>
  <sgmo:NumberOfAdditionalGeneTargets id="F_000274" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120601_20120630" decimals="INF" unitRef="U_sgmoTargets">2</sgmo:NumberOfAdditionalGeneTargets>
  <sgmo:InitialResearchTermOfAgreement id="F_000275" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331">P6Y</sgmo:InitialResearchTermOfAgreement>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000276" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="-5" unitRef="U_iso4217USD">13000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <sgmo:MilestoneRevenueReceivable id="F_000277" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_us-gaapRangeAxis_us-gaapMaximumMember_20120131" decimals="-5" unitRef="U_iso4217USD">33500000</sgmo:MilestoneRevenueReceivable>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication id="F_000278" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="-5" unitRef="U_iso4217USD">8500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive id="F_000279" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="-6" unitRef="U_iso4217USD">180000000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
  <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement id="F_000280" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331" decimals="INF" unitRef="U_sgmoProduct">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
  <us-gaap:RoyaltyRevenue id="F_000281" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RoyaltyRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000282" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20141231" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:DeferredRevenue id="F_000283" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150331" decimals="-5" unitRef="U_iso4217USD">6800000</us-gaap:DeferredRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000284" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">542000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000285" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">542000</us-gaap:LicenseAndServicesRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000286" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">4522000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000287" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">4979000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <us-gaap:ContractsRevenue id="F_000288" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">5064000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000289" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">5521000</us-gaap:ContractsRevenue>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000290" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">4500000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000291" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">4800000</us-gaap:ResearchAndDevelopmentExpense>
  <sgmo:InitialResearchTermOfAgreement id="F_000292" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20070701_20070731">P3Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:UpfrontLicenseFee id="F_000293" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091001_20091031" decimals="-5" unitRef="U_iso4217USD">20000000</sgmo:UpfrontLicenseFee>
  <sgmo:UpfrontLicenseFee id="F_000294" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoUpfrontLicenseFeesMember_20091001_20091031" decimals="-5" unitRef="U_iso4217USD">15100000</sgmo:UpfrontLicenseFee>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000295" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoUpfrontLicenseFeesMember_20091001_20091031" decimals="-5" unitRef="U_iso4217USD">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000296" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091001_20091031" decimals="INF" unitRef="U_shares">636133</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <sgmo:RoyaltyRevenuesExpectedToBeReceived id="F_000297" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20091031" decimals="-5" unitRef="U_iso4217USD">5000000</sgmo:RoyaltyRevenuesExpectedToBeReceived>
  <us-gaap:LicenseAndServicesRevenue id="F_000298" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:LicenseAndServicesRevenue>
  <sgmo:ReducedRoyaltyRate id="F_000299" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331" decimals="3" unitRef="U_pure">0.105</sgmo:ReducedRoyaltyRate>
  <sgmo:AdditionalMilestoneReceivableUnderAgreement id="F_000300" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150331" decimals="-5" unitRef="U_iso4217USD">25000000</sgmo:AdditionalMilestoneReceivableUnderAgreement>
  <sgmo:MilestonePaymentsReceived id="F_000301" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</sgmo:MilestonePaymentsReceived>
  <us-gaap:RoyaltyRevenue id="F_000302" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">264000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue id="F_000303" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:RoyaltyRevenue>
  <us-gaap:LicensesRevenue id="F_000304" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">4256000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="F_000305" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">179000</us-gaap:LicensesRevenue>
  <us-gaap:ContractsRevenue id="F_000306" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">4520000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000307" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">285000</us-gaap:ContractsRevenue>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000308" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000309" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
  <sgmo:InitialResearchTermOfAgreement id="F_000310" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031">P3Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:OneTimeLicenseFeeEarned id="F_000311" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051031" decimals="-5" unitRef="U_iso4217USD">6000000</sgmo:OneTimeLicenseFeeEarned>
  <us-gaap:RoyaltyRevenue id="F_000312" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:RoyaltyRevenue>
  <sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing id="F_000313" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031" decimals="2" unitRef="U_pure">0.25</sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing>
  <sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement id="F_000314" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031" decimals="-5" unitRef="U_iso4217USD">4000000</sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement>
  <sgmo:AnnualFeesRelatedToAgreement id="F_000315" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031" decimals="INF" unitRef="U_iso4217USD">250000</sgmo:AnnualFeesRelatedToAgreement>
  <sgmo:AnnualFeesRelatedToAgreement id="F_000316" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031" decimals="INF" unitRef="U_iso4217USD">3000000</sgmo:AnnualFeesRelatedToAgreement>
  <sgmo:FeeDue id="F_000317" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031" decimals="-5" unitRef="U_iso4217USD">25300000</sgmo:FeeDue>
  <sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod id="F_000318" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051001_20051031">P11Y</sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000319" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000320" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331" decimals="-6" unitRef="U_iso4217USD">0</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:LicensesRevenue id="F_000321" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="F_000322" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:LicensesRevenue>
  <sgmo:GrantFundingAmount id="F_000323" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20091001_20091031" decimals="-5" unitRef="U_iso4217USD">14500000</sgmo:GrantFundingAmount>
  <sgmo:ExpectedRevenueToBeReceivedForResearchAndDevelopment id="F_000324" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20091031" decimals="-5" unitRef="U_iso4217USD">5200000</sgmo:ExpectedRevenueToBeReceivedForResearchAndDevelopment>
  <sgmo:TermsOfContract id="F_000325" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20091001_20091031">P4Y</sgmo:TermsOfContract>
  <sgmo:AgreementDate id="F_000326" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20150101_20150331">2009-10-31</sgmo:AgreementDate>
  <us-gaap:RevenueFromGrants id="F_000327" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants id="F_000328" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RevenueFromGrants>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000329" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">200000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000330" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">300000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:GrantFundingAmount id="F_000331" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140501_20140531" decimals="-5" unitRef="U_iso4217USD">5600000</sgmo:GrantFundingAmount>
  <sgmo:TermsOfContract id="F_000332" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140501_20140531">P4Y</sgmo:TermsOfContract>
  <us-gaap:RevenueFromGrants id="F_000333" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20150101_20150331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants id="F_000334" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140101_20140331" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RevenueFromGrants>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000335" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">300000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000336" contextRef="C_0001001233_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">0</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:GrantFundingAmount id="F_000337" contextRef="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20130501_20130531" decimals="-5" unitRef="U_iso4217USD">6400000</sgmo:GrantFundingAmount>
  <sgmo:TermsOfContract id="F_000338" contextRef="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20130501_20130531">P4Y</sgmo:TermsOfContract>
  <us-gaap:RevenueFromGrants id="F_000339" contextRef="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants id="F_000340" contextRef="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:RevenueFromGrants>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000341" contextRef="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20150101_20150331" decimals="-5" unitRef="U_iso4217USD">700000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses id="F_000342" contextRef="C_0001001233_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_sgmoBetaThalassemiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCaliforniaInstituteForRegenerativeMedicineMember_20140101_20140331" decimals="-5" unitRef="U_iso4217USD">400000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000343" contextRef="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_20150331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000344" contextRef="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_20141231" decimals="-3" unitRef="U_iso4217USD">1640000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000345" contextRef="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_20150331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000346" contextRef="C_0001001233_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_sgmoCereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_20141231" decimals="-3" unitRef="U_iso4217USD">230000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000347" contextRef="C_0001001233_20150331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000348" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1691000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000349" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">1073000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000350" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1262000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000351" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">834000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000352" contextRef="C_0001001233_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">2953000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000353" contextRef="C_0001001233_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">1907000</us-gaap:AllocatedShareBasedCompensationExpense>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>sgmo-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Schema Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-04-28T18:51:15.9825191+00:00 -->
<!-- Version            : 2.0.4.0 -->
<!-- Package ID         : EFBAF9CDBCE805F8860901001F3B60C6-0001001233-001503 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:sgmo="http://www.sangamo.com/20150331" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20150331" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" namespace="http://fasb.org/us-types/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" namespace="http://fasb.org/us-gaap/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" namespace="http://xbrl.sec.gov/country/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.sangamo.com/20150331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" id="Role_StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="Role_StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurement" id="Role_DisclosureFairValueMeasurement">
        <link:definition>100070 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100080 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShare" id="Role_DisclosureBasicAndDilutedNetLossPerShare">
        <link:definition>100090 - Disclosure - Basic and Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliances">
        <link:definition>100100 - Disclosure - Major Customers, Partnerships and Strategic Alliances</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssets" id="Role_DisclosureIntangibleAssets">
        <link:definition>100110 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100120 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100130 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100140 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementTables" id="Role_DisclosureFairValueMeasurementTables">
        <link:definition>100150 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100160 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables">
        <link:definition>100170 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsTables" id="Role_DisclosureIntangibleAssetsTables">
        <link:definition>100180 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100190 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" id="Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
        <link:definition>100200 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementAdditionalInformationDetail">
        <link:definition>100210 - Disclosure - Fair Value Measurement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementScheduleOfChangesInEstimatedFairValueOfContingentConsiderationLiabilityDetail" id="Role_DisclosureFairValueMeasurementScheduleOfChangesInEstimatedFairValueOfContingentConsiderationLiabilityDetail">
        <link:definition>100220 - Disclosure - Fair Value Measurement - Schedule of Changes in Estimated Fair Value of Contingent Consideration Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail" id="Role_DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail">
        <link:definition>100230 - Disclosure - Marketable Securities - Schedule of Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail" id="Role_DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail">
        <link:definition>100250 - Disclosure - Basic and Diluted Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail">
        <link:definition>100260 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
        <link:definition>100270 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail" id="Role_DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail">
        <link:definition>100310 - Disclosure - Intangible Assets - Carrying Value of Intangibles Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>100340 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="sgmo_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_EscrowLiability" name="EscrowLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_CollaborationAgreements" name="CollaborationAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_NetProceedsFromIssuancePublicOffering" name="NetProceedsFromIssuancePublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_BiogenIncMember" name="BiogenIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ShireAgMember" name="ShireAgMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_SigmaAldrichCorporationMember" name="SigmaAldrichCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ContingentConsiderationLiabilityMember" name="ContingentConsiderationLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_NumberOfResearchProgram" name="NumberOfResearchProgram" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_BetaThalassemiaMember" name="BetaThalassemiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_SickleCellDiseaseMember" name="SickleCellDiseaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_OtherProjectsMember" name="OtherProjectsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_MilestoneRevenueReceivable" name="MilestoneRevenueReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_MilestonePaymentsReceived" name="MilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_InitialResearchTermOfAgreement" name="InitialResearchTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" name="ResearchServiceRevenueUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_AggregateNumberOfGeneTargets" name="AggregateNumberOfGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfInitialGeneTargets" name="NumberOfInitialGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfGeneTargets" name="NumberOfGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfAdditionalGeneTargets" name="NumberOfAdditionalGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_UpfrontLicenseFeesMember" name="UpfrontLicenseFeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_UpfrontLicenseFee" name="UpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_RoyaltyRevenuesExpectedToBeReceived" name="RoyaltyRevenuesExpectedToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_ReducedRoyaltyRate" name="ReducedRoyaltyRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_AdditionalMilestoneReceivableUnderAgreement" name="AdditionalMilestoneReceivableUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_OneTimeLicenseFeeEarned" name="OneTimeLicenseFeeEarned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" name="PercentageOfRoyaltiesToBeReceivedFromSublicensing" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" name="MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_DowAgroSciencesMember" name="DowAgroSciencesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_AnnualFeesRelatedToAgreement" name="AnnualFeesRelatedToAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_FeeDue" name="FeeDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" name="MinimumSublicenseAnnualFeesSpecificReckoningPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_CollaborationAgreementRelatedCostsAndExpenses" name="CollaborationAgreementRelatedCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_GrantFundingAmount" name="GrantFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" name="ExpectedRevenueToBeReceivedForResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_TermsOfContract" name="TermsOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_AgreementDate" name="AgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" name="CaliforniaInstituteForRegenerativeMedicineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_IntangibleAssetAbstract" name="IntangibleAssetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" name="CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" name="CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>sgmo-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-04-28T18:51:15.9825191+00:00 -->
<!-- Version            : 2.0.4.0 -->
<!-- Package ID         : EFBAF9CDBCE805F8860901001F3B60C6-0001001233-001503 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20150331.xsd#TemplateLink" roleURI="http://www.sangamo.com/20150331/role/TemplateLink" />
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_EscrowLiability" xlink:type="locator" xlink:label="sgmo_EscrowLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sgmo_EscrowLiability" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10270.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreements" xlink:type="locator" xlink:label="sgmo_CollaborationAgreements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndOtherIncome" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="sgmo_CollaborationAgreements" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromGrants" order="10100.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10220.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_MarketableSecurities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11550.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11560.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecurities" order="11570.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>sgmo-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-04-28T18:51:15.9825191+00:00 -->
<!-- Version            : 2.0.4.0 -->
<!-- Package ID         : EFBAF9CDBCE805F8860901001F3B60C6-0001001233-001503 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="sgmo-20150331.xsd#TemplateLink" roleURI="http://www.sangamo.com/20150331/role/TemplateLink" />
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="10210.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ContingentConsiderationLiabilityMember" xlink:type="locator" xlink:label="sgmo_ContingentConsiderationLiabilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="sgmo_ContingentConsiderationLiabilityMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="12310.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10880.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="11620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="12020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="12360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="12700.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10110.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfAdditionalGeneTargets" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfGeneTargets" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfInitialGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfInitialGeneTargets" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_AggregateNumberOfGeneTargets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfResearchProgram" xlink:type="locator" xlink:label="sgmo_NumberOfResearchProgram" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_OtherProjectsMember" xlink:type="locator" xlink:label="sgmo_OtherProjectsMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SickleCellDiseaseMember" xlink:type="locator" xlink:label="sgmo_SickleCellDiseaseMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BetaThalassemiaMember" xlink:type="locator" xlink:label="sgmo_BetaThalassemiaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_BetaThalassemiaMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_SickleCellDiseaseMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_OtherProjectsMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfResearchProgram" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="11120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" order="11180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" order="11240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestoneRevenueReceivable" order="11300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentsReceived" order="11480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="11540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="11600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenue" order="11750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11840.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="12030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="12090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="12150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="12210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" order="12480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="12750.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" xlink:label="us-gaap_ContractsRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:type="locator" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicensesRevenue" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="10710.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:type="locator" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ReducedRoyaltyRate" xlink:type="locator" xlink:label="sgmo_ReducedRoyaltyRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:type="locator" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_UpfrontLicenseFee" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFee" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_UpfrontLicenseFeesMember" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFeesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="10920.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="11020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestoneReceivableUnderAgreement" order="11120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentsReceived" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11350.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:type="locator" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="locator" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_FeeDue" xlink:type="locator" xlink:label="sgmo_FeeDue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:type="locator" xlink:label="sgmo_AnnualFeesRelatedToAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="locator" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="locator" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:type="locator" xlink:label="sgmo_OneTimeLicenseFeeEarned" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="10860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="11040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="11210.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail">
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:type="locator" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AgreementDate" xlink:type="locator" xlink:label="sgmo_AgreementDate" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_TermsOfContract" xlink:type="locator" xlink:label="sgmo_TermsOfContract" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" xlink:type="locator" xlink:label="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_GrantFundingAmount" xlink:type="locator" xlink:label="sgmo_GrantFundingAmount" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BetaThalassemiaMember" xlink:type="locator" xlink:label="sgmo_BetaThalassemiaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:type="locator" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_2" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="sgmo_BetaThalassemiaMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_TermsOfContract" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromGrants" order="10830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="10910.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:type="locator" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:type="locator" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10130.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10210.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>sgmo-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-04-28T18:51:15.9825191+00:00 -->
<!-- Version            : 2.0.4.0 -->
<!-- Package ID         : EFBAF9CDBCE805F8860901001F3B60C6-0001001233-001503 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="sgmo_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and entity information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="sgmo_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_EscrowLiability" xlink:type="locator" xlink:label="sgmo_EscrowLiability" />
    <label xml:lang="en-US" xlink:label="sgmo_EscrowLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Escrow liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_EscrowLiability" xlink:to="sgmo_EscrowLiability_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</label>
    <label xml:lang="en-US" xlink:label="sgmo_EscrowLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Escrow liability</label>
    <label xml:lang="en-US" xlink:label="sgmo_EscrowLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Escrow Liability</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value; 160,000,000 shares authorized, 69,497,256 and 69,062,394 shares issued and outstanding at March 31, 2015, and December 31, 2014, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreements" xlink:type="locator" xlink:label="sgmo_CollaborationAgreements" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAgreements" xlink:to="sgmo_CollaborationAgreements_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreements</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueFromGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueFromGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Grants</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used in computing basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gain on available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <label xml:lang="en-US" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NetProceedsFromIssuancePublicOffering" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Indefinitelived Excluding Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Interest Receivable Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by / (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract]</label>
    <label xml:lang="en-US" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from public offering of common stock, net of issuance costs</label>
    <label xml:lang="en-US" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Public Offering</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Taxes paid related to net share settlement of equity awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment included in accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Customers, Partnerships and Strategic Alliances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Estimated Fair Value of Contingent Consideration Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <label xml:lang="en-US" xlink:label="sgmo_BiogenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BiogenIncMember" xlink:to="sgmo_BiogenIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_BiogenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen Inc [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_BiogenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen Inc [Member]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <label xml:lang="en-US" xlink:label="sgmo_ShireAgMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shire ag.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShireAgMember" xlink:to="sgmo_ShireAgMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ShireAgMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shire AG [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShireAgMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shire Ag [Member]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <label xml:lang="en-US" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sigma-Aldrich corporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SigmaAldrichCorporationMember" xlink:to="sgmo_SigmaAldrichCorporationMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sigma-Aldrich Corporation [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sigma Aldrich Corporation [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues Recognized under Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Values of Intangibles Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Indefinite Lived Intangible Assets Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government sponsored entity debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ContingentConsiderationLiabilityMember" xlink:type="locator" xlink:label="sgmo_ContingentConsiderationLiabilityMember" />
    <label xml:lang="en-US" xlink:label="sgmo_ContingentConsiderationLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ContingentConsiderationLiabilityMember" xlink:to="sgmo_ContingentConsiderationLiabilityMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ContingentConsiderationLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ContingentConsiderationLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liability [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents and marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total contingent consideration liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of contingent liability</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value as of December 31, 2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value as of March 31, 2015</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Security Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Information By Category Of Debt Security [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Amortized Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized (Losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairments of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Losses Investments Availableforsale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding excluded in calculation of diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfResearchProgram" xlink:type="locator" xlink:label="sgmo_NumberOfResearchProgram" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfResearchProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of research program.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfResearchProgram" xlink:to="sgmo_NumberOfResearchProgram_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BetaThalassemiaMember" xlink:type="locator" xlink:label="sgmo_BetaThalassemiaMember" />
    <label xml:lang="en-US" xlink:label="sgmo_BetaThalassemiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beta thalassemia.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BetaThalassemiaMember" xlink:to="sgmo_BetaThalassemiaMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_BetaThalassemiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beta-thalassemia [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_BetaThalassemiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beta Thalassemia [Member]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SickleCellDiseaseMember" xlink:type="locator" xlink:label="sgmo_SickleCellDiseaseMember" />
    <label xml:lang="en-US" xlink:label="sgmo_SickleCellDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sickle cell disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SickleCellDiseaseMember" xlink:to="sgmo_SickleCellDiseaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_SickleCellDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sickle cell disease [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_SickleCellDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sickle Cell Disease [Member]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_OtherProjectsMember" xlink:type="locator" xlink:label="sgmo_OtherProjectsMember" />
    <label xml:lang="en-US" xlink:label="sgmo_OtherProjectsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other projects.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OtherProjectsMember" xlink:to="sgmo_OtherProjectsMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_OtherProjectsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Projects [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_OtherProjectsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Projects [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfResearchProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of research programs</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfResearchProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Research Program</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate additional revenue recognition milestone method revenue achieved.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate additional revenue recognition milestone method revenue eligible to receive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <label xml:lang="en-US" xlink:label="sgmo_MilestoneRevenueReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone&#8203; revenue receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MilestoneRevenueReceivable" xlink:to="sgmo_MilestoneRevenueReceivable_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MilestonePaymentsReceived" xlink:to="sgmo_MilestonePaymentsReceived_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements number of products approved under agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Compensation Earned</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential amount eligible to receive for certain milestones</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Additional Revenue Recognition Milestone Method Revenue Achieved</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential amount to be funded for achievement of specified commercialized and sales milestones</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestoneRevenueReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone revenue receivable</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestoneRevenueReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Revenue Receivable</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Received</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of products approved</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements Number Of Products Approved Under Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Revenue</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial research term of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_InitialResearchTermOfAgreement" xlink:to="sgmo_InitialResearchTermOfAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research program to develop laboratory research reagents</label>
    <label xml:lang="en-US" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Research Term Of Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:type="locator" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research service revenue under collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recognition of upfront fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Services Revenue</label>
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services</label>
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Service Revenue Under Collaboration Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licenses Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" xlink:label="us-gaap_ContractsRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contracts Revenue</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_AggregateNumberOfGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate number of gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateNumberOfGeneTargets" xlink:to="sgmo_AggregateNumberOfGeneTargets_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfInitialGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfInitialGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of initial gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfInitialGeneTargets" xlink:to="sgmo_NumberOfInitialGeneTargets_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfGeneTargets" xlink:to="sgmo_NumberOfGeneTargets_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfAdditionalGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfAdditionalGeneTargets" xlink:to="sgmo_NumberOfAdditionalGeneTargets_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Number Of Gene Targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of initial gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Initial Gene Targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Gene Targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Gene Targets</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IND or CTA submission amount</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Additional Revenue Recognition Milestone Method Revenue To Be Recognized On Acceptance Of Application</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Milestone Method Revenue Recognized</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_UpfrontLicenseFeesMember" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFeesMember" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFeesMember" xlink:to="sgmo_UpfrontLicenseFeesMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_UpfrontLicenseFee" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFee" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFee" xlink:to="sgmo_UpfrontLicenseFee_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:type="locator" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived" />
    <label xml:lang="en-US" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty revenues expected to be received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ReducedRoyaltyRate" xlink:type="locator" xlink:label="sgmo_ReducedRoyaltyRate" />
    <label xml:lang="en-US" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduced royalty rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ReducedRoyaltyRate" xlink:to="sgmo_ReducedRoyaltyRate_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:type="locator" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone receivable under agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:to="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</label>
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fee</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued under license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering, common stock shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <label xml:lang="en-US" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty revenues expected to be received</label>
    <label xml:lang="en-US" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Revenues Expected To Be Received</label>
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount received on commercial license fees</label>
    <label xml:lang="en-US" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduced royalty rate</label>
    <label xml:lang="en-US" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduced Royalty Rate</label>
    <label xml:lang="en-US" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding available under the amended agreement</label>
    <label xml:lang="en-US" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Receivable Under Agreement</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:type="locator" xlink:label="sgmo_OneTimeLicenseFeeEarned" />
    <label xml:lang="en-US" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">One time license fee earned.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OneTimeLicenseFeeEarned" xlink:to="sgmo_OneTimeLicenseFeeEarned_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="locator" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" />
    <label xml:lang="en-US" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalties to be received from sublicensing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="locator" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment and royalty revenue of previous agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:to="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <label xml:lang="en-US" xlink:label="sgmo_DowAgroSciencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dow agro sciences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DowAgroSciencesMember" xlink:to="sgmo_DowAgroSciencesMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_DowAgroSciencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dow Agro Sciences [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_DowAgroSciencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dow Agro Sciences [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time license fee earned on exercise of option</label>
    <label xml:lang="en-US" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Time License Fee Earned</label>
    <label xml:lang="en-US" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalties to be received from sublicensing</label>
    <label xml:lang="en-US" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalties To Be Received From Sublicensing</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment And Royalty Revenue Of Previous Agreement</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:type="locator" xlink:label="sgmo_AnnualFeesRelatedToAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual fees related to agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AnnualFeesRelatedToAgreement" xlink:to="sgmo_AnnualFeesRelatedToAgreement_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_FeeDue" xlink:type="locator" xlink:label="sgmo_FeeDue" />
    <label xml:lang="en-US" xlink:label="sgmo_FeeDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fee due.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FeeDue" xlink:to="sgmo_FeeDue_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="locator" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" />
    <label xml:lang="en-US" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum sublicense annual fees specific reckoning period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual fees</label>
    <label xml:lang="en-US" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Fees Related To Agreement</label>
    <label xml:lang="en-US" xlink:label="sgmo_FeeDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee due</label>
    <label xml:lang="en-US" xlink:label="sgmo_FeeDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fee Due</label>
    <label xml:lang="en-US" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum license annual fees specific reckoning period</label>
    <label xml:lang="en-US" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Sublicense Annual Fees Specific Reckoning Period</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:type="locator" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement related costs and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement related costs and expenses</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Related Costs And Expenses</label>
    <label xml:lang="en-US" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue attributable to research and development</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_GrantFundingAmount" xlink:type="locator" xlink:label="sgmo_GrantFundingAmount" />
    <label xml:lang="en-US" xlink:label="sgmo_GrantFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant funding amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_GrantFundingAmount" xlink:to="sgmo_GrantFundingAmount_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" xlink:type="locator" xlink:label="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" />
    <label xml:lang="en-US" xlink:label="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected revenue to be received for research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" xlink:to="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_TermsOfContract" xlink:type="locator" xlink:label="sgmo_TermsOfContract" />
    <label xml:lang="en-US" xlink:label="sgmo_TermsOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Terms of contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_TermsOfContract" xlink:to="sgmo_TermsOfContract_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AgreementDate" xlink:type="locator" xlink:label="sgmo_AgreementDate" />
    <label xml:lang="en-US" xlink:label="sgmo_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AgreementDate" xlink:to="sgmo_AgreementDate_lbl" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:type="locator" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" />
    <label xml:lang="en-US" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">California institute for regenerative medicine.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Institute for Regenerative Medicine [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Regenerative Medicine [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Project</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProjectMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Project</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProjectMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Project [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_GrantFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds due under the agreement</label>
    <label xml:lang="en-US" xlink:label="sgmo_GrantFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Funding Amount</label>
    <label xml:lang="en-US" xlink:label="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected amount to be received for research and development</label>
    <label xml:lang="en-US" xlink:label="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Revenue To Be Received For Research And Development</label>
    <label xml:lang="en-US" xlink:label="sgmo_TermsOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement to receive</label>
    <label xml:lang="en-US" xlink:label="sgmo_TermsOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Terms Of Contract</label>
    <label xml:lang="en-US" xlink:label="sgmo_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement date</label>
    <label xml:lang="en-US" xlink:label="sgmo_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Date</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_IntangibleAssetAbstract" xlink:type="locator" xlink:label="sgmo_IntangibleAssetAbstract" />
    <label xml:lang="en-US" xlink:label="sgmo_IntangibleAssetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IntangibleAssetAbstract" xlink:to="sgmo_IntangibleAssetAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_IntangibleAssetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Acquired Indefinite Lived Intangible Assets By Major Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Acquired Indefinite Lived Intangible Assets By Major Class [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets By Major Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Major Class Name [Domain]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:type="locator" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" />
    <label xml:lang="en-US" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cere one hundred and ten treatment of alzheimer disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:to="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CERE-110 for the treatment of Alzheimer&apos;s disease ("IPR&amp;D") [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cere One Hundred And Ten Treatment Of Alzheimer Disease [Member]</label>
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:type="locator" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" />
    <label xml:lang="en-US" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cere one hundred and twenty treatment of parkinson disease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:to="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CERE-120 for the treatment of Parkinson&apos;s disease ("IPR&amp;D") [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cere One Hundred And Twenty Treatment Of Parkinson Disease [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Indefinite Lived Intangible Assets [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total identifiable intangible assets</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment charge</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Recognition of income tax benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>sgmo-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-04-28T18:51:15.9825191+00:00 -->
<!-- Version            : 2.0.4.0 -->
<!-- Package ID         : EFBAF9CDBCE805F8860901001F3B60C6-0001001233-001503 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.sangamo.com/20150331/role/TemplateLink" xlink:href="sgmo-20150331.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sgmo-20150331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="sgmo_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_EscrowLiability" xlink:type="locator" xlink:label="sgmo_EscrowLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sgmo_EscrowLiability" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreements" xlink:type="locator" xlink:label="sgmo_CollaborationAgreements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_CollaborationAgreements" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromGrants" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="sgmo-20150331.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurement" xlink:href="sgmo-20150331.xsd#Role_DisclosureFairValueMeasurement" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurement">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecurities" xlink:href="sgmo-20150331.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecurities">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShare" xlink:href="sgmo-20150331.xsd#Role_DisclosureBasicAndDilutedNetLossPerShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliances" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssets" xlink:href="sgmo-20150331.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="sgmo-20150331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxes">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="sgmo-20150331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sgmo-20150331.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementTables" xlink:href="sgmo-20150331.xsd#Role_DisclosureFairValueMeasurementTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="sgmo-20150331.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="sgmo-20150331.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="sgmo-20150331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ContingentConsiderationLiabilityMember" xlink:type="locator" xlink:label="sgmo_ContingentConsiderationLiabilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10050.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="sgmo_ContingentConsiderationLiabilityMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureFairValueMeasurementAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementScheduleOfChangesInEstimatedFairValueOfContingentConsiderationLiabilityDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureFairValueMeasurementScheduleOfChangesInEstimatedFairValueOfContingentConsiderationLiabilityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementScheduleOfChangesInEstimatedFairValueOfContingentConsiderationLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfAdditionalGeneTargets" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfGeneTargets" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfInitialGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfInitialGeneTargets" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_AggregateNumberOfGeneTargets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_NumberOfResearchProgram" xlink:type="locator" xlink:label="sgmo_NumberOfResearchProgram" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_OtherProjectsMember" xlink:type="locator" xlink:label="sgmo_OtherProjectsMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SickleCellDiseaseMember" xlink:type="locator" xlink:label="sgmo_SickleCellDiseaseMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BetaThalassemiaMember" xlink:type="locator" xlink:label="sgmo_BetaThalassemiaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_BetaThalassemiaMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_SickleCellDiseaseMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_OtherProjectsMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfResearchProgram" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestoneRevenueReceivable" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentsReceived" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenue" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" xlink:label="us-gaap_ContractsRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:type="locator" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicensesRevenue" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:type="locator" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ReducedRoyaltyRate" xlink:type="locator" xlink:label="sgmo_ReducedRoyaltyRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:type="locator" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_UpfrontLicenseFee" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFee" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_UpfrontLicenseFeesMember" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFeesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestoneReceivableUnderAgreement" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentsReceived" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:type="locator" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="locator" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_FeeDue" xlink:type="locator" xlink:label="sgmo_FeeDue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:type="locator" xlink:label="sgmo_AnnualFeesRelatedToAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="locator" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="locator" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:type="locator" xlink:label="sgmo_OneTimeLicenseFeeEarned" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail">
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:type="locator" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_AgreementDate" xlink:type="locator" xlink:label="sgmo_AgreementDate" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_TermsOfContract" xlink:type="locator" xlink:label="sgmo_TermsOfContract" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" xlink:type="locator" xlink:label="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_GrantFundingAmount" xlink:type="locator" xlink:label="sgmo_GrantFundingAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_BetaThalassemiaMember" xlink:type="locator" xlink:label="sgmo_BetaThalassemiaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:type="locator" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="sgmo_BetaThalassemiaMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_TermsOfContract" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromGrants" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:type="locator" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:type="locator" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_IntangibleAssetAbstract" xlink:type="locator" xlink:label="sgmo_IntangibleAssetAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IntangibleAssetAbstract" xlink:to="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="sgmo-20150331.xsd#sgmo_IntangibleAssetAbstract" xlink:type="locator" xlink:label="sgmo_IntangibleAssetAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IntangibleAssetAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="sgmo-20150331.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!J:8UQ[@$``#H7```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-%.VS`4AN\G\0Z1;U'C
MV@$&J"D7,"X'TN`!//NTB>K8EFU8^_8[2:%"J&M5K1+GIE$;^_Q?K>B3\D]N
MEITM7B&FUKN:B7+,"G#:F];-:_;\=#^Z9$7*RAEEO8.:K2"QF^G)M\G3*D`J
M<+=+-6MR#M><)]U`IU+I`SB\,_.Q4QF_QCD/2B_4'+@<CR^X]BZ#RZ/<SV#3
MR1W,U(O-Q8\E_KPFB6`3*V[7"_NLFJD0;*M51E+^ZLRGE-%;0HD[AS6I:4,Z
M10S&MR;T=_X=\+;O`8\FM@:*1Q7S3]4A!E]:_L?'Q6_O%^7N(5LH_6S6:C!>
MOW1X`F4*$91)#4#N;#E<RTZU[IU[1_ZP./'A(HX,TO^_8?"!')((1T6$XXP(
MQSD1C@LB'-^)<%P2X;@BPB'&5$"H&%504:J@XE1!1:J"BE4%%:T**EX55,0J
MJ)A54C&KI&)62<6LDHI9)16S2BIFE53,*JF855(QJZ1BUHJ*62LJ9JVHF+6B
M8M:*BEFKKS)KQF80^/#Y_X_I,&9/-97RRD(Z\NOD>NB^Y$9%,+]RQ`[UZ``?
M9^_AT,KJVP;+Q",?PF;NKGQL.!^C#PF[W@B'`[R7N?WN4<!!$',+FSIW6RVZ
M2<2>^/#`3[TL]$VT`;,EFP_-]_0O````__\#`%!+`P04``8`"````"$`M54P
M(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."
M2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA
M5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E
M/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;
MJ)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI
M^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0`K,%S4`P(`
M`#$6```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````"\F,UNVS`0A.\%\@X"[S'-
MW<1)BL@YM"B0:YL^`"'1EA"9$DCVQV]?PHBI&F@G%V$O`KB"J<'L>CY1CT^_
M#T/UTX78C[Y69K56E?/-V/9^7ZOO+U^N[U45D_6M'4;O:G5T43UMKSX\?G6#
M3?E'L>NG6.5=?*Q5E]+T4>O8=.Y@XVJ<G,]W=F,XV)278:\GV[S:O=.T7F]T
M^'L/M;W8LWIN:Q6>6\.J>CE.^='O;S[N=GWC/H_-CX/SZ1_/T+_&\!H[YU+>
MU(:]2[4JI:A/=PROLF:E_R,G^R$KYQ[)H8VP'-H@.?RPI)S&#LVGSO9^;E8I
M(15DEE11YF-644IO(T,&R>$;83E\@^3<":NY0V(,":LQ!.5(FV.@.W0K[`[=
M(G=8.HH91C$O&L6QL\&UWU+(Y(O9]C<Z7)21.=*#C.=8&@L&8H'R6X4H-&D-
M6[4HI0H,YJ$II3,?'I`<:5I!6$D/#IP;(VX-](:D04X0Y"P=.0PSAQ=E9TS'
M(1\UYAP^K='?2)J5$)5&6HV!<DB:W`3)38N2NZ3M/"VE=`Y@>(CB14,OY;.O
MFZ6<EOITA>%BI!EI(".--",-9"1+DX!ALZ1!`#D@W2G8*"-MC8'>D#0C"3*2
M%F5D2;DY;4KI''SP?,G2F<,P<U@:F@RA*0TIS*C<8\FOH(7?^N)#[_8/````
M__\#`%!+`P04``8`"````"$`0XBN)6X#``!]"P``#P```'AL+W=O<FMB;V]K
M+GAM;)2676_:,!2&[R?M/T2Y7_/-VJI0]5-#6BLDNO;2<A,#'HF-;&?`O]])
M4L()!@17X`2_O.?UXV/?W*Z*W/G'E.92]-W@PG<=)E*9<3'MNW_>GG]<NHXV
M5&0TEX+UW373[NW@^[>;I53S3RGG#@@(W7=GQBRN/4^G,U90?2$73,";B50%
M-3!44T\O%*.9GC%FBMP+?;_G%90+MU&X5J=HR,F$I^Q1IF7!A&E$%,NI`?MZ
MQA?:'=Q,>,[>FXH<NEB\T@)\KW+7R:DV3QDW+.N["0SEDG4>J')Q7_(<WEY%
M?N1Z@[;(D7(R-J%E;MZ@O(TZY!7&8=BK?EE%\<[94F\G54-G]<%%)I?53R':
M=3N*P,"R?O7!,S.#][[OM\]^,3Z=F<U#D/>0?IT@_$_]Z8BZO$TB!%:*/`G#
MS9H,19,^E["$5>I#J"QP'77-X8L:9D%E'*L\2)$QH5E&X)N6.<\HA$7N:4Y%
MRI!*U$,RX7DRX*!U$R&9.O`3W(P-F"JPFQBIQ">:^5+!9B#]-IKD/)D0U82C
MJ='`-=U3S361$S)23`/!-;CUHHW+HD`JT4_DYN>NFV?*%7FG><G("Z.Z5!"(
M,'@Z;-NVF,O=Z2]4S9FAGSDC8Y:6BAL.VQHMRQ6:?;4[NZHAK3T_\KRL`'EE
MAOR66I,14T@F!N);$X&_J_-"_TI%'DIM9`';E8RH,@*^5-N84*S3@=:B=@@Q
MBBFOJKG3FAE<20PKL[5@D3J$5E<P\D97G?ICS&5@@3DV,IU#"O4^*:#1Z7H9
ML6.,9&`Q>9P"S&2,H0PL*O=S`/5`&)T8,)2!1>5>'O:H8"8#"\KCZ]FI"M,9
M6'A:"[K'"B8TL!`]L$*V3H(1A0Z]TQ`/Y%OM5:K6:,$3C&AH(7I`YRZ#TZC3
MGD/,*PQ.])/.6%;""=<VUA`3#(,=G?T+/FYD<&M-.GXLD/?K?)4%)_O6#^8X
MM#@^WE(P.G#:;C=T<_36?_)U#AYG$(II'26=A,Z$&>:V0B&&&096U,>Z'/2)
MK1!F.K28/EX:Y-L*11AJ&)SE"/+="F&J(XMJ>Y\^4*76<'6LSB:DD^!V&%E4
MVSH;@FA.AD@GPFL&@YW"<#<G6**^"&&=CA^+ZD/=HWF.=3#5<*,#/UX='MS.
M4IJG<&VL/NI[5YSTFK[@;6[.@_\```#__P,`4$L#!!0`!@`(````(0"5ST:#
M[0,``%$-```8````>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE%=-CZ,X$+V/
MM/\!<4_`0"!$24836KTSTJRT6NW'F8"3H`:,L-/I_O=3=CF`G9G>Y-(=\//S
MJU?E2F7]^:VIG5?:\XJU&Y?,?=>A;<'*JCUNW'_^?IXM78>+O"WSFK5TX[Y3
M[G[>_O9I?6']"S]1*AQ@:/G&/0G1K3R/%R?:Y'S..MK"RH'U32[@L3]ZO.MI
M7JI-3>T%OA][35ZU+C*L^GLXV.%0%?2)%>>&M@))>EKG`O3S4]7Q*UM3W$/7
MY/W+N9L5K.F`8E_5E7A7I*[3%*MOQY;U^;Z&N-](E!=7;O5P0]]41<\X.X@Y
MT'DH]#;FU$L]8-JNRPHBD+8[/3ULW"]DE9'$];9K9="_%;WPR6>'G]CE][XJ
MOU<M!;<A3S(#>\9>)/1;*5_!9N]F][/*P)^]4])#?J[%7^SRE5;'DX!T+R`B
M&=BJ?'^BO`!'@68>+"13P6H0`'^=II*E`8[D;^K_I2K%:>.&\7R1^"$!N+.G
M7#Q7DM)UBC,7K/D/0413(4F@24)0K]>#>TD\%*3B>\I%OEWW[.)`T<"1O,ME
M"9(5$%\#0QE#J+^*%$*4)%\DB^*"(#BDYW4;1VOO%1PM-&2'D,1U!@@Q$=D5
M(1,!Z@:)$+<M,80,_MS[JR*YR5*T,,_;W4("$Y'=(N)X@!@:P;JIQH^U23!4
MP,2*.!EHE:$[A$0J_]+A;/+".#AZY&`)WK@0U9"#>&D=C)"ERB$)XL1.TG0]
M64RV&ZJ@J.^W0X(M5:FE"B&14K4,?',UFZXNHC$B0U+\B"0)-B4EUJ$[A,1H
M5!BEME'3]24AOZ@;N`_W&R7!9MW8Z=DA9%(WDQ>&'?*;:7+O/RY8";;LL*[*
M#B':CBA=6G9EQGK@+\,AAX:L]!%9$FS)&FGQ'B$$945):*G.ILMA'(T]RQ!%
MH-O<;Y9"6[)&8I2E,=JN-"&V,!.P2(*Q09C2K/[]<1X)MMAI`TCLKJ@Q*&T6
M!X%=V"8@B<D(,*7)[GEWB1'LM8:T\<YHUQ"#;8`L+%,S38'+X=A"3%6RD=ZO
M"MNNH6K,A%:%F*MAOMW+,V(`$DCFSVN?/-3+%=HJL['U:6G8K=&19-(9U7*F
M*52W,$UZJ'_+0<B^AZ/[6@EB\'MEM@B)!<@TB09\8-)#?9S<-G*[,^TT)E6=
M?.;/?<O%S`9,+JOIFM7,Y2SU_X,*C*VV>\OQ1FGW$(,E%J?!I'OJ3!H`<'>T
M%R7B9(N37T/[(\UH77.G8&<YM1*(?7B+$_5.3M1J)AX68*#M\B/](^^/5<N=
MFAY@JS]/(+4]CL3X(%BG)J\]$S#*JH\G^.E"88SQYP`^,":N#W+6&WX,;7\`
M``#__P,`4$L#!!0`!@`(````(0#(Z^41D00``!L1```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;)2876_B.A"&[U<Z_R'*_1(2(%`$K`I1SZZT*QT=
MG8_K$`Q$36(4A]+^^YWQ)&'L4#YZ`61X/7T\8\_8S+Z]YYGS)DJ5RF+N^KV^
MZX@BD9NTV,W=?_]Y^3IQ'57%Q2;.9"'F[H=0[K?%'U]F)UF^JKT0E0,>"C5W
M]U5UF'J>2O8BCU5/'D0!WVQEF<<5/)8[3QU*$6_TH#SS@GX_]/(X+5SR,"WO
M\2&WVS01D4R.N2@J<E**+*Z`7^W3@VJ\Y<D][O*X?#T>OB8R/X"+=9JEU8=V
MZCIY,OVQ*V09KS.8][L_C)/&MW[HN,_3I)1*;JL>N/,(M#OG)^_)`T^+V2:%
M&6#8G5)LY^ZS/XT"W_46,QV@_U)Q4NRSH_;R]&>9;GZFA8!H0YXP`VLI7U'Z
M8X,F&.QU1K_H#/Q5.ANQC8]9];<\?1?I;E]!ND<P(YS8=/,1"95`1,%-+QBA
MIT1F``"O3I[BTH"(Q._Z_91NJOW<'82]T;@_\$'NK(6J7E)TZ3K)454R_Y]$
M>D:MDZ!V`N^U$W_4&P:C\>01+X/:R_#L);@7Q:-IZ2A%<14O9J4\.;#T`%P=
M8ES(_A0<8WA""#)-I@W89_&"0*&39_0R=\>N`\,5)/EM,0C]F?<&B4EJS9(T
M\'K6!'U3L^KZL;Q$C0)S#E-HYP&AY?.XG-X&%\6(B^E&_B49#+8PL-BZ&DL1
M=15AV#HQ:"&5G!:C/OQT43;4.`B6'PM@,+;"LR3-L)W9RC9$S&`@0?)MI`$L
MA.N!Q$%S%^9]SFDX:*=,L24-0R+#1"\3J(;P9XZ(N&!@"@QDB!A'OHZ*8AMU
M:/[C)6D8JFV(F,%`"4V4^Q**@VXEE#0,R39$S&`@P6[DT4&DVPG%05:4!G9"
M20-).B=]9*W#5:-I=EC$#`8E]EFK_MRFQ$$693BR<DF:4*^R4"\B:YFM2'$.
M;<0,!N.3R7A]G:'89`N"<Q6@+4$:8@NL%:X5*U(P-F8PV'S8HX\'4(\R*0>L
M5A%E+9J,=`RQ/YHA7M4"1LDM)B;6;2O/V&>NQ]*G:F_6E[%)L:Q%%,WAQ4S7
M$@Y*GK7%!,4BSD!O`%+)-P$G-B")ZG2/+N;;)PTG9!:3$"LX([QO8_M4]TW2
M)YNT:0YL:X_M;5-[XJC-,+LI^UC)'T>E^F^BVD5(NX:N>>YTK06/'Q9T],F7
M9F"QN#].2RW!H.VT93QQ0E7@M(WE(NWE+TU:K/N/TU*W,&FM<\S29RV%RE''
M$G&+R865WN*Z?;;QJ3_`0FJ;2O=P4XMX%%E;T:01UYA<6-T9UXV-3;W`C%-G
M#9*HV=A8>LP-M?)92ZGYF,7DPPK/^.[<UM073$[[6..SYE'GT[9$7&-P!1<:
MS.U\ZE&WSC:UB.6S8XFXQ>2R.LKU?`87.LG8SF<MHI,IE6D[H;7DC(R7UW9K
M$R#=1>F6E8MR)U8BRY23R"/>,P/HIJVUO0,_!UC(+/L*[L;Z(NFU7\#5]!#O
MQ*^XW*6%<C*Q!9?]WA@*1DF76WJHY$'?[=:R@DNI_KB''R$$7';Z/1!OI:R:
M!ZS:[<\:B]\```#__P,`4$L#!!0`!@`(````(0#06_5[ZP0``.$2```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;)Q8VXZC1A!]CY1_0+ROH;GX)MNK
M@6:2E1(IBG:39XS;-AJ@+<#CF;]/-<VEJ_%ZF,S#V!R?*DY=Z&IZ\_4MSXQ7
M5E8I+[8FF=FFP8J$']+BM#5_?'_^LC2-JHZ+0YSQ@FW-=U:97W>__K*Y\?*E
M.C-6&^"AJ+;FN:XO:\NJDC/+XVK&+ZR`7XZ\S.,:+LN355U*%A\:HSRS'-N>
M6WF<%J;TL"ZG^.#'8YHPRI-KSHI:.BE9%M>@OSJGEZKSEB=3W.5Q^7*]?$EX
M?@$7^S1+Z_?&J6GDR?K;J>!EO,\@[C?BQ4GGN[D8N<_3I.05/]8S<&=)H>.8
M5];*`D^[S2&%"$3:C9(=M^8364<.,:W=IDG0/RF[5<IWHSKSVV]E>O@C+1AD
M&^HD*K#G_$50OQT$!,;6R/JYJ<!?I7%@Q_B:U7_SV^\L/9UK*+</$8G`UH=W
MRJH$,@IN9HXO/"4\`P'PW\A3T1J0D?BM^;REA_J\-=WYS%_8+@&ZL6=5_9P*
MEZ:17*N:Y_]*4A-1[\1IG;B@OOW=^;03KW4"G[V3R0I`:Q,&?';&9.8Y_F(Y
M(0Y+YJ1),8WK>+<I^<V`OH6HJTLLG@*R!L\BMQY\RDSTV?Y9LB'+PLF3\+(U
M%Z8!YA5TR.O.]98;ZQ6JFK2<8,PAF!%V#%%"X99V@.+6L;%1U'%$!T%,?6!0
M,#6P^\W2Z1=DH;^[<R`!\-T'Y.#[AF/&?(XI=$QQO17F1'<X_A`BB@A:3XVH
M*]7CR(01-+P:R$++>R`Y7A]]J`-4!R(%0!JALU6-C[4)\M:$#/1)7FA9#B1E
MV;04\59+&_YP!D-$<>RE.Z)021D"C!0`R8?.GRY?D+%\9^%A<8'D#'<.=8#J
M0*0`2-L<:YM6?F'T4?DE1]&H`U0'(@5`&F$%4/,G-+JPWC]N`V&$\^BZKI9'
MR5$TZ@#5@:@#ANYR_:'SD6RQ4U`6P<=R!5F3Z^MM*SF*7!V@$I@WC0W[B>8/
MQQPI-DCM"JN=EF1AI*O6DRPYBFH=H!*0JN?NG.AUBA0+I)E`%Z@IGB:ZL=)5
MZX]82Y*B_'N9#%O*$!D=(9&*8.EBPDSN#B+GD;JHN;Z/*QNTI*7?E-^>$5MC
MA"U#52P=#TBD<K!B,504Q1.3+4<15JZ-M(!(4MNW/\FVY`Q*:6LU()&*8.UB
MLBC:'S^+1,XAI-D='O)F%Q&T)$\F&Y<B['_L1C\=(9&*8+%BCBAB)R9:3A\D
MVE]@70%11E031CA"Z`B)5`0K%5-%4RKV>1^D5\XB2'(_H9W1[D%LQ6%I&8H;
MCA`Z0B(5P4K%;%&4?J!03B*<2WTU)LJX:G.I([3ER,8F/KFW(*M^L&8Q:Q3-
M$_M`3BBL?;1K[L98UY\AT1':(E*[M[HK73'"TL64^;QT.9NP=&UK&Q!E@+5I
MUQ$ZXD0J@I6*V:(IG=#"<B)]T,+*V&J5Z@@E.A*I"%+J_*]AUUAIPVZN;7:#
MEJ0\;".$MLB#@1BI1ECZIX:=,QYVHQU\RY%;>+G3P4M=B!A:P+3]<0A8'#7T
MZXW4+D\.Y&MMSLH3"UF654;"K^)4P(5UOT?[$XLG1[SN:'A`UO`2.L8IG'`T
MN-4;P`'#)3ZQ/^/RE!:5D;$CW,J>+6`Q+.41A;RH^:5YR=[S&HX6FJ]G.$IB
M\'IKSX!\Y+SN+N#&5G\XM?L/``#__P,`4$L#!!0`!@`(````(0!ECLMF^`,`
M`(`.```9````>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;)1776^;,!1]G[3_
M@'A?P`1($R69%JINDS9IFO;Q3,!)4`$C[#3MO]^U+R&V2;OPT@;NX=QS/S'+
MC\]5Z3S1EA>L7KEDXKL.K3.6%_5^Y?[^]?#ASG6X2.L\+5E-5^X+Y>[']?MW
MRQ-K'_F!4N$`0\U7[D&(9N%Y/#O0*N43UM`:+#O65JF`RW;O\::E::X>JDHO
M\/W8J]*B=I%AT=["P7:[(J/W+#M6M!9(TM(R%:"?'XJ&G]FJ[!:Z*FT?C\V'
MC%4-4&R+LA`OBM1UJFSQ=5^S-MV6$/<S"=/LS*TN!O15D;6,LYV8`)V'0H<Q
MS[VY!TSK95Y`!#+M3DMW*_<3622![WKKI4K0GX*>N/;;X0=V^MP6^;>BII!M
MJ).LP):Q1PG]FLM;\+`W>/I!5>!'Z^1TEQY+\9.=OM!B?Q!0[@@BDH$M\I=[
MRC/(*-!,@D@R9:P$`?#7J0K9&I"1]%G]/Q6Y.*S<:3R)9OZ4`-S94BX>"DGI
M.MF1"U;]11#IJ)`DZ$BFH+ZS![>2>"A(Q7>?BG2];-G)@:8!E[Q)90N2!1"?
M`T,9?:BO10HA2I)/DD5Q01`<RO.TGH:SI?<$*<TZS`8Q,]?I,<1$)&>$K`3(
MZS5"X+;&*93P>O+/DN1#IJ0@,/UMKD!,1#)$Q'$/,31"[G2-;VN3X)4+Y'TJ
M@IG?\ZJ4;A`3J@Z0.4ZT&X;G<(QG"8;FTSS'=IT0HCG6;AB.H7-O#UF"K9#]
MN14R8NY4_Y`HF)KF1#?'\25?AJAXC"@)MD0%E_IB'1`3*E$7G\J6G&UVPT*3
MWYX9";9$$,O1!C%QEYFIG1DTH\90RYN1&?DNTB;][0Z58%,4"2VO&\2@J*D?
M68E+=#/Q[RY/&ZKF8U1)L*DJF%UXL5Z(T=I7NV%X)K!";D^(0O]G<CJ,YEN_
M8SJW]N[;U2"X&8V%,9B>#H1=$(76LDM>-9NZY,:[N4L([D=#UV"`.M#U">J-
M]@@1N>YN%X++T1`R&")%N7*Q8</(?ATDIGT^NZPG,T6C%B[![:DK&TY2!T)E
MD1^'UN8S[5%P>7&:RD9M9'E^&4R3Y7G3@?26QL?4'=/[J-5+<'>^^2;J,+KS
MUS8N&;5R%=I:),-YTI=NY/O63DXZDBN)&+5IR7#5!L,90A#.4##L#]U,_,LF
M-@LT:M>2*\LVL,\*':@;J6#P#NCLJ)N\-E%P<A\QZPIM%F\X41T(SQ(PZW;Q
M#'MP%_4#AQG##P$\*%>TW=.$EB5W,G:4AWP"[^'^+GZ`;.`#1)W6O=X`Y_\F
MW=/O:;LO:NZ4=`>/^I,9S$^+7Q!X(5BCSJE;)N#DKWX>X$N/PIG/GP!XQY@X
M7\@MV7\[KO\!``#__P,`4$L#!!0`!@`(````(0!DZ7N?E0@``-$J```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)R:66_C1A:%WP>8_R#H/9*X:+%@
M.VBQE@F0`,%@DCS3$FT3+8D"2;>[__U4L8KD71B)2C_8[4^G2G58RSTD^/CS
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M7@<KMM>A_:*=`^B+0F(I:1OU@PF[H30>!5>L5E@BA[ZH=]1THX8T2]R/YE\5
M]MV@"V/VU?@+8\7HPCB`+PRQG=!&@@(YU$N,':D1&@TZ1A[-F0$]VMUA3MV_
M.07;16`;F?,.+*YP3>9\YS1QMU`2"@0%D@)%@08`N3`CABZN+V$K?IJ:9=!O
MC9`LMIW3Q,U&IY/6?M9N`4&!I$!1H`%`1LP!.MZ(%6,C:S+6G9.`67!@TQ@+
MXH?-POS#RTD@2;C81$PB:;>*`@T`,FA.T/$&K1@;#-=DM#NG`0XI$!1("A0%
M&@`T>AO^2"VYO5MLHUN[Q6F`"PH$!9("18$&`+EXP"ZN[Q8KQG,0A6N\8G9.
MLW*[Q:XH\P]+$B?I#0H*)`6*`@T`\A.8\$>G)3+LNK&F%76VP</>>9&S%H0K
MNQ>8-R\"YAB1C"A&-"38H*WF=Z^[P+:B!EEF<2)O<+5>#AIT(FB0$NF_K=<H
M1C0DV*`MRL#@C9ES)1R=X!%9<+O`B?RB?(B:DXZ($B_J!RT8D8PH1C0DV)BM
MN^.-N2J-C='"&CA1/^:D(S:6$HNB^[`M5Y(1Q8B&!!NR)7B\(5>PL2%:HP)0
MU9L8EW1DT!"5RT[>6E2,:$BP(5N*QQMRA1L:"EEXL+>19N/!&6K)H*'VPW;X
MDG6@&-&08$.V]`)#-M*-.`U=P8;&HJC/Q<V\[`)0U?U,M02$J8CD4\&:2484
M(QH2;-!69V#PQF'A:CDV1NX)=@$H^-Z8(_Y<C(.!8U&P5I(1Q8B&!/NR]1KX
M&CEQKLIC?S3.!B`*>'^4"*:1C"A&-"38C:W6Q,WMK!2X&G_]UL*+X/X"T:#Q
M)YA&,J(8T9`@-R&)&-?77*,FE9<5*"]R*VRX[GI);U0P(AE1C&A(L"U;QL$D
MW;#EBCY<:NR&(Z3!(/&DW4E#&PE+AC*69/TJ1C0DV*89,K0Y;F>%MA6=11I]
MO:B?HH01P8AD1#&B(<%N2*88=\\>NMAP?6=Y$73CFO5$,(UD1#&B(<%N[@H4
MX5"@()%GYT57=Q8-$<(WZHU*1A0C&A)LRQ9UL+-&+CD7!>`.BR)Z3V*?+^-X
MP8A@1#*B&-&08#<#F>+V81ZZ<'!CR;4)HDT_B6_6SX1@1#*B&-&08#=W!8B0
M!PA^ZK'\X%OY4V\P/GB)>\A$UK#L/FPOBV)$0X(-DB1QXUCG"2)<T^@7TKR0
M,"(8D8PH1C0DV,4_2A#AF`3A1?T22Q@1C$A&%",:$N3&1G!X(%R?DT9-:@][
M[.)%P`4C@A')B/+$KU57?LEZU+`5]D4BQ+AJ%/$H$87TV80707\T70BFD8PH
M3[P_]R"`/L31L!DV2,+#C8D;"@WTCC=R(FBL)4,WB$PN&5&,:$BP(5O206FZ
M8<@%`#.^[G$YO^.-:$I(.C)HB,IE)^^..T8T)-@0B1#C:FTT%"7HL>=%<*;:
MY-!?CR@B*U>P9I(1Q8B&!!LD8>+&C`V%"'K'&[$0X8G;):NAQV6"-9*,*$8T
M)-@6214W;+F@`!<BJ\,1"Q.>.%?QT---@25#QB7K5S&B(<$V[XH;$8\;44Q.
MXYT7P65)$XA@&LF(ZHC=I>361G<?FCV)#=T5+R(>+Z*8/M3T(FB(!@[!-)(1
MU1%KB#R'TMV'S!!)&C<6HDL8<"%&,3OBG0@:HD1$E,B.V.&3+:NZ#]LS4D."
M9BB^*VPT:A(V8GH2>A$PQ(A@1';$&B+72'4?=H8@P89(RK@^0_%`NHC):MAY
M$33$T@732$:4)^Z$V0R=,!HVPK9LV1]=BF.KIO-$5LG.BZ`MUZPG@FDD(XH1
M[8F/4<USG/Y<PK9(PAA7D&.>-**8/LGTHMY,PHA@1#*B&-&08#<#\>+VS6_L
M<H+QU.<F_I)$&R;:'9#X9KT_P8AD1#&B(<%N[LH2UB==<NQ)IA?U8TX8$8Q(
M1I0G[N6$*!K>2B"W.%_N#3_WRM<I*]^R)#L>J\F^^+!O[]G5VM'NS<(OD7TO
MA?`DV(KF]3S"9;`U[U<-Z,-M,M2/"+=BB.MP:U[#,?W,NR\P+Q1>TK?LM[1\
MR\_5Y)B]FB$O9O:=N=*]DNC^J(M+\R+;2U&;5PF;_[Z;5T<S\WK88F;$KT51
MMW_8+^A>1GW^/P```/__`P!02P,$%``&``@````A`!D;\**9`@``2`8``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C8N>&ULC%7;CMHP$'VOU'^P_+YQ+A!V
M$6'%LMIVI5:JJEZ>C>,D%G$<V6:!O^\X)BF!;L4+Q,[QF3-G9IS%XT'6Z(UK
M(U23X2@(,>(-4[EHR@S__/%R=X^1L;3)::T:GN$C-_AQ^?'#8J_TUE2<6P0,
MC<EP96T[)\2PBDMJ`M7R!MX42DMJ8:E+8EK-:=X=DC6)PS`EDHH&>X:YOH5#
M%85@_%FQG>2-]22:U]2"?E.)UO1LDMU")ZG>[MH[IF0+%!M1"WOL2#&2;/Y:
M-DK330UY'Z()93UWM[BBEX)I951A`Z`C7NAUS@_D@0#3<I$+R,#9CC0O,KR*
MYNLI)LM%Y\\OP??F[!F92NT_:9%_$0T'LZ%,K@`;I;8.^IJ[+3A,KDZ_=`7X
MIE'."[JK[7>U_\Q%65FH]A02<GG-\^,S-PP,!9H@[F0P58,`^$52N,X`0^BA
M^]^+W%893M)@.@N3".!HPXU]$8X2([8S5LG?'A0Y40-)?"))0/WI?7PK"?&"
MNOR>J:7+A59[!#T#(4U+70=&<R!VB25@CY<QI/I>IJ#.D:P<2X9G&,%Q`]5Y
M6R;1=$'>P%)VPCQ=8Z(Q8MTC7"5`WJ`1$C_7^&_3>RD.[*0XYYRV)[\!W(.V
M^"+N-2)-!\A("3ATNQ('SC"0#X&3Z"^O%^<QDT'M^FQC%'DRCNSJ-'FW`7LO
MW"&HYTC!;,C,*_"8,P5G&R,%$.T\][Y3_E\-=^C2@_L+!1Z3=FTS2^-)&H9C
M!$RV8SDADC!.KNKC)]=WMN2ZY&M>UP8QM7-3&0/WL#M<&*O8V7ZQ_P0723=V
M9'@!@]S2DG^ENA2-034O@#(,9J!*^ZO`+ZQJNWG:*`LCW#U6<&-S:,(P`'"A
ME.T7KL6';\#R#P```/__`P!02P,$%``&``@````A`%ARXFM2`@``T@4``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C4N>&ULG)1;C]HP$(7?*_4_6'[?."'<
M%B59[8)H5^I*5=7+LW$<8A''D6TN^^\[M@$METK0%Q(G9S[.G+&3/>UD@S9<
M&Z':'"=1C!%OF2I%N\SQKY_SAS%&QM*VI(UJ>8[?N<%/Q>=/V5;IE:DYMP@(
MK<EQ;6TW(<2PFDMJ(M7Q%MY42DMJ8:F7Q'2:T](7R8;TXGA()!4M#H2)OH6A
MJDHP/E-L+7EK`T3SAEKP;VK1F0--LEMPDNK5NGM@2G:`6(A&V'</Q4BRR>NR
M59HN&NA[E_0I.[#]X@(O!=/*J,I&@"/!Z&7/C^21`*G(2@$=N-B1YE6.GY/)
MM(])D?E\?@N^-1_ND:G5]HL6Y3?1<@@;QN0&L%!JY:2OI7L$Q>2B>NX'\%VC
MDE=TW=@?:ON5BV5M8=H#:,CU-2G?9]PP"!0P46_@2$PU8`!^D11N9T`@=.>O
M6U':.L?I,!J,XC0!.5IP8^?"(3%B:V.5_!-$R1X5(+T]!*Y[2#*(^KW!:'P/
M)=U3X'J@#&^FD-"7CVE&+2TRK;8(MAXX-QUU&SF9`-GEDT+*U_.!8%S-LROR
MI:`V,---`7ED9`.#8'O-RZ4F.55,+Q5IDAXU!`P>74)R][MT1:<N>^<FKTB.
M!GRKTRN*?WB$].[WZ(H@<8R.22:C^-3"2]#X0Q(\?7APDE+_?QRXHAQ#FT<'
M:=(_<Q`T8S_I,W=P>%W]^;O@*QS+L-\ZNN1O5"]%:U##*_BW.!K!&=+A4(:%
M59V?V$)9.$S^MH9O)X=-%T<@KI2RAX4[]L>O<?$7``#__P,`4$L#!!0`!@`(
M````(0"'LWW]G`,``'\+```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME%9;;Z,X%'Y?:?\#\GL`DUL3A8P:JNZ.M"N-9G=FGATPB57`K.TT[;_?<S!0
M<$8=^L+%?/[.YW/C[#Z]E(7WS)46LHH)]4/B\2J5F:A.,?GV[^/LCGC:L"IC
MA:QX3%ZY)I_VO_^VNTKUI,^<&P\8*AV3LS'U-@AT>N8ET[ZL>05?<JE*9N!5
MG0)=*\ZR9E-9!%$8KH*2B8I8AJV:PB'S7*3\0::7DE?&DBA>,`/Z]5G4NF,K
MTRET)5-/EWJ6RK(&BJ,HA'EM2(E7IMO/ITHJ=BS@W"]TP=*.NWFYH2]%JJ26
MN?&!+K!";\^\"38!,.UWF8`3H-L]Q?.8W--M0A<DV.\:!WT7_*H'SYX^R^L?
M2F1_B8J#MR%.AAW_X05/#<\@<L3#B!RE?,*MGV$I!".Z`:`1_5]GYCY"*T%O
M9OC<F7QLPO9%>1G/V:4P7^7U3RY.9P.6EN`&],8V>WW@.H4P@"T_6B)K*@N@
M@*M7"LPG<"-[L>I$9LXQF:_\Y3J<4X![1Z[-HT!*XJ47;63YPX)H2V5)HI8$
M[E?[/5KYBVBYOOL(R[QE@7O+0B.?+L+5KY4$]E2-PQZ88?N=DE</TA5TZYIA
M\M,M\/[<*^`.Q-XC."9KB%M,-(3F>1_N@F=P?MHB#A8!UQY!QXBD0V#\0$,O
M!%PS70B"40B&"Y4=[,+0;N38O47,>\1("'AA*`3S90ZI^KYG<!/@!N=>].Q6
MH44TU=$L)(.%D?W%V/[[=A$<$SA;[^^E8]<BX-HC5F-$TB'<B$!Z#QWQOA`$
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ME\._-?0!G$MINA?T6S\Z[_\'``#__P,`4$L#!!0`!@`(````(0!'C7@P5@4`
M`+45```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;)186X_J-A!^K]3_
M$.7]$))P6P0<+7'<'JF5JJJ7YVPP$"V)49)==O]]QW$NXS$%]F79?/D\S#<S
MGC%>??_(3\Z[**M,%FO7'XU=1Q2IW&7%8>W^_1?_MG"=JDZ*77*2A5B[GZ)R
MOV]^_FEUD>5K=12B=L!"4:W=8UV?EYY7I4>1)]5(GD4!;_:RS),:'LN#5YU+
MD>R:1?G)"\;CF9<G6>%J"\OR$1MRO\]2P63ZEHNBUD9*<4IJ\+\Z9N>JLY:G
MCYC+D_+U[?PME?D93+QDIZS^;(RZ3IXN?QP*628O)]#]X4^2M+/=/%CF\RPM
M927W]0C,>=I16_.3]^2!I<UJEX$"%7:G%/NU^^PO>1"XWF;5!.B?3%PJ]+]3
M'>7EES+;_985`J(->5(9>)'R55%_[!0$BSUK-6\R\$?I[,0^>3O5?\K+KR([
M'&M(]Q04*6'+W2<350H1!3.C8*HLI?($#L!?)\]4:4!$DH_F\Y+MZN/:#6>C
MZ7P<^D!W7D15\TR9=)WTK:IE_J\F^:TI;21HC83@??L^^+*126L$/CLCX/-B
MZD]G7W`%G&[TP&=G!;Q[4,>L70R?W>+'7?!T9)M$L:1.-JM27ARH?HA==4[4
M7O*78%EE:`+NZ7CV.?N_E$&NE)%G967MSET'EE=09^^;<#Y=>>]0&VG+V=H<
MWV1$'4,5@C++.@"9#<;FHKCC=(LX`CP0V2N%2&.EUVNP$Z3(2E!G=:L!L-TK
M#$Q'(ILQFYD4IBF+61.AB3]_HF)L&^'DR33"B9%),`3:T`OUCO5VF;VM6RV"
M789ESDF:MIHSZ6,348!1(*8`1X#A-.PO[/1M9Q5Y[4(\^IS,2+"VFK)H`KZ`
M[C\F$8\P83I96`2F"8/:F`(<`886V$98BTI`""WTMB:UR-04SDD9;35G<"FB
M`*-`3`&.`,-IZ`'4:=4/;CNM%MVK&LU!3E.`42"F`$>`X30T'NST;6<5F49X
M;NZQK>8@9RG`-*!W\G2F"HM45HP9_F1ZA<*154./.O^0IGR_<M0BJFM!=&D.
MTD4!1H%8`ZW09@<1H1PM,50\F2IN9T61J?=T,VL.\IX"K`.&CA`NB+OQ`QS>
M<:#]&Y)\V+\X,[<U-6PB:D&[:4N:ZIDP]GU2BU%+&&0S"XDMA&/$E*#F(RJN
M.Q+T-+W98WW-F30*2+2C6R]9_[(;L[&%<(R80M0@1$(>ZZ^^'I]84#@+R39I
M2;KHPRL[-VH95S6S_N4@2W_KD$...:8L-1J)K/L=V-<#U9"U(">4;4L:O(@L
MA%E(;"$<(Z;O:A1^W7<]0$%!/\<#Z]#AHRG;'`XC"V$6$EL(QXCINYJ(R/<[
M^T+/3R/><[)SM^JG#C0U'&^*,(L36PAO$5V.LXE9CZ8(-2$?%Z'GJ2F"-ET?
M#=TV\!1A%B>V$-XC0Y9Q;S9EJ,'XN`P]1K$,ZQSHXVD\-R/8JL(,$N/VUXAF
M#.F,6ZL#PC%B2E)3$DEZL%OIV8JE7>E6>$1?UX89U[5IQJ`D]BG",6)J4^,2
M:;NS=?1P-30MK`Z,)G";'XHPGR*QA7",&#X'9)(_]O.H677OI-N2AEA&%L(L
M)+80CA'3]R^-\."!$=YRKHZSZ-9+UK_L9YV%<(R80J`(<.$\MBG@QLHZ*UHC
MO"7I7W[7CJV1P;@VY%G+&!(96XBZ/NM[O-:F;\/T)4LNRH.(Q.E4.:E\4S==
M(9R2>K2_A7MN+N$(OO67<"4"<24X@UN[!O?Z%W!I=DX.XO>D/&1%Y9S$'KYJ
M/)K#N"GUM9M^J.6YN?)YD35<ES7_'N%Z5,!ERW@$Y+V4=?<`7^SU%ZZ;_P``
M`/__`P!02P,$%``&``@````A`/Q)8L4(`P``+0D``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&ULE%;;;N(P%'Q?:?_!\GO)#4**@*I0=;?25EJM]O)L
M$B>QFL21;4K[]WML0X@#+>T+(?:<8<Z,D\/\YJ6NT#,5DO%F@8.1CQ%M4IZQ
MIEC@/[_OKQ*,I")-1BK>T`5^I1+?++]^F>^X>)(EI0H!0R,7N%2JG7F>3$M:
M$SGB+6U@)^>B)@IN1>')5E"2F:*Z\D+?C[V:L`9;AIGX"`?/<Y;2.YYN:]HH
M2R)H113HER5KY8&M3C]"5Q/QM&VO4EZW0+%A%5.OAA2C.IT]%`T79%-!WR_!
MF*0';G-S0E^S5'#)<S4".L\*/>WYVKOV@&DYSQATH&U'@N8+?!O,UH&/O>7<
M&/27T9WL?4>RY+MO@F4_6$/!;<A))[#A_$E#'S*]!,7>2?6]2>"G0!G-R;92
MO_CN.V5%J2#N"72D&YMEKW=4IN`HT(S"B69*>04"X!/53!\-<(2\F.N.9:I<
MX"@>3:9^%``<;:A4]TQ38I1NI>+U/PL*]E26)-R3P'5/$H2?)HGV)'`]DH3)
M))C$EZ5XMBWCTAU19#D7?(?@Z(%PV1)]D(,9,&M[(C#YO#W@BZZYU46F%-`2
M,GU>1LEX[CU##ND>L[*8*48=)G01ZS.(J(-XH*\3";Y]7J0N<D6&`P4K"YF:
MK'1CZ]Z"(P"<^;P`701N]AR(DDG7H'%R93'CHX+>@J-@["IX/Q\-7F!HYNC]
MQ!_\LL4D)KW!WKJ_%R33X[8C"<[_T)3QFT_6X>CH(E=:E,0#:1;3,Z6WX"B(
M3Q5</KRZZ%(L%M-3T%MP%,#Y[GOP?BP:[/8>GL1B,>.SL=B]V.P%\?B-6/3D
M&CS1EV/11:ZT*)D.8K&8GBF]!<>4ZU,%EV/119=BL9B>@MZ"HP`FBF/"^[D8
MM-O]:3![T/D'QMD,HV$R=CK9]VY-14'7M*HD2OE63YX0`NU6[51<!3-X.<$T
M&JRO85J:=:_;@&'5DH(^$E&P1J**YD#ICZ;PS`@[[NR-XJUY&VZX@C%EOI;P
MMX3":\\?`3CG7!UN]$#M_N@L_P,``/__`P!02P,$%``&``@````A`$U[`P<W
M`@``"P4``!D```!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULE)3;;N(P$(;O
M5]IWL'S?..%0`DJHBA"[E7:E:K6':^,XQ"*V(]L0^O8[MH&6I5K1&Q*3?[Z9
M?V:2XN$@6[3GQ@JM2IPE*49<,5T)M2GQKY^KNQPCZZBJ:*L5+_$+M_AA_OE3
MT6NSM0WG#@%!V1(WSG4S0BQKN*0VT1U7\*361E('1[,AMC.<5B%(MF20IO=$
M4J%P),S,+0Q=UX+QI68[R96+$,-;ZJ!^VXC.GFB2W8*3U&QWW1W3L@/$6K3"
MO00H1I+-GC9*&[INP?<A&U%V8H?#%5X*9K35M4L`1V*AUYZG9$J`-"\J`0Y\
MVY'A=8D?L]EBA,F\"/WY+7AOW]PCV^C^BQ'5-Z$X-!O&Y`>PUGKKI4^5_PN"
MR57T*@S@V:"*UW37NA^Z_\K%IG$P[3$8\KYFU<N26P8-!4PR&'L2TRT4`+](
M"K\9T!!Z"-=>5*XI\?`^&4_2809RM.;6K81'8L1VUFGY)XJR(RI"!D<(7(^0
M;)R,!N-)?@.%Q(J"P25U=%X8W2-8&LAI.^I7,)L!V3L;0G_>=P:6?,RC#PJA
MH+8PC?U\F.<%V4,+V5&SN-9D9P6!Y.<*(.O'*_!!EQ4,!F=\*'+QCN2LN"A@
M>%G`_ZU[,;0(HS?6IV=NS!PU81\O$HT^DLB+2PPF7A--TW\214T>)I#ED]?'
M,6W<YSCNCF[X=VHV0EG4\AJ@:3*!Y3-QF^/!Z2XT=:T=;&&X;>"CPV'F:0+B
M6FMW.OCWY?P9F_\%``#__P,`4$L#!!0`!@`(````(0!"998?V04``%\8```8
M````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE%E=CZ,V%'VOU/^`>)^`;2`0
M36:UL-JV4BM553^>&4(2M"%$P.SL_OM>^SJQ?9G,PLLD<(^OCX^OCQW/XX=O
M[<G[6O=#TYVW/EN%OE>?JV[7G`];_Y^_/S^DOC>,Y7E7GKISO?6_UX/_X>GG
MGQY?N_[+<*SKT8,,YV'K'\?QL@F"H3K6;3FLNDM]ALB^Z]MRA,?^$`R7OBYW
MJE%["G@8)D%;-F<?,VSZ.3FZ_;ZIZD]=]=+6YQ&3]/6I'('_<&PNPS5;6\U)
MUY;]EY?+0]6U%TCQW)R:\;M*ZGMMM?GM<.[Z\OD$X_[&HK*ZYE8/D_1M4_7=
MT.W'%:0+D.ATS%F0!9#IZ7'7P`BD[%Y?[[?^1[8I1.P'3X]*H'^;^G6POGO#
ML7O]I6]VOS?G&M2&>9(S\-QU7R3TMYU\!8V#2>O/:@;^[+U=O2]?3N-?W>NO
M=7,XCC#=,8Q(#FRS^_ZI'BI0%-*LN*)1=2<@`'^]MI&E`8J4W]3G:[,;CUM?
M)*MX'0H&<.^Y'L;/C4SI>]7+,';M?PABDM0M"==)X%,G87QQ$J&3P*=)PM.8
MQ<F/J00X+*72IW(LGQ[[[M6#T@/BPZ64A<PVD%G*(T#DM^6!(<DV'V4CU130
M`\SIUR?.'H.O,`V5AN0(6?N>@;B(X@V$N$$"H'?C"+(MYR@;$8[\EEX-(T?(
M6DV5'%=AO7`(@#`V@??%D6`0T1YY1#I&2&0ZMEXX'4=+.I;@K0]C,)+'I&.$
MI#AE,8\3-U[8\204X2WLL(+"GR^'!!-6I-<<(8EBQ=9A$JUO_:J)*EP`SX29
M28=8LH28!!-BI-\<(9$B)K*4L+*C$;]3N[`"YFLEP802Z31'"&J5)(*$"SO,
M0I&8N".4W-VL5?]^04LP896Y4N0(0:'BE,A8V-'DGE#9$DH2[%*R:A47-T+T
MW'%3R5A1]Z*.2@R,<+Y,"DU(35Q19MSZR(J%E)5.H</IG9)BQ+/?GSV%)K3,
M\D&M-`:KBH<BB\@2+1P$R\)T;4K`U4QZZ.S28NBXMF<),VI-#C&:7)9RPK[0
M21`0K7EB9'6I29>=3PT]V:%&?9PAYDHM(W9;.'$6W=6,V/S,37CJ]X(0R!EB
ML*",++@&=!#9LW1MXJYLB^Q>GJWHTB3%E&N,[CA.">OB?MPEMLCNV=3O!3&J
M7&/T^HM)N'##XMX*6&3Y;.KYU-1SC=%E)M(XG"AF^SZ/!&=FD;B:+7)^ALX-
M57X[4EBCULOSZN[RP*M.4;J5.MZXG1./GUGG4[./3*EJ$HA!A9(T)!57,#L.
ME6X6LD.0$\.?1U"U<ATVHL:O,;KDX>>#NX$63AP.]2;N$EQD_1R/V+:%1:8N
M4#F-P9+G:UI8=\,N+6G1LYV5HZ$[M,QX-2W$:+T82\V,89'I)`C(PMA4A,ML
MD>?SJ>='I.-<8S2S++..6)J9LRF$:6HD=ZD1UW]_&^=3MX_(9.4:<Q4MC(Q#
M:6J81`,$LP`NM466+W]]$LNGYX=<8ZR?//J-YI):9R&7RB*3YU.3IS\F<HVQ
MJ6`K7`/KZ,Z9F2_R=84FIF`2ZR*W75NPD-$-1R=!C402WSM`\$6NKM"$&JF4
M7&.@7F[.;RTQ74U7YW\3X\XB<?X?U#JZM;WMQ!-#18P]B]8;IW-YGV&[DW3U
M-=3L^R14*U>EV*QDG$"-P<)))L<_$KYC46*1IRLTH47-4V.P;.(H3.A!IW`1
M(HJ9J4U7NT7.+J;.'E/_U!@D]R"$2!-2?`6!P'9HU9Y+C]C[O`U;3&T^IEZJ
M,7I?)-'"B3YP$W;9+7)X,75X>C^3:PR*QT/P*C-ON"@)`JX(3'6XY(C'SY1N
MZO7TF)S#=:[<#_0MTUO'51?QUG$5[W/QIK*M^T-=U*?3X%7=B[RKY7`C<WN+
M]\@YV^1<7JB1]P7<+ZOWP2T`U[N7\E#_4?:'YCQXIWH/*<.5M(0>+XCQ8>PN
MZ@+QN1OA8E=]/<)%?@TWA>$*P/NN&Z\/\@KZ]J^!I_\!``#__P,`4$L#!!0`
M!@`(````(0`R_6&4CP(````'```8````>&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULE%5=;]L@%'V?M/^`>*^QG=BMHSA5DZI;I56:IGT\$XQC5&,L($W[[W>!
M-*V=KFOR$(PY]W#NN1<\OWR4+7K@V@C5E3B)8HQXQU0ENDV)?_V\.;O`R%C:
M5;15'2_Q$S?X<O'YTWRG]+UI.+<(&#I3XL;:?D:(80V7U$2JYQVLU$I+:F&J
M-\3TFM/*!\F6I'&<$TE%AP/#3'^$0]6U8/Q:L:WDG0TDFK?4@G[3B-X\LTGV
M$3I)]?VV/V-*]D"Q%JVP3YX4(\EFMYM.:;IN(>_'9$K9,[>?'-%+P;0RJK81
MT)$@]#CG@A0$F!;S2D`&SG:D>5WBJV2VRC%9S+T_OP7?F5?/R#1J]T6+ZIOH
M.)@-97(%6"MU[Z"WE7L%P>0H^L87X+M&%:_IMK4_U.XK%YO&0K4S2,CE-:N>
MKKEA8"C01&GFF)AJ00#\(RE<9X`A]-&/.U'9IL23/,K.XTD"<+3FQMX(1XD1
MVQJKY)\`2O94@23=D\"X)TG2DTDF>Q(87TC2BRS)\O]+(2$M[](UM70QUVJ'
MH/-`N.FIZ^-D!LS.G@F8_+8]X(N+N7)!/A30!DKZL,@NYN0!RL#VD.4Q)!TB
M5F\@)@<(`7D'C6#;Z1I=$.2"T8O&XD#OTU@&R-27RN6U>O5B(`!87@MXWQP'
M+C%0'3;.X]'&`5)XY^(H3H;+JW\N#T1-3Q'EP"-1HUV7`9)[44D>A]](V?N8
M@3PX'1_WS(%'\D;ML@R0("\OIL5YFN4C=4-(G*>38GJ`#,3EIXASX)&XET8-
MG10@[XH;0MX4%RZQ<#Q[NN%W5&]$9U#+:^BE.#J'!'6XPL+$JMX?P[6R</7X
MQP:^-!QZ.8X`7"MEGR?NDCQ\NQ9_`0``__\#`%!+`P04``8`"````"$`AM&X
MN3U$```1WP``%````'AL+W-H87)E9%-T<FEN9W,N>&UL[)W;<AM7EJ;O)V+>
M(<.AF:8B2)J49/E0+G?0%"6S6@<V2=5T]\1<@$"21!D$4$C`,NNJ'F)N.F(F
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MP^5_V_CF^>V\[GZYO[?SC]W/#CCNR([\<C*XZGZ;`#FI%^.94#*J7@R6O973
M<R_'S7`PJ?ZY'BRJER"SV;AB>#(LO/;9?]SOOGV^&(AAJK/;FXO9I/OMV:LW
M[[J?!2*>UE=CH0S2OAW<].`_.WC[ZN#-N^K;XW=GA\=';P^/SJKCMX<;%CN$
M0Q:<\ABJ_UC]0WW;?>YPM5B(BTIL;$)=`/#E>%(OJD-P>S5;]!9\/5A<U=7!
M<%CS%,^,6)J_NON&M0YG-S>S:76VG`V_WZ[.K@>+NJG>K98F7J"O^]KAC(-,
M&U;EKV8V&8]LBV\'D\%T6+,`TM146^_/7E2/'G=?/IY6Y]>S58/$--M(UJ1N
MFFJVO*X7'\9-737S>CB^'/>EXT4]3-+1$X"(P$'3L/57W3T/!\VUB>A0?]2_
M7XU_&$Q`>(_;$,'OZ^7@8@(@]7"U&"_'=>^AX^FR!D/+:E$/:U;BZ>Z&8%[*
MHKGCD9-%/1^,1U7](UJIZ>]RR@Z+\5"T$]3='=X)8Q4@&N/XN;O/G,^6<-W=
MSZP]\78UG4UWPHO=54\6Z-$%BDXZ3[B<2QWP2KWL/@JF!M.KL=#I$&Y7X^G.
M?#$;BNC@$+$?.F5&]0_U9&9+=5=Y-9N-/HPG/?%U%-QU]/7?'0:D3<:#B_'$
M2-SCF$3`^>#6V$&''0R'BQ7T*%[LPLI[]LAP=B.R#I98`4?4S7PRNZWKZJ*>
MUI?C/NL=-</%[$-:NR?2+^K+&F*/0-L/]7359Y@VM>^`L;?2G>1&Q)?H`$B,
M39PVXY$4BDX5=]@,Z7+PX^:G'-RXR!HQDU8:+\5;C<MN!&2XYN&??_KYIRXM
M3)]=SR9`W/R=<>KRMD?HH/L:UWV/]G;W]JLYQ@@%L:I_5>T_W]O>V[/_KQI7
MC(/5\GJV&/^A'FU7S[_<?O;EY]M//GMN(/+/O>=/MI]^^2P^/&X:<8RX9Y85
M:C585@@>K!_-_;8]@HZK;RZ0Z_`QYAXA02,NQTA'#]$'HQ'<.YLBY%(E.^,I
MJF(^1NB[J(`M5S>KB:GI$>PW'/=DM7S$U#'DOIDOZFO8F-T17/Y=5UN36=/T
ME+H3TY#807@7DA[9[>`/>?.!5N<$ZX6/52_'.!:/-UFALR6X,#?FW26V<8KA
M&H/&DUEC&+W#8VHS3&*5[CG;C_58YT&/._,\Z-&"N?K/K[76"0-8W\OJ'2K=
MQ/J!=KO^<5C/EQ7>&.8>C%>X`(./,>>EL]LSYZ=!Q:V1ULED<#$+&FAPM:B-
MB#T3C?%TTW(E%Z[WM3/A)D4:<(';&&US#XZTO@3[+M.%LI?G9]9C=#.>FE,I
M:>Y2R4&2984,Q=;=YUXC?M7E8G93A6?1R=UGDH-B:L<<!9?>M4;:5KRH"5J2
MD*.X^_;E6S=<OGG0!FL??%LO*VF)+EC?#IKQT%`Q&D]6<FQP&>S)BF.[QNR^
M$YS1E9Q-J3=4TLKP<_%G++9!@[0E`<$MM)XA9X,GF]ZKT"''KAX/X(?V"N&+
MS2'8X34^DE"/,TPP.I%EJ:X(0BNY#C\,QG#\I-Z!/CL-7NL=CFE[XW4D>!@&
MY"2_G,P^;-0%64(.9)HVN%"CWZV:8+^7,PP9[L.0*"13G4_%`>:41PIG"2!<
MW;3TBQH2H;"3=S6XF2V6XS_8!UT6.BB^DZKCU9OQ"OF95C</<??-C=B!WR"+
M^"^Z==U],ATO!^/@0&@_COV1#E3A-H]OL.P+&:KN=I*RH;%.(]XI\&8QD,E9
MX5WU5-A))_ZP%]SPKW>;;4.Q!O[[#[B!H^KBMOJTV@J4>UR"D$C7A?IX^@-Q
MC13<'9QSLL(U`M]FF1Y$HS>#90C6A/$'O=+:A".A@KHQ31?XM1@8IQ-EANV^
M&!R,>TZML*@>!>T^7UU,T):S2[Q^H<L8R<+TX*I*<OA0/H)%W<-9L\;029&;
M<XC\N?L7A*XQJTVTO)RX'\1:"N:$@P^#Q:BGO0G["O#2MAVXNB=?B[)+][<X
MU6:4Z46,#`J1I(`TOSA/]NR^$/YPTX/;A%Y7X^DT8!-ZDZ'JPGO'V^2]A/#U
M[YVMYG-')-9^1%(+[;O"H/("H;3!O(Y1UDBE,^)V-2>9XGG%%&,+(9.5)`^$
M/"`8E<$U&4+6&U1(UI=GJQN$Y%;@G8VOIB1<AMJ-&$!I"V'HA+3.ND!KS2-W
M.,MOWYT?5?M_^N-___;@[/BL>O>R.CD].CMZ>WYP?OSN;77P]D5U]O[-FX/3
M?]9W9\>OWAZ_/#X\>'M>'1P>OGO_]OSX[:OJY-WK8Y)L9UU:K3U>]Z'S:W(/
M'`L].KW5P5;3P8JPR91Y=(Q1T3F-%;@3.C8Q2#`DGF&FL3/5M^/9&9@AT]5L
MR^SO5EM_^N/_"-_^Z8__LYHM*GRNB@]ED-F6#Q]7UP."J(NZGLH`$38D*LX6
M(Q/@#^/E=?5^]VRW(MB6USA!%,G@S06KCA`H,T<?#,=P&YJ"K<;*1HUOJ@SV
M.">@36+FJX5TQ+)"]`788J5W)4N+^DI!(2&DG5!?GJ6TESUQ]*/;&#DU-PB]
M`O^MLZ/#Q[O&+(L1*)W<;FO=VVJ$/9^9V(I+*TX@!M.J79`N9[,ECP+&0MPM
M9&!,/NK<(NFD7M;%P3.]=B&,;3R;XW,#,W#<#*:#*]-U!-N`-BC\DRUQ`+YY
MT`U350@FP*84F#XKGGTL@VYI$(">$K`WC21)I!A49OFA;Y:V3/8HO+LQV&)=
MGEQ-R&_H;>%I>4U$4Y&,59$`A<,6;UIY@DJQEI`<=Q[#)>/I"/E55!'Q'===
M7I-IN!G<PG@6S%@Z,6YVJZ0[F^B`,?/P\T\Q([%+FK;664.JMR4C%R'5:X43
MB_V4TN@M\JSZ0*:4`&D!;"./''3,0@+OD;N(-,Y8)1'[UX9:P>*FHC[Q#PEU
M\33LTX<#BH-DG,]196(F(.!B.R/V)<M.9B'BD=EJ`E\B,)2(!``H^-UJBF\#
M0Z5EUKXKX<H\SFZ+&N'K(GX#J/>>>=-INKKO/4>#\8_@:PI>_8A.!(99449N
M&7AV[6G\Z$!//N[63_Y@40WRW13B)SUT,_@>CHR`F:K!ZUS=S%T9&=\.\'V&
M:"TQS$U,I\]Q],$;(.GSM>`*^?92J?9-VR!ZRL;B^E_-Q/4*(E'B63-4M?)^
MPE5%BC8#J+RU3*]>&JHJH*)5J9.#M93NSZ<J7*Z0:X"5AC/LK4ZY70TG*">M
M1*+?UUNL!A,`*@*(&QP@'`E+@^+!K)KQ5+ESM-\%7I1C*\-F.&E%'_H$OI5F
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MA-$2A+@6*+K16+%&5-(S=$?BY-VN9@D)NNHTL_.&1T(X(Y/HM1[4IR<,H`M.
M@J-0I58JF00\0+W$^Q%6<GK/CCR<%;D__!<,2Y`F)4S0[T)Z4R]^&'-&^SH%
MJA](8NMK7L$AAEOPARRI72N05<W2<8AR6)`P="\!OH+'D,81]*<1X187#C*0
M25<9QEP>M">;:<W+\8\`@?2/<$G0D\8?SMJ"&SWFM2:,M7R>@7,09(+Q6&T7
M3%I5)_A`4G%&N(PWA`2/7,GX-FJ6MW-)@;D!%ATTU6K.NY"^D6O/TX#EKZ(P
M:WFMBA6!8GQS@6L8=4O:*N(0Q8A^NB%5TE@PRMYQ@1M,*?(WQ7Y$I6'^Y.QV
M,%')5,F5RQ4Q>1UWKO_T1\PV%!FMT.D-B:RFPU4+-52\P1V2;UL=A;#T(!-$
MKX_E*+D;.QC-S%K(Q!V<O:_>SG9__HD.CB]W]I]N)WP6'$H8DI9_X30U*8ZH
M;VVUI27#:J'<`8#ZOQ/^I_F#"D2TA^Q]\NDW7T-A@463"7TH^_ID\5+XMT?.
MQS?@XVW]H3J=86CT[>4`_-V&%?3!I[:HM:U\U<P'0Y:9BQR+'^I/OMF5LP.U
MG#\*!I6'"+.9-335A(*IJ]\,IBL<TI]_\D82_M=X.S@5%54@1W#@:F$`CI#L
MH`Q="8'09H7"*@30_3@D5RXIJGZ&I"&J""T2+%/).X4]'+O;7^Y1W:"#AR19
ME-F4#47(J1ADVX602D0-E,(`LK"`"TMI=PHW,H#!.8L"QS=BP6(5D/$!B4TR
MSDK]=:5_3+SCRA8Z#$)ES1'3-II:$WF;X7%K3YSU*X/P3H0DN\592`YF.,!]
M\E=((2#*,BR1VH6[D'!FJBV"!`1Q7S@*!JCJ`90+2(M?K:/1;G5RES0E01+R
MHR4L]"U9C45]"?8,WJ!IMJ.T2^6HA8`RT02718&)RZKTCW1U/*!IYL7XZAH6
M@JE6:!AMJ*#6M*;,5$K.=1R*J--"C!&I*'3.T->VD&=KA`_^D@&V4'M&;NTJ
M.D_.7_&(U[CZ(!=_:275N>$M#X[B.]%.NMM9OA*VQS[[J89$\R$<U0>%,!L7
M$/P%_U-L[J3$/U=NVV$A8[5;'8:LK^M!,!;W;SS<$I46DE.4\$#8BQ5D]W=W
M*S?5J+'4FL;?]^G>P242:\?H*M[`*D&=2T7^#;2DF8``"4)96^QL.,Z9$[EG
M(^4V35"B+DH:,>B_Q)L%=<2<7ZW!V_*;G_]7U_$)7@=6F)HH5+A:T1\E'P-R
M1.W4W1,M)6=CN[JF!410)UV,LB1@*4`IXM(HWC@C8OKX;OEPU!,>X.60-BLP
MYZ*D1=+.O^J>*T1R`@>[HTB05^,Z+0C;F_*4Z:2(WJ0*!VPZ(01"RLR-NAZ3
M]2+S3XAIKIKPT'Y"^DW;!]\`5RHMAG4<J4+F[6/#:G;Q.V^;R/I_Z[=G[XX>
M8W(P53^$LMJOP/9X,=J9XW;>%H^>GW2?-!1K!7EP4S(PQ1J`)6`O$,0DC-(Y
M;>BWCLY.?/MI3:X/:;+E2#95;*=EBR4A:)<`V"DYEIA<;295&=0\KL)X)$V)
MB;VFZU+,\.=22P&FVS/3ME+=[5/X'AW?;?G-2TX1E7KI-RBIV>7VDEFP?^YK
M-,EV"/RBIEZX(=MMCP>!$D.88EKG]F3#%=DT&Y[(E=;HEN/CR%J)KX3J#9@`
M^R5C[U;_16$&@=?$XK8[WG0<NG,1C4CR8V(@4XI&,NR%1P4'B%3&0SU>"SS5
M_1SGAH)$X+X8WPC0"`5<17?RV8EI2',<BQUSE!+QB9DR<*?@R!(;"L7,IFM1
MD$A$=TG4F5ACHT,C[S"=,E`AIB"+N,]X.QK^@L]:GK#EYLZ0ZYHT,%;+\R3(
MQZN;B^_(KN`&U`O<)7_DX!49;3TLV9Q&_UE-V$]L-_+]I$`LTU^\&S\=U4/[
MJMKR3QYWU@@IT&S7Y7":ND!^HYTJ/.=DHWH2EKN]0L(]$2TF>*65E>*$M\$S
MK:FD?H+#O29@\Z2$PFCW=RP_M)HC5,2GPVOQ5FK&S>J4[,'Y-:$)L6$_!&2M
M@@\*-P^\7J[(N=OR6IQH1K%&U&!Y,8\<6`C&(NP4.BRQ3=[5CZ("I;M3,J^F
M"DN#QVLM7C`>%C,F@X"71#.I,CD!$%>8(60I@6.MEAX(0N*1;'8G>Y1Z$\+F
MP910C#)2.WI&^['UI/&6""+TD+Z(VA-<"=[@.O(O)Y1I27>?>7^TJI%&"[=O
MHW!YTD/I.B\>%:0PD20!,X4[I%X[.8ED1SQAMPCKAMA>I%B7LH`/$@NFO129
M=9,+$<"0["D2.7!H(<0PC$X>W?R4D.@:!"MUF[9HRG0/Z2Y$2\F4;H<K2\ZU
MFEI)#;?RJ&4]+ODF)*;0F%&OI)Q&D"*I-"7PK)8CTV]E/$=GC_AEE2(M[FUH
M1OF<KS&SN&-UBQ()D">ZD%*(CI$B52.H?P]?69>\)3_5/F[H2/MU,09FU?8I
M\B?]4Z$9":0#[0W"3(RLZOWYSM>DQ\43?94?:9<!3##%9CK#`F&_I=&DJW3"
M^L>EU(&[`B'9GTMGAA[3:ZGLPK*A+]:8.3<%SCV!V*/+*1J1'0YR.'`6PX&V
MHZ582!>(^IF8XVEUL+I:P=X8AV<&]TMO94#*URU<?3LCW`!7U@2\]HGW%B54
M2C<]5@K+EM[9_VP[1QLQG!J3*?IE$D_?O&AU++Q/NE:I/$])XW8?F==OVN_`
M&N<M`CCT8!E!YM'JE=55^`QM/76\_JT"PI#!VW\&-E6NMGR>_0O.M:)SMR@5
MC;0\&)C29*]CB2#T:+:ZP/NW1'V*A0PK,<4+3[M)706L>+6)SX054\`\$H4\
MBDRL%Q;M(QA;>&YD.&UFRMNJGT!$,1-F`H+"6PV1ZY%RU)175`XVUJ3H)QON
MZAXWR*WMNEUXG(-DQ6"BR>,Q<FTC3Q;6*G/R+Z*&BOYCV/MRO$!*4`(4ZQ92
M,0C,<Z\<HC9QO5(.`3-'59$XN9U2&<TXI*M:*[[8B=0,-S2?P5_G="554>C*
M1(+F)MU)6EL@C/9?15%5WH*N@%%;"9&-2N`-!?4_3P-$'MS[\J\KWZ<A>VPU
M!:23<LL05$F;_OS3(1J-UOY%:/GZQ>7UFY]_RK*Y]R6R>4XU+USF1%U2`2,K
M(,U#!8/V$CFH94_NS8R8Q#@/GK;>4UD1(A=Q?N%*BS>C4T5!T*(E0X"$,R.`
M"U+A_"8KS0J6I->3_6_DR41AB"L%JV?^0Q20,HU-,P;K+6YS*B(^Y1RNZZ5*
M>'@/CV0C\?#>ES*KG"59U@@_I%)LB<J@"0=AO^)*%*:;ING2`>)0TX8:GDH"
MTD'I7,(+_V=V5<*NXL^EBE+N#DEB\KT>^UY"3EG5^D58"F<9F!11J*]!BE'U
MP1X4A:+@+$'!6;$ZJ2W2`<L/LPI1#NURAD@/B)NOJJWQXY]_LA#:)#Y&0^R^
MS'E,]`<P6>SM%:%NCI2MS=L#VBV+.UJO6XA.HET[/_Z5L+@U?N"VR?T(UVFD
M`ET9BI"X_4O4B=1;F01(AY"%A`RI[TBGD/-#RY_5Z6)7#4L!,'P"_/(R$8+D
MIX68HG=BIYKW!SI5+3S*4)6GKK:0(?<?-V,FB&7D7K%F6^]O`(6@*?59>FXF
M]^/(KY$I:`N,M/!-"'A<*9D9,39M)[\]T1E,B)=+C'^`3<9B@S'AVR#%D,:6
M5M^+7T($0<'LRUB*&MG*Z%^0QKH^DL'BA5)@'VITUM@8DF9JU?BM;II5;W*?
M1]L=;3V5_;3FOJ[+)Y0[7QX<GU:_/7C]_JAZ<P34IT=OZ+WLKG_.,:/]#NTF
M("PD#K(!W=!]`)5R-<M+#JB*T#>G#%!3$KO;O0M!8RI6-QRL,+R3K]Z:1A89
MI+(AD)R8MK:*C1"W%']UD!(6J^PHS9([XHMUTIM6)4SI-SJ^:#D.Q1/KQ]NA
MHKV@X21FI[.C%*X"+E$E*((D*3I(`4?9PF,'ROW!DE00:%H,W?$'C(Y..YYR
MRX4ZON"`7WT!\6>Q*LKDDLX";FGTFHA?8^TGU?Y7U?NI*QN6^?V*=DM%EM8=
M(8.@1@S2.-8<$^"PS`0MI_1YJ@H)9(*F@%^M?N[TJ6_"VJ!TZ0MM&^\J!UR#
M@8A?W-5>+<$A?/)5]8]=L'KP2*X#K"P:,)-S5[,+F4`5(4D.>U9]1"YON$34
M[?GX+\O=Y922J6F=SNR#0N$8"=L)]&X\P.VO1+6NU/@1GGZE,JH:3GC!:W=*
M+"SKX;7-C`B(C=GX`+X17<B^H`_)VS1"!W:P"`6=2^S+EU]-\Y$Q7+OUKC+H
M<^E)Z'MQ"]CJZ1<\4_796>^3(9#8X'%00WDD14=FBMW,Y"AW>X_,^JTDW\B+
MP>T6XD+D-HBN9P2,H73S/_*=L[?8GBZM>E)8AI:89\'<,MT>9@L\[HG%R[7:
MMG?1P6[BK:=V;[Y$X./U3S_M?GQPQW0"1:3P#T+5EV>&AM!='4BIFGL/YD?=
MK5#^W8_>K+OLU$,2AH!0P"[#S@?84SQ,E+EYV=T%#V<+N$X*8503$6]^T)O:
M59.?6M*W(<G<T*N"=V,IA?O>-XKTV-!4Z5JVZP+Z^HZ+_GXAR?I>NJ])-*)=
MS%G5X00%(=_)6T3MZ.,I^F]EBR@-$KA"P7O^?(CKAQN=7H?-TY/NW1=R'6@=
MM+7L2=*W!9[=>$B/X/F/0"?\3U(>+[.MV_6$;$FH4'W\/EI@6I8\0]&N=6Z>
M,7A1419J7=!8=ZV#R/FB?5+W;\(GDFG\J,F8)N#,-BR*WN:L5XO9:LXSO$*(
MOAC_:`OK)2G`K&4M$&PLK,+*=S\WK8*;!U`XT[3O!=TJ(+56"$\6IKHO%K/O
M"?ML`T*SQ-F#:KJR&_GF2,LJ%]Z,VET::5V9TSGK_6A]UJC>D6<]V(H>5:8.
MY*-7M^-ZHLDG[L'SLM%.V#$0/AW5:(&%VVMMIMPA4DA$PYPB2H8?9CL*UD;1
M<A=H;>'R8JS'[?Z8'XN0C^PX*2COU\^-5X'94J+6KYYY>XPWGT5G,-`*5#(M
MB-5CF]1@$@US*$6)V]@<N#4S`-S)TJ8X*%A!/2NNNL#32*U/-/PZ(6=00T\$
M'.(;Q3V\4175(1,/YJ?<',&5(5'&XY(5?9)`3=Y<."8VB.L_&&G!#SL97U,/
M"D`%BHKCDV=JBW(DT5D'B0$#F\<P0MM:0)KV+1[J`MDSPH?9N^7/(A:/FJLW
M^N%X6KU#5C0K@GCJ:;N4/!B&.S6'$%R:RPZJI(*U!0VR9Q.">8X46O$)[UOM
MXV!KO=^=:B1(%8<OF\5;O>$@&0'SC,[&X@-O7W&25`7Q3&&$/@IX`4O:772:
M?9`(MMNX8L$%>N7VCEC?`>307V"(&2:3)R:+O`YEK545O3VR`4=2JP&OGD8+
MR#4^[VS?6E+B9U?MK+JQ9EVREO7DTM-#;?0#O?HB8F)9(7@BE&M9:_"Z"`_L
M?*C52@<Z%&+HR@1_FOMV2:``&(/)+0'9;G6F]LZD,%7*L9.U7-&XDVL/C%ZZ
MG9%5QP7-ZA(@=:9H+W5)Q4A*.E;24N2AXY(J0-):+8T,IL@$A4)N,1P(-*F!
M!R$-?VFY<%^-@5>N;SD!#X15]4#H.4Y'=M@#L?6`J6E4BGDM`4>5?!@W(\G>
MJ]6[,-4=.B3+_;0GRF?4K$$FVJF\G2T\K*%LP='\6<A])KD8/$ENL&!)4TM_
ME9TR6Z?_>7`S_]6+Q[$L"&&0?G7,1MUUF"YT\5?.DU,+\WDHYO6_P_%S_6_2
MZ_\">[&$1X45GY`/C+[WW5ESY:1#Q&*W)R*#6<AGE1+=B!(:+52$ALF(<1[M
M[WZA#H2)@BUJX=&VQX?B:>&=*!NR0C!N2$S,B8;1;`/RR-ZFWJEYPSA-,].(
M`39,6;]\&S_:M()C-U/E^"31A5494+9!DU1;#;?_W@):];P?J5GX(IE%G1N5
M8EHM30OZNC-NT!M%A8O,>]UGMO:WO]C;ZW[:&_#3V_Q-ZUIB]_V=[@<\'@>K
MG6T,*`I?G!(^(<4!_'V$9J*HE=^Z+_'U5'W^!Z?_<'1^\.WKHXIK?N]/C\_7
MW!\.E?KBVFF2>/?MW6/HQ;20[X?>5`Z)HLNIO^NWO4-(4*;(R)'WWPY>@Y5;
M$7C=_0F!<%:9F8;;F2.+D2&ZC"69U.@0UWN:`*(PI7UK/`V"\CM04L#=*4^*
M7#2GP<&W;(75&O'&0RR(TW:+)L'_JBOO8#"6-.]('[LU[F6II<T2DBT"LOX[
MM0),EVX`#ZW&R9WI?Q7D&0J]2B>-C(*D';M'UI@L]M`2MCXC`PK\,*X_N&,G
M6,)B1AE3/D),^0*WFS4IT:HK`W2IKN0E/R]CW)0'<EL"=,&\N@^F`:WCQ5*=
M2I+K,I>90CFVAN,=,#C=0;\J7%[<MLZ9TID-]I@#K4CK$;[)^T5N2UN:BM)E
M?6C=:8H(Q<`CJ7!%FDDTX2Z*N3RAW0(\>B:M8Y]D_:S'Q:))06\+E:3)9W;U
MGO/$:'!WL&VG*<EZCDYZ#5UL+1N)41R9-8D["4]!KD![*UGKJ^C^`*Z8W![-
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MPS0Z@E&!U4"@QYNM^8JC[)ZZF<!CW3AS3$J;&Y1#C<)P]S)!M@DJ/(`'0B52
M96?3!I^I[)(Y^1ZX>RBNAP.E(J+S`NQH%])4">EAA"'W5C>?V.YEJ<5!J/:J
M;A^A14K:K13Z!?\".T*_Q/#[<*6+`"Q78Z19=^(AW<XM;0AMSJ(%ZA6FO+5:
M"QT!3)(2&GB'82E")-.I<I6<<`H$@.R.,S]<1$4SZ^^QFV6?;S]G[O;SO3TS
M4Y]O/]UCPN=S2M@P81K-V1/4-X/?(>FIM6:[.O&^Q.9Z/'?O[(S$G]]Y/B".
ML8OC76*_6US1[N5CS=!2,5[360^`\40A1QSK\ZZ<8UF$<_>(^F?F+?_FW6EU
M^/[L_-V;H],S8#TX/7_+7]\=GYR9"C@[/STX/WHEA?#Z]?&!YEUW83TLKV=7
M!QM',[:?$ZI?V[5FQE7'=]R]]7YZ/-'AKEC\NQ5W]]1[OJ`LP0S`8<]Z';>:
M]Y\E$0%%:@MF$?,;7TV("2?5*;A3#+--J)%&#QN),0>A!))1W[V"T(=Y2Z+$
MS)\`=CJ,#?^Q"-*_(:&QRO-X7'2B,`L;X?UA0J<%MY;/0>?H-KI!JV1Y_3T\
M:!-\RHQ(<'.48\GGD&7*F,LE[K"S>5Q_(%#01`VEXEZ\/=AAP(2I9QRW90T%
MMO[EY<EC+VURX?G*<ZU<>IY=@='Q=(9#12T.?>`!AW3%!9EW>;^JF3!U;V#X
MY5+(]VKJXO*7\E0*ZKF!<?BB'_*^CW<E(E825AE3'L8Q%3C['8V22@K+`UTI
M3*#12")BH2JG("EX0X^1"-4#+'QM`.H!X)''JE<\!W[76QD:U+'4@C25*NC2
M.?B>.J:[F:8U'"`!7B9O0HU6,2!>Q&QU1:<4@'@KY;5Q?V=@2-1H_@C4*<4C
MK@WCYX:%+G,:@-IE26[%PCTIT2YR,@(*K%!W4/%:[=8Q;.V>/.'^@4?%)L09
M4T"!M!_[;#V_JHO,ZA;]B\7JJMHZ?DN2*U0-K`-(N.A@0):1&&+DP9B=4&3U
MTSCP@2>V(W^M(1]`Q83>A]EB,MKY0/6%(#:,;BDH:(-D5HK>W/O0J4L9M(R:
M\!ORT.K&L!RSFO--J.^D%8D#6!I:<20SPG[5D7<2GA5G^4V`T!QG_*LZC+-`
MS&WG>SV=N26!/V@*4WA@N]GE;,505+KF4L0ZUE+C>^R2M5+;C*?A<<E[P<.<
M,X@H"%\M`'Q!2$.P%P57028T#A?#V6`XVP$A-TI_L8U.^IZ&.LYGUDP/,]6@
MBSO+_(EY>UQK@$+OGW]Z"'8]"`WG'\@2I?2T#?S,'I<XS3+Y"5[9XWSRGBL0
M#TRHZ1V4G#J.Z`C'T5P.T?31$P:0I\2FW98RZR7<FOD25KI";$WBL137K@19
MI[/=-2(7P?U1G\4/K@,L)%*?/-]]FG8$[ZFT8KMKO_)*%#!FYHE\)Z46S5`Q
MU:@0C7Q;#/,`W0E^)OKOH_WGG^]^]F=NWY<ML::-%BGVVXWX2O-.FL2"IIY%
M:W0D.AL.5%4"\Z6$E)5U,25,6C,-8S8\'MF8JSQ@IG\T/RQ`+)-DX!@>25,E
M(DN@;]91A5WE:BMY\5'DN)L(=G^@X]FLQ]@Y5'>_/?0,0_8<Q-Q'[+OW67,V
ML02I%#'Y&GZ3_<P\EV\*HC)UGRNHBJY0X(7`7D^^?)H+!:5C<H+VJ:M]T:J'
M:<EAR97B$M.G?"'XNN8Q*IKH+S0=@:0VF!2])4!+O^PNZYS,DHDQG!"Y22SJ
M,\$PBEZYD`U.@/:59!P1-2`':,ZP;K$P57J$2H#)Z/@!F0JS.6/HZU5$Z<+$
M9V7IDKB.`BJQBWXW(DM:9M5\<:M0>99:27C(CUA%3GWE9E>P$CZ)G)5C2<8N
M/>87\)[:]]BZI.\I8.*KM83>[!<IIJ6AP+=2NIT5T*!*5A=33P2QY:]1%OSJ
M`OCTD)<`8BZ[*`L7V@`XGUAG';MMAB*[Z286_KL3ZYI--VJE)"T><L9TLD&#
MR8S^@#,V`I&TS0T_X6,0V[5!ZY<PUBC([?1B%1-0%93+W<C6%T=7P5W.B277
M38K(PO((^+"0'H#D9\7+OGFAW>I-O&?,$3:_X?5W7S1>J,+,!1UAMPJLC#'$
M]D+(=//7NT/0(1_(+,/]ZC`%"XNE.DM"/ZF0'TAJ<1+2@J2%23+<;G)?)0P&
M4W^-9"BJK*$2&E@J57$UZU-*SK(9=ZRZ'2XD2)Y3?IZS?X"?2C2M=)],GMJZ
M.]$YF!87EB&P(4+;&W:J#W&24D***,N5"-V)L&?]"8=?^(EV#.63&.:""/&J
M+,4&C.&U<N,RS8F-!'=?.*D'G=1XO'TU//,!WXK30$)B)"3*+J:4&(F"RL*I
MV*R(S&=GN:F@Y1YTT".<K\IYCM!E7F`4^VK+%F(4F.,1#,(-2(L8-H]S^XB#
M3>FCN.<L::Q1]K@#Z"[!T=4IPN1D626E7O'+S58),P%?YN?$V5Q^W=FRMES/
MZ2G5LUR+$\H\]-@(1G1X0E].]+.1L3@A"B?2KYWO7*!VQ4S!BA75SA2+V#+"
M5G@&KQ)F4%XTJC3%@N)C/_)2_=B>M)`*7HB&I7N6XF!R,W-=;>(@4:D"2LJZ
MV-](_AU17@'Y1P=X$4OFL7=099:FP%8.1A/F4"RJIJFCG;XY_;C8QZ&00P<(
M4@4.)"PE\A&MCD[%U?WQ7#G,*C-<8HY[+?0Y#Y56T[M=K1E<[Q<S2%I=X.7@
M![2<&MOP8R`?S.!,F<ANO##=\9NXD;3DT.*X2'Q\'TO9-^%P3!B[GC1GW`?I
ME]AJDA%&`Y>(0!M_"D06]Q"!C,_2C5;S9&3J1COVTY76AV4@1ZDP^Y.,1!]8
MUWO!#,'']Z*[.A!R6`@#M"9`3-HRZ8.T>8Q3@YZ7L>.P9*[59[9CQ7(O?'LR
M0'*TO-VQJE;LRP+`<#$NB91I"XR%B7FR<(D#W-UU*YO?B;3"HEBM@I82?(XX
MKKI]+'E>>"ZUA7%1_4.51_O/=O>EWJUQJ'`4'L2EIVY'9%"2><G>FR4-U#'1
M2E]'`W!_85`<:E4',SGRYNUVSWW5X_->^U4W,Y\0U?TBG(?C3*SR!5\%%FPE
MZ7MEW%,_OED+D!IY!#^]OT/(OD;B]1_PK3WR%@IBCQE,$\+PC.(H(,FW*2`7
M!7N1&?&&&D9BB0IQ)6FC&Q0PI<7SAYJC,>.*Y8!D(_6M)<5),P:GUCBK+CBJ
M=6_P[^D9)TU]>'SZACE!5ABB">U9XB6!S@<YE5*4(!].>V52BJ)2=1HHLP8]
M8BS7QN&0EK@(,ZK7I=CO0&,\3A8-.TZ9B_JW.$Z7^"TN,VO]>GTIZ&S#+"=9
MIGY=R%9Z,1Y<34GGW%LG>F*6(AJ?EJ,\@%NZA9^H^;.TQ\*/`YE<KUSWL2_6
ME7W$LG%C(=Q7R'N:48CJ/_D@=KQAF4.HO#K`<JDV9@^-,@Z,IU'+&F5%RU0H
MNQ3SC4K#/T693RR;GOVF79*Q(PI#@KESTK;JS0=1]W[P"8KL40]6!5T9TIPJ
M$8,WTKC6H$?*F48M?K59-8YD4&RVF'6XAZ]Y0]ZYQ)M,0G4QX:(\R?K9T@*O
MEV3IU%GUV^/C;?T/_WO\3X:J?_+\+Z*DRE&9D#<P%-U&(];:+@8<N)Y4J17%
M*!<M'S"?2O]2F6Q^S:^-#BPY])L5R@1E_T0_MZLY90EL?D-B?$E=I=C%U^74
M9;Y1+D:WX&$/?K>RC!;#F<V)"Y2FY=OVD6$4"<V3UBV>U%`7/3QKY;;PS)UJ
MN@08(RW71N6T(O0K((0J)T51\UX>,=<6A#E,A.1W^[5_6410<K:B@LS3";&%
MUQ]P+)J)DTLY,SI:'8X#1DGK"%J;?86(-IK."^:-DNW>$`1=@S=E,1LN0*G'
MTG,X^B!3S1KY]*LLFOJ-<W9#-S-A>=9..H1K?C<6.9/:*OWTPKLL[:W([D[1
M!S29KV[Q,YVSR)&7%4Z.TRG[\;-`B,_12K_*!7<<QF+;N::U5`?%Q?^MP_,#
MV6-$*^JE-5"LJ];UR.LI"<B0E(!()Z<^])^(/.DL/`07\[,[ZDP1DHOYN/:C
M/3[R5=E4?AG<S@.HF>-<T42Q?$!M0C$7DPRA+9N)[/:/``992?>C$GSF,?2H
M*O:+%@<G]MYRU/[3^\M1'9;H)+^%M+BC*<L[JU%/G_[9U:!X<KE0=]=!BO1.
M61)(J2RI<<OW%Z*+;.:2/+$=<YS7$[A@9JN@2&D\^B*?2K6.HOSU1:[VX<LD
M$.ZOO96*R3E7?-$O?I44OQ?_,>.>X$A9MX?4#5H%@^`GI10(-P'U8SIQZ"8H
M5@LEV`H/4K[(^8/LJF9G"!T'M21/:J`N"A!)7'.)X"^O*729NNNZWE]2Z*P@
M'?77KRAT@/CW@@*>RK\7%'!F4<MXG?\/%!1B<L=\;VQ-IUFAR.0G7?:Q%83[
MR@8R<<4^_W=5##H:0N8IE.+_TH(!"17/9\6L=I$U&RA7DDU?PEZT@-AP]V=(
M26D$20Z?Y)W)\;K3M5&4\_]G"MG).?A+,\@=KK"4ZU\G@4RPXR-Q8[@=_;J_
M7<[X>6XA*?E28M_%4]=-^*B,L2\6%=G')`TMUP'//S!EO";OZWL?ENFN-6E?
ME\DUR<@UN5I?,0>BGF-\ECUA"V0>/2N0^TOD&%,^SO.]_-KMS6#G8#)B",@U
M@8E/L%$#'UK^M4\15C/U:6P;/JWIBJ'/:+LZUW1%_B9]=L#/8H5(C-@FM%31
MCN]]TOQ7220M>DB9S*LD1U-^>[CFRN+TJLLDZ,G?K*C8\>LEG\<"7+MBGPM;
M&9\I[:@3Y=[Y(NVX\:A;A@7F;N8@WS[)J^0N3=O02NTH7OW\4^6/6O9<@1#W
M?(*2Y@%NUONLE4ZB1;&)Y"7E>3P!%8NV^JI(R[!>S!OJQ3+4*2)P$FVB3`[7
M+0"*!3TWVCE>IY8X822)`3!24!;S71QPS-6?Y8JAZ?EQ\GE*E-%S$*W7'$]#
MUS,A5(IM`/0%]PKAL?23P-7KUX?5UHN#LP>BE_,Y0C.BJ3=:^SHQEVH[K@Z3
M&@3+EG@HD#3)?)L>"]C1$#F=]HXD6)"Z4(;3#=%XY`P23@&3;@*DH!806VV1
MBN6X1D3QS[@A7*)T@M!W$*L_%5=@)[/TZQ@A+V!YR@[#K"4?V9+0]&]IS&+:
MJ?;7"NW2?)NE#,T]MP'ARX-4]KY,.U"&`GQ2/Z;FVS+62G'$6C.#?I!P>*B=
M+VN_B5S9!RGWTA$(PU[)^Z1O&8#$F(U:YZ.P&L9VVN4)E5^]ZR^+2!0':1_/
M9=G=C3EWYF[X83E=G"$#8[HW2H`6YHJPJ2<=..LY+A^AYWI;A`82:3CBJ:Q$
M[CJYTAX)IU!7/]44L6$_!$F>+!82;7Q'JCAWNZ+A/3&CN-J2X)B0+U,9CDPN
M5[J]@>/YT^?;^T^?^A5$*QE']A&ZP(]?/!.7RA_]K*@,1TABM8?2)DD'M-2:
M+RR**GQ;%EY?(D]%]3Q&U<8IALQOPD[<-*:<@G'8WXME3*[52\[3KQE@5:AR
M6`7>I3B>4_%=^*TS$9:9XYN*ZI:8=`E)(D`BU9)UZSN4D]F+X%J;)F=Y]%GA
MV7M_G:6S[,9^T6::TD7K"_H)#,EZDA<S(M:]U=Z'?0L9:($D^G*4=:?HY;M8
M9G]O][/_),Y*\)FPI$R5^"X$G2T]P!Q,)>`%8"<&C7(V],D+*B@7L*;8A[9T
MTPV6I;/?1TY?Q;#(U$,D[FHNBB(V@ROJX=R1L:ZE1T\*]/>TW<?YHP;.W\@?
MM;WO\4<[/W_2]:M>AV(RC!DIUKLS>$>!?9U/:U"96?1&#R51'NWM/DGZ1\S&
M!SFT_2OXM#T7!/5Z,M'/&N.8!-^FUYG1MGN?)6E#JW`HM>PX<V4#5?!LE*\"
M$_J=+[R>*KJE^IOM:_N9'SFEI:%H?9E]S>!A-K;0+^Q@FB7UJ^9XD?3GHBEU
M5X_3FPQ/5\-)C:L_&-)&QS?`9H84+8WN5<7-S*NA6<:8`&&N?_!?/9T^9_BA
M?$O-EXJ"ZPHMS/>V0JS)-2YG6"*ML#-"M:LWGMV]+FU>G_W2I=?G9:MIV/1?
ME8R#0W11LSI_V3S60OK;#H-59!3%O[Q\R^=&7:O$^[$+.Y]+\5;73W5.Q\'\
M^G:B,MY036?JE.1<LHLMB@I<_Z58*0\T5(SEU_FS<AI,D8::^-X7W,B%>>H?
M-894974Y=^&66"X,9-8#);,+81.SNX9'^9KB.IW*$87(=0S[Y$+H)YL=R6:?
M,^6:,!A(]3]WHJ7;#XOQ-$)M]C'+6A+0Y:!B2%P$6X0?!E`%,\$B=6$[)DI?
MC.D3:/EJCN"(#G&=X(C7YN"?*Q/8`;UY-:.J\=_78$$ZD#<?/<^J"8;UWVZ.
M2^:FXD=/BD:FL"%L'^,?PSUZ[EE>C-.A8T.S5[);G#HXLZ8N==H,6[Q<G9Z.
M\+B_&6\PBN_)2O*J6VM==$'XTLV4B,O.+4.QD$4)X,ID3,8R&?$4XZR+/7C0
MI@8"C]]M%1=+.CECP1Y1X).T$E+"9WUYCSTBJ-;T^VQ/W,?0+1'S=LVIA1&]
ME)?<'>IE.HBSO=W!R4=`\E#B+ZCBVH!2NDEP$`L63;\NI\_:\LD)K7'`HYO<
M0AY#ZG88E:(W(T(D<OHTNJD1DC2]Y$G/_3CO06(.)B24NG"Z<T?$?G,\VAAS
M*XT9;,Y4&/86=2G]061K0@0'1:+BT9F3^9'[-Z5-5ZK&?D#3"I&@!,_3?Z+-
M-D&7<@'*M`!>U-[V'B,?P-2CL@8N%/C-.#E:N=O/G._]?>_3<(D-FJ+3^"N*
M\XO1]I,^P1OW0G+QD\3KM)R90P-9I.QQ=CJ:<4!6CKHTP8Y2"TPQ+V]B%)QB
M0H!65^=("^UV*CVHY:.::+-2^AUN!BR9Z43=MU#3<9)=K!$L#;0&L$@2@[N]
MM$<-^F$B&D%1PO'G>IB4:ZL@'((M-$%J2=M+GZEM;"F`[?!ACV"S]7UK([0+
M<MLVQ'IHLZKW"V&*`K@H!(L$;G0UI;5-Y+G"-H'48.5"OR,![^EWCD2%D#0+
MKZW306@<UHV9@!ES'W#$:#J0#HK#-EL-/.U+E\0@4#VJQK:%N_MHZV16E4)L
M##*4_&@IO5BC69,/+L+AS,PMI,?N;T%C;D%[%%+J658)Z3-3_^J-[O3'=CW^
MEVRF^,QD^#1JJI<,0B705K:B^\)'MO_N5-\=_[:[!DJXE4%2BS"<X+?6Q8/%
M)F8";K>9<(VK*%ZPCO1\`?I%&(=Q7M-:E`YP\$&_(E?P`S(&()\>'+\XDPC@
MH]UV2OOS.8*<.IIP^KP/3?<4A:#LM8BAJ*X-EK/YC-PMCAWW_)FU(Y>VVOKN
M[+#!<S^'2&JU]%2D`8\MM=\<4"J)-6@993<BV^0$P'PVJR]D,SDL\CKPWP(F
MJ\7\-=)7-I9;9P5-/DY+O\M.BV;I3+6^<-J*:Q@.@/S9+Y[Q]AG7[,`$*??4
MT;U='6IR)%]^1Q]9]=;0@8JS;F[^>VBQCO%6-"<TF)]I:!P2FOWU9(UM]+ZK
M?R&11$<._%)RIW5O>B#*Z>@XWX01:G2<ZX**]6K[)7,Y%PEI,B^EQQ1SJJ`N
M@D@V9,[S./T7+`GUA(ND\%T%X23$.8ERGJ5D0\HOSN;C>"*JP2?SJ.ZR."F#
MM_TF)FJ1(2\(3]S<--6]P$:]`,.V8/,MS[C`:KYH)E3?G`64MQI4M=:ZDXC`
MK7UT#>!#3;--0ADG<*E,C4U&KO@])RIO9C8,8,?'5(-M]E:C,A6MRH?OQ4;K
MMSD$IXE/S'GUG*:GP1K)@JT``^R'B-1II1EU=B>O4+'B&IDPY\_R"6OP>ZA*
M'RP]U6P##B'>QJ,%OP7VR]`)OY;4]?-ECOPW4?1W7818DZ<Q8%Q-)<EP$[8N
M69.]N%\B68-Y>(.C(^ME3.B8,75NHH4)^&SW>4H@Y:E@)W@T])\V#`RKD@6P
M5U([:[-<C2P>$J_.25`089C0XC"Y.K9,@%D(2_U;FC>9CJ253'S:)L,K*F8V
M='GYP88#M:\:J7[&(=F0DY81\7FQ3IW@KS?R[8;VD]/.PW!?D)MXB[QPWDJ_
M+!FK'3],][SH1Z0X]@_#W^A]/@,%.^/II=\4T)@KX@^\7UT/LMH;K(WG7)J/
MMD\O-:YK`H+6'`[Y:YK5[L<"?-,<N@S.;G)A_BI">!?S_%OP]I\CAG?!9%XE
M(IDE4*KL%\^?%I;G(9>^=JIO-<;L/(\Q6^,"!AE_ZC)N;``310N#D#\O+HO=
MA1-X)[K]'R'3O9MO#Y3M39(MQV^]W[=)9.7'X)@D6>-^\O?(!&)DP5`49[Q%
MM<,7)41SP`;5"3&M363I":L5)"])P3%]8U3C/XT4W/5.S/@YC?L-8/^?YV;X
M[T2@-')/LSFZYHK\-7P.^=0A!V`I!TLIG"LE5>U_CK.<'&<B7_H\<("X!+F:
MF-O<D*5'XT&"GW_:W]MC&F9/H87:$HKS+W4CNI9;K-4CMVJ;:(K/D^4,JB-?
MR?Q;:;PN^%'+_<*@]I425Q1\X->!_>I`]X%7W(TSV3Q`Z1XS_J?U-`-S&R[.
M-:1>[INX_YP9HL=OSP_>OCK6Q/V#L[.C\]Y\T&(#NDGT(P@B:_II!%E>ZS&1
M-\]%LZ1'T#?6#3.$ON%W6$QBU!:*87T*1_,+`82!P4,X)%.!!T*]/J^-84;O
M$./$(QH$[*&^%ILR`#/A!M1,OV3B'!U;*KJL\*9HY\!EQYCK1TIL!PH:%X`R
M\Y\RB[%'_K&(C5ZSQW(>H,64,..U2#'_@<TLU0:0>=X_&6<F.9#MN23NL4DG
M1>,R:E6`6?^`_@!+%O%QT@`L/_?5)?BYCL+,!&O`L0GG%N;POB6W(W9`EA-H
M`.E!S`.["@^T6'?+PZ/3HYW]_?]-V]7V1G$#X;^R0I4*$J$DH2U\J71<$I0V
M+Z?<455"_7`D:1-Q)5&.`*WZX_L\,Q[;.VO?WFWA$^'6ZQW;XWE_>2J'34!;
MA29'BW^N+F&:O/L6V1]J^BA/L%.9`#+R.Q0JO'E?GV`F]8<M&EAT&X\(';/0
MWKU4)A!X.^GU$.?KA0>BK2#B+XZ(C040;[($(Q/K"^QH4+`_,(CE7,3U)3(L
M@8=`<=2)N$9S=>W3!9HG>BSAP/5@V1((F.B-)BR3O^K_9$^!0T+06SL>-U@T
M][#%L&S$FI8+&*,X49"I`2C\G9B*4@AKEN(*0`W5(7:4)+3Z%1Q+7*?*UL!#
MD+^_P(2!#G18Z/3X.>_#H@$2%)P#WN*+M*:*QLOI\P8^Z6K)^@`ML-6^HUK=
M_(*6H$M8*^;2F9ZM[E[A#HMQ!*-59P</:RVUU&(^SBO)1+B/XA%&^BMM6Z%5
M#"ZFH#-4)+1MHB543=`AZDV\1FPO(++(*+>Y;\*1VL#FVCYCYU/$4]:3!I%/
M;&;1MK\`6+W.*LYEPT$K.*T8J"`9A!XU9J*BL,#MHM-`RIGQN(`0$+YHR\)?
MRYN%$&2DG=&F0Q>?T!,8V]2/M>Q0H$/X7J%-SN:?+SN7+CW;@/7\**QGC+K5
MS6ST6[<J]2S#;18IU;JFL33(A_EG(W8BJH:VZ+)PQO_PN49K*:6T%A[9+66G
MC.R:&GG5PHGREE%3X+7U.K)J?:EK1M8J)3C6XR6WJ8!WFF-.#S9VD<"UO/`X
MZM+*,!QE(;3$?C@;'*54Z!=N`#Y,,R6N1^1=J"X(2W&P&<YO4=QN(5PJ#N`E
MS0V5FFX*@9$#16*D_%B$AHE^)L2+BR=<*Q;;`XX!#,WRTPN0=0]+M2@URHWL
M*99`2R;6H',)Q8-*#DN$V("Y7EIU6Q<RHP<RGF=>`CJE%FIQ);15A`BC%FTR
M4ETQ:/G-)XK6B'6!Z)!M1'O;8=83(A<VF7ZPMZWF-ID%%B/?JU\.[B/]3'"!
MWGPRZQ#N/3V7H%T?(0CA8G+ON33(7)HF;+*Y"?;;+YZC@#UX^QRWEO2>\"S1
MQ&TQ1]$%WN9L-B4<73@(MU)6HQ4PBUP'%S8@X&:N7/A;+?6(F%3;JP[!V(03
MRY);IV?731"@I2RH8HH-B!10O8W2X8^43K;/^G89C5!;SJY$?,;.VEG[L8RX
MZ@FTB*_06QJ/L=^!N`:R;K(KS`2Y1I/=<[1.A7!:J,+&3@Q;+\6]0!XNM8J!
M`EZ,VDO"_"D\4ME(W%FH>`!I+,5OIVRNH<:#B8:']'::?PX:C-8!XU^V7HZF
MZ!,":CS9/YF.9H>G)QX.TN/4UUE[Z2ROT,1<W2K`/:Y'OP\B%]>3<:50BROL
MX(8<*<FA?7*=7`FQVO:T[]%]XP4RYTXG<T9ET+ZU^;W"J0)E@$@3DEVP+D$3
M?F@J?8<$JQ$S&D5'DC8J+4#?"7@S'%EPX=E?Y99NOTH_N6/4X(>>)T$Z#V>4
MD;L]@+)OIG9`\*7%-P74\7QY)2W;0!4I#SQVW<ZF^)F6!`C86C8>JQFG&KSX
M,VOQ<62-+_W.3,^O+B_N,1,V9RS$C^I;$QL@-1F$'++Q!R#B=]O5-=6MR<#1
MDO4B"WFH![4$J7XTU,*"U-2\.980H-_]!\^`-J*K$&?V(%\O;F[EC$=W$NO"
MOV'WH6:!Z`_*_),0'T[5_!0D$#5'WARQ\-4AY+MEX0-!9C_S!=%B[(V'2=/"
M1J^J0$L0=#%#J[9,<#G3ZT>JN-8.:FS2F:"](&QZ>0F5A7:)#L05$EL]F6GM
MA7UU_OH/9,B:7:=F*[_FY3%?\<HAAXE-`!:/FH>OIWO--ZO(1]CU$;#,KBQ)
M3UC,17,*Y8)77I1JCCJY01,S^T')W"HT4_(I.F'6D\AOHXY2)4S4_-1CJ3ST
M/)$%_)G1'1,;L`C_YC&"+!FY1/(0_*TUM`23M<S`6[2L83&K2/9J[VCG^.WJ
MY?#/FW^;#2`*?>E[9M^)SS'[\$7LQFG\'EK6);45-/E<8UOZWP"H?:M[_63Z
MI/F3=C8UW4FA(G2D`-\&ST2@R+K0#)YH#2`S5E7&R;]7;*NP?BQ&E'.8<8(H
M;NB<7HV`U`^I3'!`E$:AB<%\`?4"?`*>6]I%^\B%LFERZ3]J#<8CG!YAJK!\
M<3F@=QEEP0"DNBP"],Z'^(\G5L-TUZ\[3@J1/39:;`[`F[T8M8IZCJ*-F9*J
M_X8TGT0L%4(J5<4O-H;LC*IUBBR)8/Z3<2E;0)^M)27"=6@`)<N,_*^X!_UT
M%Q=@(!0A=:!.NP9/_7_(RK#%U)!YX!7?WB$S8CO+?=H4_+&+/.E:X7;::J:&
MO_YUB@GGHI3M53M?KD.>1#H+Z1.0;H/HW!%ORL,\4".0W`N"0_/P-/'W?58U
MIUWE@.7AJ&[?!_4-5WF_T(]SA9#=A@1ACK#/:-2)Y&;Q*Z"J<"2<!U^M6-ZJ
MO1_]$H9I)8/YP/9*'/EY_CZ2PV<>THGZ%OS/R!O".\A]@+*^XQ_.M&JH_SG_
M3N>=DWM)J(#B&,V=YA;P\P2[FH7IQ6`S/VYBL5DPN%%%+V:C4NFR7-&8%-.1
M0#M3J6^0D4C`!,[ATD^SBH]1(A5C+K5"4E]$7\4>&Q[P8WN"O1!=#_^R;"`%
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MI.W%*CY<HY19E_:,E`(;:6)4/BS-IJIGW^R0WC,8'<]!9*UL`/2K#A$\P+G2
M`#O_"..)F"'TH.E/B,X6RXOVJZH?CF$DD+2P.U&,\1-2?8^[HML18K9MG566
MM18L1R'%/LX2(O0-7`_/F4O9%Y.YE.M6+F:'XM_[0LB_5J;\.D)DW[H?-V6C
M67Y5OO>+;%4[R`+HS9\O/E:1@,W1X&>P]4$=U226*F*<6JZPX0$3A.F!!7H#
M8?)L8\TT]I^"I3BKY9%2<]OGJ-DZ(-;Z&5R,SCR0*T)9)4&BU,UT6.ZPQE<E
M>(C](N-`G#-9P\-P@+7#B^=_/G:9J,$#*KFB0:@ZISCT[D9ZG\+$AS(L?A++
M"?6_!Y:P=K2D?[]^U.1C`?+:-<RR7C>;]ROQQS%L#Y!<U^W",9A3;?B=VO:1
MQB.*`7%1&6VOT70:_87"!<G?7Q`([%'-H$2>157XLTFL'),$4NG'/"NSU/3J
M18%I#=R73<3@/HKIUY'\,L$M`[+<=M]0S4VCS'O3:W$[H`![N74D(9[I??O*
M*DM:*[2.#+TOF+%Y^"`&H3YX5"7&,9B.VEMGWD*,XYKS=E<W^.;XJ5:$!!\B
M6NSZ3OR,"$Q!0%KW:"%OA2"P=9AMF96>M9L0=6,E_&?%CE((E0`(U4?!8]>+
M5%%)=3>X>N2OI+7`0KCY_`)5"5CG#99TF)&Z5.>[Y?+#3_\!``#__P,`4$L#
M!!0`!@`(````(0#%ZV7-X@P``.-Y```-````>&PO<W1Y;&5S+GAM;,Q=^V_;
MR!'^O4#_!X)IBQY01R_*DGR6#Y%BM@'2]'!QT0*]HJ`DRF;#ATI1B7U%__?.
M+%^SXFLI+;4^X6*)TLY\,]_L[.XL'[<_/'NN]M4.]T[@S_7!V[ZNV?XZV#C^
MXUS_ZX-Y-=6U?63Y&\L-?'NNO]A[_8>[7__J=A^]N/;G)]N.-!#A[^?Z4Q3M
M;GJ]_?K)]JS]VV!G^_#--@@]*X*/X6-OOPMM:[/'1I[;&_;[USW/<GP]EG#C
MK46$>%;XY;"[6@?>SHJ<E>,ZT0N3I6O>^N;#HQ^$ULH%J,\#PUJGLMF'@GC/
M68?!/MA&;T%<+]ANG;5=1#GKS7H@Z>[6/WBF%^VU=7#PH[D^S`YI\3<?-G/]
M6M=BDY?!!D#\[C^'(/K^-_&?-W]X\Z;_K^^^_\=/]N:?/_^^^-W/W^F]5`V1
M"1S4RWS;KQ4+7\>2>XD%=[?;P,\-&0'KS$$W7_S@FV_B=Q`,8![^[.YV_XOV
MU7+AR`#AK0,W"+4(6`;[V!'?\NSX%TO+=5:A@S_;6I[COL2'AWB`!4;R.\\!
MFO!@+]9P63TK1)/:-$48G$TC/$)M\L`D"P_6VV3]N\0F3M>X6=<Y_N-T,2OJ
M[9*FJQ@7!1^>HROCBN@)'U=SW30AAPSZ?70K):PC9;-E'_1=3-GU^&*6C<R1
M.9%J&1>+1=Y0X<B4Z<H&A>:[R?N+N5.^LBKKDC1\J1Z`'4ZN%QWHNC7]>V+B
MZQ)Q<N$!32IC7'0PR5SB9]TOSX\/CF?OM4_V-^VGP+-\="X=V-BON7$9Q7,\
MR5>1A8!\T:\&^><7;Q6XI>Y>/UGA'J;2;)K%9DL<`9EWV%?2N4W%%Z="YT9.
M*GF&5M?AEC1Q;/2/)#V-4?H.9HP%JHO$8L]*?=3H?4G8R6!<GO-:Y`<6I7O(
M'X[K9NNBT1A7#G#D[A:6:)$=^B9\T)+W#R\[6#?XL)K$F.C%OVOX]6-HO0R&
M;/8LUF`?N,X&43PNV6HEF2TNK^_-Y3W32Y")HJ@0:IK+20="[Q>SI7RDRQGK
MBCV)Y@]->$E&^FZ,+\E"3?AO*<VG2=\Q9(',Y&F1@]6%_MO);#:;#JZGT^G,
M&`T,@SEYE42TXV_L9QL+#M+<5$0P!@2ST71V/00@?6/*5%T4P0@`3,;CZ7@P
M&QKP/TM>W2.0[=.QKII5@D`1JP2!(E;9`E=&ZDMZ"M3Z%/=5@D`1JP2!(E8G
MDC/P1#FK!($B5@D"1:RRV;#$O@HU=,5]E2!0Q"I!H(A5:9//)`//E+-*$"AB
ME2"X-*O)L@HGUB8KTA5G9M+FQ^D2#DJ0)IO$M]'%5HVP3ET%X08V.],=O`&N
M5.-C=[>NO8U@11HZCT_X-PIV\.\JB"+8&KR[W3C68^!;+KSMI2W2OS4M8?,4
M]DGG>O3DK+^`,JX&$OLF5M&5ABSK&;B:,"9&?V*,A]?Q@DV2:L_>.`>O:%VF
MNS0NP8WHVV;#B0_]3$D2#GE]N(<L)/0)MF!4,Z8%&T!,I"$AV$*&C?E>B:B-
MI(68C:2!H(VDA:B-T'7*.E?JR4UP@'W[8X)-<]KOQR5I43WU`@GPDH@I!T':
M%/W9V*3$HXUMVMH*^:70-Q9#?+'9<8FE#2V*=C8T*+&RH86HC7S<I.QRPK/2
M!:;G$B1'_N9^?AH,4!0W+,639"?<+(NWRX23G8"Q1>$E%G/N*;8XS6A!6PD<
M,*?=R-E>1=KBB&/9-C>*;[8ZF3C`/&1MN^YGG!G\?9M-1J"^=W?[O"7G_<!I
M.7AB#)Y6A&^AB)Z\C2<>\0?P<%6C864CS=KMW)=/!V]EAR8[0XNI8$>Q6)]_
M6K`94_[YG>L\^I[-*I1Z+.;',(CL=<3.(&,;(U5X1A5X!HD@$3SGZ#<J](.?
MA/UQCGZH@)62"'Y1JA^"2UB_S'C`<^62H`8*:%#7X9&)`.H<*0(@004"/+<O
M\0&$IPH$L'Y,$4"`Y@@`3DU4G-,/!B2;00SD*D%_5RHAQZ16<BH[M+(J_8+^
M&BM-+OV>Y6:2;R'0<S?#AQH`9ZFL2K&J4@RA'7I:[@+X4.,"$T9=.4,>5!BR
MN`,?Y`"4.80D70X0I($ZC\B+2I)S0:>H1Q82YR$D*#`5J88`<)1`($0,%(V_
M`XI!T0A,HT'1$$PA<&-P?9:0VB<H$]P(J0@#X%'2*_)\/>!&C`NZ@4!0E2%)
M-`Q5I4B*056.S*D8JDJ1!(*J#$F94)4B*095.9)0H2I%$@C@$249DC*A*D52
M#*IR9$X%7D"GA`H"056&)$R,.DZ1/5HVC8NHI'XZG9Q4/]6>MXV%U$'5H@EX
M3YO'JZ=XY0A<L+4464KCU9166CO5GH+0^046F7A5Y1J*J7:HXU6XD;.F1[Z%
MUN[!?H:E:+P!]KRMKO4"DK2^<1R,/,)*3+E^J&3K6AOETOUS!I;S'=%H.5O4
M-Q;FCR*#+VXW1D@C""SNJ,:`ODXP2`\!25T$>ZYJ-\$@J1P#I0KQ)#5G.,P-
M7'RN,,%SF'P:LEECK!+EN)I0IQP&**G*^3P%6W&]NAPMW79>?:N4+4Q#Y7C1
MAO7SM9UA*J[CI;+>QO(!S$Z5*9<><&TL'T+>4&<YV8@8'2^;ZY*<R0K=C2FO
M;'1JY9P+XF.G\K2;T`W/A5=W5D*E;*Q"BW.S2'8$6G%UBB](\AH!=N'Q4C"4
MSLALM']W`8U&N53/G<IT75A5TG2JLH993]$Y;<;_D^@ZR7SPBWBGJASMB]:2
M!6OK!2,7N!VG9SSWD:ZN"V`UO)82)[KQN9*B,[BNAY5S.]PI;A4-L%-D=]N=
M+H)(6LAW,(S0#BH>\O$E",(AS^'&O7/QS)(/U\=!!M2ERV,N+S0H*R^H\$M6
M?@C.(70;BPW`7P-$KKO`?=TZ);)!V>LEL@'X:R"2B[56'5)HJ!?/)*]K\!3'
M79$!JY(2%Q(%?[</92$6XJE`Z?2R"F=]7%P>)[BJ.<D7_%G7P\[U7!4BCN&N
MQ[@&9>UYNM08UP"\CKA+0>2Z0-=C7(.RUTMD`_#70"07:W)RA*RB"P=M`)^Z
MG!`W*'N],=8`_)(Q1O=N6U0YV_M6:'A*]_[EE(Y/':Q:K(8D`SYQX=$U8)P:
M)!ND?)7GU%+B\9)7;.YQJ7)XZ<2R"B(_7G2<\1J4M>^5:N8>)WJI19C7K!"J
MB.23,GA:QM#5J3+Y_@`?I!T=D*_8CE)RC6V=-RIS>ZL\7G-I4/?*D:C2%`=?
MU&GG*VJ5CJ#52+EC1F?X2K,@G2[0\P@:MF_:)Z9*3[8)J18(Z^9<E5@HJ^=N
M3_"IO>/T(T69_/0#L%YU)Y1]VFN;6*[>"I"3`4[&PHV;<K#0?A57+BFZ4_<G
MN:!_S4`[\"CU7VEB!W]LD_-"A_04]@ZP4'9/R9H7/WV-#GK5:^3B:K/]J'?2
M=/RD^<3%3\-#]Z01AF^%3K@M]V#E>-P8Y91)\3.TRU'P,X9*3#3:4Z;R:EMZ
MI`PYN[P#+N@@M\?A;XZ37?ZAX<,LX'R-_F^U*^W=&H5FE00\X7)U<%RXVR?.
MY/'2G/5A#S>:6\0'DXLIZF1EZ^XA9@,B"S)J6UD@(9Y.8Y:ALJ!7MY4%ZF-9
M(["6R(([![66!8N/1!9>3)?;:,"8WQ87-$ED\;X?"_K>*.,1QW^""TT6P45E
MY3SB4)C;"`\H:"TKYQ&(H[+`Y+:X<AX!(9%E@)*VLG(>@04J"\*MK:R,1X/W
M_5C0]]>E//*QBM>(B>"BLG(>^5@="<8JE97SR,<JFMP65\XC2*6^AR_:RLIY
MY/.$(9@GJ(TYC[SOQX*^/\ZH?,0/!2,^EI)S!^^(C["N*N*C6$K.&A_E(\$H
MCZ7D?/'Q;0C&=RPE9PKD$8L,^$+<HHRC$>]=0]"["VN39ET^8'"<$8$!3Y-9
M'UQXA&:`#^!DUT#B'BDQ"*]X%Y+T9*^_:$NXI5TFB.\/.(R*"+I_WKF6;T5!
M^*+A=8^9.)[TL:"X/P9!YB->PA`^B@#Z$SRN%)Z$JH%?8@_Q,8PSJC9BLK[`
MNP=O@M)&#+2.T?#QA\6?-F*@=2R&3ZHX?Q(1\\'?'3*&^%R*0[>(B(^._\7>
M\)'#>QA7'R*2/MF'*(0'+B46\5UJ*.B83W@CQ$P&GR+B!SZE=VU,YI^?X+Z'
MJ4J<:9.^@[-_$>!_.43$C=B*",$K:$2$/#@1W#@WL9WOPPA+2$0`UR)G(HXR
MBJ",OUFAC[V%Z[I',5IA47YE-\S^-\_Y33&9WR-\H"^[76:V'@!';>RM=7"C
MA^S+N9Z__S.[)34$4_*K'YVO0<1$S/7\_4>\US?T8J@00+KYN(?[1\-?[1`Z
M<_V_]XO)[/V].;R:]A?3*V-DCZ]FX\7[J[&Q7+Q_;\[ZP_[R?^`R?/KQ#3P^
M]XRG"[.G(,.UW0/C9N_",XC#Q-@$_.?\V%PG'V+X[`:_`!LN/DR-Z.VSIS/?
M_1\``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M
M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9
MEEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+T@8;
MUM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2"L=C
MS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VXB+""
M5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?B8$F
M39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B
M;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-K2Q%
MFO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F?7O-
MP1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%
M;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`
M;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1
M\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1
MBR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#$%-G
M!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X9QTN
M2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<*QR0
MF"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,KG9L
MLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX15Q/
M*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2
MAAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)
M$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[
M#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H
M8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"G$#?
M7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-5
M8,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HPF%L3
M.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%RI(B
M6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1
MVVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[
M8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T
M74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY
M;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJF)2_
M(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP
M#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)LI20
MB:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>
M:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*6T$K
M3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_@-J*
MX/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL
M_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]</0.
M?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"````"$`
M\+QE$@8#``#J"```&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R45EUO
MVC`4?9^T_V#YO>0+`D&$JE!UJ[1)T[2/9Y,XQ&H21[8I[;_?M0VI#5U+7R"Q
MC\\]]YZ;W"RNG]H&/5(A&>]R'(U"C&A7\))UVQS__G5W-<-(*M*5I.$=S?$S
ME?AZ^?G38L_%@ZPI50@8.IGC6JE^'@2RJ&E+Y(CWM(.=BHN6*+@5VT#V@I+2
M'&J;(`[#-&@)Z[!EF(M+.'A5L8+>\F+7TDY9$D$;HD"_K%DOCVQM<0E=2\3#
MKK\J>-L#Q88U3#T;4HS:8GZ_[;@@FP;R?HK&I#ARFYLS^I85@DM>J1'0!5;H
M><Y9D`7`M%R4##+094>"5CF^B>;K*,3!<F$*](?1O72ND:SY_HM@Y3?64:@V
M^*0=V'#^H*'WI5Z"P\'9Z3OCP`^!2EJ17:-^\OU7RK:U`KLGD)%.;%X^WU)9
M0$6!9A1/-%/!&Q``OZAENC6@(N3)_.]9J>H<)^EH,@V3".!H0Z6Z8YH2HV(G
M%6__6E!TH+(D\8$D`?6'_?A2DL`*,OG=$D66"\'W")H&0LJ>Z!:,YD!\3,S*
M&%+]7Z:0HB:YT2R&"Y*08,_C,LF21?`()2T.F)7%3#$:,)&/6!\1V@F0-VB$
MQ$\U)F#AZ\4_2M*'?$EQ[,=;O0+Q$>MS1)H.$$\CU,[5^+8V#886<$H1IR?%
M6%G,V'2`KO':6?`BC_W(VL'WJZ,/Y1C2&\R(T]/R6,S,V!EGDQ,_U^YVE(73
MU^L"[7UY73385Y5DXX'7M-K*8IRZ.`M>7=*/1-;@]QRQ&">RL^!%AAYW<[[,
M$7W(S_W<$8M)C2-1FIVTS-K;#J<OAGGJ]$QRGOBW.U6#?55)-CEQQ&*<NC@+
M7N3L(Y$U^#U'+,:)["QXD6$V>$E?9HDYY6=_[LD!9!^3Z&Q?CR6=B-V?)2_M
M;`7:D6-?R2T56[JF32-1P7=ZG$1@];!J1]U*CSHSK(8-F#0]V=+O1&Q9)U%#
M*S@:CJ;P9`@[J^R-XKUY(VZX@AEC+FOXIJ#P=@E'`*XX5\<;_0X>OE*6_P``
M`/__`P!02P,$%``&``@````A`"<#($U+`@``@`4``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&ULE%39;MLP$'POT'\@^&Y1AQT?L!S$,-P&:(&@Z/%,
M4Y1%6!0%DC[R]UV2MN(C")P72[1F9V=F5YH^'F2-=EP;H9H<)U&,$6^8*D2S
MSO&?W\O>""-C:5/06C4\QZ_<X,?9UR_3O=(;4W%N$3`T)L>5M>V$$,,J+JF)
M5,L;>%(J+:F%HUX3TVI."U\D:Y+&\0.15#0X,$ST/1RJ+`7C"\6VDC<VD&A>
M4POZ325:<V*3[!XZ2?5FV_:8DBU0K$0M[*LGQ4BRR?.Z49JN:O!]2/J4G;C]
MX89>"J:54:6-@(X$H;>>QV1,@&DV+00X<+$CS<L</R63^0"3V=3G\U?PO3F[
M1Z92^V]:%#]$PR%L&),;P$JIC8,^%^XO*"8WU4L_@!>-"E[2;6U_J?UW+M:5
MA6D/P)#S-2E>%]PP"!1HHM3+8*H&`?"+I'";`8'0@[_N16&K'&</T6`89PG`
MT8H;NQ2.$B.V-5;)?P&4.%$=27HD@>N1)!E$_70P'-W!0H(B;W!!+9U-M=HC
M6!KH:5KJ5C"9`+-SED$^[SL#-:[FR17Y4D`;F,9NEHV3*=E!A.R(F=]BWA`$
MFG<*H.OG%;BB2P5I>B7@'4B'N!"070KXV+H#0T08==;30=;Q^GCF`=/W*W7N
MM/^91@Z<8S#1-1J.KOH$R,@/H#?LOSV^L`<;=I[OQ_8<^+)K-KX.-F!"V]NN
MX24*.];2-?])]5HT!M6\!"=Q-(1R'5ZA<+"J]9-<*0NK[V\K^-)Q6+0X`G"I
ME#T=W$O:?3MG_P$``/__`P!02P,$%``&``@````A`/S:UZ-B`@``]P4``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE%1;;YLP%'Z?M/]@^3T82$(2
M%%*UJKI5VJ1IVN79,0:L8(QLIVG__8[MA*6DZ]J7@,-WOLLY!]97C[)%#UP;
MH;H")U&,$>^8*D57%_CGC[O)$B-C:5?25G6\P$_<X*O-QP_K@]([TW!N$3!T
MIL"-M7U.B&$-E]1$JN<=/*F4EM3"4=?$])K3TA?)EJ1QG!%)18<#0Z[?PJ&J
M2C!^J]A>\LX&$LU;:L&_:41O3FR2O85.4KW;]Q.F9`\46]$*^^1),9(LOZ\[
MI>FVA=R/R8RR$[<_7-!+P;0RJK(1T)%@]#+SBJP(,&W6I8`$KNU(\ZK`UTE^
MDV&R6?O^_!+\8,[ND6G4X9,6Y1?1<6@VC,D-8*O4SD'O2_<7%).+ZCL_@&\:
ME;RB^]9^5X?/7-2-A6G/(9#+E9=/M]PP:"C01.G<,3'5@@'X15*XS8"&T$=_
M/8C2-@6>9M%\$4\3@*,M-_9..$J,V-Y8)7\'4'*D"B3ID02N1Y)D'LW2^6+Y
M!A82'/F`M]32S5JK`X*E`4W34[>"20[,+ED&_7DY&41R-=>NR)<"VL`T'C;I
M:K4F#]!"=L3<7&*2`4%`?'``JF,'T_\Z<$4C!^E`[TW>O``9$,\,3)\;>#VZ
M`\/X,!JB)]/YP!N4`V;F5^H\Z>P]0@Y<8`CQ5RB;CH0"9NDGD"SC>'C\+!^L
MV'F#7\_GP&/9V<`;\@5,YF4G_];-WJ/KP&/=Q4@W8$+<<=;P[H;5[FG-OU)=
MB\Z@EE?0P#A:@&D=WMQPL*KW"[15%MXX?]O`!Y;#?L<1@"NE[.G@O@W#)WOS
M!P``__\#`%!+`P04``8`"````"$`_?]A?1$'``!((```&0```'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6R<6MN.VD@0?5]I_P'Y?09WF[N&B8+;V8VT*ZU6
M>WGV@!FL`$:V)Y/\_5:[&KNJFH#9ES"</BY.55?7,3A/'[X=]H.O65GEQ7$9
MJ,<P&&3'=;')CZ_+X.^_/CW,@D%5I\=-NB^.V3+XGE7!A^>??WIZ+\HOU2[+
MZ@%$.%;+8%?7I\5P6*UWV2&M'HM3=H25;5$>TAK>EJ_#ZE1FZ::YZ+`?ZC"<
M#`]I?@PPPJ+L$Z/8;O-U9HKUVR$[UABDS/9I#?JK77ZJSM$.ZS[A#FGYY>WT
ML"X.)PCQDN_S^GL3-!@<UHO/K\>B3%_VD/<W-4K7Y]C-&R_\(5^7155LZT<(
M-T2A?L[SX7P(D9Z?-CED8,L^*+/M,OBH%DDT#X;/3TV!_LFS]XK\/:AVQ?LO
M9;[Y+3]F4&W8)[L#+T7QQ5(_;RP$%P^]JS\U._!'.=ADV_1M7_]9O/^:Y:^[
M&K9[#!G9Q!:;[R:KUE!1"/.HQS;2NMB#`/AW<,AM:T!%TF_-ZWN^J7?+()H\
MCJ=AI(`^>,FJ^E-N0P:#]5M5%X=_D:1<*`RB71!X=4&4OCM(Y(+`:Q=$S\9J
M/+E#RLA%@=<NRKWY0.9-4>"U"])7RA`KW&R82>OT^:DLW@=P"J"&U2FU9THM
M(++=J0CV^_).P1;9:S[:BYI+@5U!>WU]CL+P:?@56F+M."OD3(-!R]&<$5]@
M1)QB?,IDPBF)3XE"U7*&D&:;*W3"_;G:BWBN6B2R0LJTZ3Y;GU@"1@()`9A$
MZ+/[)=J+8-M(J:-0:D3.J-,H`2.!A`!,(W0QU7B]52QY&4"Z71N,V]UINFF%
ME%G31WJLQV*'8[H^"2/1:(8N*SV9:=%$"2.$:M;%9VE!]_=/RY)%6K.NZS`O
MY$R:O-0TG,UYWC%=C]1,[)C!Y6['$@(PX9-[A%LR%QZ%HF`KY*!PK:;C2!!B
M1M!1-!>I&200[01@VF$^]"^Z)4OM(U[4%7)&.)1$26.V*)(RYT5K1_84)P1@
MFNU="AF9U_O?DJ5F>0"0@YH?ICRAF"V.9WS5G%=;T01@HN?WB+9D*;H[-=C=
MR.F:1$J+&0&:9"JVRB"!-`D!F'8%AM2_X@U;JA=573E2]^&QAQ@/22C"%5H7
M(CW1TT;1NV#.ML/1']P*252I1(S'22C"E5KG(4JO=Z]"GZ+CVQ\7CN1:(0Q'
M(['3,6?H$(:*Z&/'Z+),*,(SL+[4/P-T,9Z!T+=29ZMK;F7DU."K<FRTJ^T1
MI`A7;IVHOW+T+:Y<C@Z%I!_,#KXJ3ZAIESOIYW"`<.G6?/I+1ZOBTN4`L5\(
M8,IT;3,1+A)SA@[57&R-<0S:-C]R264MJ'\&:%@T`SWSVH:X6C,4X^9#ED&G
MQWA(0A%>8VLX1&'/(8(V=6.($"]S2B5BE$02BG"EUF6(TAM#!#V)U=+K8^1@
M,URZ65*4<.%NR:UWE4\HPM5;G^FO'EV)J?=N]122KLBGA$OR<9W*)PB3K^]R
MPX8MW5#<1:P<J?OTV$.,AR04X0K_EQOJ/F[H2%2IYX8>)Z$(5PK;VK\5M&7S
M6FK9R([SXTY@A`N=X-:[#!.*</5W.:'VG5![C>Q(5^1C%"1<DH_K5#Y!N'QA
MAW;>C6!\7Y\F^I(M"N=8.5*G(O80XR$)1;A2:RID8O2;S/8'(F@72/_*[9TC
M4:7$P9I9;3Q.0A&N]"Z7T[[+^;=WCG3><:7%]]R8$Z*I$F?".$*78T(1KM^:
M$*GTC5Y`RZ*S.0JE2^NSK]F;.RUN/&.V*K_HFG:UO4.B"%=^ER=JWQ.C4-XA
M.5);^9&8VS$GP#<L03".0"N/']P@7+_U&U+YGCV.+L5V0(E?:%::6!G>?7B(
M\9"$(DRI_7WR?J7-5;=.HR-U]8H]Q'A(0A&N5!CA]6Z.T,E8+;W?9AP)>T)'
M>B)/(R?H620(QA&Z'!.*</W6\$A/W-!OV=P>_=,8(0F_L(A!$;>+Y^-F/"2A
M"!=K?::_6'0E7FRA9Q41Z\+&;1$[3!Z4/&_M\CF!A")<KG"_&[6]Y'IR7D1(
MZGI#$&).`/>77V8=@?8&QO3G173!$V^[=W.5Z!$E.G3E2)V*V$.,AR04X946
MGMAOLD7HC=?=VY&H4KRL0XS'22C"E=[E?M$E]Q,[NG(D[`DUFH03\1TZYHQ)
M-)F*_3".T>644(1G<)<+1I=<T#N$9\=JCIST;Q?"_0`R$M9CVN7N0)[#`<*E
M"P.\<2`O&)]GX/",U4Y$?+1ABS\6R<6<`<7WQ[4T3_ODUD9MM@,SP`>Q^%SO
MD)6O69SM]]5@7;S9AZRV-BV*#X!7:K'2]EF0P&.UB"_A1BW@&9;/3^!!<H,/
MVT#P'/>4OF:_I^5K?JP&^VP+$L+'*8R+$I\$XYNZ.#6/U5Z*&I[@-G_NX(E]
M!K^\AX]`WA9%?7YCMZK]/P#/_P$``/__`P!02P,$%``&``@````A`%501@U%
M!@``4!X``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULG%G;;MM&$'TO
MT'\@^!Z12U)76`XB!6D+M$!1]/),4Y1$1!0%DHZ3O^_LSEJ<&5[MESA>GQF=
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M#Z9`_V;I2T7^[U3GXN67,CO\GEU3J#;HI!5X*HJO&OK;02]!L->*_F(4^+-T
M#NDQ?K[4?Q4OOZ;9Z5R#W'/8D=[8YO#C<UHE4%%(,POF.E-27(``_.ODF6X-
MJ$C\W?Q\R0[U>>N&B]E\Z8<*X,Y36M5?,IW2=9+GJB[R_Q"D;"I,$M@D\-,F
M4<&;DX0V"?QLD@2KN9HOQJEXN"U3I<]Q'3\^E,6+`ZT'Q*M;K!M9;2"S+L^R
MMSQ0%QWS20>94$!7H.FWQV"Y?O"^@0Z)Q>P0LW2=!L,1^PY$>(=XP.].$NHF
M28;0"=T:OI+408)D<$]O]K%#R-)HI3>V)PN,`%1&$HA&JZ2#H%UH!5:^8("8
MJ&%`%AB#B#,8WKH&;UW83%/[E1*?C)B544\M_970;T__'JI54SI&"XI`"S-,
M2X,EK28O2H*8!3:5[T<+R8L!`E^MFPR,V8(STXT]WC,ZB#.$Z1*%0XQEJ);S
M^8H#]@P0A.$RN@,80Y@-6KMI#'409QBLFJG!&B*&-!4N(&6U\ILF9'STD4>L
M8%A+#98\FGTB#\00'F2!??*:?[*NQ/AXZ:"Q\4(,84`6&`,%=C)]\P8M=R\'
MS()LU3LFC`'Z1TP)BQ[6Q:`EM?F]`5$8"R)UH2N\,-H225=,TT:AD0Y[GP51
M%AAF5C@+;8N$Q4@-T$2Y_S4V86N`()0G5"J28ZP8`*:X`7!N;[)FU>7-TF(L
MB%8&PSHJ(QQXHC[HHK!#<D(TMF`KA"#*@JSP&@BW'=&G;;-!ZWQ2U$:[#B@&
M&!B?=]FL:OML^R2PH($)I\8[0%$X[[230'59\%)..K%<H^K>AG5TTKM<6$VQ
M80NBG=1GQ,&;C-B@I=M)([:@?ID8H%^FX$U&;-"26F,A.&(61`I#5]B(!>\R
M8A,U=DI:$&719\2!-L7)1FS0L@;2B"T(Y8&WX_8C'T<,//,%PHJG#9*)XBS;
MLVY!0RS1HBUBB&6'98\_FNIWO-83EW@XWED05;+/L@-AV=,.#A,UVD]HW90%
M6>%=+=QY^.`(VJX<D#<3.U/<=-L'N\V"0NG'\V8J.3=ARR/<.NQX+8_4H&7'
M=(5_^KOL.)ABQQ9$]>FS8]V7=-ZG392)XA/5?DNQ(,+"KJ`P_>\IX9M\V*`%
ME[4\(BR(<L%O)\P*TR5\EP^;J+&YL2#*HL^'PS?YL$&+&K3FQH*L?X7!0CR5
M[CD`GMB:]TY>H7>Y<(CV"1MN'DG)NSW.M@71"F%8ATX=+CO^4AFB70X_&%L0
M9='GLJ%PV6$/,>A1G=!+!W1B@`&=A/=.G.T.#UXWG6!U0A"M$%GAW2)<=MHY
M%**1CNC4<EL;UM$MPFU'=$*[9+W:GB<$63>+%OY<O(;O0X98A(NP\256HZC#
MA<=[V42);EK+[V@LB"A%5S@+X;O3E(K02(>5LB#*HL]_(^&_PTH9M*A!2RD+
M&E"*(X:4$KX\;:8B'258KD6W["R(U@C#VMT<=3CPA'Y!*QU1BOBMF?6]^3#X
MPDY_A\W[I<.!]1$_HAA:*9\MZ2]Z,U`P6@M<L1KV?L<9"3^>J`\Z*N.T%L?C
MSJ3FG#"LHS(=SCM!'[30$7V(SUI]R`K7I\-Y)^B#ILIJT?H&&F[TI#ZX8N\;
MVOK@!1Y>3>5I>4KWZ>52.4GQK"_G`K@/N*_BQ>%.;7:![CFQOH<+1;/NW?\`
M]WFW^)3^$9>G[%HYE_0(*?V9ON<J\480?ZF+F[DP>BIJN,DS_SW#S6T*-T/^
M#,#'HJA??]'-?K\+?OP?``#__P,`4$L#!!0`!@`(````(0!W)6I@=P(``,$%
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;(R46V_;(!B&[R?M/R#N
M:VRG.2I.U23*5FF5IFF':X*QC6J,!>30?[\/2+PXZ;;>),:\/+S?R?.'HZS1
MGFLC5)/A)(HQX@U3N6C*#/_XOKF;8&0L;7):JX9G^)4;_+#X^&%^4/K%5)Q;
M!(3&9+BRMIT18EC%)361:GD#.X72DEI8ZI*85G.:^T.R)FD<CXBDHL&!,-/O
M8:BB$(RO%=M)WM@`T;RF%OR;2K3F3)/L/3A)]<NNO6-*MH#8BEK85P_%2++9
M4]DH3;<UQ'U,[BD[L_WB!B\%T\JHPD:`(\'H;<Q3,B5`6LQS`1&XM"/-BPP_
M)K/5/2:+N<_/3\$/YN(9F4H=/FF1?Q$-AV1#F5P!MDJ]..E3[E[!87)S>N,+
M\%6CG!=T5]MOZO"9B[*R4.TA!.3BFN6O:VX8)!0P43IT)*9J,`"_2`K7&9`0
M>O3_!Y';*L.#430<QX,$Y&C+C=T(A\2([8Q5\E<0)2=4@*0GR`#<G_;3]T)(
M,.3C6U-+%W.M#@AZ!JXT+74=F,P`?`XLV.A"_5ND$**#/#J*9T$0!JJS7Z33
M\9SL(:7LI%D&S1BC3I/T%:NSPE4"['4>(?!KCP,HX=O)/UMRAZXLI?W[EF](
M^HK5K6(TZB0]CY"[2X__]N;$T`*7J1@,.ZY/Z3)H?$_[%ZN+%[V;[_LWNPK^
M/SON4(8AO*X8Z71RY2!H)KZ<R22.^]LP;@X1MN^&?W:#N3!*H=4DUR5?\;HV
MB*F=&Y,$H-W;,,%+F&#?[Z3;@`EJ:<F?J2Y%8U#-"S@:1V,8&1UF,"RL:GVE
MM\K"[/C'"CZ5'#HSCD!<*&7/"]=;W<=W\1L``/__`P!02P,$%``&``@````A
M`-.D5E.%`@``.@8``!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&ULE%3+
M;MLP$+P7Z#\0O$>4Y$=BP7+@-$@;H`6*HH\S3:TDPJ(HD'2<_'V7HJW8L8NX
M%TFDAC.[L[N<WSZKACR!L5*W.4VBF!)HA2YD6^7TU\^'JQM*K.-MP1O=0DY?
MP-+;Q<</\ZTV:UL#.((,K<UI[5R7,69%#8K;2'?0XI]2&\4=+DW%;&>`%_TA
MU;`TCJ=,<=G2P)"92SAT64H!]UIL%+0ND!AHN,/X;2T[NV=3XA(ZQ<UZTUT)
MK3JD6,E&NI>>E!(ELL>JU8:O&LS[.1ESL>?N%R?T2@JCK2Y=A'0L!'J:\XS-
M&#(MYH7$#+SMQ$"9TV62W4TI6\Q[?WY+V-J#;V)KO?UL9/%5MH!F8YE\`59:
MKSWTL?!;>)B=G'[H"_#=D`)*OFG<#[W]`K*J'59[@@GYO++BY1ZL0$.1)DHG
MGDGH!@/`)U'2=P8:PI_[]U86KL[I:!1-KN-1@G"R`NL>I*>D1&RLT^I/`"4[
MJD"2[DCPO2>97DK"0D!]?O?<\<7<Z"W!GD%)VW'?@4F&Q.<3PDP\=NG!.;VF
M!&.U6(2G17(SF[,G=$[L,'<!@\]7S(!@*#HHH]KERA[LE;VU/I2[L'$HDYZ7
M&?V/C`=C;0Z#G\4#;U`.F''?+X?YC(^%?(ND4]\.[YCJSZ'[B'MU[,35'0@;
M]Q4T2X;(CHQ%ID-C^UY-)M&[@?AS?2"#R;N=0Y>3V3]\GIY136\NR-\?/);=
M[1S+CMXD&V8U]+("4\$G:!I+A-[X.4RQ.X?=X8I8IKYJ;_?'V;*_.MCP`T>W
MXQ5\XZ:2K24-E$@91]?HAPG#'Q9.=Q@Y#K!V.+3]9XUW-&"#QM[O4FNW7Z`P
M&V[]Q5\```#__P,`4$L#!!0`!@`(````(0`.B+CZT0T``(-````8````>&PO
M=V]R:W-H965T<R]S:&5E=#DN>&ULK)Q=4^LX$H;OMVK_`Y7[A3C?I("I0Q)_
MQ'9BNV9WKW-"@-0!0B4Y<V;^_;8LO6Y+'0R9VIN!\]!Z9:G5+:D3S\UO?[Z^
M7/RQV1^VN[?;EG?9;EULWM:[A^W;TVWKW[_[_QJU+@['U=O#ZF7WMKEM_;4Y
MM'Z[^^<_;G[M]C\.SYO-\8(4W@ZWK>?C\7U\=758/V]>5X?+W?OFC?[RN-N_
MKH[TS_W3U>%]OUD]E(U>7ZXZ[?;@ZG6U?6MIA?'^*QJ[Q\?M>C/=K7^^;MZ.
M6F2_>5D=Z?D/S]OW`]1>UU^1>UWM?_Q\_]=Z]_I.$M^W+]OC7Z5HZ^)U/8Z>
MWG;[U?<7&O>?7F^UAG;Y#R'_NEWO=X?=X_&2Y*[T@\HQ7U]=7Y'2W<W#ED:@
MIOUBOWF\;7WSQD77:UW=W903])_MYM>A]OO%X7GW*]AO'Y+MVX9FF_RD//!]
MM_NA3*,'A:CQE6CMEQ[(]A</F\?5SY=CL?L5;K9/ST=R=Y]&I`8V?OAKNCFL
M:49)YK+35TKKW0L]`/WWXG6KE@;-R.K/VU:'.MX^')]O6]W!97_8[GID?O%]
M<SCZ6R79NEC_/!QWK__51N6(*I&N$:&?$.E=COK]WF`T))6&ECW3DGZ:EL-&
M>U(K'Y=^&GOUF`T=#$P#DCWST2A"RJ[HYY<>[=K8TT]C[[6_-@D>>;WLRJ-I
M/O,I/7*<;LL>;)Y"#]Y2O^!).Y>]3G\X*IW>,)L>_*5^,6UIAIM:P&-J49X[
M-CC/HU],VT_&1G_6L\'^_F2!>/"S^N5K#WBE8Z@,R>GJN+J[V>]^75">(_<=
MWE<J:WIC)8=@U/-3A>='T4EAJ52^*9G;%HV``N]`*>6/.V]P?7/U!Z6!M;&Y
M/V%C6TQ@H6)>R4Y=,'.![X+`!:$+(A?,71"[('%!ZH*%"Y8NR%R0NZ"H@2MR
M3^4C"I/_AX^4C/(19O<>@)W6<1P""S29NF#F`M\%@0M"%T0NF+L@=D'B@M0%
M"Q<L79"Y('=!40.60R@+"8=T*2.>WL$0(ZH5[57U&!FV[0F_US:4JC#C$T&F
M@LP$\04)!`D%B029"Q(+D@B2"K(09"E()D@N2%$GEDLHN5LN:7:%LJ:,1_F]
M(5\9(TKD;#3T;(=-*B,X;"K(3!!?D$"04)!(D+D@L2")(*D@"T&6@F2"Y((4
M=6*YAV;:<H_:9KHC=;XS._&7=QJE5+H.$WYO"&U>-3^YF:PR0K.I(#-!?$$"
M04)!(D'F@L2")(*D@BP$60J2"9(+4M2)Y2=:[):?FL-(6=N^,,3V1=>)F<JH
M\H4@,T%\00)!0D$B0>:"Q((D@J2"+`19"I()D@M2U(GE"SI-G>$+96W[0I/!
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MOF3Y0*/**@#BS!P"L58$Q%IS(-:*@5@K`6*M%(BU%D"LM01BK0R(M7(@UBJ`
M2BW;->I.6Z\O-!\H5#7)B3"#U/6*PZ?GA,\$5K6P`V*/S8"ZE2]\(+8*@/@2
M%@*Q503$6G,@MHJ!6"L!8JL4B+460&RU!&*M#(BM<B#6*H!**]L]ZH9[AGOT
MA9CN30C*>U7,(X]UK2VJYZ2@B;&BXSX:3M&0CC_LU[Z38&:P&NJ:TK`]<J1]
M2/,Z#H!X'8?0:>PM@I65JOM.9II#GGN,@;C'!%J-/::P:NQQ`7GN<0G$/6;0
M:NPQA]6',UI`^D0TJ^OW&<O%W-;9Z_>J@*N6BQW-[@4!5O5H-@UYO#-CU6M_
MO#9,(PZ/`-(<1"$02T>0IG146YQB(0CY&%HLGP"Q?/HE^04:\M,O@5@^`V+Y
M'/(?3DR!1B<R@KK"G^%B<^.ONUBC'B4&GKN1>Q]7U7A:"%9&,(CWFAFL>*_Q
M@3@6`B">@A"(M2(@UIH#L58,Q%H)$&NE0*RU`&*M)1!K94"LE0.Q5@%T(@+5
MS?T,]RASYZBC48_6+KNG+R)06^F/`4TMWB#+KS)A&_E>&91=S^LX4>.KJIM*
M`;RL`R!>UB%08V\1K+IE;QWG(C#'G[FK&(B[2H`:NTIA9<^;,[@%K+C')1#W
MF`$U]I@;JUXUE>ZIIV`=VE;MC9TV@7/6B3)WUHE&]L;>%\=B;66%L4$<"#/U
M81C)]_K:3=W.P)DWWUATN%$`Q-$3`K%5!.E!*>U<C>>R00S$L@D0RZ8L6X\2
MYZD7LN$2B.4S();/(<\3XMR\"ZN1[5I5D:BG`%5+[?0O*:P^.5SK4@8M&AS"
M[CV-G&3@S.+$6%G)P#3DI#6#UJCTA-<;M`=.TO<AQ-$1`'%TA!!B[0B(KH"U
MI.6X8PXMEH^!6#Z!%LNG0);\R,F)"VA943MP'+>$%?>809Y[S(%XLOK.K!<0
M*D=CKP!5SJBO@$_\KLR=X-;(WJ-[SH`GZO-@:F@%MT9]KEK-C%5?WYWINS2]
MGI,E?`AQ!`1`'"<AA%@[`NJ4:ZKKK*<Y1%@W!F+=!"*LFP)9KI0.-^.G'[SJ
MI,.-%?>809Y[S(%XEMS/QPMCHG.@[7!5^J@[O`SY0?GQR?%YN_YQOZ,'I,/J
MB86@MD;S&;TNH%CQKU'?VM1&COLFGK:RXM\TI",;3XT\#!@KD^:\8;_KK#$?
MVARS`1!'4&A0O[&["%9Z+Y"KQ0R#NXIE5PE$&KM*844;&X]?+J"JQYJ57$#&
MBL>;0;[Q(7)8\?3VG;I(84ST8<M:4U2SE&O*ZU^6Q6:UIG[?O7^TIB@C8%&5
M,G9R,8B+:6UW0<&"/3$%XK+%#(CGQ3>H?DP`XO`+T9"U(B#6FJ-A+7D`L5:"
MAJR5`K'6`@U9:PG$6AD:LE8.Q%H%&I9:MLO.*Z;1YSQNWC?(N7X[BV8"J]KU
M&X@]-@/BT?A`;!4`\0!#(+:*@%AK#L16,1!K)4!LE0*QU@*(K99`K)4!L54.
MQ%H%4&EENX=V$RM+G\C&]<A1YD[D:&2?N44QK:.MZMNR05TK'8ET#"M=^NEZ
M[J7<AS(OXP"(EW$(F<;.(EA9FZ>HI4&>>XR!N,<$6HT]IK!J['$!>>YQ"<0]
M9M!J[#&'U4<36D#Y1"RKVE%]2_]DL2AS9[%HY,2RL[]..L:J'LL&\7!GQLJ4
MTDZM#-.&8R.`,D=0",3*$92;*VEHR/(Q$,LG0"R??DE^@88LOP1B^0R(Y7/(
MZTJ:G)<";4YD`]J[SW&P,G<<K)%]2'=C=M+15E8V,(B+3#-8\17$!^)`"(!X
M!D(@UHJ`6&L.Q%HQ$&LE0*R5`K'6`HBUED"LE0&Q5@[$6@70B?A35:@SXD\7
MK>IG9YIQY3'G[BSB3UO5S\ZF(9W):J="F:R-O*G^=(>><T'T60?W^0"(5W4(
MU-A;!"M=2'-/Z7/\F0,H!N*N$J#&KE)844;AH[.[,2Q@Q3TN@;C'#*BQQ]Q8
MH9#6'8I"&NNXA33Z=/>L=:+,G3#6R-[412&M[,>^:P-Q(,P,0B&M,^HZ-1!?
M-@J`.'I"():.(&WO>([\7#:,@5@^`6+Y]*3\R%G2"VY86QOBP@0K[C$#XAYS
M]&AN1YV1Y\1F836RCW)_M\;6D34V@YP\X8Q\8JRL/"%K;-`R9:-!=^!^(=6'
M$`=.`,2!$T*(<V4$1+?1C^-R#BV6CX%8/H$6RZ=`EOS(J9XMH&4%M%P`>F:Z
MW&,&>>XQ!^+)<J.EX.Y$W*NJSAG[@RX"6?N#1O;V+6IL=)55"8,2$)+XU*!Z
MC0W(5(\Z[8[G?-;A0X@C(`#B.`DAQ)6I",C4V)P@F4.$=6,@UDT@PKHID.7*
MD?/8"VC1-/"JDPXWL\0]9I#G'G.@:I:\:Z=B6'!WPN&J"E-W^-^JL75T+<=:
M!QI]4F,S#:WX-PWI-,=3(\\)Q@IIKMN]=K\B`6V.V0"((R@TZ),:&ZQ,C4VL
M%OTTM0_W8ME5`I'&D:6PLG8DN8"J'FNS)!>0L>+Q9I!O?(@<5CR]0Z>:51B3
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M&M.7R25/1F/Z)KCDV6B<Z]50/1"]`OZ^>MJDJ_W3]NUP\;)YI(70+C^OV.N7
MR/4_CN9SB^^[([W\3;%*+[72R_X;>I^TK3+OXVYWQ#^HXZOJ?Q]P]S\```#_
M_P,`4$L#!!0`!@`(````(0#9A@EUO!(```9A```8````>&PO=V]R:W-H965T
M<R]S:&5E=#@N>&ULK)U;<]PXDH7?-V+_@T+O(]5=E[`]T:XJ7HIWQNSNLRR7
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MG)$YL>NO?Z^VS[=R147F;#(W2K>[>^F`_/?DX<X,#;DB-W]UO[_NOK[\^'@Z
M'9V-9Z.%6)]\V3Z_1'=&\?3D]H_GE]W#_UF;[H3V&A.G(;_06)S-+T;3\1$B
M4R<BOTYD<G%V,1Y=32^D)P.MSYRC_#K'^=EL,K^X[%H?<!39[M3EUSF.K\XN
MY_/9XO*-)A?.4WZ=Y^Q=7;UP?O)[W#E*MG9=E=_CSO'*.<HOSO'B;'(Y'\^[
M``]<G;$,13LR)/C']7:,`6'^<%Q_QQ@&Y@_H\3NC,L9(,./_R!XCHF,-Z3M'
MT1A!-7]`CV<Z_(<N,<(ZUK@.#_ISF[W=9+"Z>;GY].%I]^M$9EB)T?//&S-?
MCZ^-&J8!V_I^8GAM7I`)P:C\9F0^GLJ)2,X_RV3VYZ?Q=/;A_$^9@&Z=S><#
M-K[%$A9FMC&RJQ"L0Q"%(`Y!$H(T!)L09"'(0U"$H`Q!%8(Z!$T(VAXXE_#L
M8R3)\)^(D9$Q,<+5_0R@09L$`8$%7%8A6(<@"D$<@B0$:0@V(<A"D(>@"$$9
M@BH$=0B:$+0]X`5$IA@O((?73.2&L9;5T<N-N7^A/UL;F8API9=$5D361"(B
M,9&$2$ID0R0CDA,IB)1$*B(UD89(VR=>*&3J/B(4QEIF.IGF!^8I9R03>L]H
MX0=LN3="P%9$UD0B(C&1A$A*9$,D(Y(3*8B41"HB-9&&2-LG7GCD2GOA,<O+
M9'XF^,@%Q@AUD</U_NR(K%F],%T$8=H;P6U%9$TD(A(328BD1#9$,B(YD8)(
M2:0B4A-IB+1]XH5)QKH7IN$)S5C[L7#$C\5E$(N]T3X61-9$(B(QD81(2F1#
M)".2$RF(E$0J(C61ADC;)UXLY";JB%@8:S\6COBQN`IBL3?:QX+(FDA$)":2
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M&3NKR71OE:AC7SY(SE2M$/T-M%0^`U+Y7!W[\D$MHU`KR)?04OD*2.5K=>S+
M!SOO1JT@WT+K0-J9G>D1<74;V7Y<+9K(3R]BX3[3E)`E8O+8`IU:`2WV:`W4
MGQ6=HV9B#"N-?@*D6BF0:FV`5"L#4JT<2+4*(-4J@52K`E*M&DBU&B#5:H$Z
M+7]6-#O2(\+C-K!ZE3^;6HY<^*G<D/3"$VX]8=7/1.>H0W(-*QV2$9!:Q4!:
MJTN`U"H%4JT-D%IE0*J5`ZE5`:1:)9!:54"J50.I50.D6BU09^6'QVQ2CPB/
MV]/VPV/15"YV+SSA;M0\/`FSQSG*CSK.@ZW3VCE.[8W(^&)T&4A'D-9Q'`/I
M.$Z@,]A:"JM76]M`6EO+@+2U'#J#K16P\E;R>;!A*2&O+59`VF(-K<$6&U@-
MMMA"_D`VFWWT$</%;;O[P\6B()N#Y7%I'IB9G.]GLT-ZSFMG-1O9QU&'QH9S
MTO2((:U)E`"I=/JF]`9.*IT!J70.I-(%I.4.NS?N*>K4\PI:*E\#J7SS+OD6
MC@=F!!D;QX38F`>[/8MF<KO9.\'@!G5I'D6&,X)#NM:L8:5K302D^1`#Z65(
M@%0K!5*M#9!J94"JE0.I5@&D6B60:E5`JE4#J58#I%HMT($,-#OV(S+0;?#[
M&6C13&XW>^&A#+167@8ZI"-^/79:LRX#I^/Q+%B7(V<Q5:<82,=Q`J16*9#?
MS2!--K!2QPQ(Y7,@M2H<FKW:\Y*=*B"5KH%4N@$:['D+J\[16Y-E@W%,B#MS
M/P,=\M?D>;!)6#JK_ATMD([AM4.S>1?BR72R"&[7(W:*@73@)T`JG4+:7[/"
M$+-C!J3R.9#*%Y!_M><E.U5`*ET#J70#Z<&>MYZC'V)37NEGL3XU&R[H3&Q=
M1F[HL`OY[%"0S\&6;>FL^OD,1YUWUD"7=D6=+4;S0"B"D`[X&$C3(H&0:J=`
M,F7TYAV*MCW!WGR1L7P.+94O@%[O>@DA[7H%I%VO(:3:#=!@UUMH'<AH4WGI
MA_N-(-M"C1=DB_PU=19.VE+V"-=4A^9:[EL#C6U&CT:S17A/#2$=\C&0)D8"
M(=5.@:0C0T%V_53YC.5S:*E\`?1ZUTL(J78%I%VO(:3:#=!@UUMH=?)^3IOZ
M33_(74XOS+N5)R\_[FY__[R32R+#^T#PIQ(*^YJ5U'K"^RF'YOYZ$LS"2V?E
M);C5FGN%#=IA0=Y-D^.+^3Q<Q*&MB1,#:>(D$!IL+H65;>[`AFX#:6TM`]+6
M<N@,ME;`RIW<@;%>0EN;JX"TN1I"@\TUL'IC7;!QL7.</X9$GL;0>-X]=>G&
MT+]V/U\;0S+.]H/(R`2W!!8M-"V6IN`E5CVT8K1F%#&*&26,4D8;1AFCG%'!
MJ&14,:H9-8Q:#_DQ,F6E?IX?R.=^+&P5RIO,+9+;`RSB2S-)F-U0;\/KD#Z"
M&04W<&NU@$[$*&:4,$H9;1AEC')&!:.24<6H9M0P:AV2F5A.VP^-Y-TQH3'F
M09I8Y(7&H7YH+'KC$<QD;Z7A(12S5<(H9;1AE#'*&16,2D85HYI1PZAUZ%!X
M3$WCB,RQ)1`O<RSRPN-0/SP6O?$(9K*WTO`X+5T*8F<E$SNL$G7LW>/,@N1,
MU0J.&VBI?`:D\KDZ]N6#V_!"K2!?0DOE*R"5K]6Q+Q_<331J!?D66@?2SM1M
MCHBK+?-X<;7(O\69A8]@)M;*N\6Q:*%3Z=I9+71`1'#4*Q,#Z1*?P%&U4B#5
MVL!1M3(@U<KAJ%H%D&J5<%2M"DBU:CBJ5@.D6BT<#X3'%&F."(^MZ7CAL2C8
M?01WB<N)M9+I&6-F!:1W'6N'9EH`B]@J!M);]@1(M5+6VK!5!J1:.9!J%:Q5
MLE4%I%HUD&HUK-5Z5MZB94KA1X2G,_<7+8?\"L`LV-,MG54_>^`HTUYOMQ8^
M@H&5W5E/QY=!*3>"L@[C&$B'<0*9P<926+W6V`;*VE@&I(WED!ELK("5#-S>
M^0<EB1+RVF(%I"W6T!ILL8'58(LMY#F7)7I'#18N%W4*'T^#7`XK"<ZJG\L.
M]2L)0'8[?FADV/9E;L*4$$-9,RB!C$YP*=!KRAO(J'(&I,HY9%2Y`!K<YI?0
M4OD*2.5K:*E\`S0HWT*KD_=G`U,:>?]D+7O(\!;6(3.&>H,ZR-DEK'0%63G4
M7TN!U"J"HV9##*39D,!1KTP*I%H;.*I6!J1:.1Q5JP!2K1*.JE4!J58-1]5J
M@%2KA>.!_#-;]R/"8W?Z_;5TZC;_LN'KA8?RSUIY^>>0#LFUTW*U^>GT@AZ_
M.`LO`9V.CN.$K5)(RX:EU\U@:MRP8P:D\CF0]KR`O*W+'.AYR4X5D$K70"K=
M0'JPYZWGZ&=@6(,9WM]/N=;BD+\>T^,79R53`>;&%9".X36T['.JR>1R'`R5
MB)UB(!WX"9!*IT`R'H9";,]/4@+=S."H\CF06A4.N2=L!WI>LE,%I-(UD$HW
M0(,];V'5.?HA-M66?A:_]_&+>:(65`P<"IZU!=NUI;/R\MEJ3?5&>`TM]_K)
M8KJ8!AD704@'?`RD:9%`2+53(-DP#47;=JHW7V0LGT-+Y0N@U[M>0DB[7@%I
MUVL(J78#--CU%EJ=O!]N4W7IA_N-C+9%&F_2MLA?4^GQBX32C`XOHQW2$UP[
M*_?6RF0R&E\%BW,$(1WR,9`F1@*DVBFTY;9K*,BN4RJ?04OE<R"5+R!O7[@Y
MU/427JI=`:EV#:3:#;0'N]["\4!.RXVW%^1_Z_&+O&=&"6Z1*0CWKFE0,%DZ
M1R_!K>/"OQ6DW96S,H^`_OPTF9BUT']9.(*V)DX,I!<P<6BXN116MCF^9=]`
M61O+@+2Q'#*#YU;`"N?&0[V$MC97`6ES-80&FVM@Y4<JF$%;R!^8)TPQJ3]/
MF"%T_-.7J:U)>?.'17Y]:Q[6MYRC-W]8QX765-;.:J$39`1'3;H82),N@:-J
MI4"JM8&C:F5`JI7#4;4*(-4JX:A:%9!JU7!4K09(M5HX'LA\4W?JA^V-Z=V6
MJ;SP6&16D'V*SRC#K9&7X<Y/YM.]WY@>L$Z=E5L:+T?!%!`Y@]ZB&P-I#B20
M&6PLA96,FUZ7@AS80%ZS+@/2%G-H#;98P&JPQ1+RVF(%I"W6T!ILL8'5:Q>T
MA3*GN*RZ_E@)4_Q=#^D[%;\&Y]`;=PBPZMWS._3&0WI8N:?F/(:@K*D6`VFJ
M)9#Q9\A@/*:P\J,0CB'(:XL9D+:80VNPQ0)6@RV6D-<6*R!ML8;68(L-K%Z[
MH"V4>;Z9F:)6?[X)Q]#['M)W,L$@LN4R>?L3>ZTEK!2M&*T918QB1@FCE-&&
M4<8H9U0P*AE5C&I&#:/60]XMOREO>C$:7A,Z\R`61D&0W)[U)M+PF0<<]66Q
M%:,UHXA1S"AAE#+:,,H8Y8P*1B6CBE'-J&'4>L@/CZE!A2DTO>S>E3KRLR&F
MRA)LR8'\%2E\'J)62+85HS6CB%',*&&4,MHPRACEC`I&):.*4<VH8=1ZR`^=
MS*M>Z-[(+&,>9)9#7F8M@D5H*74CEW\:'D)KMHH8Q8P21BFC#:.,4<ZH8%0R
MJAC5C!I&K8?\\)@"SG\HLVPMJ'^C+)7F+BA>9BV".X.E6FGH]HY`:[:*&,6,
M$D8IHPVCC%'.J&!4,JH8U8P:1JV'_-#)W0^%[M_ZE)(\7*>D<\B/7%!X6L*Q
M?[>Q=]3($8K8,6:4,$H9;1AEC')&!:.24<6H9M0P:CWD1\[4</I)]\:<:$L^
M7F(YI!=^.2.T8K1F%#&*&26,4D8;1AFCG%'!J&14,:H9-8Q:#_FQD!%^3"R,
M>;`^6>07_!;!8Y?ES%EIU6(%)$=ZMXS!PK9V5C(/=!_1/+"5<\K=6/#/S502
MCAAGMO#@C3.+_$+4(B@X+F>N8M'?IEHDUUVG`8?D1T]W$3SYB*#EE>YZ_X;(
M.T%YN<`_P7!K]:[M>:?BQ]2A(*9A`0Y6O9@Z-%Q57<-*;E!ZER+8+$20Y\#*
M9Z"'S_M]6\I.)CAQNZ7LO>2]=%8]M&*T9A0QBADEC%)&&T89HYQ1P:AD5#&J
M&36,S`>YS7Q@+XX=F_8#V_:;N@_;I^_;Y?;^_OGD=O>'^7BV/$C^]&&/[9>]
M/\]FU^8>35*%CLSE2#>^Z,A"CG0%3SIR(4>ZQ`N/S/>?$`^/7%VW75TMY./1
M=2N?%SK0LXGT6?+CP)&9M");[4-')G*DJY"$[<RF<J1[[30X(E\]_^V@AS1R
ML`UIXJ"]-'!0?W;]FP3Q4&>E1X>X1.1@0"0>!\,AT3@8C,OKMLOLX(17D_FU
M>8V=>[2:+.3(H396DXOKM;QPRS[R]O&U>;>8C\B+P]?FM6`^(N_\2CN'CJS&
MXVOSE2/V68TG<N30A5^-I]?F^S7L(Q^GN3:?GN$C\EV9:_/5&#XBGX21=KHC
MY_L+)U^A_WGS?5O</'V_>WP^N=]^DT0;=?\*YLE^Q][^Y<7]:Y@ONQ?Y`+U,
M?/)U:_G_#6SEP](C\P72;[O="_XB39_O_P\&G_Y?`````/__`P!02P,$%``&
M``@````A`-\$953`!```<1(``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX
M;6RL6%UOJT80?:_4_X!XO\8+QA_(]E7L*.V5>J6J:F^?"5[;*,!:@./DW_?,
MLGSLPG7LJ"]QF)V=.7MF..OQ\NM;FEBO/"]BD:UL-AK;%L\BL8NSP\K^Y^^G
M+W/;*LHPVX6)R/C*?N>%_77]ZR_+B\A?BB/GI84(6;&RCV5Y"ARGB(X\#8N1
M./$,*WN1IV&)Q_S@%*><ASNY*4T<=SR>.FD89W85(<AOB2'V^SCBCR(ZISPK
MJR`Y3\(2^(MC?"KJ:&ET2[@TS%_.IR^12$\(\1PG<?DN@]I6&@7?#IG(P^<$
MYWYCDS"J8\N'7O@TCG)1B'TY0CBG`MH_\\)9.(BT7NYBG(!HMW*^7]D/+-BZ
MKNVLEY*@'S&_%)W_K>(H+K_E\>Z/..-@&W6B"CP+\4*NWW9DPF:GM_M)5N#/
MW-KQ?7A.RK_$Y7<>'XXERNWC1'2P8/?^R(L(C"+,R/4I4B02`,!?*XVI-<!(
M^"8_+_&N/*YL;SKR9V./P=UZYD7Y%%-(VXK.12G2?RLGID)505P5!)\J"!O-
M?7\RG<\0Y,I&3VW$Y]W9G>HDDIC'L`S7RUQ<+'0;L!:GD'J7!0A<,U+!:#CZ
M&47@AH(\4)25/;,MG+Y`75_7C+E+YQ6UB)3/9L!']]C6'E1"P&LP@JG_`2-%
M(8Q45@*]J0TM:`/RMO8P`8&H+J#A]JFY(6<TBL:-IY]\4_FP20-NV[5H9$ST
MW%0P;T[MJEKGYII1(%0=&Z\433E--:>)CG[;.)D\(?;M/)&SQ-,42%GTMO*-
MY(V3F1R8N\DE43YBW=G:%$:'I2RX%#K$30U8C9,)"PBZL*[W#CGKR94%'YWD
M,R-YXV0FIXO,>-N],:#>R0F%T6$IB\[)W(#5.)FP%CJLZYR0LYY<671.%D;R
MQLE,SG"-F*0P'^_?G:3(.#JPVJ31XHX-9*U7#]J`.GN?Z&%6*2O>=62HQ*\V
M@9:VD5QF0E,;%[11DR$V(,H^O.\EK9)8#9DRZ<A,:9;YP?8`,I).H\FGWH@N
MU^N-Q93F=EE2)D#JL&2H][;>".>.5ZN2.G$#`L[8Y!9\C6*W552F#_`I+QU?
M*Z0Z/A)4@SXJ[`?<*1GN<J=,'V!37CJV5DUU;*2J!C;778P0X]Z^4_K<Q=M(
M=K>*IK2RQJOW1I#J&N"8._L,.*7?77#*I"N)*;"L\>J!(^TUP4WDU]R[J5,R
MWD6G3#HZ4X%9X]5#1^)LHE/OQ+V%53K?1:=,&CJOI\*-EXG.-2Z(ZV^"]-:O
M@=J$ZK3ZX)E:VWKU`)`*&_2X;"HEXTYZ7"7H'7IJDTZ/J;>M5P\=Z;6!SIN[
MG^A[C'[FU5Z;='"F`+=>#;AJ!JQ&G93G![[E25)8D3C3?(?3K)>-N1H^-VP>
M;-&C"-%;66!%WC3FBCO&Q"J'SMX*S;)R\NNMN/64:ZX@S6`6ABSXEC"$#%EP
ME0^M(`LNR:&5*5:F@RLSK,@)R4"&P?QA.!8V#$6B(P[9O0"331_3PP3Q!S=,
M`HP7_0T;/]C*'C:`;G"VP:/A9$,'VZ#FLN1.$P@#_RD\\.]A?HBSPDKX'@TS
MEB];7OUD4#V4XH37'&._*#'JRW^/^&F'8[0<4_/OA2CK!QS`:7XL6O\'``#_
M_P,`4$L#!!0`!@`(````(0"$,EBKR04``&`7```8````>&PO=V]R:W-H965T
M<R]S:&5E=#8N>&ULG%A=;Z,X%'U?:?\#XKT!&PA0-1T-5+,[THZT6NW',R5.
M@AI"!'3:_ON]]C7@:_I!.@\S$WQ\.3X^/C:^^?)<'YV?HNVJYK1QV<IW'7$J
MFVUUVF_<?_[^=I6X3M<7IVUQ;$YBX[Z(SOUR^^LO-T]-^]`=A.@=J'#J-NZA
M[\_7GM>5!U$7W:HYBQ.T[)JV+GKXV>Z][MR*8JLZU4>/^_[:JXOJY&*%ZW9)
MC6:WJTIQUY2/M3CU6*05QZ('_MVA.G=#M;I<4JXNVH?'\U79U&<H<5\=J_Y%
M%76=NKS^OC\U;7%_A'$_L[`HA]KJQZQ\795MTS6[?@7E/"0Z'W/JI1Y4NKW9
M5C`"*;O3BMW&_<JN\R!TO=L;)="_E7CJC/\[W:%Y^JVMMG]4)P%JPSS)&;AO
MF@<)_;Z5CZ"S-^O]3<W`GZVS%;OB\=C_U3S]+JK]H8?ICF!$<F#7VY<[T96@
M*)19\4A6*ILC$("_G;J2U@!%BF?U[U.U[0\;-UBOHM@/&,"=>]'UWRI9TG7*
MQZYOZO\0Q'0I+,)UD0#8ZW:^M(B'A-3X[HJ^N+UIFR<'3`.O[,Z%M""[AL+#
MP)#&.-2W1@I#E$6^RBJJ%@RB@^GY>9NL;[R?H&BI(1E"8M<9(8PB\@$A)P+8
MC11AW#;%`&;P=>T'1K(39<0Y?5_V"H0B\CEB/0V+<`3I3([O<Y-@<(`A11+3
M-V<(48Y6"N?&`_+B\)(72_#&A5&-<Q"GUHL1DJ@YO(H"9K7GI#V.XDE40@M<
M;>HA;?7QG,E.EBZ)10\AAB[&`T)@30F\/R$23'5)K'%G"`F5+BRTIBLGK3P8
M21-*X/W+-9&=*+74'\LK:V0(06H\M%<5:4VCL2^A)O<I(P7>5TN"+4K62S.$
MK)5:/(TF0=#,9C-+_4E-0BJEI)9Y2':RR$T61;T0@N2N6.);>N;8CGI&4R/A
MQB"`EBNFT!8K2Y-,8Y`62^+IQ:B9;E?6IU2L"']_\ABF+,D`>Y%I#"IP%8=6
M>SZVVTG-9&`:/EHV9:H77?=I./H4YTQCC(5O/J%ZR*@T2'R@!P:KJ0>?_*A?
M/H2OW-CXM(3TQ)BM5^'43%E=%-1LGM3<FH5,8]`P01S,#(,UM,\Y]]]B9F7U
M!WIAX)IZ&:&B]1I"6>K%?"L<<GEP@C4ZV&MJIH)9";[02_,H#RUA,H:809@P
MMN8[)P`6!U.`4(:?"G0V3W0[LS.-T0P9,U)(>PZ+#(#XK2V'713L"DUC*IS%
M%&8W3EY@+=-<5T!>+($_XSJFTGTJV]DKX3Z=Q[3W2+KS(+4&D.LBFB(+C!,0
MH<@O2GB%MC+,LE6F,4:&F4_HRR_*=#[/]'02'G71&.V8(`T-RZ"G*(*MXWB2
MCI*S4O[]P.`234V5VH<KC4%R49)&4U1I;E@$`=R/C:\+2NVB[.?S[&?V:2#3
M("T<\Q/;\QJ@XXSQR9&4FK4!+,LS/M\(9H&::1!29$DXV[`)($B,KPU*\:*=
M0'ZYPL2"AN/7!/.GJ-2V&[)>?A/+3\5<=YN?8_BG`E_UHO9B_F1<S0(3WUQY
MYAZ0!F\;ZE,9S^<9SWS+-YD&#=O@&)1:)BSQBDQ6I"_T$<:VN6TSXT"@94(0
M^BA@L94A.3?;XRB95BFUT:?"G<_#G?G36M(,S70'AM/90:MFML-""0P$X2@_
M1LU#XC(552_;;';,:Y!>C2DW`@%)4@!;KX.I!"5I[0(+2<YW`T@M:J\L0!"2
M7/NSPR-I!R'?"MS`V@L64ISO"<RW-P55>N,B11[QR#)#3@"0NXFQI5$=K5UA
M(4G<'4B^,?LL&2#(2!;S"67QJ0T`;C7M[9,QR_:9!N&M362<:+3AL(:1)7C1
MB1>!M6CW(A?'8^>4S:.\Q&3PW3X^Q0O6#"Y8U6VD-S;`_>:YV(L?1;NO3IUS
M%#OHZJ]B2/P6;TCQ1]^<U47<?=/#S:;Z[P%NL@5L!OX*P+NFZ8<?\H-RO!N_
M_1\``/__`P!02P,$%``&``@````A`$HR"`>R`@``\`8``!@```!X;"]W;W)K
M<VAE971S+W-H965T-2YX;6R455UOFS`4?9^T_V#YO7PE0!J%5$VJ;I4V:9KV
M\>R``:L8(]MIVG^_:SN00+JJ?4DP]]SC<\^U+ZN;9]Z@)RH5$VV&0R_`B+:Y
M*%A;9?CWK_NK!49*D[8@C6AIAE^HPC?KSY]6!R$?54VI1L#0J@S76G=+WU=Y
M33E1GNAH"Y%22$XT+&7EJTY24M@DWOA1$"0^)ZS%CF$IW\,ARI+E]$[D>TY;
M[4@D;8@&_:IFG>K9>/X>.D[DX[Z[R@7O@&+'&J9?+"E&/%\^5*V09-=`W<_A
MG.0]MUU<T'.62Z%$J3V@\YW0RYJO_6L?F-:K@D$%QG8D:9GAVW"Y3;"_7EE_
M_C!Z4&?/2-7B\$6RXAMK*9@-;3(-V`GQ:*`/A7D%R?Y%]KUMP`^)"EJ2?:-_
MBL-7RJI:0[=C*,C4M2Q>[JC*P5"@\:+8,.6B`0'PBS@S)P,,(<_V_\`*76=X
MEGAQ&LQ"@*,=5?J>&4J,\KW2@O]UH/!(Y4BB(\D,U!_CT7M)?"?(UG='-%FO
MI#@@.#.PI>J(.8'A$HC[PIR,H=3_50HE&I);PV*YH`@%W7E:+Z*5_P2.YD?(
MQD%2C`9(.$9L>X1I!*@;)$+=4XDSZ.#KWO>*3-)84315]`IDHN@2D20#9*01
MK/NX1I,$)^',DL5LH+?&;AQD;L^!<7I[]F(D8#X6\+8Y!IQAJ&[H17H]V=A!
M%K:75_$LG,2WHW@:IR=S1[+@='_<%Y,TEK>83^0YR-S*BX-Q<'L>/.D>Z4K&
MNMZVRX`G>N+QEAL'Z>V*DM.VMH\PFPS%,9[&R:G/3I:;/.YF<BHKNJ5-HU`N
M]F:JA%#G\-8-O`T,/#L>_"$``Z<C%?U.9,5:A1I:0FK@I6"'="/++;3H[,W8
M"0VCQC[6\&6A<+P"#\"E$+I?F+LX?*O6_P```/__`P!02P,$%``&``@````A
M`+L4X^?@!0``8!8``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK)C;
MCJ-&$(;O(^4=$/=K#`8?D.W5V(`!)5(4;9)K!F,;C3$6,#N[;Y_J$W1W>=F9
M*#?C\>>JZJZ_JYNBUY^_55?C:]&T97W;F/9D:AK%+:^/Y>V\,?_Z$GU:FD;;
M9;=C=JUOQ<;\7K3FY^VOOZS?ZN:EO11%9T"$6[LQ+UUW]RVKS2]%E;63^E[<
MX)=3W519!U^;L]7>FR([4J?J:CG3Z=RJLO)FL@A^\YX8]>E4YD50YZ]5<>M8
MD*:X9AW,O[V4]U9$J_+WA*NRYN7U_BFOJSN$>"ZO9?>=!C6-*O>3\ZUNLN<K
MY/W-=K-<Q*9?4/BJS)NZK4_=!,)9;*(XYY6ULB#2=GTL(0,BN]$4IXWY9/NI
M[9G6=DT%^KLLWEKI?Z.]U&^'ICS^5MX*4!O6B:S`<UV_$-/D2!`X6\@[HBOP
M1V,<BU/V>NW^K-_BHCQ?.EAN#S(BB?G'[T'1YJ`HA)DX=!IY?84)P%^C*DEI
M@"+9MXWIP,#EL;MLS-E\XBVF,QO,C>>B[:*2A#2-_+7MZNH?9F232?5!9CP(
M?/(@SGSB.MYB2:.,>+K<$SZYIS=QEI[MS<GP(X[P*YTW?'+'Y<1VIS]SFW.W
M1>_VWIG"AJ$#PN?'9KKBCO#)'6W(=B0U&XJ`#D7^X2X_F:7%5I4629!UV7;=
MU&\&[#Q8M_:>D7UL^R2<*`\V?%\P/ZH76&,2Y8F$V9@@&I1""T7^=>NXSMKZ
M"H69<YL=MK%5B[VP(*5#P@8Z"'40Z>"@@U@'B0Y2"5@@2Z\-E/S_H0T)0[01
M6>T$D,32A!`6PB700:B#2`<''<0Z2'202D`1`K8M$F(&Q?+X#!$U0;S@M%!J
M8J8FNF,V4.\BTSTB`2(A(A$B!T1B1!)$4IDH$L".5"083YU8PXZ"LV=D/W`C
M.'$D(U<5:-\;"8$"1$)$(D0.B,2()(BD,E'D@,P4.<BQX7@3P!\\.$@@JI3(
M;\<)'*.2+)XF2V\DW`)$0D0B1`Z(Q(@DB*0R462!M51D&:\28JWFSHF:^US+
MO3?J<T<D1"1"Y(!(C$B"2"H3)7<X_)7<V9-DL@"QQF4@CJH,C,R'(W./2(!(
MB$B$R`&1&)$$D50F2LZP4$K.XXD2:S511N:KX?ACQ&'M$WT&,D)DE/;#0JV)
ML#<2-1'Q0$X?^H!"Q[W72.BD-Q*A4SFT(@=T,!^0@UBK<C#BT(:6-@![3B0Y
M&%G.:)/A.M.5=F*&O8&8;\2#2%*@L''O17H7"#O5PB:]@0B;RF$5&4@?]0$=
MJ+DJ!$?>K%^]/4<S20J.YH->H4"#520<I?0%&AZ[L7`<8B4"#;%2X4ACJ3F3
M)DIO)-D387Q3V*S[8J]`=-%W'#GP])%*?JF6_%Y8L9<6UBZR6`X4:.]H>U/5
M,>2.+IQDDI76BT8B_+)?@H-`PW:-!1H=,1$C>K1H[;FK32D=PD!UJ;J2GNP_
MZ<J:.457AJ"JAL0==Z7*L[>9E5)H#+G#@1QR*Q<VP9B(/)9<>QS)M8?")T-X
M^BXQ0X+)@57!2`NG"V9[]#G47<K\95?#A*%0'I0E.53X^PQO!(?BVMD,N3!R
MG[&C%]>>6_%7:5:5S'$N.SZH2FXE%[WMH:ID5E#AXA@Z\!%GLJ#O&3'ACG-V
ME-K+!1)9'DP5F32&8R)_J>\_$AFDZ57F_:6L,D=#@GOR-DP>%`,*,`HQBC`Z
M8!1CE&"4*DC5@G2#NA8>%-@'.V'RMJ`]#P623Q='KXG]8"5J(L`HQ"C"Z(!1
MC%&"$;G"&A:)Z<.NI-AM0U4TYV)?7*^MD=>OY+H)'+;K'K.[L)WG0V\-6>A\
M[D/?^8`O?.C-'G#;A4LUNB'T2#8,`4-CGV#I0Q>%>;STH07"/%CYT&I@'J]\
MZ!4PAWN^)WH,HAG!A![8[QP?WL=QG-W,A[=4S)]<_^EA8CO0@DIA]2/#_=X]
M.Q>_9\VYO+7&M3C!@DSI$=FP&T+VI>.[^+GNX&:/;N@+W.06<#4S)>]ZI[KN
MQ!>8D=7?#6__!0``__\#`%!+`P04``8`"````"$`_WFG,B@0``!$5P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLG&]OVS@2QM\?<-\AR/M-(MER
M_J#MHK%$BL0=<#CLW;UV$Z<U-HD#V]WN?OL;BAR1PX>QXZ!O-ML?AR/QT9`<
MC61]^/7/I\>3/Y:;[6K]_/&T.KLX/5D^WZWO5\]?/Y[^YS?UR]7IR7:W>+Y?
M/*Z?EQ]/_UIN3W_]]/>_??BQWOR^_;9<[D[(P_/VX^FWW>[EYOQ\>_=M^;38
MGJU?EL_4\K#>/"UV],_-U_/MRV:YN!\Z/3V>UQ<7L_.GQ>KYU'NXV;S%Q_KA
M876W;-=WWY^6SSOO9+-\7.SH_+??5B];]O9T]Q9W3XO-[]]??KE;/[V0BR^K
MQ]7NK\'IZ<G3W8WY^KS>++X\TKC_K*:+._8]_`/</ZWN-NOM^F%W1N[._8GB
MF*_/K\_)TZ</]RL:@9/]9+-\^'CZN;JQEQ>GYY\^#`+]=[7\L4W^_V3[;?U#
M;U;W_U@]+TEMND[N"GQ9KW]WIN;>(>I\#KW5<`7^M3FY7SXLOC_N_KW^T2]7
M7[_MZ'(W-"(WL)O[O]KE]HX4)3=G=>,\W:T?Z03HOR=/*Q<:I,CBS^'OC]7]
M[MO'T\GLK+F\F%1D?O)EN=VIE7-Y>G+W?;M;/_W/&U7!E7=2!R?TM^!D3\=)
MZ$A_0\?Z<N^1IJ$#_0T=FK-IW5Q>#:>[YT@TF&&<]#=TK*9G]553-3,WT#T]
M9Z$GG=C;SI&FUG`H^GO<.5Z'CO3WR'.L*&[\970!Y"]16<ES?_V'<&H7N\6G
M#YOUCQ.:HW2%MR\+-^.K&^>.`\DK,X;6:Y%%(>6\?'9N/IZ25A0T6YH.?WRJ
MKJ<?SO^@$+X+-K<%&VDQ9PL7K\YMFX,N!RH'.@=]#DP.;`+.2991&XKKGZ&-
M<^.TX5'=,HABU9D0;,%=VAQT.5`YT#GH<V!R8!,@A*!Y"D),:?J45QN."=>+
MUA41$XT<Z*VWJ::C.',@+9`.B`*B@?1`#!";$B$!K3Q"@OU#=]8THTBB/?,A
M&-%"DQC-I$#ST6@,!2`=$`5$`^F!&"`V)4(.&MD1<CCK00X>Q&T@<NR7V=A'
M(^[6`NF`*"`:2`_$`+$I$6.GDSYB[,Y:CCT0N5A>96,?C<:Q`^F`*"`:2`_$
M`+$I$6.GDQ9C=]M%W9R15D=N&,Z1E"40VCZ3Z7"=R3(:C;(`Z8`H(!I(#\0`
ML2D1LKBT.M]%+RFA.EH6YTC*$D@J"^7:F2RCT2@+D`Z(`J*!]$`,$)L2(0ME
M-#]'%N=(RA(('7J,EOJBRF09C499@'1`%!`-I`=B@-B4"%E<GO5S=!D\26$8
M267R!"-:C=(@ZA`I1!I1C\@@L@))A5Q*ED^HR96[ESEVH:E\=D=[,8_TEI&4
M:)(%3[3BCBVB#I%"I!'UB`PB*Y"4R"5K/TDBG_<)B0*2$F49_;P:K:)$@#JT
M4H@THAZ1060%DA*Y;"Z5:'_25H7D+XV4@*0,61([YXY78XBUB#I$"I%&U",R
MB*Q`4@:7Q:4R^'N\LTN:3`<4"?E?JHA'LW@[,Z?LW:W."6H1=8@4(HVH1V00
M68'D\&F88O@'QNS,LR75HWHHR0PWIG.7VI-5[0LB_E[5(Z=JLB5E^7P7.I(5
M3QF%2"/J$1E$-J"Z=NZE#"ZG2Z/@@`PA!8SG>5MY)&0(*)7!HT9.F2RU[X(O
MLHHRC!T9:;3J$1E$-J"2#"Z'.T*&D/*E,G@D9`@HE<&CYGHHAE!JDBT:734:
M\'!50/ZLASC3C":C3GWLZ,HLY#E;E4TT8,^6W13"@J[3,7HX\VQV>'1)XTGB
M/K^?J;P5;>!\4BVCV8@Z1G%U48QBI&A&UV/'GE'T91A%7Y;1X$O.#I>L'1$6
M(;>+H[FM/+JD<28RY/<OP6J21HKO.*&-<^Q8-5F&WX6.TZDOKC5UEJXH]CQ<
MXA`\P7.LKO31:L_!#%M-AH/-9MG)6&['<*)9<8R.@[D,IX`NZ=Q'.>HJ.X-Y
ML$K#*:!)#(&.T640;9*+QFZ2X&*4!!>[B9X-HZO!\S2_&I:]8*31EB$52G;C
MW;?5W>^W:QHW&1769W<]ADO[>?"2"><3W2NZ`J-PU30;\3QTO$H",*"&MO'8
M$0*0K9IAQ).+)MO95#"@..89KADE`<AN]A[,L)4_6'5QE0W#LN="!+H$-)W)
MN;Z_K5]>TY?":10XY+')#*=UV:U]5W&`<T0MH@Z10J01]8@,(BN06-7J/`%.
MM"B$5SI\S(4'9U3'CK-@CJA%U"%2B#2B'I%!9`62PW>):1X*[[N+K'V.2^D5
M!_<M(['@5WD)(EIQQQ91AT@ATHAZ1`:1%4A*Y)+65*(#8>%S7"%#0&+[K_)Z
M`X76D#?$S;A%U"%2B#2B'I%!9`62,KC<,Y7!391W%?!JG\4*A0*2@9*M:'/N
M&+>B%E&'2"'2B'I$!I$52"KDTM5<H7=5?MT#RBR%9"05RO+:>;2*4RGXBJ)U
M:*40:40](H/("B05HK,'A1K:E(^LC-?.3[:U!R3UR>XHYMPQBM$BZA`I1!I1
MC\@@L@))?5PVFD?0^^:8SVO%'`M(*I2E*/-ZM(H1!*A#*X5((^H1&416(*'0
M)$^>W2KTOOUJ<"6#B)&4*+LQGT>K42)$'2*%2"/J$1E$5B`I49X][]^OZ#XK
MGTN,I`SY[6JTBC($7W%Z=6BE$&E$/2*#R`HD9=B3Y!Y0!/-:=^=)"TY2OYLC
M:A%UB!0BC:A'9!!9@>3P\[SVP)@QF9UX1+=I?'WGC)([HX`.E/2B%?M2B#2B
M'I%!9`.B+)_<2QGR_/:`#)C#3CP2,@24RN#1@9)>\)66]!!I1#TB@\@&5)+A
MN!QV@CEL0$(&;T7WF7Q1VV#U>DDO&G`?Q9[C/:-FE)3T8L=72GK1@#U;=E,(
MBSR9/1`6F+%2#<6M"+*D5^6UK&!%636?5,LHWB-VC&+FKQC%E50S2JHNC*(O
MPRCZLHP&7W)VY!GK`1DP+9UX=*"D%ZQHL8XR^(YN`=M34>&.OLK63+-[)L7M
M:>P$QTE!)5KM.99AJU>.9;F]$$VT48JT[8",SCQ+/#PZ4-&;>"L131[1)69E
MNV!%I^MFRK2I0;3@)HVM@-+8`L\F\WQ]F86[Y1,L1)K+(?/,MFJ&!VQO+^E-
M0B8:I]-M0`=*>L%*!*#W=:"D%SHVOLK67,RR.R[%GM,(])YI->9KTK,;VB5>
MCW;#5N%@39U52JPXF)C)TU)>G.K[MI+>X$:&9D!I20]1BZA#I!!I1#TB@\@*
M)+7($^`WE_2FF`L'E);T$+6(.D0*D4;4(S*(K$!R^'GBNW\UFF*VRXA6@#%:
MZSI_OA"M.,Q;1!TBA4@CZA$91%8@*<-Q"?`4$V!&M*$D,F1S<AZMH@S!5]R#
M.[12B#2B'I%!9`62,KC$-%]XWU%RH:=J^:;%2(9)MMO,HU74)_B*&U"'5@J1
M1M0C,HBL0%*?/#-^=UG3O>V=;>N,I$)Y63-:186"KU0A0`H[:D0](H/("B05
M.BY7GF*NS$C*D.VD\V@590B^4AD`*>RH$?6(#"(KD)3!Y97Y1`H[[($5UF>D
M:2UNZE%:3T#4(NH0*40:48_((+("R>'3Q1/#/S!F9YXE$AZE=Y#3@)+[@H`.
MU!.B%<>*0J01]8@,(AM0X49ZFN>Q!V3`A'7P0*]%)6451JD,(3LE@>+><Y%5
M(KO0,:TG(-*(>D0&D0VH($.3IYO[91C,930$E,K`*)$AH-?K"=%@#`1VDV3D
MC))Z0NSX2CTA&K!GRV[P#M!MJ$?,CL$\T\.GG@VE#O&"U_GSB]`QO8\):!;C
MJ6,4A53<,17%'S&]3>&.T9=A%'U9X4LL$LUQJ>=@GLG@LU&7UB4RY`\I0L?T
M1IA1.F'P%:%@1:O\<-7A;BYZX8NN&26WQHSV'LO(8U47V2!L]$+'DC(>E[JZ
MF,G6VH#<0X)$QFSYF+-5O+9M0+0/L``=(WZ/!]YJ83=I;/E3$K'E4>+9L&?_
M`F`%Y03A6"I4RFK3V]TWO2'D[OUSX3QR;P.,PN$;0J&CB#_?<98&;B'^@I6O
M,5%M)KNI4NPY9CR:41J`;SF8"1UG_GTX^D6O?'O?LN/A6%+>4E*<RONV:@)5
M34!?C])J0K!*4(NH0Z00:40](H/("B2UR-/?-U<3&LR$`TJK"8A:1!TBA4@C
MZA$91%8@.?P\[3VPTV.NVP24KI9UG3]-C%:\\+2(.D0*D4;4(S*(K$!2!CK[
M8S9X9Y[M;`&1&N/*4M=9!77N'B"YCG'];1%UB!0BC:A'9!!9@:0,>?KK)L/5
M]7M^=$0Y'4@4$&D0)9ID2^2<.\8ELD74(5*(-*(>D4%D!1(242(F(\5)-)L,
ME>XC7W,97,DH8B0ERFM2T6J<3(@Z1`J11M0C,HBL0%*BX[+EF4]4T_MG1E*&
MO/04K:(,P5<,G@ZM%"*-J$=D$%F!I`S'9<LNM<C6%$:TT203)J\O1:LH0_"5
M/#9"*X5((^H1&416("G#<=GN#+-=1F)IG>3UI6@590B^XFK;H95"I!'UB`PB
M*Y"4P>5T>7WI7>]^4<('@1*0G"]90CCGCG%RM(@Z1`J11M0C,HBL0%*A4E;Z
MKO<K9YB8,I(*9?=L\V@58RCXBJ)U:*40:40](H/("B05*N6J[WL[;H;)*R,I
M47Y3&:VB1,%7*A$@A1TUHAZ1060%DA*Y;#2?9N\+HI#7)@^CJ9X[S#RI4)[J
M1JNHT-B148=6"I%&U",RB*Q`4B$Z>Z'0_HQ_YLRS)"4@&E2R+>6I+G>,BV^+
MJ$.D$&E$/2*#R`HD92BENJ[T=6P2AWGNK)3G3O,\-UIQ3+2(.D0*D4;4(S*(
MK$!"'_ITFPP3E^>^:R(-GF0$,1(3:9JGN=%J5`A1AT@ATHAZ1`:1^X1=F/-T
M$EXA_TDZ_PVQI^7FZW*^?'S<GMRMO[O/S5$*\.G#B/VW\&YGES=N2I(+:+FB
MEF'EA)9K:AFJ0GG+Y05_6B]OF=%']R@C+1VGII:AA`=])M0RE,ZA94HMPVLN
MT-)0R[`R0LN,6H:\,V]IJ`_580KGUE`?*E&46D@WNFLOM9!N="-;:B'=Z/ZM
MT#(CW>BVI=`R(77H7;5"RY3ZT+LHI1;2FE[3*+60-RIQEUI(:WJ87VHAK>DQ
M=J&E)G7H5RFE%E*'?HU1:B%UZ'<(I192A]Z_+[1,:*1442ZUT$C],XG\FI*S
MHJ^*?-&W30J^*O)%G_0HM9!J]"6+4@NI1A]W*+60:O3=`VRAKT]^+ONB#@7[
M6SIXT9X.73KRY^G-9UH:\,"W[CJ6N(O^$G?SI<3IVA8O+5W9TH6E=W-O.GHC
M%L^HIQ93;&FG5S?N^2CV::?7U%*ZM&US<=/1DS+LTU.+*;;<3FGP]`8"]KF=
MTO#I<4VIA03P3Q.RH&LK&H^O%D#+C%I*WMKJ\L9];P"/0Q\3H#ZEEG8R(=U*
M%[^=3*FE>)5K%T?%0*HIDNB'FG@&]#-*:BE[(]W\4XCS<:CT#=.7Q=?E/Q>;
MKZOG[<GC\H$VG8NA_K3Q7T'U_]B%'_E^6>_HZZ6T_]*7+>EKM4OZJ.2%^RS7
MPWJ]XW_029V/W[_]]'\!````__\#`%!+`P04``8`"````"$`.665MK(%``#N
M%```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RLF%V/HS84AN\K]3\@
M[C=\!9*@)*M)^%8K5=6VO6:(DZ`)(0)F9O??]]C&@'VRZ8S4FV'RY/@UY_7!
MG'C]]7MUT=Y(TY;U=:-;,U/7R+6H#^7UM-'_^A9]6>I:V^770WZIKV2C_R"M
M_G7[ZR_K][IY:<^$=!HH7-N-?NZZFV\8;7$F5=[.ZANYPC?'NJGR#CXV)Z.]
M-20_L$'5Q;!-TS.JO+SJ7,%O/J)1'X]E08*Z>*W(M>,B#;GD'=Q_>RYOK5"K
MBH_(57GS\GK[4M35#22>RTO9_6"BNE85?GJZUDW^?(&\OUOSO!#:[`.2K\JB
MJ=OZV,U`SN`WBG->&2L#E+;K0PD94-NUAAPW^I/E9]9<-[9K9M#?)7EO)_]K
M[;E^CYOR\%MY)>`VK!-=@>>Z?J&AZ8$B&&R@T1%;@3\:[4".^>NE^[-^3TAY
M.G>PW"YD1!/S#S\"TA;@*,C,;)<J%?4%;@#^:E5)2P,<R;]O=!LF+@_=>:,[
MWLQ=F(X%X=HS:;NHI)*Z5KRV75W]PX.L7HJ+.+T(7'L1RYLM+'/E+$#DP<!Y
M/Q"N8O:9O70MUZ.S/Q@(W[+;AFL_<#E;NN[<6_['C%X_<#$,_."MP@/#9H3K
MYVYUU0^$Z^=NU8)B8%/2?_JACV_6X(O+:B7(NWR[;NIW#1Y`6+[VEM/'V?*I
MFJ@2[O!0-S\K&Z@7JO)$938Z6`<5T4*MOVUM=[$VWJ`^BSYFAV,L.6(O(F@Q
M4ME`!:$*(A7$*DA4D*H@FP`#;!F\@<K_/[RA,M0;D=5.@(E9BA$B0@P)5!"J
M(%)!K()$!:D*L@F0C("G%QGA0+'<WTI$3=!1L&E(-;&4$]WQ&+X-LB7?(Q(@
M$B(2(1(CDB"2(I)-B60![$.2!8]3I]'P1,$>].!YZ(-@WYD$K62#]D/04`J(
MA(A$B,2()(BDB&13(MD!F4EVT&W#=F>`/[EQ4"'FE,AOUQ/834=;/%.Q90@2
MPP)$0D0B1&)$$D121+(ID6R!M42V6.Z,OGD>%PP=*-O`B3=N&WM$`D1"1")$
M8D021%)$LBF1<H9-7\KY<:(T6DZ4$V\U[(][3FS>2;#W`"?4QK$F3$^NB7`(
M$C41(1(CDB"2(I)Q8MOT%J7<::\\?7L^SIU&R[ES8K-&CF]_/9GDSHD+ETGN
MRKLU'(*&W!&)$4D021').+F3.W0MG\B=1LNY<S+-O2>3W#EQ5[RC,"U76?+A
M^R'M7H,M%7,T[HDSU%<RC&)]BFG-9=5T^%ZH9E-5J0!HR_0)%UBX;$./;-AJ
MQ_7U4&=$YZ%;[)!%(`9Z`PH%&C>-2*#E$!4+-&HE`HU:J4"C5B80TY)MH"W4
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M<>QOW\$P?[_5MY_Y"VLP&-PWCE.#.5JR$P_^KF.3;?0)"C`*,8HPBC%*,$HQ
MHD<P=&?E-\%KC1^I\)_)%6E.9$\NEU8KZE=Z7`+F;=<#YF<Y.]>'IA">9I5[
M/C1.=[@U%X<_RHA@X4,#@D<$2Q]>SG?XR@]9ZZ3H)"L?WF,X'DZ=GMBR*_$[
M>AIU)WYG^_"S$.OL'!]^+&'^-/>?P%+\Q0XR9MP89H;3IEM^(K_GS:F\MMJ%
M',%>DW7+#3^OXA^ZON:>ZP[.F5CYG>%<D<`)@4E_<ASKNA,?8&)C.*G<_@L`
M`/__`P!02P,$%``&``@````A`#X=U)E^!0``SQ,``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C`N>&ULK)C9CNI&$(;O(^4=+-\?O&$#%G`T+,:V$BF*3I)K
MCVG`&DPCV[.]?:HW+UT<,DBY&0^?J_[NJJY>W//O'^79>"-57=#+PG1&MFF0
M2T[WQ>6X,/_Z$7V;FD;=9)=]=J87LC`_26U^7_[ZR_R=5B_UB9#&`(5+O3!/
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M.3U#!^"O41:L-"`CV<?"=*'A8M^<%J87C/R)[3E@;CR3NHD*)FD:^6O=T/(?
M8>1(*2'B21%X2A$G&$T<>^9-0.2.XU@ZPE.U/G*GON,'K/4[CO"6=QN>TG$Z
MFOK^.)C^1XN!=)RTCE_L*DP8WB(\'^OJ3#K"\[&N.E`,O$GVCW2]WUE+#"ZO
ME4W69,MY1=\-F(`P?/4U8]/9"9F:JA*1X;9N?E8V4"],Y8G)+$Q('51$#;7^
MMG0GD[GU!O692YL5MG&&%FMEP8J1R6YTL-5!I(.=#F(=)#I(>\""M+2Y@<K_
M/W+#9%AN5%0K!7K)TA*A+)3+1@=;'40ZV.D@UD&B@[0'!HF`V8L2X4&QW%Y*
M5$TP+U@T^C7A3X>!KH2-,VZ3LT9D@\@6D0B1'2(Q(@DB:9\,4@#K$$J!ZX_:
MM>C+,X4)P60#Q]Y4T=,BC6!%Z8P">YB[=6O45@DB6T0B1':(Q(@DB*1],L@4
M1(8RY?@CMOK>KQ?FR#.CXED)$G139XW(!I$M(A$B.T1B1!)$TCX9Q`Q[QR#F
M^X$RZV&@@@2S;AH(XHK=E*^%@K`T=C5A!\.:V+9&*H<1(CM$8D021%)!7)=U
M<1`[+/H/Q,ZLA[$+XO+##%_UUY+T8A?$'\P'6]M?MJU1&SLB.T1B1!)$4D%N
MQ`X=>B!V9CV,79!^[)+T8A?$GXE=U79\;<C;]VW84H,/%<_H3A)^VN0D;KWX
M7FT[XZ%JTKY7JFE?=5``<'QY(`G,>I@$05Q84+K"#O2C@302!U4^'R0)VCFS
ME:1;+B))IJW-#NG$2"=!.FE?9Q`[.S(]$#PW'T8O$=M.V_`G[G`TULJH5Q8*
MP9[=^CF^MD=LI=5XS*O'"69:7J-.1@WT3J&NL5BANXTE6F/VQ!N&D78RT-@P
MC^P,UC^'WE]!'7%D@UU4]7HET;C?1;T#:VDDOW?$$5-(>;TZDE;>1"3-#;3A
MB)1,KZX4ZGH4*YE..5%HRI6GGC;K4J7"A8<)8F>S?H+80=T-V*>;T9R*_&5%
M`4`L-Q+G06M\UC\Y3$6K/X'&</)IZPA%O):.7E<3&XG\_KR]48!"WO=YQ.[,
MUVHB4LJ]U4JAKK'X2XTERDHTYLST+2)5RG@7@R]QG%]Y;.'Y_4&O/\LOC$&;
M8'F`[,I@Q947YK1WQL5H@]$6HPBC'48Q1@E&[.Z!U8+HEZ@U<9<@O@]+4AW)
MFIS/M9'35W9/`,E;SELL+C%6?@BG(IB$.G<\=;NAO=D$(9PNL,=F$L+.>X-/
MPRV?#II./`UAD\+V<*WRQ(=7LU^QZY8;]BLWA.\>K+."`/A^J>D\C<,G2-T-
MAW$(AV+@5NL!URG7[$A^SZIC<:F-,SE`&FU^%*[$A8SXT<C:>J8-7*3P,CO!
MQ1F!3V";?6(<*&W4#]9`>Q6W_!<``/__`P!02P,$%``&``@````A`"`K+<TL
M!0``'!(``!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK%A=CZ)(%'W?
M9/\#X7U$$%").FD5!+.;;#:SN\\TEDI:*`/TQ_S[N?4%]>&PG<V^C./QW%-U
M3]VJNM6KKQ_5S7I#35OB>FV[DZEMH;K`I[*^K.V_OB5?%K;5=GE]RF^X1FO[
M.VKMKYM??UF]X^:EO2+46:!0MVO[VG7WR'':XHJJO)W@.ZKAES-NJKR#K\W%
M:>\-RD\TJ+HYWG0:.E5>UC93B)K/:.#SN2S0'A>O%:H[)M*@6][!_-MK>6^%
M6E5\1J[*FY?7^Y<"5W>0>"YO9?>=BMI65439I<9-_GR#O#]</R^$-OUBR%=E
MT>`6G[L)R#ELHF;.2V?I@-)F=2HA`V*[U:#SVGYRHZ/KV<YF10WZNT3OK?1_
MJ[WB]T-3GGXK:P1NPSJ1%7C&^(50LQ.!(-@QHA.Z`G\TU@F=\]=;]R=^3U%Y
MN7:PW`%D1!*+3M_WJ"W`49"9>`%1*O`-)@#_6E5)2@,<R3_6M@<#EZ?NNK9G
MX2283V<NT*UGU'9)221MJWAM.US]PT@NEV(B/A>!3R$R\1:!&X1$9"00?J6C
MPR</'.=#U5(^?'*^-W']Z;\-L^1A\"F&F2R"P`\7\X?C.<PDZOD^[_+-JL'O
M%A0RV-#><[(MW,B%M1)NLQ1[_W]F/_A.5)Z(S-J>VQ8XVT+-O&V\>;!RWF"=
M"\[9FAQ79>P$@RPJD=WK0*P#B0X<="#5@4P'CA+@@"V]-U!!_X<W1(9X([+:
M"D`R2S-",$3(7@=B'4ATX*`#J0YD.G"4`,6(V0,C9E`LC[>DJ`D2!9M/K@E_
MIB:Z91S7[\W9&<C>0&(#20SD8""I@60&<I01Q0(X")1:&$^=L&%'P5:4]D.H
MY<Y)L/,'DJ^1=CVI+P4#B0TD,9"#@:0&DAG(4484.R`SQ0YV;$S(X3/N#`FD
MSHA\M@P)A_VQ,Y"]@<0&DAC(P4!2`\D,Y"@C2LZAEO-XHH2M)LJ0<#G4.D,\
M=O70`X\AQ$:I)N9JX<0]27B8<"%Z*].3\V!(IWW4B'36DX3T4996[(##7BF!
M<3L(6[6#(1YM!NB<=QR1[&#(8D9O%-^;+GW-BIX@YIMP$<D*0S;MH\A%!;)3
M33;K"4+V*,LJ-I"V4[Y`QVT@;-4&A@2SH2H8,I-L8$@X6!5S9.`D/$K*FR/#
MV9H:.IFA<Y1UE$2AU5`2)5O>"R90JN,IDS@U989X<+A(1;Y05W;'2:S#HWN#
M(S#!/LP-IFI8S$@^5*U$TOJ,I%<2RWO@R+`WTYXC"VFC97RT@-:G&_K:[\=>
M!`92S"2MUG]RDP:J=G((2FB8JN<O56-VG"67%8?\X>B-!003'_%/:$G%)B"I
MVH36()\):,E:Q)GNEU"APJIAI$F3]YETXW37LGC98I@PD!X4(SD^>)O*6CVX
MF,7*;UT&^=#[]!E[>EGM.(L_.%AOR@)#.="L1QX8RL7N!GI!"OE%/Z\#AV:R
MH9\9,1,CLD/37<P-DYF,1P=3328-X)C)W_#]9R:#-;W+K(]47.;0D.`.WI#T
M8!B@O0G%)I28T,&$4A/*3(@\9(=),"_8PY0]DBK47-`.W6ZM5>!7\NB$@,VJ
MA]F+>!M$T#5`1>FXZXFGLO;+/HS@%C<CTC""*]C$]_,HIMM(TTGG$=Q5)A_>
MZ$]T#VG\+7F[/^!O8:(/^;,(6N('^G[T!$Z8/VS]")I&P)U^9'B;W_,+^CUO
M+F7=6C=T!ANGM%5LV.N>?>EX;3WC#E[EM,RN\%<8!._`*;EESAAWX@L9H/^[
MSN8'````__\#`%!+`P04``8`"````"$`I2E$B3,+``"H-```&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6RLFUUOX[H1AN\+]#\8OC^Q)5FV8R0YB/5)
MH06*XK2]]CI*8JQM!;9WL^??=RB2XI"OXH^B-^O-H^%0,QJ1[UCRP^^_=MO!
MS_IPW#3[QV%P-QX.ZOVZ>=GLWQZ'__HC_VT^'!Q/J_W+:MOLZ\?AG_5Q^/O3
M7__R\-D<OA_?Z_HT(`_[X^/P_73Z6(Q&Q_5[O5L=[YJ/>D]'7IO#;G6B/P]O
MH^/'H5Z]M(-VVU$X'D]'N]5F/U0>%H=K?#2OKYMUG3;K'[MZ?U).#O5V=:+S
M/[YO/H[&VVY]C;O=ZO#]Q\=OZV;W02Z^;;:;TY^MT^%@MUZ(MWUS6'W;4MR_
M@LEJ;7RW?X#[W69]:([-Z^F.W(W4B6+,]Z/[$7EZ>GC94`0R[8-#_?HX?`X6
MU208CIX>V@3]>U-_'MG_!\?WYK,X;%[^MMG7E&VZ3O(*?&N:[])4O$A$@T<P
M.F^OP#\.@Y?Z=?5C>_IG\UG6F[?W$UWNF"*2@2U>_DSKXYHR2F[NPEAZ6C=;
M.@'Z=[#;R-*@C*Q^M9^?FY?3^^,PFM[%LW$4D/G@6WT\Y1OI<CA8_SB>FMU_
ME%$;4><DU$[HL\?)F8&1'DB?>F`0W063\51.?F;<1(^C3STNM"=]9AQY;:.E
M3SUN>C>/X\ET/CL_X50/G'4#KSM1NLW:">GSIA.]U^/H\[83#:B"U`65I:0O
MUKF<CE1!M/65KDZKIX=#\SF@FY8N^?%C)9>`8"&]FLI2Z>UJ[:M2HQJ37IZE
MF\<AY8VJZ$CWQ\^G<'K_,/I)-;W6-DNT"5R+Q%C(`I9N4Q]D/LA]4/B@]('P
M0<7`B-+2Y88*_?^1&^E&YL9$M32`)<M+A+$P0U(?9#[(?5#XH/2!\$'%@),(
MNG&=1/0O.Z86I/7CD'S96IB-W0"7RB:8=$E)@*1`,B`YD`)("40`J3AQ0J>U
MQPE=WA\36D7.IT".HC7628%7[$MEPU,`)`62`<F!%$!*(`)(Q8F3`HK62<'Y
MT*4U+2;TP2Y_Z%U^;43KI34:QZY1TAEU=P&0#$@.I`!2`A%`*DZ<=-`FX:1#
MK9AW<FLYGQDYL,V,B6>IR-0N#0F0%$@&)`=2`"F!""`5)T[,M+`[,9\/5%J[
M@2H2MB*G7=D3393":-=Z160:64U,W9K(.B.3PQQ(`:0$(H!4BH1AJ\/X+B`U
M--\AS\<NK=W8%>&Q:\)B5R2F#Q;[S(N],^IB!U(`*8$(()4B/;&3,+DA=FGM
MQJX(CUT3%KLB\;U2#>/`6P:R[G@7MO;17JJVF@I-HFX[*;M1K189!Q,WF:([
M;KQ6W*M3_%(6W9"%UMQ-@T8SJC%V?>?N*27:2@MXI7_DU+273KO`,F-E%XW<
MH'EG51ATWZ'2(.M+&&1]50:UOMPT2)ET_8T0*%5%&X')\%*C&94;2X,G$Q-M
M%;$2,8AKBB#V-$6FK2:3MI*".(S<!.?6C3FEPB`K1$J#SDXFC%743C:=>B=3
MF>.XG@129=V01VGNE9-",ZI8F\?`.X.DG8=JQUZ`5*/(ED!FT$PG+8*DJ<E"
M7EP:\>)2B'D6QO.\]3SQKT9ESJ^GTJ0:XQEB6^SI?;/^OFPH;JJOGJ587@_=
MDFA-9^-?!@K-Z:[J$A=,O(@38\4+4`V,22/9@5B`VBIN(X[&L;=[Y=ISQ%8N
M@W@!7C.9T`-C-5DPGGMA5,9S3P5*J7<NOW\T'U_EE\JI2[!6C#S!"LUM@`D)
M7%F_#*6(,D0YH@)1B4@@JASDKFI2YWV1BY[RXN%KA<C#5VAF[Z]$"F$*GZ$4
M488H1U0@*A$)1)6#W/"EY./A7XA9*42ZV;O;()QYA;<,E!'EW"RS":(4488H
M1U0@*A$)1)6#W"Q(\<>S<%V7%RC-2+<KRX;?YFDC)QMJ'$,I6F6(<D0%HA*1
M0%0YR,V&E(,\&Q=J0JE'66,L#7['%V@K9^\/0`)U5J9T4CO0H`Q1CJA`5"(2
MB"H'N9F1&I%GAFU,%Y*DU"4ER42Q#!3BW1^B%%&&*$=4("H1"425@YSP2<>[
MX9^/N35WE8M&O"$PB.VV&EUH!:V526F.J$!4(A*(*HUZFJ+P-B'<FGMI4-J8
MIC"GGF@K^C`HU>A"5VBMS,`<48&H1"0051KUI4%*/GXS7*@&I1#Y'4!.V^Z&
MIT$CG@:%OFX0M1LRL!G0;JP.*<QDK$>T`[]H$JV!\5P9-ZBJ0BG;;LB'4GE.
M/A1RV\3`[X_:>5Q=;Y#5'9E!MK7+#6)*WB";NM(@ZTL89'U5!J%X#WUQ>:$L
M4$2V'D@R.5O%&-*@!O(V40\D>6UW(FP3C97JW.*)MU/EYCBO'3V7532EM3HS
MES!67\Q5F>,]U21UXPW5I&2F4TU:>9[O$DG0MO>@W9A2C5@OEQFDNL1)'$+2
MM!M>6QKQVE*(>1:>Y_N9=YTK<X(]E>9K5[8;7]\FTG<K,@%.YA2ZT";J@4X!
MJH$7VD0]4'=N\7CJ?3>5&\^\`I7GB%?@-9,);[(X]/1IY4SF;O=]JCB(VV^Z
MV_Q>UR:&6NW:"EMJQ'K"!%&**$.4(RH0E8@$HLI!;BZD,.6W(ZNU"PN<EK0\
M?(583YC0URM^FX@H0Y0C*A"5B`2BRD%N^+[PO1"SDK9\'0YG7I4O0V7$NJ`$
M48HH0Y0C*A"5B`2BRD%.%B)?_U[7)K;#+CT-U$8\&XA21!FB'%&!J$0D$%4.
M<K-QFPRF=5*OLW;##&?>/K(T5G0[V&8R]$HGL59&EZ6(,D0YH@)1B4@@JASD
M9D:JS_]IL9#2Q=N,-.)M(J(4488H1U0@*A$)1)6#W/!O$\(1"F&->']D$&L,
M-+K0)EHK4RLYH@)1B4@@JC2BMH#<NVFX30C3U@Z77B$G#1KQ-"ATH4W4[LG*
MIJ$;:%"!5B4B@:C2J"\-4O/QF^'\UA$IB<CEF$9.&K2VY&E0Z.LV4;OA;:+Q
MS(260:Q-M`._:!.M@4ED9=STE(64;3?D0ZD\)Q]:^-%]P]9([[%I0B);UA.M
M4N:D4HVFMM_.#+)6N1G(DZ)],?5I!EI?PB#KJW)\N7>'+RXOE`6*R$BAB:,R
M0N^12Z*MJ(NP:5`#I=KI\H=MHG$_;1_FA"#2C6-[0Q4&L8['H+-S"7>N8.P%
M45DO%(2;1JD;;Z@F:>XV.Y%"<I_OLA&&WKL'B;&RUS;5:&*_%<@,,H_\X`&8
M<<-K2\_/:TLAYED8S^HM@0"Z1,>QFR%?NC+E?GV7&&FQ:LMHJ9%LX;O$X<-$
M8V4'IAI->>'VU)^:<:J^.J"6VWN^FQO/O`#5&%*PIMC+JR83QDH].@_GWF)2
M.7,YZ9WT:>+;F\36C5N8&O$F$5&**$.4(RH0E8@$HLI!;BY\1<Q*[?SR1N^.
M^_>E1KQ)1)0BRA#EB`I$)2*!2+[F+D]5G9<*7[VVKEXKWM6'MSJIM]OC8-W\
MD*^DTQ[P]-!A_;Y\%"R>R1.5J7>$.H"%E-9]1T(ZTJX<_IC)F%Z_;W<B.-*]
MF.\=>0[FBV?:`GKFH2/R&5#?D7LZTMY<GC?Z1F,AOSWH&1.2M_YY0O*F;E7/
M&_V:X+DW3@JF-S.4F%[[B!+6=TX32E</?XX7STIH>">TC!?T/F1/<-,%O3/8
MPP.:0;6ROJ>`7/7.D8;A(E/ZT1M3TA'1>R2-HH44Y7@&:32A(WU!IE&\R$B>
MX9B2CHC>(\N("HQV2!R3SA;T+F$/GR_H/;L>?K_(^@JHO%_0*VD]]N&88N^=
M.0SH2&\Y!'19Z&$W>EL&5*;TX)>.C+HDT^]$/E9O]=]7A[?-_CC8UJ]TTX[;
M;_D.ZI<FZH^3?BGD6W.B7XC06DT_%J!?!-7TGO[XCL3W:].<S!]R@NXW1D__
M!0``__\#`%!+`P04``8`"````"$`]@?(FH8"```M!@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6R45%UOFS`4?9^T_V#YO1A(2%H44J6KNE5:I6G:
MQ[-C+F`58V0[3?OO=XT3EC35EKX`-L?GW'ONO5Y</ZN6/(&Q4G<%3:*8$NB$
M+F57%_3GC[N+2TJLXUW)6]U!05_`TNOEQP^+K3:/M@%P!!DZ6]#&N3YGS(H&
M%+>1[J'#/Y4VBCM<FIK9W@`OAT.J96D<SYCBLJ.!(3?G<.BJD@)NM=@HZ%P@
M,=!RA_';1O9VSZ;$.72*F\=-?R&TZI%B+5OI7@922I3([^M.&[YN,>_G9,K%
MGGM8G-`K*8RVNG(1TK$0Z&G.5^R*(=-R44K,P-M.#%0%727YS8RRY6+PYY>$
MK3WX)K;1V\]&EE]E!V@VELD78*WUHX?>EWX+#[.3TW=#`;X94D+%-ZW[KK=?
M0-:-PVIGF)#/*R]?;L$*-!1IHC3S3$*W&``^B9*^,]`0_CR\M[)T34$G<31-
ML_EE@GBR!NONI.>D1&RLT^IW0"4[KL"2[ECPO6>91=D\GIQ!PD)$0X*WW/'E
MPN@MP:9!2=MSWX))CL1O9X2I>.S*@PLZIP1CM5B%IV6:I0OVA-:)'>8F8/`Y
M8I(1P5!T5$:U\Y4]V"M[;WTH-V'C4.9O($<RD_?(>#`6YR#X-)N,X0?E@)D.
M#7.8S_0]0AZ,EF/Q1YM.K=R!L%T/0-,QG*,TD>G03=^AZ67BV_$_-?4'ATA&
M:W<[1]YFV=NRLU/9*XSWWVWD#QU+[G:.)6>O),-XANY58&KX!&UKB=`;/WHI
M]N.X.]X*J]37Z?7^-%\-MP4;?^"T]KR&!VYJV5G20H64<31'+TR8][!PNL?(
M<62UPS$=/AN\E@%;,HX07&GM]@L49N-%O_P#``#__P,`4$L#!!0`!@`(````
M(0#?VN?]S00``#T2```9````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*Q8
MVVZK.!1]'VG^`?%^0@RYHB1'@:HS1YJ11J.Y/%/B)*B`(Z!-^_>S;(QC&WJA
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M-.>M&RPF\^4T((`[#[1N[C.>TG72I[IAQ;\M2%2DDO@R"3YE$C)9S>>SQ6J)
M).\,#.1`?(Z>W6LK$<+<)4VRVU3LZF"U@6M]2?C:)2$2=XJT-)1&;TD$;7B2
M/<^R=9>N@^IK]/5YYR^"C?>,7J02$_4QQ$3$'8*W$/041RCU/W#D63A'WE9.
M.NH"&FF+4(>P"4$HG=#P\NFTX6`L%$T;0FQM6@R9*7*Q'C'$F(V9FX/16:PK
MU1A"YF:5D03IW>N!8@6RM4!N70N^@((Y<HU<03R-8*K:(R/P7HW[PN0>*Y!-
M:V'2>K]%'-R3:6E.%4F0*9,%BA7(YH-A/9FF0(^4B:<Q99(14Z:5R3U6()L6
M/]FT[?^^3!S<DVEM3A5)$&;4VF:!8@6R^:Q-/JT=82^,E(FG,662$4Q\H^5/
M3>ZQ`MFT"(X:7:>OKG*1QR36A3"WQJQGC9P`!J[%^::;(QEP\#EB(Q43:2QF
MK1]C3IV9;VG6#1Q@-N#;BV#"3[GWUQEI?1>VA3ZT7MV%\$93R;+1N$,99NO/
M%&/#2`FW6&WMB[5&9I_A)\U9YR=#'_"3*'QH5=S\V.1G.3WGQQO[@7;*\F_:
MR=`'W"3*Y';S6Y,;]UU+.]]?3Q`>N^ZD@^M:RI"Y5VVGY8<:WQ&K_H[@)FR1
M(_[R*^2DG>OD9,@D9_LM4:B>DW`KMLG-Q/?-T=))5]?9*:/7%YCMOD2A>NRX
M,=OLY)X8VUB>RC(4&3*T"VP31D??:BSW9XW=!SM!NCG6R6VS!9:Q1MS=.$U(
M\C8JOJ%LQ?R!D\$G"^$B(Q43J4S%NI"IF&W!-U2/W<#A$*S\+VP%7QX&VF+K
M0B8YVY-O*$6NO9^UUY""5B<:TSROG90]\;N7'^`"H<+MQ3`BRS!&CY"B]V:%
M-\($K#=[L@[WF'UHS!ICQ(%EC8G\*6Z@XA+9>Z/NIM:;_2+<#S);A/@Z.#`[
M2AG"[U?A?K"0"!4.%1BABL$B"(K`UXJ!J0F*P($]]&:.-Z*Y5GD101WPL_X8
MW-;W_D`\XI,,Q7UH.Q0/0EQW!O+/POT@HUF(ZT@?'Z$$@?=4";B\7Y(3_3VI
M3EE9.SD]8H%-Q>:LVNM_^]"P"S8>KO"LP;5=_'O&SS04U\0IWRQ'QIKN`1-[
MZH>?W7\```#__P,`4$L#!!0`!@`(````(0!,;/]^Z@P``%HZ```9````>&PO
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MPW']]87N^Z^@L]Y`N_R/D-_O-L?#Z?!TOB*YEKY0><\WK9L6*=W?/N[H#M2P
M-X[;I[OFEV!8A(-FZ_ZV'*#_[K8_3];/C=/SX>?LN'M,=J];&FW*D\K`U\/A
MNS*-'Q4BYY;PGI89R(Z-Q^W3^L?+N3C\C+:[;\]G2G>7[DC=V/#Q[_'VM*$1
M)9FKL*N4-H<7N@#ZM['?J:E!([+^ZZX94N#=X_GYKMGN777[U^V`S!M?MZ?S
M=*<DFXW-C]/YL/^?-@J,E!;I&!'Z-"+!U:#;[?0&?1*I<:3?EM'ITSCVKOK!
M]4W[%WXT>TL_^L15\T77Q+LQ?O1I_+I7G;#;'Y1W6^,8T/B4$=4/5<APT`VZ
M/350=:YMN-(/5=3/W&6`<54_&,^`[_.3R0EZB$\_5"J?2D_0ARO]8%QK$]32
MLZN<K./U>7U_>SS\;-`*0//G]+96ZTDP#"AKF*9ZW*J)^]&\I0FK5+XHF;LF
M70Q-R1,5VY_W8:]_V_J3"F1C;!ZD3>!:C&"AJD')CGTP\<'4!S,?1#Z(?3#W
MP<('B0]2'RQ]L/)!YH/<!X4%6I2>*D<TL_\?.5(R*D<8W0<`*VE>0F`!E[$/
M)CZ8^F#F@\@'L0_F/ECX(/%!ZH.E#U8^R'R0^Z"P@),06B]$0MKTA'A_;4>-
M*"]:Q:T:"?K7[H`_:!M:5C#B(T'&@DP$F0HR$R02)!9D+LA"D$205)"E("M!
M,D%R00J;."FAA=A)27TJE#6M>/1\L-:K@9<+8T2+8F44]-NNT:@R0L+&@DP$
MF0HR$R02)!9D+LA"D$205)"E("M!,D%R00J;..FAD;X@/<JZ3`\&]4&3W@W7
MA2:AWN^4#PM#PLIFHDF_W*B5#Y2IL)D)G<AXT8>5]XZ;][@RPB7.C1"'7QC"
MEYA47C72:64$Z:607@GI3-CD1H?OOK!MG/30!N2"]"AK-SV:A!QJ9`C?^U@3
MM7^TAK7K#NND,L*]3XT0#^M,2$>5ERW=<Z7CR@C2<R&]$-))Y54CG59&D%X*
MZ960SBHO6]K;-.65$:0+6]I)(NV^+DBBLG:3J(F=1$.L)&K2===$;^&<5$:X
MYJD1LI(HI*/*RQZ.&R^)E1&DYT)Z(:23RLN2'GB/WK0R@O122*^$=%9YV=+>
MOC:OC"!=V-).$FED+TBBLG:3J$D_*/?@G?#ZQENX1L:`4S'6).SQNFD(;Q6G
MAI3GY7(EG1G"*W(D=&*A,Q<Z"Z&3")U4Z"R%SDKH9$(G%SJ%K>/D@0ZB%^1!
M6;MYT$1M"GFUZWB%,C)&5GT9PMF9&-*NLC,5-C-#>-<8"9M8Z,R%S4+H),(F
M%3I+8;,2.IFPR85.8=LXN0AH%"](1FGN9L.@MO/PZ7B+R\A84=L`=3J&(RVZ
MG,>NMW1,8-4OJXYV]0-/>@IIJX"`K`J"3FVT&%8T=ZUK\M:<.>0YX@*((R;0
MJHV8PJHVXA+R''$%Q!$S:-5&S&'UX8@6D"ZCN=-%G:/MGD;]62#0QVXZ#"#K
M#P9YU>MO_6%EE2\0W^_$H,[UQW-#7T";BWX&':NB@5@ZAC3YUTT$(;^`%LLG
M0"R??DI^"4>^^A40RV=`+)]#_L.!*>!42KLI5B?S"U*L#_).BC7JT`>/W2!T
MMQLCU52DA=U9$0RR'I>PLIZ70%P+,R`>@@B(M6(@UIH#L=8"B+42(-9*@5AK
M"<1:*R#6RH!8*P=BK0+HG0I4Q_0+TF-.]78%:M2A#TY/5U2@MFK;%6B0DU>Y
M8!OY3EF4[2`(O>5S&E0Z6!5F0#RM(Z#::#&LVF6TT-OBS_%KKJ`%$(=*@&I#
MI;"BJ[?&S;NY):PXX@J((V9`M1%S8]6IAM+?Y12L0T/IEK'J%UPP3TQ[P9XG
M&KD/]JZ_YU5M>K^,#>)"F!BK3E>GJ1WVO'&;0H>=9D!</1$06\60[I72WJ%W
M+AT60"R;`+%LRK*UV1:WNH(6RV=`+)]#G@?$.U,7CI.;6M5KL%.KOE@(NU>$
M?_$X5H[>[DTC;S'P1G&DNGGDZ"P&QI$7K8FQZ@S*3`2=WG7/6_2G$.+JF`%Q
M=4008NT8B#:R'Q??'%HLOP!B^01:+)\".?(#;TU<0LNIVIZ7N!6L.&(&>8Z8
M`_%@=;U1+R!4WHT[`VB'Y\R`7^1=F7MYU\A]1G>\&QZIK]'\XM:HR_VHB;'J
MZH,Q?1?>Z7BKQ!1"7`$S(*Z3"$*L'0.%Y9QJ>_-I#A'670"Q;@(1UDV!G%3*
MA)O[=S;G,N'&BB-FD.>(.1"/4L\[R13&1']U[B9<-35$R??4U]N-\_-N\_WA
M0&5!N]%W)H)Z-)IO$G5KA.85'KP/ZMM.RG#7>:@-O/2-C)53_\:1%D"K(,7I
MS5B992[H=]O>')M"FVMV!L05%.$Z:\/%L-+/`CE;]-58IX&%#)5`I#94"BO*
M/=^_G$!51,M*3B!CQ?>;0;[V(G)8\?!VO3Y(84ST/;MS2C5H_#D5=*_*-K*:
M4W\<WCZ:4S3OJDFE9+S%12/NE%V+"64L..EC]0TYZ?2Y&S,!XG&9&J1+1'?+
M@+C\(CBR5@S$6G,XVHN'OHB0M1(XLE8*Q%I+J;4"8JT,CJR5`[%6`<?RNMR4
MJ3Z.G;)WRMU.C6[[./6ND7?\]B;-*#!6]N;?(,[8!%9\-U,@MIH!\0U&0&P5
M`['6'(BM%D"LE0"Q50K$6DL@MEH!L58&Q%8Y$&L50*65DQ[J[U^2GM+<K1R#
MW#VW:*89*_OH#$=G.1)G,UCIUD\[\`_E4RAS2<R`>!I'D*D-%L.*2HI7R*ZW
M[Y]#GB,N@#AB`JW:B"FL:B,N(<\15T`<,8-6;<0<5A\-:`%E6<OT]>I%DT6W
MFNQ:+A5H5^XVPKWGZPA65BT#\>U.##*MM/=FAFAUS2##%10!L7(,9?*OFP9"
M?@$MED^`6#[]E/P2CES9*R"6SX!8/H>\[J3)<2G@\\YJ0'O+"Q;K4)E[JX%&
M[B;=K]F1<716`^UH?^\$*SZ"3(&X$&9`/`(1$#>L8B#6F@.QU@*(M1(@UDJ!
M6&L)Q%HK(-;*@%@K!V*M`NB=^E-=J,\_2T/=M'+J3R/O["SJ3UO9>V>C17LR
MNR3\O;.Q0O>GW0^\`^*4=;"?GP'QK(Z`:J/%L-*--'^7/L>ON8`60!PJ`:H-
ME<**!N;C%6$)*XZX`N*(&5!MQ-Q8\5"*1AKK^(VTD+;@E\P39>Z5L4;N0UTT
MTLHX;C\<B`MA8A`::>&@[3U0I])I!L35$P&Q=`QI]XGGR<^EXP*(Y1,@ED_?
ME1]X4WK)CM;<$`<F6''$#(@CYHAH3D?A(/!JLW"<W*V<:F_9J\-G>VRT#(O\
MFU:9.]^].Q\91V>=,(Z\GDV,%7ILO7:O[V5H"B$NG!D0%TX$(=:.@6BG_W%=
MSJ'%\@L@ED^@Q?(ID",_\+IG2V@Y!2TG@!Z9-D?,(,\1<R#38Z/!\JNEX'"B
M[JD.G!E0?]:B9ZW(NT;NXUOTV(PC70@6\;%!=H\-R'2/PNLP\+[KF$*(*V`&
MQ'4208@[4S&0Z;%Y13*'".LN@%@W@0CKID!.*@?>92^AY6S:9<+U6%H'\PSR
M'#$'JD8IN/$ZA@6'$PE771A1\I?VV$+=RW'V"1K]HL=F')WZ-XZU3:")<>QB
MF6NW;[S&XA3:7+,S(*Z@"$*UX6)8F1Z;F"WZFNT>FPR50*0V5`HKRCTO2'("
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M.9MV]M?#F=[IHPS3&UGT#N>67H:Z5@7Y=#B<\1\*W*K>"KW_!P``__\#`%!+
M`P04``8`"````"$`E_.=B/$/``"L30``&0```'AL+W=O<FMS:&5E=',O<VAE
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M<KX6WLLF`N7^XF'S=?WS\5CO?D6;[;?O1PKWB*Y(7=CTX:_YYG!/=Y1DKOHC
MI72_>Z0.T)\73ULU-.B.K/_\>-FGAK</Q^\?+P?CJ]%-;Q"0^<67S>&XW"K)
MRXO[GX?C[NF_VB@P4EID8$3HTX@$P=6P/[J9-"H=GD/C29_&LW_5GXR"T5@U
MW^%(WS;]ID_C.+D*AKVWW,;&C3[1TZO):#0<3VZZV[LQCO0)QW=>(F5:TU/Z
M/.\2;XTC?1K'F_=<8D!CJ&DPH*"=V=>`AH'VY?'PSH`$&`3J+Z;9=X4DP!A0
MP_;<_B*>`0?TO?U%1`,.*8ET#+D`D51_>5]'KW6V-<D[7Q_7GS[L=[\N:$:D
MT!Q>UFI^#:9*#FFKFS\E\FMY3`FL5#XKF8^7=`&4H@>:?/[XU!\//US_01/&
MO;&YDS:!:S&#A9H=E.S<!PL?+'T0^B#R0>R#E0\2'Z0^R'R0^Z#P0>F#R@>U
M!:XI/*<840K\/V*D9%2,<'?O`*R@>0&!!5SF/ECX8.F#T`>1#V(?K'R0^"#U
M0>:#W`>%#TH?5#ZH+>`$A"86)R#M:QQR0UG3:F;E1C`8N3?Z3MO0#(0[/1-D
M+LA"D*4@H2"1(+$@*T$205)!,D%R00I!2D$J06J;.*&@.=L)A9J_^J.KTQKZ
M[AE,"=$D2([6%.:'R1C1/'DR"H;^+'8R0BSG@BP$60H2"A()$@NR$B01)!4D
M$R07I!"D%*02I+:)$SFZTR)RP>A*;7^Z\TDY-I'"_;W39,Q3VTR0N2`+09:"
MA()$@L2"K`1)!$D%R03)!2D$*06I!*EMXL2`]AE.#+IOO+)V;[PF_>9DT*S8
M,T/TMKQ9PS49W32[@F&_=^OM"Q8G`\1S*4@H2"1(+,A*D$205)!,D%R00I!2
MD$J06I-^7\WR3AQHXW1&')2U&P=-[#@88L5!DY$[=_7==6AQ,CK%0I!0D$B0
M6)"5((D@J2"9(+D@A2"E()4@M28ML:`;=$8LE+4;"TWL6!ABQ4*3$1VHK'5D
MX,7B9'2*A1%JQD^3;J$A@].^(3IYV=)>RL4G(TBOA'0BI-.3ERWM+9'9R0C2
MN9`NA'1Y\K*EQ^X-J4Y&D*YM:2>AZ,Z>$41E[091DSXM7E:`;MS^S(R1KF8T
M<YTAXU,X%H;PTK0T9'*R"0VY/9%(Z,1"9R5T$J&3"IU,Z.1"IQ`ZI="IA$YM
MZSBQ4'6`,X+1F+O1,&A`0E8X)EXX8&7E&1!GS`*(4V8)Q%8A$&_((R"VBH%8
M:P7$5@D0:Z5`;)4!L58.Q%8%$&N50&Q5`;%6#=18N>%1QTZ[!-"]"5#%'"]9
M#!K0-L,*SZT?'NU(Y32D[QR.M"ZRXZCG.BY@I7<0P4UOXDDOC47?RBD@*ZF@
MT]E:#*M76UM!FEM+@+BU%#J=K66PHHG,N@/>B2*'/+=8`'&+);0Z6ZQ@U=EB
M#?FF17>XJ$/Q&<-%GZ'I7(6HWZG:'HT@+YN]U6\&*SN;C2-?\\)846%;U9Q:
MQX9QXO0((<U)%`&Q=/RF]`I.+)T`L70*Q-(9I"DCNJ(N>EY`B^5+():OWB5?
MP[%E1E"G[3-";`[G=H@U&M(56!?H;39GJD!+`\&9$0RR5E!864LH$.=#",2W
M(0)BK1B(M59`K)4`L58*Q%H9$&OE0*Q5`+%6"<1:%1!KU4`M&:B.U&>$QYS`
M[?!H-*2;;85'9*"V&M@9:!"/^(6JFE,0A\,F`P=!,/36Y:6Q&+!3",3C.`)B
MJQC([:8W.:Y@Q8X)$,NG0&R5&?1ZSW/I5`"Q=`G$TA509\]K6#6.[B2K3NQG
MA%@?\)U)5B-W31YYYX"9*G?Y&6@0C^&%L1J.=&%_T!][._,E=-@I!.*!'P&Q
M50QI=\T2(19]2J#%\BD0RV>0?[7GN70J@%BZ!&+I"M*=/:\=1S?$Y.B$F"N7
M;VS`E*.W/];(RV?O9#93CZ;(T<EGX\CSSL)8#2=Z11V.>R-/:`DA'O`A$*=%
M!"'6CH'HJ&#-.R+:II\LGTCY%%HLGP&]WO4<0JQ=`''72PBQ=@74V?4:6BT9
MK>H-9V2T+D_0\.%MDT;NFCH4D[:I:[#C7#U7I+B/N$JW``IT1O=ZP['84QLA
M'O*A\>IS8D008NT8R%W[19"%?"+E4VBQ?`;T>M=S"''7"R#N>@DAUJZ`.KM>
M0ZN1=W-:U2/L(#<Y/58_>+@X?M_>_[C;T;BG75]+A@\H%.99JJYJ.+'7:.2N
M)]XL/%//;_T$-XZT2%L9)TY8QLI,D\'-:"06<:/-B1.B.4Z<R*!19W,QK'1S
M+9OV%:2YM02(6TNAT]E:!BMS<2UC/8<V-U<`<7,EA#J;JV!%DYAUQ[WA7T.^
M9:)0=11_#)GG(LT8^GWW\MH8HG%V&D2Z'.,,(HW&G!:S0*"Y1`N)EA*%$D42
MQ1*M)$HD2B7*),HE*B0J):HDJAWDY#D5=]T8M>2S%8O&W%VQ#;*KQ$#6=ML@
M?G;2\S9P"[;`.K&4*)0HDBB6:"51(E$J4291+E$A42E1)5%M4$OUOJ^J3';Z
MO!$:792RTZ11H%,IKPLS(#LTVO&-QRG&D:PX/"='H%!:11+%$JTD2B1*)<HD
MRB4J)"HEJB2J#6H+CZIIG!$>9>YECD9.>`RRPZ/1&T]8J(/-SHAW!4N#=-?U
M,Q8@KJ9&[&A-\D,O.6.V0JA7T.*5)@%B^90=;7EO&YZQ%>1S:+%\`<3R)3O:
M\MYNHF(KR-?0DJM6GW8FY\15F7MQU<C=X@S]1RY-.^X9QJ`QY^L"B`?$$HY\
M9T(@7N(C.+)6#,1:*SBR5@+$6BD<62L#8JT<CJQ5`+%6"4?6JH!8JX9C2WAH
MSW).>)2Y%QZ-O-.'MTN<J0=FY&A7](!X"EP8-.0"V%):A4"<G!$0:\52:R6M
M$B#62H%8*Y-:N;0J@%BK!&*M2FK5CI6[GU#UC3-F15T.<18MC=P*P-`[T\W4
M.83"8U<`#!K2<<S:KOH'!%CID_4@F'BEW"64>1B'0#R,(\AT-A;#ZK7&5E#F
MQA(@;BR%3&=C&:QH(VQ=O[==SR'/+19`W&()K<X6*UAUMEA#OB6757GDC,&B
MJRG.8-'(RV6_DM#75M01S/]S@^Q*`I`^CK>-#"/#N1%"F3,H@@Q/<#'0:\HK
MR+!R`L3**618.0.BU;\KYJ+CA90OH<7R%5"G?`VMIO?N;$#CYYP`*W-OLM;(
M?<(V\G)VUC=6O(+,#7+64FTU9JLE'#D;0B#.ADAJQ4"LM8(C:R5`K)7"D>]R
M!L1:.1Q9JP!BK1*.K%4!L58-QY;\4Y60,_)/%TZ<_#.U%)J-K?$G\D];.?EG
M$(_X!3WS5M$WM?G!X$8\?C$6]L-Q($Z3"(BE8X-HF;:[Z4V-*^F8`+%\"L3R
M&>1U7::EY[ET*H!8N@1BZ0K2G3VO'4<W`U59Y(P0ZRJ*$V*-W/58/'ZA2JI8
MCPWB,;PP5N8Y5;\_";RALH0..X5`//`C(+:*@=RZH@BQZ%,"1Y9/@5@^,^CU
MGN?2J0!BZ1*(I2N@SI[7L&H<G1"KN=$)\7L?OS2.[G1KD/>LS3NNS8R5G<]P
MY(WP`LC\_&0\&`^\<"PAQ`,^!.*TB"#$VC$031G6O./)KZ#%\@D0RZ?08OD,
MZ/6NYQ!B[0*(M4L(L78%U-GU&EJ-O!ON\\I"M$/VUU2#5!-\\\3C%UCQ2C('
MX@M<&&1^M=+O]X);;W%>PHN'?`C$B1$!L78,;;H"[N=(!%E?H/5,/H$6RZ=`
M+)]!7O_@IJWK.;RXZP40:Y=`K%U!N[/K-1Q;<EJ5<^QI^V\]?J%[(F*OD3K`
M6??4*YC,C*.3X-IQ3!^6HW^Z,HYC]0B(_N-<7ZV%[F_@EM#FQ`F!^`9&$.IL
M+H:5;DYNV5=0YL82(&XLA4QG8QFL<&URJ.?0YN8*(&ZNA%!G<Q6LW$AYH[^&
M?,L\H:I0_A`Z_^G+0!>S[!V!06Y]:^37MXP5C?'3H<N@,9_#%D`\02[AR$D7
M`G'217!DK1B(M59P9*T$B+52.+)6!L1:.1Q9JP!BK1*.K%4!L58-QY;,5W4G
M.VS=5?^!+E,YX='(6<.'(L.UD9/AQL_=:HH,-U9F:9ST/(.EZ1%M21'W$(AS
M(#)HT-E8#*O.M7(%>6XQ`>(64VAUMIC!JK/%'/+<8@'$+9;0ZFRQ@M5K-[2&
M<DN*JR*8/5;4*F&G^+L>TJN!XIVZ#7IKAR!K<,:Q^ZGY`E;FJ7G+&#+*G&HA
MNL2I%D&&1N3K2U(,*S<*WCRZ@CRWF`!QBRFT.EO,8-798@YY;K$`XA9+:'6V
M6,'JM1M:0[EEOJ%>=HZA]SVD5XGL#R*#.$EFL&(TEV@AT5*B4*)(HEBBE42)
M1*E$F42Y1(5$I4251+6#W"V_*ES9>?[&FJ#K7+0F<%Z('SK>#;25NQ,<>^?Q
M&:QX.9L#N5.DMPPLC)6IY@0M.6[:;YG62/F<RU7FWC%6(W>'XK_%83;05LX.
M12-ZAH#%:V&LAE0YX%EF[!V)E]!R]G36CTO=>*HJA!W/OS=OZUJ&L_1KY,54
M[,R,E1U3C=[:W1LK9S(:>T_.E@,C+P-+I\3NZW[?7-/(N`$WR/Y!D$1SB182
M+24*)8HDBB5:291(E$J4291+5$A42E1)I%Z?I')&WR\]-O7KD/0;59XV^V^;
MV>;Q\7!QO_NI7G5$#V0_?3AA\QZFP<WT,RE1JGC?W`U[>$63]PV]N^ESLPAY
M_([>Z=2<%'S>G]:M]H-IW?P.P+/_/)Q^IHFTK4O4HS8^FM9-(GA"=\$M]:C9
MS?G?#,;4=EL;\WYOJG[C(UN?]P/ZINT"Y_W^=$&_1I`^]-.,J?KAA?R&?E4Q
M5;^9D-_0#R*HG;9OYN-IU=KGFVG5S';>5<XGTT63P1Z/)E/Z/[>RY70RI?\P
M*WDYF59Z)C@)T;NR7M;?-MEZ_VW[?+AXW'RE`=9K7I>PUV_;TO\XFI\'?MD=
MZ2U9E/#T3A]Z*]J&7J?34Z_%^+K;'?$/:OCZ])ZU3_\#``#__P,`4$L#!!0`
M!@`(````(0!D4<_'E@```*H````0````>&PO8V%L8T-H86EN+GAM;#R.P0H"
M(11%]T'_(&_?.#.+B%`'"OJ"^@!Q7J.@3_%)U-]GFS87#A?.O6IYIRA>6#ED
MTC`-(P@DE]=`FX;'_78X@>!F:;4Q$VKX(,-B]COE;'17;P.);B#6X%LK9RG9
M>4R6AUR0>O/,-=G6L6Z22T6[LD=L*<IY'(\R=0$8Y435<)EF$*&?`!%_*8V2
M_Q7S!0``__\#`%!+`P04``8`"````"$`R:QUG=P"``"I"0``$``(`61O8U!R
M;W!S+V%P<"YX;6P@H@0!**```0``````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````"<5MM.XS`0?5]I_R'*.Z100*LJ#8("HA+=K93"/EHFF5!O'3OR.%6[
M7[^3I)<4W&CAS9<YGN,S,QZ'UZM<>DLP*+0:^F>G/=\#E>A4J+>A_SQ[./GA
M>VBY2KG4"H;^&M"_CKY_"Z=&%V"L`/3H"(5#?VYM,0@"3.:0<SRE;44[F38Y
MMS0U;X'.,I'`G4[*')0-SGN]JP!6%E0*Z4FQ.]!O3APL[5</3752\<.7V;H@
MPE%X4Q12)-S2+:.)2(Q&G5GO?I6`#(/V9DCL8DA*(^PZZH5!>QK&"9<PHH.C
MC$N$,-@OA(_`*]&F7!B,PJ4=+"&QVG@H_I)LY[[WRA$J.D-_R8W@RA*MRJR9
MU&-9H#71;VT6.`>P&`9DT"S6P[9M>RPNHOYE;4&C0\OJA(8);1QRG`DK`7]E
M4VZL@W+_LLVY9M$P;@AMH\@H-]B]LJ07&ZLFVD*WF>_N,-(4:(60,AJAEB+E
MEB:W7'*5D)H[PTJ7QDLWY.PSF-B2M_Q3;C:0K[@Y=U*[Y2B0Z8Q-#2"50)V0
MM8)QF>=.R`,E%'OAL@0V`8ZEH3LHZS2=<+,`RU\EL$T*4W4Z+2L>2>WW3LBR
M"L)/L.Q)([(I&"=DPO]HPT8E6IW3<\&JK%$TF(L"&7="QG1!]28J/C>([_)Y
M%^(Q/3<YL!E?'2$;6YTLB'&=-SF]*EC+YG39+;`[D&Z%B1`1=\OG%+H;T"6>
MF]8'];H<'-&H"W+DVE4B<K-VJGL$<I.F@E[6ST!B:A)I26_O+@WV->]6=X-P
MUZ\;LN&EG%ZZ2\`=DNX:<)=\-Z;OY-:-N?@"IND.FU:RT[S;SY73S\>T''%C
MUM3ZJE?J/R';R'#)QD<@^T>!M:WK#N.$'"N!9KT-.>B)[[K@DU`+?"YF^HZZ
MQ;;-'RZ&\9P;2*D!;O?W"^$C=7@CJT-&<WK\(-W:?-RH/B4OS<\K.KLX[?5[
M]-]HK87!_H\5_0,``/__`P!02P,$%``&``@````A`!*SG"$R`0``0`(``!$`
M"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````)R104_#(!B&[R;^AX9["VVG64C+$C4[N<3$&8TWA&\=
ML5`":+=_+^NZ.J,GC^1]>7B^CVJQTVWR"<ZKSM0HSPA*P(A.*M/4Z&F]3.<H
M\8$;R=O.0(WVX-&"75Y4PE+1.7APG047%/@DDHRGPM9H&X*E&'NQ!<U]%ALF
MAIO.:1[BT378<O'.&\`%(==80^"2!XX/P-1.1#0BI9B0]L.U`T`*#"UH,,'C
M/,OQ=S>`T_[/"T-RUM0J[&V<:=0]9TMQ#*?VSJNIV/=]UI>#1O3/\<OJ_G$8
M-57FL"L!B!WVTW(?5G&5&P7R9L]V;ZY-O-]6^'=623'84>&`!Y!)?(\>[4[)
M<WE[MUXB5I#\*B6SM)BO"T++&27E:X5/K?$^FX!Z%/@W\01@@_?//V=?````
M__\#`%!+`0(M`!0`!@`(````(0!J:8UQ[@$``#H7```3````````````````
M``````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U
M````3`(```L`````````````````)P0``%]R96QS+RYR96QS4$L!`BT`%``&
M``@````A`"LP7-0#`@``,18``!H`````````````````30<``'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A`$.(KB5N`P``?0L`
M``\`````````````````D`H``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(
M````(0"5ST:#[0,``%$-```8`````````````````"L.``!X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"+0`4``8`"````"$`R.OE$9$$```;$0``&0``
M``````````````!.$@``>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+`0(M
M`!0`!@`(````(0#06_5[ZP0``.$2```9`````````````````!87``!X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`&6.RV;X`P``
M@`X``!D`````````````````.!P``'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"+0`4``8`"````"$`9.E[GY4(``#1*@``&0````````````````!G
M(```>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0`9
M&_"BF0(``$@&```9`````````````````#,I``!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L!`BT`%``&``@````A`%ARXFM2`@``T@4``!D`````````
M`````````RP``'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`
M"````"$`A[-]_9P#``!_"P``&`````````````````",+@``>&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L!`BT`%``&``@````A`$>->#!6!0``M14``!D`
M````````````````7C(``'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M+0`4``8`"````"$`_$EBQ0@#```M"0``&0````````````````#K-P``>&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0!->P,'-P(`
M``L%```9`````````````````"H[``!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L!`BT`%``&``@````A`$)EEA_9!0``7Q@``!@`````````````````
MF#T``'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M`!0`!@`(````(0`R
M_6&4CP(````'```8`````````````````*=#``!X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"+0`4``8`"````"$`AM&XN3U$```1WP``%```````````
M``````!L1@``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4``8`"````"$`
MQ>MES>(,``#C>0``#0````````````````#;B@``>&PO<W1Y;&5S+GAM;%!+
M`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3`````````````````.B7``!X
M;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A`/"\91(&`P``Z@@`
M`!D`````````````````K9X``'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"+0`4``8`"````"$`)P,@34L"``"`!0``&0````````````````#JH0``
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(````(0#\VM>C
M8@(``/<%```9`````````````````&RD``!X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L!`BT`%``&``@````A`/W_87T1!P``2"```!D`````````````
M````!:<``'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"+0`4``8`"```
M`"$`55!&#44&``!0'@``&0````````````````!-K@``>&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+`0(M`!0`!@`(````(0!W)6I@=P(``,$%```9````
M`````````````,FT``!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`
M%``&``@````A`-.D5E.%`@``.@8``!D`````````````````=[<``'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"+0`4``8`"````"$`#HBX^M$-``"#
M0```&``````````````````SN@``>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L!`BT`%``&``@````A`-F&"76\$@``!F$``!@`````````````````.L@`
M`'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(````(0#?!&54
MP`0``'$2```8`````````````````"S;``!X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"+0`4``8`"````"$`A#)8J\D%``!@%P``&```````````````
M```BX```>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@````A
M`$HR"`>R`@``\`8``!@`````````````````(>8``'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+`0(M`!0`!@`(````(0"[%./GX`4``&`6```9````````
M``````````GI``!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&
M``@````A`/]YIS(H$```1%<``!D`````````````````(.\``'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`.665MK(%``#N%```
M&0````````````````!__P``>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M`0(M`!0`!@`(````(0`^'=29?@4``,\3```9`````````````````&@%`0!X
M;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A`"`K+<TL
M!0``'!(``!D`````````````````'0L!`'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"+0`4``8`"````"$`I2E$B3,+``"H-```&0``````````````
M``"`$`$`>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````
M(0#V!\B:A@(``"T&```9`````````````````.H;`0!X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`-_:Y_W-!```/1(``!D`````
M````````````IQX!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4
M``8`"````"$`3&S_?NH,``!:.@``&0````````````````"K(P$`>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0"7\YV(\0\``*Q-
M```9`````````````````,PP`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`BT`%``&``@````A`&11S\>6````J@```!``````````````````]$`!
M`'AL+V-A;&-#:&%I;BYX;6Q02P$"+0`4``8`"````"$`R:QUG=P"``"I"0``
M$`````````````````"X00$`9&]C4')O<',O87!P+GAM;%!+`0(M`!0`!@`(
M````(0`2LYPA,@$``$`"```1`````````````````,I%`0!D;V-0<F]P<R]C
=;W)E+GAM;%!+!08`````+0`M`"0,```S2`$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IntangibleAssetAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charge</a></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" onclick="toggleNextSibling(this);">$ 1,870</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IntangibleAssetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_IntangibleAssetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairments of investments</a></td>
        <td class="nump"><a title="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3&#8212;MARKETABLE SECURITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Sangamo generally classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value, with the unrealized holding gains and losses included in accumulated other comprehensive income. Investments that have maturities beyond one year as of the end of the reporting period are classified as non-current. The Company&#8217;s investments are subject to a periodic impairment review, and the Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company&#8217;s investments (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Losses)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,062</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,444</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,533</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,558</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,831</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,671</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,217</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,399</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,374</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no other-than-temporary impairments of its investments for the three months ended March 31, 2015 or the twelve months ended December&#160;31, 2014. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for  investments in certain debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Debt Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Equity Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001564590-15-002929-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-15-002929-xbrl.zip
M4$L#!!0````(``R$G$:4+%@*KZ\``*&]$0`1`!P`<V=M;RTR,#$U,#,S,2YX
M;6Q55`D``UCN/U58[C]5=7@+``$$)0X```0Y`0``[%WM<ZLVUO^^,_L_L'FF
MG7;V<<R;WW)S[X[C)+>>3>)L[-O=?NHH(-O:RXLKL!/WKU\)<`P8#,)@8YNV
M,W5`2+]S=-YT.!+7_WC7-6X!L85,X_.%<,E?<-!03!49D\\7<ZL&+`6A"\ZR
M@:$"S33@YXLEM"[^\>6O?[G^6ZW&O;S<<EW%1@MXBRQ%,ZTYAC\-'W_F_G/S
M\L#U#?J@`KE;4YGKT+"Y&C>U[=E5O?[V]G8Y1@:YBX!VB;%ZJ9AZG:O55CWW
M,`0V0<7=`AMRSC]7G,@+C1HOU\3V2&A?-80KH7'9:8L-H2/\G>>O>-[7P:\N
M59SO']+!)7\I7_J;/0/E.YA`KG_K:W9W?].][_1N;WIW;;YQWVXW^0XO\+QP
M+]TT^5ZSQO/.GZ(DD9]"@Y?\R,W9$J/)U.9^4GYV(',OE_2_6],PH*;!)?<C
M-S0-B[349\!87G)=3>->Z",6]P(MB!=0O?1Z?'_%&D=FR;"NYC;^?.'C'[UU
M:>))7>3Y3IW<O?`:(LN41:$5VUBJ>RV\![8U]*9PU;4UT<U`<PL8$Z";SO2)
M#BLD8=68=J5MZ5Q#QO=78'UT_DXO!-J_24YKH=/IU)V[JZ8&X>5<C^Y;M7'=
M7LY@G32JD580(^7CN>2'@@_0!JK]\8R?@$;=O;EJ2O2%]K!FYQA8KT[CU1W*
M(;G&"[4UC\BM"0"SR&?HC8A'5(B">"RH7$[,19W<B&BNF'/#QLOH1[R;]#$I
M]-@<8V(+XI[S[D:,!]^5:?1#]$[$`\A80,N.?L2]%P'/LF<X^A%ZASX@A!Y`
M2DQ[I$0T-P!2K.@'G%O^1XB><IRCJ=J5I4RA#E[@F'/D]8K.^^<+"^DSC<JY
M<PU@!9L:3*<9SA-3#,>D%Z)\M9627;Y;:@;%2:^3=9>LN8%L#JF?+[[];DT!
M)M;?N4[NZ!!0>__%O7Q=7_WM/%:GSVWTX-F=;\/;C5Z\6U?D'F-785PJ6B`5
M>G]Y#SU1K0:VB3\NIQG::56/?M[I]A8:ID[<6$S'49Q9][GY\'7=ASV&;BH$
MS]B<8*!OS@2Y=^7=3,5$KS-UKMBQG=&;J3L;`3R!=H2,T,Z\FZDZFY'[&[W0
MB_%/*Z9APW>W@][O:Q?]NZ,R`B_\_N&@5AV3F`39R_6\$-Z3*V,$,><H<E!'
M5P:@U__GQ9=U_]?U]6,?$QGH^7I&7(JIKL<A3A7;-++YXH8TU))<U]=7/QI"
M0_4UDXBUH5VKOD;7=5_GUW6/"<D<D7E9E`_."#>^L+^X7H%$=O)U?75M-_K*
M,=$^^C[F+Q_Z9/*C5/3)-4',D[Z5QLJEF,B`QLKI-%;.5V.ELLVXE/>,EV&B
M@Q8I-XWUPOD>C;<AGA&Q63X!'7;?D>4XSAMD3J#1-Y1'J+]"?`"?184<3N@R
MW1_*P/>9AA1DN[`X%9$&;K;`H^@JBJ3PPM(?8S;=91.Z<(."$.%D>@(C^F*F
M(+JRN]BD"1].$8;=R;E-=X#L\YEL--%!5U,Q4J8]$\],["2WSF[RM['AU(2A
M[Z0N*.[1<N:*@G?GT33@\A'@[]"^GQNJY1>#,L_^)D7IYG[U?#3=N<U[0;&V
MA_X>(/PKT.;P9OGQ\Q?"4X"5Z?(!+J#FG^*/)GUC-K<MY[[@S?/)RD<Z%K')
MS!9&Q@I.)<S[$^9**%,*9;D$(-[X]$Q=AYB^EGL&I/]CF>9=U3F2[".9S-VU
M64SKFHY4.O9E!,0R>*9C%N5'\%\34[*MP?@6OMI=0[W[8T[@#*$RQ\A&T`J*
MH[N(@+3MNLFQB&5*:EFG?PM/CD0,<K=HE5P=2*Z.RCR72PD89?;;\*NY@-B@
M^(<ST[!,#-4[)UV#D06M2I0_9",+JXY$:`YM.2LI/(P45G:V!"I3>CFN!""O
M3/U^RB]./U.?9]5(F3+UY9:/LB1%*V'>:Z:^$LJ",_4%"$"&7&RYI_EHTINE
MU.;=,_7EEHZR1*B5*.\Y4U]NL2Q11K5<8G#H?%,E5U6F_N!*L*<<Z1F*<EDR
M]2=H.2LIK#+U1V9G<\W4EUN.*P'8Q='2W08]TA<R)@0N^661B7$W&SP@\(HT
M\LBQ2$*N%LW9AI&.,T<B$KO;!"F;&ZUDK$`9*Y6-E,Y4(4HOMI4`,+XQ`-:4
MZO4":.3NT53?[)QFC2+[Z&L38B>SW#I[-)-9B&:.3:P[CO!FV0,VG)AXZ7I<
MS]$N_3/<70"D@5<-DJ<L0N[&:OQ4MVNDY!.;X"1Q\TQ>!15BHPH1Z_.JV3]"
MF2_1RXM*(<ZE%+O2DW*]&3D"]:EDFDFF3UL83K5PJEPR=%HQ\_$L!<^K>N8(
M9?XT8N:358C3+(JH]*1<,?,1J$\ET_N*F0L[-[D4QP5G.S?9XTA^AS%V"4@5
M:7/ZJ9KUI-Z]*]I<A>H]-G7Z,9:Y[<C38'P'L(&,B?4,\9">X7^SC.[`KU)#
MVU2^#V9'>:YG@>QA4\`-)I[:J:"'$L0]'Z=>"6*93Y+W"8-PM#["^?;.7DYO
MCCB;?<\<S*I.QW`V^]%,>#7/.T6YWO0=X%L*7GOZ:3U:&4:6DK>TJLN<45*Z
M&`-C`G6W4M'&0+%')O$G='5Q;^*!/878NEE^9(F=`:`-1E.@`<N".@*5E+"O
M[W.9#!;P45-6"7J"H`^1\EV#/:AIMXCT:<%*U,LOZC&3=FK"7OI%=?F=<@&O
M:S,&T=4\'MTZ\N#.*38*.Y*DVSG[J&+#L9+D^DJH&I7)K53CO+V&<_$9F_^%
M2G`'5.4S2JX8$3-7>8R"U:+R%Y5:E-A;;'Q$55S)JWC*Z:D]?$153#?9XA[?
MRD1,=G,UV4V)KR9[E\ENIIOL9DWB#S#9*W='36C@_&WPCO2Y'M#_<U?[=$YJ
MQ4G&H[3]_"XB(RGN,:&\84_V7#I7:BG:3Z20>YT?R^?63SB@+6:.#_3F8(N>
M5G-X<A']MD_$DSGG6^1?P?MQPI._C0V%"`/?JM'_DH3!;5868>C0GKP?E3#D
M*`R=FL"G$`:G62F$(?>$V+?9&).V#T@ALPGOH6]G3"5VQY8CBYO,2GGR5QZO
M,X_7W0F&SK,CB/6@"E6:4V[-60VY928+6%JLU6(?2XN$`./$5XE[B2L.M6I,
MFMHS647N/78\OE7E_MW?F90;5'[PU.H02J=(E16O%.D8/=*M^4;H-X<*@H82
M/K1FGPNQQBJ7T2CUBNQ(Q'0?QB!2=(K)9#3293(:>\QDE$EQ*GVI],67N6CL
M,7.Q70TVZF20X:N3J;Q,WF4Q?O8>D:R?DB4Y+S^WO1"N4O"#U+U5"EXI^/$%
MLF>2BZP4YU1RD*51G//(/5:*<V0YQ_QJH'I`0^2^@4"?K&B1/;<A:?H")]!P
MON>Y@(]0)8PSUN<"'4MMU+XKD%A9>6J520<7RDH6#R^+Q5;Y'%3$CB6*/AM9
M*TD46RWDSC+Z.P^!.Y(%T#D(W)DN-XCD-58BV*A$L&1NETA;(YU0-DY,*"N[
M6&:A/%0Q&)@AF_#@3ZCV3,NV!N-OQ@R;"Z@^8Y-T&_[415<WR;4_O6\<>6V6
M@]5A/PFG_95"$Z25>98J\UR$)J1+`.<O=^4\SU!*YV^D_/W-&:IVM=JL5/LL
M3O$]/]6NXM=*M<_A%.*^H<(Q,I`-'\CDJ7W#)I*#7C78)53;1$B<K]#V*!/6
M^@0Q'!CPE[FA8J@2T1M!8X0A<+YC/AAWM3^GD$PFWOA@2KG=)",K6+0F"\..
M9/?Q7@6HW*?2G8$`%?+9YCP$Z(V0L/2QY!G@[P2C:51&*%:&TO'LK.Q0>C&J
M3-'AQ:@0:Z28.AS:)+JBF!Y,Q8DF_6\$HV/NN_<9?=UU=,F!+02SO>]+P993
M6Q?G)RQ'LMP\?F$YY$HK45B^.JMHC3"EJ^K$>ENVNZ8^>]N2BC%G:%U2"\RY
MV9<#"DQQ%D:%Z.K65.9.-<UR!AW)N:>20_ZYX+RV+W"\^;G[L,$0^-J_KNOA
M#M?#=,DEE5Z^U\#$/X[`-LX8:!9T!PITN4G0LT/VG<L,_X@BVXA^78SM?W/X
M>V0I0/N-.*5[<L7R`Y#8`02'#O4=-[B+<&-XF6WX?PE1@_OZ7@\_PD!%QF2X
MU%]-S3]D@VW(X=?'@3MHH,?U0'>.]KS`B:.'ADVWX/C':S*.UWWZVGT<<#?]
MP;#7OWOJW0VY_E//A1`U5AA)#]*DN$872>__A$L_E!8;%+\5C.U_/7QOCG%`
M("+DO<V&H+9:`VWK/\R`>Z1!W",W)B8.D-]A&_P!X`GDNHH"-9K^ARKG].SG
M16"HC8DP==TTAK:I?!].`8;68&[3E1P5(A\L(<&ZR;PL$C51H8)T8G`^7_2?
M[B^X.5G^.LV__6XYG5]\:78:;;'5:04F:PL&%^_Z=81%`U;ZO[L_YF@!-,)K
MJVOW`,9+TOI7H,W]4RDD&DO*1!_LFA1`C2Q3%H76M^$ML2H-L=$DCU_7F=#L
M2$""[75S(.D(:/(2ORO^[@(@#;QJ])W3D+0?0F6.$7T+Y`F^'WNBV4[/?*'%
M-^56`'TBE!V0)UA\%JX++;$CB;L@[].-D]`BG2N03!)Y+@)QHL-(SVNITP[`
MC1T_`\P$/\/"6%F4LL`DII)N1;76S9Z@'8$TT0VE9VBS*04YN@U#-K0)+HM)
M8'FIF17N,X8S@%0OQH_`F>C=TG.UT0[:@\BQV>")25Z.Q=J&Q#,%O!<BO1@I
MQ(FSN@DQ1S_G&"L?<$94N9&4H^?+E22G=L--XD=(4)X^CP^BWAR8!5B>+JTM
M,0&+Q92CTQ)YJ2,'P[,LB'+T3T*';[<ZJ1'%Q@1/IJ%L`LW1/8F=MI@V0%F#
MV0U^COY*;HE-?D?XJT*E9XVL5XD]H+;`R8<31^>'G:/[$CN=1LA!Q&/(A%;*
MT9L)<DB4TZ-->!'J5H\14_O5--4WI/G3(%*"6V,S6JV@E+#B"E(5A38Q3\9@
M^QOMH'2D1Y'@@9AXE@Z%S_Y':KN4F$!C84PPZHL<FQ%>@AMBXIC4887GWO7C
M24S&,5@9B<Q@<`[=\9(P)/@7%IZ(LB0*8C(&;Y7Q#);4=M,7!XJ"YU!]0.`5
M:3%+=2DQ6<>P3FOSH0@B/:1<:$EP+RQ,)]9.SHT6VNQ.GVGF$L(;:!"S&14\
MR8EO0)CR/5(8_A8461'GZ%_$=H,=L5//<V<IV'Q;38,_&2SGZ%'$EFL&HH9,
M!R9'QY(,9L7%6SB&A&'J"UQ`8QZQ9I?S="Z"T`YJ3?3PK!!S=#`=QYHS(MQJ
M=>0<W8W0Z81R1TG693NT/+T0WVZ+3-!"G(V,'>0<W8\@\')GV]S&11"I@.;H
M6P1)R`;T9FXA`UI6S]1?D>$4%M#=,23(ALX^&0NIT/VHR(<UB"2FD>?*IAU*
ML^P$,GIB1N#=)VS1).7HBEIR.W)VXF#$:J0?7XZN2!)XH16GBJG`Y.B*I&8C
MM+2-!4/?4R*GQ-:B.<.54"@A<,0AO5OHRD#:YPN;A`"I&!>-SJVXN2+=!<J`
MWJ15W8U0_\_CPY`6"H&:6X*KD/'JF7`WF'![/"X:M_=>.)P=;N3HM)JA1$QX
MV/2@<G17S0[/`*JKJHA:)*`]`Z3V#6_;GN\A/\P<?59#YIM2Z+UL(I9=L.?H
MQAJ2W!#:.V%_@38@SD*]`]@@.F61F'^NSS5:AT&,+JUK\V%OYK@^JDF2U&X&
M[58RF%W`Y^B?:A)9+(7"6%;POOM.CH5,T0S#*2UG7$"WB/'!M*PG:`_&Q._Y
M*<ES415*K;"!RHVB'-UA+4^2'(V9FAH)F"R:(`ZL)YLY+MQ$GL0\057>')L%
M6XXK-I%O-B6)"9LO`B$.>SO28I.%24BRXRXVP<B&VV??GP$>8*?\677\[#/$
M3DV:'SJK_PS7PJVQ?Y3%\9>T7ID!STX$L#K1O1+@E@!VY_;4Q/3<`1_P%JL'
MC:M"%)PWAG$!5AA!)JBL_G(O4/N6-0_"9'6&\76=<J<E-II;4+J#,R-D=6[Q
M"(GKESKRK@BC"V1;K-YL!T;&E\>FQ,KJW79@Z096=PNKJ6G@U?N`[,?YI/[5
M:(NM(CUEKD=LM@3^(_$<@X(-9Y(?"V[[29G`:7A9U&28Z_C9R;S1,UB^TJ+[
M`$:V@O:4+Y@V:JI"`!CP)?FC+#QLA))@Z?#Y8;79=O2DS9W*'2$*6`H\22XE
M"YO:@M!,!6?+;E$_1K:]0FF+3YR*Y&`!7SR<C,B3_$P6[I*H-%0KQX`\80>=
M'SO;#J6T=56ALO4$/)G!)WFC+(R7FK*<'?Q@YF3XC8EW-Z"%A3BF3BNT@-F`
MP("P")<D-%IB*Q/"=9+`C[$(EU1KBJ(0C7$-@@EE$8ZIUFH*C"A76QN(]#I)
M&+>=#VBG$%?5"*I0-`I6I$4XL5#153J@*U;3B,!])S(G4^#-A6E8-W!L8B_%
M-0+O])P[8C-,3$)9@)=]&^K.*S1ZNA\)T)S9<X?U4UN$.ZPU^68K1'!AQ!R$
M:T6XXEJ+6+!#<HUTX%E*KQ3(3W$1#KP6?@\<@R,(]@G:D;:PP[8E.27$AB0$
M=3<P?$ID247[^8C+%F2KEQ:KW-8-L)!"(SRDS>U`-J/#MKO9AU5,RL#5^$N^
MO8:;@"DS`4F5^[',3D.`(&8DX-\03:;D:G=!='<"G^;T-(G!V'G0EX+80A?;
MONMX(5KG1L10Z)\-8[YT"DG'5*16E@\ZB09W<J<S[EW3-P-#]SC:7TS-J<X'
MR*`*.3#6NSRZ&%GDUBWYTYBXYRYLOC43&`_22)EU"*Y3BR)C_\Q*VHV7Q<9&
ME,H7SJN(`:+(93MQ)*VS$T-O[+>`R80Z:8]?1D?8E+*AOH6DG8*<6(K\UJ"3
MP"0K<-\AT7[X14080NC4@#28=J.BB&A$"&TF9J>"5J.[K7Q-!N-;9+G;`LC#
MSQCJ:*Y;?6-!0MA0HEM@/)<E;;6!'%P*9X.9-ZF98YRMI'8V*BMV)G45&-'3
MV74:TV](8UYA37#K8FBK0S0,1JC)1\QD49P.WV*&FKX"V'?,O]6;TI]].IUS
M>@AK4M&PX*>]B%BDMD-I\TZ$'9R;100KC1*PLJ_/`,+N&;_A_:KK[:P:W<ZZ
M95NMD'PP3Q9'N[&_=@>PT67TB7D4(>G@GGSR*`EX-I(_F)[!?`O=_Y/)=S>&
M;9Y7$]B^+20?Z9/)X0:=$!NZO"@K(D22"R8L=`*.GYQ"(B.I%3JM*PVJW>@H
M(NP113[%Q#"2X9VEL])#3_U6Z?[P9F8A^=2A3-Z5%Q((2P,S9U(33S#*5(ZR
M#T+3[$_V$UI(Q"3*K8TW*QEPYDUK$?&,$'Z]7PRIJ^W/+]"I(8\AL)!T"_&@
M218T'ET^=!62D!%:&R??Y4=7:">GGY@BXA$I_(HY`<\.\`O)R[3;[8UW;"P4
MT(/T@#5]QN:"1/_JS?*;14.4CXJ`KF*CA;M%.>+]I)^\8M(S4B<H:KOA+8KV
M(@(7LDIJ;;R:S(UV8E*=!>'(["I_S!&&CP!_AS8UL^NDMI_$(D(8J1,^0S,5
MK-TH23R5*M-D-5NMW2G!I@*AZE0#T&/#B+][!#9MNAR,DZ@JY&52N]/8.".,
M#6*.%!81A(A\J]W,E<+PM,>>4^8GK9!\"!\Z2B0]M#Q(*B+R$,1F+A3%&%(W
MR\UB^)-.[LJ8R))#^9[=\!9%>Q'QC-0.':J;!^G.)@;2D5^UZ4X;NN?_>?ZJ
M(64P)B%28(^*D'@`6:87SM+*W*3'%*V,7F`],D?@_=_(GD[=5]/TP,FD]QS)
M)Y9E$-I6I&*RHHSW%BO>T)1UQ+Y\(>GHLFSQB=!JQSJ'2$39"4@ZO"SC/IYV
MO/].04",]MTC@SS(8BR2#CK+.CU"&F.1$FY1I!>2/*$&JCCBHT^E=LM:P@M,
M/ZF%Q#$=44SSV8MH=/G054@P(S3#)Y?D35CLX>9"THEP$LL!5KS0WO=W282D
M0^,8P\IV:!V:B0+GJ!8G]ZPBLF*`5M\]X$J]F=M/IOT;\?8`^6LADXZ7R[9H
M"V4-TN(*O30'%K(&XV?2FE`.O/*>(9H8:(P4&EV[N5E:[6;2#ZA!:T3(N-%"
M7HWQ4T8_:O8G%2U^G-B?_OH7^L>,L^RE!C]?Z`!/D%%[-6W;U*_XF?W)NV*;
M,^=/.D8-&?0[=%?\#Y_&9-3:FU,)>O5*P@[WPACH2%M>C9!.UI9/\(U[,75@
MN/<L]">\$FA7[I]TW"O#Q(3C;N?T8U+6F%P@5PWHMEH`C`@WKCBOX06%_C08
MW7'"CT"???J_MBB(GVZZP_Z0&]QSSR]WP[NG47?4'SQQW:=;;OCM\;'[\AN]
M-^Q_?>K?]WO=IQ'7[?4&WYY&_:>OW//@H=_KWPTYRH[ZC)4US?6?&AS;5^*E
MV/PA';-<#E#A00H+^]B8Y4@:9XXYOZSM0*R?-/FR(?_`//,>(SR0NPK#:`HY
M0)1%GP&#F@ZBMV!.%!&J5#-4^J+*^641-5*=#VB-79<--$*S]QE$AT%#8$R`
M;G(WR!P2A2.AF_7_'-'E2^ZGE:R)_">OU<<5X1-G8LXF*'R->BX<7Z.?N2E8
M0.X50H.;T==IF)9M&PYTK-(XD7O[7WMOV]PVDF2-?M^(_0\(;\^&'4&I15*O
M]O1$R++=X]UVV]>2YWGN_3(!`B4)8Q!@XT5NS:^_F55XI4@)I""A"CB[,V-)
M!`M5>2KS9%5E99(';WW;/=^UKM1E1O^6/Q8+[K1=V`/ZND?=7_@D:!(0-9(0
M@\TKP_("%IP"V@Y<:Y%&[(HF5A+*CD8I?Y<_B<05Y_Z1+A5)@#^L;`[Q$^__
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M#@NR+FF9)'M2T=@']#07(NO.DBJ.C][$%JU]Y]9X;^=_[XR2OK.^7S0C"`3/
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M'36G%20M!.3(1M8L"R5EQLIC2>-*WZ1,RB]G%MPI0D<+OE&`^T7N=C87BVPK
MT%+F8RXBZXR,"4.=.R_Y[Z](WF6>-"EQKXC;9"1%4AN^@H-F0NSE,ZULFK\M
MF]N9V8H5RFW&W8KB,5VI)Y@+B6'#2$J/R2B23I9LBC[DV1ZFA`9;0X*7CX*L
MF"B+5T3J(?D)]9``)['<F7O<X<SS(JOL>P2?E(NRT'$8R("XE'19F5G'BYQT
MKI+3QJ,:;])8?UQ[Q+LL4_F)G'92Y*0&#-N_4O<JF[NS,%5O=[+UJX)2-I/)
ME?OO5X)(E+)D7,[\P3QN+]@OI*%)8E3#C<,T<E@+3ITDE3Z)ZJ$CR<?U>!L[
M)](PKNAG?ZU['OSQM=3+'AGX(C.0!#7*\LF0)N;[BS0!W7P:RS0GXHH4A&9.
M$JA3%KM,9,73SJGFEU(:F5DT3FEG2_?#BD5TXSF9PBZR34[2`1$H[\2BR4\:
M2^L(OA5&)I<KTCLBF\=DH,LH>-)MTG-2*%=&?Y-O?$TO"1VU*:+TC,C&D6U>
M>G^R;8CH85K&S#VIHZ.BW\0E1:6*N-3B6ZG\$?O2^610Y);D7F4I-ZEX#M]F
MJXLFN5VP)9+NL_2C8BM=T'=I`#'OP_!*(,J^2@9:L(EPPIBUU9O/:$F5V_?B
M5;D,B9R((^;IW(KE45.E`9I3I*`T`4K#+==AX:WM2VQI*E^FO(N4OUG47#I"
MQDV)7V/;?X2&3]9/^VTU>(4B;#;M/Y%58^_#>N^K652]5\'SA7WCC)3<<)$S
MTNGY-^OW<+=TCR=[>R<[X^G(6F$E*EM&Q>O>J4DJJ2'_2NW5+_D56:NO6,B7
M<HHH.=]5=CF87?:]"__!KC8G9'RZI%YF)DY`8?V/':2TABP'H5S\\4BI5[Z>
MGN=]=LL^9[PE_'(?(TYYVI<372VY/*71\K6Q<A^%W.-4+%6Z19[R/ZKO((>&
MO!`1<0IGZ4J1G;&K[A79"4E6JUV9K"E^.Z?4R*AK)@J=9S,4N-56J,<_R&@4
M9H:]W#OML@FLM2Q7_7:6XWN4NU$5WXG;))4/'6DHR$'-W*][!5*X+_0D=:'L
M1SPJW=;%@A1&3J(57F,A,VE=*]L'^7M]Y<P)FY#+!G=?EW:M+_?I0Z$"58>H
M8O))$R-Q2=*3_<V,W:@P==0P/;$C^-*.-/99ZVS!F"[R`4IRB%CCI9>5QB+;
MZJ'QL.%F;V6118PL^Y7YN[+M@!Q%Z>7=9!-I(0]F>%#TD]P^DC.!+.I5[D-?
MUH9X;;N9VYQ*_W[UM]1^1OZ=W%UR\U<67\E>G_F5--=%(60I]`KAJ:VT?!G"
MDU%!J58^65^HL5U+71"+,S%4W34E"D8I<M5TLUEZ[`#+C1WI?V86GZT.FYG!
MF'_[,LDFQ9JYOMO0,%>_0_JO]ECR=6>F[S*!A1VYV39C9O8*XYN9VM76/0E?
MWP\1V6&R0*1RO[Q@Y_I%^8F,>[-F#'_TRPL.5R`UBA<V'RX7OR_8NF6_9R-5
MW]B17MXB%J_S'][0HM]-KE^?[.].COY2\^@/=H^F?WE3?7=4^=EEZR9[2+.E
M>(UJ;+H[I6_2TB@1.]PWENZ/R%Z\V,;SKLZO_[878?SF_'9.BPGU\_(4DZ_(
M*/)X6A&L_"EQ&X[@Y'#W\*@V^.TZ_/P+@\PK)R]5[8]>I9XZ.&!BRZAS>9;&
MRAD?6=?AC[JCX`7+;GNYGYESCZL(+O]N]>$ZKY9?+=DUL_0%C^5O?F.MA$[]
M&)4_LCH4O]4.+:%#T*$M=2C;V>2I3W.1EY4T3?,Y>\\$IZ<DH^?&O_`);9K@
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M4]KH.[8\L]G+?]^U/I;6/=_+K?8BY7S4Q`/9>36MD"MO+'=D2U?0D]T-JGL0
M^<ZR7-<ZU%(:/;QSPMM0Q2@+B:KPA,H>=V7/MS;?:O-#3K[S:U9YF3)"G<N1
M3?AU/OO[*#M+\V^S1TY_M5[*GYC[@GQ"\22:R+>]]4*:&O+`K?+=_*^N<+*S
M./675TMM9&$1Y09"<4;%`\A6J:M6J$^Q`]R9E2B+\V4!1<6$RP-8V"[[^=DL
M)Y,0Y?+\[L:Z.L#+=MQRW4T7(<]#FD!2D,K38BW.7:TXC_E8M55_Y^@DG[(>
M;]O[OFJ>&Z>_2QN1,4[9F-JS4@<J<3IC**7RIT$V%&*>;,_)S:FKRC[>TCPN
M3C[+$5@R'Q`OQE1'%,%EFV75SE5]SXJ\ZR<.Y998KV;;I^R(Q@X"]@263FHD
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M+XO%S[>C2-1RKTNZE5F`4AFB*=\KGRWBY*C9?`N^[F1D!^Y]#K-PY$9\Z7><
M%SOC_0FW^!A8I^E52N90.F(,^8<B0&WEV-^&]`_-2UG(;N43W^0.K3PY?L6G
MT[+IG?'!R+KGF"*#4W:*DX3Z(9MP5IMOA6L@H[)EM!$M4]_+96K-#IQF7$$3
M.+N%QH%=EFW]*D/GZ&_44E`[H,C/MV4'.:J[_&U='&#NIRX=V%8=&I*=&Z:S
MI.RMN-M;N^RM4^NM"O1S5&_5&6M8V*I<\_/P6<LMA*4.@%WY[3@<62J4T,L]
M(JGG9`M21W#D%"U88AE8HBQ*PIL%5QGS!DEF`%>]A7VNH!I'QA:&'L\WY.M"
M9(=-!D6R"<D-;4[)14AD1!.0;%G$RU5Z+7WY4-D@LFG,Y_FQUX+7?TFR3.UN
M*.*,]63<FSJSI,\<.0KU=1I=M6-\:UD&DCT4<YV[D[PCR$&/NSUB4YHOG^S;
M+74_%^;>26/-SME.!BFQCD8$D=H**;<GSL@<A;2$C.M'B<7G+RMO?L43@54O
MZZ-%^N;+'0+;XK6_+Z0:%`F]K7E(JW6UC&:5]$1Q>I]=1\D&?5F+8)'IUU6O
MG5JO:?9GG54QH2E'B0F.IIJSCYGKQJJU?:XOU4@2FAK47G1;;H*76L43?LZ+
MO2)4N3P%EK*0&PT5E[UTNJ7?0!9D[O%RYRH,71GV6W--U9P1N;=0CBL[*I/>
M@EIO1>*27?-X18B)BMB)R]L6>0!JYJ4J"\"1FG=ZL5L;2V;OXIH58Z?D1\B:
MK78_U#O55E'\VGKIO2IGB=QD4OM$^=R(1%*&%/BWQ0:7"J]:#E?(+[)0KU_*
MU6WMZWG,"_?@E3P^>.EM^/K"R<IJD,N3#A5`3L!R_EA/A:M7M\N*UI@J@LK-
MG-S%"\G]4W$[ZFZ*7$"HZO-R/<!%1XHH#K7ZNS/R:MQ57"[&RUY51V^]))W*
MG=!U$LK4M#BTO4,+:[I"2W1!%E2.2.UFWKT2PIX%,T9=D=2UL+P5EK47Y-.W
M_@YUS)LQ365<V2'1&LZA3S/M]@LB6W`"A%B*-_,2<MA*,E(+9W7MZ&XXAYK\
M3;GISK9ZMF5>2>3\B)NV]3N['VPODA>32^]L]:7<S7)E].E2[J028?GA].-7
MZQ^GOWU[;WUZ3]A^??_I_>\7CU@Y=.8HW/59BILXQ0ZENO$1%_N1Y61=<P&`
MU+`:T<@GR>5UP^R.2^7^BAV3*UA>E1^5QZP[<H^%_KP3UZ]N-KM%4@F=O5@5
MO1F+Z@@J[97W4'[(57\1REDY&Y?7&7>H1U'E8+QTG&U5USQ1EK\PC3R@-;=I
MU(9#W15/%'W1P/^=V6HO6*3T;!JK2T>J`>F_E*WRC3A:SX<_XM<M7?VFJ3']
MBW8.[F^\.V.-7],J4E&EW#0)^1]YVJ/<&T5#ZM)-Y7(*WQ.+8W4_2.TR5\!0
ME"BO(/-H>;-I1.!R\FUJ6`;8JHDC=^V*F?^F/7'OZRKNR6OK_UF6\1WARO@+
M)7AYC5O.V?+0(IRQ7ZBN0V2'<2XMQAUF6_E\_MM([;*62^_,[9(N&VMEX>PP
M'%4T;F6(1O_AF+[F@&E'7?7+W!)VU85S'7A_I+D9R4,`,B@*H$@`URI,6GD,
MN:.YVD9)$Y4&)7SD%^^*73[*7F07(6>W!$&2^%FL=7[9+;OB<_NJ5_O5%VLE
M)=U$/OA]@-UVF-TR(:F0]3K1-;@J*;>"I962;GIFS!0!,#'X/$\J3G*MRR5U
MO90?AFE,KXU?;4L<ZSPW!<.DB:O3+D2E"[`B7/D1`5=93)$C#RP;QU^1J]PD
MUDK)]H4UNZ(&0NK0?WV0_U>\)^N),D\L\_P/7Z7L]G:/#BI_O&!@ZG]Z6Z*G
M>G:PMSH.2DI;=NNU&NN;!_&OFD[^O3XA^`]WG'DYS-?_59DKQXV\XD?.BV`6
M+QH&CW4`R?A!1.0-E8$!0CTCO21$N&!.A^CL'P]+8>JY6G16FKL1J9M'>!H#
M2R.U^;G&,\_-.27!9`2;RUSN?UGJ*;5%K7($#$JO]"&B0H%:@@GLU"T[W0?C
M?\GRBGN#TC3>Y+94-M!/E96:<6H'?@._]0Q`/14-_+:>WR:=TMNX@B++>26W
M@?^6=BO#Q/:-4T*PG1XX;:5FL*:PICVUIMGALW9Z"GL*>PI["GMJ&L99=(EV
M>@I["GL*>PI[:AK&67B8=GH*>_H4N]LRMU&)WMF'#WL?SCH(%VH!EAH*W67L
MD/&]K[=5GR<'X!F#@_0`Y/&NQW-@\B!-/9]Y`VP-83MI#S:H7[?J!^UJD`(1
M+*4/(&`IP`:6&A*.8"FPE&F`@*4`&UAJ2#B"I<!2I@$"E@)L8*DAX0B6:NW$
ML+,$`QLA,Y[N'FD,SME2LH^MCP_[E%M`#VCTB5R"-3,*E9/&J$!YH#PZH_+<
MC`^.@9H`%7!,;V""\H!C3`,$:@)4P#'FP`3E`<>8!@C4!*B`8\R!"<JCW46[
M=G+(;037Y&AW>J`Q9)_HX]N\?L!E&KA;9VIL%R0-$\CI`9@9`0--[HD/S3K^
MI"U@)ZT"UE_=&Q^-]HY/NH91X\O^>L"D28PIB`Q$UDO]`I&9CB"(S`B80&1]
M1`E$I@MR(#+3$:R4B^X:2[`9V&R`*('-=$$.;&8Z@F`SP[#2^(I@!V>=FM\;
M-+,RSP`MH/9Q':VDR8;!U`[:)AD+X,@\^?[R`+*BZP&3)C'!X$33#2<XL;?0
M@A/!B5!)<*+9*($3`2TX44^L'[?A#6+45"]!C":@!&($M"!&/;$&,9J#E<:W
M7M=JZQ"2Q7Z2-UOMF2^L6#AIY"6>0,%)??`Q*]QL+:G!YFD'&]+/]P-'Y-%`
MD133``%+`3:PU)!P!$N!I4P#!"P%V,!20\(1+`66,@T0L!1@`TL-"4>PE':W
M29_V#%'W)+EGX7PN(L>S?6MA+T14.4KL^G0>?H5!X3$P;#JB@GSZR9OI>#3>
M/]86(B@.ZK68!@C4!*B`7_2+9X7V@&1Z`PC4!*B`9+"(T101\(OA@$!-@`KX
M!8L8[6$9[/T[_<_.HD48V8FP7#%+6C@Y0T2.?O2#D(!!H@*G('DSF8XFAX?:
M0@3%0<2G:8!`38`*^$6_FB#0'I!,;P"!F@`5D`P6,9HB`GXQ'!"H"5`!OV`1
MHSTL&M\ZZZ"&H>[':=]VSW>MJ_!&1,&<NF;%BS"(PTBX%OWF);=MG;(A7;<^
M&MAY1`&R<1N)',HN-ZS,M'\XVCLXZ!I')-HV(YH4E&:Z802EF8H<*,VX4%70
M&FAM@"B!UH`<:`TK-5`:**TG*('2@!PH#2LUT)JF-PT[."_5O/S?19C8?M<A
M!W!#3(_A0<GBWD*+DL5MQ1#O[8WV#T^Z!AI.C!F1Q2!%TRTG2+&WT((4]5G=
M@Q@UU4L0HPDH@1@!+8A1.ZRQ6C0#)Y!B'U$"*0):D**>6&.U:`Y6)MZ==<-T
MY@MKLMOZ6;#.<,F#8,NQXVM+_)%Z)'SJ8&S9@6O1$+Z+Q&:AZ']O=B/T>FXI
M]0Z`VL+AJ8$[5(?G)VT1W<+/>0RB_=7>R?AH='#0>:66C6WLT%11\S!N<"&X
ML-\*""[LO?82%>X=;[T/#BK4U,B""DU`"51H#+2@PMYK[R//A,&%FEI9<*$)
M*($+C8$67#@,[=7[6C#X<.NCX)_E<6/QG.O=;".?FCC^4AGHR2)9WS/UEMHK
MU>&G0O>7%WLO+$?X/N-',Z'X/9L9\O=LSCGT9A$5,RR;'@2*;R]B\3K_X8V5
M3:&]>L'3-0?B'9BM=958*_9%C;4-`U.=@;/0=^NS6`)XG$_4>^=TWWV#Y[+X
M!@%"/2.])$3&^R^Z1&?_>%@*\TXX8CX3D34=CZS)WGA?9[UY/O[5`)G6XK">
MVH%Z;%J.OJJ6/ERD;9"Y02CI1%!-8HZ'I&D?;"^R_F'[J;`^"3M.(\$E1+0-
M==0@U%@#T,!O0P!03T4#OZWGMTFG]#9NZSK5D#3Q4<G@P'8ZJ6$'.&VE9K"F
ML*8]M::_B1OA6V/M]!3V%/84]A3VU#2,E3V=:*>GL*>PI["GL*>F8:SLZ50[
M/84]?8K=[2>*,=XX8J@W06VG<2R2^'77ZJ-#?)`>@.CC>CPJGAO!H=K!UB1H
M&P'9^N/XK*%?9J+RW&X"6$I+-0%+F0<;6*H?.(*EP%*F`0*6`FQ@J2'A")8"
M2YD&"%@*L(&EAH0C6$J[&NQ/>V*H>;GULZ7\^EL?'SY'.1I8,_TP@373#I63
MQJA`>:`\.J/RW(P/CH&:`!5P3&]@@O*`8TP#!&H"5,`QYL`$Y0''F`8(U`2H
M@&/,@0G*H]U%NW9RR&T$U^1H=WJ@,62?Z./;K#JU=9D&KGF9&F'Y]`L8:')/
M?&C6T8B"*BT`UE_=FX[&Q\B=HCM*FH28@L?`8[W4+_"8Z0B"QTQ`"3S61Y3`
M8[H@!QXS'4$#ZE>"S<!F/48);*8+<F`STQ$$FQF&E<87!#LXZ=3\UN"CZO*T
M"PN\#Z.C.EI)D@V#J1VT3?(5P)%YZNWESDPM-+*3@&!0HNEV$Y386VA!B:!$
M:"0HT6B40(F`%I2H)]:/V^X&,6JJER!&$U`",0):$*.>6(,8S<%*XQNO:[5U
M"(EB/\E;K?;,%U8LG#3R$D^@V*0^^)@5;+:6U&#SM(,-J>?[@2-R:*!`BFF`
M@*4`&UAJ2#B"I<!2I@$"E@)L8*DAX0B6`DN9!@A8"K"!I8:$(UA*N[ND3WN&
MJ'N"W+-P/A>1X]F^M;`7(JH<)79].@^_PJ#P&!@V'5%!+OWDS70Z.MH_UA8B
M*`YJM9@&"-0$J(!?](MGA?:`9'H#"-0$J(!DL(C1%!'PB^&`0$V`"O@%BQCM
M81GL_3O]S\ZB11C9B;!<,4M:.#E#1(Y^](.0@$&B`J<@>3.9C(['4VTA@N(@
MXM,T0*`F0`7\HE]%$&@/2*8W@$!-@`I(!HL831$!OQ@."-0$J(!?L(C1'A:-
M;YUU4,%0]^.T;[OGN]95>".B8$Y=L^)%&,1A)%R+?O.2V[9.V9"N6Q\-[#RB
M`-FXC40.19>;03D^G(X.I^.N<42B;3.B24%IIAM&4)JIR('2C`M5!:V!U@:(
M$F@-R('6L%(#I8'2>H(2*`W(@=*P4@.M:7K3L(/S4LW+_UV$B>UW'7(`-\3T
M&!Z4+.XMM"A9W%H,\=YH?#+I&F@X,69$%H,43;><(,7>0@M2U&=U#V+45"]!
MC":@!&($M"!&[;#&:M$,G$"*?40)I`AH08IZ8HW5HCE8F7AWU@W3F2^LR6[K
M9\$ZPR4/@BW'CJ\M\4?JD?"I@[%E!ZY%0_@N$IN%HO^]V8W0Z[FEU#L`:@N'
MIP;N4!V>G[1%=`L_YS&(]E=[)Y/I:'JTWS70&]O8H:FBYF'<X$)P8;\5$%S8
M>^V=CL;'6V^#@PDUM;%@0A-0`A,:`RV8L/?:^\@C87"AIE867&@"2N!"8Z`%
M%PY#>_6^%0P^-.16\%IM;:7^J,[(_.;9,\^7Y[FONPZHN(\%!VC;](YH6O),
MX'68`=M)>[!!_5"*06=4GMM7`$MIJ29@*?-@`TOU`T>P%%C*-$#`4H`-+#4D
M',%28"G3``%+`3:PU)!P!$N9<X%TN,57S^@3DA+7777"(/9(*';BA8'E9P>-
MM[H>UB-/AH%!44B#85C,$Y);W(/@>'2\M]<UBDAK879P+W@,/&8T<N`QTQ$T
M(#07;`8VZS%*8#-=D`.;F8X@V,PPK,!F/4,);*8+<F`STQ'$'J,)*.E^8;*#
MU+DHHXJ$#YW['3K6`$`@UF,<$QU3_R-&JW7/I3,+.S1%U"2R&$P()@03ZH4H
MF%"?'6GPH::6%GQH`DK@0V.@!1\.0WO!A^9@!3[L&4K@0V.@!1_V7GNQ4VH"
M2IN?\?XL2W`6S[G>S3;RJ8GC+YL(86VWV^A")MQ9Z+M5T7H)S51GDUYNAL+'
MX$;$R5R6.MUN0(=+`]K?/=C?2*Q/<1I]+:RS<+ZP@UOK2@0BLGW_UG)\.XZ]
M2X\ZX]%P73%++"^(DRA5X[=CZS=Q(WQ23NMCY>^.'5@S47[=K3QI_;@6@17.
M8A'=R`*Q<UDKUEI$GD/OH<Y:'HO%<VR_4CS62J[MQ"+%9Q/@4HM>8/DBICXX
MB7>3MQ++)])8N+O6_]GN/=Q`$-*K;FS/YR^.K#AUKNOCIF=D.RZ]B\P8#39P
MKOD%%K5#\V-4_H4_#B\MW_M>K84[XI\3ZL-5%*8+>H;^,K>3R/M3-LQ?XCJZ
M9'53=1UZ'KK"CW<M`BH6=_Z>]2BD[XK$CFZM)"2!B:(M^NB&KU;'%KUR%H7?
M^4=^@1<X8;0((SL1EFT%Z7PF(NZN%RS2A/I$G_LI6^H1C2!.E-SM!;7WIS?G
M+TE3S=^@5X4TMMO7%6'<>L)WJ95(T"OXRQ([EH[LPL^NL'WZ]A]IF/!?O3A.
MZ==X$0F;OY;\"'?X1GA>3[@JUIHL9QX_'EY>YL.*!/U(CPK+M1.['$4^"2(2
MHAT1J@OB%IH!+$H2[@>2CB.BQ*9!9NV3*&\7_`XF+'Z,9HL2#K5UR[.<9]N(
MY1J'<\&28,''"77#CMSJLSRKZ'F2'K^29M:N]5X!&4;JB4R&I.CY]USO4HXD
M(6TDM*5ZTG0/:%RW<@[S7XJNSFSJ"S^7#=,)`]5I[C^)1<YKOQA`ABC/G6*V
MRT9I2(PS#T244XU`=UCC^`EAD_"*]U8>6N[D[I9&<GRLE]FOY"DXJ^4IR!.B
MW_:(#3X&UF>R3FP+)GOCZ4C.A)P>;.>/U(MHWIS1Q&2NR#3.85-`LZG,W"!G
MBIQ$<2*MA6M=VEXDK9?4%"=<D_QA8=\J2TMVC#M,'2G>%B>A\_V:X"=E'S&Q
MA&GB>P';XH!M$;\P$=$\SG61OGU%?[>O(B&X5>N'EUP7[>4FM=*7XNVL&>$/
M-GJ7-1%<D2#Y8_JC%[D[Y(_28&GZB8`:HBZ[3'7A0@K&">?4`<>CZ4EJG5L7
MTB4W=1)F2M<C&\7$D\OU,@KG1?>D95EZ?:W)6.H;#56RU(IVB;F%?RF'N21^
MZGU<08M^*8%2O&9S@[/L@6R2T8>N%SMA&O"/LOS[I1_^H&[8_FWLD1D]YYX4
M)B&FN2%'9L6T@B!W@/J6%&]2]IK\A'2^4$^7QGJ6)M)D^=[<D^P1OB;1,K9>
MP)]+I.FSC"S+SCMAK.8.26KATS?DHZ1PN0FC?_]%_$OS)_N)VR"!ISX;XUO%
M<#0">B!KE1^X3).4AE$,6?4]`UOV8J$XF(DQEY'%W!HK,\@:EQL%ZA:-1"Y?
MZ*NO=_9VQ[G'7'7&KFF"5_RH)<@*MVJZ*ZT/OX!;V-(6/<[;?P)#=)Z2__9'
M*@W$M4W:&>>\M&(FK[4F%7D1?(6ERGRDPA>H@"G-Q,NO<NG"_WWWRA)_+J1Z
MLZDAG1+SO"=$!RY_XDIBX#T(.0?/$_I'F1'JX.=%UAGI-(?J-YHQ6:LT/]X1
ME>9S^IHL%7EV07)-*AEP7S_)'D['(S;(!Z.LXTY("O5O-KIS.=4R@U<WP&O%
MX@J''"WN^.S6^FF\>VP1RK[\)!6Y=/*'\M%6[('R$\D%D!U?D`]'+R+W*%.3
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MT617T2`TPV.1![%DX9*.D\XYLH1C\ZB!2(:E1.):!#&'KG(,YEQP!&W9?1GM
M>FW+P-8D[^9,W(8!Q_<)ZU;84>::RP`K_O-E%A7`L9;R1%Y$7JC"^^J1N(3:
M#A_;TYM46%`6;%+,PZ,W2\+DX)UTQH$R'!=@9TU[3O7\/A(WGOBA`@VKT4I%
MF`(+J/H%YYKFJE#QP#8'&JC0BE7Q'<OHS@1''/%S'.K#<8]>S/%+_TK=*Q79
M,1-*UCLD25(',><@U^BV-MXB'B*V>/J&:4RO=60TIA?4(HVHCQ(X:K@8SLK1
M5")F52B&"*YHVC`VI'TJ3.E/#I3@IH@VG>OET7+`STR(++J9>U^59@VB<NPJ
M(.32"^R`P\+*P$\5]DF398<'P]$;\8(#G\IH"Q:J$'=@6YH+LLLR4BN+_:#N
M\^2O-"*E($-2\YF7CSI.+R\]Q\M&35I/V.6QJS9'8'L+J1PLVAL1W>9S((MB
MS51XRSC29=K4(;Z2YV`6YR$G<IS.J<M21=9#4,[^EU(^-%T)D/C5ZSN2Z2*>
MA*BZ24!)!SNH!VMB2BH+"#76-E80)CBFG1]%/-=R[HYG5UL]2"".&_E(?0?D
M^=9O@*3AQ=;-=T':,V(`"7IC*B3@ECN`4,]HBA(BDQ>=@O,P.KTR8;_26BO6
M655@O;2#!-8+UDL/>&"]=$(#U@N`0$>,AP3K>@-`@MYL&9K9][U]4[#J7'W@
M!V`5HP<\IW..A?BW<'56%["-=I#`@L&"Z0'/MR+83&=]@0G3#A*8,)@P/>"!
M"=,.$I@P0P&!">L$GO?YC0"=U0463*]=R[4US[?-F](KE=*'@K1-;V,02AKQ
M4I-L*4-2M+,P3HQ3,7"9&3C!%,(4F@/AKWQ-US@=@RTT`R?80MA"<R!\^9O,
M5'!?/C8]U0SFT`R<8`YA#LV!4&8\_(>1V99A$-O9]WWR%'GKHE6?')GG26;U
M2:L<H?H?+#X/*CU)!HH4@]K!UJ3\^N"3>1J`(XJB/(C*$V4=UX&CS`0$+`78
MP%)#PA$L!98R#1"P%&`#2PT)1[`46,HT0,!2@`TL-20<P5+:E4%^VD/#\73W
M2&-PSNSXVA)_I!X)F2L<O.[Z#![.A'X!2+!F1J&R5:X[*`^41SM4GIOQP3%0
M$Z`"CND-3%`><(QI@$!-@`HXQAR8H#S@&-,`@9H`%7",.3!!>5H[-FOKB+.=
M'&L;P34YVIT>:`S9)_KX-J^=?ID&[M893]H%2<.KXWH`9D;`0),+XT.SCC]I
M"]A)JX#U5_?&1Z.]XY.N8=3XRK\>,&D28PHB`Y'U4K]`9*8C*'7OOXXGXTGG
MR@<V`YL-$"6PF2[(@<U,1Q!L9AA68+.>H00VTP4YL)GI"&*3T0B8=+\BV,%9
MI^;W!B_"Q/:[#A>`X]&#N(X'K[7#,S$2VB89"^##/+D/,X#<Z'K`I$E,,#C1
M=,,)3NPMM.!$?7:I08R:ZB6(T0240(R`%L2H)]8@1G.P`C'V#"40(Z`%,6J'
M-791C8!)]UNO:Q5U",EB3V]LS[=GOMBAIW=BVQ=6+)PT\A)/;)\Y%FGH]>,U
MI*$';-NZ(X-W-0S`$?DT4"S%-$#`4H`-+#4D',%28"G3``%+`3:PU)!P!$N!
MI4P#!"P%V,!20\(1+*7=K=*G/4O4/5GN63B?B\CQ;-]:V`L158X2NSZEAU]A
M4(3,``W;UGDID$[_&="9CD?CR5A;B`:H+YH$VH)60"LZHP):T1F=R9&V\`Q0
M5T`IA@,"-0&E#)U2-+HL"*4!M_0&$*@)N&7HW,*[8/O'VD(T0'T9]M4Z_8_#
MHD48V8FP7#%+6C@,0Y"-?FX`3OD'B0K\@>3-9#J:'&Y]*@;%Z5YQ$,2I&2!0
M$Z`"?LE@.M`6'>@,J,4T0*`F0`74HE])1&@/2*8W@$!-@`I(IKH_=J@M1%`<
M[:Z/=5"44/=#M&^[Y[O657@CHF!.7;/B11C$821<BW[SDMNVSM:0>EL?#>P\
MC@"9M8U$#B64&R;.WC\<[1U.NL81F;/-B!H%I9EN&$%IIB('2C/NW@-H#;0V
M0)1`:T`.M-8RE"\[OR$.-GL`HE<@,7W!,<`4@L1,10XDML%VX\'6T9Q@,IU4
MKL/;A!V<CFI>O>\B3&R_ZP`#N""F!^N@V'!OH46QX;:"N?;V1OO[^UT##2?&
MC!!BD*+IEA.DV%MH08HM83W=.H8(?*BI.H(/34`)?`AHP8?:8;W]<2WX4.OC
M6M`@;"5HL.?0@@;;W"L]/.D::'!A7Z_#NF$Z\X4UV6W]P%=GN.1IK^78\;4E
M_D@]$CYU,+;LP+7L&]OS;9+)#C6T$],G!ER)W0C%_EI+`R*=MG!Z:N`.U>G1
M.I_]<R+:7^V=C(]&!]-IUT!O;&.'IHJ:7SH"%X(+^ZV`X,+>:^_VQ\&@04T-
M+&C0!)1`@\9`"QKLO?;J>VD7-*CUI5VP']BOWWH']NN]]LH-T8/.RX2"`I_K
M\+>#2(U6RH>N!J<JZ5GHNUNC]0AHW@E'S&<BLJ;CD379&W=^Z^P^'GPNZZ8#
M,`8$,2UY)O`ZS(#MI#W8^NM:&(`CBBJ@:(]I@("E`!M8:D@X@J7`4J8!`I8"
M;&"I(>$(E@)+F08(6`JP@:6&A"-82KM[HT][;JAY3N"SI?NAK[L^B8<S859@
M$ZR9=JB@FKH1,$%YNHJH!<=`38`*.*;_,$%YP#&F`0(U`2K@&'-@@O*`8TP#
M!&H"5,`QYL`$Y4%]S>3UY&AW>J`Q9)_HXUN+>OQ=)-9E&KA;)U-%!GE]=*SS
M@`$DB&\Q-<!S1NJT`%A_=6\Z&A^C()CN*&D28@H>`X_U4K_`8Z8C*'7OOXXG
MXTGGR@<V`YL-$"6PF2[(@<U,1Q!L9AA68+.>H00VTP4YL)GI"&*/T024=+\@
MV,%)I^:W!F5MR:Z#!>!W]""J`]6Q^PDMJF/KX,)T9FJAD5J5"@$EFF(W08F]
MA1:4J,\>-8A14[T$,9J`$H@1T((8]<0:Q&@.5B#&GJ$$8@2T($;ML,8FJ@DH
MZ7[C=:V>#B%1[.F-[?GVS!<[]/1.;/O"BH631E[BB>VSQB(%O7ZT]MPIZ.&-
MF`%;$V]D\)Z&`3@BEP8*I9@&"%@*L(&EAH0C6`HL91H@8"G`!I8:$HY@*;"4
M:8"`I0`;6&I(.(*EM+M3^K1GB;HGRCT+YW,1.9[M6PM[(:+*46+7I_3P*PP*
MD!F@8=LZ*052Z3]'H-%T=#0^T!:B`>J+)G&VH!70BLZH@%9T1F<ZU1:>`>H*
M*,5P0*`FH)2A4XI&=P6A-."6W@`"-0&W#)U;>!=L_UA;B`:H+\.^6J?_<5BT
M"",[$98K9DD+AV$(LM'/#<`I_R!1@3^0O)E,1L?3L;8007$0Q&D:(%`3H`)^
MT:]H%;0')-,;0*`F0`4DD\'T<KSUCB:TIGTX7H%3M,#!`.LU0.TP`!5PBMH8
M&V\=VP?%,>>@K-TDHL]:BU#WT[-ON^>[UE5X(Z)@3EVSXD48Q&$D7(M^\Y+;
MM@[5D');'PWL/(``&;6-1`Z%DYM!.3Z<C@Z/MCZR0\IL357N2;T24)JYAA&4
M9BIRH#3C+CR`UD!K`T0)M`;D0&MM'TON[W6-(>CL2<XJP6*PA6`QLY$#BVVP
MW[C]%0$PF4XJU^$]P@Z.1S6OVW<1)K;?=80!7!#3HW509;BWT*+*<&O17'NC
MR?BH:Z#AQ)AQ+P6D:+KE!"GV%EJ08DM8;Y^Z%'RHJ3J"#TU`"7P(:,&'VF']
M\J#S:Z0@1*WOEH('33>6X,'>0@L>;'&S='PRZ1IH<&%?+\2Z83KSA379;?W$
M5V>XY'&OY=CQM27^2#T2/G4PMNS`M>P;V_-MDLD.-;03TR<&7(K=",7^6DL#
M0IVV<'IJX`[5Z=$ZE?US(MI?[9U,IJ/IR4G70&]L8X>FBII?.P(7@@O[K8#@
MPMYK;_>E+$&#H,$!H@0:-`9:T&#OM?<1Q\#@0:V/@4%_H#_0'^@/]/?0CNC1
M?M=`@P);/_W].>$CQN(YU[O91CXU<?RE.M#)(EG?M<>\9G_W8/\O79_>7@OK
M+)PO[.#6NK9=^LP*DVNV-M<V]5K,N4QH=&MY](@7S>71;GAI>?2/%]R(.%%_
MHE=9]#7Z;R2$-:?77<>6H&&ZUB<[<JZMZ7AD3?;&!U;^X`_AWRP]^4XX8CX3
MD<J;-C[<>Y-]:W_76IH,&<A__3F-=ZYL>_'Z8]F9C\$[,4M.`Y?>_%W(R?'^
MC]1+;L^+LV?Z\$Q$B>T%%Y'-*GH:QR*)WWFQXX=Q&HD+$N);/W2^_^T__\.R
M_IJ_Y;T=!?1T_$5$Y]=VY3'+<W]Y\>&?9&G'!^,7ED/#HH^^BLM?7IS)O])_
M)M/I/UD$],M8_3"=CE_\C<?3XIS-IL<L]-V-I]8CYM'OGR_>6_N5C'=O3\\_
MGEFGO[^SWGW\[=O%^W?6[^\OK-\^GY];7]Y_M<[_?OKUO;6='AWF_>U":^XJ
ML!S_6SOV'"L0B443*+86(K)BGB&D5+$U$R*@.3%?I`E-\]FM17A[/.VD*A1?
MH@_X=]55X>[8-R*RK^B!E+6"U4XV*1606B/=(7'QY`O3)$[L0+;HTA3/&J9.
M>*&[:[WS?/GB%;WS8LNQ?2?U[>6>K>N5U;A7'`&R"!-.B6[[U#!UPKNI1H`\
MU._M9H>TU[J9V;?"L=-86.=V<&7/0Y:[%UAV!9(P)IF$P4@):C5:XD_'3UWJ
M.DM)7%X*)[DK]FH0#MFAV(L3%BSCI";+@M\3CRSR+,@P<[O476\G!VC78DY(
M9%3/'8SC=/8O>BM]7&^M!F763=>ZC,*YZ@-Y.C8_R*/FSN>3CO]$K=\SYN;,
MPO.-R8*F*GWO:'0XV1\=[NW)OQ^-IGN3T?3P<&31,!8T!!JI?_LPKZRU^'5B
M.`M]WYYQ16UJ]S2B:7$EF(Q6,$J5*B:#I8J#"E5\.OV?SU^MLV_G%Y\_O?]Z
M/K*^G'Z]^)U^^OO'+^>20LXOOIY>O/^5">6WWSZ>_G[V_OP1W*&1+"KSAC3A
M](KFN'*HGGATJLL>Z;CG;#+>QXR.]?`WSQ$!V<%BI-8/+[FVWGKA%5'DQ\#9
M90OQ]Y1>S6:(5CN"C)+3ECQTH(*/@?4_=I"R4RVM54X)U#_!)42\@(RK;?WJ
MAS.RP%]%+-C,C<@[)HL5+J306)3DM<]%Y!"W>O]6`FXB[I=L2W/=F^R]R21?
M/%!\-'[SJHK-R%JD49S2:-CV*^K(>\YORMIQBBXPA9!=CQTNDT*LIGH_(OH7
MW\D&7['U#TD&]F(1A<17TM!S2TYE7&SV*Y-@9L<D(!I;]N;"AAR]B:U_>X%C
M79*M)NIX]_OISLQ3;$3-)X(FU<O_[\.75U8BG.N`%KI7M_*%UV(>7I&DO2!<
MV,DU.24C`H#IB[\ZH]4#+X1\FY8'<\^6_2,_[SNMU!WALU-#Z)!\7YZ?O7O5
M*X?E&W5%$>_R#!FMPOU?(4U;_Y;9S$W9/_@1,M'*J<L(7$7V/'XMV[LCU.QC
MV1P_0++,_[9K?<CH?]VW1E67BJF=O0W>29'324$DI^#MJ.P0O\FMJA.[`\HE
M)3<C3*^NY3LOO2A.K&MIC!S?"SSR6JPD\K+)6CY",ZMJK?*V::ZF:\58.C:1
ML.7"E1VAY6&6`JA(96311"*QVI'L,GM)RR/?=*CDU\V].,[<,9M-,:^GO2MI
M2VC`//?>1>F5]?+C[^]>L=82<RA#P^];D@![MXERTL@*R!'R`-1H5.>S.3'*
M!;,"/NI43-ZL9(DP\MV='^1'EDA4AC6R"*/TD@:G5A'+=J1P-'UE$%U^/T_4
MN!%6N]9IHGQN:I>=87(@O4N/OE/(F6SW7&V#"+N<\KS;H9IUU'9#Y:N.%SGI
MG)UF1Y1BB`0_ICQ\N0.K7&VQD.L%UA#[N[!X0EN\91.).3TNAUP"2SW,E(($
MGD9L0N=A)$I5X34I8:Q\=WZ!$^Y0C^=D*','_5O@L4-^GI`EYX=ORTV991F6
M$*^TEX1[^=TFTAY5#8O-?XU5'^<+>B\S2SX.-4E(W$7_)?$5DNB51<X''0E'
MT"+#9033!2VQ2#TR2*Q+6B(1^C]-]G;W+.JGS_)(2:F4=\'S1+H7JR<Y>2:\
M8:V6H4EE8_`'M43&-`X)84OXWI54T:3HB_73>'*X.RW>2'-H8=\J1U:^G1LC
MM?`(_=S2W=6A4<4M&*U4<WX!6262$RD,S>$?S,'T[T_CPZ/=@RU??]=.2):G
M%71<>=]NJ:#>?$:N$'U:G89RGKKJ=4X8R^U1)XV40\>T&/":DSZ4/E43\YQ1
MJ=J6*?2YAE&%^E:APDM+]H>HW8W@N!^$46.)E?L(U,E4O:?<$'K<>U:,C:=$
MG,[S7:2E`;(O4`ZRZ*9%CP02K36VB&3[T^1DNGN<3Z^J@_CEFKV_\4I)LQY6
M9V7!#?3!2H\F,Y8%-2Z![5V6I,647_.3[[>GV5^D&E/_RGD3.)%\A.$(;VU?
M3KRBHW<-_349>;EA9-&3/+?5L=6.2Y,OX4T;AQN[$LJ)H$6.+[=T%&0\RU+%
MC=P:S0]:()`Y'_&A0PE((<!K^T:HK=.*R9,G%(4<RD?4,B)[A!E/T#`$/ZP&
M=LNVL?H%TK_@?M)_!'?0=!8[U\K\C\<:DLDIS825YN&>6?3CNA#;2,VE&0LX
MV"%9T_?XG"4#*-BA>47SEO^DS$!YQ$2FBE9[J=QOECN!&_6B7`)*%4^3ZS"B
M]\B-Y:O4<]F9NM\!+@U4]A%[;EX@>T.S._?3E)+&E>DX%T(Y@:Z@5::7>Y1V
M9>JJN<<ZPL:&YWKU;;R!6PX]+%_-JDT-WV9JK;9+Z1GV?Q/>F^6#LHI=_51O
M=,TWJHU&PL_?FMF[E]ZKTBM3(R=_8E:833>3-(GBQW5(R)),):]&"4M?>*QC
M52>AMA8G2\"S4*)!7\S@"AW)B/*/++C,'#N\>4S63*YB4E_N5LN=XP:MCV@@
MU9$P]&IS0MH`ZX<=UX22!AG`9!#L#$ZY5\&SJ=R3XEE:W8Z1`I(+@!NU&DE]
MMR8L1IYZ<D>HZDDU+NG!9^;<]LN)-1/J_$-R=V7,M.IPG#!BHO&9(VO[Z(5)
MS)>12W17F7B%U:[.=>G*5263*S0U'%X%DE)L7I+1@--\5>!%LL`MK5%N<\)4
M9S7*-O#O2Q.^)B#>'"(OR)YY/A?)E2L^.R9AS/Q;R=TD[UWK:_;*#086A,E#
M8Y$K)KFH*E9,6=<S.EZQ"LF]"=9F>2B>+WO9TN62R=XA07'(%E&C=H5FYB)Y
MU"I$>R8Y+T^$Y&Z&7`>OE6GN>9"#PU,_7^0%ZLPH)O!&.6'OS,B`L_@S-V2D
M7.?:PE@VP]!GSY`/2'_E@[;<CO/&!,\]A5]E]X]Y)^()6?6OBTFW2*-%&$L[
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M[.+E^>Y)QL3LIM!@"5=&?X?G%3M!)`:UW<;&@<R2/(*V>'-T+GTJZ0O*]6QE
M*S`/9RA\D7JGLN'=';X<#4FX?K1='Q;#1CZHD)L+^:!XM3G>WQT7R\V*R]>Z
MRNFF89G+$%<)O[2O]LJSQBWB"J1#P^MCWP]_L`O-BAJF,3T0OWJ]I4`?CCU\
M4+9/4;64/=CE`=5"#^3B+@MB_>7%W@MY(,9AJC3MB]^S`%CY>Q9:ZTC'N@BD
MS:)@Y;GA(A:O\Q_>6%FD[-[>7ZH!KVM2_700F7UX^)>'0JC56-N(H;YSBE\+
MUI5SY;A15%S?KS\\5U"[08!0ST@O"9'#%UV",WT8G5[IR\4=8M%9;Y[OFH$&
MT+268>ZI[XDPQ[24D[57NJ4/%VF;.M<@E#0BJ":)5(>D:,52R#@]`Z&!T'H&
MH)Z*!D);3VB33@EMO-]2ZO`A:2)O^1FG@R`[/7#:2LM@3&%,^VM,M<VX`6/:
MZLIA[KFN+YZU,LJZ$YC>Y$+Y6L08%6>YV>EE[:K?ZVU5[#G*$@TKRY`!]82:
MN"M(.J0?;)/V<(/^=:M_4*].RAR"ILQ2$]"4@;"!IGH")&BJQ;5P9]&(&X$S
MGNX>:8S/U\I5F_"R"-^^%*+K/29X%OIMSL.RF9#?FOV%P;L#X]'!I/,B1="7
MUA:LH)6N`8&:@%8&3RN'AWOZ`C0\;3'@J+6=(,U^K3F7;NAVO6&C;7RF'GB9
ML;/6)$X(YE$_Y":M0M=?+:0%[?95=SNSE-"X3HYEP6C&VT4PFJG(@=&:8;F_
M_08M^$PG?>OV_';M`GNC&KN]0>R"LT-WO4=E5-GC4RX_H8LN=;Z%B&+'O=NU
M1[7C-C">CO8.#KO&&;6.S3AF-HH`]4<)5&@,M*#"_JOO>+1WW'EP%:BP];7[
MSS(#;?'<$]7%K0R=KV*O[6N[*7^?Y#5Z9&I6-YE5B2S.K"S^7,BT\V6]K#N9
M\<L$SDM)K5<5A>1B!'EM:ZYN'NYP<1KZCDS^?$::3OT,Z-F/09QX29JH2A-?
M!;U)J/K-UB?A>@ZG_WYY]O'KIU<C55'ZI_'N?I%>F[M.?RAKGE7JES=/*;U<
MC?H>\7`G5;;];)!QI0[5JIJD]X@Q'\ZX/IQJT;A6AK/=O!T?-]#+RD34IHKQ
M^;5'<OW(^3N"O&[FK_/9W]>4-.:6WGGV54!@][G$\:26O5[4RQP[=X2;EQ^P
MU]8L5G*^IV2Q?&!5Q>)J1V2Y-=G24M'BLAYA5L%B15EB510V68;3K<#)"DM*
MPZK')6&55CY0PS@(Z86R9DE9W6'7*FOQ+HU\M&9`<[NHOE$IN'>GSUR:J>QQ
M6:1$EM7DU!,6VT0KH<DFDJQV1%[MX#),H]K']`VN`,*&EJW+S`]#$II/<Y;M
MR`?;2<(HMO[Q\>.(_X?^]^/_E3W^OZK<YXH**45US_R=M=?E-7[2."^"Q"5(
M^5WEJ/@WKO"\N/9\KJ7+\S*E-GA2CC)9%=VVK4OODB9/Y2U%D8!J`3%9NFJY
MXB\_^'=5$B,)@QJF&?*[V?NX>D-1@&7$A5?R\CEY317?F\N29F&@RMFX(B;O
M5$[.'V&U@E0=G2]+A3+NG2NRZHO(YTN]_LZ*BC*/J\6S:J;7Y_BJNCMEJ9V5
MM77NSN:Z`M:G,[>]?C+72W=DQ8N6Y,?.1.S]:=W2DTK9O;B*'AE(&C6#IFIL
MSE-9#:>T8OP5Q<F*QM=4`NY588[2<M7J0MT[-=?4\2X+^C6M8/W[.S8%[U.N
M1T2_G^4U1B]D!>_32@7KEV<7IZ^DT^CGG5O1BY45:==6FBZF7^97LI6Z4_4F
M+Q,M/^&F[,LDKUKB.&*1V'FQO&(\U-526_)*FJK/#4K3>LHY\3/?,OLEZ\9.
M[EX7_9-^:*]F9+7^49-*RN/IPY64EZ;SHPHI3Z=;%S+>LHYRN8HHWE54@*UR
M8579[IN<%464Q7^YY9^.RU$M56X^WGOBNLT7F\@_KZ!6]&.CDK>U6K=WJN?&
MH:]JS<GIPO4TD[C"EV)U=;B:@RRK`,O2D-7:N4]2#O?.I.Z1$7BX^NT=ANJB
M^.VR!X+:MZA].\S:M]'F-6$W+7;[4(5;HXO;WC%G[=6V)5]'%L?+/<YJ_6#>
M8RSI_4Z)]ZIJ\G9"N53//=+'U&#7C710!I2[G&TX/+8*Z!WOY-F*@,;>GSN\
M!Z!1W<_#W>-U93_[[,5M5/53"6+SHI_9V0_*?N:GY2C[.:PRAF9$/Z%N@LY5
MU8:D+RC[J2TTJ)(V!`#U+"H"@M*9H%"W!V4_#80)A#8$`/54-!`:*M7U2!-1
M]E-WA#2VE2C["6,*8UHSIBC[J35"!N2BW?@$IC=W(5>4_53'EZCZJ2=@)B1Z
M0SDU(V%#.;6>`(E\]P^A@JJ?F@$"F@)LH*EA`0F::G$IW%DPXD;@:%^!!54_
M>Z%#G6,R-,NF=W:[P;L#!_L3?0$:GK9HDHP5I`)2T1D5D(K6\(!4M(+#@'-6
MU/Q$S<\!*%GG^VJHD&8F<JB0UK!"VNA@LK7O@1IIFFH<:GZ:@!(8#<B!T=IG
MM).CDZYA!*.9?WZ+JI^H^FD81F9LOJ/H6>]V\%'TK)5C@-'>H;97L%#T3*\C
M9U`AJ!!4J!FBH,+6J/!@,NX:9U`AZG\^^%[4_URJ_YDE"U^J6[E?J9`CZU;N
M5_)?HVYE(>OEZI3>U=S>.?7=B%.3GX71(J^ZZ`76;^I:>1C=6D7TPU=A<V62
M>&1=\"M5'</3P)MGY:/.B@(\UI<H3`0U\T55HN%&SX3OJ_3I[P.2D%`UD[:3
MK*XU+E.?"USN'17%#T2]N&6#4I8,RKVE+->B]E)^]*I6'K+>VJCH5U8"+)&U
M@FX\-W]4OH*+.<5Q7H2!'EA$GDBX>.=2D;ZLEE!9*[`L_L=E_I:J$<@J+^OJ
M9Q8)\",UR<H:1K*(4UX&(*N!4#Q]Z0G?':D.,,46)6MH@)Z3^DD:53/RIW%>
M2",7Q"(2-UZ8Q@1<49^).OHN_,%B"\\=CTNTQ-9OOYU9+]^=GC<4+U?>E!^6
M@G;"0%9]LI4=4C4#[A1^JPC)+U5P63HQC81'VZ"08KW^`&G%BCE@Q[$7)UF/
M27C4U4`HK943@NM2B4M2@D3."E+$[R+)@.'B/CDZ8K[PP]O<W*ZJ5K/4N95P
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MK@I!6C^-#RH%NE?4)U157%85+N0:3M7R0.M*FA1%4$C;E?>C*D)E`BND4Y2<
MR4H`9L0WWLL+K4=BP4JM"N85)9-DQ13U0#Y.[EDXH]56GMAF;444"7&FW?FW
MJ<NR>-^JRGV5V5`1A13R3P<5L%1I+UE>T%Y7OF]U-9::G2KT10I*EHRJOX>^
MOJY+6?'81O4'J9GQWN[!7^KE!:4MSBL'>K+:CTP9M&O5:T^NJZ*8*YJ3SKE0
MY)+\*E6H<C>!='MN?Q=W:SA)^Y`+)EU(>F$Z)BV[RJ;23Y.*7'IEJC>K0"-%
MB0HT]V\!H`(-*M`8N?^.%)XZ)_@?DKZ@`HVVT"!A_Q``U#._+0A*9X)""FE4
MH#$0)A#:$`#44]%`:"B:T"--1`4:W1'2V%:B`@V,*8QIS9AJ>_T!QK35E<-S
MY^$;9/D9>7;93OF9/AW&Z`&8/G[)HRZH(.1=/]B0U[\G0"+U8D>7*T%39JD)
M:,I`V$!3/0$2--76.MB,,JRZ9P+.PK&S\.K.$P'#F3`IS][PC-G6^12>)>GA
MX#V`R?8Y@:`MW=NPYV9XD`K41`-40"I:PS/>.]07H.%IB^[GJB@WLXS8;Y6;
MVX]=:/8^&%,/R,S82D-^?C.10W[^IOGY)P=;^QX#B/+2`R5-SF'!:,;;13":
MJ<B!T1JNI;>O-P,^TTG?.CRP1;&9]HK-/'41)V38-VC?'1GV>[=YCPS[[:S#
M#R9[7>.,#/MFG#:#"D&%H$+-$`45MA5A=;QU#@<0H4XF%J5F!E9JIBS?4"DU
ML[<[J9>:J:9]1ZF90M9+I6;NE-/@TC`^?8O_FM7I$/VJ!5,IV7"PIAQ,4*FM
ML"(U_%*Z\'>GYW>JQ?#?5M:*J=8\J#TTJE0^D85?8OGY$]=]D44A;N4'5R((
M&8XPLFP_R;H8I(XON)J#0VY&&!4U(4A!23OBO%*$G#$RN_=(_4+_\M/%WZUL
M*L6[2[GY.;D]R;VL8,']5$T4+>R0P&0&_Z+TC*QTX7M<M4!*@.%W(F\A2U=P
M`9(PBJV7_-'%A_@5-\0_R\'8;%;HH]_I[Q+MZY2FGAIVI62%Z]E7`=DCSQFQ
M((AJ9?V+3`:+ZUN?WD*_+])H$<8\KHME1',@7=F@S=6;O(3GT:HR,US_0M8&
M^9\T$#PWCT>R-?$G3[XXJ[$2JA&NRES/DV.F*NRLFK/TL2P)4XB0+&M>HHBK
M8="(,R'+4A,51'EBT/C90*O:-LU*R(SX#5GMGUK-'X?$%_.G;LKU26R_7E&H
MCOC,"Y?*CRA!YV+)"V!D@J'VKJZD(ML6&8(=659G=7$'6>_@L"2)4;5JB*I]
M,R=I<O=_FNQ.J]4B9.&,LCQ15J[GI_T*XQ`,!;1ED8917I]%5359JK6DBD6M
MJ-O`TT?8JA81"VHDOZH*4'BLL4%6;$(5;9&RW+4^I!%/W'D8"3659-&>ZXI)
M*.I2B";UBF2M&B\BA.Q(OI:[Q=K*)6+N&H`']5^6JIBIDAR)K[*73%3Y#)I9
MJI"+K-?BBJR.5E')8W8K!Z34($ZY%DDQE%AJT3MZ=*ZL/-<^J4Q9RYZ+HCA/
M75\3+MV3B,R&YJ51+HO*5_7J1D7Y$PG&G:(H>066O"=ES83,TYCTJL#&7>LG
MZ[\47,:394[J-$_G]1(K<F)+6^BFHEJBA#2%""YCZU%I3!F;\BU>3-U(I/GT
M`FFDU.38M4Z#("65ER^A45P)9=E^FASLC6@%S*_Z:5I16<F=?`0ERZ!4%)Y9
M9CR6?<RL3SZ5W%"HUU_;-T+.VC"X"GER9,5R;/*I\BHZ7/%H?<T1V>656EH,
M;>EK=B+?R";N#7L(M(2D-_NWH[4&FJ?NG:([-Y4"3+EQJP/IA*GOLJ;ZX0_Y
M,%%9342[]5(VRE21D;@EC;E=ZG^]:57<APF-W'S";DZ/24J81;*5F7)-0C9D
MJDGY+NGBW&2V6@HA>T?%0"\Y5S89F[J3T;`2FC13'.P;)979J4RP<M#H\R`D
MX=`4BUA,"^Y,PE.Q]-L:V%<N-U,6\`HC63Q/+!*VK[Y'+?(*R8N<=!XG/*_(
MTM8K];$@"BJML7FSH?;-'M'"1:X-@[`(UF8A1^M7FRN+`]5GK!%+R0VD_@@1
M?R`9L2SD%"MJD7X(Z<^9M6MGW=CQBOF,FJ?G`L\FTT,+@H0+ZC&=?1699\SK
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M7J4>=UR[3/2CZHC*8ICU$>5^3>D`SD3R0XB@5MM6:6>Y<F382J!CGIVYQ2Z6
MC/:*$J#+#S\HC4Q?E![([216H[P\X]I%T#3SS')^KOC'$KMKFSU/$52I61;=
MI"^I^5I]0L[C(;@Q=J(JN]I%4<HU\&3KD)I#PW-$V7)EZNQVG9O-=O-E9Y;[
ML79+?]KJEGZ/Y@FQ]"=;5GK=5R(M:TA+"V>S.3\LI'>>\(;>%='A%UI4D1,3
M7WN+DHCE5QQB`4DD<4)$E9N*19B(W'82F(H5Y49K99.4C7[!X/<QMZH;_7NV
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M>(5E5S"D?`ZZXXJ%D+C?'?&"6F-_7->E@3RL9=$[1=YXN4A]MG7"2%*GW,.6
M6^9R2_R"CX6L\=&H*JBST)6R(U66]=!I^"/KG"U8&)2KB_'>WN'>7J]6`GFN
M_\>[_LO>]DHE_4$3DOCE:)EP]MLEG!87"T_=U:40M"RT[*\_I_'.E6TO7E=J
M+MR(TT@>.7$'WWFQXX=Q&HD+`ORM'SK?__:?_V%9?\V_^#%(Z%F/\#PEX2?Q
MBB]8GOO+BP__W-NC#DY?L.KSY/DJ+G]Y<2;_2O^93*?_Y`'0+V/UPW0Z?O$W
M[NP3A<$]XU[S[Y\OWEN'A3,^>?/Q]XO3WW_]^/:W]];I^?G[B_-'<'9GBGW7
MQF2<G4\(RY8S0JKHQR]?Y?CYO^_4R7BL@A5^A"4UY7;9H6GLN:1;F:7G)9%T
M`FSGC]2+O9QPSTA[F&QWE]KWLIW/>D_H/?2O=^GQDH55U!67'-4B=GRYA9B2
M1^!+/2.J6/A"O26R[!EU)PRJX1743DA,PLK_`&FH3;\\7(#H*DKD/I`\NN18
M+7+QYEE\BKA,^8#S4II&>MH5ZFA0+;'XO6Y^$IGOX'IQWMG^[1W1-(BB6[9]
MO+X5N:<@@S9R9.-\DMD1HT)SS??#'[2DEINO81J3].-7K[>4S,-AK0\*Z0EB
MBJ63L#R@FI54_*KBLG]YL?="[3,L;%HQ7!6_9S'=\O<L6ES5YBIBP[/`;NE7
M+6+Q.O_AC94%?^_MU5(W/GO-U8V31E=N!+17A\R$.//.4VJ@\)_.A?^&5+-/
M'NKHK"JHSZ<=)+!>L%YZP`/KI1,:K27I>>I$2X]-A-M7==*'?K1-'&@02AIQ
M$BIEUR&L[U,;IVQ@-3-P@E&$430'PN*B7V87MRZ;!+NHC<9U6/-BX^WP8>5:
MZ7QI/*P<169@@CK,!L*&.LP]`1)ULQY"Y;E=!="4EFH"FC(0-M!43X`$3;6U
MU'WR'+.]7^J>O?_Z?F<\WLLNT@DKB82=Y,&II_Z_KP7U*?IO>Q'&;V++55D+
MMM4M%'_6S]ZAG&W[J.B=-!M.0GEW0E^@AJ<UFM1Z`+F`7'1&!>2B-3SCT>%^
MYW6%H"_FG+.V$U+9&[C4BG2R9D7ZQ8Z^>T',%]Q;69'V/K1(#U#-V)9#H68S
MD4.AYF=;]PX@-$PCK+H_V06O&6\=P6NF(@=>:UB_<+KU@AM\II.^=7@$O'85
MOE&)WXW@&D]WCS1&[$*F-_>X6]ZE)W/`+.=`BKO>YT)=YAYLX*,N<^].`5"7
M69/U.NHS:VIJGWF]#D($(?9;`4&(_5??\>CXJ/.S=5!AZTO]GV6*T>*Y%G,T
M-Q/"VFX_I@LZY+U]MT&V[WIIX*(46I%.V;43VW(%M1`G6:GL("3)T(^QK$?M
MWUHQZ9YW2;]P!27O\E)$LA1+GH-?94,.DBCTK:LH3!=%E7;UFSSJ%Z[*>5\+
M3:]$HE>*T&2'_[O6>3J+Q1\IB7VIZ"MUV/&R:F=<BXY>[G'J>/E(_@)9$B`/
M.UBJ;,#E=2)['LOR75Q?>91G3)[9,\_/"M78SK4G;E@D62IEF<HY+\_"%0JX
MA/.E3"9<R?8LQZF2$.?O43G<;9<+W@FNJ'VIBN7L6K\2'$'VM"HU$"\--2_!
M.Q,^]:9([:S:S>KRJH+V@:I1<9ER(6I9`O92E3T0_B4GJ5959FER?Q>)*G+M
M>`M;EFTXK9;7W22;_)WY510QLWX:[YZ4]<+I`2]2Y7:O2;W$4GFY.-]\4B4D
M*H][JFRIK,/G!58UAW>62K^HHN<XJA_<>ZX>P1_*.A*2G.7;>&8+52""$`X7
M6>GM^.'T]PVRV"^GO:?NB`O[SP?RW>\/-M_]42W?_=GG3^^MB]/_^[Y/J>ZK
M9:[F-F^U>@$7+R8CRJ4?$OO//#NYK-<2B4M?%D.AKP6DI?RYD,9"I387\T48
M<=7-T@['=4.<YT-7%2Q579,L_3E9+-]3]BTO;W_I!78@ZYU$@LN62&.71HLP
MSDR<U*NLJ33.ZEUZ<F;+SN4/2[6-Q<J1J5*@:D"9QM%K2"-BU5UJDLOOQ*,R
M4;X3<6V<W,HN9$&E?]^725_6U^!R&_Q@46UG96]8_'DE&UF?.S.8U'!`'>/:
MI;+HMC)MB3>7XN1".:HH*+5+SA_W@:TL(1`QJ&75GU7%-J^)3<-(L@J/6RR;
MW'4%V5ADJP8A[;ZL"GF9,D6'EY=<O4"6:"TKO=F<Z)[KS>Q:WQ*O*I@Z##F=
M94+GHN8S42W,4RDI2D\&JLCZW$M4>UE=^_!'7DV)+#R7HY?EBN)J`9^/@:0I
MW\J+O>35;L8GQX<C3LYOSQ7+R#*H]`K?CI3-KK26U3Z]TP_NM^+0G!&((+RH
M&/3=^;<T\)F@J4B8EK+:MEZ"CI6R-G$;526)ZL3++8><P[5J-*K0E%VA:57U
MGNMP%&^L%]\H#(,JV<%?MMU_I3$S=#:;DKH74-1U*+T$Z1@PVF4=W<S_R`&W
MZQVMF*V9",2EES1A_?4D7J?[\H'/EZS*Y'S(*915`#IC`W5.KH]XRX;B2U:F
M:J5'<#!8C^"XXA&<7WP^^]^=MZ?G[]]9Y!M\>?_[^>G%Q\^_]\P[4.5(I)[(
MX]CXFM<3J@PUD8;S/:O%Z53F5,7SE=1:*,"&7F\9CMVX:A3*IJ!L"LJFZ!-.
MAL(#*P`I\ID>=IK/=/HP.KW*57IQAT5TUAOD)=TF4N^IHRU1A4!W+M+V]H!!
M*&E$4$BXO:8*@7%Z!D(#H?4,0#T5#81F0@6)IE%9@V<\5-O1'2&-;>566@9C
M"F/:7V.*$CU:(Z3[I=6-CUYZ$V,LS\CE26-VOAF_[CHN7(>#%SW`Z<DM&\3M
MZP<;BB#T!$CDH=03%6B*?IB`J0R$#4S5$R#!5&TM>SN+..Q36J:O:^ZU=+V3
M!*="ORUX&+46\D,\2Y['P7L"X]'AR5A?B(:G+V98L6$IB1F8#$U3P"Q:PS,>
M[1U-]85H>/JB^ZEJ!P5Y-%]S_BH"$<D+_:YENW,O\%0*H)O.*\%J&Y"I!W!F
M[*^A/H&9R*$^05,/9'(XZ1I&C2.]]$!)'XT#J1D"%$BM?\B!U)IA>3S=.G@9
ME*:3ONE8^O;IBNY,CG:G!QI#=M$HFU/7VUDH,]"#?7J4&>C=9C_*#+2!\61T
M<M#YB0'*#!AC9,&&A@`%-@0;@@TWWKT^V3OJ&F>PH?E%=^[OYYU\VH_,DEU/
MN4W/>/'G2\ZDGW()F*LO9`^<6_6_Q7>JF;4/GR6S]N'R]L3NY/`OS7)MJ\DB
MZQTXFTR^S>:5%!RG@O["!16"+']^B5T?\FK7JL&D@9VZ7J+R8J_*D%T6PJCG
MRLZ*.5AOO?#<\62]C9'U,7!VK9=YJO+)WINED@^3\1LK2ZQ=>6BIO@,]]*I2
MQV$1"39R,I.W+4M#<.$&54SHV^[YKG6EPC6X>I#CB`5WVBXF/GW=H^XO_*RN
MA\<9-;QY95A>P*+,ZD($+A?NB%.NZ)3EVH]2/ZN&$(FKU,_R@V=U&\Z%DT:J
M:@@_\?[/K,(##6GNQ5R4P7IY_O[LU=VJ%ES`2)8ORHN`T`CR5I>[=!F&"3TJ
M.*\_UPZ@$<YN-QLW0^Z+1*S$<Y>`DR\.%UZ0E0B@&6I?R8]'LFNJ#(&"_R7/
M$"Z#1>_A\A%RRG&-@322=0TJS[Z2L\DC#J/N!8)F2<Q56KA+MG5I>Q'C6VI:
M"7N>P'W7^EQ4ILCJ0&V2G#T24LCYFTD/J677<U1%J$S>>;NR8$-6Y(.W'F5A
MJ_QEM\*.^"7<D7?4W'R6E^?BW.CY&U4)CC6Z-+-].7?C:\'E2[C"&+UP;6/[
MJCH6R4Z6)KN,PKDJ.U-J[`-Z6LV"OZKZR@="SAKO[?SOG5'2=];W2Q8DN?3\
M2DTOBV9Y7NIF95?BZS#U799L)&S9(>K^O]+`D;@7S:S\;ET'N%B7(.7<L,N-
M9;%V=`]1>#/6K3/UMYCX_CVI$JD[C:W"R$?/PLCC8]TIF23$>EK*J%]LK.BM
M*,6S1HUY*O`[N,R,G)2-C7_&&''%H#.SS>WO9.,*F<I0QSA.YPM%;](2JF)\
MM4I7JAA6659CK;K>*3LG=9>,.3.:%097(?]QQAHSJG9-J")-K`K44M'!7'WY
M2PX3+I<LK`Z8=8Q9F&Q".:I*);VL/&&U$,YHN?@AM1>EMD\OD\3$/2%V$38[
MY7)D(VN6QEX@N#Y7.)]Y0>8,E'V3,BF_G/&+JL-XI<IQ*394@)>U@]B8+3*G
MWE+&;2XBZXQ,'4.=NU;Y[Z_4F=DUZ:*(E,2]H@Q?7D6H7DA0U1V*BQI`9=.R
MI-2:([C=BN(QF1;%O%3A+BD]ILI(NH"R*?J0YW^8QO7"BC$1*E?+5`_)3ZB'
M!#B)Y<[<JQ9/S`H\2KDH_HC#0)8;24FE%`DX7N2D<Z[%)1W1*JL79<E8IO(3
M.>VDR$D-&+9_I>Y5-G=G89K4"\9)*.^K%Z>4)?,TF-W8R[`7:FFN:%L--P[3
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M)+>+K%9PYG[&5KJ@[](`9/%@7D!%V5>).03;+J[82$U[\QFM1'/B*5Z5RY!8
MD\AKGLZY!F&]`9IE9#EH2I2,(I>OX:WM2VS+TH[9%T7-$R9DW)2(/[;]NNG9
M2,,G2]MEE4I_VVKP"M783*D_D;EEM\AZ[ZM9=%K.*!ZWQTN*C"W=<)%3Y>GY
M-^OW<+=<54SV]DYVQM.1M<)*5`JU%:][IR:IY*S\*[57O^179*V^8B%?RBFB
MY'Q7_>5@=GG)4C@V=K4YF3=4>FF2,F7QQO^Q@Y26WN4@U,IH/%+JE6]#S/,^
MNV6?,T(5?KG]P[6AJQ-=K50]I='RM;'R:]F(>%FYU=)?\RZS0HKE.\C3(O<H
MJQG*/A[9&;OJ]Y&=D"RZVL?*FN*WDQ^:<^I,%#J?U<ZLM$(]Y@*+A9EA]_M.
MNVP":RW+S1+>LE<^9.;?59PZ6;31)UZ5AH(\Y\POO%<@A5]%3U(7RG[$H]*?
M7BQ(8>0D6N'.%C*3UK6RZY*_UU=>IK`)N6QP]W5IU_IRGSX4*K"FS#5I8B0N
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MY=^M/ESGU?*K);MFEK[@L?S-;Y87S`JZRJGP0V?"T"'HT)8ZE&VY\M2GN<C+
M2IJF^9R]9X+34Y+1<^-?^(0V37#?SS9V21>O/?H*+09O624CD:E`]0EYOA84
M+=&RMFB,",4-HYUB-RZ4Q>QKZ^V7_SC__/[5B%T?^\;V?)[P;^@M7N3N\!;`
M;>71BR_+3TIUYA;XM;PE5FDC.[*9D4=2>"5R.5'K_<OWYU]4HX'PI,F1S9&,
M+7H=-UMIDM\&98>R=Z3LM*S@#:5$:6$:5P^5/9>7)[2NO0[=S'_?SC*D<7ZX
M()<XK*QUC5'ON+--O+$B/-ZY[PR(VF9(96."3\ON^-55?WJ4;6;$Q8)Q*==D
MI;E1?6N%EPA1MG"X;W^E7`KF8)<KW-SJ\W*X<E!TAP3N09]F7)4X=JW_PZMF
MWBZX;31OZETL-DSB-<0BWU79NLFFI[31=VQY9K.7_[YK?2RM>[Z76^T%:5)L
M$0]DQ_RT0JZ\L=R1+5U!3W8WJ.Y!Y#O+<EWK4$MI]/#."6]#%:,L)*JB.BI[
MW)4]W]I\J\T/.?G.KUGE/_+?U8$AV81?Y[._C[)#/O\V>^3T5^NE_(FY+\@G
M%$^BB7S;6R^DJ2%/`BO?S?_J"B<[)%1_>;741A9-4FX@%(=G/(!LE;IJA?H4
M.\"=68G3;...]^3K$RZ/^V&[[.>'QHY@G2F6YW<WUM7)8K;CENMNN@AY'M($
MDH)4GA9K<>YJQ7FHS*JM^CM')_F4]7C;WO=5\]PX_5W:B(QQRL;4GI4Z4(G3
M&4,IE3\-LJ$0\V1[3FY.757V\9;F<7$D6XZ`YC9UA1=CJB.*X++-LFKGJKYG
M1=[U$X=R2ZQ7L^U3=D1C!P%[`DLG-1)JVX_#]7A7MBB]()MLDJV*[[LI6T-Y
MM'.;?U-]4H:(+)M$84?Y=OC2^5?ANZB-U"AK-YN<ZX['JGN=Q;OB%0=9Q="4
M[:D8U)N:$<W."XMNK$D"+=^@=M!J1XL1&S/9LW?B4O"!8,7L9_&&Z@URZU1M
M]!4OJ1S(%4J960(W@T"&*?+21H8J*G'V:N*N"I`K!'1%K62&JCS?E"[6CHS%
M6SH:SK>4\GB]^HP@R?]!NJ$,9%[=2CZ[%G6:':ZXE"<Z90`(^RQ%6*[L8=F/
MTEU0SR]]'*MY?==MR.=?V<&B3T5/60I>H(Z=\^TH$K7<ZY)N918Y54:VRO?*
M9XOP0FHVWX*O.QG9@?O#\1\/QGC40T)H+E7"%*,P")D:I#`>O"IP@@B1+(;"
MD6<(I<MT7FSJ]R=2Y&-@G:97*5ERZ4/R;/U0!/VM'/O;D/XAE8I3FN4KG_@F
M-Y?EH?<K/EB73>^,#T;6/2<L&9RR4^5E&=;X;X57(^/P9007K;#?RQ5VS82=
M9C1'NG>FSO`X6,ZRK5]E."+]C5H*:F<K^=&\["#'\9>_K8NMS%WLI;/FJB]&
MLN.[7$G96W&WMW;96Z?66Q4\Z:C>JN/AL#"SN='*`Z8MMQ"6.KMVY;?C<&2I
M\$PO=^:DB2(SECJ"H]%HK17+F!AE#!/>Y[C*G(8@R6SWJK>PNQA48_/8.-+C
M^5E"78CL:\I`4[9^.4?DWD019AK1!"0S'/%*FUY+7SY4YI/,,;LB^8G=@I>N
M2;+LE;BAB#/"EK&$ZKB5/G/D*-37:735CE%KG@S.>RC*/O>$>3.3`TEW>^0(
MT'SY9-]NJ?NY,/=.&FMV3M0ROHIU-"*(U"Y.N;-R1N8HI-5O7#\%+3Y_67GS
M*YX(K'I9'RW2-U]N;M@6;UOX0JI!)*XY>NN&KY.XPE<[`*R2GB@"#[(+2-F@
M+VO!-Y[<`I&]=FJ]IMF?=5;%V:8<X"8X$&S.[G&N&ZNV)7)]J0;!T-2@]J+;
M<O^^U"J>\'->IQ;AW^4!MI2%W".IK#;*]8)T><B"S#U>J5V%H2M#J6M>M9HS
M(G=TRG%EIWS2T5%+Q4A<\JHB7A$=HX*-XO)^31[4FSG8R@)P].N=7NS6QI+9
MN[AFQ=B?^A&R9JN-&_5.M<L5O[9>>J_*62+WQ]065SXW(I&4T1#^;;$WIR+#
MEB,M\JM+U.N7<F%>^WH>KL,]>"5//EYZ&[Z^\`^==)YF^W?*5C*P'D\3=06@
MNM-7M,94$53N8N7>:4B>JPHY4K>1Y-J'Z9,=<%K*T&>%(YTM7.^,O!HR%I?[
M"&6OJJ.W7I).Y?[S.@EE:EJ<-]^AA35=B6GVD`65(U(;L7<O`;%GP8Q15R1U
M$3!OA67M!?GTK;]#G5!G3%,95W:^M89SZ--,N_V"R&C2\D4TN6.KO(0<MI*,
MU)I?732[&XFB)G]3;GIXX;#I2J"^COA@>]$_.$SM5(;&GP;N;V5@_"=U=<+]
M''S-KP;2`[]S8%CVJ[PQ=<$[NJM6&H=[S[/2F&CH=E_4@QRKMU!X+O!.MF/'
MY/Z0!TJ/J+.)XE1TYY)/>.G/V=T+%8-7OZO:X%**7-MRSY3R9GN`E[1"#7_P
M[/1Y45Y1G5J7RT/JE_+#,(WIM?&KUULNCM9=OU?`-,+P"7(02/NR(O[J$2?(
MV2&I(W=@&Q\HDUXT.3SN(#?)P=Z#A6O46-M((G)G0Z"6KT+.E>-&ZM[W!$#/
ME=7%($"H9Z27A,AX_T67Z.P?#TMAZG?V=5::YTNSHP$LK:73?>H\24PP+>6.
M[Y5>Z4-$VJ;X-P@EG=BI2<KX(6D:+X,MN0ZV/E56:L:I'?@-_-8S`/54-/#;
M>GZ;=$IOXRV2XPZ>_V09!^.4$&RG!TY;J1FL*:QI3ZWI;WRL8HVUTU/84]A3
MV%/84],P5O9TZY*TL*<Z*2+L:2]@A#TU%V-E3[4M&09[VNKN]E(QU"<O2;PN
M7*@WM6M4J.3K;=7G.:IY#ZODDPEUNAO0%&I`:0?;27NP0?VZ53]H5X.<3F`I
M?0`!2P$VL-20<`1+@:5,`P0L!=C`4D/"$2P%EC(-$+`48`-+#0E'L%1K)X:=
M)1C8")GQ=/=(8W#.EI)];'U\V*?<`GI`HT_D$JR94:B<-$8%R@/ET1F5YV9\
M<`S4!*B`8WH#$Y0''&,:(%`3H`*.,0<F*`\XQC1`H"9`!1QC#DQ0'NTNVK63
M0VXCN"9'N],#C2'[1!_?9JGQK<LT<+?.U-@N2!HFD-,#,#,"!IK<$Q^:=?Q)
M6\!.6@6LO[HW/AKM'9]T#:/&E_WU@$F3&%,0&8BLE_H%(C,=01"9$3"!R/J(
M$HA,%^1`9*8C^-]YD?!)Y\H'-@.;#1`EL)DNR('-3$<0;&885AI?$>S@K%/S
M>X-F5N89H`74/JZCE339,)C:0=LD8P$<F2??7QY`5G0]8-(D)AB<:+KA!"?V
M%EIP(C@1*@E.-!LE<"*@!2?JB?7C-KQ!C)KJ)8C1!)1`C(`6Q*@GUB!&<[#2
M^-;K6FT=0K+83_)FJSWSA14+)XV\Q!,H.*D//F:%FZTE-=@\[6!#^OE^X(@\
M&BB28AH@8"G`!I8:$HY@*;"4:8"`I0`;6&I(.(*EP%*F`0*6`FQ@J2'A");2
M[C;ITYXAZIXD]RR<ST7D>+9O+>R%B"I'B5V?SL.O,"@\!H9-1U203S]Y,QV/
MQOO'VD($Q4&]%M,`@9H`%?"+?O&LT!Z03&\`@9H`%9`,%C&:(@)^,1P0J`E0
M`;]@$:,]+(.]?Z?_V5FT"",[$98K9DD+)V>(R-&/?A`2,$A4X!0D;R;3T>3P
M4%N(H#B(^#0-$*@)4`&_Z%<3!-H#DND-(%`3H`*2P2)&4T3`+X8#`C4!*N`7
M+&*TAT7C6V<=U##4_3CMV^[YKG45WH@HF%/7K'@1!G$8"=>BW[SDMJU3-J3K
MUD<#.X\H0#9N(Y%#V>6&E9GV#T=[!P==XXA$VV9$DX+23#>,H#13D0.E&1>J
M"EH#K0T0)=`:D`.M8:4&2@.E]00E4!J0`Z5AI09:T_2F80?GI9J7_[L($]OO
M.N0`;HCI,3PH6=Q;:%&RN*T8XKV]T?[A2==`PXDQ([(8I&BZY00I]A9:D*(^
MJWL0HZ9Z"6(T`240(Z`%,6J'-5:+9N`$4NPC2B!%0`M2U!-KK!;-P<K$N[-N
MF,Y\84UV6S\+UADN>1!L.79\;8D_4H^$3QV,+3MP+1K"=Y'8+!3][\UNA%[/
M+:7>`5!;.#PU<(?J\/RD+:);^#F/0;2_VCL9'XT.#CJOU+*QC1V:*FH>Q@TN
M!!?V6P'!A;W77J+"O>.M]\%!A9H:65"A"2B!"HV!%E38>^U]Y)DPN%!3*PLN
M-`$E<*$QT((+AZ&]>E\+!A]N?13\LSQN+)YSO9MMY%,3QU\J`SU9).M[IMY2
M>Z4Z_%3H_O)B[X7E"-]G_&@F%+]G,T/^GLTYA]XLHF*&9=.#0/'M12Q>YS^\
ML;(IM%<O>+KF0+P#L[6N$FO%OJBQMF%@JC-P%OIN?19+`(_SB7KOG.Z[;_!<
M%M\@0*AGI)>$R'C_19?H[!\/2V'>"4?,9R*RIN.1-=D;[^NL-\_'OQH@TUH<
MUE,[4(]-R]%7U=*'B[0-,C<()9T(JDG,\9`T[8/M1=8_;#\5UB=AQVDDN(2(
MMJ&.&H0::P`:^&T(`.JI:."W]?PVZ93>QFU=IQJ2)CXJ&1S83B<U[`"GK=0,
MUA36M*?6]#=Q(WQKK)V>PI["GL*>PIZ:AK&RIQ/M]!3V%/84]A3VU#2,E3V=
M:J>GL*=/L;O]1#'&&T<,]2:H[32.11*_[EI]=(@/T@,0?5R/1\5S(SA4.]B:
M!&TC(%M_')\U],M,5)[;30!+::DF8"GS8`-+]0-'L!18RC1`P%*`#2PU)!S!
M4F`ITP`!2P$VL-20<`1+:5>#_6E/##4OMWZVE%]_Z^/#YRA'`VNF'R:P9MJA
M<M(8%2@/E$=G5)Z;\<$Q4!.@`H[I#4Q0'G",:8!`38`*.,8<F*`\X!C3`(&:
M`!5PC#DP07FTNVC73@ZYC>":'.U.#S2&[!-]?)M5I[8NT\`U+U,C+)]^`0--
M[HD/S3H:45"E!<#ZJWO3T?@8N5-T1TF3$%/P&'BLE_H%'C,=0?"8"2B!Q_J(
M$GA,%^3`8Z8C:$#]2K`9V*S'*('-=$$.;&8Z@F`SP[#2^()@!R>=FM\:?%1=
MGG9A@?=A=%1'*TFR83"U@[9)O@(X,D^]O=R9J85&=A(0#$HTW6Z"$GL++2@1
ME`B-!"4:C1(H$=""$O7$^G';W2!&3?42Q&@"2B!&0`MBU!-K$*,Y6&E\XW6M
MM@XA4>PG>:O5GOG"BH631E[B"12;U`<?LX+-UI(:;)YVL"'U?#]P1`X-%$@Q
M#1"P%&`#2PT)1[`46,HT0,!2@`TL-20<P5)@*=,``4L!-K#4D'`$2VEWE_1I
MSQ!U3Y![%L[G(G(\V[<6]D)$E:/$KD_GX5<8%!X#PZ8C*LBEG[R93D='^\?:
M0@3%0:T6TP"!F@`5\(M^\:S0'I!,;P"!F@`5D`P6,9HB`GXQ'!"H"5`!OV`1
MHSTL@[U_I__96;0((SL1EBMF20LG9XC(T8]^$!(P2%3@%"1O)I/1\7BJ+410
M'$1\F@8(U`2H@%_TJP@"[0')]`80J`E0`<E@$:,I(N`7PP&!F@`5\`L6,=K#
MHO&MLPXJ&.I^G/9M]WS7N@IO1!3,J6M6O`B#.(R$:]%O7G+;UBD;TG7KHX&=
M1Q0@&[>1R*'H<C,HQX?3T>%TW#6.2+1M1C0I*,UTPPA*,Q4Y4)IQH:J@-=#:
M`%$"K0$YT!I6:J`T4%I/4`*E`3E0&E9JH#5-;QIV<%ZJ>?F_BS"Q_:Y##N"&
MF![#@Y+%O846)8M;BR'>&XU/)ET##2?&C,ABD*+IEA.DV%MH08KZK.Y!C)KJ
M)8C1!)1`C(`6Q*@=UE@MFH$32+&/*($4`2U(44^LL5HT!RL3[\ZZ83KSA379
M;?TL6&>XY$&PY=CQM27^2#T2/G4PMNS`M6@(WT5BLU#TOS>[$7H]MY1Z!T!M
MX?#4P!VJP_.3MHANX><\!M'^:N]D,AU-C_:[!GIC&SLT5=0\C!M<""[LMP*"
M"WNOO=/1^'CK;7`PH:8V%DQH`DI@0F.@!1/V7GL?>20,+M34RH(+34`)7&@,
MM.#"86BOWK>"P8>&W`I>JZVMU!_5&9G?/'OF^?(\]W77`17WL>``;9O>$4U+
MG@F\#C-@.VD/-J@?2C'HC,IS^PI@*2W5!"QE'FQ@J7[@")8"2YD&"%@*L(&E
MAH0C6`HL91H@8"G`!I8:$HY@*7,ND`ZW^.H9?4)2XKJK3AC$'@G%3KPPL/SL
MH/%6U\-ZY,DP,"@*:3`,BWE"<HM[$!R/CO?VND81:2W,#NX%CX''C$8./&8Z
M@@:$YH+-P&8]1@ELI@MR8#/3$02;&885V*QG*('-=$$.;&8Z@MAC-`$EW2],
M=I`Z%V54D?"A<[]#QQH`",1ZC&.B8^I_Q&BU[KET9F&'IHB:1!:#"<&$8$*]
M$`43ZK,C#3[4U-*"#TU`"7QH#+3@PV%H+_C0'*S`ASU#"7QH#+3@P]YK+W9*
M34!I\S/>GV4)SN(YU[O91CXU<?QE$R'<W^VL.W_].8UWKFQ[\?J#[47_L/U4
MG,:Q2.+3P*UDF_TD[#B-A/LY^,H512.:/?3`[V$0Y;^^M6,OON`17U"/W_JA
M\_UO__D?EO77.^W?WZQLYUL0SF(1W7!S'X-%FM#'8>#0M^3UU.(-EN?^\N+#
M/\F,C`_'+_@.*XOKJ[C\Y<69_"O]9S*=_G.R-SZ@7\;JA^ET_.)O+(0:)+5?
M5/54I0J_O-BCIH7O\V2G'A:_9VHD?\\4U"&81%2H8Z9+-(-]>Q&+U_D/;RRE
M;\?UA,7/>Q]ZK64_[GL:99Z*+-U46'9LA9?6.^&(^4Q$UG0\LFB.=%[)\3X_
M:ECL:$;TX=#84-_(PO%!8S3ZJS1:A`U"7TR+$#Q^SMPH.L-U=FT'5\+R`NNR
M<!5T7:'AEH*!>V"XI6`6<@>XK]`(RY=:;V;APD(&TZMVO9!V+YJL\$*>[IZ"
MSBC=V:;X9$?.=;Y'<="U?X]#N1YL7.!0KG>['SB5:P/CG:XQQHF<AB=RX\EB
M]9&<'.G)8OM3MQ9/Q>KG;J<WMN?S5SZ$T;GMBW-N4[YGY3':Y)'':!O(L;/I
M4P5P?_=@/SM3N;@65G;P)_SPAQ6G<^HR]2&V$OKH+)PO[."V"%\[>A-;7G`C
MXF1.#<762R^@Y\(TM@,W?O7:*J'O[H"1D&MRPMC!DGI=K=8*HZBQMD$I)EBJ
MSO>FGHO?JP*>A;Y;IQ,)Q'$CZ]!W0)Z/T`%)PXBWS=WB]HP80(+>F`H)N.4.
M(-0SFJ*$"'G<78+S,#J],F&_1F$<ZZPJL%[:00+K!>NE!SRP7CJA`>L%0*`C
MQD."=;T!($%OMHS5Z?O>OBE8=:X^\`.PBM$#GM-Y&"7T(E=G=0';:`<)+!@L
MF![P?`LB0<.""=,'$I@P0P&!"8,)@PF#"3,8$)BP3N!Y'R?>W$Y@P;1!Q(!=
MR[7%D+:]2-\KE=*'@K3-=V`02AKQ4I/K\T-2M+,P3HQ3,7"9&3C!%,(4F@/A
MK[87=![4!EL(6S@4E&`+M87PY6]A'(OXO@0]>JH9S*$9.,$<PAR:`Z%,@?4/
M(]-OPB"VL^_[Y#F3UD6K/CDR&^2C>`0TG[1*&J?_P>+SH-*3['#(.:4=;$WJ
M,@T^NYL!.")+_J;5!OO$468"`I8";&"I(>$(E@)+F08(6`JP@:6&A"-8"BQE
M&B!@*<`&EAH2CF`I[>IB/NVAX7BZ>Z0Q.&=V?&V)/U*/A,P5#EYW?08/9T*_
M`"18,Z-0V2K7'90'RJ,=*L_-^.`8J`E0`<?T!B8H#SC&-$"@)D`%'&,.3%`>
M<(QI@$!-@`HXQAR8H#RM'9NU6[O^L3G6-H)K<K0[/=`8LD_T\:U%/?XN$NLR
M#=RM,YZT"Y*&5\?U`,R,@($F%\:'9AU_TA:PDU8!ZZ_NC8]&>\<G7<.H\95_
M/6#2),841`8BZZ5^@<A,1U#JWG\=3\:3SI4/;`8V&R!*8#-=D`.;F8X@V,PP
MK,!F/4,);*8+<F`STQ'$)J,1,.E^1;"#LT[-[PU>A(GM=QTN`,>C!W$=#UYK
MAV=B)+1-,A;`AWER'V8`N='U@$F3F&!PHNF&$YS86VC!B?KL4H,8-=5+$*,)
M*($8`2V(44^L08SF8`5B[!E*($9`"V+4#FOLHAH!D^ZW7M<JZA"2Q9[>V)YO
MSWRQ0T_OQ+8OK%@X:>0EGM@^<RS2T.O':TA##]BV=4<&[VH8@"/R::!8BFF`
M@*4`&UAJ2#B"I<!2I@$"E@)L8*DAX0B6`DN9!@A8"K"!I8:$(UA*NUNE3WN6
MJ'NRW+-P/A>1X]F^M;`7(JH<)79]2@^_PJ`(F0$:MJWS4B"=_C.@,QV/QI.Q
MMA`-4%\T";0%K8!6=$8%M*(S.I,C;>$9H*Z`4@P'!&H"2ADZI6AT61!*`V[I
M#2!0$W#+T+F%=\'VC[6%:(#Z,NRK=?H?AT6+,+(38;EBEK1P&(8@&_W<`)SR
M#Q(5^`/)F\ET-#G<^E0,BM.]XB"(4S-`H"9`!?R2P72@+3K0&5"+:8!`38`*
MJ$6_DHC0'I!,;P"!F@`5D$QU?^Q06XB@.-I='^N@**'NAVC?=L]WK:OP1D3!
MG+IFQ8LPB,-(N!;]YB6W;9VM(?6V/AK8>1P!,FL;B1Q**#=,G+U_.-H[G'2-
M(S)GFQ$U"DHSW3""TDQ%#I1FW+T'T!IH;8`H@=:`'&BM92A?=GY#'&SV`$2O
M0&+Z@F.`*02)F8H<2&R#[<:#K:,YP60ZJ5R'MPD[.!W5O'K?19C8?M<!!G!!
M3`_60;'AWD*+8L-M!7/M[8WV]_>[!AI.C!DAQ"!%TRTG2+&WT((46\)ZNG4,
M$?A04W4$'YJ`$O@0T((/M<-Z^^-:\*'6Q[6@0=A*T&#/H04-MKE7>GC2-=#@
MPKY>AW7#=.8+:[+;^H&OSG#)TU[+L>-K2_R1>B1\ZF!LV8%KV3>VY]LDDQUJ
M:">F3PRX$KL1BOVUE@9$.FWA]-3`':K3HW4^^^=$M+_:.QD?C0ZFTZZ!WMC&
M#DT5-;]T!"X$%_9;`<&%O=?>[8^#08.:&EC0H`DH@0:-@18TV'OMU??2+FA0
MZTN[8#^P7[_U#NS7>^V5&Z('G9<)!04^U^%O!Y$:K90/70U.5=*ST'>W1NL1
MT+P3CIC/1&1-QR-KLC?N_-;9?3SX7-9-!V`,"&):\DS@=9@!VTE[L/77M3``
M1Q150-$>TP`!2P$VL-20<`1+@:5,`P0L!=C`4D/"$2P%EC(-$+`48`-+#0E'
ML)1V]T:?]MQ0\YS`9TOW0U]W?1(/9\*LP"98,^U0035U(V""\G0540N.@9H`
M%7!,_V&"\H!C3`,$:@)4P#'FP`3E`<>8!@C4!*B`8\R!"<J#^IK)Z\G1[O1`
M8\@^T<>W%O7XNTBLRS1PMTZFB@SR^NA8YP$#2!#?8FJ`YXS4:0&P_NK>=#0^
M1D$PW5'2),04/`8>ZZ5^@<=,1U#JWG\=3\:3SI4/;`8V&R!*8#-=D`.;F8X@
MV,PPK,!F/4,);*8+<F`STQ'$'J,)*.E^0;"#DT[-;PW*VI)=!PO`[^A!5`>J
M8_<36E3'UL&%Z<S40B.U*A4"2C3%;H(2>PLM*%&?/6H0HZ9Z"6(T`240(Z`%
M,>J)-8C1'*Q`C#U#"<0(:$&,VF&-35034-+]QNM:/1U"HMC3&]OS[9DO=NCI
MG=CVA14+)XV\Q!/;9XU%"GK]:.VY4]##&S$#MB;>R.`]#0-P1"X-%$HQ#1"P
M%&`#2PT)1[`46,HT0,!2@`TL-20<P5)@*=,``4L!-K#4D'`$2VEWI_1ISQ)U
M3Y1[%L[G(G(\V[<6]D)$E:/$KD_IX5<8%"`S0,.V=5(*I-)_CD"CZ>AH?*`M
M1`/4%TWB;$$KH!6=40&MZ(S.=*HM/`/4%5"*X8!`34`I0Z<4C>X*0FG`+;T!
M!&H";ADZM_`NV/ZQMA`-4%^&?;5._^.P:!%&=B(L5\R2%@[#$&2CGQN`4_Y!
MH@)_('DSF8R.IV-M(8+B((C3-$"@)D`%_*)?T2IH#TBF-X!`38`*2":#Z>5X
MZQU-:$W[<+P"IVB!@P'6:X#:80`JX!2U,3;>.K8/BF/.05F[242?M1:A[J=G
MWW;/=ZVK\$9$P9RZ9L6+,(C#2+@6_>8EMVT=JB'EMCX:V'D``3)J&XD<"B<W
M@W)\.!T='FU]9(>4V9JJW)-Z):`T<PTC*,U4Y$!IQEUX`*V!U@:($F@-R('6
MVCZ6W-_K&D/0V9.<58+%8`O!8F8C!Q;;8+]Q^RL"8#*=5*[#>X0='(]J7K?O
M(DQLO^L(`[@@ID?KH,IP;Z%%E>'6HKGV1I/Q4==`PXDQXUX*2-%TRPE2["VT
M(,66L-X^=2GX4%-U!!^:@!+X$-""#[7#^N5!Y]=(08A:WRT%#YIN+,&#O846
M/-CB9NGX9-(UT.#"OEZ(=<-TY@MKLMOZB:_.<,GC7LNQXVM+_)%Z)'SJ8&S9
M@6O9-[;GVR23'6IH)Z9/#+@4NQ&*_;66!H0Z;>'TU,`=JM.C=2K[YT2TO]H[
MF4Q'TY.3KH'>V,8.314UOW8$+@07]EL!P86]U][N2UF"!D&#`T0)-&@,M*#!
MWFOO(XZ!P8-:'P.#_D!_H#_0'^COH1W1H_VN@08%MG[Z^W/"1XS%<ZYWLXU\
M:N+X2W6@DT7R0->R5_[UYS3>N;+MQ>O3_.#S0QB=V[XX+TX]+^@U;_W0^?ZW
M__P/R_IK_H5SYUJXJ2\^7YZ%/GV3:W-Z-^(T(K%="4XR')\&[N]AX*SY^(+E
M:SN)%P;Q!;^Y>)'EN;^\^/!/,@+CP^D+RZ&!T4=?Q>4O+\[D7^D_D^GTGUE7
MSL*4'HAH]B6WO]MS<?JG%_\SOIJ';[WP2@0?`^>3F,]$],_)WOB`OCQ6/TRG
MXQ=_8V%L(7XIX<YF717X_=V#_:R<PE=Q(X*4NA$))[P*Z.6NE=)3D95<"\N^
MBH24N_7#2ZXM)1N+WB0_3:[I4VM.;[N.+4%?<JU/=N1<6]/QR&)QR=-Q^F'?
M(B6W[)B^Z?OAC]AZZ07T[3"-Z8'XU6NKG&CMSN<'I?T4F?#&AWMOE@=4FRY2
MD3/#^,N+/9JLPO?9])$1+7[/C*K\/3/7CN`I6QCGS+)*55G$XG7^PQLKL[Y[
M]1*_:\)'.F#[P\,'BWFHL;;!RU6<9Z'OU@E`SI7C1HK9=Y?ZN1PE@P"AGI%>
M$B*'+[H$9_HP.KW2EXL[Q**SWCR?ZZH!-*U%+3[UVH,YIJ4X_U[IECY<I.UU
M#(-0THB@F@3G#TG1BJ60<7H&0@.A]0Q`/14-A+:>T":=$MIXOZ7K:$/21-[R
M,TX'079ZX+25EL&8PICVUYAJ>XH+8]KJRF'NN:XOGO6V_;H3F-Z<KV?GFE8D
M?#L1KI6$^>EEY>0Y#%YOJV*H=Z]?W)D6Z4<0R*(?;)/V<(/^=:M_4*].4F>!
MILQ2$]"4@;"!IGH")&BJQ;5P9]&(&X&C>;&BKRJZEY>\5GAII8O+B)ZU+H7H
M>H\)GH5^F_.P;";<F6)_8?#NP'AT,.D\\07T1;L<%Z`5T(K.J(!6M(;G\+#S
MXN_0%J..6ML)TNS7FC,6,@8Z%M&-YVR?"AGU'_11LLYWUE#>P4SD)JU"UU\M
MI`4M*OMICY(FQ[)@-./M(AC-5.3`:,VPW-]^@Q9\II.^=7M^NW:!/>!Z1%WO
M41F52O.4I.CKHDN=;R$B@6;O=NV10;,-C*>CO8/#KG%&_DPSCIF-(D#]40(5
M&@,MJ+#_ZCL>[1UW'EP%*C0HE73U1G9EZ'P5>VU?.TUA_809J3M)?;W_B-37
MY]=>)$ZOD/CZ3N)K*9DM\EZ/K!\"F:\KA(',U\/*Y&O&`@"I@W1.+#HD?4'F
M:VVA0:+0(0"H9UXM$)3.!(74=<A\;2!,(+0A`*BGHH'0D*RU1YJ(S->Z(Z2Q
MK43F:QA3&-.:,47F:ZT1,N`Z]L8G,+T)!UB1^5H=7R+QM9Z`F7#7"1E%C80-
M&45[`B12OFP8X`V:ZAH0T!1@`TT-"TC05(M+X<Z"$3<"1_LD9$A\W0L=ZAR3
MH5DVO2]X#=X=.-B?Z`O0\+1%D_O((!60BLZH@%2TA@>DHA4<!IRS(NTUTEX/
M0,DZWU=#DE`SD4.2T(9)0D<'DZU]#Z0)U53CD/;:!)3`:$`.C-8^HYT<G70-
M(QC-_/-;)+Y&XFO#,#)C\QUY/WNW@X^\GZT<`XSV#K6]@H6\GWH=.8,*086@
M0LT0!16V1H4'DW'7.(,*D0+[P?<B!7:6`OO@,2FPO:NY?>J[D>=<GX71(KLM
MC938=U-BLZ20$OL!FX24V$B);>2"`#F%=,XX.B1]04IL;:%!!M$A`*AGPBT0
ME,X$A9QV2(EM($P@M"$`J*>B@="0Q;5'FHB4V+HCI+&M1$IL&%,8TYHQU38>
M"\:TU97#<R<&&60^;'EVV4X^[#X=QN@!F#Y^R:,BYA"#HQ]L2#3:$R"1"Z:C
M:&_0E%EJ`IHR$#;05$^`!$VUM0XVHRZ4[JG)PEO;3VYI*:P"?;=5'!37T,^8
M(;E_^ZAL?<'K6;*P#-X#F&Q_21G:TKT->VZ&!ZE`331`!:2B-3SCO4-]`1J>
MMNA^KHK\U\N(_>8Y(H@%EUAZ]$*S]\&8>D!FQE8:$H::B1P2AC9-&#HYV-KW
M&$"4EQXH:7(."T8SWBZ"T4Q%#HS6<"V]?0)L\)E.^M;A@2VR7[>7_?JIL\HC
MY:=!^^Y(^=F[S7ND_&QG'7XPV>L:9Z3\-..T&50(*@05:H8HJ+"M"*OCK7,X
M@`AU,K'(?5T=:J>YKS]2UR^]@";I;]24^S%(J"V/OGD:QR*Y)Z_UX3UYK7N>
MF?KB6EB.'46W9!S8YG"2ZO"2,T_'PO(*"<:6+65HV4TS3%=GQ98">WA./BA-
M))[N?>)I$TBB\_,P9.W1.6O/D!+NG#*_Z*PJ2*ZC'22P7K!>>L`#ZZ43&D@J
M/`0`]8QF`2?IS$E(<[DF2[Z%[,&Z8P6CV">48!2UA?"=<&3UR=PN(A&PUG#I
M?F%UX^WP81V4=KXT'E:`@1F8((FB@;`AB6)/@$32BPUC6T%370,"F@)LH*EA
M`0F::FNI:T:N7YV1.7O_]?W.>+QGT<,<)6DED;`3CE?EL,E3_]_7@OH4_;>]
M".,WL>5ZL;!CT76H-_P-LZ[-#,W>Z7WC!4Z"C'L^GHPGT!K=8.G^HB;(!>2B
M,RH@%ZWA&8\.]SM/"@!],>><M8/$P#K#I5:DDS4KTB]V]-T+XC!H:47:^]`B
M/4`U8UL.61;-1`Y9%I]MW3N`T#"-L.K^9!>\9KQU!*^9BAQXK6'RH>G6"V[P
MF4[Z-JSLP9J7YY$)A"V/N^5=>C('3)E`)\N?T_4^%Y(J]F`#'TD5>W<*@*2*
MFJS7D5Q14U/[S.MU$"((L=\*"$+LO_J.1\='G9^M@PH-RC/<3`A;YP+>*$7O
MNCR_[^<+/[P5XEQ$-YXCSJ]IVKRU8^&>A?.%"&*;<P:?^M2$_.GSY5?AA%<!
M]=[](B(OI.=B>I=8D0GXZ%DR`1_F\TBS1,`JJR^IKZ52V,;7G.,WD?L:<4*B
MVIFQF$E$I9PM\>="5B7V`L=/7?I4I@06+$>7/^#'`VG"[81^B1/Z1Z9_YO"$
M<"$BV4Q<AB]<1T)8<^KZ=6R)@%NL9Z^Q[,"5Z1KNR3Z,-,-(,XPTP[U-L5`5
ML,[92*KY?PX[S?\S?1B=7N7VN;C#(CKK#?+X;'.R]=2GD\C:J3L7:1MM8Q!*
M&A$4$M2MR=IIG)Z!T$!H/0-03T4#H9F0<;7I*<;@&0_9J75'2&-;N966P9C"
MF/;7F"*EM=8(Z1[DO?'12V_.Y.41L3QIS,XWX]==QU'H</"B!S@]B4I#G(M^
ML"%I:$^`1-X6/5&!INB'"9C*0-C`5#T!$DS5UK*WLXC#/EUC_BIB(<^=>?'K
MBAOAAPN.U^UZ)PE.A7Y;\#!J+=RG>I:\*(/W!,:CPY.QOA`-3U_,L&+#4A(S
M,!F:IH!9M(9G/-H[FNH+T?#T1?=3U0X26&N^YOQ5!"*R?;GDM-VY%WAQPO="
M;SJOG*1M0*8>P)FQOX9\GF8BAWR>33V0R>&D:Q@UCO32`R5]-`ZD9@A0(+7^
M(0=2:X;E\73KX&50FD[ZIF.IJ*=+4CTYVIT>:`S91:-L3EUO9R$M9P_VZ9&6
MLW>;_4C+V0;&D]')0><G!DC+:8R1!1L:`A38$&P(-MQX]_ID[ZAKG,&&YB>I
MWCHK=<L)I>MYJ\_L^/HT</F?]W^D'DUE3G[\P?:B?]A^*MYYL>.'<1J):A[J
MXWOR4&<-?PQN1"SK/%_<+L3IGUZ<?_*)D+S]9$??1?(A#=SXDYC/1%2FK;9<
MX7@$;/S+BYWI"RL-//66;__TXG!_,C[Z=O[NQ=_&1WO')_3:4F"-1]*"`$X>
M%D#1PMO;XL>_>R+BX/7;WSAPO2J4XI&/P2)-8OGY.)/,$"1ZM/=0:G-3!C)^
MSJG1E6349&,#>BZ<-/(2CTQ=10B3QQ@(,FMS$3F>[7^Q%R+:;JC3\7C_N#;4
M57W>;%33YX!VTE3KM173_L-B^F3_*XQX0/'GRW=BEM`4Y.F7W)8MUH<:+<+(
M3@0_6SZRW9`GT\GA8<M#/NA@9O1-AH>M3YMOY[^&-R(*6'O.%USF(1+N>TZA
MM(B\6,1M2&*\?[AW<-"R*.ZK\Z')=#)6MO?YKIMJP=[>_N%)R_U[%M=RLJ7:
M;S-@53OG?J_IN$7WC_X].*ASVMHN;-%3L_R[-D?>P*G3:68V'/HV3OYQ`T]P
MF^7:/C70W',[GG2UR#ENX.)IL?XU1J#W.9`FC:.!$]>J=>Q",`\P^'$#[VV+
M5=U&(YT>M;VJ.VZPYZ?#XK=K,35PW]I>N&TRY,GD>#QM=\@G]_ENFJQ6M)=A
M`Z_RF19HFTAB?#@]G(Y;%L6SNID#D^U]?NO&6L!8M=R_9_$K)]NJ_18#;K*P
M.FG1^9M,F-2>:@EX8I1[U^;`GW5'[O$3L^'0?_/LF>?+:?O`^!MX?TUM:'PU
M#\^H+2^X(O-)/\6>FY79S?MSNZ7)/)8Q*Z48[A_?MK)XEAVZZ78$9;AP:1:W
M9PN?J<?/LB$X[0"TXH%/PN9/V=OY/UYR_2T(9[&(;ICW5!<YX"1PJ%U5+/LK
MS\F(IN!;._;B8M[)MJJ2N\_3>^Q`GZ3S[<AGS1M4K,['P(FH.5JHJ'^K\GK`
M>ULJ_]Y,<#NM26ZC83WS3+O/K]Q08,\[QU9O49TF9W84W5(#=T;:X"1:ET"B
MI5$\<N`-7--[MI/JKS%IW(_:;7S6G?-VQ_VH&,2U>.LQ[`<\C@8.J"93_2D.
M&2;C!AN.>D#_\-KSQO9\IHD/871N5[<13N=AE'`(+P?O5@??P-W\&'#(M*2:
MM[=G=B*NPNA6K1NR%]Q6)5)T@KX5USKQW*%HD_I^5T/I/%JDC:(5GT2D7<=P
M=2/O1J?G.LC[N8*<#B>=X-!@M[5M'+8(Z]C?[T0X#VS*;AJ1-)UV,HI&7K$N
M;+'AV>WXH!.1-G*X=;!>;1]Z3KMABT:.O@[R?JY3P:-N<&BTZFB=+38\"*$?
MNQ#.I,5M:S[".SEYTE$X3CI/?<+'_34*X_A;$`G;YU9^M;W@+<,A+NP_J^/K
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MG"99<N'W=A1XP57\140R$_'I/$R#:BS$?@,/^)'O?'N[NH&J;3CG&D*?%]Q`
MU7%;-P\__OZAAD#,[XE?_.WHD%"M*5D;XGIB!!IXQ5TA4*I`8P2FO%8]?!($
M^+KLZ]]3[ARGS8X%W\C\$H57D3VO"O0!'[LRJ/$#@Z(79NV3"?_KS_=UH#Y)
M\@_)4WC'-T+#!6OY:139P96\><;7?B/;22Y"&BG3*+&`-!AQ-4\X2T.XE;$=
M-/#)SUABY&O847+[NST7Q57CMUYX)8*/@;,2X"59[!S<MTC:J^]&MCK<"MBG
M5U>1N"+/XM1U/7["]K]2^T$JLJSI<KIZ/EG1,!"?1'(=NMD#I\ZU1S_5A-?`
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M>EOMB(P/)O7MT+4]WV*`3^>0-1^@/)EK/CXY7?-YFCV1/2#-1MWHK-"JPY:=
MKBU1S4(;MQM.6Z)HTU/;%O_]R>,ED<^=W)59-=?;=*VVA7VZ=U`_AU[N<//A
MM.SM;`7=>.]XNL%P5GNB[U5][^K8VG1CGF\!<<^,N(^V&FV"9$+:4IYM>D;/
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MIIOL6<@'ORTN(^I?1C<?1`VA1SDP#W7^A%O*?M@B,G5U[YN.[%'NS+TC:WV;
M^\XXXD?*<'PP;B##7"5DV/C'.$Z%^R[E(AFJ@HC,H_Z[^"$_J>XYWEL^K>^B
MW3]9,BB-I-=(X#)8/EXI\4>Y<MNKZ;H;`H?3P_%T^J`,E@94=>=JZ\^8S:^3
M"#?;Y%D.+FQ2#$Z'"9<UMKR1P*:Y/NT:S[:#FBUL(+7-5T9-*LUM/;>V\TV*
M46^V5')3A]:_F8SLI#;(1[F2VP^R[EDNTDB\^-O>[GCOH%@)+'>ZNH%9[.95
MMI;S/>5U>VS3>PNZM3#4YC!.ZK-W@^%L%GP\;5(1[DFF\*-#D1_:-IS>6[+M
M*8=VSSW8I?7=O7N):\?UE([GMO%4AXW'E1FDN^9T>F_ELVX`VY\LQ;TM];[Q
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MV$:.U1V(($AMGW=-OPJ92O0B7"GNQRP,[A?WG8`]+Z@$[&D%RO)FZ=VMD'PC
MY!ZI;B'\QRQ=-A1^+5K2&.%/:RK14/KTP+LZ73YF%66V39D<U-*=*-'4K+54
MRL*6BU+&YPMZP:7GD,W_'@;%R4!5KH]9M.DJU[]]&8__W\(&;RJ=M3&8^<NS
MF<LER&).9*A6&W%5JH]9I.DBU<=MO6XDNA9$?F]).F-$?L]Z^$E$_O"V8Y-2
M>/K+];$1NUONV3:I8:>_\+:=E/<*3\[87ZF[R8<T<,GX+J?UFS8I,-=>J,*9
M[7OT>>#9'X,X\9(TX;2B7\65"`1KU(WX)%S/\8(R\\^6T2'[M4L9=T50D4]^
MQER_A:&6;]RY58.O2K#!0JQS"38_EYY4Y;:-:"J2E5/\\V4^N*K0&BRG.A=:
M==K][<M^[NPLC:IV'2?3[7>UH_EID_)OG8[VSKU!'O?.>&]G.B[NWU2&MO(R
M!6]U2#VK.0P-5A0F4=2=L6X@B@:+`),(9XTH'N=?-G#I-9DN#Y]/=>*AWULC
M3:]9=L^MTS8D>*_;TZ2J6K<6>7_O(!?<07/V/FSL]:SGYB8%S;22S4/<W,0Z
M-ZD&IA5%/R=UW5O=2POAZ$AF38J(:3NEGM@X;RU3[3WI;8,MGI#KFNSJVPLO
M4;7SY&L^7WX+U$WP+U&X$-%R,GQZ"?WMWUE1E>R9V\]Y(J,'<F]I`=0T)Y'I
M!@1[N-\&P38Y#A@\(*VP>I,C@N%)>BN[?W0G[&YK?Z))R;8!PK+=[<]FL#R*
M=9M4BAL@7H]2HT[<IR;%Z08(Y*,4[[&G@A\#5UQZ]`[Q&^^K?PP2&C/G*SHE
M0269J,G!^#4,W1^>[U?A;%3][M[FW][*JH%G#$LI0Q&)SX'X.WDVD7"IYQ<B
MN(B$+6N`?;X\]?]]+;RYB.Y4:=BR$MNF(FA/@`T6ML\JP,UJ*RX56^].C(W*
M9;<AQA\DO]N*)+_8T7<OB,/`_*G8J'+V\\IPH]*14UTFXWW+W:XFQJGOAPYS
M@2IT1U)V:\DC[]Q`:5)N[V/@A'-QGE"[C.1OH<H/6-V=O_?JQF-+#!R>+%5V
M;33(QPJFP9*N/<%L><OR:/K\@FE2<Z^!8'Z5?I)/<CEUYS3?XT1Y32W-F<GA
MI`/1-*ITW9YHMIHUQ]/]#B1SWX)@Z]O3)P==S/_[G.&M5?ED[VB[H?SUYS]G
M$;/`_P]02P,$%`````@`#(2<1HM-P[)?"P``B)(``!4`'`!S9VUO+3(P,34P
M,S,Q7V-A;"YX;6Q55`D``UCN/U58[C]5=7@+``$$)0X```0Y`0``[5W_;^HX
M$O_]I/L?<JQTVM4)"/WRKJU>;T6A?5NIW5:T;V]_>W(3`]9S8M9.6MB__L8)
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MOOID]SXU;3MZ>W1\#"\[I_;Q*N=L,N-D-`ZL'YV?(I:M04O^ZS/?QY3BF?5/
MZXGY`I[T)LB?M:PNI=9`-A'6``O,7[';FE.D"PQA8'QQV5C!;_K":8OQ4?O(
MMH_;BP<;\9,74T'6GGX[7CS;:?]^?_?DC+&'FL07`0Q"TDJ226O7.3\_;T??
MPJ."7(BH_1USHE$JP)>5^81\UUP\UI0?-3M'S>-.:RK<!F!@69\YHWB`AU;$
MP$4PF^#+AB#>A$K&H\_&'`_ALY''FD?1B,3M?WC&\!2HT%W$N:3S=7"[QJY`
M_@AY+%+`1=.V?+"]WK:]SDIA4@&:,I]YLYCF4P`$Y5SH,=_%OL`NO!",$A<^
M=Z\0E:/Q-,8X$-M$&P"];R7HK<,W%\M!U`EI-)A2W+5'\33`0-Q=$)""Z)0[
MX@AXHLQ9@V#>8Z0]0R1>(A4"HS1":"+[/6EC&HC%)Q*LDZ;=F6O2#_./OST$
M8\R[0D!/O9!S8&D=&"IUFO'%AQ2]8!K9OLS6;;T,@TD(.'$`IAX2XZX?_7?]
M1TA>$87^13?H(<YG8*)_0S3$*M(HD]8LZB/'$T3<Z^E$JDB)X<D@H)GMKN.P
M$.`:8`<#="\4_XJ#$MSGT]$LQ*T?8`[ZD'1>0H(<(KK'X!41*CN\8?P)M/<)
M.R$G`<%E9GD!8IK%V?E4/XP)OF(^?V6^4\G^KA+0S/87QMPW0JD*ITD;[1/7
MQ>!+$^FH@.<(4Q"68P+*&\-T/75H*!WX,D*HT]:^0K`)YL'L$1R&`/19ZO)$
M^A5@*=46BCPZ>[-5Y29%,7JZA2KK4M7K3<6]J?.GG;$^'F*`P!W@5^R'91;?
M+`J9C+_?4\A/OET+A[.W.X)>""7!K`@+Z>WTNUT\Q.XU;&38#.,K[(.M*J>"
M6RC5Y#\^HIF<Q6".Y@PML"SIQ:B0K4F[G]%TI?=RYFX[+<W"7(6"^%B('O->
MB!]MFF$W&\`Z&&]P!7$QG^^EYY.AG*05.ZK78E4;S!0BFMFO-KGV,(=@]H:>
M#-)@-W*#9?R0XS'L=,$WN_4=YN$[)@1X,`]#F!N*ID*-M/:81X!`\]UKQ'W0
M=K'"'R@,<8C26!6AIGOL7)?(>8KH(R+@1_?0A`2(`LX>\Y\"YGQ7&JX"U'1O
M4).^U/>B[]IJ9C;J:LPH6$LA/?UB3DU>ZQK0)8$7;=%]=VGS';`VJD!GDJG/
MO):TJW6R"/!44Y+MM);"K,3:N]Q9ZP-Q9T$?7KX+M*\?G,R?:(O0\R)J3=BG
M>XOV0\X\%?;F;+",H6`<'KYLR&,ONV7;#6O""8--YNRR<=2P0@&,LDELDQK6
M&Y:G6=$!HFV@X+G3)@'BZ,,#D?94(O^Q4?(7'_KUI2F1]^0#REO$DT@0./V`
M"!1Q#A,$/GU`!)2=_P2.?QL%1YI+DK[>+;=TB:AG'TG4G%UW(O'Y1Y*X8BAE
MB0K@\H%0V1Y*2P0WUN_;C.ZLF[[B(=($"F,]OWPH<F/@B?1F^7WYTJ<?7"2R
MFN7S%1OIK'.B1&JS_+R-(SVV^4V*@&:Y<3D"%CKY3>0VRU_+ECO_^#Z1URRG
M+5M>]3R,!`.SW+AL#%)D.S++&<N6+2.M*1'4+.<K/1=D-<Q2+!LMD=\LCVNK
M_`42#!/9S?*WMLJ>DR.:R&R6W[5]O',S>Q.Q372\<L3.2,=.Y#71#\N15SF?
M/D'"1,\L!XFT>Q*)L"7=LL_MC6LJ-5S)67XK'H8/DWF(:!=W<_()'^`EG0R&
M=2>"1'O4&]"^+QQ\?:6SY)3&JKF0/4:!*(N%[8XXCA$HG!.9V5YWQCKV882H
M#&BY'FP<P"XA>4]S;HI54-Q*2O_])PRV29K3/@PH9=%&KX0@6PCIOOH03QE_
M-.]029-3&FM'/9H[9>:;?N86+B2,9+30Q(=4*JQF4:A+"9)CM5)JL-I<.]:R
MJV<TG:O>/#"L!G8&B5I8ERC))2`^[@D!O63UNL)#QO&2/RRNIV#=P%$A/N*S
M6UCOHOTXM(0%DD;`QWJC+KXF-C1#"-N4<JJZT7"OWFJZ$*RF$3(U<ZH@:BG3
MNE2*5/,`1*[#8+`MYMS4_*J:L<M:P$U-U\KS#%B:BV5J5E9!05,\WE)96(=@
M5K)=?U9X=V)JSE4AV;=N,4U-PWJWBV+;X@*FIE^E29H3AZF<3[7O6.!:DN2J
M$=M12#"3_H%'!M_S74-%B92,U:\^QXB2/['["Z/1T3@BON3GP4\.V[J<"/BJ
M#V_]T2,&%73+W)[3QX-INSMMMZ$VH2TS3+ED]FH\BPC(,M$W=8.I*+6^65;Y
M2L_>%R,DQC>4O>U\$=JD>^B+SY)?[8%%T#F!^SC^_];?R*E4#`]N(Z8_3KK!
MP2(+>("C:R$E[W*JT:U=R"+)W]7$+=9#[8+/TS(6:C;?92TB*>H5<LKVL+<1
M3])P=C.^J_3V(914J?=I58HEL50IUU1=9`?G3UM)Z1XS#R8#EVO4PW`S=3?)
M[*4RL[=:M;9*_1Q,T9PNY\!ZO*;WQO(EJ*(G)YK<7N;?V>JHX%4;2[K+6XP1
MQU<H<HP\J=D1`RI(9%&HH8(7CO#U&`_(GU&O#T-93#RRJ[!@P$KBD=`#_7T%
M$U0X^:9J#]J-&^QB'!)Q`Z]IS"*X!RM<JEFX(O3^'TV0O8$S%@WR,^LZ?X2$
MX\S+)"HRJ%#57R/3P=B-SN%D<CET?H\"N1&>/0SO$?^.`[F()YMC)3G5B=<]
MGI5%+$:PQE&\%2*4!=*C\&J9@E$%B-4T2O.=WS,#-^R_)!B/XYB-O`=1>14K
MWX=J6BA8K#1('\,72IR'(;B;T%_A)-&"U/2;;QD_`4Y>P8EQKV9?A729;^*?
MZ?!'T0]]Q'=44@[W%>U]I9[V`T3L']0!1.&>]@/$\DA7.Q"%>]I+-?8XC+RY
M;58ZD5"BN]]@?1D(V.Y&V-A##CVX%381II8KTX1;X37&U#2\':WB3,TU,37K
M;G=H5?=!2R7T'4)ZFP80MV]73"W)MB/G,D7CMFQ72R40'K!Z54%,/89A:@)B
M#>J6$^@JE<QXP#JGNO,ID+-C6#VYW0-3+'1M:AFZW>-5]D2C5/6ZCSD7MWI@
MAI6XVSU"M9V,FEII;_>05SN\-[5VGX[U9$NRAZE5`#6HG&+&3ZDZ@A]S"2F6
M"U:J$.%?!;!B.8*EZAC^52`LEE]J:KG$.A#,2T@VM?IB';B]2U&O7*I1SQT*
MN2VB3(0<WX!W%55=NP<)X+WTM)XDFGSV,$S[<GZ?8+5\6V;5QM6?B<EP=OOR
M=R:6Z9RY%S0.E>F]W/XX.##T'C5735[:2ZY2^F'=<DB2(:Q^.)Y*M);?#*XH
M3@Z1`RCEF"?<UKJ]J8U-/;!7PF/;8<&!KH5I;#\Y8^R&%,OHPS)L6&K1*DE]
MSZN+*M>:34[F0J5D<W*HZ+:9V2MM\G-37S@3(KF_*X]&XB)!JC]?6[VS`X1#
MWF.N#8Z-SO8'1WRJ(4/S:E7V"I/<[^JB*'BAFO&%1W6Q,'5.#4LQJ1FV#=N0
MP&96Q%@+:JMPE"Q%E>;>?&Y+'EZ0P/#F?U!+`P04````"``,A)Q&-C,7TL<4
M``"R:0$`%0`<`'-G;6\M,C`Q-3`S,S%?9&5F+GAM;%54"0`#6.X_55CN/U5U
M>`L``00E#@``!#D!``#M76UOXSB2_G[`_@=?!CCL8N'$3CJ9I#%]"^>M-T"Z
M$R3IO?W68"3:YK0D>BDI'?>OOZ(LBWZ1+%(2)=I68X");;%8]8@LDE4/R3_^
M\>XZG3?,?$*]3P?]P]Y!!WL6M8DW^G00^EWD6X0<_.-___)??_QWM]MY>KKN
M#*R`O.%KXEL.]4.&__K\Y6^=?U\^W7?NB??C%?FX<TVMT,5>T.EVQD$P^7AT
M]//GS\,A\9!G$>0<,F8?6M0]ZG2[<\E7#*,`E.A<HP!WHG\?.\>]_FFW]Z%[
M?/[2/_]XVO_8/SV\.#\^[5_T_][K?>SU%@3\:V9$9^$?"#CL'7XX7'SL$5D_
MT`AW[JX7'KNYO1S<7EQ=7U[=G/=.;\_/SWH7O7ZOU[\]N3SK79UU>[WHX_')
M"?S9/^V=+&I.)U-&1N.@\U?K;Y'*G:=#_M\U]3SL.'C:^9_.,_5\>-*=(&]Z
MV!DX3N>)%_$[3]C'[`W;A[%$9XXAO!C/_W2P@-_[*W,.*1L='?=Z)T?S!P]F
M3WY\]\G2TS]/YL_VC_[]Y?[9&F,7=8GG!_`21"DN)JU<_^+BXBCZ-7D4JK>#
MY-E%;4Z/9C_"HS[YZ$=5W5,K>J$2)G0RG^"?NO/'NORK;O^X>](_?/?M`X"K
MT_D#,8M1!S_A82=2]V,PG>!/!SYQ)PXW,_INS/`P4Y&Y]ES^*9?\&W*<@TXL
M^-O3W;K-Q`N.;.(>Q<\<106.]"D$=6&/-^^NC8<H=`(U]5**UZ,L=1'Q"NL:
ME]:I:E1%U\7N*V:*>BX7U:CD&$0P*WS%W00;-553!<0*RVKKCUS:/8Y\WZS[
M_?:"X2EPUO>1CUA5AIOE(V^$7!JY^GG1HTBCY;(KJDB+"M`[]:@[G<D4(](7
M]"=E5Z$?4!<&A4?$`@_^/R83?^#9SP&#BD?$`B=,N"OT7]"K@_T\<Y^@CN\5
MU;$,<VP^=$WB$>XR.2I+3^+W`'LVMN?EN;UUPQ,I"6HZU$IKQE'C&R+_-6J!
M,',8(33ANGPXPD[@S[_AF'[H]OJQ#_\M_OH['Y[LT,$/PROJ..B5@A8PRQ@P
M!I9A/I?@RGVE,#=)__D%_O*1Q>&;:?P"H%V"LC^607?XL$39_$N0A9UHIJ-?
MC:,L"-<;&__F^S,9N6C@V(Q8XRO*)E%MU/L2>YQ\JV2D*"LU)@P/1JI*+)=2
MK?22T!'V[CQ+L=JU<ID55].*G_`D9-88YBJ#$<-1@[BBH1=@-H%>-OV*7'P=
M#VKR;5):Z/?C'3=0NWFKU0[>B:]B27IYS4H+G\77$C#FC\%%7>,W[-`)QW+!
M.UU1#]R[%;S01\R&E+FWE#T$8_#^D:\JYBG+UZJ]T196$$9B?!=@5ZD55%-?
M`HJ8%PR8M:0&5#)7(9[J2:Y49F6&C+I5:QVK1_4T%,ILS#X=\*5X[[#7.^A,
M&*&,!--/!^#[0A_LIQ..%.)&1M/HCQ8(A3'XQHFJ@($!C_@?XG>8%&'[TT'`
M0JP-]=09>-I;T-"9:9Y_$JA^R$=5$T`I*]0T>#8Z:%IPS!3VGYE@_]+XJ=E\
M0XQ?7DJG>R?5B0?-F@,*B\]WT^*5R79B;_]D1^W=O,(1]AO^OG6/OQJ6M`FV
MQQ(#<ASG.%H.=%0<^[E%A/T+.2'^@A'_S"UX#ET7L>G#,.U''X!!_OCF/R%Y
M0TX$QQLB#C<4`'Z&KYZQ%8)-!'.@^%L@@$ST/GP"YJ.9)>B5.&#X-0Z@M&(P
MR2REFXU.&8*%WB7)O#90*3%)0*"RV,B3I'EM-?!]')2U88,0S>I_0>P'O._7
MQ3:BHGEZ>=U1"FCMO"$O-_J2[T!!J&KT+J_'*0;U9,5ICQ6Y+JSI"'(>$2SN
MY(W($:"[Q5,/3V?-]C;T;%]=[RP)FA6_\]ZP'T03$E#RBB<I8*;Q2S$D+B^M
MAFAJW2;5;)!J]#2MM&:%$_]VYTW"P+_G$^\3=>@WBFG`A.-J3#ANT(1^-2;T
MZS9A<6*:?/E/`H,4K.VFZLD1)<$U^"PS#*W/S,OIN@Y1RU+U;K(2-1OV[?DS
M?</,BY95$YA`48;MFRC,PHB/_6O\&HBYK'HG+"9?^UQM%A7"9:W+$:1]M?(G
M97QLA"4O5P#FZWRN'DR%)NK]3EIH#<ZE60--,$_5JTB+K,M?SM;RH,9"8"+V
MZ/:#]\2U8K!ZFX4<V?SC)?*)>@ZZPDJW`)Y"N>B**ZX[*:T'-ZJE"8F\DD2>
M92N3T]5W<EK`DQF1L91+5ZLZ?#4XTC+8#::XI#+8=2!B"![Y*3_UZ0Z5GHJ*
MK&=O9R$HMM80R!PWAHP9+E=V26H$@T#.XRJNV]/`D`VT"%1.34!E@].M"11#
M(,EW.L5B6&FPI$4:!0B_[QT(Q^L@7.P=""=K(,BS8W9TI$E+[0ATFAN')4>5
M#7FM3".S<HK";"/8MAN&C:JL-L3F?&^@D(]=7)=DY,.%T48S:XL9G4%>$#;O
MWL)+B7R2`'&R'9,`7?$U!5I1`MFIT?U%.V3IG+($G7.CU_/:T=G`%9Q#U#?;
M^6B'*(\2.L?I^,04TG9:DQ>\=3%"^878U06E-[U)7TUIS33?3$:U$L]W@Q3=
M/.5L2KAEA6[(#Z.P/S/J^]^@JR&'_,+V/7RZQ$/*\`MZK\9.Z<H,A.,S.+;:
MX%BIK#DX7,H"KM`5]8.*C%X6N:]D<9WF#8(KQ-@41LM(G_*FK0FLJT%"#_"7
M6H\Z9RE?EF9CHDUJ+V/D\5-_*$-L>N=.H*U$F]I@KD,"[ORP#S,>.O)XS[CS
M;A#S`&U_OA[E*[7%04^9!:1-B1IH4;L-8`VL=+Y;,EJG7TYC5::SA7_<%Z;J
M5'5)D>TFE"ROO>!="ZB=+J#=.]-N-#%SHTE+NVYIURTKN6Y6L@B89"_'2IQ\
ME2O4`//6(X45F7C?'"NXF-VI9V+DOL)].G)*MI.48^V:GO:NFZ)J=+:K%HKJ
M#K-TRU)4FTOVU>,_-A*#C"=6:F#(F$T:U,20,9LD6)`ADQZB,($3V!PKJ#G^
M>%WN3#(N*/A!#=(Y9,F/:N'3!3BT!MT%A$;P1S<.$^8A:`A^^9Y(?_)CD5V4
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M>_F!7P(@F9EI$>FJ5YT,1B.&1P"H`%&VVA=ZN5#U@S>P+#P)^!N!*=!DXA`K
M>A$R%M>FBBH\7T/N(T%(HM)G[,$,C8UP(+7*D)%25*DRJE2BP!U_)^4@21-1
MN`V7`6:SD$8N_+UYG\"$3FF]GR-(LQG7>(@9P_->J:+X6E'51A`WI#D`+YBY
MT.'F%S-*-X,\,;H;`ITB)Y@6`'"UI/J=5\EEBC#+Y$=\6+S-)*;[\W[QR*@=
M6H$/?I71-VQ_@W&?J0-=67VJAB8CR".:1A7!P(%A*BHU-.=)**R,&.E`DFR4
M+U=$C;.!&X>,"+]KD\9HU#'NIU1:H\D#:TRP2L.II"YS[Y[GRS;HPU&/YJLV
MU=ENI147G=/,U0"W,V+(59[0K)77OAGNG;BA6V!G[W)!W<V*OT5U)1>*U9"W
M*Z]D/2JJYLX6"JEVBY6KN24[PTHIU4JC7@T=Z$]LJ>RUSRZK;#6Q?CCX"CO.
M-8'N["LTBLWE516YQ`%Z&2,'^3YV"5)4(Z.TN2,(I^ZKI\@KJ;`.][*5P)@,
MR^6TR&D*%56HW)<)'6'OSK-4>_%J.>WO8Q(".FAA,7;%0^Z831`+IL5H+`I"
MM9_QL%RM:NM)+U\;@Z1,GR[.'BE?J[E.9#U9I=>'W#?'&*D4I52V2/F&LD],
MD<HZ,\WS3X;1.S80%#;Z9UIH1-D2BH'ZP$NSI@@FT`P,Z0\5S?;$EF`C]OAO
MXD=5.Z&N!LKEA98`L\'#`Z2\D=E8&H*DC&NK<NE+-\<W!"9&G]*@!Y/,T)/8
M!VST.0YZ4$F-"B:(?##Z\K?BTX*5,*RXKZ0Y7V'*I$!$Q!-4SHR@[FX<V->"
M_ZLFI=S:=6;Z#;NR5AEBDT2'34DC+9VYMI1X2XR2WQ*[97XY-72P.6F:[,#O
M&>Z:]<13*LZ%)V@V>(%P4TVL$LZ%`-!LQV,8@"GTG"TY:T0+DIN86@DN31ZO
MU30NZWRZ!)8/^]?Q*F-()B">[E6?RV+&BM-]]J^KY=&;!3:[&CK9V%366.@)
M'K^W\]#U[00).N=[Y5@D]HN(8[&:.T"TZ45=VM8>@<M>^9?LK5<)($T>'=TP
M(!G;XA)HS#YXV+1%E_1>R`3?_9I;E]E=*XZOD^ZM9NTYCVU:.'MV>;%0Q_9S
M-1VV:B>ZI&FZ"8ZS_N`7V$6X7E8S;R]>U!;1=:VH*B%W[EF>,7L#6;&<Z(TM
MK[V5-S<6D+S]&TLK;1"\>\W`*]$TTH1HYZ'./,#@U8\ZDAJG=+6L^KZ5D8L&
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M3Q>K_'2Q!E.*.W8@UJZ>=;#AF*/L9:J`95>WZJ7#(A5.$.`8[L\;W!'<^[!_
M.QE38GHB7;R7W`_)L*M(/.^J$RZ"TEK07:2P]PHF^71+`M#Y7@&D0D:ZV"MD
M,A.?XL"P_<-#*4&]SV>!R1PTM+/+AHV>1O:@CY,MW?>\1.VYIC_A,_4M@OEO
M=]ZC@P#$$2-6Z`0@W`S6515J;B__JI3UN[MG.9W&^H0=P-*^HG[`H8W[K?SE
MQXI2U2EB'C_Q]#E\=>8S&B]$#H]//,.TCPR)!9[X!_62J;("=TQ=M*KZ(.Q:
M[C4O/:[,74LTCX%_H07(:AN%E.7V02M8GK?SP^?P&Z&AKZYJ,>&J)L!+AW81
MH!$/`$?B"?875QFW,,`FS0=:B;3^!21O_R;_K!L;/?Q"7"PB)?+WOVXNOY\<
MJBVYU#5VO@747"[87NNJ[5K7'>#T-4[H:(ETVT^DBY<3S_%R0I%`EU&Z)<ZU
MQ+F6.-<2YUKB7$N<6W\7+7%N_XAS&1.%EC"GC3#7Y$'2NT68Z^_J,<M5,,/Z
MS;&?3.FX*5?FG328+-5UM]R)V03)G+OEE@-KPBBSQ]MB%^:=&'[<5I-LS=/]
M8VMFYA"VYHB?>N\_ZIT9?MB3AC92(&=7X)RAG8&K6(I6(&;XL5,ZN'@;\^^"
MSVKV>*P#F3DM0C!7]V_X+L)6$<Q6LR>F^J]`S.4E"6[K7LU^,LEE@M2ZI4?D
M72&'@/T>07>>'Y`@##!`\81'&(I!HWB#58--+`"E,<IFI2IN%5VS&LMWBO]8
MZ1TB?"KZ&7Q"H)@/6RNL3$1,KBM2.8YNI91JI5'8[6$X=WW2U:Z54ZUXOO-H
M^?JTV6*`-^<T7RVM73'AJB9$+_HV]&R8-@Q<GJF05C"MJ/)=*]"37\;(0;Z/
M78)4;UQ)+ZVYCSTR^B>\&74.TU+![\=;HJA^,@>:D``&A%^QOWP8?O-FMU&#
M'A/,^#K[YMUR0GNVQH:V!M_]BASNY31^9OK`8JV5N2`ZJM]E4EW6\"H]IBOV
M<G7!YO)46C[@%O$!6]I72_MJ:5\M[6M["2ZF\\2VAN!B.NE,QXE0ZO,N$[AJ
M+1_(?#^G9<DEN!T-1O"%U\-#%#I!.KHZ5[QT0[Q!0-1@^EZ.0-P`0H;@D^^_
MTN,Z='-03-BV?YGUM$BE8/;LZM">C4>QT/*>GLR6GBH08.SJ5"<;C)5TC>#L
M[!7+8$/63'!U]HI,4(9WT;LPA6=PYP7P.(&IZP!&T,"_0HQ-8>"(#JI\&(J?
M_=GOA9@"Y2II-M=?4'>]0<0[+[8?W_-A;%7'V5P1E/Q,J?V3."M0;@X8JLM6
MSIU@AA\\_$^8HC!L0P=Y^0F=9OK",`IX]WD8/B+V@W@^]>`]8.0KYU`*5U#>
M%.PM5#-P?HTQ+`%8579(2=<<P<YI(#-R#)^0%]MW7T!\#=EE\XQNVN3+J=!*
M-9>E++JVK-7`^D](&%=)6L,2V:KBM6D&1%*Q0ADI==EU9Y\*6Y^::2K^DO<I
MPU2ZX]$2[L6P'-*F:&I1KRP/3]8(:T1Z2"J>V@Q&AB"4OQ(N,Y>AY::F6Y(S
MTX.0[")$Y,Z,OCJCBE%2?;%9(+&H.80276)Q">_/OJ(NC_1$P:#T;^-04*$H
M2NEZF@VD%%=?\U37B::K>';K2)8J2A-<28G:CXU;#C\.7GWI'0/Y,C0K_SFB
M73A0]<!VH8'R:CD)(U9$G?TK*;`1]E]AHZ3$:0\30/>'W@T-GE=^SQ7FNY8*
MQ$`V"*HEQ%.'(4V9H1ZBV2"FMG#,#8Q5=(IQ?*U/ND.-_2W\Q0D\%AUYG$DQ
MVQ8<.;`2$9I*%=`,6S6Z%HKI5%YUW2$?7=BE1H0J;53[%"32X0ZHI,_;JAA1
M_A"0;_9V1GZJL]P0NV6B%3(3%]E+K+8N5*-HO.1"8$N",#6,6]EK0!-(WA(8
MY2Z$J?K:7=R$7(;)\\<15^`5:H$/_P]02P,$%`````@`#(2<1EVY895;/0``
M3U,#`!4`'`!S9VUO+3(P,34P,S,Q7VQA8BYX;6Q55`D``UCN/U58[C]5=7@+
M``$$)0X```0Y`0``[7W[;^2XT>#O!]S_P)L<@EV</6//[.[M;!X?VJ^)\7G&
M/MN3?,'B$,@2VU:6+78DM<>=O_[XU*OU("E28AL7))FVW:HJU8MD5;'JC__Q
MLD+@&:99C),_O3E^>_0&P"3$49P\_NG-)CL,LC".WX`L#Y(H0#B!?WJSA=F;
M__CS?_]O?_P?AX?@]O8,+,(\?H9G<18BG&U2^-W=Y^_!?YW<7H&K./GM(<@@
M.,/A9@63'!R"ISQ?__+NW;=OW]XNXR1(PCA`;],T>AOBU3MP>"@AGZ8PR`E5
MX"S((6#_^06\/SK^\?#HA\/W/]\?__S+C\>_'/_X]N//[W\\_GC\OXZ.?CDZ
MJ@#X*W\K4/D/`?#VZ.T/;ZM?NPG"WX)'""[/*E\[OSA97'P\/3LY/?_YZ,>+
MGW_^Z>CCT?'1T?'%AY.?CDY_.CPZ8C^^__"!?#S^\>A#E7*\WJ;QXU,.O@N_
M9R2#V[?TOV<X22!"<`M^#^YPDI%OKM9!LGT+%@B!6_I(!FYA!M-G&+T5$)'D
M(9%4DOWI385_+P\I>HO3QW?OCXX^O)-??,._^0O]6>/K+SO?__:!??OXX\>/
M[]A?BZ]F<=L7"=CC=__U^>HN?(*KX#!.J-:$%$$6_Y*Q7U[AD`E5@2[0^0WZ
MTZ'\VB']U>'Q^\,/QV]?LN@-81D`?TPQ@K=P">B_7V\O.]%]?$>_\2Z!CT3)
MHJO@`2)"+H7]RU,*E^W/H32M/49)^$A)./Z)DO"[-FCY=DU,)XM7:T08\FX,
ME5]@;I?0)D"+M-[`-,;1>6*9M>U@K=-]EP>I95YW`;9(^SWQ>]`NU;L@;=*+
M\P!9IG<'I!UZ#90AWR510?*(?H.NGN)+%%B/SV2XA(>N`(4O.4PB*)PB!8O#
M-MH9L`R&;Q_Q\[L(Q@3H\0_TPR']<'AT+)SK[\BO_G&>Y'&^/26+>1J@2P+^
MY3_AMHX742^/4_E+]C)_>M/S\+N"0/I5NLJ0A^@.!":'7^]4X?P#/32XFL(,
M;U*V!"FS,2]U_<\<#1!X`$,$"*8_OF.TU*A>I&$-=Y"&$BWY.(!9?.-=B,F"
MN<X/455#EBE>];)/H,6#O'G7I0C9XPI389.-C!`U_<T_Y+9MD40<ZF6RQ.F*
M+>&+AXP@"',5T6L`TU(%9;AV5",2F!CH-W\N-K5D;TQVS4Q5XA+WVSFT1%]L
M6)N-/HN(LZ04#<$(A!57<()?)=;_VQ22!0\ID=^3MU!UC/5GM/UA]7'[;K#@
M)@4_E^]KY2KN>GT/.-A4Q3;F6="V!0$>4007*'A45;?&0]K<JCUO7^$*\(#"
MGTOCVCF+.SG@`Q>1"@,M^KCB)$:C-+K.KO&PL<W6X#AT?QP/64\B%I2:VQ.V
M\QX/\L8G/C>=Y`"++6KN19R%`?H[#-(+\IM,5W=W'C?F:@.20_WEF`!%!1BN
MN36X2P98@4-^\;NIQX.LMJ[)W')&Z'(-P$CN5F"YUV?A,SS2Z#99M.KT#I]\
MXWN'7O>QW()FWZ<!S4#=;5</&*EJ<^,A;4[6GK>OM0(\X/#GTM-VSN).#OC`
M1:3"0&N1S5OX&-/80))_"5;*6]KV9PWCFG4PSL*:)1I`\<P;U.Q@.Q[BBT<L
M1KK<G3?072=W,,9MP<!.-VE:VX!IGAN[G]?6@BY0]HU-8*KM".<^00X*`JMP
MR3.F(WU^6ULT+F($TU."X1&GFLFPQJ.&_JP&Q=F*P;``B6;>!:.=Y7B`*?ZP
M%VEPUE[:%J]6.+G+<?C;W5-`R+[>Y*RVBVRL-'.XO9!,$[H]0-UE=QE2P+`>
M`(X75!#/G.Q5D1C68Z*WTD&=@E&0BUI*^SPCS/]V%0</,2)(E+/7.\_I9T$;
M()SDI#D.@"22^9+078S&?=SH+%"HNKQED#TP>C;9X6,0K+G?@RC/Y&^:#E#\
M^A]WA$V0<NMZ>2%K3V]P%NO6,^C!T](4'=!6C:Y`"*Z7H$`)),Z>E/D4*F4D
M06S"3L<JN,@RF&<FRM9\TDBMZD`<9&[O[L[O[^;4D`X&XWX>>,-,F<!EH,WJ
M5,8JISA!F>OH#H`1W&W`<G<^#QBZ7^97W2[V[VAP*VM\8W5=GR6S)];KTR![
M6B01_>?\7YOX.4"$B&R1GP9INB5;R;\&:*,4A=($:"0,)=@.[(#@8Y6,(?T`
M2\QS6H2>X+`1$WT7$JK(AY8SL@\5I&"1`XD6,+S3K!7/04S0('B!TSM"R1T,
M-RG93T'I1[36C6%@9HYM"*Y]._H<I+_!G.($68%MUE5%65!8FW$^"T6N/!(;
M(.@`Q0=*A')!FL1B+A.B)S#+;V$(B?$2D@PLI0>(D3`ZX=FW#(D*I`6N.>UB
M6!Q8F4T^LAXUN%ZBF53K%V&(-V29*M%_@;G)$M$+Q\P1]8!T<#06V#Q1?R6Y
M8!UF>2H#U&!_Q0X(JDEMX2:%ZR".SE_6,,E,O'\'`"/.M\*RK_8"#8`<SZQ;
MH7[^8R7>^,9K5&>S0#&I6M^2Y26-PQQ&U@_:VJ"-Q*.)Q;Z1E`2PX_><-F(J
M3#R2G?LC.+0C,]_.YM?Y$TQK03T=FVM[VD@ZNX#L6P[#`<):$'=.\^EA/1[F
MC%=L1E4.UP.XTV<CC+,0-D+BEM2V[$KQ9]:APB.U'=186\KJ3D_GT-#.2-87
MPG*;8=`J/,M!MQ+T1,'0`Y#@Y#!LEY,?D=$6\2D%1YN\]%Q42B'2$NE$9V2\
MAFF^O2&,8@TCR&YJ32LWR&%=[ZC<!\?P%-<-TL7!F6/C[44D*F(\<%:C49(/
MUF&:I[)`#3$P3+RAB,1%`T@3I0XBN(R3.(=7\3.,+I.<,"@F%LL7O?.7$&UH
M3>0GC*-O,5*Z,V<.VS#:K8?&2?Y!H!0;K@,0)X?K%(<PHU'9#!(SX#GP"#Y#
MA)F,YTU1&(H=C^7['HFXR'-(Y(!A!Q5QBZUA00"0%$QBO"9&.=+8W!E1%^>F
M-(L^=;>@QD[4<U*-JT0$S`XB'0#&AB=<'C5XF&+^DW0_[]MC0%:.#0[YW!8)
MFOA8P+'J1X%&A2E<Q7WFU](&.W<"/:,C/`Y".Y/HF;R00DZ^9*O/[AX]8101
M1T-W_?G6I"I:':81PU7!V_>Y5Y>+D\NKR_O+\SNP^'(&[NZO3__S+]=7Y[=W
MOP_6./L#./\_7R_O_SZGIFL+%)MR=@^$)^RI@I0=:*MH`<<[=8EVA:01]P_Z
MH(P5SV0W$5")<];K"`HB:;<5>Q<37+._Q1YFNJ(@RY-N@BV-Q!*K)+])-S#:
M98'6)D@'[*@"+@4,#FOJUAP["]X$''_5CGPHM-.1;$O=G3)_]T.*J"%`@9@M
M1P(U:#'+J6R1XC]?K1'>0G@"$[B,S3+1`Y!,9=4#U(F1,7&$>$5KRW@';9:4
M$!2`!T'"S&:F(C2LQT=O!83JLI&X@$3693`*K^&N64&M^T:C4X%7A*(:C5==
M-#KQ/F=P"8GHHEOX#).-295P%P0C96X'YJ"KI\`#4HYH5F<R(`.LQA[O^(T:
MK!8X)EU<Q^UGK6U;G>U..XN\/-F.JNTZK6XN'>\AY]HF-BS5+-/2`\2&^W"9
M<=GQV-X4=@U+IMN#6\G%.)9"EQ^?."=SLLGB!&;9*5X]Q`D[%YSB)(^31T(!
M^93%$4S9KXL=E)F1C$1D),)1.!T$!PO<Y!Q60=Z_@9[*X.QH`K;*_7V5NC!N
M20FHD`(J6E`CICRB3.T#I`^Z#UXJZ_"XM;`;UBAGW`76X<J8!R]^&*BRF%H6
MQGZ^>2R2YC))L-5BBA.;2@6UX9%G_/[;U2''O\/-P*G&SG'&U3EFFJY8>+6*
M\Q6[)YE$Q=(2:NIG+QBSYDK=$%ULK`IDO/U5%=VLO:\4Q(,UF.:G*-"N%-A%
MVCXI..H-:Z/4QWIQSY3E/%5<HGX',I2SEB'HE>PX*=*9J"S'@S*<2H]O_::(
M.\\:NYPJ&#<NGYR9,M[Q_7\>O3TZ!NL@!<\4W1_`\4]'!T='['\@XVW'@TW^
MA-/XWS`Z`#]]//CAX_\^>/_C3VR](#\>_?3^X,/''^27XRRC*3GZ1URV*P=!
M#CZS"R8?C@\`;4Q^P+YR!D.X>H"I_/4/!_0JRAJ&>?P,T:R'ADYEP$/2\DCP
MJ"9SWDQ^PBZ)4<1Z3`?H)HBCR^0T6,=DOUQY5:UR`@5H9AGK0<`.R@H*G(!V
MKCF,$Q!RM+.6$:@+#.OSSVOAH!VY4'S@,@$"8VTBPT2=A?(@3F!T'J0)\:'9
M(@PWJPT*<AB14WT<QEJ;,Q5HAFUHA@`[J<J1.$#$D<S;-DA94EB?<5Y+1=B-
M1`<D/E`5T5F[B%S5KTF\[,H.,=MU"I]@DI$MQ642XA6\PEGV!>;7R_O@16L%
MT@5M6D"E@\6M<6'>8:A*`H@9#>`[1*CX?N:J-R-1XY',WA^QHEV)\GML->R`
MHP<4/VL+>;VDX>*9(@_C(@[6#KFN@L595YS!KS"#6GC!:EC!=3C!BRMTALF/
M#EA.;EU-D"9AAW\O+4%9?AHWY1S>D)OZ9MS4<;B;(+U.V?RJB,4M;F#*AN$9
MAN:ZP8T-VG1!=AW`*T)WGL3*!@76'C[K9Y_?PFD+LA&,X#H%'"</N0&"E4]R
MG-J(^/C(11'&-32>73!CY=*$Z-I8=@+:GAA-IX#:C:6=;7X*H\TXQ#C31:<8
MIC&(2Y:J&&4,$H0=WG-H$QD!3]1X90`-@?0I?Y55_C&_1^DO6]D^C<)KSKM6
M@V.'^TYG7;?J/YYWR+66D/HL8=R`Z^D$TF,3H^=:GV)$'L.\''CQF$(V[5:I
MD*O_>?TYUQV@G,R[EC<?8)#2T'NT26FJ/7^"8`W3&$>`JAJ[ED+G8_`KYMEF
M!?`2$!G`+0B^!6E$*W4Q.9`#R">/DQ]"VK6?6@@(`,W&Q\LX!.M-2L[HM'TD
M6*?X.:8/TK1E]85!4+SQ?,.WA[0!JXC*\21D'G$M!C.;5%MU@C!L7]D*S7*7
M2A9F+H=M^S%6>T@66)%+CE5&6+O1^.S=9PV3BG4P+F;!<`RS%MUU<AH/L<(C
MKJ(Z0P=L;?:EK;Y?:U]2O"0<M=&\Z*39I6NX(%K\*0T4=SX]#X]1XQ*.DTE1
MO$WU(T/@@8]H8?FNDVBRQ"?VUMT$H.#!IU;N.EW43!:SD>[659K+AQ8>.VQM
M6;DLK%A.5JIIFD2OV>71Y%&,##3:5?4`,6MBW`7/0<-HB:H833GKCFM8'%B9
M33ZR'C6Y+M%,?<5!KJ"+)#HKQSP(:O2<<"\@TX&&W3`=[B8\&GJA)A^LQ3-?
M98$:8EBP"R$%+FDCTXRI@`DQ341;/T:K.(FI3=([*`:6,0C*;"Y#/U0'LRXX
M0MY4M(9RUND7BG+"FISS5R:H+@[6(K2&;5([V5DG1^V7;"W6KK;R>&>7Y-4F
M26ES9'-3Y'@S-*T&ES771CI<?7P<=TM(]O68E72S-)#099SXH<,MW&_3XB9O
M_.+TCB97"NDG&HU'EFR8T1F`K*Z?X]?+(K5#,$PBM0%S,LR.X>'7C-F%!GXI
M9?8!D0,"P6J\\H[YJ,%WN@OA%TDXEHF475HOC5+R)AD;8G77A6<[@4N<BLLT
M]\$+S,Y?R"8)IU&<!.GV,H<KUF:)/$G>"C&'P%](/^_JB(P1N5LG%#E:D1X8
M/?(F64XIFC\#[%:S=K+(#N7U.K6H7D7`](BE*TI204DKX,3*%9F1"VKT`D8P
MJ%,,),D3>C1"F]@!B_[U^MZH!<0('=B!-E)^'[G\$OA(J^&%'Q"@^>;4+T?0
M+9`=(^Y@E4?,;S4>V@Q08`$"S20*_P7F9L>NQH-&_*W!L+^PT8NSJ&7C/Z7^
MMO,7]_+`%UZBDHU3'Z-DTP)Y+^@DR.*01KYCM,GUK@@,@C)B]P!4^R<LAH`G
M1C@*>K!BZDUK2WD-]9R*KBHQK,E#?Z4CS*/HKU'<)@-<5BQ[PA%.8C-_@_'C
M$T&V>"9;KD?X94/[>%TO&4F5@NX1IF2*P4B&9L@<M"'D)?&;3%97K]8;%EIZ
M\-PB1^H#MB.*O9.],&M)`A`T`$X$[<3!C;Q"QTP&7U0]7R_Y^LQZHNXT,3%K
M'*H)VK#CA!86R^TH9,T[D:C8WO!6KRU]6/PHBS>5-Q[)<5_VHU6OW+6W=Y.A
MZF@/]#5)88#H?=F_8$0=P:<@3NC[7B=W,-RDO$M$&F?D3V?L+M`-NP9DTNK*
M'0UF&1Q'Y#BH77\B+T,CFV!3T`8>"56`EK(_!S&BU[`.ES@]S`)Z'ZL@<]:T
MG&N5PU/)\A6JE\PR=C?N*ND$@E!`*>4QTNL$E,0"02W@Y`).[]1-OUI8;>*D
M>L&87H/M@F@_8%07Y=RA(Q698`U.^<E_U,9Z847*1M!Q"YD\?Y/B$,*(95#H
M3?^`L/UF\X#B\'JYA*GBQ7L=:/HWE)4`.[FO3!F\%JA%W%\@!VN&'6"!?K[+
MPWI"Q/H\=7Q+M++E/@VRIPN$OQG=;>B',_;\M0/2W6&+H@(,EW_GJFX)M1^B
M.MCF6*6(<E/$-^+2_\GV:P:CRZ2H>EK0;OU\P&E+TMA$^6QA-#U*6D#N\LI.
M2<&LEW8LZP5V(X*]UX%*7HSY,DD4.-D"2A;M4=^F&QUU$1-?.%I$_]QD?+;1
M/;Z%5*UB!&OAFGNLR&L35^(&O^$H`_NDN)A,45!)6\&DDLXRW4!^2S^'5!EE
MGJ*LE`_\<$Y.]0Y/(=17IF-H5[WN,2A(!(V\/_VCGKN;V+&=07*"#&/F5<EG
M!%ESB21:K'":Q__F1QX-1Z4&SW#@Z#!H%W-@2ZS\%ED%W;SC8#4DATW8Z+F4
M4(N`"HS\AEF/J%Q-[4CY"U<P7R_/XBS$&SY_\2:%JWBSRBZ39R@\B-9&P!"#
MZ;`'`V0NRBRK!-#&;VN.EF8C5D'Z&\QY5S@OLA`CE0#;X?_^"'QGR$<J++@J
M\^LE**A@MBWI`!5"IBD@$+51D.6`89)IKY%=$,S"4:W`'`T6/7R@B%@YC\0T
M:PRJ7Q18C4O>L5W&_V19'.0%%ET<=Z+E)YLL3F"6$<0/<<+P%O-\<_(I(YM9
MT8DL36FNF!D@3QM?4O>Q89&^]D?DA(;ML8[93$:2D4),1)W+5/\RB,44!KK$
M%D.T<_JQI*48@#+K@).I]1//).G7KXO"VTF:087H<H1X#FHT@"K=0&CP)=LR
M;$2^I.O)DOQI[D:MUL2J9/%83@B-R4YUD64P)ULH.O0QB7.(XF<8G;^$:,/*
M,S".OL4(Z3C'<7C,+OJ,0.GD,K6@`,0%8;->PK(A>6R3W7LJ9>$@2D)X\6DA
M;DX+:!`#"FJ`)&>B@-H2IBF-18Z^%#D(RC!`TPO5P24<'Z](JHH):S+.7Y$4
MX3*.JW*E>)8[E`1]"LG9Y@SR?RNQ>S&JVK";O#)4T]NMB@C<E&^';*^3-9)5
MW`/2Z'1E.N&LB2L#\6)S+N^%*.4Z)M`"B;>>"I)SVB?.`^TR@P;B-M0G\4X"
MMS"$\3,-LQ(U'&>2_9`MR;(/B8L(==%4)BTP^65_2O+LM<%AEOHO.P5;%-B+
M'AJ@Q$_3N_.9(PM^E\2,-L(=>/;$UP#M)"4DL/AL<%T2&S*S5O;Y*ATUD^*R
MNNV4U41F=$-G2,61W`6+G:]L-L:/DN,,2PV#)6&J('-A?`)OT5"TTL*.;T;]
M,D4MJ?<:ISK#]T?""@8LY5V<'N61L6RAMVB5^\2KXPV?#T?K3?@J7AD&;F>]
M[,=@V4?W(7-0,RF]M)RRQ\J=Q&ZH<K#TR[:U1*^T\`YS?>_$K+0X"S)XZ900
M^U6WV"<R[?/5&N$MA+<0L07(ED'WP;4DWVX43HR7":Q:F\$,&`HBP`./[GEF
MO@KB[37:(1[OB2C[#%3B!@*Y!T8I]P%BVM$X2]P!9DEF#;@N:H/%;LB'85GJ
M0NJUIU:F^2R0/LLI!"0P3M4=<L2M*QU3&HMIADME;AI6LDL\Q3CGARUX![X3
M=WJ^;[W4L[\7#MNLV(9(]E874*D&%BX6SNDA>"7SE%>1M3':U!)-Y"Y*A@0!
MGE]%-M6+80]A)(*]UP$5C]&F&WY<12:G='$Q<A'^:Q.G\'-Q`:9LD*3C&Q0!
M&HE=";:3`#5Y_"F@D6F\].^*D)X,L1$_O957W0HE1GI35N`$)=)*SZ]IC*O2
M_N8N8"&YST%.*=A>+T<;FCYP,R'JXK&_M`I\L:_V9RQF/)K-^R12::.RVQ4;
M5$+QLQBQI(#6X\YHLDV71:@EBW.^O2%LI6.DSLEOV2C648MB#U0[GK83@?/E
M<2TP\W"Q1.O5^C@LT[Y%<H"U?LMO>+F4F`%#S4SSO$N*'IYGISO'SG)VF2CB
M%1<'%J^C7+HZ8>T,.]O9U<<SZYQ>X2).@B2<,LJEC=&FEF@BM[\5+PCP/,IE
MJA?#'L)(!'NO`RH>HTTWM*-<"OR9NF-O5?]O:JUZ&QUZ^47WU0HG(*,-+MCD
M7?K+HJ5OB+/VD@G/7KDB[OIQ32(%'"N0:"<]G(G*A7M\'[S\+<Z?GGA_]PN<
MCF^G8HYCU,9?%YV+8QR?!\HJ,U-1&R+:&K)!2B"#>8YX#V&BT_1H1T]YWX(T
M\B+\::P5+8<],W'LDP9T'`1E41`Y$-*[G!5"`*$$S-I%ILWYT<82U.&RAD*F
MX=,.8*-C:ZUP7:])Q5K36(Q\B9#V2ZXC(MK#29^EU!KQ+)90UEB$">BN34`>
M'J.F.S[-LF6>*+BR+/;)7@=7='7"VM%IMB.3CT>E:68/$3KI&#KR#XWU/@>(
M;@;X'*1FX:6.#]"#:S8=1P.%&_N.9:TH'4U*!4X3'^P#+`F:=8J1B73Q&!;O
MB22%I3(K98,GZ8<*;CD);*<:V.`$W_^6"^*VTG1+3/^OM&.>G==;,^KO\B#-
MKRIOVJ:>!^`!/L9)(H(8_,E]>LOS)!I^1TBOE7:]G9OM%K%.0D89W$^BPO5?
MYG!E%IA6!VJVB*K"=]`7=K->\Q!#@$`49R'"V29E9YF$4]6:FIHW`JTM8VS,
MZWV0I]S_"'E5\DC$_,J-#\,\=;FCZ(?#[AM'<4Y4*R/.?4-O=9QL\B\X_SO,
M;X)8:R2[.DS#95$-O).X`JL$.`!K5@I0*^B@VQZTB?BD$\^N]6I+&9NR>P\D
M6FQR>">H*E8@T0*"%Q#$X.\TX$]03S7?@%X5)L[@!J,X-!UFU`/%M&U]!T#;
MK>D%&B#Q>#*,3T$N6)U=C@?QG019G%TO;X@DY%!-LL[<Q8])O(Q#6CRU0]\]
M?,E/D&:\>!P>L\;+(U`Z:+Q)J:$;L2H];$VXVZQ60;JE?ZL0!UH4?-8>WS84
M!=N4SIXJ!:KJPW5#'^@>;T`)P*^4(,`HFF;7=Q'$*3MQGA4G"J.EIA^.D3C[
M0%H5%T4$&"900>7)BJ,D(*S#-<>K3AL!1LO*`"!K.N5P8:AHUF<84&QS%WRK
M26=`GVPXZPDD,6#>4[O:RORD,_@@*]?S;7F-PZP1LSI4P^X2J@@LMYDHT`**
MMZBVS[>5BR^>.&D#T6)S#CMVX!5R:"<11E!YZVB'M"0ZA6D>Q,E]&M!B&-Z>
MKK0T(]_OCH:Q-F"5'!?W`16NA\UD&FZTJ=V0'(CI%6I.BZ]ES7R$NZTHTZ[G
M95E!3BP0U,H)(26]TZ^RYT%*4W4T.<HJ\DS6U&X81CK0!<ZJ#"42FI@5M8A^
MK(V#`L&JG'*\[C61&RU</4"LZ([C*%;(HE9G,=K02E=:PL&&:Q<ZY9,B]2X%
M`WSS418]ACRU$[U.'X-$3(2E4]TPBB,93ZO&M*Z7(FD9H#OR&SXFSL3C6D)H
M)%8KN*VJ0)4B4"-)3N0MHXK72U"0!4JZ/''^=A4).Q&:XV7E%"/"($QK%I]A
M99SBR!.2%EBS7*PZ!A?GF'_B%)QNLAROR*\/P$V0Y@GY]!2O>1/\.R+"'#Z2
M)6N!4$RKQN=-K!N(&8]@]GZ(5&;8JWBK,T5G/2K(<87$930'+I9DF:QFFH"-
M1*F%PZHP)6:V%NV.AZQ*U(LUR$S,>!2KG8?HNL@PC+8I@#,,?PQ"=CJAMGU6
MQK3Q+W5180/&^2T6U"&16?U^,?USG)?O!6/:R+L+HNT6WG(BJ7?>6D4X6(-E
MSCWQ#GY#%]P'QY8V.76Z4J?FSC<H"*1?@>QX6-?,[[?EJ7UJB9O=%2YNOXM+
M\Z>TN0<+9CW0"_+R3KV)VQV+R6QP]"BD=N=*EU+FMZ3+*32R0P$C!Y3T@**'
M@1\^WI*R8+OR<;Q2*)-X4B71:#$9C<JMC;1C=7!CBK8..!SNR.&EZ@]H@8GN
M]_%]?R5NY!9%GY;2+TZ]7HI:Y49%\I;__Y@J_$&(8TJK!X!/5%GO0:F\JMQV
MB^*56.B]C%!5/,3>FK7L6_G/Y(;U-2/.Z#S+XQ6Q>:VN+,TGC810!V+?(`A\
M:@X%ACEMH8/5N)\;WK`5E1R][N&H$RT58])N88@?DY@ZM1&>7P&8$=,'X=I7
M;X$25'#.J>'J8L+:;/-9)*A3&K/Y]2_P6V5E2W%"/H8\G3]ZZZ0/V[`#DQX:
M%^85POK-L[L\2**YVU0:RQ:/9>X>R5'8)$%>VVW5T,^]^2HN]?`LSR*ISN\5
M-Z"B:W(^I'?K>;N-+SA)Y8]L.WE/ZXW'71BSB'W<W29KA+AH)U/<3&Z_I<:.
M7<VV3P=@\1S$B-)VN,3I(1M14RD*IX4YO%?;(W4TM#(KCD2_MF*:\M:+"W#V
M5;3MUIQE#7A5ZB@\6D7]1'*8%I942)1:&8%K&LP19+%O5>D$_#3**)W1]?7S
MEM'X-<$/&4R?*:67R7J3TPU6$I*GF*&,<WY6\8_3-XND.'"`X1.,-H@=IT^?
M:$%:1OOUR'-@5'6+]"O[X=5<:%^;7[,NVE>F:;N^;=BA<?]5I1,P0D&=TNE]
M6['FTX[K077ZG9&K4@)GUI]H&+);1U*Y23=KFR(-@6$#]ODM'&%[!3[>GK^Q
M4YW<B*2:7"]O80:),&D7T#/X#!%F7>,J5=%TK:%YZ7M\`U.RS5Z1%[C.GXC.
ML<V-CJW9Q&HD=7L$.+3<ZR60U+%M986^6K6ZI)#.@!`T,N7B5!*=HG3.6EKA
M0,NP.V&^"HU"DRJ3HSM*FX08QCI(\^V78`47+[%6ZJS]><,K*KN@[%M^%0N@
M:.:].M3#?:S"&L\XC3J8#'ZE.*91Z5NX%J-W%X\I%-Z@_L)G>!7$6A.P-(`:
MIG<4X;]RB]`7'C9FXCX(JLC'2:R@0`M:K(RC'K(S.CB/6L^/1Q^$[;!1>B<Q
M?H3)91)^AJL'F*J81_MS6HQM`V&'=Q$.-RM9.O3FSQP';='\=@X-[V4Q[N.#
M)^RL56=Q7A(,X%>.PWAFI1-:D3*9:J9Q]Q2GQ.`U#:/QE+X<:P"<&`7#`(+'
M^4RBG;6XFP->L+%VF&0\7'P:;0H.Z$0U$A_'FD'\N`H6*$KC\.D4IVO,(^&Z
M9M$/Q4"^?0#=F`W%>"A0@K#$.:,=*<D&J[/,2SG4[*XFA`K"\8;H_D50Y1V`
MSCLX.C,9QU.NX@2RL25ZQRD;^`PW\.-1NZC/$G&CH#MN=%`&CO(R<+2L!(XH
M@7R&S*RA2*O:A%V(;L\U!S649DRPL4=G'&=#NGK29+P,)>SX\SWYE-$Q5S@9
M43+FE(R1T6WK%#DKU\YDA?"_800V2033,C[A1S+$G9*U9D<<B>YU*E1+_J2S
M7U0FJ[["SHY257+G*@8K>7Y)K&$9)W$.KPBA._V#;'@N310CE4@+FX,PM9B2
MR8MJ,EYS(4G(/.CW,U;TK?[$@.G[)^86/U!2`1@9+>W&9K?P\]4:X2V$=S!]
MCD-8WG>NWD%>(&;-K"%EN5;R&;KL6O)('V"=B)'J8YF>Z7H#\"&`[6.,IW<A
MKG2KU<DXD=EKU*,61R7I!(+06I>!FGZ5Q/)"D6+?+`9J\R8%^WMS1\=_640Z
M[\4(IY.C;%R*\*`RS;Z&N;AOX\,U&Y]OUTQ9E<9Z0-\3!F37RZ[!2)J%:LH@
MC31`$;JK;MD,,ST1L0$N0=N\K#D=@*XXL2%C_1<=VI7:];)_RMED=7,*C-"O
MF],`ZDIZKNKF7HOI==?3:3)W'P2H;X!J)76VJK%Y_A=2@DHBU.LK%`$95@WW
MP'11EBK0@8A*)ZN(I">[/UWEMHJDL!;W?)4*:@J$F<O=L$#<M/FZ^X2?89K0
MD/_=F@Z`(3O8<U8(F\89S,::CAE\L]Y6!J@<-!9[>_<6/!:$@$Q2`LA/U!OZ
M:'^CM`#;$,&>25P8\5=P!TH20$$#J!`QKWT7A^F3;?'Q+S%,::'#]HH6.>@>
M_50ACCO[]P)W&28Z``4^+Z(\:G)K"^$HL-![&>T&7TZVU882!5[`$$]YP"O>
MO=KK9Y<A^H<\3<#C9*B"PVE4UB]KTY)EF]&I\W-?Y+9K@K7F5JW&..DQKWA]
MUN0C8X[@6'^GV@MFG+!V(=HW*>[_CKW83JI(I,UXNOCD)_=W#8-CXDM1MR0F
M,X+W=HS@O74C>._6"-Y[:P1-B0P8P7LG1F"5^_U&T"V)R8S@@QTC^&#="#ZX
M-8(/WAI!4R(#1O#!B1%8Y7Z_$71+PM$D-=DZBP;D=4_W;4\;#NYJ`G(Q*TWB
M8,F'><>E=7(=#S/%*PZC5N9.>;2NO]DI'4^-4S&D7-^=JT"S((`VP"Y5?N;I
M@,H2ZE3_;H9Y+8T.\Z@CG-;E?\8)W'X.TM]@?K%)(H,T31<$LR1T*S`')0,4
M#U@Q1&!),7FQYQF0!E9CE'><1U6F<QS@HI?ICI+ZJQ5,PSA`-\$:IB;)_%8`
MANGB%E@NDO<2#5A3/+ZE#_ME@I7XY1O_T0[K&8J1+3_*[M>UYM=%[VO-WA^J
MX/2;3ZA!=M(-I-(A/*QU"$<2^7QM033EAPVXZ;>LZFYI2%"C6X=,^6IHYZTZ
M&M3/%-0:40Y_9=)5Q#+BV>X"7+GK,V+[4L"5'QU'W*B<Y6LF5Q9ZD'BH7KNQ
M1->:Y6:;'F2TLPO]IS+VJ.!W.658:^NN#M1L.ZD*W[XGN<<YV6*&=$P4+%'/
MNJG7EB`VYN0^2$MN#ZB(J)4U1WI5*R%*W!/=-:&G<7JAK"PSU(K^M#YO>`%A
M%Y0K:UD5N"H'XGFOA_3(`:LPR3.>RYA/R>CN>SAN)N:PM6_DLM$#Q&P`2Q<\
M2XI.E;MW66`7H[S3_F%9864>^B@780QB.S:?MZ]L`D<:QA`D(RGT`W6V<QJ*
M1<QL'(I"PWI\]%9`PE:JYQ4E@]%XC9--1LXT67:*5P]QPH3=$2VJ]CWC$PHO
MD\6*MONGO=SZ`TS'(_GQD?,C@8]T%J(,G#$BZ)3$)67*LYR-6%'B(H0V6RW[
MW^+\:6?67U8?H9?=-H["@F@&RRC69)<`:S76HVFQ8U9KUMOF+@_2O!J!X@H4
MB(O3(0M.@@_'!X"*VXM`DA.]&JB_MR2SUZ9#NP&F"HV`$MDR.C-KS,[,=L9M
MEM%Q!M1KM]7!9-XYZC()4P(.$D-B_T[AQC0)FE0EM6ASD&1J62OWT:69Z9P%
M%V<@O]>N7U9<8(\'%"WH)/%`4C]BM^OQ@L(W)>=)U+4E^<RZJHO]R(\3MQ7M
MF99K/@-V$.C(=HT#\-U.<!V:]SM[!SQ]X;;VZ51B\CX($EF2H;-$8"5+8E"O
MUP[`.&6T`\M%<^U&O-:+(KU>06`E)OG&]&I.[ER!WXYN*]`I(&RU/=F*,O`M
M;[\E;&ZK?PM'$:1AI;P2=/MV4>V$LI45\[->_->5'3;DHO]R$J94P4E;;4BL
M15NW0GH37@=BLW7NR3GP'JYHSZQT>[E:DTTF&Q*4PBC.KW"6P:QL`GV9G`=I
M0C:]F;R601OB5>[.Z'?E<$B$D7(XH\>^V3-204YH!06QH*3V`'!Z`2>XVLN;
MG/HES0>@I)I/J_#B(I1[W<23R?PUZB&JJN!]EPIV:^!EJ8%5!;RN*>"T_4Z*
MO3WQU%GM3*&_N1Z&99:)'P!KW\<4&`\)RD.*T[=+,LIBP[I\]%A$J"$=@6RV
M=G@J)_,KDV)Y3<#.P@I7[HK=->(+5W[4L9M)6S-8=&6A#GT&R>H'C7J$ZG:=
MVV'%8H73G"[/=,B+T7(W!'*<2^V';K]*L`#/IMYXL<@IRJQMK5/AGO_R::Y\
MK3;5+[BIK2H,-ZL-HG5*GU*R$?Z:I#!`E+I/9&][0M=N>!^\6+(W562V):V&
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MQ]"3;3L`W5(YIV28;8O=4>0@;]ZN>;.>;"90+#RAN%ZG$J%>_='V7"?;3B<X
M8:5A.].^!"NH7S`X#,NB8I1@)W,1!X`B]<]1M$AKT-J;[/-8,@-V1]%-6XYV
ME^/PM^NU66_^EH?-]GE-.`X.`Q0%P&M^_=F'BK)NSN-!SOC$951E,`<_;578
MR,5VMX3(_;[U:F0MF2WTDRTW^F>AGGJE^5>I$<IE;^]Z9:%TS2]%LKPKG;[F
M;1PW>5>C"=V01#B'ZG#<KA=ZO,FS/$@B>L\?2O6)$Q`&**0I6JH\>`G8>Y"_
M)#`'B&9HV9@&2N8>^YZ&.MES/%71[;OJ6'8YG#2SZ1)?-G3/=+V\A1FD/1=N
M4OR8!BL5?]#_O/Y,@@Y03@9&<%S4"E.!#:PYNOD&10R)`JOPZ9W;Q4;B7"31
M&1U4B->4J8N'+$^#4&L5&8)D9./]0*T:KT3%&CM7D(%?);I9MY"*@L)ZO)M'
MN\I>C+3U(J7F'A/O1V\=7^"4Y7"SDRT=J::;";"$T*:NZN&VOY4I]#IHZ'6%
ML@,@:0,Y!H(Z0/X/</H.9I^M:5>3AJW$1&K[KC5#CK!"5*DO]Z6^7!3Z0D/Y
ME+8IX_8C&$E)U0_N6T(XM=:4N/^_K['N:UHTR8ZO:4IMW[7&HJ_ACD8MW=%Q
M:#J!>7#_%*`@R^`J#C0G\'4\K7]@:@7DY+A$,=%N'!+5?(>D?M;C8<YXQ>:J
M,Z1H#BL\'CT(SR'=J"09W"N0K&96=W'X&X*G$*&S.*/-+S4-J_-Y?9EW@')B
M7!P7"`DR$'%L\]G7D`RP"H,\XW<M4KO+[-&&YI1X5*.;(@%G`W2K61M;#F]2
M_$\8ZO18['Y67^HM8)Q8&"_S7@M$\QE7'\OQ$$\\8N]NIRZ)9;0M.:,9:9'K
MYLA)MZC:(:KR(;--O'S>P?&-@I[UY+7#4-SYXCXP#U7X-FFL@R+4K[2J/6;.
M/U>>QP_UZRZCVGEY/UA85\(I_=_GX"5>;5;ZBMAXT'#B806&?644X+TH\FOG
M,^[EA2\\1>KLG#VG7)5_=T*Y]6+$[+2C&MG72U"$U@0:LT/%XO$Q99TJ%E$4
MT\UW@&[A,TPV4#3(9(6@,8)9CA/BUO(G'(DO+,*GF'R*E`\A5G#I[ZHMH'5R
MR"GH`D%!&%%&AIC\6Y`&5I(VL&+$%5\*!'GS'9!LJ@^V+:_.Y+=]6SA'\6/\
M@.`])E^%\;/2/5T'2">UCAW\GIH)%'32?%3**=U+B^E6,@NFTR%,71LJ@)=X
M"3#5F^N#(/3UNQN:$VTMT/W^=S^_/_KPAZJF"KSSZ9Z"<+`BVXSUXB;8LKX,
M0LO4=P\]$$9H11.86Z4`:X%.^J$9E^YAB>SH0CNS=%7A%"-"$Q9S>Y/H*@YA
MDL$%<5U\?J_<1Y.-;;0)\VRQ)CMS@NYK$L&T^)JRXEC#IZ]FEE`[4<H:;:R@
M`W'J0%"0!Y+BE+06%()`D`@VE,;RR_-ILFV%PBZDYV\E)JU7)^_%WI(6JZOY
M9$>(IZY[V:7!1=446T*SIL7L:0U4C[[8J87JDLEKT0T9T+50&U4E$7`:3:-7
MWH1)JJ9S@W/"A9B<^`)V9Z;M+,=J"T.8YK2C;G$(-([B><,'H2;E^;<D"`B$
MH$(2*'>9G*CB2Y*L&3CB*$30JR)$,QZ(4E!G&S'=$&$R9D]D)Y.M81@O8_+'
M$*]6,`UCT765[H%HA[AL7BURQ#-KZB3IHRY)4&C*)=>'\UK"IWB?W2.YK_2C
M)ND50=DBW<T)N)WS.\=?3ZG?X;M$(Q7>F'"O3H3M^;"=D]ZK>%<ATOJIE^Z\
M!%6@)`N4239)&9"D`49;^>5IRD'P-D#Y5AB_UNFL\:39%KH&Q,'YB,.7?GG6
MQG0=K,;]W/"&K:C.40';+#5\23<"=-O"CRGW,%U=+_7#;T-@]*-J_1"=!,L$
MRK)6@.COBCI+#\)?BG+"&MSS4R:M-]%$T0;=]4?\#`V$@Z<CC0MYI3!X[.H6
M[LO[">.5NE:\(D7&.LA.NNB<P25,4Q@9K#H[CQKYQP84%Z/*.0*Y\,RY[G1Q
M&P_PPQ_.H@931ZT]4O?O8/I,]F<"%MM[U7>5VLN1`61];ZB-Q,FB53B0C)-1
M''QY'#JL)X#F7\C,A8['\=UQ;D:>>Y)(T)49^-0>($8^H!.>'55\AND#KJS6
M95R);)HV:R+U)`=+.*O/'98+5N:7CS(0'KDXX)+#KL33Y9T]=W"M.T#AW8RW
M=C.]2S,+)-`7(3X>:&C$*R;=`0K%&>&M[/@HNU91U2%I&L01>1%]Z.+XKA^R
MYWU<^IQ./^-$7V6NU$1A=Y\UXFD3C'V5O:<SH>?4T4XNXR$V>,31(AHL@(\[
MK10Y-1G0_@03>!^DCS!7NCJJ`&1$87<+/,>%VF75V"/!"7*.U(.:ZS[Y[-10
M=_)-M^!1`A*!'1/EZ`-AWKAS%YKCWIVQ"&WYH18*<FFV\.SBF*E*C-$%2THP
MG?3]DKJ*N*W)N:RU&"/Q#BCFLF\%Z%@+*K=X_%*(?ADU5:.'=3ZNU;7I"P,+
M]>B:)V=O@9HO4&;J*2YP/^X%7*^+[?46;8NBKV^`:L03MLMDE4WV3\1WF_QV
MSVB;#';H]MM9W>'S/7Z/'?Y7JB7[1.'\IO$]/I%?^C>,KI-%2!>W@"QQA!_K
M-8I#ON)J'SL=DC+IK61%JCR]J\R+E]."?D!3<\4;,%LJW\&#$[5[!;9PMUE+
M)5ZOLE9]\^67,X!3<'J_`-GF815G&4L"MPXF>6U\V-E%FE;"WV-P4GR5&NMU
M`DK*V:I1TCY1DW0U?I<TZP3)3:`;7MK2131!U?J\U_6,Y8K'LW6O9%CD534,
MN:3!;#_WE1<TB*S7!82Z_5F[`>@O1UVPG.QX!++B[OB2H)MO6S(H!ZS$(]]X
M7G5++0P?W73-+?6H3KC,N5,TT[8S;-X_H76U&H:J!&94'5`+1'<U#T7!'ZME
M]V/:L8J$6FJR.OGFIS3J-1)E40\K]%:V"=6ER'P-LN((IUIU/%ITAE<;LV12
M_<)0=OZRAF$.(W%VTNNFI`3+H/!Y&*R;4N?&%3(`!>8RH#)SNR4=X6%=;FIK
M$HPV(8PD?'(&5E><ED=-"N2;4!Q5P#,T()7J01#-6=_>R74\P!?M5I9%1*-R
M15U>&3?LHZ4%TR"*I@[>3>RV#`*M*JT")`7^M+LRD2TV9;(W.X"!,Y"UHX_K
M,\\D)QTVWOPRRS8P.MND<?)X`],81W\-T`9^@=_87[2&6B@"--IO*\&VKT2G
M>+7""<C8)/B8H1<VOM,';\XCD9XHL1%;?1>;L":&$7"4@.,$'"E@6`%!R_\\
ME)9U:F5LQGMFT\QV(-H46`.X@P9-FP=B40`OEY!B/6!MEPK+RQAZ88`>&EJ7
M-(<MK96QWDMNV-8XVAYC\^ZPV-=LI.NDZ/U+H?K[%$TF)<8R.VGZ/A-=4ZR5
M)O(6;E((M/JA;-)62S*8W_9S<_*L7TW</7;Z1B^JDUJHT0A2)S_!57E^0?9N
MU$D%ST&,*@>V_(ELY`A*V@RP=T/GY1O*4H7R;%KM!5><3?6:4G7$#*X3>!^O
M8'D44F\&W/^\P2#$=E!N9DW2>D2"K)91@PS?C(,G!V2!51BE&S0BZWM(^?((
MKY?<'\0PJRY<%X3`.[:;(]B(L2FKA@%D?:711N)$G4HJV&PI24=C=P&HK&GE
M54',?+IF+G8\CO-C9TB0#4E]MT4["<+G&&\R_>BF&?#QDR=4\$PSE(+UOTWK
MVV/>#Y*3XT/L<Y0*=,VS4!>!KL:>X6\$`KX+8TC>2[<HJ.-I?9UK!>1$J0@F
MJB889`+7?*K2SWL\S!JO^%SK6T:83/$`B6AT`9!#PI$NS6XFF<:)X233^H-F
M4S>K,%P4JB;^3#)MY3/NY84O/$7J[)S]#%,;Z)[`PXX##(V?P!<:/<G84H[7
M;97H7KP1*EX&4"35E-G(P18SG0MJ(7##0\&>O3+:>5LZI[9XVWI`$E`:P)V%
MMYUO2UWO<B>1H"W?*D=%^]D#V9NVV&=71T\$C2MALDO^065'3OE'<R9L/$6E
M2?O^\:QPLXW>^JP_72.:S5NPB^/'R/#6(DDV`:)5Q[<0!2PD;U`#TPO$H.BE
M!YZ;*A>&D$70B78RE-0+>7"T4Y(/5N:;[E&-P#I3:QE6^[J^R/F33H1+U\IH
M,V.%6X.)N.65]8,^;#M6K!.P%/T='^03DA7E-YP4:5&-D(\^:).`CRX61^$>
MOJTMMA>0K"ZE+Q!#D4*Z&>&T@#4C9LY8C['D\4C>^^C(:VG24G+&J2SG!*,:
MK>RZCT!%=X*=J_D<?K262.1.U`>R4$G1F3E%<SF@MAB%ENO9MQ=N!!!*_*!J
M`Y($4-`@"FO,MK7M+8J%H9WB+,_(OIK6A-!VK,I+HR;4L9.1!Q!,,?^XN(0E
M=\4A)8*=P*`@PY<)QZI";I]CK,3KO1!HO9I75YIVIII-\J*H[1W+:X-R567(
MV3'ZW/P=G7:';DX%X(?\(,_3^&&3!\5<5]$2G8JK$C@Q<Y"?TB#)1740+R]3
M]H)MC^I;QBX4)_Z,H6%C3UD9%$,TG\?JX3H>X(ON"5$6/-9;R?`P)T[;YS\K
MJX`9<'TE,<'C1(V*\M&=CE0B1HW33@.=3]U&Z0`>+0-=E647O:^7LOVXLC;N
M/*>O:`T03G2(WV/'2[+J<BSS*487IW$?.[1O6\JE^$SG)FWC*9.^8Q4`COK9
MR3U&-.O-V78&XVX^Z$KP-$`Q\6Q)'%PF61[GFQPRDZ?=*NE^ZQE^AE$<QK1W
MD58-CSY@@ZVW)@XWQZF""!!+*L1B4=(!5H*0&8]2II+&H[B]+U*MG:E*D5[6
M1%HE`D@J1A=,S//"J.==+[3?U<U<FV`=YS11+,Z7U\NO"9]&?9/B-4QI<OC\
M)42;B"?VR6::_(ZGE4^VXCO;ZY1\^B?9X"Q>8JU+B4[0F\V"L4^)@UH/#GS6
M$3T.%09/(([7I1R%ARGH$Y&:ZR60)(*21B")Y`4R53+!R59^<0NN4R!(!;]2
M8J?Q10*E?B%EXT$C$==@O$K+;6<O[F6!+ZQ$-2Z.W@ZX"ILU+PUF--M7O2PX
M-C'IBG#!7Q[GD]<=%Z,Z-L\7=:I*H0@Y\:"E3L1I_UX<-=YYIY>T*(YD6T_Q
MTC2D?S;^I9V$?NJ#98J6DEC*SRMB!?-Y?(HLOQ*Z><=SZQ&8=GY&8ZYEVR<2
M->D[:Z%/+?)RF>2$_/@!P466P7SQD.F%1#N?US]Q=X!R$BXI<8&`(ILO(#(D
M`*S"'<^8+?2SPF2&A&R4!9II-LMWX1.,-HC.,`C_M8E3&%V2;<:2#GR"5]3-
M-YB0G6P_!__$Z2DB.G%/TZ$Z.VP;V,S:TXQ&;-]U2IK8$`9!%2C)`HPNT%20
MC)ZP&&V`$0=^9>3->J7*HA)A^S+;:X5!4^B*$\^BP2_=<)\V:",5T,3B8`!.
M0<`A:I?OG$9O*E\\DL/[(TO4%*.RF4X7+!M@3,F6+\$*GN%5$"O-;1L%WH6$
MVS#-8;$'-4%36CRVX5[IJ]MQ-^_W2]+J]MR4,?B5TV$X,.$4IO`Z@7_9)!%9
M]Q=)=`^3^Q0&.3VMD1T*^O<3C%<P/8LS&&3:^7\SZ`;I8A-$;BH!""6`7NQ\
MXK2PF%T.$Y!+<M@80TD0B#A%,Y8$C-(`/%X`>R7M6H7`^>WYX?'Q$8O1TN!Y
M3<0%%;\/UCC[0R8E#;Y[<WES^_M@M?[#V9OOQ]<-S,<+F=JC&D\[%P@:6,"6
M4`$*,MC1HM!X0<G(22^[[_V-8-I67OTF2'^+DPPGMGR7*@(;"JV&:T(/Q@BJ
M:_A:TN2C$]/4AFX_IB.)?9/\KC=[W^'-"BJF]F93LJ/7H7$#J/FT@A9=GV;G
M@*48/KJ*$WB9PY56'$0?MM&&6Q>-@R0X/U-U;;=_I:@!PSUK'-18UG@LL_=(
MKC(QIQ'%')*OG8,C+VJ*D\=/&$??8H1<7"B[QWF`0!P1YQ0O8W:=+&[DV<9<
MB;M<K8,XY4ZX^7[EZ[/8Q"2O6](#PJ<@?33)$)?B"_$*W@<OXNK@"4S(^XQ-
MQWWD9"=LS#;9EU=;I)=C><GB&C/T(`]>P`/'/'&"[GRU1G@+H>APSV8<G)#U
M+#K%*\H0?ML3L26#?+I>EB.#^>UM5M(W(F=GE8"161F+M+C-[$E"@:"4SZ8`
MC%90)1:4U+*>9.7(=C'4@E=D>I7N<Z&2K1E`Z^)^;>K7DB><2/,<I26HL[TC
MIUU6O',ER--/%/:`,0P^=T)TD4Y@2TZ!#4AT\^8,AD6#-1CFIQC0@`2FS=&U
MOJQ)-JX7D$U)N,NP[8])]"7,!IGFJS"&#4,MU67'--K+H,4!0?\&B!(X(\DH
M0'8QY*F])-V+/MPZHL,&C/1;3*@AH4;]O&R/,VVL\A.[1HH(+8MH%2<Q+42E
METJ-[4D1H)&HE&#;MRF!EIE44$/LA57IB1`;L=-W<:&ZI*AIU7'.8UUVSHQ&
MB0+KJ(U4P#(5#FYYV3XQ>Y*7<*5YV+%L7X^6H>D5S$V?AT;S0)V[4,,PS"[5
M=X!ST<"QV:#QEUE;*`S)`JLRR4.^HRK+J_TBI[X@)0P11NV.1)"EE;57A&B6
MTU4";M\V>%Z3S4L_?&#N+*RZ,V$PLR;G]02)S7CJO=!D^EVB[%Z"SG=E)CZ3
M5><W\C/YB7R@TB8__#]02P,$%`````@`#(2<1IW(+^S))0``%,P"`!4`'`!S
M9VUO+3(P,34P,S,Q7W!R92YX;6Q55`D``UCN/U58[C]5=7@+``$$)0X```0Y
M`0``[5WK;^,XDO]^P/T/N5[@L(M#$CN/GDYC^A;.JR>X="=(W#N[GP:*S-B<
MED6O'NFX__HC)5F4;3U8%"DIM`:+[<0QB\4?R6*Q7OSU[Z]S9^\%>3XF[J=W
MPX/!NSWDVF2"W>FG=Z&_;_DVQN_V_,!R)Y9#7/3IW1+Y[_[^O__Y'[_^U_[^
MWL/#Y=[(#O`+NL2^[1`_]-!?'[_\;>^?YP^W>[?8_?YD^6CODMCA'+G!WO[>
M+`@6'P\/?_SX<?",7<NUL>4<>-[DP";SP[W]_17E"P]9`>5J[](*T%[TW\>]
MH\'P=']PLG_T83S\\/%T^'%X>G#VX>AT>#;\G\'@XV"0(?"/>%1[F?\H@8/!
MP<E!]FOWEOW=FJ*]F\O,UZZNST?79Q>7YQ=7'P:GUQ\^O!^<#8:#P?#Z^/S]
MX.+]_F`0_7IT?$Q_')X.CK.<D\72P]-9L/=7^V\1RWL/!^Q_E\1UD>.@Y=Y_
M[ST2UZ??G"\L=WFP-W*<O0?6Q-][0#[R7M#D(*'HK#"D,^7ZG]YE\'M]\IP#
MXDT/CP:#X\/5%]_%W_S(?@=\_77K^S^.HV\/S\[.#J._IE_U<=X7*=GAX3^_
MW#[:,S2W]K'+5HW-.O#Q1S_Z\);8T:0*\+57^`WVV_[J:_OLH_WAT?[Q\.#5
MG[RCD.WM_>H1!SV@YSWV[[>'F[7N?,N=6G,2K;>C:.Z.AX?LBX=C-%\X=+7=
MQF-E77R<>>CYTSM_.B?[JR^S?OZ2]]U@N:#[P\?T+W34AY*L!-8K<<E\&?.T
MVCFK?T?NY,H-<+"\<9^)-X_0K.+U@1+Z`T(H=R`+CZY,-XB^R$:]]EWT&B!W
M@B8K"HQW+4.->*'<.,1>&W725;12?&0?3,G+X01AUM<)^X$A<K(_&";KY"_T
MHS]BZG03SHG[&!#[^^/,HH.\"X-(WE$9N`Z(PU8O\58?.M83<CZ]$Z5TJ)[U
M:^P@[X*NPBGQEC!>-YHJ9>XB]#PZ?]?T1+"<?R'+NW(G3(J+<EC<7@.&%[0G
MSW)NZ.I]_3\$1'&KL08&']`4^[07-_AJS84QS&^KE+VQ9[&5_;B</Q%'E*^-
M1DH96@F.>.'<(P^3R37]S!=EKH2`1D;9"J_!9J:Y%B9C&(!;N*"Q4@9'M(-)
MA(-C"4OJC49:$!M3'J!`Q6T*V=D^U-DG?Y0=E:,GMO/M0(03`+&4Q:P^,/+L
MM5XLSU[U0'_<4@;6];GD&X<+BTG]?7N&G52/>/;(',1>P@7)0Y=X$^316P[3
MW0\&]*JSH(O3HY0^O3MZMQ?ZE$FR8.0LA_T-/2-Z#DUN8X@*V8]X#^AE`T7?
M?&,(;>P'#M$O/42D5):E4`V/>ZA(Q<G$P3KKP<H%:TW;2.$Z.NWA(KF:8PK1
M<2_,5Q#E*_T<J5ZFKR.U=7U+H3KI9?H*JN+;.$>K%^KK"VO#NI("==J+\XT=
M6&HR2W%[WX",__5PT\*IQ(#[2.DA!LX%H6+&]=&$_N`3!T_HYY-SRV$V\L<9
M0D%Z_R^UXTK0:\><"V%4Y!;^;/E/T22&_O[4LA;Q51PY@;_Z9/-.GGS\QRVV
MGK"#`XQ\ND*CQ38C#EU:_M6_0[J:1&[(XK2$3`KR@ZG'?@L,CVPJ'$+F*YG<
M!3,J%LF<KKT971'X!=VX=`6A6^+[7U%P]SRV7B&C`9/6/-0'%%C819,KRW.I
M`/,S_%VB9VQC(6,,A)KNN9M,<"Q?[RT\N7$OK`4.+"<CM4'3)4!-\X`R??W#
M<D(A,UUQV\:W.L2F)T*E`;1QP,X`)BRI^`_H.D:N384G%/A",IJ'D)'WDL>$
M=A8O$[V'2KA,MU^):\>:.X3O:EJ:!W,>^E3F^3Z=\R?L1MI).N%,D_`Q7<>)
MTA+SMY0;:<V.&IK3!_2"W!#5F\P<(LWMF@LXWWFMF\5;@NDB"E"7SI5/KUP_
MTC4G[+W9:J=?K?-"JIS02P59(G2.7*J3!#+3745)_T!(2(^6>VMI/3F(GC`)
M0_46,8ALX]M11I$HH]+<`')O736'4T%3]P+T_:W+>L7:2EIH9BRZ4\5]R1U`
M!00TL_V9D,D/[`B%I&RWT<P<LS4_8Q>SR,$71"]!@>5.,1,0$4Q7K[83,N.7
MS"#@M#4/]MXC"^0%RWO'BHV#=&,MF!Y/;^20@973T;T]7RSL,!%^3;Q'RT&/
MB"[D&BJV&+U&9([,L;;>L#D)),%K7FOM%B!Z:&`[0),+RY^QVRK]ARW7%SK3
M[/X:7%B>MZ2;$&Q^`)/6OKG1PL*3J]<%,^Y*3$\!@8;4O0=D(PH=W8=4B-30
M[_+I:#]%`N31]<`[EQA!"9'61*K,1%03TVWF4KW5N['!UR2GC(9=0*`1MN7Y
M;8S1U$%V]WR]RH2Z)SZ&!F_"Z+7A))8:,2F>&!X>95S@0<4JW@)E:W<9'.TC
M)I@(6([R.!;CPC/`D`F<ICR:Q;@@*3!<)3I4H\$K'8>I7%GF2!DNS@60*K@4
MI1#]TDMU\$4X!>]#+]_S;"(I/F>]0"^`9J@A98@$EM,9:.1T@JS%DD-EN!0O
M%]]EENH4HJ'A4KQ<98)Z*5+8S,N&$8<M!P[S,E_$X2AP+7)L=E@(K=S#*1@G
MZL5-1PXO68N2N/,_!=&\W`WIZ(I\(`M-4</WQNJ5`I$U.==@H9B@%+U?C!7S
M8/1*X\0X8,;*?C'`\N,!4W@^&*M\PM934<1F"M39+DA\`:#*I-/10+UL[XAN
M4>=8+`F]3I$;[H)<!R-7,RZ?H[L+AX#TNBS.[T@!-/>RK4C?S6"EX29N@!`L
MS=OBV/4;-0<[D2OID89[?4>@@R^T]<S,%")S;^TPB$1R;U/0S+VOPT`3R<!.
M03/WF@Y<:="D?(Z@L2=!7=F?`4G#[=T`5:.Z+$<*H(9;_1:`[=>2N8_@GJ$`
MVU::1*2JL$PN\<Y7F5GGNK$Z$U)%Q<7H-%<L(^[\QO=#/EU2_*](-,WZ*`QF
M=+O_K,E^EDQS0Z`K]\Z+5OHDTF_OD1>Q(SF48G)]Q'M'_)-"LV5P/6.%^&UO
M7(Z;P0JG(MQ6\IH7\#78YJ`(L_P:ADW84UO1.]._^G?/=XO$.*^BF&$YX2[J
MFP4<ZSU5?T?LY2@T&;W0#J?H:SA_0M[=<[06,TOQW/*Q32]'E]@)`Y@:)-N#
M9G5B9999G8@U1EA)2O-0OJ*`FT8@C&\TU)YWS+H:6Z])?D(2@P%AN)!$(ZPS
ME*ZIU(^=$2&=<KY-S]$S\5#*'_*O7JG,I_*;'@;>\H9N[,A11EM224#YFZZ2
M?^##U\1&0UGG=%]$EKV81]CH\RGH+B,1@\N@DMECN<V;8CG9)G(,\\:Z:^[0
M7>Q9#HMHF\RQ&]6?9Z]")@Q`F*\DI;^$!Z)*(TLLND0OR"%1_+[$0"H(-;V`
M9"[8)42TST(4.`-:]KQ-,\PQ"?Z9O;,@PV6V,;1&X`45_-83B0^,T=1#L<XI
MPD5Y^X8F568I;K=M1&%(-7H9G@M)M'G-K1H7*<.<FP&,-3D5+E)2M7L,?N1(
M!)P2`<>-(,9:CP#(9`$Y;L`;V7DY4Z)F&/PBC[BF1H252EZ;PUCY#(*K\C+!
M`3-69H,`R[DZ\O(<QH:>R,BJK#&`E^?HQ7FQE8?7X3!6EH-0TF@)Y"4]C(U,
M!T.=8W/F,*F3_F<Q3"Z:,H_0VP)JPYO`2WKT8DW`1\3+>_3R3=YIR*M]F/KH
M7]9+O!8=G75,*/*;%]+ONOM\FW'MX7:;8>HR3]*5DFFB6GH.`]]<#UD.BWWZ
MC3A1:1T+NPS2.Y>7<AIYV*=_NJ2_NM/X,6J9\>OCH??`;P0IQ;U&F75;<->,
MIA0CW9%@+1`.U<K.0$-&>T=.;P6@Z=O?'']C;<0*\"\]7[@#PM0<ES4-P?)G
MUP[YH5QEVJ3;>54I95CW.P=1SFATB9[@(&3AP7'A@,EY&'PEP;]0P+)+0?J2
M,$W=YS]Q;8KCC?N"?&;>HULSB0)VIY&I1>9(!1`U\HV*/QP\<(X,'5Q+PXK/
M3;I)Z('KHTL4_UM_=$5T]>O=C)%[C[Q@*C'/E]]\5A0TW28C.\`O<>VA'!,I
M4%&OU9/^Q])LA":1-9AE7;#$Q>@:+//4M@`QW<.QEM'Q]("B5/`QH1K*[SB8
MS6+UD)423HQH*-*!Z`D7`0T:I70?T(@KNG;R(+T/GQQLWSU314HPL1-"K=,[
M3^HX5-1C.\#P4URW2!+NJ:$]/"8CFQX4'BHL;RVS:T6H-BAS665SVOD7*V"W
MU>7=\Q?+^XX"5JB3WV!E9;`@\:;GL_80Q0AV>K\J%&3@'ML!)@UAT"[(A'O2
M'\N[IM7>N!L%&H%1O57$&A_.JBANH@FM5:FK,[(RNHT/4J1\<KWABO70^,"3
M1X%6RRR)8EB%U\#?#Y?MH;49Y^]&J9G?++TV!L66U/;38<!7L:&4&Q]H*OT3
M(Y]D"H4P5<T#7&T.!4FPE:1TS]6<[G9OY8E8?X"%O\_BL/=9ZKU(7ZL?S2"(
M5QH>>1YE/3:W7\S8CW2OS9DD83:5\N+$0PA>C;&DVTM=V[0#-MRH89Q)4!3A
M.R=>@']&O=X]7V(_/CCHB4B/RCD.YWZL[`LGWM7M0;MP6WC(QA$W]&<G9I'J
M/QDN81).A)[NV9S\&28`C@D]#8EKX^@PY'[_,1&\MT@]**VE_SX0IOZ-4^&E
M']QC<Q%"J6.X9CA0#IV.A%$4CY"HGSB>Q6ALA)#B7240;67N(W;ZL-1SKNC,
M2>W(E&A5"`A4^]F!W-:F`)?5JG7DRW8N`:BI22BZL^U`CFU3$#=F(-"9]+MC
M<U;/"*8SM7C')J+2ZLH3E(U52AM;]`"[/8?=6%DCX1PI!;/<T\/3FM7)C,YI
M-1H@W?(-\@1H=1JZ\4"*^9)YLK3!FK>N-5H>G\"A-5;?5@UL69P+3TCOCR=!
M.+<"HE(,S;4M:36=U@JN2\'78&?J2!D/12X!<`!G"JVY]=841]=F)D$P>IAC
M;'"1'HTHP\/04\3--?XTN*I+TAM2H!4:=W9H:==-GTGAUU"0SJR#$9RBE4*K
MH0!=MT6(;/X<@24'<H"-O>2I!WA31L,31]-G9!66Q'LK$EL%\-5YR2G"YI:8
MUX=OW1QW#KYZJ?)&3T18M8040`W&(J,`W"JFD2*GWD2TB":+\NT%IN*WJK22
MHGBB7'K&*%ZY73BAP&JM>"$>CJ"YEU]PK:.UY2A:L2E%\O3M/GW*(L@<XH=Q
MN5__[OD^.UWNY#&<SRUO>??\B*<N?L8VN^/'7AI6XXY0G3V3E5I:H4QM5^T4
M+5,T!LV)7_FLE7$TIN"<.\`B//7ZT9_IM-&W5(9+"956PURJ1T=4352CS[!K
M%W/7%O8BC>(+56CI[]GJ+H+BJXQ$VV(IES>].RWMDG,A)T\J"&D6&'F]RXB,
M<CIM"@VA$1+A^3!++I25"A*4"]75AMJ3"[F\Z2Z8D"8BL(B)IR#RS*W88%>]
M8)FIG4QO@,@++.R./8L9*>-`*CX"*9&BCP?MU292QA.VMYB5JC8A3K7=>!WP
MZ$D3DVZ6R-MXFN0K"EAX].KY%XD[736QML5@!9=Z]_3F`SM2$JV$B&:1M-FS
MC``JIM&FN*D<6<DK2<9*AR_6G\2["/V`S&GG]Y87N/3?&5XPB?G(WIE$4[J7
M'`<S)Q=<5Y*BWK;\@+*M^TV?]*7F%Y1)B*NI-('(ZG[SQYM:;I+ORM\'B`T8
M67O&W7-BX;4<_G2`C(12U&&K#Z(JQ8Q(+@RSI.%F8B-0W!4U;UN>;?&E^U:S
MWEWMVYT`.<T":I7)2O=6,3LR@@A(N$V!(X<!`4ZD:0(E??86+$NV6K8O1CA+
MVJMPQCW5%AUE=/27$MWL7+)V:#&9]E]1+1]?WO/%.[#MHR#`PLJ1@A*@G$C;
MPJ"`.\WU'=/NXZ=55]TF$;`7Q`]\'O.:YC#(B([:7>DN=2G*WU.6/QD!5+>G
M-F64(I2(PG5AEJ2K$R#30ER12?%%#<49?44_,GU[=!BA:\=6A(B#9?S_4D(6
M3ENS5$U2O5E)&8H\FXX:HQ,@IGDXWWPJI:[\`,^I;`*5P=ULJ;N*>;P/-A9Y
MG:4E2K$/4&LZ0*UR2AH](=\"<)N;<0<>^88!)"!I.6;&UNZ`808_>QM]V[R5
M$-$Q"QV!ZJ/5A-K6,DLX;"C:,E.**.%A<D>O3"SA@JZ^Z&#XYI(G'WE1S;(;
M=Q$&J[I^<0'B>K&F2OMO*D0UMI+3^T`Y]_0+7XGKK0TFFMUZD"GLO8_I;2NF
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M69UW>O@%RZ_6'%V2N85!KS$"B&H>WF:WHU<,VD;Y[74_J9?*N1J[>`Q]OEIE
MKWT4^NY$H:M<-US7/3+5=*%A<Y,J>;4#;JA204^DCJ8=<$3!3W]2I*<TZG-Z
M:VAM*),I5D-CQ5P-K,JU?XZ=L>M,[Q&AYF;(I\'8>L!*K^RY"I,&,P9_-'I@
M@+5P,Q%)RAQ83J1M>U\!=TW=,/F+D+?L1<A<;FH:ZX!=]`F"VB5;[01!Z<DU
MRYF1GUHC):1$2+4MJDIY;$I@K9Y.>T3>"[91?N'\D1/MU<B<D<0:_D23N(AV
ME/A14Z0I9Z+/0>J`6%2?@Z1QQ9@E2?,"']/DFKP_^G$E[FR%\D)G.BLI5O$$
M^24*:&L%\:3M,=WVZ=`1-/0*TDS\6$X,&D105E'2G>X2J6<UQU!"1#/[U;4]
MRSG/;Z_;&9G[LD+-.0`0?0/AT%*Q#HH[AKKZJP03,`)`E)QVS_E\CCSF!KRW
M%L@3'T0%`=V"@;AH&>_NZ]"=^'"^BR@T%D<YIDQ>L#`OJL[]!,;/0*@U.B!H
MX$5>ZZ;D5Q3U[=\RF^\Q'/I2,BT,X4C-$(Y:',)0S1"&30\AJ^RF'_Z&J43W
M[-D2'E<%)-S4,,^7VSQ$@$,WO2A%W<GXCY_)"_+<Z`:S8+$R5'^XBGR7'O91
M%.G-U4;XVI2CK_V\CUVMJ.[H*@AIOQC\23QV9-#;94%$/GS?`8BV/SSHIA,F
M^0:N#^"@1X6=]KF3;S5W,FM,/3$UFD']]B(2,F0'8NJ@(AH&XW9PHK%A4/"C
MG`AK(1P^8\.7:L$GIZ+RH##S,\]UB%'1^\^Z%#TR&F>QRV4>B&*79+YFS3_Z
M0?:(/$CSC"D<P/<]@```C[8!_-`#"`#P>`O`)F)>#3QV\FSMZT?,B8F8EC@H
M"L')]Z3P!6AL?A7`/96]T!3XTCA@QEX#Y0`K<)IRO/K;WE;"D*C#/`7QV'Q%
M1>OM1$V813H=I^8KWDHC8K+B0CSXA\-MK,C5#G=^U%B*["_&VI*T(UL22;B"
M=ZCA[".!Y>P"O%7!IBN,J?YJ:##Y:#+!\0!N7):J&?6M+.I;@'H7P[/+V-;\
MC$#HT_7J^U3??<+NJBA)GAJ738N]F+$?;]S1G*62LR2-<LUO"'&,-L92[RAN
MV%'<V,SJR,DYBS>RBZ8L!ZE]09K)7H\`\F_<U8,'D_3[U6BI2[C1P4\7A;7:
M@38?`?D[#F9;M97]]>+*_L.&3I,P'=&J&RE9FX$_'#QPCEH)'Q7AO8#U.'WP
MQK4]2@Y=HOC?)L`$,M116+N])GMUHKVX,[7SJ#&A=Q'MN,?`\H(NW78UXPT4
M/SL04=6)E;XZ1;G;6[G3+%[O5V[#ZG*>>3!;*253*EY"^96DWK8J"V6[K0<8
M(&=9&17=>=O%*?*V'<[#J%+%9X_X_C>7"C:'%9"XI;^=HV?BL4>]U8Q3N+,.
MPO'9PFYC<&QTUAX<<^(%C"%61T31H-=)]LGSZH<W"BXLSUO2@Q1\VQ`DV%@I
M\^)UM.VY`-5B$B+<U+ZC&]U?XP&>/U=-2W=U=5;"<CRSW#&:LQAZ;WDS7]`M
M$96\I"H8#IB,1SZO4'3C7EF>2Q>5OXIS85$<V;,=G'*GD0GM>>^I*^5\F;"R
MC&-:DJE<PI/A!4GV-2&*9&M&!DJPG4^@+V71E[+H9BF+/H.]SV#O,]B;SF`7
MT4EK/,M32;3W!#1L'P7,S4Z];".Z_.MED!N;:]%T!KFQ`<'-9)`;ZRYJ,X/<
MW+S\6F*R/%7OV-1L<`VI>N9F*VM*U3,W.UDR52_?*+0#R<B:4AM[Q3A?J`G:
M?M>/`4,SMF&F]0R,&OT)/*_4V*HW^EU"V5RP2@<81]S8.V`MF0%TCJ9P?C!6
M)Y+S0U=FVFZYTSF4QMX*-4%9D?NYTQN]%$[A`)T4S/?JSZF.)-+J!%,TQ"O-
MI6WB8:8=@GDCL)"G+*LS7Y;DVAD'=`;!]PW8VEH)OE:7]"U)O8O!U^TE?9?=
M(N+[0^9^4'P+4!5&!NJRL0@3O\CC(^%IA5#MAD%)>/2"5WO0')OUI")+O;'9
MV^78">EI]A5%8-PC+WI[4IUHK-U/VT)2?@":@XK=`$\83_@ELTRO7FTGI&._
MICN(O1T:!LF#H2M[2\IX5+<`%'FLID/=L=;UN-Q6E_0C<]M8('KT1//=0B[2
M,J=Q*W/YU9HC>(A;-:UN+\SS93X!:#2<5C::BZ"K-XHZ879*>M8,U);LE=`.
MBVFTJ0M6CBS?SJUDTG8K2$_E#B,-R9\=B/YKXABIG*[LL;D#@8+">@@IU99V
M(":P\_(CSZ]I;C"A\LN0NHE870=Y`)D)M46CF-B+T`_(G'9^;WF!2_^=X06K
MVOH8L'CA*;9'CH,MUU9K@5;=<=MV%X4CTJML/Z`7Y(8H"6Z)!#YV$.7;15]0
M,".3]2_\Y`")J.$RU*%/U(^F4R]R:G$01;L=D_-,UW?NR+;1(F`S0H^`Q<+!
M=C01(B-NC!4H/%]#=GY3(BE+GY%+3RAOB@*AN[<(%5FFZK"BA($;-B?U(,DC
M(;V&ZP!33D3SI?V!BE9ZM+/@ETOV@!%9,)?$U>L"N;""C!6$-`_C,CFBDUT)
M87RK*701)`MI!<`8>7.ZX>B<1K7)A)=!%1G="X$L+2=82@"XV1**WP5Q*$62
M5#MF=>9MMF;2H?NK?7'OD4EH!SZ5JQYY09-O]-SWX$`KZP\ZT/0$N;>644?T
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M9#&9(O?&M:&+=;.=]OE8A!0=*W/'N6!V<.0M+"]8RH6V`(AJK[&UWBUT]>2W
M;RRJI,Z>EH\HJ=]K.T)$(J:DBE*;OC+!4>;&E]2?PIV*+5&VSTB5Z-B!@)!2
MF4ND3HD=".F`'\2D2&78J;`.'5M7D<ZX`X6.U*KS:J8@>YOAU5J,+16@]J))
MRB_-'$]CJROIP;/0%L)K@QA;?TD/HKDFKA3-DQ-ST915%#;LD2E6I\;*1LUJ
M`C<H[T`QJVV;^R846POKO;'Z9YZ/A!0Z;#@@Q@;V=E8AO]V.KQZ:>_=6ZG<E
M54YD#JC!IZU:0#7%%:0S,32VB(^6I:TD]H6#;^YYUS'P<T*L=J#VFI99*(O4
MXY@:J[CHQ70[%C.%]*07%A!(E47FIA-PVLL)J-*R$<W-H>S%`V0M5X7S\\J7
MO945N$2W,C92+'_I[RA*[BAIVDZ*[(=>D$JIO;DY7;P<J[%Q%UJ-%'FI>QS3
M7I[*8)H/YK`7J#)@%J3;IK":^PY+UXP(POG9Z=ST=S:X#@&O%I#"W83*UK4*
M'`D>F:=)UB^P313C@/'PQNIR"`Y.=UQZO)M\B9SJ[;::PZT34XL,KUM-H7D4
M*[GTB+P72BNA$\W8ND4(G.HM0?GMI]DK71!L>\7@U5@:>42TIP_$$D`N86"S
M;7<3IK8/YO8S:0M3#:=S:^1,/&S/5@_98DA-8!$J;R+KLT\<ZQ/'^L2Q/G&L
M3QSK[F6Y3QSK$\<Z@UJ?.-9N]+RY[XS7P*I<$>=91,;&#;RE>.C!L<';7:M9
M.V,&X&`:+`\*["9$R*K#<[.4YQN](.^)O!F,BL*H!J<&>U2+89&UQG+8^AWG
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MI!<9.DK9#$Z,O5YHP37'O,^A-#9J4E>XGJ#WAD?.]$)`#<);?C\>@]-##)$'
M0M[B%-P//;C`]2L2MWK6HPI:LCGQ(KQB=(\EJ,H-)":H+P:MKVIK;U'0547P
M>`>+_:Q%@%Z2'_1WXML8L;_=N/>.12=@ZF$[=`)*O!OAN2K8?,N!NK7&;VZA
MGOPLC0?D4"PG%\0/&+3)KA=RS<M0A<<2N^R=EL?PR5GI?VYH.<SP^4@5;/R,
M;7H&?"=N>J$!!!G#24/9I\0NQ:9Y[>O@(.>4\P3X,9&(:BXE4C<(G*Z"]1L2
MJP..7C`)?3BK<L2A0Z"3;C-Q-V5VT8@\1G[V/G=-C^=T^=!5(LR_!.6W7]FJ
M`.4[%XWQ''$[VNK%%$$L"]OWP;9]L&W"Y,9K7^*CVVBHF\WX1))@<[VA[B66
M\[2:R$K)-FN"17#P*F]D<O!WZW*FC[A^^Q'7R1WK,;EC`2.M"UKW$=9]A'4?
M8=U'6/<1ULH![B.L^PCKSJ`F'V%=H#CTD=5]9'7WG7#-1E8/^U=J](0!#WLE
M04[&<//*NIPX,1'+;0O4)A1;"^O86#4ISV)("LV7'!!S-:`*0-;-SCM0!K2S
MZLUM3@;":1]BI"4#X=38DU4+KH6>SYVHN]GL`]J#]P97?M6P-B4B'!HM_FD0
MU'+!,!QMHVL]ZXCT+HV3XAD>YBJO.E!=A;[Q7`YC=5U-4@`>S<AS/<R]>>K`
M&ACSRK,]>OU6+NEK.]5KJ/X1[KQCJVOI"!>6@REZ+K9N7#_`01@@"N0#FB+:
MC/+X@KZ@";8II*VE(BAE\8VE(:@9NU%Q_:JB(*+]SRX-GZE,"8`A4EN-P0'V
MZ=O3D'K<&ZV@G4;NA[OGE>@4[G:K';3C5>YR`MS:M8TMYSQ9+\R='''H$**)
MO@[="55W1G/F7!9F,*]I=Z,&MX_/]H.VBQ[.I>)M/+,<R_?1'%O0YW/S6VN>
MF7N/_$F7*SPV=Z.A[M@_:X$#>OC\3&3SW?,W=^$1NJ<H'POD,>O+U:OMA)/8
M\D+7-?WL9R3<SY?)=Y9W7L(U.'101_<FQV`7'>7"^@-P\\`)=U?B]>'C;RA\
MO(\2[J.$^RCAMV+&Z:P7OCC(T,AY>#-!AB;'*.LHWPK7PW8@M+F/YWR3XES+
MI6\'(LAUWM5)H0&"QQ`:&\B2;ZLAY?8CCHNQ;_%V5JN[S8NM-'9Y:G%%YQFK
M.9:]=@;!4LXST9<DED-[RTO%@>PU75`\VKJ7D0?V]==C<"',+4<Q#^<S]I;0
MI1"IP5D#L;_:@WIN*&EWBJG"-*+*9N!?6)ZWI`=T5,W^[IG_V8__+A664Z^3
MM@-K)+G7:T6_H>-[QBX.T"T[]#=YC"]EE,G/A$Q^8&<#S'*[.IRV9I?!R/YW
MB#W&22EC4O$%<-I@3RGRT)V+?J.:+^V'RI+Q#[IREV,/60&3-'?/]Y;W';L^
M<>FB0Y8/]IA*=U!_*,C-=#-R?LX0GB-/U3B$J&M>?!4+(PZ[8U=UN:),4N3;
M'?+YDG,%=>*"23?FKA44!%D.:[AIY7N#UPI=(PEQM):W;T,1%!I1KE-5'O"=
M<J;6W@6DQE[?`7>IK&@5AS7_Q-@!-VB=@YK44T%VP/.I!UU1194#;.QS=7ID
M,/QZPYW-QAJ)I>^3XE(XYY*LT8O?2C[8YI#5I7%)4.Z:D:B]=UMNY@L+>[$X
MW>2*+UJ'+=IZ5J):_?2W&,`MIA[4_.Q4+M!;DCOT:VALO2*E(@="M'UI(\2M
M;BM1PD3B&SE'+EV)H`CN0A*:K3Z7R2)7,(1*4MIM=4F_?'7(Q-*7DFGWWE$]
M/@*8#HW2L"OJ+1`R`:C4F6/.8JA<-(W*T33O\(S>ECZG5\O)!9FS\48=Y7^:
M`")UH-3NI^TS1GX`FIV!3B3)4/P<>!$K(!>@($7MCV*LAQK(B/%B&IJ9OZ++
ME"P12AZ\SD<R`9K^Q.([;3)U661Q7.(GXES*@ZN\:\U0?8X2*!PZ2Z/)G&KN
M;(98.D4R9_"\7D&"K>3U20]*B%PCNM4C%;=12-!MLH)DG+REA-H9!MQU6T*F
M,3>MFMU>PW.KE`'=]YST-&?1JYR];'!;-(`G-H#52^4R!T_=GMK4EQ6AE.MV
M5KI:=LH3K6.C;]UZ"J393CBBJP^%:KAVRKTLH@Q49AMM:#`[X3D&`B>HS^Z4
M3UBS-%1^A]H!+[*N*R\1N<[O0$IXI3V$P$TX*6SJ:[(*)F_\>LB89YHD_>7_
M`5!+`P04````"``,A)Q&K62)UI,-``"?A0``$0`<`'-G;6\M,C`Q-3`S,S$N
M>'-D550)``-8[C]56.X_575X"P`!!"4.```$.0$``.U=ZT\C.1+_?M+]#[Y\
M.,WH-B\8Y@#!KD(">T@P(,+N[;>5Z782+]UVUG8'LG_]E=W/I-])&(*NT4C3
MW2Z7J_I7KH?;F+.?7ET'+8B0E+/S5K_3:R'"+&Y3-CUO>;*-I45IZZ<?__ZW
MLW^TV^CA880&EJ(+,J+2<KCT!/DTOOV,?KMXN$%C:T9<C$;<\ES"%&JCF5+S
MTV[WY>6E,Z$,,XMBIR.$W;&XVT7M=LAW*`A6(`(:8460^3E%![W^4;OWI7UP
M_-@_/CWJG_:/.B?'!T?]D_Z_>KW37B_!X%=?!93X`0:=7N=+)TEVCZUG/"7H
M>I0@N[RZ&%R=#$<7P\OCWM'5\?'7WDFOW^OUKPXOOO:&7]N]GKD].#R$R_Y1
M[S`I.9\O!9W.%/ID?38BHX>._C?BC!''(4OT3S3F3`*E.\=LV4$#QT$/NHM$
M#T02L2!V)^`H_3<(H#!YRH"#YYZW$B_Q]4DX'2ZF75N)KEK.21>(VD!%!+5:
M03_*%D2JJ)_I(XG5F?)%UV_K@IR@2[]]V`\[`=::GXRZ3;!\,D.%+;K3E]5.
M4LU%]CBZ17?HKW6@5@X]M3+(-8F]IHD6Z:#7.^KZC0GYIQC/,\77#1G2VX1F
M"P,-&>2:A&:C`?(<PJN5"BR<A/06]Y@2R^PA@L8,(!S*G@M&T<U/6$:CO*;H
M7PX-=?_DY*1K6D-2AJDEL\4Q31D`6)X0X`_RE`A:LRQCZO(5J21F4^QR,_$/
MS"2*B<FK-<L>0;=D<*\P+<(I@942],E3Y(H+=T0FV'/`H#SVIX<=.J'$!H?G
M$.VN5@@2S0J+*5'?L$OD'%NDJE99F`""_>YOMS>^HVS!C$?HC+IS+A3RI_X-
MMXPC++``?=<.C:VM'[7[!_!R.J\2I&69<N99:G<+$4)+W$B$V(PW$B&<_7KL
MH[Q1L]U%_?'6C4H/>J(5[G^MI'#:*+>1@;-OVXJ1#!F51#$\,CUJESA*1B&B
M'4_5/)&*P\JNI-%/:@J3"A+595F/&_JBPNB%,:?^Z,F0$MZTX_A228JLL+2!
M),FX$-W5?2.9T:6^,%$(,5=UA4@%H/H")%*NX+HN*AE)6WTQXA#O7[;C:%])
MB'2*4%^&,,O3%W7'7\\0-Q@]S$G-5>WQUS/:0`#,&%=F5'.OG\SGE$UX<`L/
M=+`[%=PAC^#P$+7/6X_$G3M0ZMR8]$PW_?)P79I9=#5A=[5OO:0QDBF4RB90
MEU$C?4__0,V6*-_"H9`>ZZR[WF.=F2>)?<=^--=S`:4-\U],HG=`4M33PH[E
M.1MTC"7+[Q<\#<%8PRA\3P]D@DSJ?(J%I6F+$^SN7/`Y$8I"-$ODYX;!3)#)
M>4NGP^T0QM]!PP[@%I*D!E@%SX"^]E("(4,.BBK-8A@3&<3D#P@[T3`ZVH(D
M,&$<\I;%1O=]7BJ@7_>EKAI,]CL=132EK_2=%'?P4UW%H0MQ\G6^T<W[JBXX
MEKKJKONB;*WO$U2UE8^\>V5?KO`K9]Q=^B*&3C?\?\#L2P:"+:\AD@C7"-4R
MH>,!R'^O1%[D[/L9WCZZQ,Q&/CN4X%?/_V_LQ3</'-O[_VU1'(/89BUAR)E-
M&`P-%Y([U(;G]@5V=-4]GA&B9`+,.KW*,.UK3".&2*]/!CQ1DBD*N"*?;0/M
M+J&]QU"WJ!E1%-[49CBOLB@#_6`CT-&GE5$^-T:PI1%$K?)N<@<AS:A8?:+G
M="\#_[`B^#%[Q"<H'J"!?8>PZV\\@LR`AB[(#9>;H9_F4F8$7S8R@I5QD!ZH
M,89=&@.6LRN'OVQH!%'O,O"/-@,?^",S0`-Z>7H>?>V^P)(".LEB`9+OL>>Z
M6"SO)F,Z970"\11R<LNLIE(VO0<(+*AOD@G\;AB6F<97D^)'8\&-&4[COU+N
MZ(P_&%*W)09%\:@H'+8QF!H&<X6I^!4['KDE6-_K"9AI")F$90#_.P6P9H,,
M'Y1@U$!6`[);+)Z)PD\.&1/+$U3ES=U,PC+(CE.0Q6Q0S*=!K*97ML!MCJCC
M0:C[1I3.9NZ)&,^@QLGUNP5=RE`\R?2LEO&D`4L$/$U6A8`K,FP;4&M-PS^X
M&'I2<9<(71(K!O_/Z%SJ`*F@?B%3@-!QJ*YJ\V9H/1XEL/=[&9,71D#1$#^@
MY"!^8`V'0=$XC1W4L(-KT(!-*;C'@92K2V<%1&5(]E-(QBR0SZ-!J19*0$8>
M\6O.3$RVEV%SD(&-[HU,]P:6&K",%;>>(33I0M.=0U68^I101EH&UF$*+,.H
M;3BA)*L&N.]4:+Y9P5FU\.Q_>9/"$WT*KYK5ZFUKT$==;V1;2`%Y&>Y'%>M1
M],EGV."X;6%:@&,!>1F.Z86CS"*U@?$[%#:%"&_"J0S\]*+21D5.8QR[J'8*
MT,\A+8,WO0"5JGP:Z':7:Q<`6-BA#,;T"E1>WMV@N:ND*<J2LQJ#CW:7?WIT
M@1W]8+#`U-&O_HJ+,4Z&87#/0VZ26_];H*1V\$'^AN(GZE"U'$&TI4[E!.T=
M1"NQT(/T8EE.,MA.U@#9-/$WRX02/Z!(C?:$B[96))F=Z,`4ZX)6E$&1-NB3
MKT\S/;:='@/;-M)A)[%OL*8=%_$H,[CTFEZNP<7#)/<X-J:P,T]IS8CM.00<
MSPQX$7G-+J6BKMZ)$-'KK2Z[=8([';7,W-++E/G^+1#,>#%?-$09BH1+]C0[
M<QJG]1:6FE41QS9S;7[/RD2;`KNKRZ/,BM+KI]FE]JH1)<9I3&%7IE`W?M7E
M468*Z573/%-HPM?WVCQ0UR8VYU9F'>FUU2I;#AIC><^UN_H>96?LR\PI:XEW
MDU6^QK[>T;X>R((P3_]O\2FC?Q'[%P;)XF`JB$D]=V=J%4<JL[I=K2VW42@0
MBB5"GA8)13(U)O@]7%SXMO]+U6Q,IRX>.+:@UFS(Q9S[=<M;N\$M12@SVJPM
MFQNZRL@T7T!49&1M!\*BA+2-5]T;DQ[Q%[CGTJ)$MUVS>T?OC9@"9)ZCO/H9
MXKL)4V;FZ2\*.S)SD%H_XN-`;+WT801'"<D;DW]/DQ_J\\ZX8!1?,ZFH\D],
M>R!3PLS:TX+<$IM:E+VUN>]&D!)3/]S1/E[]RU:1O"@2&,$#E!09A3(W1KY3
M(U__`C[$0BPIFP;KO'&S]-L+S'1#5F6&5F&;L3$B?[!X!3@Q7O1-OK&0[2VD
MKO>JT[_,%K*V-:=MH?$/;[(IO3[PE;J689Y>W4]N96_@WBG<V?MILI]>ONI+
M4F`!FW,K,XKT.G_NUIV"IF#,_P=3.>LF#]6#N]5#]\Z"(WP-BOJXJ-^+#D8:
M/$G(Y"SE'_EWWJI&ZY__9`Z!/H5G$*RO%7&UC"TDO2<_\X,>/PONS4-""B0M
MY%_/B:#<?C1L;$\$OX?!J&/VKYRWE/"`%0X&#.^[.0I>2DOPE^AS<*A+ZG%2
M;)<SL!2QW$)P_^A@523W!#OF!"_3]\D_<N:\90G(@%6^/D.N^85K-6'Y*$.]
M<IMWK%\58#93\!M1]X);A-CR2G#W6DI/=[SWGAQJW4TF1)M4J&Y%XKU1WB9/
M1;I?4`ZU$`2^6^(^$1%JF7KLZ^.?>W]J<Q=3]JZ3;#RC@@RFJU*O/=P[F;.7
M/]=T*";:-YW*]NNL*E>5>M^T_.9IN>XF^H]"8&'-P`-,!78CGY#7G/0"E"DR
M)>+[.('<Z0Z.Z'$&O@%*&I?BM4F?W;AO8(RI]>R0(7$<R-,()%_K$RBG>=_T
MN%,S(L!4_B"6DJLZ9#;MF_R#*03[*5:)U;[@PU_PV<_X+>H0J2``WA(UXW9`
M,+!F%*[L4-^=L-J;D%N6;VRA[:5#S9K$(P=20A=D!V\P@^>'>9611K&RH($>
M(7PQ113[DH&7Y&B1"O=X:7+K`"<[I6.:X,,@N5I&,/N&6KJ$C@N*,,B"6[0]
M<(N#^5SPQ?I>A^RJ9`MV>Q?"K_5<UK/;SS4>B7#O)BG]RZB2:H5"O:]>H:AC
M(A8`5C!=#1S9)6:HZ@8=/\RLB-QZ:*X_$T8>S9\]DBG7GTFS=_8;2AE8:(9"
M111[JTZ!'A]#@3AQ*%`EAVCOE-HB'7KD%R3>MW;'!I9%YN:/<H'Z\[E#K5"X
M;1.ORB-]&'?URWPBH,0/@NT5(6MU37[[OA4W*4ES5?A`\#SP)7;4,MR>J;]2
M6(K8@1VNI)252/<E?R[5FT"*1^Q0)YBL<>Z0;@E,$>P0A`.4U3N[LLBO)$J9
ML(;)3GYK==D7$$N*H#L(-]0E\;R[Q(+%]IK;_$'4N_=-#4_!]_O6J$^$2<PV
M_;%A;#XRZ$/!X^\1&W3<,P-?KUZA6EOU/N9$K`7EGDQ9^F9]/XS##O:4AILS
M5X-I3N.^1=(!"((='>L?B/Z+91!#T@ZKD.;#P`4*C+PHMH1W>R-^Z3(3HZX7
M^PH2HS*&Z*\/?P.?\LR9/G7."!3/POH]]V\!(GNQ(##((9=*[XH-=G:4?/W.
M[?11;.%G`4'NRF/ZK\T/7'W87ZAP5LM'T2K,8E?K+S]*ZHW,_CJ2_@U1('#X
M/.FB-NO[0;(/O3PH_<,7DMMO4H_W;]+&O^26R.K7'JY(#4_>V<U4WD6_]NV\
M=K]]RP36-NRN;_;*;=ZS_5U#(@B4&_\!'PCY`,SX1\(>!<'FR(>[R<#Y:T:@
M%!&97Z<W[+QO4*;5>('V94*3>RR>P5UQ5O$U5.W_GF_BK.O_,6.X_!]02P$"
M'@,4````"``,A)Q&E"Q8"J^O``"AO1$`$0`8```````!````I($`````<V=M
M;RTR,#$U,#,S,2YX;6Q55`4``UCN/U5U>`L``00E#@``!#D!``!02P$"'@,4
M````"``,A)Q&BTW#LE\+``"(D@``%0`8```````!````I('ZKP``<V=M;RTR
M,#$U,#,S,5]C86PN>&UL550%``-8[C]5=7@+``$$)0X```0Y`0``4$L!`AX#
M%`````@`#(2<1C8S%]+'%```LFD!`!4`&````````0```*2!J+L``'-G;6\M
M,C`Q-3`S,S%?9&5F+GAM;%54!0`#6.X_575X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(``R$G$9=N6&56ST``$]3`P`5`!@```````$```"D@;[0``!S9VUO
M+3(P,34P,S,Q7VQA8BYX;6Q55`4``UCN/U5U>`L``00E#@``!#D!``!02P$"
M'@,4````"``,A)Q&G<@O[,DE```4S`(`%0`8```````!````I(%H#@$`<V=M
M;RTR,#$U,#,S,5]P<F4N>&UL550%``-8[C]5=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`#(2<1JUDB=:3#0``GX4``!$`&````````0```*2!@#0!`'-G
M;6\M,C`Q-3`S,S$N>'-D550%``-8[C]5=7@+``$$)0X```0Y`0``4$L%!@``
0```&``8`&@(``%Y"`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>23
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E
M-C`W93,Q,3<B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F
M9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93<Q
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VYD
M96YS961?0V]N<V]L:61A=&5D7U-T871E;64R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0F%S:7-?;V9?4')E<V5N=&%T:6]N7V%N
M9%]3=6UM/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M1F%I<E]686QU95]-96%S=7)E;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DUA<FME=&%B;&5?4V5C=7)I=&EE<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D)A<VEC7V%N9%]$:6QU
M=&5D7TYE=%],;W-S7U!E<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DUA:F]R7T-U<W1O;65R<U]087)T;F5R<VAI<'-?83PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?
M07-S971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M26YC;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VX\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"87-I<U]O9E]0<F5S96YT871I;VY?
M86YD7U-U;6TQ/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^1F%I<E]686QU95]-96%S=7)E;65N=%]486)L97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y-87)K971A8FQE7U-E8W5R:71I
M97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^36%J;W)?0W5S=&]M97)S7U!A<G1N97)S:&EP<U]A,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?07-S971S
M7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N7U1A8FQE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE
M;G1?4W5M;6%R>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1?061D:71I;SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R
M96UE;G1?4V-H961U;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DUA<FME=&%B;&5?4V5C=7)I=&EE<U]38VAE9'5L93PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DUA<FME=&%B;&5?4V5C
M=7)I=&EE<U]!9&1I=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D)A<VEC7V%N9%]$:6QU=&5D7TYE=%],;W-S7U!E<C$\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y-86IO<E]#=7-T
M;VUE<G-?4&%R=&YE<G-H:7!S7V$R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^36%J;W)?0W5S=&]M97)S7U!A<G1N97)S:&EP<U]A
M,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DUA:F]R
M7T-U<W1O;65R<U]087)T;F5R<VAI<'-?830\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y-86IO<E]#=7-T;VUE<G-?4&%R=&YE<G-H
M:7!S7V$U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M36%J;W)?0W5S=&]M97)S7U!A<G1N97)S:&EP<U]A-CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?07-S971S7T-A
M<G)Y:6YG7U9A;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DEN=&%N9VEB;&5?07-S971S7T%D9&ET:6]N86Q?23PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]!9&1I
M=&EO;F%L7TEN9F]R;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N7U-T;V-K0CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO
M>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7
M;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO
M>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO
M>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS
M93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO
M>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H
M:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L
M(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E
M,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-S$P,S0T,%\T
M8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O5V]R:W-H965T<R]3:&5E=#`Q
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,4-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$
M;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^07!R+B`R-"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!!;F0@
M16YT:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M43QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L
M86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/DUA<B`S,2P-"@D),C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@
M1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O
M8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/E$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^4T=-3SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4T%.1T%-3R!"24]3
M0TE%3D-%4R!)3D,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,3`P,3(S,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&
M:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y,87)G92!!8V-E;&5R871E9"!&:6QE
M<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2PU.#(L-SDW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T
M8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S
M,3$W+U=O<FMS:&5E=',O4VAE970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%/04<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!"
M86QA;F-E(%-H965T<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C4L,C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V+#`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R:V5T86)L92!S96-U<FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S`L-C0W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<R
M+#DS,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT97)E<W0@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#8S.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#,V.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I
M9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#,L.30V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3DP+#@W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36%R:V5T86)L92!S96-U<FET:65S+"!N;VXM8W5R<F5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL.#(R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L,C8P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L.3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PT-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S+"!I
M;BUP<F]C97-S(')E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#<P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU.#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4X-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S
M."PU,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-#,L,C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#`V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PW,#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8V]M
M<&5N<V%T:6]N(&%N9"!E;7!L;WEE92!B96YE9FET<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PW,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@U,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-C<F]W(&QI86)I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$L,3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.2PP-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PY-C@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PX.#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R
M<F5D(')E=F5N=65S+"!N;VXM8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L,#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,L,30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT(&-O;G-I9&5R
M871I;VX@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@=&%X(&QI86)I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#`Q-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#4W.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6ET;65N=',@86YD(&-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=&]C:VAO;&1E<G,G(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,2!P87(@
M=F%L=64[(#$V,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D+"`V.2PT.3<L
M,C4V(&%N9"`V.2PP-C(L,SDT('-H87)E<R!I<W-U960@86YD(&]U='-T86YD
M:6YG(&%T($UA<F-H(#,Q+"`R,#$U+"!A;F0@1&5C96UB97(@,S$L(#(P,30L
M(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-30P+#8S-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S-"PU,3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA
M=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,S
M,RPX-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,S(X+#4U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I
M=F4@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`W+#0X.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P-BPV,S,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,X+#4P-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C0S+#(Q,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93<Q,#,T
M-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V
M,#=E,S$Q-R]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1D%#
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T
M960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-T871E;65N="!/9B!&:6YA;F-I86P@4&]S:71I;VX@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E
M<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y+#0Y
M-RPR-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV.2PP-C(L,SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-CDL-#DW+#(U
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8Y+#`V,BPS.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-S$P,S0T,%\T8F,T7S0P
M9#1?.#0Q-E]F9#)E-C`W93,Q,3<O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%,DM!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYD96YS
M960@0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@3W!E<F%T:6]N<R`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2979E;G5E<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO
M;B!A9W)E96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$R+#8W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-RPU-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&=R86YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-30X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#0Y,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,3$V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PY.#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP.#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#<S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L-C0T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PW,3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-2PW,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-BPR,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-RPV,3$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!A;F0@;W1H
M97(@:6YC;VUE+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]S<R!B969O<F4@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+#`V-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#4W,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E;F5F:70@9G)O
M;2!I;F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#4L,S$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H-RPU-S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N970@;&]S
M<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,"XP."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,@=7-E9"!I;B!C;VUP=71I;F<@8F%S:6,@
M86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV.2PR.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPQ.3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?-#!D-%\X
M-#$V7V9D,F4V,#=E,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$1!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E;65N=',@
M;V8@0V]M<')E:&5N<VEV92!,;W-S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE;G0@3V8@26YC
M;VUE($%N9"!#;VUP<F5H96YS:79E($EN8V]M92!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4L,S$Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RPU
M-S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#:&%N9V4@:6X@=6YR96%L:7IE9"!G86EN(&]N(&%V86EL86)L92UF
M;W(M<V%L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E(&QO<W,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H-2PR-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@W+#4V,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?-#!D
M-%\X-#$V7V9D,F4V,#=E,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O5V]R
M:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Q!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E;65N
M=',@;V8@0V%S:"!&;&]W<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG($%C=&EV:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4L,S$Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H-RPU-S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N
M970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@<')E
M;6EU;2!O;B!M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DU,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!C;VYT:6YG96YT(&-O;G-I9&5R
M871I;VX@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#@P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT86YG:6)L92!I;7!A:7)M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@W,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5N969I="!F<F]M(&EN8V]M
M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S0X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY.970@8VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L
M:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YT97)E<W0@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S,P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPR,#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P
M86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@
M86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,BPT-S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PW,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8V]M<&5N<V%T:6]N(&%N9"!E
M;7!L;WEE92!B96YE9FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PQ-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PW,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PX.#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V
M:61E9"!B>2`O("AU<V5D(&EN*2!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS.3,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,S<Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DEN=F5S=&EN9R!!8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@;6%R:V5T86)L
M92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M.2PT,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,38L-S<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%T=7)I=&EE<R!O9B!M87)K971A8FQE('-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#DU-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M+#<X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#@T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!P<F]V:61E9"!B>2!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-#0X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX.#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1FEN86YC:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<'5B;&EC(&]F9F5R
M:6YG(&]F(&-O;6UO;B!S=&]C:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RPW.#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A>&5S('!A
M:60@<F5L871E9"!T;R!N970@<VAA<F4@<V5T=&QE;65N="!O9B!E<75I='D@
M87=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3<X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPU.#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P
M<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPQ-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$L,S<Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8W)E87-E
M(&EN(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Y+#(R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-BPV,S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',L(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L,#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3@V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S+"!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-2PR-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C8L.#(S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE
M;G1A;"!D:7-C;&]S=7)E(&]F(&YO;F-A<V@@:6YV97-T:6YG(&%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y+"!P;&%N="!A;F0@97%U:7!M96YT(&EN8VQU9&5D(&EN(&%C
M8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-3<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T
M7S@T,39?9F0R938P-V4S,3$W+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D)A<VES(&]F(%!R
M97-E;G1A=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M3TQ)0TE%4R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
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M.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H92!A8V-O;7!A;GEI;F<@=6YA=61I
M=&5D(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N
M=',@;V8@4V%N9V%M;R!":6]38VEE;F-E<RP@26YC+B`H)B,X,C(P.U-A;F=A
M;6\F(S@R,C$[(&]R('1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3LI(&AA=F4@
M8F5E;B!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@52Y3+B!G96YE<F%L
M;'D@86-C97!T960@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&9O<B!I;G1E<FEM
M(&9I;F%N8VEA;"!I;F9O<FUA=&EO;B!A;F0@<'5R<W5A;G0@=&\@=&AE(')U
M;&5S(&%N9"!R96=U;&%T:6]N<R!O9B!T:&4@4V5C=7)I=&EE<R!A;F0@17AC
M:&%N9V4@0V]M;6ES<VEO;B`H4T5#*2X@06-C;W)D:6YG;'DL('1H97D@9&\@
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M=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A<F4@;F]T
M(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(')E<W5L=',@=&AA="!M
M87D@8F4@97AP96-T960@9F]R('1H92!Y96%R(&5N9&EN9R!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$U+B!4:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA
M;F-E('-H965T(&1A=&$@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"!W97)E
M(&1E<FEV960@9G)O;2!T:&4@875D:71E9"!C;VYS;VQI9&%T960@9FEN86YC
M:6%L('-T871E;65N=',@:6YC;'5D960@:6X@4V%N9V%M;R8C.#(Q-SMS($9O
M<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@
M,C`Q-"P@87,@9FEL960@=VET:"!T:&4@4T5#+B!4:&5S92!F:6YA;F-I86P@
M<W1A=&5M96YT<R!S:&]U;&0@8F4@<F5A9"!I;B!C;VYJ=6YC=&EO;B!W:71H
M('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@9F]O=&YO=&5S('1H97)E
M=&\@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30L
M(&EN8VQU9&5D(&EN(%-A;F=A;6\F(S@R,3<[<R!&;W)M(#$P+4LL(&%S(&9I
M;&5D('=I=&@@=&AE(%-%0RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ.'!T.VUA<F=I;BUL969T.C(N,C8E.W1E
M>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L
M:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY5
M<V4@;V8@17-T:6UA=&5S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M
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M;W-E(&5S=&EM871E<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HQ.'!T.VUA<F=I;BUL969T.C(N,C8E.W1E>'0M
M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY2979E
M;G5E(%)E8V]G;FET:6]N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M
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M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P
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M96YU92!!<G)A;F=E;65N=',@*$%352`R,#`Y+3$S*3QF;VYT('-T>6QE/3-$
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M=&\@=&AE(&%D;W!T:6]N(&]F($%352`R,#`Y+3$S+"!T:&4@0V]M<&%N>2!R
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M:7,N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US='EL
M93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^375L=&EP;&4@16QE;65N="!!<G)A
M;F=E;65N=',@869T97(@=&AE(&%D;W!T:6]N(&]F($%352`R,#`Y+3$S+CQF
M;VYT('-T>6QE/3-$9F]N="US='EL93IN;W)M86P[/B!!4U4@,C`P.2TQ,R!A
M;65N9&5D('1H92!A8V-O=6YT:6YG('-T86YD87)D<R!F;W(@8V5R=&%I;B!M
M=6QT:7!L92!E;&5M96YT(')E=F5N=64@87)R86YG96UE;G1S('1O.B`\+V9O
M;G0^/"]P/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.30N,C<E.VUA<F=I;BUL
M969T.C4N-S,E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z,RXS,R4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y;&4],T1M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MF;VYT+69A;6EL>3HG
M4WEM8F]L)SMF;VYT+7-I>F4Z,3!P=#L^)B,Q.#,[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.38N-C<E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O;G0M9F%M
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M969T/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[
M('=I9'1H.CDT+C(W)3MM87)G:6XM;&5F=#HU+C<S)3LG/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C,N,S,E.W=H:71E+7-P86-E
M.FYO=W)A<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HV<'0[9F]N="UF86UI;'DZ)U-Y;6)O;"<[9F]N="US:7IE.C$P<'0[
M/B8C,3@S.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I
M9'1H.CDV+C8W)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C9P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SYR97%U:7)E(&%N(&5N=&ET>2!T;R!A;&QO8V%T92!A<G)A;F=E;65N="!C
M;VYS:61E<F%T:6]N('1O(&5A8V@@96QE;65N="!B87-E9"!O;B!A('-E;&QI
M;F<@<')I8V4@:&EE<F%R8VAY('=H97)E('1H92!S96QL:6YG('!R:6-E(&9O
M<B!A;B!E;&5M96YT(&ES(&)A<V5D(&]N('9E;F1O<BUS<&5C:69I8R!O8FIE
M8W1I=F4@979I9&5N8V4@*%933T4I+"!I9B!A=F%I;&%B;&4[('1H:7)D+7!A
M<G1Y(&5V:61E;F-E("A44$4I+"!I9B!A=F%I;&%B;&4@86YD(%933T4@:7,@
M;F]T(&%V86EL86)L93L@;W(@=&AE(&)E<W0@97-T:6UA=&4@;V8@<V5L;&EN
M9R!P<FEC92`H15-0*2P@:68@;F5I=&AE<B!64T]%(&YO<B!44$4@:7,@879A
M:6QA8FQE.R!A;F0@/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S
M93IC;VQL87!S93L@=VED=&@Z.30N,C<E.VUA<F=I;BUL969T.C4N-S,E.R<^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,RXS,R4[
M=VAI=&4M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C9P=#MF;VYT+69A;6EL>3HG4WEM8F]L)SMF;VYT
M+7-I>F4Z,3!P=#L^)B,Q.#,[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$=VED=&@Z.38N-C<E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M;&QI;F<@<')I8V4@;65T:&]D+B`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D
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M9G1E<B!*86YU87)Y)B,Q-C`[,2P@,C`Q,2P@=&AE($-O;7!A;GD@86QL;V-A
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M(&5X:7-T<RP@=&AE($-O;7!A;GD@=7-E<R!%4U`@9F]R('1H870@9&5L:79E
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M:7)E*2P@:6X@2F%N=6%R>2`R,#$R(&%N9"!":6]G96X@26YC+BP@9F]R;65R
M;'D@0FEO9V5N($ED96,@26YC+B`H0FEO9V5N*2!I;B!*86YU87)Y(#(P,30@
M=V5R92!E=F%L=6%T960@=6YD97(@=&AE<V4@86UE;F1E9"!A8V-O=6YT:6YG
M('-T86YD87)D<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M;B!T:&4@0V]M<&%N>28C.#(Q-SMS('!E<F9O<FUA;F-E+B`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[=&5X
M="UI;F1E;G0Z-"XU-"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^36EN:6UU;2!A;FYU86P@<W5B;&EC96YS92!F965S(&%R92!A;'-O(')E
M8V]G;FEZ960@87,@<F5V96YU92!I;B!T:&4@<&5R:6]D(&EN('=H:6-H('-U
M8V@@9F5E<R!A<F4@9'5E+B!2;WEA;'1Y(')E=F5N=65S(&%R92!G96YE<F%L
M;'D@<F5C;V=N:7IE9"!W:&5N(&5A<FYE9"!A;F0@8V]L;&5C=&%B:6QI='D@
M;V8@=&AE(')E;&%T960@<F]Y86QT>2!P87EM96YT(&ES(')E87-O;F%B;'D@
M87-S=7)E9"X@5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!C;W-T(')E:6UB=7)S
M96UE;G0@<F5V96YU92!U;F1E<B!C;VQL86)O<F%T:79E(&%G<F5E;65N=',@
M87,@=&AE(')E;&%T960@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S
M(&9O<B!S97)V:6-E<R!A<F4@<F5N9&5R960N($1E9F5R<F5D(')E=F5N=64@
M<F5P<F5S96YT<R!T:&4@<&]R=&EO;B!O9B!R97-E87)C:"!O<B!L:6-E;G-E
M('!A>6UE;G1S(')E8V5I=F5D('=H:6-H(&AA=F4@;F]T(&)E96X@96%R;F5D
M+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M<F=I;BUT;W`Z,3AP=#MM87)G:6XM;&5F=#HR+C(V)3MT97AT+6EN9&5N=#HP
M)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4F5C96YT($%C8V]U
M;G1I;F<@4W1A;F1A<F1S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DEN($%U9W5S="`R,#$T('1H
M92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@:7-S=65D
M($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`H05-5*2!.;RX@,C`Q-"TQ
M-2P@/&9O;G0@<W1Y;&4],T1F;VYT+7-T>6QE.FET86QI8SL^1&ES8VQO<W5R
M92!O9B!5;F-E<G1A:6YT:65S(&%B;W5T(&%N($5N=&ET>28C.#(Q-SMS($%B
M:6QI='D@=&\@0V]N=&EN=64@87,@82!';VEN9R!#;VYC97)N/"]F;VYT/B`H
M05-5(#(P,30M,34I+B!!4U4@,C`Q-"TQ-2!R97%U:7)E<R!M86YA9V5M96YT
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M92!C=7)R96YT(&=U:61A;F-E+B!!4U4@,C`Q-"TQ-2!I<R!E9F9E8W1I=F4@
M9F]R('1H92!#;VUP86YY(&EN('1H92!F:7)S="!Q=6%R=&5R(&]F(#(P,38@
M=VET:"!E87)L>2!A9&]P=&EO;B!P97)M:71T960N(%1H92!#;VUP86YY(&1O
M97,@;F]T(&)E;&EE=F4@=&AE(&EM<&%C="!O9B!A9&]P=&EN9R!!4U4@,C`Q
M-"TQ-2!O;B!I=',@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S
M('=I;&P@8F4@;6%T97)I86PN/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DEN($UA>2`R,#$T('1H
M92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@:7-S=65D
M($%352`R,#$T+3`Y+"`\9F]N="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC
M.SY2979E;G5E(&9R;VT@0V]N=')A8W1S('=I=&@F(S$V,#M#=7-T;VUE<G,\
M+V9O;G0^)B,Q-C`[*$%352`R,#$T+3`Y*2X@5&AI<R!S=&%N9&%R9"!O=71L
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M:6YC:7!L92!O9B!!4U4@,C`Q-"TP.2!I<R!T;R!R96-O9VYI>F4@<F5V96YU
M97,@=VAE;B!P<F]M:7-E9"!G;V]D<R!O<B!S97)V:6-E<R!A<F4@=')A;G-F
M97)R960@=&\@8W5S=&]M97)S(&EN(&%N(&%M;W5N="!T:&%T(')E9FQE8W1S
M('1H92!C;VYS:61E<F%T:6]N('1H870@:7,@97AP96-T960@=&\@8F4@<F5C
M96EV960@9F]R('1H;W-E(&=O;V1S(&]R('-E<G9I8V5S+B!!4U4@,C`Q-"TP
M.2!P<F]V:61E<R!C;VUP86YI97,@=VET:"!T=V\@:6UP;&5M96YT871I;VX@
M;65T:&]D<SH@*&DI)B,Q-C`[87!P;'D@=&AE('-T86YD87)D(')E=')O<W!E
M8W1I=F5L>2!T;R!E86-H('!R:6]R(')E<&]R=&EN9R!P97)I;V0@<')E<V5N
M=&5D("AF=6QL(')E=')O<W!E8W1I=F4@87!P;&EC871I;VXI.R!O<B`H:6DI
M)B,Q-C`[87!P;'D@=&AE('-T86YD87)D(')E=')O<W!E8W1I=F5L>2!W:71H
M('1H92!C=6UU;&%T:79E(&5F9F5C="!O9B!I;FET:6%L;'D@87!P;'EI;F<@
M=&AE('-T86YD87)D(&%S(&%N(&%D:G5S=&UE;G0@=&\@=&AE(&]P96YI;F<@
M8F%L86YC92!O9B!R971A:6YE9"!E87)N:6YG<R!O9B!T:&4@86YN=6%L(')E
M<&]R=&EN9R!P97)I;V0@=&AA="!I;F-L=61E<R!T:&4@9&%T92!O9B!I;FET
M:6%L(&%P<&QI8V%T:6]N("AM;V1I9FEE9"!R971R;W-P96-T:79E(&%P<&QI
M8V%T:6]N*2X@5&AI<R!G=6ED86YC92!I<R!E9F9E8W1I=F4@9F]R(&%N;G5A
M;"!R97!O<G1I;F<@<&5R:6]D<R!B96=I;FYI;F<@869T97(@1&5C96UB97(F
M(S$V,#LQ-2P@,C`Q-BP@:6YC;'5D:6YG(&EN=&5R:6T@<&5R:6]D<R!W:71H
M:6X@=&AA="!R97!O<G1I;F<@<&5R:6]D+"!A;F0@96%R;'D@87!P;&EC871I
M;VX@:7,@;F]T('!E<FUI='1E9"X@5&AE($-O;7!A;GD@:7,@8W5R<F5N=&QY
M(&EN('1H92!P<F]C97-S(&]F(&5V86QU871I;F<@=&AE(&EM<&%C="!O9B!T
M:&4@<&5N9&EN9R!A9&]P=&EO;B!O9B!!4U4@,C`Q-"TP.2!O;B!I=',@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+B`\+W`^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T
M,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P
M-V4S,3$W+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G0\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY&86ER(%9A;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-
M96%S=7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY.3U1%(#(F(S@R,3([1D%)4B!604Q512!-14%355)%345.5"`\+W`^
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M;G0@8V]N<VED97)A=&EO;B!L:6%B:6QI='DN)B,Q-C`[5&AE(&9A:7(@=F%L
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M87,@9F]L;&]W<SH@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:6QI=&EE<SL@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M;&P@=&5R;2!O9B!T:&4@87-S970@;W(@;&EA8FEL:71Y.R!A;F0\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MM
M87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`S.B!0<FEC97,@;W(@=F%L
M=6%T:6]N('1E8VAN:7%U97,@=&AA="!R97%U:7)E(&EN<'5T<R!T:&%T(&%R
M92!B;W1H('-I9VYI9FEC86YT('1O('1H92!F86ER('9A;'5E(&UE87-U<F5M
M96YT(&%N9"!U;F]B<V5R=F%B;&4@*&DN92XL('-U<'!O<G1E9"!B>2!L:71T
M;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y*2X@/"]P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT
M.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H92!F
M86ER('9A;'5E(&UE87-U<F5M96YT<R!O9B!O=7(@8V%S:"!E<75I=F%L96YT
M<RP@879A:6QA8FQE+69O<BUS86QE(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!A
M;F0@8V]N=&EN9V5N="!C;VYS:61E<F%T:6]N(&QI86)I;&ET>2!A<F4@:61E
M;G1I9FEE9"!A="!T:&4@9F]L;&]W:6YG(&QE=F5L<R!W:71H:6X@=&AE(&9A
M:7(@=F%L=64@:&EE<F%R8VAY("AI;B!T:&]U<V%N9',I.B`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT
M<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#@E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE
M.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DUA<F-H(#,Q+"`R,#$U/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#$T('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z-#@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`S/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%S
M<V5T<SH\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C$W+#`X.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&]T
M86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ-RPP.#D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z.24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,S$L,30X/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C4P)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HR-RXS-7!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^0V]R<&]R871E(&1E8G0@<V5C=7)I
M=&EE<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(W+C,U<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T('-E
M8W5R:71I97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,30V+#`U-3PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXR,#`L-#8Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`P+#0V
M.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(Q-RPU-3@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C$W+#`X.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,C`P+#0V.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z.7!T.SXF;F)S
M<#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#@E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/D1E8V5M8F5R(#,Q+"`R,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#$T('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z-#@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`S/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%S
M<V5T<SH\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/DUA<FME=&%B;&4@<V5C=7)I=&EE<SH\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[=VAI
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS,RPW-#@\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(W
M+C,U<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY#;W)P;W)A=&4@9&5B="!S96-U<FET:65S
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,BPX,3,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$V,RPV,S$\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C(R,"PQ.3(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,C`L,3DR/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M(&5Q=6EV86QE;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C(R,"PQ.3(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z9&]U8FQE
M(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT
M;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,2PX,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PX,#`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL
M93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY);G9E<W1M96YT<R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M;"`R+B!);G-T<G5M96YT<R!C86X@8F4@8VQA<W-I9FEE9"!A<R!,979E;"`R
M('=H96X@;V)S97)V86)L92!M87)K970@<')I8V5S(&9O<B!I9&5N=&EC86P@
M<V5C=7)I=&EE<R!T:&%T(&%R92!T<F%D960@:6X@;&5S<R!A8W1I=F4@;6%R
M:V5T<R!A<F4@=7-E9"X@5VAE;B!O8G-E<G9A8FQE(&UA<FME="!P<FEC97,@
M9F]R(&ED96YT:6-A;"!S96-U<FET:65S(&%R92!N;W0@879A:6QA8FQE+"!S
M=6-H(&EN<W1R=6UE;G1S(&%R92!P<FEC960@=7-I;F<@8F5N8VAM87)K(&-U
M<G9E<RP@8F5N8VAM87)K:6YG(&]F(&QI:V4@<V5C=7)I=&EE<RP@<V5C=&]R
M(&=R;W5P:6YG<RP@;6%T<FEX('!R:6-I;F<@86YD('9A;'5A=&EO;B!M;V1E
M;',N(%1H97-E('9A;'5A=&EO;B!M;V1E;',@87)E('!R;W!R:65T87)Y('1O
M('1H92!P<FEC:6YG('!R;W9I9&5R<R!O<B!B<F]K97)S(&%N9"!I;F-O<G!O
M<F%T92!A(&YU;6)E<B!O9B!I;G!U=',L(&EN8VQU9&EN9RP@;&ES=&5D(&EN
M(&%P<')O>&EM871E(&]R9&5R(&]F('!R:6]R:71Y.B!B96YC:&UA<FL@>6EE
M;&1S+"!R97!O<G1E9"!T<F%D97,L(&)R;VME<B]D96%L97(@<75O=&5S+"!I
M<W-U97(@<W!R96%D<RP@='=O+7-I9&5D(&UA<FME=',L(&)E;F-H;6%R:R!S
M96-U<FET:65S+"!B:61S+"!O9F9E<G,@86YD(')E9F5R96YC92!D871A(&EN
M8VQU9&EN9R!M87)K970@<F5S96%R8V@@<'5B;&EC871I;VYS+B!&;W(@8V5R
M=&%I;B!S96-U<FET>2!T>7!E<RP@861D:71I;VYA;"!I;G!U=',@;6%Y(&)E
M('5S960L(&]R('-O;64@;V8@=&AE('-T86YD87)D(&EN<'5T<R!M87D@;F]T
M(&)E(&%P<&QI8V%B;&4N($5V86QU871O<G,@;6%Y('!R:6]R:71I>F4@:6YP
M=71S(&1I9F9E<F5N=&QY(&]N(&%N>2!G:79E;B!D87D@9F]R(&%N>2!S96-U
M<FET>2!B87-E9"!O;B!M87)K970@8V]N9&ET:6]N<RP@86YD(&YO="!A;&P@
M:6YP=71S(&QI<W1E9"!A<F4@879A:6QA8FQE(&9O<B!U<V4@:6X@=&AE(&5V
M86QU871I;VX@<')O8V5S<R!F;W(@96%C:"!S96-U<FET>2!E=F%L=6%T:6]N
M(&]N(&%N>2!G:79E;B!D87DN(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^0V]N=&EN9V5N="!#;VYS:61E
M<F%T:6]N($QI86)I;&ET>2`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M>2!G<F%N=',@82!T:&ER9"UP87)T>2!L:6-E;G-E('1O(&1E=F5L;W`@86YD
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M<')O<')I871E(&1I<V-O=6YT(')A=&5S+B`\9F]N="!S='EL93TS1&QE='1E
M<BUS<&%C:6YG.BTP+C%P=#L^5&AE($-O;7!A;GD@:&%S(&-L87-S:69I960@
M=&AI<R!L:6%B:6QI='D@87,@3&5V96P@,RX\+V9O;G0^(#PO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
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M97,N($1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$U+"!T:&4@<F5C;V=N:7IE9"!A;6]U;G0@;V8@=&AE(&QI86)I;&ET>2!F
M;W(@8V]N=&EN9V5N="!C;VYS:61E<F%T:6]N(&1E8W)E87-E9"!B>2`D,2XX
M(&UI;&QI;VX@9'5E('1O('1H92!D96-R96%S92!I;B!T:&4@<')O8F%B:6QI
M='D@;V8@:6YC=7)R:6YG('!O=&5N=&EA;"!F=71U<F4@<F]Y86QT>2!P87EM
M96YT<R!A<W-O8VEA=&5D('=I=&@@=&AE(&EM<&%I<FUE;G0@;V8@=&AE(&EN
M+7!R;V-E<W,@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT("A)4%(F86UP.T0I
M(&%S<V5T<R!A8W%U:7)E9"!F<F]M($-E<F5G96YE("AS964@3F]T92`V*2X@
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L
M92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!W:61T:#HX,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.#`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/D9A:7(@=F%L=64@87,@;V8@1&5C96UB97(@,S$L(#(P,30\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C$L.#`P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C@P)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ-24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HX,"4[(&)O<F1E<BUB;W1T
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M87)I86YT.B!N;W)M86P[)SY&86ER('9A;'5E(&%S(&]F($UA<F-H(#,Q+"`R
M,#$U/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,34E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/"]D:78^#0H\<"!S
M='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7-I>F4Z.7!T.SXF;F)S<#L\+W`^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T
M,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P
M-V4S,3$W+U=O<FMS:&5E=',O4VAE970P.2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA<FME=&%B;&4@4V5C=7)I=&EE<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DEN=F5S=&UE;G1S($1E8G0@06YD($5Q=6ET>2!396-U<FET:65S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36%R:V5T86)L92!396-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/DY/5$4@,R8C.#(Q,CM-05)+151!0DQ%(%-%
M0U52251)15,@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M<FME="!V86QU92X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H92!T86)L92!B96QO=R!S=6UM
M87)I>F5S('1H92!#;VUP86YY)B,X,C$W.W,@:6YV97-T;65N=',@*&EN('1H
M;W5S86YD<RDZ(#PO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z,3`P)3LG
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HU,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC
M;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E
M+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC
M.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG
M:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO
M<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/E5N<F5A;&EZ960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
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M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D-O<W0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ
M93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1V%I;G,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC
M.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M:6%N=#H@;F]R;6%L.R<^36%R8V@@,S$L(#(P,34\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^0V%S:"!E<75I=F%L96YT<SH\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3`E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ-RPP.#D\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$W+#`X.3PO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXQ-RPP.#D\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXS,2PQ,C$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q
M,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C,L,C8Q/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,RPR-C8\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$T-BPP
M-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M,30V+#`U-3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^,C`P+#0T-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXS,CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`P+#0V.3PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(Q-RPU,S,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(Q-RPU-3@\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D1E
M8V5M8F5R(#,Q+"`R,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.F1O
M=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U
M8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D
M97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI;F1E;G0Z,'!T
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(W+C,U<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY-;VYE>2!M87)K970@9G5N9',\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS,RPW,34\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXS,RPW-#@\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(W+C,U<'0[.W1E
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[=VAI=&4M<W!A
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXH,3@\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXR,BPX,3,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3`E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/C$V,RPV-S$\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M-#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$V,RPV,S$\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(R,"PR,3<\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXR,C`L,3DR/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M:71I97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,S,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C(R,RPS-S0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\
M+V1I=CX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[/B9N8G-P.SPO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M92!M;VYT:',@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"X@/"]P/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V
M7V9D,F4V,#=E,S$Q-R]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"87-I8R!A;F0@1&EL=71E
M9"!.970@3&]S<R!097(@4VAA<F4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%87)N:6YG<R!097(@4VAA<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"87-I8R!A;F0@1&EL=71E9"!.970@3&]S<R!097(@4VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3D]412`T)B,X
M,C$R.T)!4TE#($%.1"!$24Q55$5$($Y%5"!,3U-3(%!%4B!32$%212`\+W`^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[=&5X="UI;F1E;G0Z
M-"XU-"4[)SY"87-I8R!N970@;&]S<R!P97(@<VAA<F4@:&%S(&)E96X@8V]M
M<'5T960@8GD@9&EV:61I;F<@=&AE(&YE="!L;W-S(&)Y('1H92!W96EG:'1E
M9"UA=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]U
M='-T86YD:6YG(&1U<FEN9R!T:&4@<&5R:6]D+B!$:6QU=&5D(&YE="!L;W-S
M('!E<B!S:&%R92!I<R!C86QC=6QA=&5D(&)Y(&1I=FED:6YG(&YE="!L;W-S
M(&)Y('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&%N9"!P;W1E;G1I86P@9&EL=71I=F4@<V5C=7)I=&EE
M<R!O=71S=&%N9&EN9R!D=7)I;F<@=&AE('!E<FEO9"X@/"]P/@T*/'`@<W1Y
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M(#(P,30@=V5R92`W+#8R-"PV,#`@86YD(#<L,S`R+#,V-BP@<F5S<&5C=&EV
M96QY+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q
M,3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C
M-%\T,&0T7S@T,39?9F0R938P-V4S,3$W+U=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA:F]R
M($-U<W1O;65R<RP@4&%R=&YE<G-H:7!S(&%N9"!3=')A=&5G:6,@06QL:6%N
M8V5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3W)G86YI>F%T:6]N($-O;G-O;&ED871I;VX@06YD(%!R97-E;G1A
M=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA:F]R($-U
M<W1O;65R<RP@4&%R=&YE<G-H:7!S(&%N9"!3=')A=&5G:6,@06QL:6%N8V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y
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M051%1TE#($%,3$E!3D-%4R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N
M="!W:71H($)I;V=E;B!);F,N(&EN($AU;6%N(%1H97)A<&5U=&EC<R`\+W`^
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M:7IA=&EO;B!#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N="`H
M=&AE("8C.#(R,#M":6]G96X@06=R965M96YT)B,X,C(Q.RD@=VET:"!":6]G
M96XL('!U<G-U86YT('1O('=H:6-H(%-A;F=A;6\@86YD($)I;V=E;B!C;VQL
M86)O<F%T92!T;R!D:7-C;W9E<BP@9&5V96QO<"P@<V5E:R!R96=U;&%T;W)Y
M(&%P<')O=F%L(&9O<B!A;F0@8V]M;65R8VEA;&EZ92!T:&5R87!E=71I8W,@
M8F%S960@;VX@4V%N9V%M;R8C.#(Q-SMS('II;F,@9FEN9V5R($1.02UB:6YD
M:6YG('!R;W1E:6X@*%I&4"D@=&5C:&YO;&]G>2!F;W(@:&5M;V=L;V)I;F]P
M871H:65S+"!I;F-L=61I;F<@8F5T82UT:&%L87-S96UI82!A;F0@<VEC:VQE
M(&-E;&P@9&ES96%S92`H4T-$*2X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M=')I86P@9F]R('1H92!F:7)S="!:1E`@5&AE<F%P975T:6,@9&5V96QO<&5D
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M:6]N(&9O<B!:1E`@5&AE<F%P975T:6-S(&EN=&5N9&5D('1O('1R96%T(%-#
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M97`@:6X@86YD('1A:V4@;W9E<B!A;GD@<F5M86EN:6YG(&%C=&EV:71I97,@
M;V8@4V%N9V%M;RX@1G5R=&AE<FUO<F4L(%-A;F=A;6\@:&%S(&%N(&]P=&EO
M;B!T;R!C;RUP<F]M;W1E(&EN('1H92!5;FET960@4W1A=&5S(&%N>28C,38P
M.VQI8V5N<V5D('!R;V1U8W0@=&\@=')E870@8F5T82UT:&%L87-S96UI82!A
M;F0@4T-$)B,Q-C`[9&5V96QO<&5D('5N9&5R('1H92!":6]G96X@06=R965M
M96YT+"!A;F0@0FEO9V5N(&%G<F5E<R!T;R!C;VUP96YS871E(%-A;F=A;6\@
M9F]R('-U8V@@8V\M<')O;6]T:6]N(&%C=&EV:71I97,N(#PO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT
M+6EN9&5N=#HT+C4T)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY386YG86UO(')E8V5I=F5D(&%N('5P9G)O;G0@;&EC96YS92!F964@;V8@
M)#(P+C`@;6EL;&EO;B!U<&]N(&5N=&5R:6YG(&EN=&\@=&AE($)I;V=E;B!!
M9W)E96UE;G0N($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!W:6QL(&%L<V\@
M8F4@96QI9VEB;&4@=&\@<F5C96EV92`D,3(V+C,@;6EL;&EO;B!I;B!P87EM
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M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M=',@*&DI)B,Q-C`[=&AA="!C86X@8F4@86-H:65V960@8F%S960@:6X@=VAO
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M:&EE=F5D(&%N9"`H:6EI*28C,38P.W1H870@=V]U;&0@<F5S=6QT(&EN(&%D
M9&ET:6]N86P@<&%Y;65N=',@8F5I;F<@9'5E('1O('1H92!#;VUP86YY+B!!
M8V-O<F1I;F=L>2P@8V]N<VED97)A=&EO;B!R96-E:79E9"!F;W(@=&AE(&%C
M:&EE=F5M96YT(&]F(&UI;&5S=&]N97,@=&AA="!A<F4@9&5T97)M:6YE9"!T
M;R!B92!S=6)S=&%N=&EV92!W:6QL(&)E(')E8V]G;FEZ960@87,@<F5V96YU
M92!I;B!T:&5I<B!E;G1I<F5T>2!I;B!T:&4@<&5R:6]D('=H96X@=&AE(&UI
M;&5S=&]N97,@87)E(&%C:&EE=F5D(&%N9"!C;VQL96-T86)I;&ET>2!I<R!R
M96%S;VYA8FQY(&%S<W5R960N(%)E=F5N=64@9F]R('1H92!A8VAI979E;65N
M="!O9B!M:6QE<W1O;F5S('1H870@87)E(&YO="!S=6)S=&%N=&EV92!W:6QL
M(&)E(')E8V]G;FEZ960@;W9E<B!T:&4@<F5M86EN:6YG('!E<FEO9"!O9B!T
M:&4@0FEO9V5N($%G<F5E;65N="P@87-S=6UI;F<@86QL(&]T:&5R(&%P<&QI
M8V%B;&4@<F5V96YU92!R96-O9VYI=&EO;B!C<FET97)I82!H879E(&)E96X@
M;65T+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M;R!U<V4@8V5R=&%I;B!:1E`@86YD(&]T:&5R('1E8VAN;VQO9WD@8V]N=')O
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#ML:6YE+6AE:6=H
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M+"`R,#$U+"!T:&4@0V]M<&%N>2!H87,@9&5F97)R960@<F5V96YU92!O9B`D
M,30N,2!M:6QL:6]N(')E;&%T960@=&\@=&AE($)I;V=E;B!!9W)E96UE;G0N
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+69A;6EL>3I4:6UE<R!.
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M,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ
M,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\=&%B
M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL
M87!S93L@=VED=&@Z,3`P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HV-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
M97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O
M;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C,Q)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$T)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q
M-3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E=F5N=64@<F5L
M871E9"!T;R!":6]G96X@0V]L;&%B;W)A=&EO;CH\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXV-C`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,3,N-W!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^4F5S96%R8V@@<V5R=FEC97,\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$R)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PU,S,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$;6ED9&QE(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^,2PP.#,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-
M"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP
M=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#L^
M)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M:79E($UE9&EC:6YE("A#25)-*2P@=V5R92`D,2XT(&UI;&QI;VX@86YD("0Q
M+C,@;6EL;&EO;B!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C
M:"`S,2P@,C`Q-2!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+B!296QA=&5D(&-O
M<W1S(&%N9"!E>'!E;G-E<R!F;W(@;W1H97(@<')O:F5C=',@:6YC;'5D:6YG
M('-I8VML92!C96QL(&1I<V5A<V4@=6YD97(@=&AE($)I;V=E;B!A9W)E96UE
M;G0@=V5R92`D,2XQ(&UI;&QI;VX@86YD("0P+C`@;6EL;&EO;B!D=7)I;F<@
M=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q
M-"P@<F5S<&5C=&EV96QY+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[
M=&5X="UI;F1E;G0Z-"XU-"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^26X@2F%N=6%R>2`R,#$R('1H92!#;VUP86YY(&5N=&5R960@:6YT
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M0V]M<&%N>2!A;F0@4VAI<F4@;6%Y(&1E=F5L;W`@<&]T96YT:6%L(&AU;6%N
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M9R!O<B!D:6%G;F]S:6YG(&AE;6]P:&EL:6$N($EN($IU;F4@,C`Q,BP@4VAI
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M96-I9FEE9"!C:7)C=6US=&%N8V5S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G
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M:6-A;"!4<FEA;"!!<'!L:6-A=&EO;B`H0U1!*2P@=VAI;&4@4VAI<F4@:7,@
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M97AT97)N86P@<')O9W)A;2UR96QA=&5D(')E<V5A<F-H(&-O<W1S+B`\+W`^
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M;G-E(&9E92!O9B`D,3,N,"!M:6QL:6]N('5P;VX@96YT97)I;F<@:6YT;R!T
M:&4@4VAI<F4@06=R965M96YT+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@
M=VEL;"!A;'-O(&)E(&5L:6=I8FQE('1O(')E8V5I=F4@)#,S+C4@;6EL;&EO
M;B!I;B!P87EM96YT<R!U<&]N('1H92!A8VAI979E;65N="!O9B!S<&5C:69I
M960@<F5S96%R8V@L(')E9W5L871O<GDL(&-L:6YI8V%L(&1E=F5L;W!M96YT
M(&UI;&5S=&]N97,L(&EN8VQU9&EN9R!P87EM96YT<R!F;W(@96%C:"!G96YE
M('1A<F=E="!T:')O=6=H('1H92!A8V-E<'1A;F-E(&]F(&%N($E.1"!O<B!#
M5$$@<W5B;6ES<VEO;B!T;W1A;&EN9R`D."XU(&UI;&QI;VXL(&%S('=E;&P@
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT
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M;R!E=F5N=',@*&DI)B,Q-C`[=&AA="!C86X@8F4@86-H:65V960@8F%S960@
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M(&)E(&%C:&EE=F5D(&%N9"`H:6EI*28C,38P.W1H870@=V]U;&0@<F5S=6QT
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M8W)I=&5R:6$@:&%V92!B965N(&UE="X@26X@,C`Q-"!386YG86UO(')E8V]G
M;FEZ960@82`D,2XP(&UI;&QI;VX@;6EL97-T;VYE('!A>6UE;G0@<F5L871E
M9"!T;R!O=7(@:&5M;W!H:6QI82!P<F]G<F%M+CPO<#X-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N
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M<R!O9B!-87)C:"`S,2P@,C`Q-2P@=&AE($-O;7!A;GD@:&%S(&1E9F5R<F5D
M(')E=F5N=64@;V8@)#8N."!M:6QL:6]N(')E;&%T960@=&\@=&AE(%-H:7)E
M($%G<F5E;65N="X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!W97)E(&%S
M(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ(#PO<#X-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=VED=&@Z,3`P)3LG/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV-B4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M;VYT:',@96YD960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C,Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z-C8E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^,C`Q-3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,30E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&UI9&1L92!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV-B4[/@T*/'`@<W1Y;&4],T0G
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M964\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXU-#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-"PU,C(\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-2PU,C$\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG
M:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7-I>F4Z,3)P=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G
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M(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U
M(&%N9"`R,#$T+"!R97-P96-T:79E;'DN(#PO<#X-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP
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M;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/DEN($IU;'D@,C`P-R!386YG86UO(&5N=&5R960@:6YT
M;R!A(&QI8V5N<V4@86=R965M96YT("AT:&4@)B,X,C(P.U-I9VUA($%G<F5E
M;65N="8C.#(R,3LI('=I=&@@4VEG;6$M06QD<FEC:"!#;W)P;W)A=&EO;B`H
M4VEG;6$I+B!5;F1E<B!T:&4@4VEG;6$@06=R965M96YT+"!386YG86UO(&%G
M<F5E9"!T;R!P<F]V:61E(%-I9VUA('=I=&@@86-C97-S('1O(&]U<B!P<F]P
M<FEE=&%R>2!:1E`@=&5C:&YO;&]G>2!A;F0@=&AE(&5X8VQU<VEV92!R:6=H
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M<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+69A;6EL>3I4
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M('1H92!3:6=M82!!9W)E96UE;G0@87,@97AP86YD960@:6X@,C`P.2P@4VEG
M;6$@;6%D92!A;B!U<&9R;VYT(&-A<V@@<&%Y;65N="!O9B`D,C`N,"!M:6QL
M:6]N(&-O;G-I<W1I;F<@;V8@82`D-"XY(&UI;&QI;VX@<'5R8VAA<V4@;V8@
M-C,V+#$S,R!S:&%R97,@;V8@4V%N9V%M;R!C;VUM;VX@<W1O8VL@86YD(&$@
M)#$U+C$@;6EL;&EO;B!U<&9R;VYT(&QI8V5N<V4@9F5E+B!4:&4@=7!F<F]N
M="!L:6-E;G-E(&9E92!W87,@<F5C;V=N:7IE9"!O;B!A('-T<F%I9VAT+6QI
M;F4@8F%S:7,@9G)O;2!T:&4@969F96-T:79E(&1A=&4@;V8@=&AE(&5X<&%N
M9&5D(&QI8V5N<V4@=&AR;W5G:"!*=6QY(#(P,3`L('=H:6-H(')E<')E<V5N
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M9V%M;R!H87,@<F5C96EV960@=&AE(&5N=&ER92`D-2XP(&UI;&QI;VX@;V8@
M8V]M;65R8VEA;"!L:6-E;G-E(&9E97,@86YD(&ES(&5L:6=I8FQE('1O(')E
M8V5I=F4@<F]Y86QT>2!P87EM96YT<R!O9B`Q,"XU)2!O9B!N970@<V%L97,@
M86YD('-U8FQI8V5N<VEN9R!R979E;G5E+B`@26X@861D:71I;VXL('5P;VX@
M=&AE(&%C:&EE=F5M96YT(&]F(&-E<G1A:6X@8W5M=6QA=&EV92!C;VUM97)C
M:6%L(&UI;&5S=&]N97,@4VEG;6$@=VEL;"!M86ME(&UI;&5S=&]N92!P87EM
M96YT<R!T;R!386YG86UO('5P('1O(&%N(&%G9W)E9V%T92!O9B`D,C4N,"!M
M:6QL:6]N+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
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M;&]W<R`H:6X@=&AO=7-A;F1S*3H@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="US:7IE.C$R<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/@T*/&1I
M=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ
M93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,S$E.SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB;W1T;VTZ<V]L
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,S$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
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M:"`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O
M;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HV-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXR-C0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
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M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,3`V
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXQ-SD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HV-B4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY4;W1A;#PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M-"PU,C`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXR.#4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T
M>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB
M<W`[/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#L^)FYB<W`[
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M;B!A;F0@)#`N,"!M:6QL:6]N(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DN(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y
M;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^06=R965M96YT('=I=&@@1&]W($%G<F]38VEE;F-E<R!I;B!0;&%N
M="!!9W)I8W5L='5R92`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
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M96YS92!A9W)E96UE;G0@=VET:"!$05,@*'1H92`F(S@R,C`[1$%3($%G<F5E
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M;"!L:6-E;G-E(&9E92!O9B`D-BXP(&UI;&QI;VXL('!A>6UE;G0@;V8@=&AE
M(')E;6%I;FEN9R`D,BXS(&UI;&QI;VX@;V8@=&AE('!R979I;W5S;'D@86=R
M965D("0T+C`@;6EL;&EO;B!I;B!R97-E87)C:"!M:6QE<W1O;F5S+"!D979E
M;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;6EL97-T;VYE('!A>6UE
M;G1S(&9O<B!E86-H('!R;V1U8W0L(&%N9"!R;WEA;'1I97,@;VX@<V%L97,@
M;V8@<')O9'5C=',N($9U<G1H97)M;W)E+"!$05,@:&%S('1H92!R:6=H="!T
M;R!S=6)L:6-E;G-E(%-A;F=A;6\F(S@R,3<[<R!:1E`@=&5C:&YO;&]G>2!T
M;R!T:&ER9"!P87)T:65S(&9O<B!U<V4@:6X@<&QA;G0@8V5L;',L('!L86YT
M<R!O<B!P;&%N="!C96QL(&-U;'1U<F5S+B!386YG86UO('=I;&P@8F4@96YT
M:71L960@=&\@,C4E(&]F(&%N>2!C87-H(&-O;G-I9&5R871I;VX@<F5C96EV
M960@8GD@1$%3('5N9&5R('-U8V@@<W5B;&EC96YS97,N($EN($1E8V5M8F5R
M(#(P,3`L('1H92!#;VUP86YY(&%M96YD960@=&AE($1!4R!!9W)E96UE;G0@
M=&\@97AT96YD('1H92!P97)I;V0@;V8@<F5A9V5N="!M86YU9F%C='5R:6YG
M('-E<G9I8V5S(&%N9"!R97-E87)C:"!S97)V:6-E<R!T:')O=6=H($1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,3(N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF
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M;G5A;"!F965S(')A;F=E(&9R;VT@)#(U,"PP,#`@=&\@)#,N,"!M:6QL:6]N
M(&%N9"!T;W1A;"`D,C4N,R!M:6QL:6]N(&]V97(@,3$@>65A<G,N(%1H92!#
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M960@86-C97-S('1O(%-A;F=A;6\F(S@R,3<[<R!:1E`@=&5C:&YO;&]G>2!O
M<B!T;R!D979E;&]P(&]R+"!E>&-E<'0@:6X@;&EM:71E9"!C:7)C=6US=&%N
M8V5S+"!C;VUM97)C:6%L:7IE(&%N>2!P<F]D=6-T<R!D97)I=F5D(&9R;VT@
M=&AE($-O;7!A;GDF(S@R,3<[<R!:1E`@=&5C:&YO;&]G>2X@/"]P/@T*/'`@
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M="!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q
M-2!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+B`\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z
M,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D9U;F1I;F<@9G)O
M;2!297-E87)C:"!&;W5N9&%T:6]N<R`\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT+6EN9&5N=#HP)3MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^0V%L:69O<FYI82!);G-T
M:71U=&4@9F]R(%)E9V5N97)A=&EV92!-961I8VEN92`M($A)5B`\+W`^#0H\
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M96%M(%)E<V5A<F-H($%W87)D('1O(&1E=F5L;W`@86X@2$E6+T%)1%,@=&AE
M<F%P>2!B87-E9"!O;B!T:&4@87!P;&EC871I;VX@;V8@6D9.(&=E;F4@961I
M=&EN9R!T96-H;F]L;V=Y(&EN(&AE;6%T;W!O:65T:6,@<W1E;2!C96QL<R`H
M2%-#<RDN(%1H92!F;W5R+7EE87(@9W)A;G0@<W5P<&]R=',@86X@:6YN;W9A
M=&EV92!R97-E87)C:"!P<F]J96-T(&-O;F1U8W1E9"!B>2!A(&UU;'1I9&ES
M8VEP;&EN87)Y('1E86T@;V8@:6YV97-T:6=A=&]R<RP@:6YC;'5D:6YG(&EN
M=F5S=&EG871O<G,@9G)O;2!T:&4@56YI=F5R<VET>2!O9B!3;W5T:&5R;B!#
M86QI9F]R;FEA+"!#:71Y(&]F($AO<&4@3F%T:6]N86P@365D:6-A;"!#96YT
M97(@86YD(%-A;F=A;6\@0FEO4V-I96YC97,N(%-A;F=A;6\@<F5C96EV960@
M9G5N9',@=&]T86QI;F<@)#4N,B!M:6QL:6]N(&9R;VT@=&AE('1O=&%L(&%M
M;W5N="!A=V%R9&5D(&)A<V5D(&]N(&5X<&5N<V5S(&EN8W5R<F5D(&9O<B!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@969F;W)T<R!B>2!386YG86UO(&%S
M('!R97-C<FEB960@:6X@=&AE(&%G<F5E;65N="P@86YD('-U8FIE8W0@=&\@
M:71S('1E<FUS(&%N9"!C;VYD:71I;VYS+B!4:&4@87=A<F0@:7,@:6YT96YD
M960@=&\@<W5B<W1A;G1I86QL>2!F=6YD(%-A;F=A;6\F(S@R,3<[<R!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@969F;W)T<R!R96QA=&5D('1O('1H92!A
M9W)E96UE;G0N(%1H92!3=&%T92!O9B!#86QI9F]R;FEA(&AA<R!T:&4@<FEG
M:'0@=&\@<F5C96EV92P@<W5B:F5C="!T;R!T:&4@=&5R;7,@86YD(&-O;F1I
M=&EO;G,@;V8@=&AE(&%G<F5E;65N="!B971W965N(%-A;F=A;6\@86YD($-)
M4DTL('!A>6UE;G1S(&9R;VT@4V%N9V%M;R!R97-U;'1I;F<@9G)O;2!S86QE
M<R!O9B!A(&-O;6UE<F-I86P@<')O9'5C="!R97-U;'1I;F<@9G)O;2!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@969F;W)T<R!S=7!P;W)T960@8GD@=&AE
M(&=R86YT+B!!<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$S+"!A;&P@<F5V
M96YU97,@=6YD97(@=&AE(&%W87)D(&AA9"!B965N(')E8V]G;FEZ960@86YD
M(&%L;"!F=6YD<R!H860@8F5E;B!R96-E:79E9"X@/"]P/@T*/'`@<W1Y;&4]
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M(&%N9"!D979E;&]P;65N="!P97)F;W)M960@=6YD97(@=&AE($-)4DT@,C`P
M.2!G<F%N="!A9W)E96UE;G0@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD
M960@36%R8V@@,S$L(#(P,34@86YD(#(P,30L(')E<W!E8W1I=F5L>2X@4F5L
M871E9"!C;W-T<R!A;F0@97AP96YS97,@:6YC=7)R960@=6YD97(@=&AE($-)
M4DT@9W)A;G0@86=R965M96YT('=E<F4@)#`N,B!M:6QL:6]N(&%N9"`D,"XS
M(&UI;&QI;VX@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@
M,S$L(#(P,34@86YD(#(P,30L(')E<W!E8W1I=F5L>2X\+W`^#0H\<"!S='EL
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M;B!3=')A=&5G:6,@4&%R=&YE<G-H:7`@07=A<F0@=&\@9G5N9"!C;&EN:6-A
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M:7,@9W)A;G0@=&\@8V]M;65N8V4@:6X@,C`Q-2X\+W`^#0H\<"!S='EL93TS
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M9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DN(%)E
M;&%T960@8V]S=',@86YD(&5X<&5N<V5S(&EN8W5R<F5D('5N9&5R('1H92!#
M25)-(%-T<F%T96=I8R!087)T;F5R<VAI<"!!=V%R9"!W97)E("0P+C,@;6EL
M;&EO;B!A;F0@)#`N,"!M:6QL:6]N(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS
M(&5N9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DN
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^0V%L:69O<FYI82!);G-T:71U=&4@9F]R(%)E9V5N97)A=&EV
M92!-961I8VEN92`M($)E=&$M5&AA;&%S<V5M:6$@/"]P/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[=&5X="UI;F1E
M;G0Z-"XU-"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^26X@
M36%Y(#(P,3,@0TE232!G<F%N=&5D(%-A;F=A;6\@82`D-BXT(&UI;&QI;VX@
M4W1R871E9VEC(%!A<G1N97)S:&EP($%W87)D('1O(&1E=F5L;W`@82!P;W1E
M;G1I86QL>2!C=7)A=&EV92!:1E`@5&AE<F%P975T:6,@9F]R(&)E=&$M=&AA
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
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M965M96YT(&9O<B!B971A+71H86QA<W-E;6EA('=A<R`D,"XW(&UI;&QI;VX@
M86YD("0P+C0@;6EL;&EO;B!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+B!296QA
M=&5D(&-O<W1S(&%N9"!E>'!E;G-E<R!I;F-U<G)E9"!U;F1E<B!T:&4@0TE2
M32!G<F%N="!A9W)E96UE;G0@=V5R92`D,"XW(&UI;&QI;VX@86YD("0P+C0@
M;6EL;&EO;B!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S
M,2P@,C`Q-2!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+B`\+W`^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T
M,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P
M-V4S,3$W+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=&%N9VEB;&4@07-S971S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1V]O
M9'=I;&P@06YD($EN=&%N9VEB;&4@07-S971S($1I<V-L;W-U<F4@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1A;F=I8FQE($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY.3U1%(#8F(S@R,3([24Y404Y'24),12!!4U-%5%,@
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HV<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.W1E>'0M:6YD
M96YT.C0N-30E.R<^26YT86YG:6)L92!A<W-E=',@9F]R($E04B9A;7`[1"!C
M;VYS:7-T(&]F('1W;R!C;&EN:6-A;"!P<F]D=6-T(&-A;F1I9&%T97,@9G)O
M;2!O=7(@,C`Q,R!A8W%U:7-I=&EO;B!O9B!#97)E9V5N92X@25!2)F%M<#M$
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M92!P<F]J96-T(&ES(&-O;7!L971E9"X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R
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M<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.B`\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP
M)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^
M#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M
M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT<CX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB;W1T;VTZ
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,30E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
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M87)C:"`S,2P@,C`Q-3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO
M<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY$96-E;6)E<B`S,2P@,C`Q-#PO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/D-%4D4M,3$P(&9O<B!T:&4@=')E871M96YT(&]F
M($%L>FAE:6UE<B=S(&1I<V5A<V4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q
M,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ,B4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PV-#`\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^0T5212TQ,C`@9F]R('1H92!T<F5A=&UE;G0@;V8@4&%R:VEN<V]N)W,@
M9&ES96%S93PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,S`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB;W1T
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M:6)L92!A<W-E=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X
M="UI;F1E;G0Z-"XU-"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P
M,34L('1H92!#;VUP86YY(')E8V5I=F5D(&-L:6YI8V%L(&1A=&$@9&5M;VYS
M=')A=&EN9R!N;R!S=&%T:7-T:6-A;&QY('-I9VYI9FEC86YT(&1I9F9E<F5N
M8V4@8F5T=V5E;B!T:&4@8V]N=')O;"!G<F]U<"!A;F0@=&AE(&=R;W5P('1R
M96%T960@=VET:"!#15)%+3$Q,"!F;W(@06QZ:&5I;65R)B,X,C$W.W,@9&ES
M96%S92X@4W5B<V5Q=65N=&QY+"!T:&4@0V]M<&%N>2!D96-I9&5D('1O(&1I
M<V-O;G1I;G5E('1H92!#15)%+3$Q,"!A;F0@0T5212TQ,C`@8VQI;FEC86P@
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M(&5N9&5D($UA<F-H(#,Q+"`R,#$U+"!T:&4@0V]M<&%N>2!R96-O9VYI>F5D
M(&$@)#$N.2!M:6QL:6]N(&EM<&%I<FUE;G0@8VAA<F=E(')E;&%T960@=&\@
M=&AE<V4@87-S971S+B!4:&4@:6UP86ER;65N="!I<R!R96-O<F1E9"!I;B!2
M)F%M<#M$(&5X<&5N<V4@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@
M8V]N<V]L:61A=&5D('-T871E;65N=',@;V8@;W!E<F%T:6]N<RX@/"]P/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V
M7V9D,F4V,#=E,S$Q-R]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M;F-O;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3D]412`W)B,X
M,C$R.TE.0T]-12!405A%4R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E
M>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/D1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$U('1H92!D969E<G)E9"!T87@@;&EA8FEL:71Y(&]F("0P+C<@;6EL;&EO
M;B!T:&%T('=A<R!R96-O<F1E9"!U<&]N(&%C<75I<FEN9R!T:&4@25!2)F%M
M<#M$(&%S<V5T<R!I;B`R,#$S('=A<R!A9&IU<W1E9"!D=64@=&\@=&AE(&EM
M<&%I<FUE;G0@;V8@=&AE<V4@87-S971S+B!4:&ES(')E<W5L=&5D(&EN('1H
M92!R96-O9VYI=&EO;B!O9B!A("0P+C<@;6EL;&EO;B!I;F-O;64@=&%X(&)E
M;F5F:70N(#PO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E
M,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-S$P,S0T,%\T
M8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O5V]R:W-H965T<R]3:&5E=#$T
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O
M8VLM0F%S960@0V]M<&5N<V%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!/9B!#;VUP96YS
M871I;VX@4F5L871E9"!#;W-T<R!3:&%R96)A<V5D(%!A>6UE;G1S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DY/5$4@."8C.#(Q,CM35$]#2RU"05-%
M1"!#3TU014Y3051)3TX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HV<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.W1E>'0M:6YD96YT.C0N-30E.R<^5&AE(&9O;&QO=VEN9R!T86)L
M92!S:&]W<R!T;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS
M92!I;F-L=61E9"!I;B!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T
M96UE;G1S(&]F(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!M;VYT:',@96YD
M960@36%R8V@@,S$L(#(P,34@86YD(#(P,30@*&EN('1H;W5S86YD<RDZ(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z,3`P
M)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HV-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,S$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,S$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC
M.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY-87)C:"`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
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M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HV-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HV-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ+#8Y,3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ+#`W,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ+#(V,CPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$R)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^.#,T/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T
M<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,C<N
M,S5P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;B!E>'!E;G-E/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$L.3`W/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P
M9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W+U=O
M<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13%!04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%!O;&EC
M:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0
M<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
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M;W`Z-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#MT97AT+6EN
M9&5N=#HT+C4T)3LG/E1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&-O;F1E
M;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@;V8@4V%N
M9V%M;R!":6]38VEE;F-E<RP@26YC+B`H)B,X,C(P.U-A;F=A;6\F(S@R,C$[
M(&]R('1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3LI(&AA=F4@8F5E;B!P<F5P
M87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@52Y3+B!G96YE<F%L;'D@86-C97!T
M960@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&9O<B!I;G1E<FEM(&9I;F%N8VEA
M;"!I;F9O<FUA=&EO;B!A;F0@<'5R<W5A;G0@=&\@=&AE(')U;&5S(&%N9"!R
M96=U;&%T:6]N<R!O9B!T:&4@4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M
M;6ES<VEO;B`H4T5#*2X@06-C;W)D:6YG;'DL('1H97D@9&\@;F]T(&EN8VQU
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M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A<F4@;F]T(&YE8V5S<V%R
M:6QY(&EN9&EC871I=F4@;V8@=&AE(')E<W5L=',@=&AA="!M87D@8F4@97AP
M96-T960@9F]R('1H92!Y96%R(&5N9&EN9R!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$U+B!4:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T
M(&1A=&$@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"!W97)E(&1E<FEV960@
M9G)O;2!T:&4@875D:71E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E
M;65N=',@:6YC;'5D960@:6X@4V%N9V%M;R8C.#(Q-SMS($9O<FT@,3`M2R!F
M;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"P@87,@
M9FEL960@=VET:"!T:&4@4T5#+B!4:&5S92!F:6YA;F-I86P@<W1A=&5M96YT
M<R!S:&]U;&0@8F4@<F5A9"!I;B!C;VYJ=6YC=&EO;B!W:71H('1H92!F:6YA
M;F-I86P@<W1A=&5M96YT<R!A;F0@9F]O=&YO=&5S('1H97)E=&\@9F]R('1H
M92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30L(&EN8VQU9&5D
M(&EN(%-A;F=A;6\F(S@R,3<[<R!&;W)M(#$P+4LL(&%S(&9I;&5D('=I=&@@
M=&AE(%-%0RX@/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^57-E(&]F($5S=&EM871E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MM87)G:6XM;&5F=#HR
M+C(V)3MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y
M;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^57-E(&]F($5S=&EM871E<R`\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[=&5X="UI;F1E;G0Z-"XU-"4[)SY4:&4@<')E<&%R
M871I;VX@;V8@9FEN86YC:6%L('-T871E;65N=',@:6X@8V]N9F]R;6ET>2!W
M:71H(&=E;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@
M<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME(&5S=&EM871E<R!A;F0@87-S
M=6UP=&EO;G,@=&AA="!A9F9E8W0@=&AE(&%M;W5N=',@<F5P;W)T960@:6X@
M=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!T:&4@86-C;VUP86YY:6YG
M(&YO=&5S+B!/;B!A;B!O;F=O:6YG(&)A<VES+"!M86YA9V5M96YT(&5V86QU
M871E<R!I=',@97-T:6UA=&5S+"!I;F-L=61I;F<@8W)I=&EC86P@86-C;W5N
M=&EN9R!P;VQI8VEE<R!O<B!E<W1I;6%T97,@<F5L871E9"!T;R!R979E;G5E
M(')E8V]G;FET:6]N+"!C;&EN:6-A;"!T<FEA;"!A8V-R=6%L<RP@9F%I<B!V
M86QU92!M96%S=7)E;65N=',L(&)U<VEN97-S(&-O;6)I;F%T:6]N<R!I;F-L
M=61I;F<@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&-O;G1I;F=E;G0@8V]N<VED
M97)A=&EO;B!L:6%B:6QI='D@9F]R('!A>6UE;G1S('1O(&9O<FUE<B!#97)E
M9V5N92P@26YC+B`H0V5R96=E;F4I('-T;V-K:&]L9&5R<R!A;F0@:6YT86YG
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@4F5C
M;V=N:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV
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M,C$W.W,@<')O9'5C="!S86QE<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E
M.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DUU;'1I<&QE($5L
M96UE;G0@07)R86YG96UE;G1S('!R:6]R('1O('1H92!A9&]P=&EO;B!O9B!!
M4U4@3F\N)B,Q-C`[,C`P.2TQ,RP@4F5V96YU92!296-O9VYI=&EO;B8C.#(Q
M,CM-=6QT:7!L92!$96QI=F5R86)L92!2979E;G5E($%R<F%N9V5M96YT<R`H
M05-5(#(P,#DM,3,I/&9O;G0@<W1Y;&4],T1F;VYT+7-T>6QE.FYO<FUA;#L^
M+B!&;W(@<F5V96YU92!A<G)A;F=E;65N=',@96YT97)E9"!I;G1O(&)E9F]R
M92!*86YU87)Y)B,Q-C`[,2P@,C`Q,2P@=&AA="!I;F-L=61E(&UU;'1I<&QE
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
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M>6QE.FYO<FUA;#L^($%352`R,#`Y+3$S(&%M96YD960@=&AE(&%C8V]U;G1I
M;F<@<W1A;F1A<F1S(&9O<B!C97)T86EN(&UU;'1I<&QE(&5L96UE;G0@<F5V
M96YU92!A<G)A;F=E;65N=',@=&\Z(#PO9F]N=#X\+W`^#0H\9&EV(&%L:6=N
M/3-$;&5F=#X-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!W:61T:#HY-"XR-R4[;6%R9VEN+6QE9G0Z-2XW,R4[)SX-"CQT<CX-
M"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HS+C,S)3MW:&ET92US
M<&%C93IN;W=R87`^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z-G!T.V9O;G0M9F%M:6QY.B=3>6UB;VPG.V9O;G0M<VEZ93HQ
M,'!T.SXF(S$X,SL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T1W:61T:#HY-BXV-R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z.30N,C<E.VUA<F=I
M;BUL969T.C4N-S,E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE
M/3-$=VED=&@Z,RXS,R4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MF;VYT+69A;6EL
M>3HG4WEM8F]L)SMF;VYT+7-I>F4Z,3!P=#L^)B,Q.#,[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.38N-C<E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O;G0M
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M960@;VX@=F5N9&]R+7-P96-I9FEC(&]B:F5C=&EV92!E=FED96YC92`H5E-/
M12DL(&EF(&%V86EL86)L93L@=&AI<F0M<&%R='D@979I9&5N8V4@*%1012DL
M(&EF(&%V86EL86)L92!A;F0@5E-/12!I<R!N;W0@879A:6QA8FQE.R!O<B!T
M:&4@8F5S="!E<W1I;6%T92!O9B!S96QL:6YG('!R:6-E("A%4U`I+"!I9B!N
M96ET:&5R(%933T4@;F]R(%1012!I<R!A=F%I;&%B;&4[(&%N9"`\+W`^/"]T
M9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT
M86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY
M-"XR-R4[;6%R9VEN+6QE9G0Z-2XW,R4[)SX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@<W1Y;&4],T1W:61T:#HS+C,S)3MW:&ET92US<&%C93IN;W=R87`^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T
M.V9O;G0M9F%M:6QY.B=3>6UB;VPG.V9O;G0M<VEZ93HQ,'!T.SXF(S$X,SL\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HY-BXV
M-R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT
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M+"`R,#$Q+"!T:&4@0V]M<&%N>2!A;&QO8V%T97,@<F5V96YU92!T;R!E86-H
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M;6)(+"!F;W)M97)L>2!3:&ER92!!1R`H4VAI<F4I+"!I;B!*86YU87)Y(#(P
M,3(@86YD($)I;V=E;B!);F,N+"!F;W)M97)L>2!":6]G96X@261E8R!);F,N
M("A":6]G96XI(&EN($IA;G5A<GD@,C`Q-"!W97)E(&5V86QU871E9"!U;F1E
M<B!T:&5S92!A;65N9&5D(&%C8V]U;G1I;F<@<W1A;F1A<F1S+B`\+W`^#0H\
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5C96YT($%C8V]U;G1I;F<@4W1A;F1A<F1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HQ.'!T.VUA<F=I;BUL969T.C(N,C8E.W1E>'0M
M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY296-E
M;G0@06-C;W5N=&EN9R!3=&%N9&%R9',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R
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M+B`R,#$T+3$U+"`\9F]N="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC.SY$
M:7-C;&]S=7)E(&]F(%5N8V5R=&%I;G1I97,@86)O=70@86X@16YT:71Y)B,X
M,C$W.W,@06)I;&ET>2!T;R!#;VYT:6YU92!A<R!A($=O:6YG($-O;F-E<FX\
M+V9O;G0^("A!4U4@,C`Q-"TQ-2DN($%352`R,#$T+3$U(')E<75I<F5S(&UA
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M=6YD97(@=&AE(&-U<G)E;G0@9W5I9&%N8V4N($%352`R,#$T+3$U(&ES(&5F
M9F5C=&EV92!F;W(@=&AE($-O;7!A;GD@:6X@=&AE(&9I<G-T('%U87)T97(@
M;V8@,C`Q-B!W:71H(&5A<FQY(&%D;W!T:6]N('!E<FUI='1E9"X@5&AE($-O
M;7!A;GD@9&]E<R!N;W0@8F5L:65V92!T:&4@:6UP86-T(&]F(&%D;W!T:6YG
M($%352`R,#$T+3$U(&]N(&ET<R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T
M871E;65N=',@=VEL;"!B92!M871E<FEA;"X\+W`^#0H\<"!S='EL93TS1"=M
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M(&UA:6X@<')I;F-I<&QE(&]F($%352`R,#$T+3`Y(&ES('1O(')E8V]G;FEZ
M92!R979E;G5E<R!W:&5N('!R;VUI<V5D(&=O;V1S(&]R('-E<G9I8V5S(&%R
M92!T<F%N<V9E<G)E9"!T;R!C=7-T;VUE<G,@:6X@86X@86UO=6YT('1H870@
M<F5F;&5C=',@=&AE(&-O;G-I9&5R871I;VX@=&AA="!I<R!E>'!E8W1E9"!T
M;R!B92!R96-E:79E9"!F;W(@=&AO<V4@9V]O9',@;W(@<V5R=FEC97,N($%3
M52`R,#$T+3`Y('!R;W9I9&5S(&-O;7!A;FEE<R!W:71H('1W;R!I;7!L96UE
M;G1A=&EO;B!M971H;V1S.B`H:2DF(S$V,#MA<'!L>2!T:&4@<W1A;F1A<F0@
M<F5T<F]S<&5C=&EV96QY('1O(&5A8V@@<')I;W(@<F5P;W)T:6YG('!E<FEO
M9"!P<F5S96YT960@*&9U;&P@<F5T<F]S<&5C=&EV92!A<'!L:6-A=&EO;BD[
M(&]R("AI:2DF(S$V,#MA<'!L>2!T:&4@<W1A;F1A<F0@<F5T<F]S<&5C=&EV
M96QY('=I=&@@=&AE(&-U;75L871I=F4@969F96-T(&]F(&EN:71I86QL>2!A
M<'!L>6EN9R!T:&4@<W1A;F1A<F0@87,@86X@861J=7-T;65N="!T;R!T:&4@
M;W!E;FEN9R!B86QA;F-E(&]F(')E=&%I;F5D(&5A<FYI;F=S(&]F('1H92!A
M;FYU86P@<F5P;W)T:6YG('!E<FEO9"!T:&%T(&EN8VQU9&5S('1H92!D871E
M(&]F(&EN:71I86P@87!P;&EC871I;VX@*&UO9&EF:65D(')E=')O<W!E8W1I
M=F4@87!P;&EC871I;VXI+B!4:&ES(&=U:61A;F-E(&ES(&5F9F5C=&EV92!F
M;W(@86YN=6%L(')E<&]R=&EN9R!P97)I;V1S(&)E9VEN;FEN9R!A9G1E<B!$
M96-E;6)E<B8C,38P.S$U+"`R,#$V+"!I;F-L=61I;F<@:6YT97)I;2!P97)I
M;V1S('=I=&AI;B!T:&%T(')E<&]R=&EN9R!P97)I;V0L(&%N9"!E87)L>2!A
M<'!L:6-A=&EO;B!I<R!N;W0@<&5R;6ET=&5D+B!4:&4@0V]M<&%N>2!I<R!C
M=7)R96YT;'D@:6X@=&AE('!R;V-E<W,@;V8@979A;'5A=&EN9R!T:&4@:6UP
M86-T(&]F('1H92!P96YD:6YG(&%D;W!T:6]N(&]F($%352`R,#$T+3`Y(&]N
M(&ET<R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N(#PO<#X\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-PT*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q
M-E]F9#)E-C`W93,Q,3<O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S
M=7)E;65N="`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@1&ES8VQO<W5R97,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=6UM87)Y(&]F($9A:7(@5F%L=64@365A<W5R96UE;G1S(&]F($-A
M<V@@17%U:79A;&5N=',L($%V86EL86)L92UF;W(M4V%L92!396-U<FET:65S
M(&%N9"!#;VYT:6YG96YT($-O;G-I9&5R871I;VX@3&EA8FEL:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G
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M:7(@=F%L=64@:&EE<F%R8VAY("AI;B!T:&]U<V%N9',I.B`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT
M<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#@E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE
M.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DUA<F-H(#,Q+"`R,#$U/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#$T('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z-#@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`S/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%S
M<V5T<SH\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C$W+#`X.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&]T
M86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ-RPP.#D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,3<L,#@Y/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C4P)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HQ,RXW<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY-87)K971A8FQE('-E8W5R:71I97,Z/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,C<N
M,S5P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D-O;6UE<F-I86P@<&%P97(@<V5C=7)I=&EE
M<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M.24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C4P)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HR-RXS-7!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^0V]R<&]R871E(&1E8G0@<V5C=7)I
M=&EE<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z.24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(W+C,U<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T('-E
M8W5R:71I97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,30V+#`U-3PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXR,#`L-#8Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`P+#0V
M.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(Q-RPU-3@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C$W+#`X.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,C`P+#0V.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z.7!T.SXF;F)S
M<#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#@E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/D1E8V5M8F5R(#,Q+"`R,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#$T('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z-#@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`S/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%S
M<V5T<SH\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS+#$X,CPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/DUA<FME=&%B;&4@<V5C=7)I=&EE<SH\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[=VAI
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS,RPW-#@\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(W
M+C,U<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY#;W)P;W)A=&4@9&5B="!S96-U<FET:65S
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,BPX,3,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$V,RPV,S$\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C(R,"PQ.3(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,C`L,3DR/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M(&5Q=6EV86QE;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C(R,"PQ.3(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z9&]U8FQE
M(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT
M;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL
M93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,2PX,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PX,#`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-C:&5D=6QE(&]F($-H86YG97,@:6X@17-T:6UA=&5D($9A
M:7(@5F%L=64@;V8@0V]N=&EN9V5N="!#;VYS:61E<F%T:6]N($QI86)I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78^
M#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S
M93IC;VQL87!S93L@=VED=&@Z.#`E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C@P)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY&86ER('9A;'5E(&%S(&]F($1E8V5M8F5R(#,Q+"`R
M,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$U)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HX
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,34E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z.#`E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M:"`S,2P@,C`Q-3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$U)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV
M/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.CEP=#L^)FYB<W`[/"]P/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V
M7V9D,F4V,#=E,S$Q-R]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY-87)K971A8FQE(%-E8W5R
M:71I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY);G9E<W1M96YT<R!$96)T($%N9"!%<75I='D@
M4V5C=7)I=&EE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($EN=F5S=&UE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4]
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M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL
M87!S93L@=VED=&@Z,3`P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO
M<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O
M;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@
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M<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/E5N<F5A;&EZ960\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[/@T*/'`@<W1Y
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D-O<W0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M1V%I;G,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^*$QO<W-E<RD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@
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M<SH\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXQ-RPP.#D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C$W+#`X.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1O=&%L/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^,3<L,#@Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,C<N,S5P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D-O;6UE<F-I86P@<&%P97(@<V5C=7)I
M=&EE<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXS,2PQ,C$\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXS,2PQ-#@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C(W+C,U<'0[.W1E>'0M:6YD96YT
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXR,RPR-C8\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C$T-BPP-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,30V+#`U-3PO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`P+#0T-#PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`P
M+#0V.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(Q-RPU,S,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C(Q-RPU-3@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/D1E8V5M8F5R(#,Q+"`R,#$T/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.CDE.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.F1O
M=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/D-A<V@@97%U:79A;&5N=',Z/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[=VAI=&4M
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M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C(W+C,U<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY-;VYE>2!M87)K970@
M9G5N9',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RPQ.#(\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,3,N-W!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RPQ.#(\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXS,RPW,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.CDE.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q
M,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z.24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C(L.#,Q/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
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M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH,3@\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HY)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,BPX,3,\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$V,RPV-S$\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.CDE
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXH-#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$V
M,RPV,S$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C(R,"PR,3<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,S,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.CDE.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXR,C`L,3DR/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M8FQE+69O<BUS86QE('-E8W5R:71I97,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HY)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,S,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z.24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(R,RPS-S0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US
M:7IE.C$R<'0[/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V
M7V9D,F4V,#=E,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O5V]R:W-H965T
M<R]3:&5E=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Q!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP<R!A;F0@4W1R
M871E9VEC($%L;&EA;F-E<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y":6]G96X@26YC(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT($%R<F%N9V5M96YT+"!#;VYT<F%C="!T;R!097)F
M;W)M(&9O<B!/=&AE<G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S(%)E8V]G;FEZ960@
M=6YD97(@06=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#MT97AT
M+6EN9&5N=#HT+C4T)3LG/E)E=F5N=65S(')E8V]G;FEZ960@=6YD97(@=&AE
M(&%G<F5E;65N="!W:71H($)I;V=E;B!F;W(@=&AE('1H<F5E(&UO;G1H<R!E
M;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"!A<F4@87,@9F]L;&]W<R`H
M:6X@=&AO=7-A;F1S*3H@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE
M.C$R<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/@T*/&1I=CX-"CQT
M86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O
M;&QA<'-E.R!W:61T:#HQ,#`E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,S$E.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,S$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY-87)C:"`S,2P\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&UI9&1L92!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV
M-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&UI9&1L92!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HV-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^4F5C;V=N:71I;VX@;V8@=7!F<F]N="!F964\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&UI9&1L92!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1M:61D;&4@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.D%R:6%L.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M;6%L.R<^,RPP-38\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ+#`X,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV
M/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z
M.'!T.SXF;F)S<#L\+W`^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T
M.SXF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&ER92!!1R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N
M9"!$979E;&]P;65N="!!<G)A;F=E;65N="P@0V]N=')A8W0@=&\@4&5R9F]R
M;2!F;W(@3W1H97)S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<R!296-O9VYI>F5D('5N
M9&5R($%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[=&5X="UI
M;F1E;G0Z-"XU-"4[)SY2979E;G5E<R!R96-O9VYI>F5D('5N9&5R('1H92!A
M9W)E96UE;G0@=VET:"!3:&ER92!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"P@=V5R92!A<R!F;VQL;W=S("AI
M;B!T:&]U<V%N9',I.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z
M,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\9&EV/@T*/'1A
M8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L
M;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HS,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P
M,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO
M<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$T)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q-#PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$;6ED9&QE(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;&%T960@=&\@4VAI<F4@0V]L;&%B;W)A=&EO;CH\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X
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M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXU-#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$;6ED9&QE(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXT+#DW.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$;6ED9&QE(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXU+#`V-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[.V9O
M;G0M<VEZ93HX<'0[/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US
M:7IE.C$R<'0[/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VUA+4%L9')I8V@@0V]R
M<&]R871I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG
M96UE;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5V96YU97,@4F5C;V=N:7IE9"!U;F1E<B!!9W)E96UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=M
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M(#(P,30L('=E<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H@/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C8V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M
M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,S$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,S$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC
M.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY-87)C:"`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HV-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXR-C0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,3`V/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXQ-SD\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^-"PU,C`\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXR.#4\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X\+V1I=CX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#L[
M9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7-I>F4Z,3)P=#L^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93<Q,#,T-#!?-&)C-%\T,&0T7S@T
M,39?9F0R938P-V4S,3$W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-R]7;W)K<VAE
M971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY);G1A;F=I8FQE($%S<V5T<R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D=O;V1W:6QL
M($%N9"!);G1A;F=I8FQE($%S<V5T<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%R
M<GEI;F<@5F%L=65S(&]F($EN=&%N9VEB;&5S($%S<V5T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[=&5X="UI;F1E;G0Z-"XU-"4[)SY4:&4@8V%R<GEI
M;F<@=F%L=65S(&]F('1H97-E(&EN=&%N9VEB;&5S(&%S<V5T<R!A<F4@87,@
M9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H@/"]P/CPO9&EV/CQD:78^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT
M<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z
M(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O<F1E
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,30E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M
M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY-87)C:"`S,2P@,C`Q-3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY$96-E;6)E<B`S,2P@,C`Q-#PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D-%4D4M,3$P(&9O<B!T:&4@=')E
M871M96YT(&]F($%L>FAE:6UE<B=S(&1I<V5A<V4\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
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M.R<^,2PV-#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^0T5212TQ,C`@9F]R('1H92!T<F5A=&UE;G0@;V8@4&%R
M:VEN<V]N)W,@9&ES96%S93PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,S`\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV-B4[(&)O
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M;&4@:6YT86YG:6)L92!A<W-E=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
M/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P7S1B8S1?-#!D
M-%\X-#$V7V9D,F4V,#=E,S$Q-R]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E
M9"!#;VUP96YS871I;VX@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E($]F($-O;7!E
M;G-A=&EO;B!296QA=&5D($-O<W1S(%-H87)E8F%S960@4&%Y;65N=',@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.V9O;G0M9F%M:6QY.E1I
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M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T("AI;B!T:&]U
M<V%N9',I.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[
M('=I9'1H.C$P,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SL[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M87)I86YT.B!N;W)M86P[)SY4:')E92!M;VYT:',@96YD960\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C,Q)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$T)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q-3PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N
M="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D-O<W1S(&%N9"!E>'!E;G-E<SH\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C8E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[=VAI
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PV.3$\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[=VAI
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PP-S,\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-C8E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,3,N-W!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1V5N97)A;"!A;F0@
M861M:6YI<W1R871I=F4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^,2PR-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8V)3L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,BPY-3,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93<Q,#,T
M-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V
M,#=E,S$Q-R]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q3$%)
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
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M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($%S<V5T<R!!;F0@3&EA
M8FEL:71I97,@365A<W5R960@3VX@4F5C=7)R:6YG($%N9"!.;VYR96-U<G)I
M;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U:79A;&5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<L,#@Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#$X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#`L-#8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C(P+#$Y,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U
M:79A;&5N=',@86YD(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C$W+#4U.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R,RPS-S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-O
M;G1I;F=E;G0@8V]N<VED97)A=&EO;B!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;F5Y(&UA<FME="!F=6YD
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64@07-S971S($%N9"!,:6%B:6QI=&EE<R!-96%S
M=7)E9"!/;B!296-U<G)I;F<@06YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<L,#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ.#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UE<F-I86P@<&%P97(@
M<V5C=7)I=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@07-S971S($%N9"!,:6%B:6QI
M=&EE<R!-96%S=7)E9"!/;B!296-U<G)I;F<@06YD($YO;G)E8W5R<FEN9R!"
M87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@;6%R:V5T86)L92!S96-U<FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PQ-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPW-#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M=F5L(#$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&86ER(%9A;'5E($%S<V5T<R!!;F0@3&EA8FEL:71I97,@
M365A<W5R960@3VX@4F5C=7)R:6YG($%N9"!.;VYR96-U<G)I;F<@0F%S:7,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$W+#`X.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E
M<75I=F%L96YT<R!A;F0@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP.#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$X,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V96P@,2!;
M365M8F5R72!\($UO;F5Y(&UA<FME="!F=6YD<R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@
M07-S971S($%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!/;B!296-U<G)I;F<@
M06YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E
M<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L
M,#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPQ.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQE=F5L(#(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($%S<V5T<R!!;F0@
M3&EA8FEL:71I97,@365A<W5R960@3VX@4F5C=7)R:6YG($%N9"!.;VYR96-U
M<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&UA<FME=&%B;&4@<V5C=7)I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#0V.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R
M,"PQ.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!M87)K971A8FQE
M('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M,"PT-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,C`L,3DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,979E;"`R(%M-96UB97)=('P@0V]M;65R8VEA;"!P
M87!E<B!S96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!!<W-E=',@06YD($QI
M86)I;&ET:65S($UE87-U<F5D($]N(%)E8W5R<FEN9R!!;F0@3F]N<F5C=7)R
M:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!M87)K971A8FQE('-E8W5R:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#$T.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#<T
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5V96P@,R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@07-S971S($%N9"!,:6%B:6QI
M=&EE<R!-96%S=7)E9"!/;B!296-U<G)I;F<@06YD($YO;G)E8W5R<FEN9R!"
M87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@8V]N=&EN9V5N="!C;VYS:61E<F%T:6]N
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L
M=64@07-S971S($%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!/;B!296-U<G)I
M;F<@06YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;6%R
M:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,RPR-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,BPX,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O<G!O<F%T92!D96)T('-E8W5R:71I97,@
M6TUE;6)E<ET@?"!,979E;"`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!!<W-E=',@06YD
M($QI86)I;&ET:65S($UE87-U<F5D($]N(%)E8W5R<FEN9R!!;F0@3F]N<F5C
M=7)R:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!M87)K971A8FQE('-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#(V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R
M+#@Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S
M96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!!<W-E=',@06YD($QI86)I;&ET
M:65S($UE87-U<F5D($]N(%)E8W5R<FEN9R!!;F0@3F]N<F5C=7)R:6YG($)A
M<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!M87)K971A8FQE('-E8W5R:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-BPP-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C,L-C,Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T('-E8W5R:71I
M97,@6TUE;6)E<ET@?"!,979E;"`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!!<W-E=',@
M06YD($QI86)I;&ET:65S($UE87-U<F5D($]N(%)E8W5R<FEN9R!!;F0@3F]N
M<F5C=7)R:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!M87)K971A8FQE('-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-BPP
M-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-C,L-C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYT:6YG96YT(&-O;G-I9&5R871I;VX@;&EA8FEL:71Y
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1F%I<B!686QU92!!<W-E=',@06YD($QI86)I;&ET:65S($UE87-U
M<F5D($]N(%)E8W5R<FEN9R!!;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!C;VYT:6YG96YT(&-O;G-I9&5R871I;VX@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT
M:6YG96YT(&-O;G-I9&5R871I;VX@;&EA8FEL:71Y(%M-96UB97)=('P@3&5V
M96P@,R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D9A:7(@5F%L=64@07-S971S($%N9"!,:6%B:6QI=&EE<R!-
M96%S=7)E9"!/;B!296-U<G)I;F<@06YD($YO;G)E8W5R<FEN9R!"87-I<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@8V]N=&EN9V5N="!C;VYS:61E<F%T:6]N(&QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P
M,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R
M938P-V4S,3$W+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14=(
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE
M;G0@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&
M86ER(%9A;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@
M=F%L=64@;V8@8V]N=&EN9V5N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93<Q,#,T-#!?-&)C-%\T,&0T7S@T
M,39?9F0R938P-V4S,3$W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-R]7;W)K<VAE
M971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$552#X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT("T@4V-H961U;&4@;V8@
M0VAA;F=E<R!I;B!%<W1I;6%T960@1F%I<B!686QU92!O9B!#;VYT:6YG96YT
M($-O;G-I9&5R871I;VX@3&EA8FEL:71Y("A$971A:6PI("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!6
M86QU92!$:7-C;&]S=7)E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87,@;V8@1&5C
M96UB97(@,S$L(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,2PX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#@P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87,@;V8@36%R
M8V@@,S$L(#(P,34\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93<Q
M,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D
M,F4V,#=E,S$Q-R]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$59
M4T%)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DUA<FME=&%B;&4@4V5C=7)I
M=&EE<R`M(%-C:&5D=6QE(&]F($EN=F5S=&UE;G1S("A$971A:6PI("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4V-H961U;&4@3V8@079A:6QA8FQE($9O<B!386QE
M(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4L,C4V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V
M+#`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3(V+#@R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3`L,3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP.#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M;W)T:7IE9"!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,3<L-3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C(S+#,Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"!'86EN<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L
M:7IE9"`H3&]S<V5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5S=&EM871E9"!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,3<L-34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C(S+#,W-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^079A:6QA8FQE+69O<BUS
M86QE('-E8W5R:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!/9B!!=F%I;&%B;&4@1F]R
M(%-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!#;W-T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L-#0T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(P+#(Q-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1W)O<W,@56YR96%L:7IE9"!'86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"`H3&]S<V5S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!&
M86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L
M-#8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C(P+#$Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36]N97D@;6%R:V5T(&9U;F1S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@
M3V8@079A:6QA8FQE($9O<B!386QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W+#`X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L,3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP.#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!E<75I=F%L96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE($]F($%V86EL86)L92!&
M;W(@4V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP
M.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#$X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<L,#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UE<F-I86P@<&%P
M97(@<V5C=7)I=&EE<R!;365M8F5R72!\($%V86EL86)L92UF;W(M<V%L92!S
M96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4V-H961U;&4@3V8@079A:6QA8FQE($9O<B!386QE
M(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@0V]S=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,3(Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L-S$U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!5
M;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%<W1I;6%T960@1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S$L,30X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L-S0X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W)P;W)A=&4@9&5B="!S
M96-U<FET:65S(%M-96UB97)=('P@079A:6QA8FQE+69O<BUS86QE('-E8W5R
M:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY38VAE9'5L92!/9B!!=F%I;&%B;&4@1F]R(%-A;&4@4V5C
M=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!#;W-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,RPR-C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPX,S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A
M;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S(%5N<F5A;&EZ960@*$QO<W-E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D($9A:7(@5F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#(V-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#@Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^52Y3+B!G
M;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S96-U<FET:65S(%M-
M96UB97)=('P@079A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M8VAE9'5L92!/9B!!=F%I;&%B;&4@1F]R(%-A;&4@4V5C=7)I=&EE<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%M;W)T:7IE9"!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#8L,#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,38S+#8W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"`H3&]S
M<V5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S
M=&EM871E9"!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$T-BPP-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$V,RPV,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D
M,F4V,#=E,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-S$P
M,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O5V]R:W-H965T<R]3
M:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%1T@^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^36%R:V5T86)L92!396-U<FET:65S("T@061D:71I;VYA;"!);F9O<FUA
M=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV97-T;65N=',@
M1&5B="!!;F0@17%U:71Y(%-E8W5R:71I97,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<BUT:&%N
M+71E;7!O<F%R>2!I;7!A:7)M96YT<R!O9B!I;G9E<W1M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?
M.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W+U=O<FMS
M:&5E=',O4VAE970R-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E&04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0F%S:6,@86YD($1I;'5T960@3F5T($QO<W,@4&5R(%-H
M87)E("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H4W1O8VL@
M;W!T:6]N<R!;365M8F5R72D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E
M(%-E8W5R:71I97,@17AC;'5D960@1G)O;2!#;VUP=71A=&EO;B!/9B!%87)N
M:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@;W5T<W1A
M;F1I;F<@97AC;'5D960@:6X@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@
M;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L-C(T+#8P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<L,S`R+#,V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P
M-V4S,3$W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4W,3`S-#0P
M7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-R]7;W)K<VAE971S+U-H965T
M,C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$595D-)/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/DUA:F]R($-U<W1O;65R<RP@4&%R=&YE<G-H:7!S(&%N9"!3=')A=&5G:6,@
M06QL:6%N8V5S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$T/&)R
M/E!R;V=R86T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3(\8G(^5&%R9V5T<SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/E1A<F=E=',\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O
M(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(')E<V5A
M<F-H('!R;V=R86US/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,30L.3@P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L,#@S+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0FEO9V5N
M($EN8R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!!<G)A;F=E;65N
M="P@0V]N=')A8W0@=&\@4&5R9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M979E;G5E<R!U;F1E<B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!A;6]U;G0@96QI9VEB
M;&4@=&\@<F5C96EV92!F;W(@8V5R=&%I;B!M:6QE<W1O;F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C8L,S`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L
M(&%M;W5N="!T;R!B92!F=6YD960@9F]R(&%C:&EE=F5M96YT(&]F('-P96-I
M9FEE9"!C;VUM97)C:6%L:7IE9"!A;F0@<V%L97,@;6EL97-T;VYE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38W+#4P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S
M=&]N92!R979E;G5E(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Y,RPX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N=',@<F5C
M96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!P<F]D=6-T<R!A<'!R;W9E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F]Y86QT>2!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@<')O9W)A;2!T;R!D979E;&]P
M(&QA8F]R871O<GD@<F5S96%R8V@@<F5A9V5N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/C0P(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0FEO
M9V5N($EN8R!;365M8F5R72!\($)E=&$M=&AA;&%S<V5M:6$@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O
M(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE(')E=F5N
M=64@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0FEO
M9V5N($EN8R!;365M8F5R72!\(%-I8VML92!C96QL(&1I<V5A<V4@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2
M97-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T
M('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE(')E
M=F5N=64@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y":6]G96X@26YC(%M-96UB97)=('P@3W1H97(@4')O
M:F5C=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE
M;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&ER92!!1R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H
M(&%N9"!$979E;&]P;65N="!!<G)A;F=E;65N="P@0V]N=')A8W0@=&\@4&5R
M9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<R!U;F1E<B!A9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!O=&5N=&EA;"!A;6]U;G0@=&\@8F4@9G5N9&5D(&9O<B!A8VAI979E
M;65N="!O9B!S<&5C:69I960@8V]M;65R8VEA;&EZ960@86YD('-A;&5S(&UI
M;&5S=&]N97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@<')O9'5C=',@87!P<F]V960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@<F5V96YU97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H('!R;V=R
M86T@=&\@9&5V96QO<"!L86)O<F%T;W)Y(')E<V5A<F-H(')E86=E;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#@P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A
M=&4@;G5M8F5R(&]F(&=E;F4@=&%R9V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&EN:71I86P@9V5N92!T87)G971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M9V5N92!T87)G971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97(@;V8@861D:71I;VYA;"!G96YE('1A<F=E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.1"!O<B!#5$$@<W5B;6ES<VEO
M;B!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36EL97-T;VYE('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAI<F4@04<@6TUE;6)E<ET@?"!-87AI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($%R<F%N9V5M96YT
M+"!#;VYT<F%C="!T;R!097)F;W)M(&9O<B!/=&AE<G,@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI
M;&5S=&]N92!R979E;G5E(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,S,L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?
M9F0R938P-V4S,3$W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4W
M,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-R]7;W)K<VAE971S
M+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5.64%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DUA:F]R($-U<W1O;65R<RP@4&%R=&YE<G-H:7!S(&%N9"!3=')A
M=&5G:6,@06QL:6%N8V5S("T@4F5V96YU97,@4F5C;V=N:7IE9"!U;F1E<B!!
M9W)E96UE;G0@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y":6]G96X@26YC(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]G
M;FET:6]N(&]F('5P9G)O;G0@9F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$L-3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@<F5V96YU97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H('-E<G9I8V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#4V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP.#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H:7)E($%'(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F5V96YU97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]G;FET:6]N(&]F('5P9G)O;G0@
M9F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O
M>6%L='D@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<V5A<F-H('-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#4R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L.3<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PP-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#4R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;6$M06QD<FEC:"!#;W)P;W)A
M=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E)E=F5N=65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296-O9VYI=&EO;B!O9B!U<&9R;VYT(&9E93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@
M<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&EC96YS92!F964@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L,C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C@U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F
M9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93<Q
M,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W+U=O<FMS:&5E=',O
M4VAE970R.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P149604<^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^36%J;W(@0W5S=&]M97)S+"!087)T;F5R<VAI<',@86YD(%-T<F%T
M96=I8R!!;&QI86YC97,@+2!!9W)E96UE;G0@=VET:"!3:6=M82U!;&1R:6-H
M($-O<G!O<F%T:6]N("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`P-SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V
M96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R
M($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T+#DX,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R
M+#`X,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-I9VUA+4%L9')I8V@@0V]R<&]R871I;VX@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O
M(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@<')O9W)A
M;2!T;R!D979E;&]P(&QA8F]R871O<GD@<F5S96%R8V@@<F5A9V5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5P9G)O;G0@
M;&EC96YS92!F964\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!U8FQI8R!O9F9E<FEN9RP@8V]M;6]N('-T;V-K('-H87)E
M<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-BPQ
M,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%M;W5N="!R96-E:79E9"!O;B!C;VUM97)C:6%L(&QI8V5N<V4@9F5E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M961U8V5D(')O>6%L='D@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&=6YD:6YG(&%V86EL86)L92!U;F1E<B!T:&4@86UE
M;F1E9"!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!P87EM96YT<R!R96-E:79E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;6$M06QD<FEC:"!#
M;W)P;W)A=&EO;B!;365M8F5R72!\(%5P9G)O;G0@;&EC96YS92!F964@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R
M86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^57!F<F]N="!L
M:6-E;G-E(&9E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L
M,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!U;F1E<B!L:6-E;G-E(&%G
M<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:6=M82U!;&1R:6-H($-O<G!O<F%T:6]N(%M-96UB97)=('P@3&EC
M96YS92!A9W)E96UE;G0@=&5R;7,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V96QO
M<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R($]T
M:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F]Y86QT>2!R979E;G5E<R!E>'!E8W1E9"!T;R!B
M92!R96-E:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93<Q,#,T-#!?-&)C-%\T,&0T
M7S@T,39?9F0R938P-V4S,3$W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V4W,3`S-#0P7S1B8S1?-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-R]7;W)K
M<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5&3$%'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DUA:F]R($-U<W1O;65R<RP@4&%R=&YE<G-H:7!S(&%N
M9"!3=')A=&5G:6,@06QL:6%N8V5S("T@06=R965M96YT('=I=&@@1&]W($%G
M<F]38VEE;F-E<R!I;B!0;&%N="!!9W)I8W5L='5R92`M($%D9&ET:6]N86P@
M26YF;W)M871I;VX@*$1E=&%I;"D@*$QI8V5N<V4@86=R965M96YT('1E<FUS
M(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#`U/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E87)C:"!A
M;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O(%!E<F9O
M<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE
M;G0@<F5L871E9"!C;W-T<R!A;F0@97AP96YS97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]W($%G<F\@
M4V-I96YC97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG
M96UE;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S96%R8V@@<')O9W)A;2!T;R!D979E;&]P(&QA8F]R871O<GD@<F5S
M96%R8V@@<F5A9V5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]N92UT:6UE(&QI8V5N<V4@9F5E(&5A<FYE9"!O;B!E>&5R
M8VES92!O9B!O<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F]Y86QT>2!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(')O>6%L
M=&EE<R!T;R!B92!R96-E:79E9"!F<F]M('-U8FQI8V5N<VEN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5V:6]U<VQY(&%G
M<F5E9"!R97-E87)C:"P@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T
M:6]N(&UI;&5S=&]N92!P87EM96YT<RP@86YD(')O>6%L=&EE<R!O;B!S86QE
M<R!O9B!P<F]D=6-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&964@9'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(&QI8V5N<V4@86YN=6%L(&9E97,@
M<W!E8VEF:6,@<F5C:V]N:6YG('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,3$@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@86=R965M96YT
M(')E;&%T960@8V]S=',@86YD(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!A='1R:6)U=&%B;&4@=&\@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&]W($%G<F\@4V-I96YC97,@6TUE;6)E<ET@?"!-:6YI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($%R<F%N9V5M96YT
M+"!#;VYT<F%C="!T;R!097)F;W)M(&9O<B!/=&AE<G,@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N
M;G5A;"!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;W<@06=R;R!38VEE;F-E<R!;365M8F5R72!\($UA>&EM=6T@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R
M86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YN=6%L(&9E
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S$P
M,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R
M938P-V4S,3$W+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14]$
M0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^36%J;W(@0W5S=&]M97)S+"!0
M87)T;F5R<VAI<',@86YD(%-T<F%T96=I8R!!;&QI86YC97,@+2!#86QI9F]R
M;FEA($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E($UE9&EC:6YE("T@061D
M:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N
M(#,Q+"`R,#`Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M>2`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE
M;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@9W)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#@R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#4T."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;&EF;W)N:6$@26YS=&ET=71E(&9O
M<B!296=E;F5R871I=F4@365D:6-I;F4@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V
M96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R
M($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1G5N9',@9'5E('5N9&5R('1H92!A9W)E96UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D(&%M;W5N="!T;R!B92!R96-E:79E9"!F;W(@
M<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G<F5E;65N="!T;R!R96-E:79E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06=R965M96YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/D]C="`S,2P-"@D),C`P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@9W)A;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE
M;G0@<F5L871E9"!C;W-T<R!A;F0@97AP96YS97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86QI9F]R;FEA($EN<W1I='5T
M92!F;W(@4F5G96YE<F%T:79E($UE9&EC:6YE(%M-96UB97)=('P@0F5T82UT
M:&%L87-S96UI82!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!!<G)A
M;F=E;65N="P@0V]N=')A8W0@=&\@4&5R9F]R;2!F;W(@3W1H97)S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&=6YD<R!D=64@=6YD97(@=&AE(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPT,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9W)E96UE;G0@=&\@
M<F5C96EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S96%R8V@@9W)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@
M<F5L871E9"!C;W-T<R!A;F0@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&%G<F5E;65N
M="!T97)M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!!<G)A;F=E
M;65N="P@0V]N=')A8W0@=&\@4&5R9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-E87)C:"!G<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VQL86)O<F%T:6]N(&%G<F5E;65N="!R96QA=&5D(&-O<W1S
M(&%N9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W
M93,Q,3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?
M-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W+U=O<FMS:&5E=',O4VAE970S
M,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P151"044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M26YT86YG:6)L92!!<W-E=',@+2!#87)R>6EN9R!686QU92!O9B!);G1A;F=I
M8FQE<R!!<W-E=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;FET92U,
M:79E9"!);G1A;F=I8FQE($%S<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@:61E;G1I
M9FEA8FQE(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$L.#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#15)%+3$Q,"!F;W(@=&AE('1R96%T
M;65N="!O9B!!;'IH96EM97(G<R!D:7-E87-E("@B25!2)F%M<#M$(BD@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY&:6YI=&4M3&EV960@26YT86YG:6)L92!!<W-E=',@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&ED96YT:69I86)L92!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C0P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#15)%+3$R,"!F;W(@=&AE
M('1R96%T;65N="!O9B!087)K:6YS;VXG<R!D:7-E87-E("@B25!2)F%M<#M$
M(BD@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&:6YI=&4M3&EV960@26YT86YG:6)L92!!<W-E=',@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&ED96YT:69I86)L92!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?
M-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O
M5V]R:W-H965T<R]3:&5E=#,S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5T4^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YT86YG:6)L92!!<W-E=',@+2!!9&1I=&EO;F%L
M($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YT86YG:6)L92!!<W-E="!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEM<&%I<FUE;G0@8VAA<F=E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L.#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W
M93,Q,3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93<Q,#,T-#!?
M-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W+U=O<FMS:&5E=',O4VAE970S
M-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P149'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN
M8V]M92!487AE<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96YE9FET(&9R
M;VT@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#<T."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E8V]G;FET:6]N(&]F(&EN8V]M92!T87@@8F5N969I=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4W,3`S-#0P7S1B8S1?
M-#!D-%\X-#$V7V9D,F4V,#=E,S$Q-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<O
M5V]R:W-H965T<R]3:&5E=#,U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D)!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@+2!3
M=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS92`H1&5T86EL*2`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]S=',@86YD(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS
M871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R+#DU,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PY,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-O<W1S(&%N9"!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PP-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]S
M=',@86YD(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(V
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@.#,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E-S$P,S0T,%\T8F,T7S0P9#1?.#0Q-E]F9#)E-C`W93,Q,3<-"D-O;G1E
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M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S-2YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?
M3F5X=%!A<G1?93<Q,#,T-#!?-&)C-%\T,&0T7S@T,39?9F0R938P-V4S,3$W
$+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFVAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2007</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 14,980,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 12,083,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UpfrontLicenseFee', window );">Upfront license fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_UpfrontLicenseFee[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_UpfrontLicenseFee<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, common stock shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">636,133</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Amount received on commercial license fees</a></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ReducedRoyaltyRate', window );">Reduced royalty rate</a></td>
        <td class="nump"><a title="sgmo_ReducedRoyaltyRate[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">10.50%</a><span style="display:none;white-space:normal;text-align:left;">sgmo_ReducedRoyaltyRate<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdditionalMilestoneReceivableUnderAgreement', window );">Funding available under the amended agreement</a></td>
        <td class="nump"><a title="sgmo_AdditionalMilestoneReceivableUnderAgreement[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AdditionalMilestoneReceivableUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
        <td class="nump"><a title="sgmo_MilestonePaymentsReceived[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">sgmo_MilestonePaymentsReceived<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member] | Upfront license fee [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UpfrontLicenseFee', window );">Upfront license fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_UpfrontLicenseFee[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_UpfrontLicenseFeesMember]" onclick="toggleNextSibling(this);">15,100,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_UpfrontLicenseFee<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_UpfrontLicenseFeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued under license agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_UpfrontLicenseFeesMember]" onclick="toggleNextSibling(this);">4,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_UpfrontLicenseFeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member] | License agreement terms [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_RoyaltyRevenuesExpectedToBeReceived', window );">Royalty revenues expected to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_RoyaltyRevenuesExpectedToBeReceived[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_RoyaltyRevenuesExpectedToBeReceived<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">$ 200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdditionalMilestoneReceivableUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional milestone receivable under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_AdditionalMilestoneReceivableUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial research term of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ReducedRoyaltyRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduced royalty rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_ReducedRoyaltyRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RoyaltyRevenuesExpectedToBeReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty revenues expected to be received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_RoyaltyRevenuesExpectedToBeReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UpfrontLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_UpfrontLicenseFee</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember', window );">Biogen Inc [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">$ 1,523</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">$ 660</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement', window );">Research services</a></td>
        <td class="nump"><a title="sgmo_ResearchServiceRevenueUnderCollaborationAgreement[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">1,533</a><span style="display:none;white-space:normal;text-align:left;">sgmo_ResearchServiceRevenueUnderCollaborationAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="nump"><a title="sgmo_ResearchServiceRevenueUnderCollaborationAgreement[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">423</a><span style="display:none;white-space:normal;text-align:left;">sgmo_ResearchServiceRevenueUnderCollaborationAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">3,056</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">1,083</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">542</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">542</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement', window );">Research services</a></td>
        <td class="nump"><a title="sgmo_ResearchServiceRevenueUnderCollaborationAgreement[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">4,522</a><span style="display:none;white-space:normal;text-align:left;">sgmo_ResearchServiceRevenueUnderCollaborationAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="nump"><a title="sgmo_ResearchServiceRevenueUnderCollaborationAgreement[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">4,979</a><span style="display:none;white-space:normal;text-align:left;">sgmo_ResearchServiceRevenueUnderCollaborationAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">5,064</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">5,521</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">264</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fee revenues</a></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">4,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">179</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">$ 4,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue[us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember]" onclick="toggleNextSibling(this);">$ 285</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_SigmaAldrichCorporationMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research service revenue under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_ResearchServiceRevenueUnderCollaborationAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail) (License agreement terms [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 31, 2005</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses" onclick="toggleNextSibling(this);">$ 200,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses" onclick="toggleNextSibling(this);">$ 300,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OneTimeLicenseFeeEarned', window );">One-time license fee earned on exercise of option</a></td>
        <td class="nump"><a title="sgmo_OneTimeLicenseFeeEarned[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_OneTimeLicenseFeeEarned<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">2,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing', window );">Percentage of royalties to be received from sublicensing</a></td>
        <td class="nump"><a title="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement', window );">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</a></td>
        <td class="nump"><a title="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">4,000,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FeeDue', window );">Fee due</a></td>
        <td class="nump"><a title="sgmo_FeeDue[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">25,300,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_FeeDue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod', window );">Minimum license annual fees specific reckoning period</a></td>
        <td class="text">11 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue attributable to research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
        <td class="nump"><a title="sgmo_AnnualFeesRelatedToAgreement[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_RangeAxis=us-gaap_MinimumMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">250,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AnnualFeesRelatedToAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
        <td class="nump"><a title="sgmo_AnnualFeesRelatedToAgreement[us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">$ 3,000,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AnnualFeesRelatedToAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_DowAgroSciencesMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AnnualFeesRelatedToAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual fees related to agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_AnnualFeesRelatedToAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_CollaborationAgreementRelatedCostsAndExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FeeDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fee due.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_FeeDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial research term of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment and royalty revenue of previous agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum sublicense annual fees specific reckoning period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OneTimeLicenseFeeEarned">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One time license fee earned.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_OneTimeLicenseFeeEarned</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalties to be received from sublicensing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EODBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>May 31, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009</div>
        </th>
        <th class="th">
          <div>May 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">$ 820,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">$ 548,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember', window );">California Institute for Regenerative Medicine [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_GrantFundingAmount[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">5,600,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_GrantFundingAmount<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="nump"><a title="sgmo_GrantFundingAmount[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">14,500,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_GrantFundingAmount<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment', window );">Expected amount to be received for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">5,200,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_TermsOfContract', window );">Agreement to receive</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementDate', window );">Agreement date</a></td>
        <td class="text">Oct. 31,  2009<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember', window );">California Institute for Regenerative Medicine [Member] | Beta-thalassemia [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_GrantFundingAmount[us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_BetaThalassemiaMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">6,400,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_GrantFundingAmount<br>/ us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis<br>= sgmo_BetaThalassemiaMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_TermsOfContract', window );">Agreement to receive</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_BetaThalassemiaMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis<br>= sgmo_BetaThalassemiaMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_BetaThalassemiaMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis<br>= sgmo_BetaThalassemiaMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_BetaThalassemiaMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">700,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis<br>= sgmo_BetaThalassemiaMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_BetaThalassemiaMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis<br>= sgmo_BetaThalassemiaMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_CaliforniaInstituteForRegenerativeMedicineMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License agreement terms [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">$ 200,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreementRelatedCostsAndExpenses[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember]" onclick="toggleNextSibling(this);">$ 300,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreementRelatedCostsAndExpenses<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= us-gaap_LicenseAgreementTermsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_AgreementDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_CollaborationAgreementRelatedCostsAndExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected revenue to be received for research and development.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_ExpectedRevenueToBeReceivedForResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grant funding amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_GrantFundingAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_TermsOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Terms of contract.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_TermsOfContract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2&#8212;FAIR VALUE MEASUREMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for sale-securities and the contingent consideration liability.&#160;The fair value of these assets and contingent liability was determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value measurements of our cash equivalents, available-for-sale marketable securities and contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,558</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,374</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally classifies its debt instruments as Level 2. Instruments can be classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingent Consideration Liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2013, the Company acquired Ceregene and recorded a liability for the estimated fair value of contingent consideration payments to former Ceregene stockholders, as outlined under the terms of the merger agreement with Ceregene. These contingent payments are owed if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. The fair value of this liability is estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. <font style="letter-spacing:-0.1pt;">The Company has classified this liability as Level 3.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent changes in the fair value of this contingent consideration liability are recorded to the research and development (R&amp;D) expense line item in the Condensed Consolidated Statements of Operations as operating expenses. During the three months ended March 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of the in-process research and development (IPR&amp;D) assets acquired from Ceregene (see Note 6). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of December 31, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of March 31, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Intangible Assets - Carrying Value of Intangibles Assets (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total identifiable intangible assets</a></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" onclick="toggleNextSibling(this);">$ 1,870</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember', window );">CERE-110 for the treatment of Alzheimer's disease ("IPR&amp;D") [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total identifiable intangible assets</a></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember]" onclick="toggleNextSibling(this);">1,640</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember', window );">CERE-120 for the treatment of Parkinson's disease ("IPR&amp;D") [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total identifiable intangible assets</a></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember]" onclick="toggleNextSibling(this);">$ 230</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 25,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 6,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent" onclick="toggleNextSibling(this);">170,647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent" onclick="toggleNextSibling(this);">172,932</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
        <td class="nump"><a title="us-gaap_InterestReceivableCurrent" onclick="toggleNextSibling(this);">398</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestReceivableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestReceivableCurrent" onclick="toggleNextSibling(this);">423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestReceivableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">6,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">10,368</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">587</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">623</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">320</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">320</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">183</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">203,946</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">190,879</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesNoncurrent" onclick="toggleNextSibling(this);">29,822</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesNoncurrent" onclick="toggleNextSibling(this);">47,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,479</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets, in-process research and development</a></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" onclick="toggleNextSibling(this);">1,870</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">1,585</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">1,585</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">157</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">238,505</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">243,212</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">6,806</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">8,704</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
        <td class="nump"><a title="us-gaap_AccruedEmployeeBenefitsCurrent" onclick="toggleNextSibling(this);">1,703</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedEmployeeBenefitsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedEmployeeBenefitsCurrent" onclick="toggleNextSibling(this);">2,853</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedEmployeeBenefitsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EscrowLiability', window );">Escrow liability</a></td>
        <td class="nump"><a title="sgmo_EscrowLiability" onclick="toggleNextSibling(this);">275</a><span style="display:none;white-space:normal;text-align:left;">sgmo_EscrowLiability</span><span></span></td>
        <td class="nump"><a title="sgmo_EscrowLiability" onclick="toggleNextSibling(this);">275</a><span style="display:none;white-space:normal;text-align:left;">sgmo_EscrowLiability</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">11,184</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">9,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">19,968</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">20,882</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues, non-current</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">11,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">13,149</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" onclick="toggleNextSibling(this);">1,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">31,017</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">36,579</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 160,000,000 shares authorized, 69,497,256 and 69,062,394 shares issued and outstanding at March 31, 2015, and December 31, 2014, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">695</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">690</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">540,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">534,518</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(333,869)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(328,550)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(25)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">207,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">206,633</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 238,505</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 243,212</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EscrowLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Escrow liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_EscrowLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Goodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EALAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (5,319)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,572)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">147</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">123</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" onclick="toggleNextSibling(this);">241</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" onclick="toggleNextSibling(this);">295</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">2,953</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">1,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liability</a></td>
        <td class="num"><a title="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" onclick="toggleNextSibling(this);">(1,800)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</span><span></span></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" onclick="toggleNextSibling(this);">50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible impairment</a></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" onclick="toggleNextSibling(this);">1,870</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(748)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" onclick="toggleNextSibling(this);">25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" onclick="toggleNextSibling(this);">(45)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">3,730</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(2,205)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">101</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(71)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(2,477)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">1,732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(1,150)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(1,723)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenues</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">34</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">18,888</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by / (used in) operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(2,393)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">11,379</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireMarketableSecurities" onclick="toggleNextSibling(this);">(39,423)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireMarketableSecurities</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireMarketableSecurities" onclick="toggleNextSibling(this);">(16,773)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireMarketableSecurities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" onclick="toggleNextSibling(this);">58,955</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" onclick="toggleNextSibling(this);">20,786</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(1,084)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by investing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">18,448</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">3,887</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_NetProceedsFromIssuancePublicOffering" onclick="toggleNextSibling(this);">93,786</a><span style="display:none;white-space:normal;text-align:left;">sgmo_NetProceedsFromIssuancePublicOffering</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
        <td class="num"><a title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" onclick="toggleNextSibling(this);">(7)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">3,178</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">7,585</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">3,171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">101,371</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">19,226</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">116,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">6,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">10,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">25,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">126,823</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property, plant and equipment included in accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_CapitalExpendituresIncurredButNotYetPaid" onclick="toggleNextSibling(this);">$ 579</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net proceeds from issuance public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 2,953</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 1,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">1,691</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">1,073</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 1,262</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 834</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent liability</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" onclick="toggleNextSibling(this);">$ 1,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</span><span></span></td>
        <td class="num"><a title="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" onclick="toggleNextSibling(this);">$ (50)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYSAI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Marketable Securities - Schedule of Investments (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 25,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 6,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 126,823</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 10,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost" onclick="toggleNextSibling(this);">217,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost" onclick="toggleNextSibling(this);">223,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" onclick="toggleNextSibling(this);">32</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" onclick="toggleNextSibling(this);">33</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" onclick="toggleNextSibling(this);">(7)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">217,558</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">223,374</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">200,444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">220,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">32</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">33</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">(7)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">200,469</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember]" onclick="toggleNextSibling(this);">220,192</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue[us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue[us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue[us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashEquivalentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue[us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashEquivalentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashEquivalentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashEquivalentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities [Member] | Available-for-sale securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">31,121</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">33,715</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">27</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">33</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">31,148</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">33,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities [Member] | Available-for-sale securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">23,261</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">22,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(18)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">23,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">22,813</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">146,062</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">163,671</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(7)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">$ 146,055</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">$ 163,631</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InformationByCategoryOfDebtSecurityAxis<br>= us-gaap_AvailableforsaleSecuritiesMember<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1&#8212;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (&#8220;Sangamo&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2015. The condensed consolidated balance sheet data at December&#160;31, 2014 were derived from the audited consolidated financial statements included in Sangamo&#8217;s Form 10-K for the year ended December&#160;31, 2014, as filed with the SEC. These financial statements should be read in conjunction with the financial statements and footnotes thereto for the year ended December&#160;31, 2014, included in Sangamo&#8217;s Form 10-K, as filed with the SEC. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements prior to the adoption of ASU No.&#160;2009-13, Revenue Recognition&#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)<font style="font-style:normal;">. For revenue arrangements entered into before January&#160;1, 2011, that include multiple deliverables, the elements of such agreements were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements after the adoption of ASU 2009-13.<font style="font-style:normal;"> ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (VSOE), if available; third-party evidence (TPE), if available and VSOE is not available; or the best estimate of selling price (ESP), if neither VSOE nor TPE is available; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG (Shire), in January 2012 and Biogen Inc., formerly Biogen Idec Inc. (Biogen) in January 2014 were evaluated under these amended accounting standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company&#8217;s performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred to the extent such amounts have been agreed to with the respective collaboration partner. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Standards </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2014 the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-15, <font style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font> (ASU 2014-15). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting ASU 2014-15 on its consolidated financial statements will be material.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 the Financial Accounting Standards Board issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with&#160;Customers</font>&#160;(ASU 2014-09). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&#160;15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">160,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">160,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">69,497,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">69,062,394</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">69,497,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">69,062,394</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Schedule of Investments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The table below summarizes the Company&#8217;s investments (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Losses)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,062</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,444</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,533</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,558</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,831</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,671</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,217</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,399</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,374</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Apr. 24, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">SGMO<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">SANGAMO BIOSCIENCES INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001001233<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Large Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">69,582,797</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EALAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember', window );">Biogen Inc [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues recognized under the agreement with Biogen for the three months ended March 31, 2015 and 2014 are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Biogen Collaboration:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,523</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">660</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,533</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,056</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,083</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues recognized under the agreement with Shire for the three months ended March 31, 2015 and 2014, were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Shire Collaboration:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,522</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,979</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,064</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues recognized under the agreement with Sigma for the three months ended March 31, 2015 and 2014, were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Sigma Collaboration:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenues</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee revenues</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,256</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2KAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreements', window );">Collaboration agreements</a></td>
        <td class="nump"><a title="sgmo_CollaborationAgreements" onclick="toggleNextSibling(this);">$ 12,671</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreements</span><span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAgreements" onclick="toggleNextSibling(this);">$ 7,568</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAgreements</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">820</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">548</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">13,491</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">8,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">14,980</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">12,083</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">4,732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">3,644</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">19,712</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">15,727</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(6,221)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(7,611)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
        <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">154</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(6,067)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(7,572)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (5,319)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,572)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.08)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.12)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">69,283</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">63,199</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_CollaborationAgreements</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 940<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35710027&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6&#8212;INTANGIBLE ASSETS </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Intangible assets for IPR&amp;D consist of two clinical product candidates from our 2013 acquisition of Ceregene. IPR&amp;D is an intangible asset classified as indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of these intangibles assets are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERE-110 for the treatment of Alzheimer's disease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,640</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERE-120 for the treatment of Parkinson's disease</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable intangible assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2015, the Company received clinical data demonstrating no statistically significant difference between the control group and the group treated with CERE-110 for Alzheimer&#8217;s disease. Subsequently, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. Given these results, the Company does not believe the programs have an alternative future use for itself or other market participants. Accordingly, during the three months ended March 31, 2015, the Company recognized a $1.9 million impairment charge related to these assets. The impairment is recorded in R&amp;D expense in the accompanying condensed consolidated statements of operations. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Major Customers, Partnerships and Strategic Alliances</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5&#8212;MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Biogen Inc. in Human Therapeutics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014 Sangamo entered into a Global Research, Development and Commercialization Collaboration and License Agreement (the &#8220;Biogen Agreement&#8221;) with Biogen, pursuant to which Sangamo and Biogen collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&#8217;s zinc finger DNA-binding protein (ZFP) technology for hemoglobinopathies, including beta-thalassemia and sickle cell disease (SCD). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Biogen Agreement, Sangamo and Biogen jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP Therapeutic developed under the Biogen Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (IND) application for ZFP Therapeutics intended to treat SCD. For both programs, Biogen is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Biogen Agreement. At the end of specified research terms for each program or under certain specified circumstances, Biogen retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any&#160;licensed product to treat beta-thalassemia and SCD&#160;developed under the Biogen Agreement, and Biogen agrees to compensate Sangamo for such co-promotion activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo received an upfront license fee of $20.0 million upon entering into the Biogen Agreement. In addition, the Company will also be eligible to receive $126.3 million in payments upon the achievement of specified research, regulatory, clinical development milestones, as well as $167.5 million in payments upon the achievement of specified commercialization and sales milestones. Biogen reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. In addition, Sangamo is eligible to receive contingent payments upon the achievement of specified regulatory, clinical development, commercialization and sales milestones. The total amount of potential regulatory, clinical development, commercialization and sales contingent payments, assuming the achievement of all specified milestone events in the Biogen Agreement, is $293.8 million, including Phase 1 contingent payments of $7.5 million for each of the beta-thalassemia and SCD programs. In addition, if products are commercialized under the Biogen Agreement, Biogen will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Biogen Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All contingent payments under the Biogen Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Biogen Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&#160;that can be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance, (ii)&#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&#160;that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Biogen Agreement, assuming all other applicable revenue recognition criteria have been met. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the Biogen Agreement, Sangamo grants Biogen an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Biogen Agreement. Sangamo also grants Biogen a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, of Sangamo&#8217;s interest in certain other intellectual property developed pursuant to the Biogen Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Biogen apart from the research services to be performed pursuant to the Biogen Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a forty-month estimated initial research term during which the Company will perform research services. As of March 31, 2015, the Company has deferred revenue of $14.1 million related to the Biogen Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Biogen for the three months ended March 31, 2015 and 2014 are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Biogen Collaboration:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,523</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">660</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,533</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,056</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,083</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related costs and expenses incurred under the Biogen agreement related to the beta-thalassemia project, which is co-funded with California Institute for Regenerative Medicine (CIRM), were $1.4 million and $1.3 million during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses for other projects including sickle cell disease under the Biogen agreement were $1.1 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Shire International GmbH in Human Therapeutics and Diagnostics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2012 the Company entered into a collaboration and license agreement (the &#8220;Shire Agreement&#8221;) with Shire, pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&#8217;s novel ZFP technology. Under the Shire Agreement, the Company and Shire may develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets will be used for treating or diagnosing hemophilia. In June 2012, Shire selected a fifth gene target for the development of a ZFP Therapeutic for Huntington&#8217;s disease. Shire has the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. The initial research term of the Shire Agreement is six years and is subject to extensions upon mutual agreement and under other specified circumstances. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Shire Agreement, the Company is responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimburses Sangamo for agreed upon internal and external program-related research costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement. In addition, the Company will also be eligible to receive $33.5 million in payments upon the achievement of specified research, regulatory, clinical development milestones, including payments for each gene target through the acceptance of an IND or CTA submission totaling $8.5 million, as well as $180 million in payments upon the achievement of specified commercialization and sales milestones. The Company will also be eligible to receive royalty payments that are a tiered double-digit percentage of net sales of licensed product sold by Shire or its sublicensees developed under the collaboration, if any. To date, no products have been approved and therefore no royalty fees have been earned under the Shire Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All contingent payments under the Shire Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Shire Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&#160;that can be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance, (ii)&#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&#160;that would result in additional payments being due to the Company. Accordingly, revenue for the achievement of milestones that are determined to be substantive will be recognized in their entirety in the period the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Shire Agreement, assuming all other applicable revenue recognition criteria have been met. In 2014 Sangamo recognized a $1.0 million milestone payment related to our hemophilia program.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a six-year initial research term during which the Company will perform research services. As of March 31, 2015, the Company has deferred revenue of $6.8 million related to the Shire Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Shire for the three months ended March 31, 2015 and 2014, were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Shire Collaboration:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,522</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,979</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,064</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related costs and expenses incurred under the Shire agreement were $4.5 million and $4.8 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2007 Sangamo entered into a license agreement (the &#8220;Sigma Agreement&#8221;) with Sigma-Aldrich Corporation (Sigma). Under the Sigma Agreement, Sangamo agreed to provide Sigma with access to our proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (DAS). Under the Sigma Agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using Sangamo&#8217;s ZFP technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company&#8217;s ZFP technology in the research field. Sangamo has transferred its ZFP manufacturing technology to Sigma. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2009 Sangamo expanded the Sigma Agreement. In addition to the original terms of the Sigma Agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the Sigma Agreement as expanded in 2009, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock and a $15.1 million upfront license fee. The upfront license fee was recognized on a straight-line basis from the effective date of the expanded license through July 2010, which represents the period over which Sangamo was obligated to perform research services for Sigma. Sangamo is also eligible to receive commercial license fees of $5.0 million based upon a percentage of net sales. As of March 31, 2015 Sangamo has received the entire $5.0 million of commercial license fees and is eligible to receive royalty payments of 10.5% of net sales and sublicensing revenue.  In addition, upon the achievement of certain cumulative commercial milestones Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Sigma for the three months ended March 31, 2015 and 2014, were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Sigma Collaboration:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenues</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee revenues</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,256</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related costs and expenses incurred under the Sigma agreement were $0.2 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreement with Dow AgroSciences in Plant Agriculture </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2005 Sangamo entered into an exclusive commercial license agreement with DAS (the &#8220;DAS Agreement&#8221;). Under the DAS Agreement, Sangamo provides DAS with access to our proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP transcription factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic, therapeutic or prophylactic purposes. The DAS Agreement provided for an initial three-year research term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants or plant cell cultures. Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended the DAS Agreement to extend the period of reagent manufacturing services and research services through December&#160;31, 2012. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DAS Agreement also provides for minimum license fees each year due to Sangamo every October, provided the Agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years. The Company does not have any ongoing performance obligations under the agreement with DAS. DAS has the right to terminate the agreement at any time; accordingly, the Company&#8217;s actual license fees over the term of the DAS Agreement could be lower than $25.3 million. In addition, each party may terminate the DAS Agreement upon an uncured material breach by the other party. In the event of any termination of the DAS Agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted access to Sangamo&#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no revenues or related costs and expenses recognized under the DAS Agreement during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Funding from Research Foundations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">California Institute for Regenerative Medicine - HIV </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2009 CIRM, a State of California entity, granted a $14.5 million Disease Team Research Award to develop an HIV/AIDS therapy based on the application of ZFN gene editing technology in hematopoietic stem cells (HSCs). The four-year grant supports an innovative research project conducted by a multidisciplinary team of investigators, including investigators from the University of Southern California, City of Hope National Medical Center and Sangamo BioSciences. Sangamo received funds totaling $5.2 million from the total amount awarded based on expenses incurred for research and development efforts by Sangamo as prescribed in the agreement, and subject to its terms and conditions. The award is intended to substantially fund Sangamo&#8217;s research and development efforts related to the agreement. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo resulting from sales of a commercial product resulting from research and development efforts supported by the grant. As of December&#160;31, 2013, all revenues under the award had been recognized and all funds had been received. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no revenues attributable to research and development performed under the CIRM 2009 grant agreement during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM grant agreement were $0.2 million and $0.3 million during the three months ended March 31, 2015 and 2014, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 CIRM agreed to fund a $5.6 million Strategic Partnership Award to fund clinical studies of a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of its ZFN genome editing technology in hematopoietic stem progenitor cells (HSPCs). The four year grant provides matching funds to support evaluation of the Company&#8217;s stem cell-based ZFP Therapeutic in a clinical trial in HIV-infected individuals conducted at City of Hope. The Company expects funding for this grant to commence in 2015.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no revenues attributable to research and development performed under the Strategic Partnership Award during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM Strategic Partnership Award were $0.3 million and $0.0 million during the three months ended March 31, 2015 and 2014, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">California Institute for Regenerative Medicine - Beta-Thalassemia </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2013 CIRM granted Sangamo a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its ZFN gene editing technology in HSCs. The four-year grant provides matching funds for preclinical work that will support an IND application and a Phase 1 clinical trial in transfusion-dependent beta-thalassemia patients. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo, or its collaborators, from sales of a commercial product resulting from research and development efforts supported by the grant, in accordance with Title 17, California Code of Regulations, Section&#160;100600. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue attributable to research and development performed under the CIRM grant agreement for beta-thalassemia was $0.7 million and $0.4 million during the three months ended March 31, 2015 and 2014, respectively. Related costs and expenses incurred under the CIRM grant agreement were $0.7 million and $0.4 million during the three months ended March 31, 2015 and 2014, respectively. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Changes in Estimated Fair Value of Contingent Consideration Liability (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 1,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
        <td class="num"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(1,800)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Carrying Values of Intangibles Assets</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The carrying values of these intangibles assets are as follows (in thousands): </p></div><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERE-110 for the treatment of Alzheimer's disease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,640</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERE-120 for the treatment of Parkinson's disease</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable intangible assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b),(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (&#8220;Sangamo&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2015. The condensed consolidated balance sheet data at December&#160;31, 2014 were derived from the audited consolidated financial statements included in Sangamo&#8217;s Form 10-K for the year ended December&#160;31, 2014, as filed with the SEC. These financial statements should be read in conjunction with the financial statements and footnotes thereto for the year ended December&#160;31, 2014, included in Sangamo&#8217;s Form 10-K, as filed with the SEC. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements prior to the adoption of ASU No.&#160;2009-13, Revenue Recognition&#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)<font style="font-style:normal;">. For revenue arrangements entered into before January&#160;1, 2011, that include multiple deliverables, the elements of such agreements were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements after the adoption of ASU 2009-13.<font style="font-style:normal;"> ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (VSOE), if available; third-party evidence (TPE), if available and VSOE is not available; or the best estimate of selling price (ESP), if neither VSOE nor TPE is available; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Symbol';font-size:10pt;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG (Shire), in January 2012 and Biogen Inc., formerly Biogen Idec Inc. (Biogen) in January 2014 were evaluated under these amended accounting standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company&#8217;s performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred to the extent such amounts have been agreed to with the respective collaboration partner. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Standards </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In August 2014 the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-15, <font style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font> (ASU 2014-15). ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting ASU 2014-15 on its consolidated financial statements will be material.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 the Financial Accounting Standards Board issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with&#160;Customers</font>&#160;(ASU 2014-09). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&#160;15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7&#8212;INCOME TAXES </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#8217;s history of losses. Accordingly, the Company&#8217;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2015 the deferred tax liability of $0.7 million that was recorded upon acquiring the IPR&amp;D assets in 2013 was adjusted due to the impairment of these assets. This resulted in the recognition of a $0.7 million income tax benefit. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8&#8212;STOCK-BASED COMPENSATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,262</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">834</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,953</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The fair value measurements of our cash equivalents, available-for-sale marketable securities and contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,266</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,558</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,089</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,469</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government sponsored entity debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,374</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,192</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Estimated Fair Value of Contingent Consideration Liability</a></td>
        <td class="text"><div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of December 31, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of March 31, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ (748)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Recognition of income tax benefit</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1LAI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities" onclick="toggleNextSibling(this);">200,469</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities" onclick="toggleNextSibling(this);">220,192</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">217,558</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">223,374</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure" onclick="toggleNextSibling(this);">1,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">31,148</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">33,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money market funds [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">17,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember]" onclick="toggleNextSibling(this);">3,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_MoneyMarketFundsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">200,469</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">220,192</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">200,469</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">220,192</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Commercial paper securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">31,148</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">33,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">1,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">23,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">22,813</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities [Member] | Level 2 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">23,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">22,813</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government sponsored entity debt securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">146,055</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">163,631</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government sponsored entity debt securities [Member] | Level 2 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">146,055</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">163,631</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=sgmo_ContingentConsiderationLiabilityMember', window );">Contingent consideration liability [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=sgmo_ContingentConsiderationLiabilityMember]" onclick="toggleNextSibling(this);">1,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= sgmo_ContingentConsiderationLiabilityMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=sgmo_ContingentConsiderationLiabilityMember', window );">Contingent consideration liability [Member] | Level 3 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=sgmo_ContingentConsiderationLiabilityMember]" onclick="toggleNextSibling(this);">$ 1,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= sgmo_ContingentConsiderationLiabilityMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial and nonfinancial obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=sgmo_ContingentConsiderationLiabilityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=sgmo_ContingentConsiderationLiabilityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share - Additional Information (Detail) (Stock options [Member])<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options outstanding excluded in calculation of diluted net loss per share</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">7,624,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">7,302,366</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (5,319)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,572)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on available-for-sale securities</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (5,269)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (7,563)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4&#8212;BASIC AND DILUTED NET LOSS PER SHARE </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of stock options, which are anti-dilutive. The total number of shares subject to stock options outstanding excluded from consideration in the calculation of diluted net loss per share for the three months ended March 31, 2015 and 2014 were 7,624,600 and 7,302,366, respectively. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYVCI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Program</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Targets</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Targets</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs</a></td>
        <td class="nump"><a title="sgmo_NumberOfResearchProgram" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">sgmo_NumberOfResearchProgram</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 14,980,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 12,083,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember', window );">Biogen Inc [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved', window );">Potential amount eligible to receive for certain milestones</a></td>
        <td class="nump"><a title="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">126,300,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
        <td class="nump"><a title="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">167,500,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
        <td class="nump"><a title="sgmo_MilestoneRevenueReceivable[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">293,800,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_MilestoneRevenueReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_MilestonePaymentsReceived[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">sgmo_MilestonePaymentsReceived<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">40 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember]" onclick="toggleNextSibling(this);">14,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember', window );">Biogen Inc [Member] | Beta-thalassemia [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
        <td class="nump"><a title="sgmo_MilestoneRevenueReceivable[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_BetaThalassemiaMember]" onclick="toggleNextSibling(this);">7,500,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_MilestoneRevenueReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_BetaThalassemiaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_BetaThalassemiaMember]" onclick="toggleNextSibling(this);">1,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_BetaThalassemiaMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_BetaThalassemiaMember]" onclick="toggleNextSibling(this);">1,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_BetaThalassemiaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember', window );">Biogen Inc [Member] | Sickle cell disease [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
        <td class="nump"><a title="sgmo_MilestoneRevenueReceivable[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_SickleCellDiseaseMember]" onclick="toggleNextSibling(this);">7,500,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_MilestoneRevenueReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_SickleCellDiseaseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember', window );">Biogen Inc [Member] | Other Projects [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_OtherProjectsMember]" onclick="toggleNextSibling(this);">1,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_OtherProjectsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_OtherProjectsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_BiogenIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= sgmo_OtherProjectsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">13,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">180,000,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">6,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">4,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">4,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateNumberOfGeneTargets', window );">Aggregate number of gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_AggregateNumberOfGeneTargets[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">7</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AggregateNumberOfGeneTargets<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfInitialGeneTargets', window );">Number of initial gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_NumberOfInitialGeneTargets[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">4</a><span style="display:none;white-space:normal;text-align:left;">sgmo_NumberOfInitialGeneTargets<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfGeneTargets', window );">Number of gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_NumberOfGeneTargets[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">sgmo_NumberOfGeneTargets<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfAdditionalGeneTargets', window );">Number of additional gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_NumberOfAdditionalGeneTargets[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">sgmo_NumberOfAdditionalGeneTargets<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication', window );">IND or CTA submission amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">8,500,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="sgmo_MilestoneRevenueReceivable[us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 33,500,000</a><span style="display:none;white-space:normal;text-align:left;">sgmo_MilestoneRevenueReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= sgmo_ShireAgMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate additional revenue recognition milestone method revenue achieved.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateNumberOfGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_AggregateNumberOfGeneTargets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreements number of products approved under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial research term of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone&#x200B; revenue receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfAdditionalGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_NumberOfAdditionalGeneTargets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_NumberOfGeneTargets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfInitialGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of initial gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_NumberOfInitialGeneTargets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of research program.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>95</ContextCount>
  <ElementCount>151</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShare</Role>
      <ShortName>Basic and Diluted Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Major Customers, Partnerships and Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Fair Value Measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurement - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurement - Schedule of Changes in Estimated Fair Value of Contingent Consideration Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureFairValueMeasurementScheduleOfChangesInEstimatedFairValueOfContingentConsiderationLiabilityDetail</Role>
      <ShortName>Fair Value Measurement - Schedule of Changes in Estimated Fair Value of Contingent Consideration Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Marketable Securities - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestmentsDetail</Role>
      <ShortName>Marketable Securities - Schedule of Investments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Basic and Diluted Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Basic and Diluted Net Loss Per Share - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Intangible Assets - Carrying Value of Intangibles Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsCarryingValueOfIntangiblesAssetsDetail</Role>
      <ShortName>Intangible Assets - Carrying Value of Intangibles Assets (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20150331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive had a mix of decimals attribute values: -6 -5.</Log>
    <Log type="Info">Element us-gaap_ResearchAndDevelopmentExpense had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_RevenueFromGrants had a mix of decimals attribute values: -6 -5 -3.</Log>
    <Log type="Info">Element us-gaap_RoyaltyRevenue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '100260 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100280 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100290 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100300 - Disclosure - Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 100010 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 100030 - Statement - Condensed Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 100050 - Statement - Condensed Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>sgmo-20150331.xml</File>
    <File>sgmo-20150331.xsd</File>
    <File>sgmo-20150331_cal.xml</File>
    <File>sgmo-20150331_def.xml</File>
    <File>sgmo-20150331_lab.xml</File>
    <File>sgmo-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,262</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">834</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,953</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
